<SEC-DOCUMENT>0001477932-25-003730.txt : 20250515
<SEC-HEADER>0001477932-25-003730.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515092041
ACCESSION NUMBER:		0001477932-25-003730
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cosmos Health Inc.
		CENTRAL INDEX KEY:			0001474167
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				270611758
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41308
		FILM NUMBER:		25949233

	BUSINESS ADDRESS:	
		STREET 1:		5 AGIOU GEORGIOU, PILEA
		CITY:			THESSALONIKI
		STATE:			J3
		ZIP:			55438
		BUSINESS PHONE:		312-536-3102

	MAIL ADDRESS:	
		STREET 1:		5 AGIOU GEORGIOU, PILEA
		CITY:			THESSALONIKI
		STATE:			J3
		ZIP:			55438

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cosmos Holdings Inc.
		DATE OF NAME CHANGE:	20140106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIME ESTATES & DEVELOPMENTS INC
		DATE OF NAME CHANGE:	20091008
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cosm_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2" xmlns:cosm="http://cosm.com/20250331"><head><title>cosm_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;margin-left:7%;margin-right:7%;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2025-01-01to2025-03-31" id="ixv-11299">0001474167</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2025-01-01to2025-03-31" format="ixt:booleanfalse" id="ixv-11300">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2025-01-01to2025-03-31" id="ixv-11301">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2025-01-01to2025-03-31" id="ixv-11302">Q1</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2025-01-01to2025-03-31" id="ixv-11303">2025</ix:nonNumeric><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2025-01-01to2025-03-31" id="ixv-11304">COSM</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" unitRef="USDPShares" decimals="INF" id="ixv-11305">0.001</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" unitRef="Shares" decimals="0" id="ixv-11306">300000000</ix:nonFraction><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-12-31" unitRef="Shares" decimals="0" id="ixv-11307">86497</ix:nonFraction><ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" contextRef="From2025-01-01to2025-03-31" id="ixv-11308">true</ix:nonNumeric><ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" contextRef="From2025-01-01to2025-03-31" id="ixv-11309">false</ix:nonNumeric><ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" contextRef="From2025-01-01to2025-03-31" id="ixv-11310">false</ix:nonNumeric><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" contextRef="From2025-01-01to2025-03-31" id="ixv-11311">false</ix:nonNumeric><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2024-12-31_cosm_ShareExchangeAgreementMember_cosm_IccMember" unitRef="USD" decimals="0" id="ixv-11312">0</ix:nonFraction><ix:nonFraction name="cosm:CommonStockShareAuthorized" contextRef="AsOf2024-12-31" unitRef="Shares" decimals="0" id="ixv-11313">300000000</ix:nonFraction><ix:nonNumeric name="cosm:WeightedAverageRemainingContractualTermOutstandingEnding" contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember" id="ixv-11314">P3Y2M27D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cosm-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="From2025-01-01to2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-04-01to2025-04-24_us-gaap_SubsequentEventMember_cosm_GrigoriosSiokasMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GrigoriosSiokasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_OtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:NutraceuticalsAndPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:PharmamanufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_WholesaleMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:WholesaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:TotalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_UkMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:UkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_UkMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:UkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_GreeceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:GreeceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_BulgariaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:BulgariaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_BulgariaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:BulgariaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_CyprusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:CyprusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_CyprusMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:CyprusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_CroatiaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:CroatiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_CroatiaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:CroatiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_AlbaniaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:AlbaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_AlbaniaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:AlbaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-08-21_cosm_BoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-08-21_cosm_TwoZeroTwentyThreePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TwoZeroTwentyThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-19_cosm_TwoZeroTwentyTwoPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TwoZeroTwentyTwoPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-04-03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_BoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_BoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cosm_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-01-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-07-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-10-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-11-01to2023-11-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-11-01to2023-11-21_cosm_FourThirdPartyConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:FourThirdPartyConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-07-02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-06-01to2022-06-25_cosm_PhaseTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PhaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-06-01to2022-06-25_cosm_PhaseOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PhaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_cosm_NationalMedicinesAgencyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cosm:NationalMedicinesAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_cosm_NationalMedicinesAgencyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cosm:NationalMedicinesAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_InterestExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_InterestExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_FinanceLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_OperatingLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">cosm:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentythreeTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-06-01to2020-06-23_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyThreeTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-06-01to2020-06-24_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyFourTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_DebtAgreementJuneOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJuneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-05-01to2020-05-12_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyFourteenTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyFourTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:DeemberTwentyTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyTwentyNineTwentyTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyFourTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyFourteenTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentythreeTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentythreeTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentythreeTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-07-30_cosm_DebtAgreementJulyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJulyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-11-19_cosm_DebtExchangeAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyThreeTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyThreeTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_DebtAgreementJulyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJulyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2017-05-12_cosm_DebtAgreementJulyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJulyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentySevenTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_DebtAgreementJuneOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJuneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:DeemberTwentyTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyTwentyNineTwentyTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyFourteenTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJuneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentySevenTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentySevenTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_DebtAgreementJulyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJulyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_DebtExchangeAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_DebtExchangeAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_COVIDLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_COVIDLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_COVIDLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_COVIDLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cosm_COVIDLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_ThirdPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_ThirdPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_ThirdPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_ThirdPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cosm_ThirdPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_TradeFacilityAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_TradeFacilityAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_TradeFacilityAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cosm_TradeFacilityAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_EFGMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:EFGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_EFGMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:EFGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:PancretaOfGreeceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:PancretaOfGreeceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:AlphaBankOfGreeceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:AlphaBankOfGreeceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:NationalBankOfGreeceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:NationalBankOfGreeceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-01-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_PancretaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PancretaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_PancretaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PancretaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_AtticaBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:AtticaBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_AtticaBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:AtticaBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_EFGMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:EFGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_EFGMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:EFGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_AlphaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:AlphaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_AlphaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:AlphaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_NationalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_NationalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-05-01to2021-05-17_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-12-01to2023-12-29_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-06-01to2023-06-28_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_InventoriesRelatedAgreementMember_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cosm:InventoriesRelatedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_InventoriesRelatedAgreementMember_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cosm:InventoriesRelatedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-12-31_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_MariaKozariMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_MariaKozariMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_MariaKozariMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_MariaKozariMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_MariaKozariMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_KanarogloySiaEpeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:KanarogloySiaEpeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_BasothoInvestmentLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BasothoInvestmentLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_BasothoInvestmentLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BasothoInvestmentLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_BasothoInvestmentLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BasothoInvestmentLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_PanagiotisKozarisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PanagiotisKozarisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_PanagiotisKozarisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PanagiotisKozarisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_cosm_PanagiotisKozarisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PanagiotisKozarisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-12-31_cosm_PanagiotisKozarisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PanagiotisKozarisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_GrigoriosSiokasMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GrigoriosSiokasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_DimitriosGoulielmosMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DimitriosGoulielmosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_GrigoriosSiokasMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GrigoriosSiokasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_GrigoriosSiokasMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GrigoriosSiokasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_DimitriosGoulielmosMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DimitriosGoulielmosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_DimitriosGoulielmosMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DimitriosGoulielmosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_GeorgeTerzisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GeorgeTerzisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-02-01to2023-02-28_cosm_CanaHoldingsLaboratoriesHoldingLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:CanaHoldingsLaboratoriesHoldingLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_LoansPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_LoansPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_LoansPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cosm_LoansPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_NotesPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_NotesPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_NotesPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_NotesPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cosm_NotesPayableRelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-09-01to2024-09-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-09-01to2024-09-26_us-gaap_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-09-01to2024-09-26_cosm_WarrantExchangeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-09-01to2024-09-26_cosm_WarrantInducementLetterMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:WarrantInducementLetterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-26_cosm_WarrantExchangeMember_cosm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-26_cosm_WarrantExchangeMember_cosm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-26_cosm_WarrantExchangeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-26_cosm_WarrantInducementLetterMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:WarrantInducementLetterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-01-28_cosm_WarrantInducementLetterMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:WarrantInducementLetterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-24_cosm_TreasuryStocksOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cosm:TreasuryStocksOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-04_cosm_WarrantExchangeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_TreasuryStocksOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cosm:TreasuryStocksOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_TreasuryStocksOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cosm:TreasuryStocksOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-10-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_CustomerListsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_CustomerListsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_TradeNameMarkMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cosm:TradeNameMarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_TradeNameMarkMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cosm:TradeNameMarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_SoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cosm:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_SoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cosm:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_VehiclesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_VehiclesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cosm_CosmoFarmacyLPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:CosmoFarmacyLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:CosmoFarmacyLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_ShareExchangeAgreementMember_cosm_IccMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:ShareExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cosm:IccMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_ShareExchangeAgreementMember_cosm_IccMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:ShareExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cosm:IccMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-06-01to2023-06-30_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CANAPharmaceuticalLaboratoriesSACanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-06_cosm_BuildingAcquisionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingAcquisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-02-01to2023-02-28_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CANAPharmaceuticalLaboratoriesSACanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-04-24_cosm_BuildingAcquisionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingAcquisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-15_cosm_GreeceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:GreeceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-06-01to2023-06-15_cosm_GreeceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:GreeceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_BuildingAcquisionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingAcquisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-01-23_cosm_CloudscreenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CloudscreenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_ZipDoctorIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:ZipDoctorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-04-03_cosm_ZipDoctorIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:ZipDoctorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-04-03_cosm_ZipDoctorIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:ZipDoctorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_UnitedKingdomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:UnitedKingdomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_PancretaBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PancretaBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_PancretaBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PancretaBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_GreeceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:GreeceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_LeaseholdImprovementsAndTechnicalWorksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:LeaseholdImprovementsAndTechnicalWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_ComputerEquipmentMember_cosm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_FurnitureAndFixturesMember_cosm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_FurnitureAndFixturesMember_cosm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_MachineryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_TopMember_us-gaap_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TopMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_BuildingsMember_cosm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_BuildingsMember_cosm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_VehiclesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CANAPharmaceuticalLaboratoriesSACanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CANAPharmaceuticalLaboratoriesSACanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_SubscriptionReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_cosm_CommonStockShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_cosm_CommonStockShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_SubscriptionReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cosm_CommonStockShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_cosm_SubscriptionReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_cosm_CommonStockShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cosm_CommonStockShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cosm_SubscriptionReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cosm_CommonStockShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-05-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>WASHINGTON, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2025-01-01to2025-03-31" id="ixv-13325">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-13326">&#9746;</ix:nonNumeric></strong><strong> </strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the quarterly period ended <strong><span style="text-decoration:underline"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2025-01-01to2025-03-31" format="ixt:datemonthdayyearen" id="ixv-13327">March 31, 2025</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-13328">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the transition period from __________ to __________</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission file number: <strong><span style="text-decoration:underline"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2025-01-01to2025-03-31" id="ixv-13329">000-54436</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:98%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2025-01-01to2025-03-31" id="ixv-13330">COSMOS HEALTH INC.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="width:98%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:stateprovnameen" id="ixv-13331">Nevada</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2025-01-01to2025-03-31" id="ixv-13332">27-0611758</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Company or organization)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(I.R.S. Employer </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Identification No.)</p></td></tr><tr style="height:15px"><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td/></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2025-01-01to2025-03-31" id="ixv-13333">5 Agiou Georgiou Str</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="From2025-01-01to2025-03-31" id="ixv-13334">Pilea</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2025-01-01to2025-03-31" id="ixv-13335">Thessaloniki</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:countrynameen" id="ixv-13336">Greece</ix:nonNumeric></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2025-01-01to2025-03-31" id="ixv-13337">55438</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Registrant&#8217;s telephone number:&#160;<strong><span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2025-01-01to2025-03-31" id="ixv-13338">312</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2025-01-01to2025-03-31" id="ixv-13339">536-3102</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Securities registered under Section 12(b) of the Exchange Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Title of each class</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of each exchange on which registered</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2025-01-01to2025-03-31" id="ixv-13340">Common Stock, par value $0.001</ix:nonNumeric></strong></p></td><td/><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>The <ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:exchnameen" id="ixv-13341">Nasdaq</ix:nonNumeric> Capital Market</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Securities registered under Section 12(g) of the Exchange Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Title of each class</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of each exchange on which registered</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Check whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="From2025-01-01to2025-03-31" id="ixv-13342">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="From2025-01-01to2025-03-31" id="ixv-13343">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160; &#160;No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Large accelerated filer</p></td><td style="width:20%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744;</p></td><td style="width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accelerated filer</p></td><td style="width:20%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:entityfilercategoryen" id="ixv-13344">Non-accelerated Filer</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Smaller reporting company</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-13345">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Do not check if a smaller reporting company)&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Emerging growth company</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-13346">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-13347">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Applicable only to Corporate Issuers:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-05-15" format="ixt:numdotdecimal" unitRef="Shares" decimals="INF" id="ixv-13348">28,751,422</ix:nonFraction> as of May 15, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="toc"><strong>TABLE&#160;OF CONTENTS</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">PART I</p></td><td/><td/><td/></tr><tr style="height:15px"><td style="width:7%;"/><td/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#fs">Item 1.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#fs">Condensed Consolidated Financial Statements (Unaudited).</a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td/><td/><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#i2">Item 2.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#i2">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">36</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td/><td/><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#i3">Item 3.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#i3">Quantitative and Qualitative Disclosures about Market Risk.</a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">47</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#i4">Item 4.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#i4">Controls and Procedures.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">47</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#p2">PART II</a></p></td><td/><td/><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td/><td/><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii1">Item 1.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii1">Legal Proceedings.</a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td/><td/><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii1a">Item 1A.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii1a">Risk Factors.</a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td/><td/><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii2">Item 2.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii2">Unregistered Sales of Equity Securities and Use of Proceeds </a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td/><td/><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii3">Item 3.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii3">Defaults Upon Senior Securities.</a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii4">Item 4.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii4">Mine Safety Disclosures.</a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii5">Item 5.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii5">Other Information.</a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td/><td/><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii6">Item 6.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#ii6">Exhibits.</a></p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">50</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#sig">SIGNATURES</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">51</p></td><td/></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span class="atag" style="display: inline" id="fs">COSMOS HEALTH INC.</span></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;" colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED CONSOLIDATED BALANCE SHEETS</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31, 2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Unaudited)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">ASSETS</span></strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>CURRENT ASSETS:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11199" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">742,881</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11200" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">315,105</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Accounts receivable, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11201" name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,251,895</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11202" name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,478,263</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Accounts receivable - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11203" name="cosm:AmountAccountsReceivableRelatedPartiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,422,015</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11204" name="cosm:AmountAccountsReceivableRelatedPartiesCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,230,308</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Marketable securities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11205" name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,278</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11206" name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">21,148</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11207" name="us-gaap:InventoryNet" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,736,222</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11208" name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,355,365</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Loans receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11209" name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">666,225</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11210" name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">614,473</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Loans receivable - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11211" name="us-gaap:LoansAndLeasesReceivableRelatedParties" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">768,891</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11212" name="us-gaap:LoansAndLeasesReceivableRelatedParties" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">557,473</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Prepaid expenses and other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11213" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,383,105</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11214" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,310,388</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Prepaid expenses and other current assets - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_11215" name="cosm:PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,848,487</ix:nonFraction></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11216" name="cosm:PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,578,825</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>TOTAL CURRENT ASSETS</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11217" name="us-gaap:AssetsCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">27,844,999</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11218" name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,461,347</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11219" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,016,068</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11220" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,689,505</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Goodwill and intangible assets, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11221" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,802,529</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11222" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,756,534</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Loans receivable - long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11223" name="cosm:LoansReceivableNoncurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,927,994</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11224" name="cosm:LoansReceivableNoncurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,876,523</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Loans receivable - related party - long term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11225" name="cosm:LoansReceivableRelatedPartyNoncurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,875,384</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11226" name="cosm:LoansReceivableRelatedPartyNoncurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,898,280</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Operating lease right-of-use asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11227" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">671,605</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11228" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">696,166</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Financing lease right-of-use asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11229" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,451</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11230" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,607</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Advances for building's acquisition</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11231" name="cosm:AdvancesForBuildingsAcquisition" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,000,020</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11232" name="cosm:AdvancesForBuildingsAcquisition" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,000,020</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Other assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11233" name="us-gaap:OtherAssets" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,154,594</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11234" name="us-gaap:OtherAssets" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,108,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Other assets - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11235" name="cosm:OtherAssetsRelatedParty" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,889,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11236" name="cosm:OtherAssetsRelatedParty" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,811,425</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>TOTAL ASSETS</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11237" name="us-gaap:Assets" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">57,191,944</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11238" name="us-gaap:Assets" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">54,311,892</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">LIABILITIES AND STOCKHOLDERS' EQUITY</span></strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>CURRENT LIABILITIES:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Accounts payable and accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11241" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,672,962</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11242" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,157,658</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Accounts payable and accrued expenses - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11243" name="cosm:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">614,554</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11244" name="cosm:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,269,403</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Accrued interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11245" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">255,192</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11246" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">221,820</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Lines of credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11247" name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,305,377</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11248" name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,985,052</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11249" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,763,723</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11250" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,548,480</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Notes payable - related party </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11251" name="cosm:NotesPayableRelatedPartiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,012</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11252" name="cosm:NotesPayableRelatedPartiesCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,558</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Loans payable - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11253" name="cosm:LoansPayableRelatedPartiesCurrent" contextRef="AsOf2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11254" name="cosm:LoansPayableRelatedPartiesCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,194</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Operating lease liability, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11255" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">203,601</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11256" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">196,718</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Financing lease liability, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11257" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,376</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11258" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Other current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11259" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,751,190</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11260" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,350,173</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>TOTAL CURRENT LIABILITIES</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11261" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">26,585,987</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11262" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,757,540</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Notes payable - long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11263" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,088,540</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11264" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,560,433</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Operating lease liability, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11265" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">466,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11266" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">498,398</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Financing lease liability, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11267" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,788</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11268" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,399</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11269" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,097,008</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11270" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,959,193</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>TOTAL LIABILITIES</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11271" name="us-gaap:Liabilities" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">31,240,232</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11272" name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">29,778,963</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Commitments and Contingencies (see Note 14)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11273" name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11274" name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>STOCKHOLDERS' EQUITY:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock, $<ix:nonFraction id="fid_8807" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.001</ix:nonFraction> par value; <ix:nonFraction id="fid_8809" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">300,000,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_8812" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">27,284,633</ix:nonFraction> and <ix:nonFraction id="fid_8811" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">23,689,135</ix:nonFraction> shares issued and <ix:nonFraction id="fid_8814" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">27,198,136</ix:nonFraction> and <ix:nonFraction id="fid_8813" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">23,602,638</ix:nonFraction> outstanding as of March 31, 2025 and December 31, 2024, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11276" name="us-gaap:CommonStockValue" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">27,285</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11277" name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,689</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11278" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">142,785,641</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11279" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">141,583,625</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Subscription receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11280" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11281" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Treasury stock, at cost, <ix:nonFraction id="fid_8815" name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">86,497</ix:nonFraction> shares as of March 31, 2025 and December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11282" name="us-gaap:TreasuryStockCommonValue" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">917,159</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11283" name="us-gaap:TreasuryStockCommonValue" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">917,159</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11284" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">114,840,372</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11285" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">114,022,275</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Accumulated other comprehensive loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11286" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,103,663</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11287" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,134,931</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>TOTAL STOCKHOLDERS' EQUITY</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11288" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,951,712</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11289" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">24,532,929</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11290" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">57,191,944</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11291" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">54,311,892</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">COSMOS HEALTH INC.</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;" colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">INCOME (LOSS)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>REVENUE</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11292" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,712,528</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11293" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,584,473</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>COST OF GOODS SOLD</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11294" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,662,729</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11295" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,250,847</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>GROSS PROFIT</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11296" name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,049,799</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11297" name="us-gaap:GrossProfit" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,333,626</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>OPERATING EXPENSES</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">General and administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11299" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,478,702</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11300" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,418,138</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Salaries and wages</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11301" name="us-gaap:SalariesAndWages" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,040,019</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11302" name="us-gaap:SalariesAndWages" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,258,179</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Sales and marketing expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11303" name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">28,155</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11304" name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">173,630</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Research and development costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11305" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,629</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11306" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Depreciation and amortization expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11307" name="us-gaap:DepreciationAndAmortization" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">320,439</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11308" name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">319,787</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>TOTAL OPERATING EXPENSES</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11309" name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,882,944</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11310" name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,169,734</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>LOSS FROM OPERATIONS</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11311" name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">833,145</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11312" name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,836,108</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>OTHER INCOME (EXPENSE)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Other income (expense), net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11314" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">68,137</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11315" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">191,824</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11316" name="us-gaap:InterestExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">187,107</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11317" name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">168,672</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Interest income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11318" name="us-gaap:InterestIncomeOther" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">91,326</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11319" name="us-gaap:InterestIncomeOther" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">105,765</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Gain on equity investments, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11320" name="cosm:GainLossOnSalesOfEquityInvestments" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,142</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11321" name="cosm:GainLossOnSalesOfEquityInvestments" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,755</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Foreign currency transaction, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11322" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">175,824</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11323" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">161,254</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>TOTAL OTHER INCOME (EXPENSE), NET</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11324" name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,048</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11325" name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">30,582</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>LOSS BEFORE INCOME TAXES</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11326" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">818,097</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11327" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,866,690</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>INCOME TAX EXPENSE</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11328" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11329" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>NET LOSS</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11330" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">818,097</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11331" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,866,690</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11332" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">818,097</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11333" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,866,690</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>OTHER COMPREHENSIVE INCOME (LOSS)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Foreign currency translation adjustment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11335" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,031,268</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11336" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">599,276</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>TOTAL COMPREHENSIVE INCOME (LOSS)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11337" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">213,171</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11338" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,465,966</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>BASIC NET LOSS PER SHARE</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11339" name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.03</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11340" name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.11</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>DILUTED NET LOSS PER SHARE</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11341" name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.03</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11342" name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.11</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Basic</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11344" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">26,037,608</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11345" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">16,851,747</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11346" name="us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">26,037,608</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11347" name="us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">16,851,747</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="37" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">COSMOS HEALTH INC.</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;" colspan="37"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common Stock </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Additional </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Treasury Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Other</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>No. of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Paid-in Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;Subscription </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;Receivable </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>No. of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Accumulated</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Comprehensive</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Loss</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stockholders'</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Equity</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance at January 1, 2024</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11348" name="us-gaap:SharesIssued" contextRef="AsOf2023-12-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">15,982,472</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11350" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,983</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11351" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">129,008,301</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11352" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_cosm_SubscriptionReceivableMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11349" name="us-gaap:SharesIssued" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">86,497</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11353" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">917,159</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11354" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">91,644,233</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11355" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">419,844</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11356" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">36,043,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Foreign currency translation adjustment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11357" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11358" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11359" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11360" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11361" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11362" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">599,276</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11363" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,715,087</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Proceeds from sale of common stock, net of financing fees of $19,467</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11364" name="cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">901,488</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11366" name="cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">901</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11367" name="cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">628,525</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11368" name="cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11369" name="cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11370" name="cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11371" name="cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11372" name="cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">629,426</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares issued in lieu of cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11373" name="cosm:SharesIssuedInLieuOfCashAmount" contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11374" name="cosm:SharesIssuedInLieuOfCashAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">108,297</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11375" name="cosm:SharesIssuedInLieuOfCashAmount" contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11376" name="cosm:SharesIssuedInLieuOfCashAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11377" name="cosm:SharesIssuedInLieuOfCashAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11378" name="cosm:SharesIssuedInLieuOfCashAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11379" name="cosm:SharesIssuedInLieuOfCashAmount" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">695,405</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares issued pursuant to warrant exchange agreement</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11380" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementShares" contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">950,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11382" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">950</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11383" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">950</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11384" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11385" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11386" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11387" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11388" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11389" name="cosm:StockBasedCompensation" contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11390" name="cosm:StockBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">231,897</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11391" name="cosm:StockBasedCompensation" contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11392" name="cosm:StockBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11393" name="cosm:StockBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11394" name="cosm:StockBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11395" name="cosm:StockBasedCompensation" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">994,307</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11396" name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11397" name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11398" name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11399" name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11400" name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,866,690</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11401" name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11402" name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,868,868</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance at March 31, 2024</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11403" name="us-gaap:SharesIssued" contextRef="AsOf2024-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,834,023</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11405" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">17,834</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11406" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">129,976,070</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11407" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_cosm_SubscriptionReceivableMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11404" name="us-gaap:SharesIssued" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">86,497</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11408" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">917,159</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11409" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">93,510,923</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11410" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,019,120</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11411" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40,515,948</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common Stock </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Additional </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Treasury Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Other</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>No. of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Paid-in Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;Subscription </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;Receivable </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>No. of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Accumulated</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Comprehensive</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Loss</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stockholders'</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Equity</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance at January 1, 2025</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11412" name="us-gaap:SharesIssued" contextRef="AsOf2024-12-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">23,689,135</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11414" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,689</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11415" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">141,583,625</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11416" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_cosm_SubscriptionReceivableMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11413" name="us-gaap:SharesIssued" contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">86,497</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11417" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">917,159</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11418" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">114,022,275</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11419" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,134,931</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11420" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">24,532,930</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Foreign currency translation adjustment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11421" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11422" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11423" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11424" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11425" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11426" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,031,268</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11427" name="cosm:ForeignCurrencyTranslationAdjustmentNet" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,031,268</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11428" name="cosm:StockBasedCompensation" contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11429" name="cosm:StockBasedCompensation" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">556,611</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11430" name="cosm:StockBasedCompensation" contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11431" name="cosm:StockBasedCompensation" contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11432" name="cosm:StockBasedCompensation" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11433" name="cosm:StockBasedCompensation" contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11434" name="cosm:StockBasedCompensation" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">556,611</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares issued pursuant to warrant exchange agreement</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11435" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementShares" contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,542,126</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11437" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,542</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11438" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,542</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11439" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11440" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11441" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11442" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11443" name="cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Debt exchanges</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11444" name="cosm:DebtExchangesShares" contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,053,372</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11446" name="cosm:DebtExchangesAmount" contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,053</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11447" name="cosm:DebtExchangesAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">647,947</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11448" name="cosm:DebtExchangesAmount" contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11449" name="cosm:DebtExchangesAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11450" name="cosm:DebtExchangesAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11451" name="cosm:DebtExchangesAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11452" name="cosm:DebtExchangesAmount" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">649,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11453" name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11454" name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11455" name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11456" name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11457" name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">818,097</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11458" name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11459" name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">818,097</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance at March 31, 2025</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11460" name="us-gaap:SharesIssued" contextRef="AsOf2025-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">27,284,633</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11462" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_cosm_CommonStockShareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">27,284</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11463" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">142,785,641</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11464" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_cosm_SubscriptionReceivableMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11461" name="us-gaap:SharesIssued" contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">86,497</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11465" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">917,159</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11466" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">114,840,372</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11467" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,103,663</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11468" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,951,712</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">COSMOS HEALTH INC.</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;" colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Net Loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11470" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">818,097</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11471" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,866,690</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"><span style="text-decoration:underline">Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:</span></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Depreciation and amortization expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11473" name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">315,836</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11474" name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">312,298</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Amortization of right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11475" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,603</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11476" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,489</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Bad debt expense </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11477" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">18,687</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11478" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">31,071</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11479" name="us-gaap:LeaseAndRentalExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">63,236</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11480" name="us-gaap:LeaseAndRentalExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">77,167</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Interest on finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11481" name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">195</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11482" name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">725</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11483" name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">556,611</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11484" name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">340,194</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Deferred income taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11485" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,392</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11486" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,344</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Gain on net change in fair value of equity investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11487" name="us-gaap:GainLossOnInvestments" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,142</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11488" name="us-gaap:GainLossOnInvestments" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,755</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"><span style="text-decoration:underline">Changes in assets and liabilities:</span></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"/><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Accounts receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11490" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">170,948</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11491" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">238,025</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Accounts receivable - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11492" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">134,483</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11493" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">348,639</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11494" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">192,792</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11495" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">196,020</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Prepaid expenses and other assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11496" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">92,249</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11497" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">106,353</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Prepaid expenses and other current assets - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11498" name="cosm:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">134,754</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11499" name="cosm:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">974,442</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Accounts payable and accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11500" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">83,627</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11501" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">599,161</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Accounts payable and accrued expenses - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11502" name="cosm:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">18,934</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11503" name="cosm:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">319,713</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Accrued interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11504" name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,308</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11505" name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">62,387</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11506" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">63,238</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11507" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">76,344</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Other current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11508" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">169,429</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11509" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">261,313</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11510" name="cosm:IncreaseDecreaseInOtherLiabilities" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,272</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11511" name="cosm:IncreaseDecreaseInOtherLiabilities" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">701,821</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>NET CASH USED IN OPERATING ACTIVITIES</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11512" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">186,316</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11513" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">3,412,103</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Proceeds from loan receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11515" name="us-gaap:ProceedsFromSaleOfLoansReceivable" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,734</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11516" name="us-gaap:ProceedsFromSaleOfLoansReceivable" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">207,119</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Purchase of intangible assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11517" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,273</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11518" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Sale of intangible assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11519" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11520" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,997</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Purchase of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11521" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,530</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11522" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">82,662</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>NET CASH (USED IN) PROVIDED BY&#160;INVESTING ACTIVITIES</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11523" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,069</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11524" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">126,454</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Payment of note payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11526" name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">184,153</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11527" name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">364,354</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Proceeds from note payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11528" name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">737,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11529" name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Payment of related party loan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11530" name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,302</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11531" name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,599</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Payment of lines of credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11532" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,756,201</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11533" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,974,114</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Proceeds from lines of credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11534" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,775,739</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11535" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,932,222</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Proceeds from the issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11536" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11537" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">649,039</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Payments of financing fees </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11538" name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11539" name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">19,465</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Payments of finance lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11540" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,398</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11541" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,787</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>NET CASH PROVIDED BY FINANCING ACTIVITIES</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11542" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">560,862</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11543" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">206,942</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Effect of exchange rate changes on cash </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11544" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,299</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11545" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">110,611</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>NET CHANGE IN CASH </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11546" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">427,776</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11547" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,968,096</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>CASH AT BEGINNING OF PERIOD</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11548" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">315,105</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11549" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,833,195</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>CASH AT END OF PERIOD</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11550" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">742,881</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11551" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">865,099</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><span style="text-decoration:underline">Supplemental Disclosure of Cash Flow Information</span></strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Cash paid during the year:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11554" name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">104,800</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11555" name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">234,732</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><span style="text-decoration:underline">Supplemental Disclosure of Non-Cash Investing and Financing Activities</span></strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Closing of acquisition of Cloudscreen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11557" name="cosm:ClosingOfAcquisitionOfCloudscreen" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11558" name="cosm:ClosingOfAcquisitionOfCloudscreen" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">637,080</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock issued to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11559" name="cosm:CommonStockIssuedToEmployees" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">311,301</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11560" name="cosm:CommonStockIssuedToEmployees" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock issued to consultants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11561" name="cosm:CommonStockIssuedToConsultants" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">245,310</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11562" name="cosm:CommonStockIssuedToConsultants" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5964" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 &#8211; BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The terms &#8220;COSM,&#8221; &#8220;we,&#8221; the &#8220;Company,&#8221; the &#8220;Group&#8221; and &#8220;us&#8221; as used in this report refer to Cosmos Health Inc. The accompanying unaudited condensed consolidated balance sheet as of March 31, 2025 and unaudited condensed consolidated statements of operations and comprehensive income&#160;(loss) for the three months ended March 31, 2025 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of the management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2025, are not necessarily indicative of the results that may be expected for the year ending December 31, 2025, or any other period. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2024, included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 (&#8220;Form 10-K&#8221;). The accompanying condensed consolidated balance sheet as of December 31, 2024 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes on the accompanying balance sheet. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s unaudited consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), which contemplates the continuation of the Company as a going concern. For the period ended March 31, 2025, the Company had revenue of $<ix:nonFraction id="fid_10900" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,712,528</ix:nonFraction>, net loss of $<ix:nonFraction id="fid_10901" name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">818,097</ix:nonFraction> and net cash used in operations of $<ix:nonFraction id="fid_10902" name="us-gaap:NetCashProvidedByUsedInContinuingOperations" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">186,316</ix:nonFraction>. Additionally, as of March 31, 2025, the Company had positive working capital of $<ix:nonFraction id="fid_10899" name="cosm:WorkingCapital" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,259,012</ix:nonFraction>, an accumulated deficit of $<ix:nonFraction id="fid_10898" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">114,840,372</ix:nonFraction>, and stockholders&#8217; equity of $<ix:nonFraction id="fid_10897" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,951,712</ix:nonFraction>. It is management&#8217;s opinion that these conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of 12 months from the date of this filing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s revenues are not able to sustain its operations, and concerns exist regarding the Company&#8217;s ability to meet its obligations as they become due. The Company is subject to a number of risks to those of smaller commercial companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the need to obtain additional capital, competition from larger companies, and other pharmaceutical and health care companies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management evaluated the above conditions which raise substantial doubt about the Company&#8217;s ability to continue as a going concern to determine if it can meet its obligations for the subsequent 12 months from the date of this filing. Management considered its ability to access future capital, curtail expenses if needed, expand product lines, and acquire new products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management&#8217;s plans include expansion of brand name products to the market, expanding the current product portfolio, and evaluating acquisition targets to expand distribution. The exclusive distribution agreement signed for its Sky Premium Life products in the United Arab Emirates (&#8220;UAE&#8221;) and the significant orders already received, are expected to substantially strengthen its operating cash flow. Furthermore, the Company intends to vertically integrate the supply chain distribution network. On top of that, the Company plans to access the capital markets further in order to raise additional funds through equity and/or debt offerings. More specifically, commencing from August 2025, the Company will be eligible to utilize an S-3 registration statement, (12 months following the date that the Company had regained compliance with Listing Rule 5250(c)(1) (the &#8220;Filing Rule&#8221;)), to be in a position to raise equity capital more efficiently in conjunction with utilizing potential equity proceeds by its outstanding warrants. Management&#8217;s plans also include postponing certain debt repayments, through achieving favorable amendments to its debt facilities and in parallel intends to make substantial efforts to receive additional debt financing. Moreover, the Company&#8217;s management is considering of postponing certain repayments of suppliers and creditors. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Considering the above, management is of the view that substantial doubt exists for the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_11563" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_87df9c"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 2 &#8211; ORGANIZATION AND NATURE OF BUSINESS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cosmos Health Inc. and its subsidiaries (Nasdaq: COSM), (&#8220;us&#8221;, &#8220;we&#8221;, the &#8220;Group&#8221;, or the &#8220;Company&#8221;) are an international healthcare group headquartered in Chicago, Illinois. The Group is engaged in the nutraceuticals sector through its own proprietary lines of products &#8220;Sky Premium Life&#8221; and &#8220;Mediterranation&#8221;. The Company is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the Group is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK, serving retail pharmacies and wholesale distributors. The Company is strategically focusing on the research and development (&#8220;R&amp;D&#8221;) of novel patented nutraceuticals and specialized root extracts, as well as on the R&amp;D of proprietary complex generics and innovative OTC products. The Company has developed a global distribution platform and is currently expanding throughout Europe, Asia, the UAE and North America. The Company has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009. On November 14, 2013, we changed our name to Cosmos Holdings Inc., and on November 29, 2022, we changed our name to Cosmos Health Inc. Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (&#8220;SkyPharm&#8221;), a subsidiary that used to focus on the trading, sourcing and export of nutraceutical and pharmaceutical products. In February 2017, the Company acquired Decahedron Ltd., a UK Company (&#8220;Decahedron&#8221;) which is a fully licensed second-generation wholesaler specializing in imports and exports of generics and OTC pharmaceutical products within the EEA (European Economic Area) and distributor of Sky Premium Life nutraceutical products in the UK.&#160;On December 19, 2018, the Company acquired Cosmofarm&#160;S.A. (&#8220;Cosmofarm&#8221;), a pharmaceutical wholesaler specializing in the distribution and export of pharmaceutical products through its extensive pharmacies network. On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (&#8220;ZipDoctor&#8221;), a telehealth company, a direct-to-consumer subscription-based telemedicine platform. On June 30, 2023, the Company acquired&#160;Laboratories Holdings (Cyprus) Limited (&#8220;Cana&#8221;), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana&#160;S.A. (&#8220;Cana SA&#8221;), a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Acquisition Accounting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_11565" name="cosm:AcquisitionAccountingPolicy" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_90fc7a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cloudscreen</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $<ix:nonFraction id="fid_8855" name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">637,080</ix:nonFraction> and consisted of <ix:nonFraction id="fid_8856" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">280,000</ix:nonFraction> shares of common stock with a fair value of $<ix:nonFraction id="fid_8857" name="us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">319,200</ix:nonFraction> and an amount of $<ix:nonFraction id="fid_8858" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">317,880</ix:nonFraction> to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, Business Combinations, (&#8220;ASC 805&#8221;) and recorded $<ix:nonFraction id="fid_8859" name="us-gaap:AssetAcquisitionPriceOfAcquisitionExpected" contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">637,080</ix:nonFraction> as &#8220;Other assets&#8221; related to the technology platform acquired. The total amount was reclassified to &#8220;Goodwill and intangible assets, net&#8221; in January 2024 with the closing of the agreement (refer to Note 5).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>ZipDoctor</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (&#8220;ZipDoctor&#8221;), a&#160;telehealth company for a total sum of $<ix:nonFraction id="fid_8844" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-04-01to2023-04-03_cosm_ZipDoctorIncMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">150,000</ix:nonFraction> in cash and $<ix:nonFraction id="fid_8845" name="us-gaap:AcquisitionCosts" contextRef="From2023-04-01to2023-04-03_cosm_ZipDoctorIncMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,788</ix:nonFraction> in fees. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, <em>Business Combinations</em>, (&#8220;ASC 805&#8221;) and recorded $<ix:nonFraction id="fid_8846" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="AsOf2023-04-03_cosm_ZipDoctorIncMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">158,788</ix:nonFraction> as an intangible asset related to the technology platform acquired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2024, the Company recognized an impairment charge of $<ix:nonFraction id="fid_8869" name="us-gaap:AssetImpairmentCharges" contextRef="From2024-01-01to2024-12-31_cosm_ZipDoctorIncMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">131,032</ix:nonFraction> related to the technology platform. This decision followed management&#8217;s assessment that the asset&#8217;s recoverability was no longer supportable due to changes in market conditions and a shift in strategic priorities. Specifically, the telehealth platform was no longer in use and did not generate revenues, as the Company elected not to focus on the telehealth business segment. As a result, the unamortized balance of the intangible asset was effectively written off. The impairment charge was recorded within &#8220;Other income (expense), net&#8221; in the Consolidated Statement of Operations for the year ended December 31, 2024.&#160;</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_87df9c" continuedAt="cont_9e31b2"><ix:continuation id="cont_90fc7a" continuedAt="cont_bd872f"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Bikas</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 15, 2023, Cosmos Health Inc. entered into an Assignment and Assumption Agreement (the &#8220;Agreement&#8221;) with Ioannis Bikas O.E., a Greek Company (&#8220;Bikas&#8221;). Bikas is owner of a pharmaceutical distribution network in Greece and agreed to sell to the Company their distribution network and customer base. The purchase price of the network was &#8364;100,000 ($<ix:nonFraction id="fid_8847" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-06-01to2023-06-15_cosm_GreeceMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">109,330</ix:nonFraction>) of cash, and &#8364;300,000 ($<ix:nonFraction id="fid_8848" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="From2023-06-01to2023-06-15_cosm_GreeceMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">316,081</ix:nonFraction>) of the Company&#8217;s stock. The Company issued <ix:nonFraction id="fid_8849" name="cosm:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" contextRef="From2023-06-01to2023-06-15_cosm_GreeceMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">99,710</ix:nonFraction> shares of common stock related to the acquisition of the customer base, based on the fair value of the stock on the acquisition date. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded $<ix:nonFraction id="fid_8850" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="AsOf2023-06-15_cosm_GreeceMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">425,411</ix:nonFraction> as an intangible asset related to the customer base acquired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Buildings Acquisitions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 24, 2023, the Company purchased a building for a total sum of $<ix:nonFraction id="fid_8851" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-04-01to2023-04-24_cosm_BuildingAcquisionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,054,872</ix:nonFraction> in cash.&#160;The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded the cost of the building as &#8220;Property, plant and equipment&#8221; on the consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 6, 2023, the Company agreed to purchase land and building located in Montreal, Canada from a third-party vendor. The total purchase price amounts to $<ix:nonFraction id="fid_8854" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-01-01to2023-01-06_cosm_BuildingAcquisionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,950,000</ix:nonFraction> and the closing date of the agreement based on the amendment signed on July 19, 2023, was December 31, 2023. Pursuant to the last amendment signed on December 31, 2024 the closing date was extended to December 31, 2025. As of March 31, 2025, the Company has made prepayments of $<ix:nonFraction id="fid_10904" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="AsOf2025-03-31_cosm_BuildingAcquisionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,000,020</ix:nonFraction> classified as &#8220;Advances for building&#8217;s acquisition&#8221; on the Company&#8217;s condensed consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cana </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 30, 2023, the Company acquired Cana Laboratories Holding (Cyprus) Limited (&#8220;Cana&#8221;), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana&#160;S.A. (&#8220;Cana SA&#8221;) for &#8364;800,000 ($<ix:nonFraction id="fid_8861" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-06-01to2023-06-30_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">873,600</ix:nonFraction>) in cash and <ix:nonFraction id="fid_8860" name="cosm:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" contextRef="From2023-06-01to2023-06-30_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">46,377</ix:nonFraction> shares of common stock, with fair value of $<ix:nonFraction id="fid_8862" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="From2023-06-01to2023-06-30_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">138,667</ix:nonFraction> as of the date of acquisition. Moreover, on February 28,<sup style="vertical-align:super"> </sup>2023, the Company had signed a Secured Promissory Note with Cana, whereby Cana borrowed the sum of &#8364;4,100,000 ($<ix:nonFraction id="fid_8853" name="us-gaap:ProceedsFromSecuredNotesPayable" contextRef="From2023-02-01to2023-02-28_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,457,520</ix:nonFraction>), included in the total consideration of $<ix:nonFraction id="fid_8852" name="us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets" contextRef="From2023-02-01to2023-02-28_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,469,787</ix:nonFraction>. The Company accounted for the acquisition as a business acquisition in accordance with ASC 805. The fair value of Cana assets acquired, and liabilities assumed was based upon management&#8217;s estimates assisted by an independent third-party valuation firm. The fixed assets of Cana (which included land, building &amp; machinery) were valued as of December 31, 2022 and the Company believes that nothing has materially changed between such date and the acquisition date (June 30, 2023). The following table summarizes the preliminary allocation of purchase price of the acquisition:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_11564" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Consideration </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8833" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2024-01-01to2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,331,120</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Fair value of common stock issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8839" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="From2024-01-01to2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">138,667</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fair value of total consideration transferred</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_8832" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2024-01-01to2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,469,787</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recognized amounts of identifiable assets acquired</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8840" name="us-gaap:Assets" contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,796,911</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8834" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">297,340</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property, plant and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8835" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,488,818</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identifiable intangible assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8836" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">562,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8837" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">3,235,233</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total identifiable net assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8841" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,910,036</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Bargain purchase gain</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_8838" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,440,249</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_9e31b2" continuedAt="cont_750851"><ix:continuation id="cont_bd872f"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the prior year period, Cana had minimal operations as it was in financial difficulties and seeking for an investor. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis of Financial Statement Presentation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6006" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Principles of Consolidation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5983" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our consolidated accounts include our accounts and the accounts of our wholly owned subsidiaries, SkyPharm S.A., Decahedron Ltd., Cosmofarm S.A., Cana Laboratories Holdings (Cyprus) Limited and ZipDoctor Inc. The Group&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;). The consolidated financial statements reflect the consolidation of all entities in which the Company has control, as determined by the ability to direct the activities that significantly affect the entities&#8217; economic performance. All significant intercompany balances and transactions have been eliminated.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Transactions in and Translations of Foreign Currency</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5984" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The functional currency for the Greek subsidiaries of the Company (CANA Laboratories, Cosmofarm S.A. and SkyPharm SA) is Euro (&#8364;) and for the UK subsidiary (Decahedron Ltd) is GBP (&#163;). ZipDoctor Inc. is a U.S. based entity. As a result, the financial statements of the subsidiaries (except for ZipDoctor Inc.) have been translated from the local currency into U.S. dollars using (i) year-end exchange rates for balance sheet accounts, and (ii) average exchange rates for the reporting period for all income statements accounts. Foreign currency translations gains and losses are reported as a separate component of the condensed consolidated statements of changes in stockholders&#8217; equity.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Use of Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5985" name="us-gaap:UseOfEstimates" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The Effects of War in the Ukraine</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5986" name="cosm:EffectsOfWarInTheUkrainePolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company and, as such, is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_750851" continuedAt="cont_a33cb2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Credit Losses</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5987" name="cosm:CreditLossesPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which amends the requirement on the measurement and recognition of expected credit losses for financial assets held. Furthermore, amendments ASU 2019-10 and ASU 2019-11 provided additional clarification for implementing ASU 2016-13. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early adoption permitted. The Company adopted the standard on January 1, 2023, and the standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. The Company is exposed to credit losses primarily through sales to its customers and the loans that it has provided. The Company assesses each customer&#8217;s/ borrower&#8217;s ability to pay, and a credit loss estimate by conducting a credit review which includes consideration of established credit rating, or an internal assessment of the customer&#8217;s creditworthiness based on an analysis of their payment history when a credit rating is not available. The Company monitors credit exposure through active review of customer balances. In accordance with ASC 326 and the Current Expected Credit Loss (CECL) framework, the Company has elected to apply the practical expedient available for its trade receivables, which are short-term in nature and do not contain a significant financing component. The Company applies a loss-rate method for calculating expected credit losses (&#8220;ECL&#8221;) on accounts receivable, based on a combination of historical experience, industry data, and adjustments for current conditions and reasonable and supportable forecasts. Receivables are grouped into four aging buckets, with loss rates applied as follows: 1% for receivables aged 0&#8211;30 days, 2% for receivables aged 31&#8211;60 days, 3% for receivables aged 61&#8211;90 days, and 5% for receivables aged over 90 days. These loss rates are based on management&#8217;s expectations, which are further supported by external benchmarks, due to the Company&#8217;s limited history of actual write-offs. The resulting provision for expected credit losses is recognized in net income and is included in &#8220;General and administrative expenses&#8221;. Receivables that are deemed uncollectible are written off against the allowance when it is determined that they are no longer recoverable.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cash and Cash Equivalents</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5988" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Accounts Receivable, net</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5989" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable, prepaid expenses and other current assets and other assets reflects the best estimate of probable losses inherent in the receivables&#8217; portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of March 31, 2025 and December 31, 2024, the Company&#8217;s allowance for doubtful accounts was $<ix:nonFraction id="fid_10906" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,658,962</ix:nonFraction> and $<ix:nonFraction id="fid_10907" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,799,219</ix:nonFraction>, respectively. Below is the summary of changes in the allowance for doubtful accounts:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_9426" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Balance as of January 1st, 2025 </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9448" name="cosm:ChangesInAllowanceForDoubtfulAccountsBeginningBalance" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,799,219</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Provisions for credit losses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9449" name="us-gaap:ProvisionForOtherCreditLosses" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Write-offs </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9450" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Foreign exchange adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9451" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">878,430</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10929" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">18,687</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Balance as of March 31, 2025</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9452" name="cosm:ChangesInAllowanceForDoubtfulAccountsEndingBalance" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,658,962</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Tax Receivables</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5990" name="cosm:TaxReceivablesPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company pays Value Added Tax (&#8220;VAT&#8221;) or similar taxes (&#8220;input VAT&#8221;), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (&#8220;output VAT&#8221;) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of March 31, 2025 and December 31, 2024, the Company had a VAT net receivable balance of $<ix:nonFraction id="fid_10908" name="us-gaap:ReceivablesNetCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">528,203</ix:nonFraction> and $<ix:nonFraction id="fid_10909" name="us-gaap:ReceivablesNetCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">534,263</ix:nonFraction> respectively, recorded in the condensed consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_a33cb2" continuedAt="cont_d43ee3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Inventory </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5991" name="us-gaap:InventoryPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company writes down inventories to net realizable value based on physical condition, expiration date, and current market conditions, as well as forecasted demand. The Company&#8217;s inventories are not highly susceptible to obsolescence. Many of the Company&#8217;s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. No significant judgments have been applied in estimating the selling price of our inventory.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Property and Equipment, net </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5992" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_9427" name="us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Estimated</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Useful Life</strong></p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="width:77%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Leasehold improvements and technical works</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:1%;"/><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_9458" name="cosm:PropertyPlantsAndEquipmentEstimatedUsefulLives" contextRef="From2025-01-01to2025-03-31_cosm_LeaseholdImprovementsAndTechnicalWorksMember">Lesser of lease term or 25 years</ix:nonNumeric></p></td><td style="width:1%;"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_9459" name="cosm:PropertyPlantAndEquipmentUsefulLifes" contextRef="From2025-01-01to2025-03-31_cosm_BuildingsMember_cosm_BottomMember" format="ixt-sec:duryear">25</ix:nonNumeric>-<ix:nonNumeric id="fid_9460" name="cosm:PropertyPlantsAndEquipmentUsefulLife" contextRef="From2025-01-01to2025-03-31_cosm_BuildingsMember_cosm_TopMember" format="ixt-sec:duryear">30</ix:nonNumeric> years</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vehicles</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_9453" name="cosm:PropertyPlantAndEquipmentUsefulLifes" contextRef="From2025-01-01to2025-03-31_us-gaap_VehiclesMember" format="ixt-sec:duryear">6</ix:nonNumeric> years</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Machinery</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_9454" name="cosm:PropertyPlantsAndEquipmentUsefulLife" contextRef="From2025-01-01to2025-03-31_cosm_MachineryMember" format="ixt-sec:duryear">20</ix:nonNumeric> years</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Furniture, fixtures and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td/><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_9455" name="cosm:PropertyPlantsAndEquipmentUsefulLife" contextRef="From2025-01-01to2025-03-31_us-gaap_FurnitureAndFixturesMember_cosm_BottomMember" format="ixt-sec:duryear">5</ix:nonNumeric>&#8211;<ix:nonNumeric id="fid_9456" name="cosm:PropertyPlantsAndEquipmentUsefulLife" contextRef="From2025-01-01to2025-03-31_us-gaap_FurnitureAndFixturesMember_cosm_TopMember" format="ixt-sec:duryear">10</ix:nonNumeric> years</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Computers and software</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td/><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_9457" name="cosm:PropertyPlantsAndEquipmentUsefulLife" contextRef="From2025-01-01to2025-03-31_us-gaap_ComputerEquipmentMember_cosm_BottomMember" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric id="fid_10931" name="cosm:PropertyPlantAndEquipmentUsefulLifes" contextRef="From2025-01-01to2025-03-31_cosm_TopMember_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td><td/></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Depreciation expense was $<ix:nonFraction id="fid_10913" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">97,539</ix:nonFraction> and $<ix:nonFraction id="fid_10914" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">112,874</ix:nonFraction> for the three months ended March 31, 2025 and 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment additions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and Equipment additions are recognized as assets when it is probable that future economic benefits associated with the asset will flow to the entity and the cost of the asset can be measured reliably. Additions are initially measured at cost, which includes all costs directly attributable to bringing the asset to its working condition and location for its intended use. This may include purchase price, freight, installation, and any directly attributable professional fees. They are capitalized if their cost exceeds a certain threshold. The threshold is determined based on materiality considerations. Costs below the threshold are typically expensed as incurred. After initial recognition, additions are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is calculated systematically over the estimated useful life of the asset. They are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying amount exceeds the recoverable amount, an impairment loss is recognized, and the carrying amount of the asset is adjusted accordingly. Borrowing costs directly attributable to the acquisition, construction, or production of qualifying assets, including Property and Equipment additions, are capitalized as part of the cost of those assets. </p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_d43ee3" continuedAt="cont_5c3404"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Intangibles, net</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_5993" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license and a useful life of 10 years for the pharmaceutical and nutraceutical products licenses included in Note 4 as &#8220;Licenses&#8221;. A useful life of 10 years is also used for the platforms included in Note 4 as &#8220;Software&#8221; and the customer bases. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset&#8217;s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2025 and December 31, 2024, no revision to the remaining amortization period of the intangible assets was made.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amortization expense was $<ix:nonFraction id="fid_10916" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">208,833</ix:nonFraction> and $<ix:nonFraction id="fid_10917" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">189,855</ix:nonFraction> for the three months ended March 31, 2025 and 2024, respectively.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Impairment of Long-Lived Assets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5994" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. For the three months ended March 31, 2025, and 2024, the Company has recorded no impairment charge.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_5c3404" continuedAt="cont_62b9f3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Equity Method Investment</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5995" name="us-gaap:EquityMethodInvestmentsPolicy" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in &#8220;Equity earnings of affiliate&#8221; in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Investments in Equity Securities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5996" name="us-gaap:InvestmentPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for sale in current operations are reported as a component of current assets on the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets on the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, investments consisted of <ix:nonFraction id="fid_10918" name="us-gaap:OtherInvestmentsAndSecuritiesAtCost" contextRef="AsOf2025-03-31_cosm_PancretaBankMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">16,666</ix:nonFraction> shares which traded at a closing price of $<ix:nonFraction id="fid_10919" name="us-gaap:SharePrice" contextRef="AsOf2025-03-31_cosm_PancretaBankMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.95</ix:nonFraction> per share or value of $<ix:nonFraction id="fid_10923" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" contextRef="From2025-01-01to2025-03-31_cosm_PancretaBankMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,749</ix:nonFraction> of National Bank of Greece. Additionally, the Company has $<ix:nonFraction id="fid_10924" name="us-gaap:EquitySecuritiesFvNiRealizedLoss" contextRef="From2025-01-01to2025-03-31_cosm_PancretaBankMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,665</ix:nonFraction> in equity securities of Pancreta Bank, which are revalued annually. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fair Value Measurement</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5997" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company applies ASC 820, Fair Value Measurements and Disclosures, (&#8220;ASC 820&#8221;), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1:&#160;Observable inputs such as quoted prices (unadjusted)&#160;in active markets for identical assets or liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2:&#160;Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3:&#160;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, ASC 825-10-25, Fair Value Option, (&#8220;ASC 825-10-25&#8221;), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our financials also included the following financial instruments as of March 31, 2025 and December 31, 2024: cash, accounts receivable, inventory, prepaid expenses, loans receivable, accounts payable, notes payable and lines of credit. Except for the loans receivable which carry fixed interest rates, the carrying value of the remaining instruments, approximates fair value due to their short-term nature.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><ix:continuation id="cont_62b9f3" continuedAt="cont_77c718"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Customer Advances</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5998" name="cosm:CustomerAdvancesPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company&#8217;s products. The Company records these receipts as current liabilities until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer&#160;advances balance and credit the Company&#8217;s revenues.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Revenue Recognition</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_7889" name="us-gaap:RevenueRecognitionDeferredRevenue" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 606,&#160;<em>Revenue from Contracts with Customers</em>&#160;(&#8220;ASC 606&#8221;), the Company uses a five-step model for recognizing revenue by applying the following steps: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identification of the Contract: The Company identifies a contract with a customer when it enters into an agreement that creates enforceable rights and obligations.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identification of Performance Obligations: The Company identifies distinct performance obligations within each contract, which represent promises to transfer goods or services to the customer.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Determination of Transaction Price: The Company determines the transaction price, which represents the amount of consideration to which it expects to be entitled in exchange for transferring promised goods or services to the customer, excluding any amounts collected on behalf of third parties.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Allocation of Transaction Price: The Company allocates the transaction price to each distinct performance obligation based on its standalone selling price. If the standalone selling price is not observable, the Company estimates it using an appropriate method.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Recognition of Revenue: Revenue is recognized when (or as) the Company satisfies a performance obligation by transferring a promised good or service to the customer. This typically occurs at a point in time or over time, depending on the nature of the performance obligation.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Wholesale revenue and sales of own branded nutraceutical and pharmaceutical products</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has contracts or signed partnership forms (usual in the wholesale sector of the pharma industry) with its customers, stipulating the enforceable rights and obligations. The Company is responsible for transferring the goods to the customer&#8217;s location, which represents its sole performance obligation. Thus, the transaction price, which is predetermined in most of the products sold, is exclusively allocated to this performance obligation. Revenue is recognized at a single point in time, which is upon issuance of the corresponding sales invoice. The Company has assessed the impact of the items invoiced but not delivered to the customer&#8217;s location as of March 31, 2025 and December 31, 2024 and deemed that it had no material effect. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Pharma manufacturing</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has active contracts with its customers, stipulating the enforceable rights and obligations. The Company is responsible for the manufacturing and the packaging of specific products assigned by its customers, which represents its performance obligations to which the Company allocates the transaction price determined. The customers are responsible for providing the raw materials to the Company. Revenue is recognized over a period of time, which is during the production and packaging period of the respective products. As of March 31, 2025 and 2024&#160;&#160;there were no products or batches of products for which the production or packaging phase was in progress. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Medihelm SA </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective January 1, 2023, and pursuant to the distribution agreement with Medihelm SA (&#8220;Medihelm&#8221;), the exclusive distributor of the Company&#8217;s proprietary line of nutraceutical products, the Company determined that the transaction price for sales to Medihelm was variable in nature. In accordance with ASC 606, <em>Revenue from Contracts with Customers</em>, and specifically ASC 606-10-32-5, the Company applied the &#8220;expected value&#8221; method to estimate the transaction price, subject to the constraint on variable consideration. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This approach was necessitated by the existence of significant overdue receivables from Medihelm, which raised substantial doubt regarding full collectability of the contractual amounts. The Company reassessed the estimate of the transaction price at each reporting date, considering changes in facts and circumstances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There was no impact on revenue recognition for the three-month period ended March 31, 2025 and no further adjustments to variable consideration were necessary.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_77c718" continuedAt="cont_3aacf6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stock-based Compensation</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5999" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (&#8220;ASC 718&#8221;) and Staff Accounting Bulletin No. 107 (&#8220;SAB 107&#8221;) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, &#8220;Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.&#8221;</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Income Taxes</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6000" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is <ix:nonFraction id="fid_11192" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-01-01to2025-03-31_cosm_GreeceMember" unitRef="Pure" decimals="INF" scale="-2">22</ix:nonFraction>% in Greece and <ix:nonFraction id="fid_10926" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-01-01to2025-03-31_cosm_UnitedKingdomMember" unitRef="Pure" decimals="INF" scale="-2">25</ix:nonFraction>% in the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At March 31, 2025, we believe our United Kingdom and Greece deferred tax assets will not be realized, as such, we did not record a reversal on the full valuation approach we followed during the year ended December 31, 2024.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Leases</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6001" name="us-gaap:LessorLeasesPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for leases in accordance with ASC 842. For all leases, the Company recognizes a right-of-use (ROU) asset and a lease liability on the balance sheet. The ROU asset represents the Company's right to use the underlying asset for the lease term, and the lease liability represents the obligation to make lease payments arising from the lease, both measured at the present value of future lease payments. Lease payments are recognized as an operating expense on a straight-line basis over the lease term. The interest on the lease liability and the amortization of the ROU asset are recognized separately in the income statement. Initial direct costs incurred by the Company in negotiating and securing leases are capitalized and amortized over the lease term on a straight-line basis. The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company&#8217;s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company&#8217;s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt on the date of inception.&#160;</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_3aacf6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Retirement and Termination Benefits</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6002" name="us-gaap:PostemploymentBenefitPlansPolicy" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee&#8217;s work experience and remuneration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of March 31, 2025 and December 31, 2024, was $<ix:nonFraction id="fid_10927" name="us-gaap:OtherLiabilities" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">398,838</ix:nonFraction> and $<ix:nonFraction id="fid_10928" name="us-gaap:OtherLiabilities" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">377,264</ix:nonFraction>, respectively, and has been recorded as a long-term liability within the consolidated balance sheets (&#8220;Other liabilities&#8221;). The Company engaged an actuarial expert for the first time, during the period ended December 31, 2023. Management did not engage an actuarial expert since then, since there were no circumstances indicating that there would be a significant change to the liability recorded and thus the movement compared to 2023, solely relates to the foreign exchange effect.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basic and Diluted Net Loss per Common Share</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6003" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic income per share is calculated by dividing the income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_9430" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average number of common shares outstanding Basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10933" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">26,037,608</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10932" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">16,851,747</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Potentially dilutive common stock equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average number of common and equivalent shares outstanding &#8211; Diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10937" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">26,037,608</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10939" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">16,851,747</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes potential common shares that were excluded as their effect is anti-dilutive:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_9429" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9488" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,926,506</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9487" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">8,558,380</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9492" name="cosm:PotentialCommonShares" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,926,506</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9491" name="cosm:PotentialCommonShares" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">8,558,380</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recent Accounting Pronouncements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6004" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no new material accounting standards issued in the first fiscal quarter of 2025.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><ix:nonNumeric id="fid_5965" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 3 &#8211; EQUITY METHOD INVESTMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>CosmoFarmacy LP</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a&#160;<ix:nonNumeric id="fid_10952" name="cosm:MaturityPeriodOfLicense" contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember" format="ixt-sec:duryear">30</ix:nonNumeric>-year term through May 31, 2049. The unaffiliated third party is the general partner (the &#8220;GP&#8221;) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR&#160;<ix:nonFraction id="fid_10949" name="cosm:InitialShareCapital" contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember" format="ixt:numdotdecimal" unitRef="EUR" decimals="0">150,000</ix:nonFraction>&#160;($163,080) which was later increased to EUR&#160;<ix:nonFraction id="fid_10950" name="cosm:InitialShareCapitalIncreased" contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember" format="ixt:numdotdecimal" unitRef="EUR" decimals="0">500,000</ix:nonFraction>&#160;($543,600). The GP contributed the pharmacy license (the &#8220;License&#8221;) valued at EUR&#160;<ix:nonFraction id="fid_10951" name="cosm:PharmacyLicenseValue" contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember" format="ixt:numdotdecimal" unitRef="EUR" decimals="0">350,000</ix:nonFraction>&#160;(30-year term) to operate the business of CosmoFarmacy in exchange for a&#160;<ix:nonFraction id="fid_10953" name="cosm:EquityMethodInvestmentsOwnershipPercentage" contextRef="AsOf2024-09-30_cosm_CosmoFarmacyLPMember" unitRef="Pure" decimals="INF" scale="-2">70</ix:nonFraction>% equity ownership. The Company is a limited partner and contributed cash of EUR&#160;<ix:nonFraction id="fid_10954" name="cosm:CashContributedToLimitedPartner" contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember" format="ixt:numdotdecimal" unitRef="EUR" decimals="0">150,000</ix:nonFraction>&#160;($163,080) for the remaining&#160;<ix:nonFraction id="fid_10955" name="cosm:EquityMethodInvestmentOwnershipRemainingPercentage" contextRef="AsOf2024-09-30_cosm_CosmoFarmacyLPMember" unitRef="Pure" decimals="INF" scale="-2">30</ix:nonFraction>% equity ownership. CosmoFarmacy is not publicly traded, and the Company&#8217;s investment has been recorded using the equity method of accounting. &#160;During the 12-month period ended December 31, 2024, the Company determined that its investment in CosmoFarmacy LP was fully impaired. As the entity is currently dormant and has not published or provided any financial statements, whether audited or unaudited, to substantiate the carrying value of the investment, management concluded that there was no reasonable expectation of recovery. Accordingly, the Company recognized a full impairment loss on the investment, writing off its entire carrying amount. As a result, the Company has determined that the investment no longer holds any recoverable value. The value of the investment as of March 31, 2025 and December 31, 2024, was $<ix:nonFraction id="fid_10962" name="us-gaap:Investments" contextRef="AsOf2025-03-31_cosm_ShareExchangeAgreementMember_cosm_IccMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction>.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5966" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 4 &#8211; PROPERTY AND EQUIPMENT, NET </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and equipment, net consists of the following at March 31, 2025 and December 31, 2024:&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6009" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Land</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8902" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_us-gaap_LandMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,465,629</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8903" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LandMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,322,780</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Buildings and improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8904" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_us-gaap_BuildingImprovementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,713,642</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8905" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_BuildingImprovementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,526,432</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8888" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,552</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8889" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,405</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vehicles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8890" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_us-gaap_VehiclesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">277,896</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8891" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_VehiclesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">265,261</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture, fixtures and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8892" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,973,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8893" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,846,657</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8901" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,434,100</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8900" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,964,535</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8896" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,418,032</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8897" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,275,030</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8898" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,016,068</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8899" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,689,505</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5967" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE&#160;5 &#8211; INTANGIBLE ASSETS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Goodwill and intangible, net assets consist of the following at March 31, 2025 and December 31, 2024: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6010" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">License</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8908" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2025-03-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,585,857</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8909" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,257,938</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Trade name / mark</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8910" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2025-03-31_cosm_TradeNameMarkMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">392,197</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8911" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_cosm_TradeNameMarkMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">390,188</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer base</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8912" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2025-03-31_us-gaap_CustomerListsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">626,397</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8913" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_us-gaap_CustomerListsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">626,397</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8926" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2025-03-31_cosm_SoftwareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,053,554</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8927" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_cosm_SoftwareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,113,840</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8930" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,658,005</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8931" name="us-gaap:OtherFiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,388,363</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated amortization &amp; impairment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">License</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8920" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2025-03-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,311,124</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8921" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,117,341</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Trade name / mark</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8922" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2025-03-31_cosm_TradeNameMarkMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">36,997</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8923" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_cosm_TradeNameMarkMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">36,997</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer base</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8924" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2025-03-31_us-gaap_CustomerListsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">189,526</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8925" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_CustomerListsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">174,279</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8928" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2025-03-31_cosm_SoftwareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">367,526</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8929" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_cosm_SoftwareMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">352,909</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Subtotal</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8914" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,752,832</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8915" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,706,837</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Goodwill</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8916" name="us-gaap:Goodwill" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">49,697</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8917" name="us-gaap:Goodwill" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">49,697</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8918" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,802,529</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8919" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,756,534</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At March 31, 2025, the estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal years is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6011" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8932" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">881,066</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8933" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">877,344</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8934" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">879,895</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8935" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">878,532</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8936" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">871,974</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8937" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,008,821</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8938" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,397,632</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_5968" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 6 &#8211; LOAN RECEIVABLE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 30, 2021, the Company entered into an agreement for a ten-year loan with Medihelm SA to memorialize &#8364;4,284,521 ($<ix:nonFraction id="fid_9539" name="us-gaap:PaymentsOfLoanCosts" contextRef="From2021-10-01to2021-10-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,849,221</ix:nonFraction>) in prepayments the Company had made. The prepayments to Medihelm SA had been made in accordance with the parallel export business, through which Medihelm supplied and would supply SkyPharm SA with branded pharmaceuticals. This business is no longer in place for the Company and thus the Company entered into this agreement with Medihelm SA in order for the outstanding amount to be settled. Interest is calculated at a rate of <ix:nonFraction id="fid_9540" name="us-gaap:ShortTermDebtInterestRateIncrease" contextRef="From2021-10-01to2021-10-30" unitRef="Pure" decimals="INF" scale="-2">5.5</ix:nonFraction>% per annum on a <ix:nonNumeric id="fid_9544" name="cosm:ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable" contextRef="From2021-10-01to2021-10-30" format="ixt-sec:duryear">360</ix:nonNumeric>-day basis. Under the terms of the agreement, <ix:nonNumeric id="fid_9545" name="cosm:DecriptionOfLoanPayment" contextRef="From2021-10-01to2021-10-30">the Company is to receive 120 equal payments over the term of the loan</ix:nonNumeric>. During the three-month period ended March 31, 2025, the Company accrued interest income of &#8364;43,179 ($<ix:nonFraction id="fid_10964" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">45,472</ix:nonFraction>) in connection with the note receivable governed by this agreement. No principal or interest payments were received during the period. The Note is considered fully recoverable as of March 31, 2025.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5969" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 7 &#8211; INCOME TAXES </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company had no U.S. taxable income for the three months ended March 31, 2025, and 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s Greek subsidiaries are governed by the income tax laws of Greece. The corporate tax rate in Greece is <ix:nonFraction id="fid_10965" name="cosm:CorporateTaxRate" contextRef="From2025-01-01to2025-03-31_cosm_GreeceMember" unitRef="Pure" decimals="INF" scale="-2">22</ix:nonFraction>% on income reported in the statutory financial statements after appropriate tax adjustments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s United Kingdom subsidiaries are governed by the income tax laws of the United Kingdom. The corporate tax rate in the United Kingdom is <ix:nonFraction id="fid_10966" name="cosm:CorporateTaxRate" contextRef="From2025-01-01to2025-03-31_cosm_UnitedKingdomMember" unitRef="Pure" decimals="INF" scale="-2">25</ix:nonFraction>% on income reported in the statutory financial statements after appropriate tax adjustments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, and 2024, the Company&#8217;s effective tax rate differs from the U.S. federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in in the United States and the United Kingdom. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. As of March 31, 2025, and December 31, 2024, the Company has maintained a valuation allowance against all net deferred tax assets in the United States, Greece, and the UK.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended March 31, 2025, and 2024, the Company has not recorded any tax benefits/expenses in any jurisdiction where it is subject to income tax.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5970" name="cosm:CapitalStructureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_4ff67b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE&#160;8 &#8211; CAPITAL STRUCTURE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Preferred Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is authorized to issue <ix:nonFraction id="fid_10968" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="-6" scale="6">100</ix:nonFraction> million shares of preferred stock, of which <ix:nonFraction id="fid_11021" name="cosm:PreferredStockLiquidationPreference1" contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">6,000,000</ix:nonFraction> are designated as Series A convertible preferred stock. The preferred stock has a&#160;liquidation preference over the common stock and&#160;is non-voting. As of March 31, 2025 and December 31, 2024, no preferred shares were issued and outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Treasury stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 and December 31, 2024, the Company held <ix:nonFraction id="fid_10989" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31_cosm_TreasuryStocksOneMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">86,497</ix:nonFraction> and <ix:nonFraction id="fid_10990" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31_cosm_TreasuryStocksOneMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">86,497</ix:nonFraction>, respectively, shares of our common stock at a cost of $<ix:nonFraction id="fid_11003" name="cosm:CommonStockSharesValue" contextRef="AsOf2025-03-31_cosm_TreasuryStocksOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">917,159</ix:nonFraction> and $<ix:nonFraction id="fid_11004" name="cosm:CommonStockSharesValue" contextRef="AsOf2024-12-31_cosm_TreasuryStocksOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">917,159</ix:nonFraction>, respectively. Shares of our common stock that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. The Company repurchased no shares of our common stock during the three months ended March 31, 2025. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_4ff67b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 24, 2023 the Company announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $<ix:nonFraction id="fid_10999" name="cosm:AuthorizationToRepurchaseCommonStock" contextRef="From2023-01-01to2023-01-24_cosm_TreasuryStocksOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">3</ix:nonFraction> million of its common stock. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is authorized to issue <ix:nonFraction id="fid_10985" name="cosm:CommonStockShareAuthorized" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="-6" scale="6">300</ix:nonFraction> million shares of common stock. As of March 31, 2025 and December 31, 2024, the Company had <ix:nonFraction id="fid_10987" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">27,284,633</ix:nonFraction> and <ix:nonFraction id="fid_10988" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">23,689,135</ix:nonFraction> shares of our common stock issued, respectively, and <ix:nonFraction id="fid_11014" name="cosm:CommonStocksSharesOutstanding" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">27,198,136</ix:nonFraction> and <ix:nonFraction id="fid_11015" name="cosm:CommonStocksSharesOutstanding" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">23,602,638</ix:nonFraction> shares outstanding, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Issuance of Common Stock</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Between January 13, 2025, and March 4, 2025, the Company issued an aggregate of <ix:nonFraction id="fid_11194" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-04_cosm_WarrantExchangeMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,053,372</ix:nonFraction> shares of common stock to Mr. Grigorios Siokas, the Company&#8217;s Chief Executive Officer, in settlement of outstanding obligations totalling $<ix:nonFraction id="fid_11026" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-09-01to2024-09-26_cosm_WarrantInducementLetterMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">649,000</ix:nonFraction>. The liabilities settled pertained to unpaid salaries and performance-related bonuses previously accrued by the Company and owed to Mr. Siokas. The shares were issued at the respective fair market value of the Company&#8217;s common stock on the dates of issuance. The transaction was accounted for as a non-cash settlement of related party debt.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 26, 2024, the Company had entered into a Warrant Inducement Letter (the &#8220;Letter&#8221;) with an investor pursuant to which the Company issued <ix:nonFraction id="fid_11006" name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2024-09-26_cosm_WarrantInducementLetterMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">9,748,252</ix:nonFraction> new warrants (the &#8220;New Warrants&#8221;) and reduced the exercise price of <ix:nonFraction id="fid_11009" name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2024-09-26_cosm_WarrantExchangeMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,874,126</ix:nonFraction> warrant shares from $<ix:nonFraction id="fid_11012" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-26_cosm_WarrantExchangeMember_cosm_TopMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.45</ix:nonFraction> to $<ix:nonFraction id="fid_11013" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-26_cosm_WarrantExchangeMember_cosm_BottomMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.8701</ix:nonFraction> to induce exercise and receive gross cash proceeds of $<ix:nonFraction id="fid_11028" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-09-01to2024-09-26_cosm_WarrantExchangeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,240,977</ix:nonFraction> (the &#8220;Original Warrants&#8221;). Of the <ix:nonFraction id="fid_11031" name="cosm:OriginalWarrantsSharesIssued" contextRef="From2024-09-01to2024-09-26" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">9,748,252</ix:nonFraction> warrants <ix:nonFraction id="fid_11195" name="cosm:OriginalWarrantsSharesIssued" contextRef="From2024-09-01to2024-09-26_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,874,126</ix:nonFraction> of them have a term of <ix:nonNumeric id="fid_11036" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="From2024-09-01to2024-09-26_cosm_WarrantExchangeMember" format="ixt-sec:duryear">5</ix:nonNumeric> years (&#8220;Series A Warrants&#8221;) and the remaining <ix:nonFraction id="fid_11196" name="cosm:RemainingWarrantsSharesIssued" contextRef="From2024-09-01to2024-09-26" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,874,126</ix:nonFraction> have a term of <ix:nonNumeric id="fid_11037" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="From2024-09-01to2024-09-26" format="ixt-sec:duryear">1.5</ix:nonNumeric> years (&#8220;Series B Warrants&#8221;). The Company issued <ix:nonFraction id="fid_10983" name="cosm:CommonStocksSharesIssued" contextRef="AsOf2024-09-26" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,332,000</ix:nonFraction> shares of common stock, held <ix:nonFraction id="fid_11033" name="cosm:SharesHeldInEscrow" contextRef="From2024-09-01to2024-09-26_cosm_WarrantExchangeMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,542,126</ix:nonFraction> shares in escrow until the investor&#8217;s beneficial ownership limitation allows for the transfer of the escrow shares. The <ix:nonFraction id="fid_11040" name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2025-01-28_cosm_WarrantInducementLetterMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,542,126</ix:nonFraction> shares were issued on January 28, 2025, but were already valued in the year ended December 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Warrant Classification</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company determines the classification of its warrants upon issuance by identifying the instrument issued to determine if it is debt or equity classified. The Company determined its warrants meet the scope exception in ASC 815-10 and are equity classified because, (a) the warrant is indexed to the Company&#8217;s own stock, (b) require settlement in equity shares, and (c) the Company has enough authorized and unissued shares.&#160;</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5971" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_cfdcf5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 9 &#8211; RELATED PARTY TRANSACTIONS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Doc Pharma S.A.</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Doc Pharma S.A. is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the son of Grigorios Siokas, the Company&#8217;s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_cfdcf5" continuedAt="cont_c36a9f"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Prepaid expenses and other current assets &#8211; related party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 and December 31, 2024, the Company had a prepaid balance of $<ix:nonFraction id="fid_10458" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,549,574</ix:nonFraction> and $<ix:nonFraction id="fid_10457" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,284,052</ix:nonFraction>, respectively, to Doc Pharma. For the year ended March 31, 2025 the prepayment of approximately $<ix:nonFraction id="fid_11045" name="cosm:PrepaymentOfInventory" contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.9</ix:nonFraction> million relates to purchases of inventory pursuant to the CMO agreement signed between the Company and Doc Pharma SA on October 10, 2020, $310k concern the purchase of pharmaceutical and nutraceutical licenses according to the May 17, 2021 R&amp;D agreement and the remaining $<ix:nonFraction id="fid_11046" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-3" scale="3">378</ix:nonFraction>k relate to the current portion of the Royalty Agreement signed on December 31, 2024 between the and DocPharma SA (refer to &#8220;Research and Development&#8221; section of the MD&amp;A). The non-current portion of the Royalty Agreement of $<ix:nonFraction id="fid_11047" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,889,300</ix:nonFraction> is included in &#8220;Other Assets &#8211; Related Party&#8221; in the Company&#8217;s Consolidated Balance Sheets as of March 31, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accounts payable and accrued expenses - related party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 and December 31, 2024, the Company had an accounts payable balance to Doc Pharma of $<ix:nonFraction id="fid_10450" name="cosm:AccountsPayableRelatedPartyCurrent" contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">345,702</ix:nonFraction>&#160;and $<ix:nonFraction id="fid_10449" name="cosm:AccountsPayableRelatedPartyCurrent" contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">249,768</ix:nonFraction>, respectively. The March 31, 2025 balance mostly concerns a checks payable balance that our subsidiary, Skypharm SA, owes to Doc Pharma SA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accounts receivable - related party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, the Company had a receivable balance of $<ix:nonFraction id="fid_10454" name="cosm:AmountAccountsReceivableRelatedParties" contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,469,234</ix:nonFraction>&#160;and $<ix:nonFraction id="fid_10453" name="cosm:AmountAccountsReceivableRelatedParties" contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,295,706</ix:nonFraction>&#160;from Doc Pharma S.A. as of March 31, 2025 and December 31, 2024, respectively, which concerns trading receivables balances with the Company&#8217;s Greek and UK subsidiaries. As of March 31, 2025, a cumulative allowance for doubtful accounts of approximately $<ix:nonFraction id="fid_11048" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.4</ix:nonFraction> million has been recognized, effectively offsetting this balance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Sales and Purchases</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended March 31, 2025 and 2024, the Company purchased a total of $<ix:nonFraction id="fid_11049" name="cosm:PurchaseOfInventory" contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">300,208</ix:nonFraction> and $<ix:nonFraction id="fid_11051" name="cosm:PurchaseOfInventory" contextRef="From2024-01-01to2024-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">189,048</ix:nonFraction>&#160;of products from Doc Pharma S.A., respectively. During the three months ended March 31, 2025, and 2024, the Company sold&#160; $<ix:nonFraction id="fid_11052" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">130,362</ix:nonFraction> and $<ix:nonFraction id="fid_11053" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">384,321</ix:nonFraction>&#160;of products to Doc Pharma, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Other Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 10, 2020, the Company entered into a contract manufacturer outsourcing (&#8220;CMO&#8221;) agreement with Doc Pharma whereby Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company&#8217;s specifications based on strict pharmaceutical standards and good manufacturing practice (&#8220;GMP&#8221;) protocols as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named &#8220;Sky Premium Life<sup style="vertical-align:super">&#174;</sup>&#8221;. The duration of the agreement is for five years, however, either party may terminate the agreement at any time giving six-month advance notice. Doc Pharma is exclusively responsible for supplying the raw materials and packaging required to manufacture the final product. However, it is not responsible for potential delays that may arise, concerning their import. Doc Pharma is also obligated to store the raw and packaging materials. The delivery of raw and packaging materials should be purchased at least 30 and 25 days, respectively, before the delivery date of the final product. The Manufacturer solely delivers the finished product to the Company. There is a minimum order quantity (&#8220;MoQ&#8221;) of&#160;<ix:nonNumeric id="fid_11054" name="cosm:PiecesPerProduct" contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember">1,000 pieces</ix:nonNumeric>&#160;per product code. Both parties have agreed that the Company will deposit 60% of the total cost upon agreement and assignment and 40% of the total cost including VAT charge upon the delivery date. The prices are indicative and are subject to amendments if the cost of the raw material or the production cost change.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended March 31, 2025 and 2024, the Company has purchased &#8364;208,568 ($<ix:nonFraction id="fid_11055" name="cosm:PurchaseOfInventory" contextRef="From2025-01-01to2025-03-31_cosm_InventoriesRelatedAgreementMember_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">219,645</ix:nonFraction>) and &#8364;65,161 ($<ix:nonFraction id="fid_11056" name="cosm:PurchaseOfInventory" contextRef="From2024-01-01to2024-03-31_cosm_InventoriesRelatedAgreementMember_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">68,621</ix:nonFraction>) respectively, in inventory related to this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 17, 2021, Doc Pharma and the Company entered into a Research and Development (&#8220;R&amp;D&#8221;) agreement whereby Doc Pharma will be responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life<sup style="vertical-align:super">&#174;</sup>. These products will be sold in Greece and abroad.&#160;<ix:nonNumeric id="fid_10476" name="us-gaap:ManagementFeeDescription" contextRef="From2021-05-01to2021-05-17_cosm_DocPharmaSaMember">The total cost of this project will be &#8364;1,425,000 plus VAT and will be done over three phases as follows: Design &amp; Development (&#8364;725,000); Control and Product Manufacturing (&#8364;250,000) and Clinical Study and Research (&#8364;450,000). SkyPharm has bought a total of as of 81 licenses at value of &#8364;554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022</ix:nonNumeric>. During the year ended December 31, 2023, 24 additional licenses were purchased at value of &#8364;475,014 ($<ix:nonFraction id="fid_10463" name="us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases" contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">525,461</ix:nonFraction>) and during the year ended December 31, 2024, 60 additional Sky Premium Life licenses were purchased for &#8364;710,000 ($<ix:nonFraction id="fid_10483" name="us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases" contextRef="From2023-01-01to2023-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">734,921</ix:nonFraction>). During the three months ended March 31, 2025, no additional licenses were purchased. The agreement will terminate on&#160;<ix:nonNumeric id="fid_10461" name="cosm:AgreementTerminate" contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember" format="ixt:datemonthdayyearen">December 31, 2025</ix:nonNumeric>.&#160;&#160;</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_c36a9f" continuedAt="cont_c0e6a2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Purchase of branded pharmaceuticals</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2023, the Company approved the purchase of five proprietary and innovative branded pharmaceuticals with significant market presence and material profit contribution from Zakalia Ltd., the parent company of Doc Pharma, for &#8364;1,800,000 ($<ix:nonFraction id="fid_10474" name="cosm:PurchaseOfPharmaceuticalsMedicine" contextRef="From2023-06-01to2023-06-28_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,965,600</ix:nonFraction>). The transaction was settled on a non-cash basis through the reduction, of an equivalent amount, of prepaid expense balances the Company held with Doc Pharma. The purchased branded pharmaceuticals are presented in &#8220;Goodwill and intangible assets, net&#8221; on the accompanying consolidated balance sheets. During the year ended December 31, 2024, the Company recognized an impairment charge of $<ix:nonFraction id="fid_10485" name="us-gaap:AssetImpairmentCharges" contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">160,947</ix:nonFraction> related to two licenses that are no longer expected to be commercialized. The impairment was recorded after management&#8217;s assessment determined that the recoverability of these assets was no longer supportable due to changes in market conditions and strategic priorities. No additional impairment charge was recorded within the three-month period ended March 31, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 29, 2023, the Company approved the purchase of additional 19 generic licenses from Doc Pharma, of a total value of &#8364;3,200,000 ($<ix:nonFraction id="fid_10475" name="cosm:PurchaseOfPharmaceuticalsMedicine" contextRef="From2023-12-01to2023-12-29_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,539,840</ix:nonFraction>). This transaction was also settled on a non-cash basis through the reduction, of an equivalent amount, of prepaid expense balances the Company held with Doc Pharma.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Loans receivable - related party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The balance of prepaid expenses due Doc Pharma as of December 31, 2022, had increased to &#8364;7,103,706 ($<ix:nonFraction id="fid_10486" name="us-gaap:OtherExpenses" contextRef="From2022-01-01to2022-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,599,545</ix:nonFraction>), which was mainly attributable to the prepayments SkyPharm S.A. made in accordance with the CMO agreement and the extensive orders and sales of the SPL products the Company expected to achieve within 2023, mainly through its Amazon channels in the UK, Singapore, Canada and other countries. However, as the benefit from a significant portion of the prepaid balance would not have been realized within a 12-month period, the Company opted to secure a portion of the outstanding prepaid balance through a loan agreement. SkyPharm S.A. (the &#8220;Lender&#8221;) entered into a loan agreement with Doc Pharma (the &#8220;Borrower&#8221;) for &#8364;4,000,000 ($<ix:nonFraction id="fid_10452" name="us-gaap:PrepaidInterest" contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,279,200</ix:nonFraction>), all of which was financed through the outstanding prepaid balance. The duration of the loan is for a&#160;<ix:nonNumeric id="fid_10447" name="us-gaap:DebtInstrumentTerm" contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember" format="ixt-sec:duryear">10</ix:nonNumeric>-year period up to&#160;<ix:nonNumeric id="fid_10448" name="us-gaap:DebtInstrumentMaturityDate" contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember" format="ixt:datemonthdayyearen">December 31, 2032</ix:nonNumeric>&#160;(the &#8220;Maturity Date&#8221;). The loan bears a fixed interest rate of&#160;<ix:nonFraction id="fid_10446" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember" unitRef="Pure" decimals="INF" scale="-2">5.5</ix:nonFraction>% payable on a monthly basis and will be repayable in 120 equal instalments of &#8364;33,333.33 ($<ix:nonFraction id="fid_10477" name="cosm:PaymentReceivedFromInstallment" contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">37,150</ix:nonFraction>). The loan may be prepaid anytime during its duration in full or partially based on the Company&#8217;s product requirements and other factors, without Doc Pharma incurring any prepayment penalty. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 and December 31, 2024, the loan had a current portion of &#8364;712,200 ($<ix:nonFraction id="fid_11058" name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">768,891</ix:nonFraction>) and &#8364;500,000 ($<ix:nonFraction id="fid_11059" name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">517,550</ix:nonFraction>), and a non-current portion of &#8364;2,663,379 ($<ix:nonFraction id="fid_11060" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,875,384</ix:nonFraction>), and &#8364;2,800,000 ($<ix:nonFraction id="fid_11061" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,898,280</ix:nonFraction>), respectively, which is classified as &#8220;Loans receivable &#8211; related party&#8221; on the accompanying consolidated balance sheets. During the three-month period ended March 31, 2025, the Company received no principal repayments or interest repayments. Additionally, during the three months ended ended March 31, 2025 and 2024, the Company recorded &#8364;43,179 ($<ix:nonFraction id="fid_11063" name="us-gaap:InterestIncomeOther" contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">45,472</ix:nonFraction>) and &#8364;49,041 ($<ix:nonFraction id="fid_11064" name="us-gaap:InterestIncomeOther" contextRef="From2024-01-01to2024-03-31_cosm_DocPharmaSaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,235</ix:nonFraction>) as interest income relating to this loan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Cana Laboratories Holding Limited&#160;</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cana was considered a related party as the Company had signed a binding letter of intent and an SPA for the acquisition of Cana. The acquisition was completed on June 30, 2023 according to the SPA signed on May 31, 2023. Thus, all balances between the Company and Cana were eliminated upon consolidation as of December 31, 2023. The Secured Promissory Note discussed below was included in consideration transferred upon acquisition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Loans receivable - Related Party - Long Term</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 28,<sup style="vertical-align:super">&#160;</sup>2023 (Issue Date), the Company signed a Secured Promissory Note with Cana Laboratories Holdings (Cyprus) Limited (the &#8220;Holder&#8221;), whereby the Holder borrowed the sum of &#8364;4,100,000 ($<ix:nonFraction id="fid_10428" name="us-gaap:ProceedsFromSecuredNotesPayable" contextRef="From2023-02-01to2023-02-28_cosm_CanaHoldingsLaboratoriesHoldingLimitedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,457,520</ix:nonFraction>) from the Company.&#160;<ix:nonNumeric id="fid_10429" name="cosm:DescriptionInterestOfSecuredPromissoryNote" contextRef="From2023-02-01to2023-02-28_cosm_CanaHoldingsLaboratoriesHoldingLimitedMember">Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023)</ix:nonNumeric>. The maturity date (&#8220;Maturity Date&#8221;) of this Note shall be five (5) years from the Issue Date. The Principal Amount, as well as all accrued interest shall be due and payable on the Maturity Date. Following the completion of Cana&#8217;s acquisition on June 30, 2023 the balance of the Note was eliminated on a consolidated level.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_c0e6a2" continuedAt="cont_dbe449"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Panagiotis Kozaris</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Panagiotis Kozaris is considered a related party due to the fact that he is a former General operational manager and current employee of Cosmofarm S.A.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Prepaid Expenses and Other Current Assets - Related Party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time-to-time the Company purchases back shares that Panagiotis Kozaris owns and records them as treasury shares. The Company pays Panagiotis Kozaris in advance for the shares owned and obtains the shares upon execution of a cumulative stock-purchase agreement (&#8220;SPA&#8221;). During the years ended December 31, 2023 and 2022, the Company paid Panagiotis Kozaris an additional sum of $<ix:nonFraction id="fid_10488" name="cosm:SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" contextRef="From2023-01-01to2023-12-31_cosm_PanagiotisKozarisMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">51,159</ix:nonFraction>&#160;and $<ix:nonFraction id="fid_10489" name="cosm:SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" contextRef="From2022-01-01to2022-12-31_cosm_PanagiotisKozarisMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">143,056</ix:nonFraction>&#160;respectively for shares owned, however, no SPA for these funds has been executed as of December 31, 2024. The Company intends to execute a cumulative SPA for these amounts within 2025. The total balances owed of $<ix:nonFraction id="fid_10442" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2024-12-31_cosm_PanagiotisKozarisMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">194,215</ix:nonFraction>&#160;and $<ix:nonFraction id="fid_10443" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2025-03-31_cosm_PanagiotisKozarisMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">194,215</ix:nonFraction> are included in &#8220;Prepaid expenses and other current assets - related party&#8221;, on the accompanying consolidated balance sheets as of March 31, 2025 and December 31, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Basotho Investment Limited</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basotho Investment Limited is considered a related party once Panagiotis Kozaris (former general operational manager and current employee of Cosmofarm SA) is one of its directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>General and administrative expenses</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 21, 2023, the Company issued <ix:nonFraction id="fid_10445" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31_cosm_BasothoInvestmentLimitedMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">120,000</ix:nonFraction> shares of common stock to Basotho Investment Limited for services rendered. The amortization of the fair value of these shares for the three-month period ended March 31, 2025 and 2024 was $<ix:nonFraction id="fid_11065" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31_cosm_BasothoInvestmentLimitedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction> and $<ix:nonFraction id="fid_11066" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-03-31_cosm_BasothoInvestmentLimitedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">30,900</ix:nonFraction>, which was recorded as general and administrative expense. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Maria Kozari</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Maria Kozari is considered a related party to the Company due to the fact that she is the daughter of Panagiotis Kozaris, a former Operational General Manager and current employee of Cosmofarm S.A.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accounts Receivable - Related Party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During 2021, the Company, through its subsidiary, Cosmofarm SA, commenced a partnership with a pharmacy called &#8220;Pharmacy &amp; More&#8221;, owned by Maria Kozari. The transactions with the respective pharmacy were in Cosmofarm&#8217;s normal course of business, however, a more flexible credit policy was allowed as the pharmacy was new and needed to be established in the market. During the three-month peirod ended March 31, 2025 and 2024 the Company&#8217;s net sales to Pharmacy &amp; More amounted to $<ix:nonFraction id="fid_11067" name="cosm:NetSales" contextRef="From2025-01-01to2025-03-31_cosm_MariaKozariMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">100,870</ix:nonFraction>&#160;and $<ix:nonFraction id="fid_11068" name="cosm:NetSales" contextRef="From2024-01-01to2024-03-31_cosm_MariaKozariMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">86,678</ix:nonFraction>, respectively. As of March 31, 2025 and December 31, 2024 the Company&#8217;s outstanding receivable balance due from the pharmacy amounted to $<ix:nonFraction id="fid_10456" name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-03-31_cosm_MariaKozariMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,188,908</ix:nonFraction> and $<ix:nonFraction id="fid_10455" name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31_cosm_MariaKozariMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,183,429</ix:nonFraction>, respectively, and are included in &#8220;Accounts receivable - related party&#8221;, on the accompanying consolidated balance sheets. As of March 31, 2025 and December 31, 2024, a cumulative allowance for doubtful accounts of approximately $<ix:nonFraction id="fid_11069" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="From2025-01-01to2025-03-31_cosm_MariaKozariMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">773,051</ix:nonFraction> and $<ix:nonFraction id="fid_10491" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="From2024-01-01to2024-12-31_cosm_MariaKozariMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">735,000</ix:nonFraction>, respectively, has been recognized, effectively offsetting this balance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company plans to acquire Pharmacy &amp; More within fiscal year 2025. Upon acquisition, the Company intends to offset the outstanding receivable balance with the corresponding purchase price and additionally plans to make Pharmacy &amp; More the&#160;first shop-in-shop of its own branded line of nutraceutical products, Sky Premium Life&#174; (SPL).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Other Related Parties</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, the Company has the following material related-party balances as of March 31, 2025: a) a balance of $<ix:nonFraction id="fid_10431" name="us-gaap:AccruedSalariesCurrentAndNoncurrent" contextRef="AsOf2025-03-31_cosm_GeorgeTerzisMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">76,865</ix:nonFraction> relating to unpaid salaries and bonuses due to Grigorios Siokas, the CEO of the Company, classified as &#8220;Accounts payable and accrued expenses - related party&#8221;&#160;in the Company&#8217;s consolidated balance sheets, b) a balance of $<ix:nonFraction id="fid_11070" name="cosm:UnpaidSalariesAndBonusesDues" contextRef="AsOf2025-03-31_cosm_GeorgeTerzisMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">168,000</ix:nonFraction>&#160;relating to unpaid salaries and bonuses due to George Terzis, the CFO of the Company, classified as &#8220;Accounts payable and accrued expenses - related party&#8221;&#160;in the Company&#8217;s consolidated balance sheets c) a balance of $<ix:nonFraction id="fid_11071" name="cosm:AccountsPayableRelatedPartyCurrent" contextRef="AsOf2025-03-31_cosm_KanarogloySiaEpeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,000</ix:nonFraction>&#160;relating to unpaid salaries and bonuses due to Nikolaos Bardakis, the COO of the Company, classified as &#8220;Accounts payable and accrued expenses - related party&#8221;&#160;in the Company&#8217;s consolidated balance sheets.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_dbe449" continuedAt="cont_61e8c7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Notes Payable &#8211; Related Party</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s related party notes payable as of March 31, 2025 and December 31, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6012" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Beginning Balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10411" name="cosm:NotesPayableRelatedParty" contextRef="AsOf2024-12-31_cosm_NotesPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,558</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10410" name="cosm:NotesPayableRelatedParty" contextRef="AsOf2023-12-31_cosm_NotesPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,283</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Payments </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10413" name="us-gaap:PaymentsForLoans" contextRef="From2025-01-01to2025-03-31_cosm_NotesPayableRelatedPartyMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10412" name="us-gaap:PaymentsForLoans" contextRef="From2024-01-01to2024-12-31_cosm_NotesPayableRelatedPartyMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10415" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-01-01to2025-03-31_cosm_NotesPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">454</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10414" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-01to2024-12-31_cosm_NotesPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">725</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ending Balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10416" name="cosm:NotesPayableRelatedParty" contextRef="AsOf2025-03-31_cosm_NotesPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,012</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10417" name="cosm:NotesPayableRelatedParty" contextRef="AsOf2024-12-31_cosm_NotesPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,558</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Dimitrios Goulielmos</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dimitris Goulielmos was the Company&#8217;s former CEO and a Director of the Company. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of March 31, 2025 and December 31, 2024, the Company had a principal balance of &#8364;10,200 ($<ix:nonFraction id="fid_10437" name="us-gaap:NotesPayable" contextRef="AsOf2025-03-31_cosm_DimitriosGoulielmosMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,012</ix:nonFraction>) and &#8364;10,200 ($<ix:nonFraction id="fid_10436" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_cosm_DimitriosGoulielmosMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,558</ix:nonFraction>), respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2025, the Company recorded a foreign currency translation loss of $<ix:nonFraction id="fid_11072" name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" contextRef="From2025-01-01to2025-03-31_cosm_DimitriosGoulielmosMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">454</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Loans Payable &#8211; Related Party</span></em><span style="text-decoration:underline"> </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s related party loans payable as of March 31, 2025 and December 31, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6013" name="cosm:ScheduleOfRelatedPartyLoansPayableTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10419" name="cosm:LoansPayableRelatedParty" contextRef="AsOf2024-12-31_cosm_LoansPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,194</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10418" name="cosm:LoansPayableRelatedParty" contextRef="AsOf2023-12-31_cosm_LoansPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,257</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10420" name="us-gaap:ProceedsFromLoans" contextRef="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10423" name="us-gaap:PaymentsForLoans" contextRef="From2025-01-01to2025-03-31_cosm_LoansPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">108,500</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10422" name="us-gaap:PaymentsForLoans" contextRef="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,210</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Set-offs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11042" name="cosm:LoanPayableSetOffs" contextRef="From2025-01-01to2025-03-31_cosm_LoansPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">102,039</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11043" name="cosm:LoanPayableSetOffs" contextRef="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10425" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-01-01to2025-03-31_cosm_LoansPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">267</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10424" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">853</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10426" name="cosm:LoansPayableRelatedParty" contextRef="AsOf2025-03-31_cosm_LoansPayableRelatedPartyMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10427" name="cosm:LoansPayableRelatedParty" contextRef="AsOf2024-12-31_cosm_LoansPayableRelatedPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,194</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_61e8c7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Grigorios Siokas</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of March 31, 2025 and December 31, 2024 the Company had an outstanding principal balance under these loans of $<ix:nonFraction id="fid_10439" name="us-gaap:NotesPayable" contextRef="AsOf2025-03-31_cosm_GrigoriosSiokasMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction> and $<ix:nonFraction id="fid_10438" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_cosm_GrigoriosSiokasMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,194</ix:nonFraction>, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2025, the Company recorded a loss of $<ix:nonFraction id="fid_11073" name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" contextRef="From2025-01-01to2025-03-31_cosm_GrigoriosSiokasMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">267</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5972" name="cosm:LineOfCreditFacilitiesDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_cc484b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 10 &#8211; LINES OF CREDIT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s lines of credit as of March 31, 2025 and December 31, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6014" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">National</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9929" name="us-gaap:LineOfCredit" contextRef="AsOf2025-03-31_cosm_NationalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,816,515</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9964" name="us-gaap:LineOfCredit" contextRef="AsOf2024-12-31_cosm_NationalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,012,642</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Alpha</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9931" name="us-gaap:LineOfCredit" contextRef="AsOf2025-03-31_cosm_AlphaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">769,867</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9965" name="us-gaap:LineOfCredit" contextRef="AsOf2024-12-31_cosm_AlphaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">960,867</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pancreta</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9933" name="us-gaap:LineOfCredit" contextRef="AsOf2025-03-31_cosm_PancretaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,437,670</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9966" name="us-gaap:LineOfCredit" contextRef="AsOf2024-12-31_cosm_PancretaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,583,291</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Attica Bank</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11078" name="us-gaap:LineOfCredit" contextRef="AsOf2025-03-31_cosm_AtticaBankMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">849,483</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11079" name="us-gaap:LineOfCredit" contextRef="AsOf2024-12-31_cosm_AtticaBankMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">EFG</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11076" name="us-gaap:LineOfCredit" contextRef="AsOf2025-03-31_cosm_EFGMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">431,840</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11077" name="us-gaap:LineOfCredit" contextRef="AsOf2024-12-31_cosm_EFGMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">428,252</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9963" name="us-gaap:LineOfCredit" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,305,376</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9962" name="us-gaap:LineOfCredit" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,985,052</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has three lines of credit with the National Bank of Greece, which are renewed annually. The three lines have interest rates of 6.00% (the "National Bank LOC"), 3.6% (the "COSME 2 Facility"), and 3.6% plus the six-month Euribor rate and any contributions currently in force by law on certain lines of credit (the "COSME 1 Facility").</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The maximum borrowing allowed for the 6% line of credit was $<ix:nonFraction id="fid_9937" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2025-03-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,398,000</ix:nonFraction> and $<ix:nonFraction id="fid_9968" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2024-12-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,175,000</ix:nonFraction> as of March 31, 2025 and December 31, 2024, respectively. The outstanding balance of the facility was $<ix:nonFraction id="fid_9947" name="cosm:OutstandingDebtBalance" contextRef="AsOf2025-03-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,975,052</ix:nonFraction> and $<ix:nonFraction id="fid_9969" name="cosm:OutstandingDebtBalance" contextRef="AsOf2024-12-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,165,058</ix:nonFraction>, as of March 31, 2025 and December 31, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The cumulative maximum borrowing allowed for the COSME 1 Facility and COSME 2 Facility (collectively, the "Facilities") was $<ix:nonFraction id="fid_9939" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2025-03-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,079,600</ix:nonFraction> and $<ix:nonFraction id="fid_9970" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2024-12-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,035,100</ix:nonFraction> as of March 31, 2025 and December 31, 2024, respectively. The outstanding balance of the Facilities was $<ix:nonFraction id="fid_9949" name="cosm:OutstandingDebtBalance" contextRef="AsOf2025-03-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">895,406</ix:nonFraction> and $<ix:nonFraction id="fid_9971" name="cosm:OutstandingDebtBalance" contextRef="AsOf2024-12-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">895,987</ix:nonFraction> as of March 31, 2025 and December 31, 2024, respectively.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains a line of credit with Alpha Bank of Greece ("Alpha LOC"), which is renewed annually and has a current interest rate of 6.00%. The maximum borrowing allowed was $<ix:nonFraction id="fid_9941" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2025-03-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,079,600</ix:nonFraction> and $<ix:nonFraction id="fid_9972" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2024-12-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,035,100</ix:nonFraction> as of March 31, 2025 and December 31, 2024, respectively. The outstanding balance of the Alpha LOC was $<ix:nonFraction id="fid_9951" name="cosm:OutstandingDebtBalance" contextRef="AsOf2025-03-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">769,868</ix:nonFraction> and $<ix:nonFraction id="fid_9973" name="cosm:OutstandingDebtBalance" contextRef="AsOf2024-12-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">960,868</ix:nonFraction>, as of March 31, 2025 and December 31, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company holds a line of credit with Pancreta Bank ("Pancreta LOC"), which is renewed annually and has a current interest rate of 4.10%. The maximum borrowing allowed as of March 31, 2025 and December 31, 2024 was $<ix:nonFraction id="fid_9943" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2025-03-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,619,400</ix:nonFraction> and $<ix:nonFraction id="fid_9974" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2024-12-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,552,650</ix:nonFraction>, respectively. The outstanding balance of the Pancreta LOC as of March 31, 2025 and December 31, 2024, was $<ix:nonFraction id="fid_9953" name="cosm:OutstandingDebtBalance" contextRef="AsOf2025-03-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,437,670</ix:nonFraction> and $<ix:nonFraction id="fid_9975" name="cosm:OutstandingDebtBalance" contextRef="AsOf2024-12-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,583,291</ix:nonFraction>, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains a line of credit with EGF ("EGF LOC"), which is renewed annually and has a current interest rate of 4.49% plus 3-month Euribor. The maximum borrowing allowed as of March 31, 2025 and December 31, 2024, was $<ix:nonFraction id="fid_9945" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2025-03-31_cosm_EFGMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">431,840</ix:nonFraction> and $<ix:nonFraction id="fid_9979" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" contextRef="AsOf2024-12-31_cosm_EFGMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">414,040</ix:nonFraction>, respectively. The outstanding balance of the EGF LOC as of March 31, 2025 and December 31, 2024 was $<ix:nonFraction id="fid_9977" name="cosm:OutstandingDebtBalance" contextRef="AsOf2025-03-31_cosm_EFGMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">431,840</ix:nonFraction> and $<ix:nonFraction id="fid_9976" name="cosm:OutstandingDebtBalance" contextRef="AsOf2024-12-31_cosm_EFGMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">428,251</ix:nonFraction>, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 27, 2025, the Company entered into a bond loan agreement with Attica Bank, <ix:nonNumeric id="fid_11082" name="cosm:LineOfCreditBorrowingsLoanDescription" contextRef="From2025-01-01to2025-01-27">providing for maximum borrowings of up to &#8364;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#8364;700,000 ($749,600), which were classified as Notes Payable in the Company&#8217;s consolidated financial statements. The remaining borrowing capacity of &#8364;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral</ix:nonNumeric>. These subsequent drawdowns are classified as Lines of Credit due to their secured and contingent nature. The facility bears interest at a floating rate of 2.95% plus the applicable 6-month Euribor, recalculated periodically in accordance with market conditions. The loan agreement includes standard covenants and collateral arrangements customary for this type of facility.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_cc484b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the aforementioned line of credit agreements, the Company is required to maintain certain financial ratios and covenants. As of March 31, 2025, and December 31, 2024, the Company was in compliance with these ratios and covenants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All lines of credit are guaranteed by customer receivable checks, which are a type of factoring in which postponed customer checks are assigned by the Company to the bank, in order to be financed at an agreed upon rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Interest expense on the Company&#8217;s outstanding lines of credit balances for the three months ended March 31, 2025 and 2024, was $<ix:nonFraction id="fid_9981" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">61,035</ix:nonFraction> and $<ix:nonFraction id="fid_9980" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">44,568</ix:nonFraction>, respectively.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5973" name="us-gaap:DebtDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_152461"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 11 &#8211; NOTES PAYABLE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s third-party debt as of and for the nine&#160;months ended March 31, 2025, and the year ended December 31, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6015" name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_28ef63"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>March 31, 2025</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trade </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Facility </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Third </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Party</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COVID </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Loans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance, December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10164" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,397,385</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10087" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,557,023</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10167" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">154,505</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10202" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,108,913</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10093" name="cosm:ProceedFromDebt" contextRef="From2025-01-01to2025-03-31_cosm_TradeFacilityAgreementsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10094" name="cosm:ProceedFromDebt" contextRef="From2025-01-01to2025-03-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">755,720</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10095" name="cosm:ProceedFromDebt" contextRef="From2025-01-01to2025-03-31_cosm_COVIDLoansMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10198" name="cosm:ProceedFromDebt" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">755,720</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10104" name="cosm:PaymentsOfDebt" contextRef="From2025-01-01to2025-03-31_cosm_TradeFacilityAgreementsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10105" name="cosm:PaymentsOfDebt" contextRef="From2025-01-01to2025-03-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">183,455</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10106" name="cosm:PaymentsOfDebt" contextRef="From2025-01-01to2025-03-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,060</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10200" name="cosm:PaymentsOfDebt" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">188,515</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10123" name="cosm:ForeignCurrencyTranslation" contextRef="From2025-01-01to2025-03-31_cosm_TradeFacilityAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,075</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10124" name="cosm:ForeignCurrencyTranslation" contextRef="From2025-01-01to2025-03-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">110,051</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10125" name="cosm:ForeignCurrencyTranslation" contextRef="From2025-01-01to2025-03-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,019</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10208" name="cosm:ForeignCurrencyTranslation" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">176,145</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance, March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10859" name="us-gaap:NotesPayable" contextRef="AsOf2025-03-31_cosm_TradeFacilityAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,457,460</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10131" name="us-gaap:NotesPayable" contextRef="AsOf2025-03-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,239,339</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10132" name="us-gaap:NotesPayable" contextRef="AsOf2025-03-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">155,464</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10214" name="us-gaap:NotesPayable" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,852,263</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - long-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10139" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2025-03-31_cosm_TradeFacilityAgreementsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10140" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2025-03-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,968,180</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10141" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2025-03-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">120,360</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10137" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,088,540</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - short-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10860" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2025-03-31_cosm_TradeFacilityAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,457,460</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10148" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2025-03-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,271,159</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10149" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2025-03-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">35,104</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10146" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,763,723</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_28ef63"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trade </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Facility </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Third </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Party</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COVID </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Loans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance, December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11083" name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31_cosm_TradeFacilityAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,908,195</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11084" name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,511,148</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11085" name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">186,884</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11086" name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,606,227</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10168" name="cosm:ProceedFromDebt" contextRef="From2024-01-01to2024-12-31_cosm_TradeFacilityAgreementsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10178" name="cosm:ProceedFromDebt" contextRef="From2024-01-01to2024-12-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">828,080</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10175" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10211" name="cosm:ProceedFromDebt" contextRef="From2024-01-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">828,080</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10170" name="cosm:PaymentsOfDebt" contextRef="From2024-01-01to2024-12-31_cosm_TradeFacilityAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">388,163</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10179" name="cosm:PaymentsOfDebt" contextRef="From2024-01-01to2024-12-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">634,653</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10192" name="cosm:PaymentsOfDebt" contextRef="From2024-01-01to2024-12-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">22,806</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10199" name="cosm:PaymentsOfDebt" contextRef="From2024-01-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,045,622</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10173" name="cosm:ForeignCurrencyTranslation" contextRef="From2024-01-01to2024-12-31_cosm_TradeFacilityAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">122,647</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10180" name="cosm:ForeignCurrencyTranslation" contextRef="From2024-01-01to2024-12-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">147,552</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10193" name="cosm:ForeignCurrencyTranslation" contextRef="From2024-01-01to2024-12-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">9,573</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10207" name="cosm:ForeignCurrencyTranslation" contextRef="From2024-01-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">279,772</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance, December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10174" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,397,385</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10185" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,557,023</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10194" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">154,505</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10209" name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,108,913</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable &#8211; long-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10189" name="cosm:ProceedFromDebt" contextRef="From2024-01-01to2024-12-31_cosm_COVIDLoansMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10857" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-12-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,437,798</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10195" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-12-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">122,635</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10212" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,560,433</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - short-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10176" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,397,385</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10858" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31_cosm_ThirdPartyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,119,225</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10196" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31_cosm_COVIDLoansMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">31,870</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10213" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,548,480</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_6016" name="cosm:ScheduleOfOutstandingDebtTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="5" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Our outstanding debt as of March 31, 2025&#160;is repayable as follows:</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10215" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,763,723</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10216" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">819,335</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10217" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">666,070</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10218" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">378,706</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030 and thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10219" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">224,429</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total debt</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_10220" name="us-gaap:LongTermDebt" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,852,263</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: notes payable - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10221" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,763,723</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10222" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,088,540</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_152461" continuedAt="cont_44281e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Trade Facility Agreements</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the &#8220;TFF&#8221;) with Synthesis Structured Commodity Trade Finance Limited (the &#8220;Lender&#8221;) as amended on November 16, 2017, and May 16, 2018. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No principal repayments were made during the three-month period ended March 31, 2025. As of March 31, 2025, the Company had an outstanding principal balance of &#8364;1,350,000 ($<ix:nonFraction id="fid_11088" name="us-gaap:DebtCurrent" contextRef="AsOf2017-05-12_cosm_DebtAgreementJulyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,457,460</ix:nonFraction>), which is fully classified as &#8220;Notes Payable&#8221; in the Company&#8217;s consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">June 23, 2020 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 23, 2020, the Company&#8217;s subsidiary, Cosmofarm, entered into an agreement with the National Bank of Greece S.A. (the &#8220;Bank&#8221;) to borrow a maximum of &#8364;500,000 ($<ix:nonFraction id="fid_10291" name="cosm:DebtAmountReceivedFromRelatedParty" contextRef="From2020-06-01to2020-06-23_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">611,500</ix:nonFraction>).&#160; The outstanding balance was &#8364;58,824 ($<ix:nonFraction id="fid_11090" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">63,506</ix:nonFraction>) and &#8364;88,235 ($<ix:nonFraction id="fid_10346" name="us-gaap:DebtCurrent" contextRef="AsOf2024-12-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">91,232</ix:nonFraction>) as of March 31, 2025 and December 31, 2024, respectively, of which $<ix:nonFraction id="fid_11091" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2025-03-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">63,506</ix:nonFraction> and $<ix:nonFraction id="fid_10347" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">91,232</ix:nonFraction> was classified as&#160;&#8220;Notes payable &#8211; long-term portion&#8221;&#160;respectively,&#160;on the&#160;accompanying consolidated balance sheets. During the three-month period ended March 31, 2025, the Company repaid &#8364;29,412 ($<ix:nonFraction id="fid_11092" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2020-06-01to2020-06-23_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">31,753</ix:nonFraction>) of the principal balance.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">November 19, 2020 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of &#8364;500,000 ($<ix:nonFraction id="fid_10244" name="us-gaap:DebtCurrent" contextRef="AsOf2020-11-19_cosm_DebtExchangeAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">611,500</ix:nonFraction>). During the three-month period ended March 31, 2025 the Company repaid &#8364;27,778 ($<ix:nonFraction id="fid_11096" name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-01to2025-03-31_cosm_DebtExchangeAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">29,999</ix:nonFraction>) of the principal and as of March 31, 2025 the Company has accrued interest of &#8364;4,372 ($<ix:nonFraction id="fid_11094" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-03-31_cosm_DebtExchangeAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,720</ix:nonFraction>) related to this note and a principal balance of &#8364;83,333 ($<ix:nonFraction id="fid_11089" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_DebtExchangeAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">89,967</ix:nonFraction>), all of which is classified as &#8220;Notes payable&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">July 30, 2021 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of &#8364;500,000 ($<ix:nonFraction id="fid_10245" name="us-gaap:DebtCurrent" contextRef="AsOf2021-07-30_cosm_DebtAgreementJulyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">578,850</ix:nonFraction>). During the three-month period ended March 31, 2025, the Company repaid &#8364;28,434 ($<ix:nonFraction id="fid_11098" name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-01to2025-03-31_cosm_DebtAgreementJulyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">30,697</ix:nonFraction>) of the principal. As of March 31, 2025 the Company had accrued interest of &#8364;16,677 ($<ix:nonFraction id="fid_11100" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-03-31_cosm_DebtAgreementJulyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,004</ix:nonFraction>), principal of &#8364;177,909 ($<ix:nonFraction id="fid_11101" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_DebtAgreementJulyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">192,071</ix:nonFraction>), of which $<ix:nonFraction id="fid_11103" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2025-03-31_cosm_DebtAgreementJulyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">66,896</ix:nonFraction> is classified as &#8220;Notes payable &#8211; long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">June 9, 2022 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 9, 2022 the Company entered into an agreement with a third-party lender in the principal amount of &#8364;320,000 ($<ix:nonFraction id="fid_11117" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" contextRef="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">335,008</ix:nonFraction>), the &#8220;Note&#8221;. During the three-month period ended March 31, 2025 the Company repaid &#8364;20,000 ($<ix:nonFraction id="fid_11115" name="us-gaap:RepaymentsOfDebt" contextRef="From2025-01-01to2025-03-31_cosm_DebtAgreementJuneOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">21,592</ix:nonFraction>) of the principal. As of March 31, 2025 and December 31, 2024 the Company has accrued interest of &#8364;4,337 ($<ix:nonFraction id="fid_11113" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,682</ix:nonFraction>) and &#8364;8,352 ($<ix:nonFraction id="fid_10361" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31_cosm_DebtAgreementJuneOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,645</ix:nonFraction>), respectively, and an outstanding balance of &#8364;160,000 ($<ix:nonFraction id="fid_11114" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">172,736</ix:nonFraction>) and &#8364;180,000 ($<ix:nonFraction id="fid_10362" name="us-gaap:DebtCurrent" contextRef="AsOf2024-12-31_cosm_DebtAgreementJuneOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">186,318</ix:nonFraction>), respectively, of which $<ix:nonFraction id="fid_11116" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">86,368</ix:nonFraction> and $<ix:nonFraction id="fid_10363" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31_cosm_DebtAgreementJuneOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">103,510</ix:nonFraction>, are classified as &#8220;Notes payable &#8211; long term portion&#8221; on the accompanying consolidated balance sheets.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_44281e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">July 14, 2023 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 14, 2023, the Company entered into an agreement with a third-party lender in the principal amount of &#8364;1,000,000 ($<ix:nonFraction id="fid_11122" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" contextRef="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,123,700</ix:nonFraction>), the &#8220;Note&#8221;. During the three-month period ended March 31, 2025 the Company repaid &#8364;54,317 ($<ix:nonFraction id="fid_11121" name="us-gaap:RepaymentsOfDebt" contextRef="From2025-01-01to2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">58,640</ix:nonFraction>) of the principal. As of March 31, 2025 and December 31, 2024 the Company has accrued interest of &#8364;3,403 ($<ix:nonFraction id="fid_11118" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,674</ix:nonFraction>) and &#8364;16,735 ($<ix:nonFraction id="fid_10369" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-12-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">17,322</ix:nonFraction>), respectively, and an outstanding balance of &#8364;760,433 ($<ix:nonFraction id="fid_11119" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">820,964</ix:nonFraction>) and &#8364;814,750 ($<ix:nonFraction id="fid_10372" name="us-gaap:DebtCurrent" contextRef="AsOf2024-12-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">843,348</ix:nonFraction>), of which $<ix:nonFraction id="fid_11120" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">586,571</ix:nonFraction> and $<ix:nonFraction id="fid_10373" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">618,616</ix:nonFraction>, respectively, are classified as &#8220;Notes payable &#8211; long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Cloudscreen Promissory Note</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The total purchase price amounted to $<ix:nonFraction id="fid_10872" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">637,080</ix:nonFraction> and consisted of <ix:nonFraction id="fid_10873" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">280,000</ix:nonFraction> shares of common stock with a fair value of $<ix:nonFraction id="fid_10874" name="cosm:CommonStockIssuedAsConsiderationFairValue" contextRef="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">319,200</ix:nonFraction> and an amount of $<ix:nonFraction id="fid_10875" name="cosm:BusinessCombinationContingentConsiderationArrangementLiability" contextRef="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">317,880</ix:nonFraction> to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. During the three-month period ended March 31, 2025 the Company repaid $<ix:nonFraction id="fid_11125" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2025-01-01to2025-03-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,782</ix:nonFraction> of the principal. As of March 31, 2025, and December 31, 2024, the Company had an outstanding balance of $<ix:nonFraction id="fid_11123" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">280,696</ix:nonFraction> and $<ix:nonFraction id="fid_10870" name="us-gaap:DebtCurrent" contextRef="AsOf2024-12-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">279,348</ix:nonFraction> all of which is classified as &#8220;Notes payable&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">July 29, 2024 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 29, 2024 the Company entered into an agreement with a third-party lender in the principal amount of &#8364;400,000 ($<ix:nonFraction id="fid_11129" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" contextRef="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">432,760</ix:nonFraction>), the &#8220;Note&#8221;. During the 3-month period ended March 31, 2025, the Company repaid no principal. As of March 31, 2025, and December 31, 2024 the Company has accrued interest of &#8364;1,358 ($<ix:nonFraction id="fid_11127" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,466</ix:nonFraction>) and &#8364;1,527 ($<ix:nonFraction id="fid_10383" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-12-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,581</ix:nonFraction>), respectively, and an outstanding balance of &#8364;400,000 ($<ix:nonFraction id="fid_11126" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">431,840</ix:nonFraction>) and &#8364;400,000 ($<ix:nonFraction id="fid_10382" name="us-gaap:DebtCurrent" contextRef="AsOf2024-12-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">414,040</ix:nonFraction>), of which $<ix:nonFraction id="fid_11128" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">335,876</ix:nonFraction> and $<ix:nonFraction id="fid_10386" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">345,033</ix:nonFraction> is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">December 20, 2024 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 20, 2024 the Company entered into an agreement with a third-party lender in the principal amount of &#8364;400,000 ($<ix:nonFraction id="fid_11131" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" contextRef="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">414,040</ix:nonFraction>), the &#8220;Note&#8221;. During the 3-month period ended March 31, 2025, the Company repaid no principal. As of March 31, 2025, and December 31, 2024 the Company has accrued interest of &#8364;6,509 ($<ix:nonFraction id="fid_11132" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,027</ix:nonFraction>) and &#8364;794 ($<ix:nonFraction id="fid_11133" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-12-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">821</ix:nonFraction>), respectively, and an outstanding balance of &#8364;400,000 ($<ix:nonFraction id="fid_11130" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">431,840</ix:nonFraction>) and &#8364;400,000 ($<ix:nonFraction id="fid_10395" name="us-gaap:DebtCurrent" contextRef="AsOf2024-12-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">414,040</ix:nonFraction>), of which $<ix:nonFraction id="fid_11134" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">287,893</ix:nonFraction> and $<ix:nonFraction id="fid_10392" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">276,027</ix:nonFraction> is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">January 27, 2025 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 27, 2025, <ix:nonNumeric id="fid_11147" name="us-gaap:LongTermDebtDescription" contextRef="From2025-01-01to2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember">the Company entered into a bond loan agreement with Attica Bank, providing for maximum borrowings of up to &#8364;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#8364;700,000 ($749,600), which were classified as Notes Payable in the Company&#8217;s consolidated financial statements. The remaining borrowing capacity of &#8364;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral</ix:nonNumeric>. These subsequent drawdowns are classified as Lines of Credit due to their secured and contingent nature. The facility bears interest at a floating rate of <ix:nonFraction id="fid_11149" name="us-gaap:SubordinatedBorrowingInterestRate" contextRef="From2025-01-01to2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" unitRef="Pure" decimals="INF" scale="-2">2.95</ix:nonFraction>% plus the applicable 6-month Euribor (2.331% as of March 31, 2025). The Note Payable portion of the facility is to be repaid in 10 equal semiannual installments of &#8364;70,000 commencing on July 27, 2026. During the 3-month period ended March 31, 2025, the Company repaid no principal. As of March 31, 2025, and December 31, 2024 the Company has accrued interest of &#8364;3,488 ($<ix:nonFraction id="fid_11137" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,766</ix:nonFraction>) and &#8364;0 ($<ix:nonFraction id="fid_11138" name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-12-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction>), respectively, and an outstanding balance of &#8364;700,000 ($<ix:nonFraction id="fid_11142" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">755,720</ix:nonFraction>) and &#8364;0 ($<ix:nonFraction id="fid_11143" name="us-gaap:DebtCurrent" contextRef="AsOf2024-12-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction>), of which $<ix:nonFraction id="fid_11150" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">604,576</ix:nonFraction> and $<ix:nonFraction id="fid_11151" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction> is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">COVID-19 Loans</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 12, 2020, the Company&#8217;s wholly owned subsidiary, SkyPharm SA, was granted a loan from the Greek government in the amount of &#8364;300,000 (approximately $<ix:nonFraction id="fid_10290" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2020-05-01to2020-05-12_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">366,900</ix:nonFraction>). During the three-month period ended March 31, 2025, an additional principal repayment of &#8364;4,688 (approximately $<ix:nonFraction id="fid_11153" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" contextRef="From2020-05-01to2020-05-12_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,061</ix:nonFraction>) was made. As of March 31, 2025, and December 31, 2024 the Company has an outstanding balance of &#8364;98,438 ($<ix:nonFraction id="fid_11154" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">106,273</ix:nonFraction>) and &#8364;103,125 ($<ix:nonFraction id="fid_10400" name="us-gaap:DebtCurrent" contextRef="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">106,745</ix:nonFraction>), of which $<ix:nonFraction id="fid_11157" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-01to2025-03-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">86,031</ix:nonFraction> and $<ix:nonFraction id="fid_11156" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-01to2024-12-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">87,337</ix:nonFraction> is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 24, 2020, the Company&#8217;s subsidiary, Decahedron, received a loan &#163;50,000 ($<ix:nonFraction id="fid_10403" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2020-06-01to2020-06-24_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">68,310</ix:nonFraction>) from the&#160;UK government. As of March 31, 2025, and December 31, 2024 the Company has an outstanding balance of &#163; 38,144 ($<ix:nonFraction id="fid_11158" name="us-gaap:DebtCurrent" contextRef="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">49,191</ix:nonFraction>) and &#163; 38,144 ($<ix:nonFraction id="fid_10406" name="us-gaap:DebtCurrent" contextRef="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">47,761</ix:nonFraction>), of which $<ix:nonFraction id="fid_11159" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">34,329</ix:nonFraction> and $<ix:nonFraction id="fid_11160" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">35,299</ix:nonFraction> is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None of the above loans were made by any related parties.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><ix:nonNumeric id="fid_5974" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_88a16b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 12 &#8211; LEASES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric id="fid_10510" name="cosm:OperatingLeaseTermOfAgreements" contextRef="From2025-01-01to2025-03-31">The Company has various operating and finance lease agreements with terms up to 10 years</ix:nonNumeric>, for various types of property and equipment (such as office space and vehicles) etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Operating Leases</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s weighted-average remaining lease term relating to its operating leases is <ix:nonNumeric id="fid_10516" name="cosm:OperatingLeaseWeightedAverageRemainingLeaseTerm" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:duryear">3.71</ix:nonNumeric> years, with a weighted-average discount rate of <ix:nonFraction id="fid_10515" name="cosm:OperatingLeaseWeightedAverageDiscountRate" contextRef="From2025-01-01to2025-03-31" unitRef="Pure" decimals="INF" scale="-2">6.74</ix:nonFraction>%.<span style="text-decoration:underline"> </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s operating leases as of March 31, 2025:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6017" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Maturity of Operating Lease Liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10497" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">181,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10498" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">218,637</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10499" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">156,745</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2029 and thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10500" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">202,251</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total undiscounted operating lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10501" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">759,386</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Less: Imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10502" name="cosm:OperatingLeaseLiabilityLessImputedInterest" contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">88,876</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Present value of operating lease liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10503" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">670,510</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company incurred lease expense, due to amortization of operating lease right-of-use assets, of&#160;$<ix:nonFraction id="fid_10511" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2025-01-01to2025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,668</ix:nonFraction> and $<ix:nonFraction id="fid_10512" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-01-01to2024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">77,167</ix:nonFraction>, which was included in &#8220;General and administrative expenses,&#8221; for the&#160;three ended March 31, 2025 and 2024, respectively.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Finance Leases </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s weighted-average remaining lease term relating to its finance leases is <ix:nonNumeric id="fid_10517" name="cosm:FinanceLeaseWeightedAverageRemainingLeaseTerm" contextRef="From2025-01-01to2025-03-31" format="ixt-sec:duryear">1.07</ix:nonNumeric> years, with a weighted-average discount rate of <ix:nonFraction id="fid_10520" name="cosm:FinanceLeaseWeightedAverageDiscountRate" contextRef="From2025-01-01to2025-03-31" unitRef="Pure" decimals="INF" scale="-2">6.74</ix:nonFraction>%. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s finance leases as of March 31, 2025:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6018" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Maturity of Lease Liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10506" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-03-31_cosm_FinanceLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,357</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total undiscounted finance lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10507" name="cosm:FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" contextRef="AsOf2025-03-31_cosm_FinanceLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,357</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Less: Imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10508" name="cosm:FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" contextRef="AsOf2025-03-31_cosm_FinanceLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">373</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Present value of finance lease liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10509" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2025-03-31_cosm_FinanceLeaseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,164</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_88a16b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company had financing cash flows used in finances leases of $<ix:nonFraction id="fid_10513" name="cosm:OperatingLeaseCashFlowsUsedInFinanceLease" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,533</ix:nonFraction> and $<ix:nonFraction id="fid_10514" name="cosm:OperatingLeaseCashFlowsUsedInFinanceLease" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,737</ix:nonFraction> for the three ended March 31, 2025 and 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company incurred interest expense on its finance leases of $<ix:nonFraction id="fid_10518" name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2025-01-01to2025-03-31_us-gaap_InterestExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">195</ix:nonFraction> and $<ix:nonFraction id="fid_10519" name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2024-01-01to2024-03-31_us-gaap_InterestExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">725</ix:nonFraction> which was included in &#8220;Interest expense&#8221;, for the three months ended March 31, 2025 and 2024, respectively. The Company incurred amortization expense on its finance leases of $<ix:nonFraction id="fid_10521" name="cosm:FinanceLeaseAmortizationExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,603</ix:nonFraction> and $<ix:nonFraction id="fid_10522" name="cosm:FinanceLeaseAmortizationExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,489</ix:nonFraction> which was included in &#8220;Depreciation and amortization expense,&#8221; for the three months ended March 31, 2025 and 2024, respectively.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5975" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 13 &#8211; OTHER LIABILITIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 the Company&#8217;s other liabilities primarily consist of obligations to local tax authorities, payroll taxes, fines, and other miscellaneous liabilities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The significant components of other liabilities are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s Greek subsidiaries have $<ix:nonFraction id="fid_10528" name="cosm:TaxLiabilitiesPayable" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,819,815</ix:nonFraction> and $<ix:nonFraction id="fid_10523" name="cosm:TaxLiabilitiesPayable" contextRef="From2024-01-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,552,488</ix:nonFraction> in settled tax liabilities as March 31, 2025 and December 31, 2024, respectively, which are payable in installments to the tax authorities.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Payroll and other tax-related current liabilities amount to $<ix:nonFraction id="fid_10529" name="cosm:PayrollTaxRelatedCurrentLiabilities" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,350,825</ix:nonFraction> and $<ix:nonFraction id="fid_10524" name="cosm:PayrollTaxRelatedCurrentLiabilities" contextRef="From2024-01-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,191,315</ix:nonFraction> as of March 31, 2025 and December 31, 2024, respectively, and represent obligations due to tax authorities within the next 12 months.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A provision of $<ix:nonFraction id="fid_11161" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">624,588</ix:nonFraction> has been recorded for potential tax liabilities related to the unaudited tax years of SkyPharm S.A., in accordance with ASC 450-20, as the Company has assessed that a loss is probable and reasonably estimable.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A provision of $<ix:nonFraction id="fid_11162" name="cosm:ProvisionForStaffLeavingCompensation" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">398,838</ix:nonFraction> has been recognized for staff leaving compensation, based on actuarial valuations performed in accordance with ASC 715-30 (Defined Benefit Plans &#8211; Pension).</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Customer prepayments totaling $<ix:nonFraction id="fid_10530" name="us-gaap:ProceedsFromCustomersForProgressPayments" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">447,872</ix:nonFraction> and $<ix:nonFraction id="fid_10527" name="us-gaap:ProceedsFromCustomersForProgressPayments" contextRef="From2024-01-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">363,708</ix:nonFraction> as of March 31, 2025 and December 31, 2024, respectively, are included in &#8220;Other Current Liabilities&#8221;, in accordance with ASC 606-10-45-2 (Revenue Recognition &#8211; Contract Liabilities).</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Liabilities that are due within 12 months from the balance sheet date are classified under &#8220;Other Current Liabilities. &#8220;Obligations that extend beyond 12 months are classified as &#8220;Other Non-Current Liabilities.&#8221;&#160;</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5976" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_a687d6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 14 &#8211; COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Legal Matters</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, the Company may be involved in litigation relating to claims arising out of the Company&#8217;s operations in the normal course of business. As of March 31, 2025, the following litigations were pending. None of the below is expected to have a material financial or operational impact. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Tax Audit-Related Fine &#8211; Cosmofarm</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A payment request was issued by the Greek court in relation to a fine arising from a tax audit of Cosmofarm for the financial year 2014. The fine was imposed under Law No. 483/16.12.2020. Cosmofarm appealed the decision under Law No. 11541/09.03.2021; however, the appeal was dismissed 120 days after its submission. The Company settled additional taxes and fines related to this matter in the amount of &#8364;91,652 ($<ix:nonFraction id="fid_11164" name="cosm:PaymentTax" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">99,644</ix:nonFraction>) but has filed a claim to recover the amount through appeal. As of March 31, 2025, the trial remains pending.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Criminal Cases Related to Dishonored Checks</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 25, 2023, a criminal case involving dishonored checks issued by Cosmofarm&#8217;s customer, Filippou, was heard at the Z&#8217; Three-Member Misdemeanor Court of Athens. The case was postponed to November 27, 2023, when the defendant was tried and found guilty.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 23, 2023, a criminal case involving dishonored checks issued by Cosmofarm&#8217;s customer, Kafantaris, was heard at the Sixth Single-Member Misdemeanor Court of Athens. The case was postponed to January 26, 2024, when the defendant was convicted under Decision No. 1599/2024.</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_a687d6" continuedAt="cont_bc6adf"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Appeal Against Decision 1389/2021 &#8211; Eleutheria Drakopoulou</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 26, 2023, the Company&#8217;s appeal against Eleutheria Drakopoulou and Decision No. 1389/2021 of the Single-Member Court of First Instance of Athens was heard at the Athens Court of Appeal. The appeal was partially accepted. The Court ordered the return of the fee to the appellants, dismissed the action against the third defendant (Kozaris), and accepted the action against the first and second defendants (Kastrantas &amp; Cosmofarm).&#160;The case was settled in two equal installments by Cosmofarm SA, of &#8364;35,000 ($<ix:nonFraction id="fid_10542" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="AsOf2024-07-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">37,880</ix:nonFraction>) on July 31, 2024 and of &#8364;35,000 ($<ix:nonFraction id="fid_10543" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="AsOf2024-10-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">37,993</ix:nonFraction>) on October 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Pending Lawsuits Against Euaggelismos &amp; Pananikolaou Hospitals</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s subsidiary, Cana Laboratories, has two pending lawsuits against Euaggelismos Hospital for unpaid bills totaling &#8364;526,436. A court date has been scheduled for one of the lawsuits on December 11, 2024, while the other remains unscheduled. The matter is currently pending a court decision. Based on legal counsel&#8217;s assessment, it is considered highly probable that the losing party will appeal the decision once it is rendered. However, counsel has also indicated that the collection of the full amount awarded to the Company is considered highly probable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There is also an unasserted claim against Papanikolaou Hospital, for a total sum of &#8364;89,300 due to unpaid bills, which will be asserted through a lawsuit. Court date is not set yet. The opinion of our legal advisor is that the success of the case and the collection of the aforementioned amount is probable and as of now negotiations are taking place in the direction of out-of-court settlement.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Both claims have been classified under &#8220;Other assets&#8221; within non-current assets in the Company&#8217;s consolidated balance sheets as of March 31, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employment Dispute &#8211; Cana Laboratories</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A lawsuit filed on April 5, 2018, by a former employee against the Company&#8217;s subsidiary, Cana, before the Athens Court of First Instance, sought the nullification of the termination of employment and compensation for unpaid wages and moral damages. Following multiple appeals, Judgment No. 1192/2024 was issued on September 26, 2023, requiring Cana to reinstate the former employee, with a penalty of &#8364;200 per day for non-compliance. According to the Company&#8217;s legal counsel, for the penalty to be enforceable, the former employee must file a new lawsuit requesting reinstatement. As of the date of this report, no such lawsuit or request for reinstatement has been received.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Lease Dispute</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A lawsuit has been filed against the Company&#8217;s subsidiary, Cana, seeking restitution of a leased property, payment of approximately &#8364;13,190 in outstanding rent, and &#8364;8,488 in compensation for use of the property. The Company has settled the monetary claims in full, rendering that portion of the case moot. However, the claim for restitution of the leased property remains pending and is expected to be accepted by the court.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Claims for Recovery of Receivables</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s subsidiary, Cosmofarm SA, is in the process of initiating legal action to recover approximately &#8364;20,301 in unpaid invoices from a certain customer. The hearing is expected to be scheduled in 2026. Based on legal counsel&#8217;s assessment, the claim is anticipated to be upheld. In addition, Cosmofarm SA is preparing to file two further lawsuits for the recovery of &#8364;15,143 and &#8364;15,255, respectively, related to unpaid invoices concerning two customers. Both hearings are expected to be scheduled in 2026, and legal counsel similarly anticipates favorable outcomes in both cases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Advisory Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 21, 2023, the Company entered into certain consulting agreements with four third-party consultants for the provision of a variety of services such as digital marketing, advisory services relating to target acquisitions and M&amp;As and other additional services as described in the respective agreements. The agreements have duration from ten to 18 months and the consultants will solely receive stock consideration for the services rendered. More precisely, they have been awarded a total of <ix:nonFraction id="fid_10538" name="cosm:StockIssuedDuringPeriodSharesAwarded" contextRef="From2023-11-01to2023-11-21_cosm_FourThirdPartyConsultantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">970,000</ix:nonFraction> shares of the Company&#8217;s common stock valued at a total of $<ix:nonFraction id="fid_10539" name="us-gaap:StockIssued1" contextRef="From2023-11-01to2023-11-21_cosm_FourThirdPartyConsultantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">999,100</ix:nonFraction> based on the fair value of the Company&#8217;s common stock as of the agreements&#8217; date. On September 17, 2024 the terms of two out of the four aforementioned consulting agreements were extended and the consultants received additional <ix:nonFraction id="fid_11165" name="cosm:ComplementaryCompensationShares" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">440,000</ix:nonFraction> shares as complementary compensation for the extended services to be provided. The additional stock based consideration was valued at a total of $<ix:nonFraction id="fid_10544" name="cosm:AdditionalStockConsideration" contextRef="From2023-11-01to2023-11-21" format="ixt:numdotdecimal" unitRef="USD" decimals="0">501,600</ix:nonFraction> based on the fair value of the Company&#8217;s common stock as of the agreements&#8217; date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 1, 2024 the Company entered into a consulting agreement with a third-party consultant for the provision of a variety of services such as preparation of press releases and other publications, relationship management and other additional services as described in the respective agreement. The agreement has a duration of 16 months and the consultant will solely receive stock consideration for the services rendered. More precisely, they have been awarded a total of <ix:nonFraction id="fid_11167" name="cosm:StockIssuedDuringPeriodSharesAwarded" contextRef="From2024-07-01to2024-07-02" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">240,000</ix:nonFraction> shares of the Company&#8217;s common stock valued at a total of $<ix:nonFraction id="fid_11168" name="cosm:AdditionalStockConsideration" contextRef="From2024-07-01to2024-07-02" format="ixt:numdotdecimal" unitRef="USD" decimals="0">264,000</ix:nonFraction> based on the fair value of the Company&#8217;s common stock as of the agreements&#8217; date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The corresponding stock-based compensation expense is accrued evenly over the term of the agreements. For the three-month periods ended March 31, 2025 and 2024 the Company has recorded $<ix:nonFraction id="fid_11169" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_cosm_NationalMedicinesAgencyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">245,310</ix:nonFraction> and $<ix:nonFraction id="fid_11171" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_cosm_NationalMedicinesAgencyMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">231,750</ix:nonFraction>, respectively, as stock based compensation for the above agreements, respectively, classified as &#8220;General and administrative expenses&#8221; in the Company&#8217;s consolidated statements of operations and comprehensive Income (loss).</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_bc6adf"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Research and Development Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company entered into a Research &amp; Development agreement with Doc Pharma S.A. on May 17, 2021. Under this agreement, Doc Pharma is responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life&#174;. More specifically, Doc Pharma is responsible for the product development and the Company has added 165 of such products codes in its portfolio as of March 31, 2025. The licenses purchased by Doc Pharma SA are capitalized and included in &#8220;Goodwill and intangible assets, net&#8221; of the Company&#8217;s Consolidated Balance Sheets as of March 31, 2025. Thus, no relevant R&amp;D expense had been charged to the Company&#8217;s Consolidated Statements of Operations and Comprehensive income (Loss), concerning this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 25, 2022, the Company signed a research and development (&#8220;R&amp;D&#8221;) agreement with a third party(CloudPharm PC), through which the Company assigned to the third party the development of new products and services in the field of health, focusing on the human intestinal microbiome. The project includes two phases. Phase 1 has a 20-month duration and its cost amounts to EUR 758,000 ($<ix:nonFraction id="fid_10536" name="cosm:ProjectCosts" contextRef="From2022-06-01to2022-06-25_cosm_PhaseOneMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">838,450</ix:nonFraction>) and phase 2, has a 22-month duration and a cost of EUR 820,000 ($<ix:nonFraction id="fid_10537" name="cosm:ProjectCosts" contextRef="From2022-06-01to2022-06-25_cosm_PhaseTwoMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">907,084</ix:nonFraction>). The amount will be due and payable upon completion of the corresponding phases. The Company records the corresponding R&amp;D expense based on the project&#8217;s progress, which is invoiced by the third party in the relevant period. For the 3-month periods ended March 31, 2025 and 2024, the Company has not incurred any costs relating to this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $<ix:nonFraction id="fid_10547" name="cosm:PurchasePriceAmount" contextRef="From2024-01-01to2024-01-23" format="ixt:numdotdecimal" unitRef="USD" decimals="0">637,080</ix:nonFraction> incorporating both cash and stock consideration the platform is included in &#8220;Goodwill and intangible assets, net&#8221; in the Company&#8217;s Consolidated Balance Sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 3, 2024, the Company and the National Hellenic Research Foundation (NHRF) (Contractor) signed a Research Study Agreement. NHRF will conduct an in vitro study to support modifications to an invention, pursuant to the prior agreement involving CloudPharm PC (signed on June 15, 2022). NHRF ensures scientific rigor, provides updates, and maintains confidentiality. Cosmos Health provides necessary support and documentation. Rights to the research protocol belong to CloudPharm PC, NHRF, and Cosmos Health, while NHRF retains control over its methodologies. NHRF cannot publish findings without Cosmos Health&#8217;s approval and cannot use the study for other purposes. The total fee to by paid by the Company amounts to &#8364;60,000 plus VAT, payable in three installments. For the 3-month period ended March 31, 2025, the Company incurred EUR 15,000 ($<ix:nonFraction id="fid_11566" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,629</ix:nonFraction>) concerning this agreement, which were included in &#8220;Research and Development costs&#8221; in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss).&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 6, 2024, the Company signed an Independent Contractor Agreement with a third-party contractor (the &#8220;Contractor&#8221;). The Contractor will provide oncology research and development services exclusively to the Company. The contract lasts three years (December 5, 2024 &#8211; December 5, 2027) and may be extended by mutual agreement. The Company may terminate the contract immediately for specific causes, including felony conviction, fraud, or loss of medical license. Either party may terminate the contract with 30 days' written notice. Certain compensation obligations will remain even after termination. The monthly consideration to be paid to the Contractor is based on the commencement of the Clinical Trials and New Drugs Applications and additional cash and stock consideration is payable based on certain milestones. None of the milestones were met as of March 31, 2025, and thus the Company has incurred no expenses as of the end of the period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 31, 2024, the Company signed an agreement with a related party, DocPharma SA (the &#8220;Licensor&#8221;), through which the Company obtained a royalty-bearing, exclusive worldwide license to actively commercialize the patents owned by the Licensor, through research and preclinical and clinical trials for the useful life of the patents, or for 20 years, whichever is longer. The patents, filed in 2016 and 2017 respectively, cover innovative treatments for cancer.&#160;The terms of the agreement include an initial payment of EUR 500,000 due by the end of 2024, followed by fixed annual payments of EUR 350,000 during the five-year Start-Up Term from 2025 to 2030. After the Start-Up Term, the Company will pay a 1.5% royalty on annual net sales of licensed products covered by an issued patent. Moreover, the Company retains an optional buy-out right for a total amount of EUR 7,500,000, which can be exercised with 60 days' notice and a 60-day close period. The Company also has the right to sublicense the patents. For the 3-month period ended March 31, 2025, the Company incurred no royalties concerning this agreement.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5977" name="cosm:StockOptionsAndWarrantsDisclouserTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true" continuedAt="cont_783369"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 15&#160;&#8211; STOCK OPTIONS AND WARRANTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Omnibus Equity Incentive Plan</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 19, 2022, the Company held a Board of Directors meeting, whereas, the Board of Directors had elected to adopt an Omnibus Equity Incentive Plan (the &#8220;2022 Plan&#8221;), that includes reserving <ix:nonFraction id="fid_10590" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-09-19_cosm_TwoZeroTwentyTwoPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,000</ix:nonFraction> shares of common stock eligible for issuance under the 2022 Plan to be registered on a Form S-8 Registration Statement with the SEC. The 2022 Plan is designed to enable the flexibility to grant equity awards to the Company&#8217;s officers, employees, non-employee directors and consultants and to ensure that it can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. According to the Proxy Statement filed with the SEC on October 20, 2022 the 2022 Plan received final approval by the Company&#8217;s stockholders&#160;at the Annual Meeting of Stockholders held on December 2, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 3, 2023, the Company approved incentive stock awards for the CFO, certain officers and directors and other employees of the Company. The awards are in the form of restricted stock and will vest in two parts: 50% on October 2, 2023 and 50% on October 2, 2024. For the three-month periods ended March 31, 2025 and 2024, the Company recorded share-based compensation expense of $<ix:nonFraction id="fid_11180" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction> and $<ix:nonFraction id="fid_11179" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">108,297</ix:nonFraction>, respectively, in connection with the &#8220;2022 Plan.&#8221;</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_783369"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 21, 2023, the Board adopted, subject to stockholder approval, the Cosmos Health Inc. 2023 Omnibus Equity Incentive Plan (the &#8220;2023 Plan&#8221;). The 2023 Plan is designed to enable the flexibility to grant equity awards to our officers, employees, non-employee directors and consultants and to ensure that we can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. Subject to certain adjustments (as provided in Section 4.2 of the 2023 Plan) and exception (as provided in Section 5.6(b) of the 2023 Plan), the maximum number of shares reserved for issuance under the Plan (including incentive share options) is <ix:nonFraction id="fid_10591" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-08-21_cosm_TwoZeroTwentyThreePlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,500,000</ix:nonFraction> shares. The 2023 Plan was approved by the Company&#8217;s stockholders at the Annual Meeting of Stockholders held on September 18, 2023. As of March 31, 2025, no shares remained reserved and available for future issuance under the Company's 2023 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 16, 2024, the Company&#8217;s Board of Directors approved incentive stock awards for the CEO, the CFO, certain officers and directors and other key employees of the Company pursuant to the 2023 Plan. <ix:nonNumeric id="fid_11182" name="cosm:DiscriptionOfIncentiveStockAwards" contextRef="From2023-04-01to2023-04-03">The awards are in the form of restricted stock and will vest in two parts: 50% on September 16, 2025 and 50% on September 16, 2026</ix:nonNumeric>. A total of <ix:nonFraction id="fid_10592" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-08-21_cosm_BoardOfDirectorsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,500,000</ix:nonFraction> shares were awarded. For the three-month periods ended March 31, 2025 and 2024, the Company recorded share-based compensation expense of $<ix:nonFraction id="fid_11183" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-03-31_cosm_BoardOfDirectorsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">311,301</ix:nonFraction> and $<ix:nonFraction id="fid_11567" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-03-31_cosm_BoardOfDirectorsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction>, respectively, in connection with the &#8220;2023 Plan.&#8221; The expense was recorded in accordance with ASC 718 (Compensation&#8212;Stock Compensation) and is included in the Company&#8217;s Consolidated Statement of Operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Warrant Anti-Dilution Adjustment and Deemed Dividend</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, there were <ix:nonFraction id="fid_11191" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-03-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,926,506</ix:nonFraction> warrants outstanding and <ix:nonFraction id="fid_11190" name="cosm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" contextRef="AsOf2025-03-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,913,172</ix:nonFraction> warrants exercisable with 12,913,172 warrants having <ix:nonNumeric id="fid_11188" name="cosm:WarrantExpirationDateDescription" contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember">expiration dates from May 2026 through October 2029</ix:nonNumeric> and <ix:nonFraction id="fid_11187" name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2025-03-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">13,334</ix:nonFraction> warrants with no expiration date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s warrant activity for the nine months ended March 31, 2025 and the year ending December 31, 2024 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6019" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Intrinsic</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance Outstanding, January 1, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10552" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">8,561,476</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">3.91</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_10568" name="cosm:WeightedAverageRemainingContractualTermOutstandingBeginning" contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember" format="ixt-sec:duryear">4.64</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,801</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10554" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">9,748,252</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10565" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.95</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10558" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,874,126</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10559" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">509,096</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance Outstanding, December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,926,506</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10562" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.63</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_10569" name="cosm:WeightedAverageRemainingContractualTermOutstandingBeginning" contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember" format="ixt-sec:duryear">3.24</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10574" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,920</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance Outstanding, March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10560" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,926,506</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10566" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.63</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_10571" name="cosm:WeightedAverageRemainingContractualTermOutstandingEnding" contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember" format="ixt-sec:duryear">2.99</ix:nonNumeric></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10576" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-03-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,814</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Exercisable, March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11172" name="cosm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,913,172</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11173" name="cosm:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.63</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_11174" name="cosm:WeightedAverageRemainingContractualTermExercisable" contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember" format="ixt-sec:duryear">3.00</ix:nonNumeric></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11175" name="cosm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_5978" name="cosm:DisaggregationOfRevenueDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 16 &#8211; DISAGGREGATION OF REVENUE</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity&#8217;s revenue is disaggregated depends on the facts and circumstances that pertain to the entity&#8217;s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table presents our revenue disaggregated by country for the three months ended:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_6020" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Country</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Croatia</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9785" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_CroatiaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,093</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9786" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31_cosm_CroatiaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">19,344</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cyprus</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9787" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_CyprusMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,562</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9788" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31_cosm_CyprusMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,737</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bulgaria</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9789" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_BulgariaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,183</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9790" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31_cosm_BulgariaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,651</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Greece</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9793" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_GreeceMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,322,494</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9794" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31_cosm_GreeceMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,225,572</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Albania</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9803" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_AlbaniaMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">36,332</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9802" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31_cosm_AlbaniaMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">UK</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9797" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_UkMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">285,864</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9798" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31_cosm_UkMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">312,569</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_9799" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,712,528</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_9784" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,584,473</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Unaudited Condensed Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_9419" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 17 &#8211; SEGMENT REPORTING</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A. Basis for segmentation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Group operates through various operating segments, which include the wholesale sector, the pharmaceutical manufacturing sector, the nutraceuticals and pharmaceuticals sector and other, with only the first three of them being reportable segments based on the criteria (quantitative thresholds) of ASC 280. The financial information utilized by our Chief Operating Decision Maker (&#8220;CODM&#8221;), which is our CEO, for resource allocation and performance evaluation is included within the operating segments described above.&#160;The reconciling items presented in the tables below are excluded from the segment data provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;). The &#8220;Other&#8221; category primarily consists of corporate expenses incurred by the Group&#8217;s parent entity, including, but not limited to, costs related to SEC legal and compliance matters, executive compensation, audit and review fees, and other corporate overhead expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>B. Information about reportable segments</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The table below presents information about the Company's reportable segments for the three-month period ended March 31, 2025. The accounting policies followed in the preparation of the reportable segments are the same with those followed in the preparation of the Company's condensed consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Three-month period ended March 31, 2025</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_9437" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Wholesale </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Pharma</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>manufacturing </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nutraceuticals &amp; Pharmaceuticals</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11570" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,504,562</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11571" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">268,557</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11572" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">939,409</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11573" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11568" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,712,528</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11576" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,320,936</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11577" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">70,975</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11578" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">270,818</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11579" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11574" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,662,729</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Gross Profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11657" name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,183,626</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11659" name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">197,582</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11661" name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">668,591</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11663" name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_11665" name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,049,799</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General and Administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11582" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">162,269</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11583" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">155,454</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11584" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">243,227</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11585" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">361,140</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11580" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">922,090</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Salaries</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11589" name="us-gaap:SalariesAndWages" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">378,595</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11590" name="us-gaap:SalariesAndWages" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">363,670</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11591" name="us-gaap:SalariesAndWages" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">297,499</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11592" name="us-gaap:SalariesAndWages" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">255</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11587" name="us-gaap:SalariesAndWages" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,040,019</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Sales and Marketing expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11595" name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">715</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11596" name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">428</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11597" name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">27,012</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11598" name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11593" name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">28,155</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and Development costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11599" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11600" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11601" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11602" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,629</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11637" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,629</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net finance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11603" name="cosm:NetFinanceCosts" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">149,274</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11604" name="cosm:NetFinanceCosts" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11605" name="cosm:NetFinanceCosts" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,493</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11606" name="cosm:NetFinanceCosts" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11639" name="cosm:NetFinanceCosts" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">95,781</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Segment profit / (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11607" name="cosm:SegmentProfitLoss" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">492,773</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11608" name="cosm:SegmentProfitLoss" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">321,970</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11609" name="cosm:SegmentProfitLoss" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">154,346</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11610" name="cosm:SegmentProfitLoss" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">377,024</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11638" name="cosm:SegmentProfitLoss" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">51,875</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Reconciling items:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11613" name="us-gaap:DepreciationAndAmortization" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,880</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11614" name="us-gaap:DepreciationAndAmortization" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">131,974</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11615" name="us-gaap:DepreciationAndAmortization" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">99,807</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11616" name="us-gaap:DepreciationAndAmortization" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">35,778</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11611" name="us-gaap:DepreciationAndAmortization" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">320,439</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11641" name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11643" name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11645" name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11647" name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">556,613</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11649" name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">556,613</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11650" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">59,428</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11652" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11654" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">109,943</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11656" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,454</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11666" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">175,825</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income and expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11627" name="cosm:OtherIncomeAndExpenses" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">27,556</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11628" name="cosm:OtherIncomeAndExpenses" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,341</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11629" name="cosm:OtherIncomeAndExpenses" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">88,701</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11630" name="cosm:OtherIncomeAndExpenses" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">193,593</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11640" name="cosm:OtherIncomeAndExpenses" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">64,995</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net profit/(loss) before Income Taxes</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11633" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">526,877</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11634" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">441,603</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11635" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">253,184</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11636" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-03-31_cosm_OtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,156,555</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_11631" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">818,097</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following summary describes the operations of each reportable segment:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_9438" name="cosm:ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock" contextRef="From2025-01-01to2025-03-31" escape="true"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:41%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Reportable segments</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:54%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Operations</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Wholesale </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Distribution and export of pharmaceutical products </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pharma manufacturing</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Production of pharmaceutical products</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nutraceutical and pharmaceuticals </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Trade of owned nutraceutical &amp; pharmaceutical products</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><ix:nonNumeric id="fid_5979" name="us-gaap:SubsequentEventsTextBlock" contextRef="From2025-01-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 18 &#8211; SUBSEQUENT EVENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Between April 21, 2025, and April 24, 2025, the Company issued an aggregate of <ix:nonFraction id="fid_10876" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-04-01to2025-04-24_us-gaap_SubsequentEventMember_cosm_GrigoriosSiokasMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,466,764</ix:nonFraction> shares of common stock to Mr. Grigorios Siokas, the Company&#8217;s Chief Executive Officer, in settlement of outstanding obligations totalling $<ix:nonFraction id="fid_11189" name="us-gaap:AssetRetirementObligationLiabilitiesSettled" contextRef="From2025-04-01to2025-04-24_us-gaap_SubsequentEventMember_cosm_GrigoriosSiokasMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">526,000</ix:nonFraction>. The liabilities settled pertained to unpaid salaries and performance-related bonuses previously accrued by the Company and owed to Mr. Siokas. The shares were issued at the respective fair market value of the Company&#8217;s common stock on the dates of issuance. The transaction was accounted for as a non-cash settlement of related party debt.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 6, 2025, the Company received a notice from the Nasdaq Stock Market LLC indicating that it had not regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) by the initial deadline of May 5, 2025. However, the Company was granted an additional 180-day compliance period, through November 3, 2025, to meet the requirement. The extension was granted based on the Company&#8217;s continued compliance with all other initial listing standards for the Nasdaq Capital Market and its intent to cure the deficiency, including through a potential reverse stock split if necessary.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i2">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Available Information</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following discussion should be read in conjunction with our interim Condensed Consolidated Financial Statements and the related notes and other financial information appearing elsewhere in this report as well as Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Form 10-K for the year ended December 31, 2024 (&#8220;Form 10-K&#8221;) and this Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Forward-Looking Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words &#8220;believes,&#8221; &#8220;project,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;strategy,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;will be,&#8221; &#8220;will continue,&#8221; &#8220;will likely result,&#8221; and similar expressions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Overview</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Summary</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are diversified, vertically integrated global healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research &amp; development of innovative medicines and repurposing drugs as well as operator of a telehealth platform. The Company, through its subsidiaries, is operating within the pharmaceutical industry and in order to compete successfully in the healthcare industry, must demonstrate that its products offer medical benefits as well as cost advantages. Currently, most of the products that the Company is trading, compete with other products already on the market in the same therapeutic category, and are subject to potential competition from new products that competitors may introduce in the future. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Revenue sources</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Full Line Wholesaler </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a full line pharmaceutical wholesaler, we distribute a comprehensive range of pharmaceutical products, including prescription medications, over-the-counter (OTC) drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products, to various businesses within the healthcare sector such as retail pharmacies, hospitals, private clinics and other wholesale pharmaceutical distributors.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Branded Pharmaceuticals &amp; Generics </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are engaged in the production, promotion, distribution and sale of licensed branded generics and OTC products throughout Europe by our subsidiaries in Greece and UK. Our capital efficient business model is based on infrastructure, efficiency and scale. We believe that there is a significant growth on opportunities through product additions and geographic expansion.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Healthcare Distribution</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We conduct direct distribution and sales of pharmaceuticals, medical devices, branded generics and OTC products. Our automated and GDP licensed distribution facilities ensure all medications reach their destination daily on an efficient and secure way. Our network exceeds over 1,500 pharmacies in Greece. We have created an upgraded and high-end distribution center in Greece due to our Robotic systems and integrated automations (&#8220;ROWA&#8221; robotics).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Nutraceutical</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have created and developed our own proprietary branded nutraceutical products, named &#8220;Sky Premium Life&#174;&#8221; which was launched in 2018 and &#8220;Mediterranation&#174;&#8221; which was launched in 2022. Utilizing unique formulations, and specialized extraction processes which follow strict pharmaceutical standards, our proprietary lines of nutraceuticals aim for excellence. We have a full portfolio of fast-moving and specialty formulas with more than 160 product codes including vitamins, minerals and other herbal extracts. Our nutraceutical products are manufactured exclusively by Doc Pharma. Our nutraceutical products have penetrated several markets within 2022 and 2023 through digital channels such as Amazon and Tmall.&#160;We focus on nutraceutical products because we foresee it as a market with high growth opportunities due to its large market size and margin contribution as the demand for nutraceutical products is increasing globally.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Regulations and Licenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Decahedron received its Wholesale Distribution Authorization for human use on February 5, 2021, from the UK Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) in accordance with Regulation 18 of the Human Medicines Regulations 2012 (SI 2012/1916) and it is subject to the provisions of those Regulations and the Medicines Act 1971. This License will continue to remain in force from the date of issue by the Licensing Authority unless cancelled, suspended, revoked or varied as to the period of its validity or relinquished by the authorization holder.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cosmofarm received its Wholesale Distribution Authorization for human use on February 15, 2019, from the National Organization for Medicines. The license is valid for a period of five years and pursuant to the EU directive of (2013/C343/01). Also, Cosmofarm was granted with GDP certificate on November 11, 2019.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our subsidiary, Cana SA, is a holder of Good Manufacturing Practices license (GMP), which means that it is certified for fulfilling the minimum standards that a medicines manufacturer must meet in the production processes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our subsidiaries are ISO 9001 certified for a management system for the trade and distribution of pharmaceuticals. As part of the certification process by the International Organization for Standardization, we need to be compliant with the General Data Protection Regulation (&#8220;GDPR&#8221;) adopted by the European Union in May 2018. GDPR applies to the processing of personal data of persons in the EU by a controller or processor.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">General Risks</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Supply chain disruption is a growing concern for the European pharmaceutical industry as it increasingly looks to cut costs by relying on &#8216;emerging markets&#8217;, where standards can be lower in terms of compliance, ethics and health and safety. Our business depends on the timely supply of materials, services and related products to meet the demands of our customers, which depends, in part, on the timely delivery of materials and services from suppliers and contract manufacturers. Significant or sudden increases in demand for our products, as well as worldwide demand for the raw materials and services we require to manufacture and sell our products, may result in a shortage of such materials or may cause shipment delays due to transportation interruptions or capacity constraints. Such shortages or delays could adversely impact our suppliers&#8217; ability to meet our demand requirements. Difficulties in obtaining sufficient and timely supply of materials or services can have an adverse impact on our manufacturing operations and our ability to meet customer demand.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may also experience significant interruptions of our manufacturing operations, delays in our ability to deliver products, increased costs or customer order cancellations as a result of:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the failure or inability to accurately forecast demand and obtain sufficient quantities of quality raw materials on a cost-effective basis;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">volatility in the availability and cost of materials or services, including rising prices due to inflation;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">difficulties or delays in obtaining required import or export approvals;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">shipment delays due to transportation interruptions or capacity constraints, such as reduced availability of air or ground transport or port closures;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">information technology or infrastructure failures, including those of a third-party supplier or service provider; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">natural disasters or other events beyond our control (such as earthquakes, utility interruptions, tsunamis, hurricanes, typhoons, floods, storms or extreme weather conditions, fires, regional economic downturns, regional or global health epidemics, pandemics, geopolitical turmoil, increased trade restrictions between the U.S. and China and other countries, social unrest, political instability, terrorism, or acts of war) in locations where we or our customers or suppliers have manufacturing or other operations.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Hikes in the price of medicine and their impact on the sustainability of the healthcare systems are garnering more and more attention. European regulators are willing to play their part in safeguarding continued access to safe and effective medicines. Regulators can speed up the approval of branded pharmaceuticals and biosimilars to boost competition and drive down prices. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cuts in healthcare spending have been frequently occurring since the financial crises of the late of 2000&#8217;s. Europe&#8217;s slow recovery has been uneven, with austerity and economic uncertainty, especially in the EU&#8217;s poorer member states, such as Greece.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Distribution and Trade Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 1, 2021, the Company&#8217;s subsidiary, SkyPharm SA, entered into an exclusive distribution agreement with a company based in Germany (&#8220;Distributor A&#8221;), whereas SkyPharm appointed Distributor A to be the responsible partner for the distribution, promotion, trade marketing, logistics and sale of the nutraceuticals manufactured and supplied by SkyPharm (Sky Premium Life&#174;), in the territories of Austria and Germany. Distributor A places purchase orders with SkyPharm at the company&#8217;s address and a purchase order is necessary to initiate any shipment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 7, 2021, SkyPharm SA signed a trade agreement with a company specializing in e-commerce mall advice and operation (&#8220;Distributor B&#8221;). Based on the agreement, SkyPharm sells its own branded products Sky Premium Life&#174; to final consumers through the e-commerce store opened by Distributor B on Tmall International MALL and Distributor B provides platform operation services to SkyPharm. The services provided by Distributor B include mall construction, mall operation and network promotion, along with collection, settlement, customer service, logistics and distribution.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 25, 2021, SkyPharm SA signed a trade agreement with a wholesaler which operates in the storage, distribution, trading and promotion of pharmaceutical products (&#8220;Distributor C&#8221;). Based on the agreement, Distributor C is appointed as the exclusive representative for the promotion and distribution of our proprietary nutraceutical products Sky Premium Life&#174; in Greece.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During July 2021, the Company&#8217;s subsidiary Decahedron Ltd created a distribution page on Amazon UK, through which it sells, advertises and promotes our own proprietary branded nutraceutical product line Sky Premium Life&#174;, directly to final consumers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 22, 2022, the Company entered into a distribution agreement with a third party in order to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits. Cosmos has exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 27, 2024, the Company signed an exclusive distribution agreement (the &#8220;Agreement&#8221;) with Pharmalink for its Sky Premium Life products in the UAE. As part of the Agreement, Pharmalink will be responsible for all key functions, including sales and marketing, regulatory affairs, logistics, supply, and distribution of Sky Premium Life&#174; products in the UAE. Cosmos Health has secured its first purchase order from Pharmalink for 130,000 units and anticipates receiving orders of more than 500,000 units in the first year and in excess of 3,000,000 units over the next five years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Acquisitions and Co-Ventures</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>ZipDoctor</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 28, 2022, the Company entered into a non-binding letter of intent (&#8220;LOI&#8221;) agreement to wholly acquire ZipDoctor Inc., a company that possesses a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. The current parent company of the acquiree will continue to manage all its aspects of the day-to-day operations, including product development, marketing, and operational support.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 17, 2023, the Company announced that it has entered into a definitive agreement to acquire ZipDoctor Inc. for a total sum of $150,000. The Sale and Purchase Agreement (&#8220;SPA&#8221;) was signed on March 17, 2023, and the transaction closed on April 3, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>CANA&#160;</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 31, 2023, the Company entered into a Stock Purchase Agreement with the owners of one hundred (100%) percent of the equity (the &#8220;Shares&#8221;) of Cana Laboratories Holdings (Cyprus) Limited (&#8220;Cana&#8221;), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana S.A. (&#8220;Cana SA&#8221;).&#160; The purchase price for the shares for the two sellers is &#8364;800,000 and 46,377 shares of Cosmos restricted common stock at an issuance price of $17.25 per share or $800,000. Moreover, on February 28,<sup style="vertical-align:super"> </sup>2023, the Company signed a Secured Promissory Note with Cana, whereby Cana borrowed the sum of &#8364;4,100,000 ($4,457,520), included in the total cash consideration provided for the acquisition. The acquisition was successfully completed on June 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cana SA is a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies. Cana stands out as it brings significant synergies and vertical integration. With a long-standing history spanning almost a century, Cana has earned the trust of industry giants like AstraZeneca, Merck, Unilever, and Procter &amp; Gamble. Cana's Good Manufacturing Practice (GMP) license enables us to manufacture pharmaceuticals, including medicines, within the EU, which creates attractive opportunities for high-margin contract manufacturing agreements with major multinational clients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Bikas</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 15, 2023, Cosmos Health Inc. entered into an Assignment and Assumption Agreement (the &#8220;Agreement&#8221;) with Ioannis Bikas O.E., a Greek Company (&#8220;Bikas&#8221;). Bikas is owner of a pharmaceutical distribution network in Greece and agreed to sell the Company their distribution network and customer base. The purchase price of the network was &#8364;100,000 ($109,330) of cash, and &#8364;300,000 ($316,081) of the Company&#8217;s stock. The Company issued 99,710 shares of common stock related to the acquisition of the customer base, based on the fair value of the stock on the acquisition date. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded $425,411 as an intangible asset related to the customer base acquired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This acquisition positively impacted on our revenue (an increase of more than $10 million annually) and enhanced the Company's gross margins due to economies of scale. Additionally, synergies with Cosmofarm's state-of-the-art facility, which employs robotic technologies for procurement, inventory management, and order execution, provide an elevated level of service to pharmacies, leading to increased orders. We are pleased to announce that we have now successfully integrated Bikas within the Cosmofarm platform.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cloudscreen</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, Business Combinations, (&#8220;ASC 805&#8221;) and recorded $637,080 as another asset related to the technology platform acquired. The total amount was reclassified to &#8220;Goodwill and intangible assets, net&#8221; in January 2024 with the closing of the agreement (refer to Notes 2 &amp; 5).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">39</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Results of Operations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Three Months Ended March 31, 2025 and 2024</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue and net loss</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended March 31, 2025, the Company reported revenue of $13,712,528 and a net loss of $818,097, compared to revenue of $14,584,473 and a net loss of $1,866,690 for the corresponding period in 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The decrease in net loss of approximately $1,048,593 is primarily attributable to a significant improvement in gross profit, driven by a shift in the Company&#8217;s revenue mix toward higher-margin product lines. In particular, the nutraceutical segment of our subsidiary, SkyPharm SA, recorded substantial growth during the period, contributing positively to overall gross profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenue for the three-month period ended March 31, 2025, decreased by approximately 5.98% compared to the same period in 2024. This decline is predominantly due to unfavorable foreign exchange movements, specifically the depreciation of the euro against the U.S. dollar, which negatively impacted the translation of euro-denominated revenues. Additionally, a marginal decrease in sales from our wholesale subsidiary, Cosmofarm SA, contributed modestly to the overall revenue decline.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cost of Goods Sold</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three-month periods ended March 31, 2025 and 2024, the Company reported cost of goods sold (&#8220;COGS&#8221;) of $11,662,729 and $13,250,847, respectively, representing a decrease of $1,588,118 or approximately 11.99%. This decrease in COGS is primarily attributable to a shift in the Company&#8217;s revenue mix toward higher-margin product lines, particularly the nutraceuticals segment, which generally carries lower direct costs relative to other product categories. The reduction in COGS is also broadly aligned with the overall decline in revenues during the same period, thus maintaining consistency in the Company&#8217;s cost structure relative to sales performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our future revenue growth is expected to continue to be affected by various factors such as industry growth trends, including drug utilization, the introduction of new innovative brand therapies, the likely increase in the number of branded pharmaceutical products that will be available over the next few years&#8217; price increases and price deflation, general economic conditions, including the effects of the current conflict in the Ukraine, the coronavirus in the United Kingdom and the member states of European Union, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in government rules and regulations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Gross Profit</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended March 31, 2025, the Company reported gross profit of $2,049,799, representing an increase of 53.7% compared to the same period in 2024. This significant improvement in gross profit is primarily attributable to a favorable shift in the Company&#8217;s revenue composition, with a greater proportion of sales generated from higher-margin product lines&#8212;most notably, those within the nutraceuticals segment. Additionally, the increase in gross profit corresponds with a reduction in COGS for the period, further reinforcing the positive impact of the evolving product mix on the Company&#8217;s margin performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Operating Expenses</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three-month period ended March 31, 2025, total operating expenses amounted to $2,882,944, compared to $3,169,734 for the corresponding period in 2024, representing a decrease of $286,790, or approximately 9.05%. This decrease was primarily driven by reductions in personnel and marketing-related expenditure, as outlined below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Salaries and Wages: Personnel expenses decreased to $1,040,019 for the three-month period ended March 31, 2025, compared to $1,258,179 in the prior-year period. This reduction reflects the impact of cost containment initiatives and a more efficient allocation of human resources.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Sales and Marketing Expenses: The Company recorded a significant decline in sales and marketing costs, particularly those associated with its branded nutraceutical portfolio. These expenses decreased by 83.78% compared to the first quarter of 2024, consistent with management&#8217;s strategic decision to temporarily scale back investment in brand promotion and advertising activities during the period under review.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Depreciation and Amortization: Depreciation and amortization expenses remained relatively stable, amounting to $320,349 in the first quarter of 2025 versus $319,787 in the corresponding period of 2024.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">General and Administrative Expenses: General and administrative costs increased modestly to $1,478,702 in the current period, up $60,564 or 4.27% from $1,418,138 in the prior-year quarter. The increase is primarily attributable to professional service fees.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Overall, the reduction in operating expenses reflects the Company&#8217;s continued focus on disciplined cost management while aligning spending with its strategic priorities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">40</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Other Income (Expense)</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three-month period ended March 31, 2025, the Company recorded other expense of $68,137, compared to other income of $191,824 for the same period in 2024. This represents a net unfavorable variance of $259,961, or 135.52% year-over-year. The variance is primarily attributable to the recognition of non-recurring charges and prior-period adjustments during the current period, which were not present in the comparative quarter. These one-off items had a material impact on the classification of other income and expense, thereby reversing the net favorable position recorded in the prior year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Interest Income &amp; Expenses</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three-month period ended March 31, 2025, interest expense totalled $187,107, representing an increase of $18,435, or 10.93%, compared to $168,672 for the prior period ended March 31, 2024. The increase was primarily driven by new debt facilities, entered into by our subsidiary Cosmofarm SA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Interest income for the three-month period ended March 31, 2025, was $91,326, reflecting a decrease of $14,439, or 13.65%, compared to $105,765 for the three-month period ended March 31, 2024. This decline was primarily due to the receipt of loan repayments during 2024, which reduced outstanding loan receivable balances and, consequently, interest earned on them.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Foreign currency translation adjustment, ne</em>t </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three-month period ended March 31, 2025, the Company recorded a foreign currency translation adjustment gain of $1,031,268, compared to a loss of $599,276 in the corresponding period of the prior year. The improvement is partially attributable to favourable movements in foreign exchange rates during the current reporting period, which positively impacted the translation of the financial statements of foreign subsidiaries. It should be noted that during the year 2024, the Company&#8217;s Parent, Cosmos Health Inc., executed a share capital increase of &#8364;18,400,000 ($20,345,432) in favour of its subsidiary, SkyPharm SA. This transaction had a substantial adverse impact on the accumulated comprehensive loss as of December 31, 2024, due to the nature of foreign currency translation under ASC 830, where equity-related transactions are translated using historical exchange rates. The exchange rate applied at the time of the capital contribution was less favourable than the year-end rate, leading to a significant unrealized currency loss on intercompany balances that is reflected in other comprehensive income. The combined effect of these factors contributed to the period-over-period fluctuation in the foreign currency translation adjustment recognized in other comprehensive income.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Capital Resources </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>As of</em> <em>March 31, 2025 compared with December 31, 2024</em>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, the Company had positive working capital of $1,259,012, compared to a negative working capital of $296,193 as of December 31, 2024. The improvement in working capital is primarily attributable to higher inventory levels and increased accounts receivable as of March 31, 2025. These increases reflect the Company&#8217;s focus on supporting sales growth and ensuring product availability. In addition, the reduction in related party accounts payable contributed to the improved position, following debt-to-equity conversions executed by our Chief Executive Officer, Mr. Grigorios Siokas, during the period. The Company believes its current working capital is adequate to meet short-term obligations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash Flow from Operating Activities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, the Company reported net cash of $742,881, compared to net cash of $315,105 as of December 31, 2024, reflecting an increase of $427,776. The improvement in net cash was primarily driven by financing cash inflows during the period, notably the proceeds from a new debt facility entered into by the Company&#8217;s wholly-owned subsidiary, Cosmofarm SA. For the three-month period ended March 31, 2025, the Company used net cash of $186,316 in operating activities, a significant improvement compared to the net cash used of $3,412,103 in the same period of the prior year. The marginally negative operating cash flow during the period is primarily attributable to consolidated operating losses, predominantly incurred at the Parent Company level. The impact of changes in working capital items on operating cash flows was limited and not a material driver of the overall cash utilization. The notable decrease in operating cash outflows compared to the prior period was mainly due to the reduction in the Company&#8217;s net loss during the period. Additionally, in the comparative period of 2024, significant cash outflows had occurred in the form of operating investments, particularly in the form of prepayments for inventory and product purchases, which were not repeated at the same magnitude during the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash Flow from Investing Activities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three-month period ended March 31, 2025, the Company used $7,069 in net cash for investing activities, compared to net cash provided by investing activities of $126,454 in the prior-year equivalent period. The cash outflows for the current period were immaterial and primarily reflect limited investment activity. The variance compared to the prior period is largely attributable to the absence of principal and interest receipts from the Company&#8217;s loans receivable, which had contributed to investing inflows during the three-month period ended March 31, 2024. As of the date of this report, the Company expects to recover the outstanding principal and accrued interest related to such loans within the next few months.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash Flow from Financing Activities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three-month period ended March 31, 2025, the Company generated $560,862 in net cash from financing activities, compared to $206,942 during the same period in 2024. The increase in net cash from financing activities was primarily driven by lower debt repayments and new financing arrangements. Debt repayments totalled $184,153 in the first quarter of 2025, a significant reduction compared to $364,354 in the prior-year period. In addition, during the first quarter of 2025, the Company&#8217;s subsidiary, Cosmofarm SA, entered into a new debt facility, which provided proceeds of $737,177. Equity financing activity during the three-month period ended March 31, 2024 included gross proceeds of $649,039 from two Prospectus Supplements to the Company&#8217;s Registration Statement on Form S-3. There were no comparable equity raises in the 2025 period. Furthermore, the Company generated $19,538 in net proceeds from its Lines of Credit during the first quarter of 2025. These inflows contributed to strengthening the Company&#8217;s liquidity position and funding ongoing operational needs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">41</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We anticipate using cash in our bank account as of March 31, 2025, cash generated from debt or equity financing, from investing activities or from management loans to the extent that funds are available to do so to conduct our business in the upcoming year. Management is not obliged to provide these or any other funds. If we fail to meet these requirements, we may lose the qualification for quotation and our securities would no longer trade on Nasdaq Capital Market. Further, as a consequence we would fail to satisfy our reporting obligations with the Securities and Exchange Commission (&#8220;SEC&#8221;), and investors would then own stock in a company that does not provide the disclosure available in quarterly and annual reports filed with the SEC and investors may have increased difficulty in selling their stock as we will be non-reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s unaudited consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), which contemplates the continuation of the Company as a going concern. For the period ended March 31, 2025, the Company had revenue of $13,712,528, net loss of $818,097 and net cash used in operations of $186,316. Additionally, as of March 31, 2025, the Company had positive working capital of $1,259,012, an accumulated deficit of $114,840,372, and stockholders&#8217; equity of $25,951,712. It is management&#8217;s opinion that these conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of 12 months from the date of this filing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s revenues are not able to sustain its operations, and concerns exist regarding the Company&#8217;s ability to meet its obligations as they become due. The Company is subject to a number of risks to those of smaller commercial companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the need to obtain additional capital, competition from larger companies, and other pharmaceutical and health care companies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management evaluated the above conditions which raise substantial doubt about the Company&#8217;s ability to continue as a going concern to determine if it can meet its obligations for the subsequent 12 months from the date of this filing. Management considered its ability to access future capital, curtail expenses if needed, expand product lines, and acquire new products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management&#8217;s plans include expansion of brand name products to the market, expanding the current product portfolio, and evaluating acquisition targets to expand distribution. The exclusive distribution agreement signed for its Sky Premium Life products in the United Arab Emirates (&#8220;UAE&#8221;) and the significant orders already received, are expected to substantially strengthen its operating cash flow. Furthermore, the Company intends to vertically integrate the supply chain distribution network. On top of that, the Company plans to access the capital markets further in order to raise additional funds through equity offerings. More specifically, commencing from August 2025, the Company will be eligible to utilize an S-3 registration statement, (12 months following the date that the Company had regained compliance with Listing Rule 5250(c)(1) (the &#8220;Filing Rule&#8221;)), to be in a position to raise equity capital more efficiently in conjunction with utilizing potential equity proceeds by its outstanding warrants. Management&#8217;s plans also include postponing certain debt repayments, through achieving favorable amendments to its debt facilities and in parallel intends to make substantial efforts to receive additional debt financing. Moreover, the Company&#8217;s management is considering of postponing certain repayments of suppliers and creditors. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Considering the above, management is of the view that substantial doubt exists for the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">42</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Strategic Plan</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our strategic plan, which strikes a balance between growth and sustainability, emphasizes synergies, vertical integration, operational efficiencies, R&amp;D, brand expansion, and the global growth of our distribution network and facilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We intend to continue to pursue active ongoing acquisitions. In fact, many of our acquisitions entail exploring opportunities, with discounted assets through business combinations or joint ventures, all to enhance our distribution network. We will expand our R&amp;D division which is a platform and incubator to develop new patented pharmaceuticals and proprietary innovative nutraceutical products. To foster organic growth, we will enhance our business development and marketing efforts, pursue global expansion via prominent retailers, pharmacies and e-commerce platforms, and recapture lost markets such as the infant and baby care categories. In addition, we will invest in the expansion of our production capacity and global network of facilities to boost sales of our brands, engage in contract manufacturing with large multinational pharmaceutical companies, produce pharma grade ethanol for hospitals, and expand into new large markets capitalizing on our comparative advantages. Last but not least, we aim to strategically invest in key personnel, from seasoned export managers to highly skilled scientists, to ensure we have the necessary expertise at our fingertips.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Growth Strategy</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our main strategy initiative is focused on continuing our progress in becoming a global healthcare company through the development of a lean, efficient and vertically integrated operating model, as well as, to expand our portfolio of our own branded nutraceutical and pharmaceutical products, grow our customer base and achieve our growth stabilization in this new market and gain an adequate size in the global pharmaceutical market. We are committed to serving our customers while continuing to innovate and provide products that make a difference in the lives of individuals. We strive to maximize our shareholders&#8217; value by adapting to market realities and customer needs. Our strategy involves the enhancement of our manufacturing capacities and building a multinational network or wholesalers, distributors, and pharmacies and simultaneously continuing to expand the portfolio of innovative products that we distribute to that network.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are committed to driving organic growth at attractive margins by improving execution, optimizing cash flow and leveraging our strong market position, while maintaining a streamlined cost structure throughout each of our businesses. We continue to further align our organization to our customers&#8217; needs in a more seamless and unified way, while supporting corporate strategy and accelerating growth.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In 2024 and during the three-month period ended March 31, 2025, we continued to execute on the core elements of our &#8220;Growth Strategy&#8221;, which remains as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>High Marking Segments</strong>: delivering on our growth areas and high-margin segments, we continued to show strong performance of our key proprietary brands such as Sky Premium Life&#174; (&#8220;SPL&#8221;), Mediterranation&#174; and C-Sept&#174; / C-Scrub&#174; with launches into new fast growing geographical regions.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">- </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Generic Pharmaceuticals:</strong> focusing on our generic medicines&#8217; capital with a view on a global commercial reach, focused portfolio and pipeline footprint, we continued to optimize our generics business and build a strong pipeline that will allow us to leverage our assets, know-how and sales network.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">- </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Manufacturing</strong> <strong>of Pharmaceuticals</strong>: directing our manufacturing business by optimizing our production facilities and establishing a global footprint in the pharmaceutical fields of contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO).</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">- </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Global Networks</strong>, leveraging our extensive global network to access new markets and business segments, amplifying our reach and impact. We aim to expand and consort our sales distribution networks of our proprietary brands through strategic agreements in new regions and territories, such as the UAE and other GCC countries, Eastern Europe etc., while strengthening our market share in core markets.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">- </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Corporate Reorganization</strong>: through vertical integration and efficiency, a <strong>corporate reorganization</strong> is underway to streamline costs and enhance asset and resource utilization through the integration of business units. A key component of this plan is to achieve operational efficiencies and economies of scale through organic growth and a cost optimization initiative aimed at significantly reducing recurring operating expenses and while maintaining the Company's growth outlook.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">- </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Innovation</strong>: stepping up innovation through taken steps to deliver innovative products pipeline, by accelerating our R&amp;D efforts on IP-driven products such as the CCX0722 obesity and weight management pill, CCDL24 an innovative treatment for gastrointestinal disorders, CNS, Prostate, Ovarian and Colorectal cancer treatments. Finally, our recently acquired AI-driven drug repurposing platform &#8220;Cloudscreen&#174;&#8221;, aims to address major health challenges in various treatment areas.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have made several strategic acquisitions of companies, products and technologies to complement our internal growth and expertise. These acquisitions have strengthened our core product technology infrastructure by providing additional manufacturing, marketing, and research and development capabilities, including the ability to manufacture our products, other product components and services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">43</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">While the Company intends to pursue these milestones, there may be circumstances where for valid business reasons or due to factors beyond the control of the Company, a reallocation of efforts may be necessary or advisable. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company intends to spend the funds available to strengthen working capital, inventories, intangible assets, acquisitions, research and development, sales and marketing expenses. Due to the uncertain nature of the industry in which the Company operates, projects may be frequently reviewed and reassessed. Accordingly, while it is currently intended by management that the available funds will be expended as set forth above, actual expenditures may in fact differ from these amounts and allocations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Product Portfolio </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our product portfolio includes generics and over-the-counter (&#8220;OTC&#8221;) pharmaceutical products, innovative medicines, as well as nutraceuticals and biocides. This structure enables strong alignment and integration between manufacturing, operations, commercial regions, research &amp; development and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas and physical wellbeing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Generic Medicines </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Generic medicines are the chemical and therapeutic equivalents of originator medicines and are typically more affordable in comparison to the originator&#8217;s products. Generic medicines are required to meet similar governmental requirements as their brand-name equivalents, such as those relating to current Good Manufacturing Practices (&#8220;GMP&#8221;), manufacturing processes and health authorities&#8217; inspections, and must receive regulatory approval prior to their sale in any given country. Generic medicines may be manufactured and marketed if relevant patents on their brand-name equivalents (and any additional government-mandated market exclusivity periods) have expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We develop, manufacture and sell generic medicines in a variety of dosage forms, including tablets, capsules, liquids, ointments and creams.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our portfolio of generic medicines includes: 1) ASTO-CHOL (Pravastatin); 2) Diorium (Omeprazole); 3) HEART-FREE (Clopidogrel); 4) the LIPICHOL (Atorvastatin); 5) Miltus (Donepezil); 6) Newzypra (Olanzapine); 7) the PNEUMO-KAST (Montelukast); 8) Sahar (Pioglitazone); 9) VIVALCID (Leucovorin); and 10) the Diabit-is&#160; (Sitagliptin).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Nutraceuticals</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Nutraceuticals is referring to a broad range of products derived from food sources that provide health benefits in addition to their basic nutritional value. While nutraceuticals are not classified as drugs, they are often used for their therapeutic effects in a manner similar to pharmaceuticals. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our proprietary nutraceutical brands are Sky Premium Life&#174; (&#8220;SPL&#8221;) and Mediterranation&#174;. Our portfolio currently includes around 165 SKUs and more specifically product codes such as Vitamins and Minerals, Amino Acids, Botanical and other Herbal extracts used for health prevention and care needs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Biocides </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our proprietary portfolio of branded biocides and antiseptic soaps comprises of our brands C-Sept&#174; and C-Scrub&#174;. The biocide C-Sept Pro 2% has a broad-spectrum antimicrobial formulation that combines 76% Isopropyl Alcohol and 2% chlorhexidine digluconate as active substances. On the other hand, our antiseptic soap, C-Scrub Wash 4% CHG, contains chlorhexidine digluconate as its active antiseptic substance, which is approved by the World Health Organization for human use. The broad antimicrobial spectrum of C-Scrub Wash 4% CHG encompasses Gram-positive and Gram-negative microbes, fungi, and viruses, and its efficacy has been demonstrated in numerous published clinical studies. C-Scrub Wash 4% CHG significantly reduces bacterial load on the skin with long lasting. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Other Pharmaceutical Products:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our portfolio of other pharmaceutical products includes brands such as: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Melatonin Spray&#174;;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Otikon&#8482;; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bio-bebe&#174;.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Melatonin Spray&#174;, is&#160;recommended for addressing&#160;insomnia&#160;and&#160;jet lag, offering a peaceful sleep. It is manufactured using nanonemulsification technology and primarily contains melatonin, a lipophilic molecule. To increase the absorption of such molecules, nanoemulsification is one of the most effective methods. The absorption of the ingredient increases proportionally with the reduction of the micelle diameter. The diameter of a nanoemulsion micelle ranges between 50 and 300nm. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Otikon&#8482; ear drops, is a class II medical device in the form of ear drops for spray application and contains natural ingredients used to relieve ear pain, remove excess ear wax (cerumen) and improve hearing. The efficacy and safety of Otikon&#8482; ear drops, or naturopathic drops, has been studied in children with ear pain associated with otitis media. Among other ingredients, it contains olive oil, mullein olive oil extract (Verbascum Thapsus), marigold oil extract (Calendula officinalis), St. John&#8217;s wort oil extract (Hypericum perforatum) and lavender oil (Lavandula officinalis). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bio-bebe&#174; is an organic infant care and nutrition brand. All product lines are made exclusively of 100% organic, high-quality ingredients, and are produced with minimal environmental impact. The range includes a variety of baby foods such as organic powder milk, pear, carrot and banana pur&#233;e, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges and organic rice creams with vanilla milk. Additional brand extensions include baby cosmetics, liquid dish soaps and detergents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">44</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In line with our growth strategy, we are constantly evaluating and optimizing our products portfolio, including through the sale of certain product rights in our operating or entering areas.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Off Balance Sheet Arrangements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, there were no off-balance sheet arrangements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Critical Accounting Policies </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2001, the SEC requested that all registrants list their most &#8220;critical accounting polices&#8221; under the Management&#8217;s Discussion and Analysis section. The SEC indicated that a &#8220;critical accounting policy&#8221; is one which is both important to the portrayal of a company&#8217;s financial condition and results, and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue Recognition: </em>The Company adopted Topic 606 Revenue from Contracts with Customers on January 1, 2018. As a result, it has changed its accounting policy for revenue recognition as detailed in Note 2. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Foreign Currency.</em> Assets and liabilities of all foreign operations are translated at period-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the period. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders&#8217; equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity&#8217;s local currency) are included in net (loss) earnings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes.</em> The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes, ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is liable for income taxes in Greece and the United Kingdom. The corporate income tax rate is 22% in Greece (tax losses are carried forward for five years effective January 1, 2013) and 25% in United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">45</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We recognize the impact of an uncertain tax position in our financial statements if, in management&#8217;s judgment, the position is not more-likely-than-not sustainable upon audit based on the position&#8217;s technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. We operate and are subject to audit in multiple taxing jurisdictions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We record interest and penalties related to income taxes as a component of interest and other expense as incurred, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740 &#8220;Accounting for Income Taxes&#8221; as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in this financial statement because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has net operating loss carry-forwards in our parent, Cosmos Health Inc., which are applicable to future taxable income in the United States (if any). Additionally, the Company has income tax liabilities in the United Kingdom. The income tax assets and liabilities are not able to be netted. We therefore reserve the income tax assets applicable to the United States but recognize the income tax liabilities in Greece and the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accounts Receivable and Allowance for Credit Losses</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows ASC 310 to estimate the allowance for doubtful accounts. Pursuant to FASB ASC paragraph 310-10-35-9, losses from uncollectible receivables shall be accrued when both of the following conditions are met: (a) information available before the financial statements are issued or are available to be issued (as discussed in Section 855-10-25) indicates that it is probable that an asset has been impaired at the date of the financial statements, and (b) the amount of the loss can be reasonably estimated. Those conditions may be considered in relation to individual receivables or in relation to groups of similar types of receivables. If the conditions are met, accrual shall be made even though the receivables that are uncollectible may not be identifiable. The Company reviews individually each trade receivable for collectability and performs on-going credit evaluations of its customers and adjusts credit limits based upon payment history and the customer&#8217;s current credit worthiness, as determined by the review of their current credit information; and determines the allowance for doubtful accounts based on historical write-off experience, customer specific facts and general economic conditions that may affect a client&#8217;s ability to pay. Bad debt expense is included in general and administrative expenses, if any.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Inventory Reserves</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our merchandise inventories are made up of finished goods and are valued at the lower of cost or market using the weighted-average cost method. Average cost includes the direct purchase price, net of vendor allowances and cash discounts, of merchandise inventory. We record valuation reserves on an annual basis for merchandise damage and defective returns, merchandise items with slow-moving or obsolescence exposure and merchandise that has a carrying value that exceeds market value. These reserves are estimates of a reduction in value to reflect inventory valuation at the lower of cost or market. The reserve for merchandise returns is based upon the determination of the historical net realizable value of products sold from our returned goods inventory or returned to vendors for credit. Our reserve for merchandise returns includes amounts for returned product on-hand as well as for new merchandise on-hand that we estimate will ultimately become returned goods inventory after being sold based on historical return rates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">46</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i3">Item 3. Quantitative and Qualitative Disclosures about Market Risk.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable. A smaller reporting company is not required to provide the information required by this Item.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i4">Item 4. Controls and Procedures.&#160;</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Disclosure Controls and Procedures</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act) that are designed to ensure that information required to be disclosed in the Company&#8217;s Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to the Company&#8217;s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Evaluation of Disclosure Controls and Procedures</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s management, with the participation of the Company&#8217;s Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the Principal Executive Officer and the Principal Financial Officer have concluded that, as of the end of the period covered by this report, the Company&#8217;s disclosure controls and procedures were ineffective due to material weaknesses stated below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has a lack of proper segregation of duties.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s internal control structure lacks multiple levels of review and oversight and does not have appropriate IT General Controls (ITGCs) for the applications used in the Financial Reporting process, caused by lack of design of relevant controls and overall IT risk management.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are in the process of remediating all material weaknesses present in our internal controls and we plan to have completed the remediation by December 31, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">- The Company has a lack of proper segregation of duties. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are in the process of updating the organizational chart in order to reallocate roles among personnel and emphasize sharing the responsibilities of key business processes by distributing the discrete functions of these processes to multiple people and departments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">- The Company&#8217;s internal control structure lacks multiple levels of review and oversight and does not have appropriate IT General Controls (ITGCs) for the applications used in the Financial Reporting process, caused by lack of design of relevant controls and overall IT risk management.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are in the process of developing multiple levels of review based on job responsibilities and level of personnel. For example, management reviews whether the bank reconciliations are being prepared on a timely basis by the preparer and whether there are discrepancies between the general ledger and the bank statements. Another example is the review of management accounting information by the CFO and his authorization for material transactions and adjustments. Furthermore, we are in the process of assessing a new financial reporting application that will be used by all the companies of the Group and would be able to support, process financially relevant information, provide financially relevant reporting and house financially relevant interfaces and application controls in order for us to more efficiently establish IT General Controls to a single and more reliable application.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">47</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Changes in Internal Controls Over Financial Reporting </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Audit Committee is in the process of evaluating our existing controls and procedures, while communicating with the Management on quarterly basis. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Audit Committee</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have a separately designated standing audit committee, which is appointed by the Board of Directors of Cosmos Health Inc. On April 28, 2022, Dr. Anastasios Aslidis was elected to serve on the Board of Directors and was appointed as a chair of the Audit Committee. Our three independent directors, Anastasios Aslidis, John Hoidas and Demetrios Demetriades serve on the Audit Committee. The primary function of the committee is to assist the Board of Directors in overseeing (1) the financial reporting and accounting processes of the Company, and (2) the financial statements audits of the Company. The Committee also prepares a written report to be included in the annual proxy statement of the Company pursuant to the applicable rules and regulations of the &#8220;SEC&#8221;. In furtherance of these purposes, the Committee shall maintain direct communication among the Company&#8217;s independent auditors and the Board of Directors. The independent auditors and any other registered public accounting firm engaged in preparing or issuing an audit report or performing other audit review or attest services for the Company shall report directly to the Committee and are ultimately accountable to the Committee and the Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In discharging its oversight role, the Committee is authorized to investigate any matter brought to its attention with full access to all books, records, facilities and personnel of the Company. The Committee shall have the sole authority to retain at the Company&#8217;s expense outside legal, accounting or other advisors to advise the Committee and to receive appropriate funding, as determined by the Committee, from the Company for the payment of the compensation of such advisors and for the payment of ordinary administrative expenses of the Committee that are necessary to carry out its duties. The Committee may request any officer or employee of the Company or the Company&#8217;s outside counsel or independent auditors to attend a meeting of the Committee or to meet with any member of, or advisors to, the Committee. The Committee may also meet with the Company&#8217;s investment bankers or financial analysts who follow the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Committee shall meet no less frequently than four times per year, with additional meetings as circumstances warrant. The Committee shall also meet periodically with management, the internal auditors, if any, and the independent auditors in separate executive sessions. The Committee shall record the minutes of all such meetings and shall submit the minutes of its meetings to, or discuss the matters deliberated at each meeting with, the Board of Directors. The Company&#8217;s chief financial or accounting officer shall function as the management liaison officer to the Committee. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">48</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="p2">PART II - OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="ii1">Item 1. Legal Proceedings.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There have been no changes since the filing of the Company&#8217;s Form 10-K for the year ended December 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="ii1a">Item 1A. Risk Factors</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is not required to provide the information called for in this item due to its status as a Smaller Reporting Company. You should refer to the other information set forth in this report, including the information set forth in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as in our consolidated financial statements and the related notes. Our business prospects, financial condition or results of operations could be adversely affected by any of these risks. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="ii2">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None. Previously reported on Form 8-K.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="ii3">Item 3. Defaults Upon Senior Securities.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="ii4">Item 4. Mine Safety Disclosures.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="ii5">Item 5. Other Information.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended March 31, 2025,&#160;no director or officer of the Company adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221;&#160;as each term is defined in Item 408(a) of Regulation S-K.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">49</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="ii6">Item 6. Exhibits.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(a) Exhibits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit No.</strong></p></td><td style="width:1%;"/><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Document Description</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex311.htm">31.1*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex311.htm">Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex312.htm">31.2*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex312.htm">Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex321.htm">32.1*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex321.htm">Certification of CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex322.htm">32.2*</a></p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex322.htm">Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.INS</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.SCH</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Schema Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.CAL</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Calculation Linkbase Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.DEF</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Definition Linkbase Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.LAB</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Labels Linkbase Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.PRE</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Presentation Linkbase Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">104</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).**</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">_____________ </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">*</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.</p></td></tr><tr style="height:15px"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">**</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">50</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="sig">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td/><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cosmos Health Inc.</strong></p></td><td/></tr><tr style="height:15px"><td style="width:50%;"/><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"/><td style="width:12%;"/></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Date:&#160;May 15, 2025</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Grigorios Siokas</em></p></td><td/></tr><tr style="height:15px"><td/><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Grigorios Siokas</p></td><td/></tr><tr style="height:15px"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer</p></td><td/></tr><tr style="height:15px"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">(Principal Executive Officer)</p></td><td/></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date:&#160;May 15, 2025</p></td><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Georgios Terzis</em></p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td/><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Georgios Terzis</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Financial Officer </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">(Principal Financial Officer, </p><p style="font-size:10pt;font-family:times new roman;margin:0px">And Principal Accounting </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Officer)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">51</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT INDEX</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit No.</strong></p></td><td style="width:1%;"/><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Document Description</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex311.htm">31.1*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex311.htm">Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex312.htm">31.2*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex312.htm">Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex321.htm">32.1*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex321.htm">Certification of CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex322.htm">32.2*</a></p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cosm_ex322.htm">Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.INS</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.SCH</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Schema Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.CAL</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Calculation Linkbase Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.DEF</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Definition Linkbase Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.LAB</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Labels Linkbase Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.PRE</p></td><td/><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inline XBRL Taxonomy Extension Presentation Linkbase Document.**</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">104</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).**</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">___________</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">*</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.</p></td></tr><tr style="height:15px"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">**</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">52</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>cosm_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cosm_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Grigorios Siokas, the Chief Executive Officer of Cosmos Health Inc., certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this report on Form 10-Q of Cosmos Health Inc. for the quarter ended March 31, 2025;</p></td></tr> <tr style="height:15px"> <td></td> <td colspan="2"></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td></td> <td colspan="2"></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td></td> <td colspan="2"></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr> <tr style="height:15px"> <td></td> <td colspan="2"></td></tr> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">a)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">b)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">c)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">d)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of a quarterly report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent function):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">b)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cosmos Health Inc.</strong></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:3%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:35%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:12%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Date:&nbsp;May 15, 2025</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Grigorios Siokas</em></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Grigorios Siokas, Chief Executive Officer</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">(Principal Executive Officer)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>cosm_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cosm_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Georgios Terzis, the Chief Financial Officer of Cosmos Health Inc., certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this report on Form 10-Q of Cosmos Health Inc., for the quarter ended March 31, 2025;</p></td></tr> <tr style="height:15px"> <td></td> <td colspan="2"></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td></td> <td colspan="2"></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td></td> <td colspan="2"></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr> <tr style="height:15px"> <td></td> <td colspan="2"></td></tr> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">a)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">b)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">c)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">d)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of a quarterly report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent function):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cosmos Health Inc.</strong></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:3%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:35%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:12%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Date:&nbsp;May 15, 2025</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Georgios Terzis</em></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Georgios Terzis, Chief Financial Officer</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">(Principal Financial Officer)</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>cosm_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cosm_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies that the Quarterly Report on Form 10-Q for the period ended March 31, 2025 of Cosmos Health Inc. (the &#8220;Company&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cosmos Health Inc.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"></td> <td style="width:3%;"></td> <td style="width:35%;"></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date: May 15, 2025</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>/s/ Grigorios Siokas</em></p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Grigorios Siokas</p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Executive Officer</p></td> <td></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Cosmos Health Inc. and will be retained by Cosmos Health Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>cosm_ex322.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cosm_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies that the Quarterly Report on Form 10-Q for the period ended March 31, 2025 of Cosmos Health Inc. (the &#8220;Company&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cosmos Health Inc.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"></td> <td style="width:3%;"></td> <td style="width:35%;"></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Date: May 15, 2025</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Georgios Terzis</em></p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">Georgios Terzis</p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">Principal Financial Officer and</p> <p style="MARGIN: 0px; text-align:justify;">Principal Accounting Officer</p></td> <td></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Cosmos Health Inc. and will be retained by Cosmos Health Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cosm-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cosm="http://cosm.com/20250331" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cosm.com/20250331">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cosm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>110200 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>110201 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited">
        <link:definition>124100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" id="CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited">
        <link:definition>148600 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>170000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/InsiderTradingArrangements" id="InsiderTradingArrangements">
        <link:definition>170001 - Disclosure - Insider Trading Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>170002 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OrganizationAndNatureOfBusiness" id="OrganizationAndNatureOfBusiness">
        <link:definition>170003 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/EquityMethodInvestments" id="EquityMethodInvestments">
        <link:definition>170004 - Disclosure - EQUITY METHOD INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>360000 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>370000 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LoanReceivable" id="LoanReceivable">
        <link:definition>370001 - Disclosure - LOAN RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>370002 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/CapitalStructure" id="CapitalStructure">
        <link:definition>500000 - Disclosure - CAPITAL STRUCTURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>845000 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LinesOfCredit" id="LinesOfCredit">
        <link:definition>845001 - Disclosure - LINES OF CREDIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/NotesPayable" id="NotesPayable">
        <link:definition>845002 - Disclosure - NOTES PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LEASES" id="LEASES">
        <link:definition>845003 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OtherLiabilities" id="OtherLiabilities">
        <link:definition>845004 - Disclosure - OTHER LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>845005 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/StockOptionsAndWarrants" id="StockOptionsAndWarrants">
        <link:definition>845006 - Disclosure - STOCK OPTIONS AND WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/DisaggregationOfRevenue" id="DisaggregationOfRevenue">
        <link:definition>845007 - Disclosure - DISAGGREGATION OF REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/SegmentReporting" id="SegmentReporting">
        <link:definition>845008 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>870000 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies" id="OrganizationAndNatureOfBusinessPolicies">
        <link:definition>870001 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessTables" id="OrganizationAndNatureOfBusinessTables">
        <link:definition>870002 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>870003 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <link:definition>870004 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
        <link:definition>870005 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LinesOfCreditTables" id="LinesOfCreditTables">
        <link:definition>870006 - Disclosure - LINES OF CREDIT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/NotesPayableTables" id="NotesPayableTables">
        <link:definition>870007 - Disclosure - NOTES PAYABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LeasesTables" id="LeasesTables">
        <link:definition>870008 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/StockOptionsAndWarrantsTables" id="StockOptionsAndWarrantsTables">
        <link:definition>870009 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/DisaggregationOfRevenueTables" id="DisaggregationOfRevenueTables">
        <link:definition>870010 - Disclosure - DISAGGREGATION OF REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/SegmentReportingTables" id="SegmentReportingTables">
        <link:definition>870011 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
        <link:definition>870012 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails" id="OrganizationAndNatureOfBusinessDetails">
        <link:definition>870013 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1" id="OrganizationAndNatureOfBusinessDetails1">
        <link:definition>870014 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2" id="OrganizationAndNatureOfBusinessDetails2">
        <link:definition>870015 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3" id="OrganizationAndNatureOfBusinessDetails3">
        <link:definition>870016 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4" id="OrganizationAndNatureOfBusinessDetails4">
        <link:definition>870017 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative" id="OrganizationAndNatureOfBusinessDetailsNarrative">
        <link:definition>870018 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative" id="EquityMethodInvestmentsDetailsNarrative">
        <link:definition>870019 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/PropertyPlantAndEquipmentDetails" id="PropertyPlantAndEquipmentDetails">
        <link:definition>870020 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/IntangibleAssetsNetDetails" id="IntangibleAssetsNetDetails">
        <link:definition>870021 - Disclosure - INTANGIBLE ASSETS NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/IntangibleAssetsNetDetails1" id="IntangibleAssetsNetDetails1">
        <link:definition>870022 - Disclosure - INTANGIBLE ASSETS NET (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LoanReceivableDetailsNarrative" id="LoanReceivableDetailsNarrative">
        <link:definition>870023 - Disclosure - LOAN RECEIVABLE (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
        <link:definition>870024 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/CapitalStructureDetailsNarrative" id="CapitalStructureDetailsNarrative">
        <link:definition>870025 - Disclosure - CAPITAL STRUCTURE (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <link:definition>870026 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/RelatedPartyTransactionsDetails1" id="RelatedPartyTransactionsDetails1">
        <link:definition>870027 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>870028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LinesOfCreditDetails" id="LinesOfCreditDetails">
        <link:definition>870029 - Disclosure - LINES OF CREDIT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LinesOfCreditDetailsNarrative" id="LinesOfCreditDetailsNarrative">
        <link:definition>870030 - Disclosure - LINES OF CREDIT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/NotesPayableDetails" id="NotesPayableDetails">
        <link:definition>870031 - Disclosure - NOTES PAYABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/NotesPayableDetails1" id="NotesPayableDetails1">
        <link:definition>870032 - Disclosure - NOTES PAYABLE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
        <link:definition>870033 - Disclosure - NOTES PAYABLE (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LeasesDetails" id="LeasesDetails">
        <link:definition>870034 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LeasesDetails1" id="LeasesDetails1">
        <link:definition>870035 - Disclosure - LEASES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
        <link:definition>870036 - Disclosure - LEASES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/OtherLiabilitiesDetailsNarrative" id="OtherLiabilitiesDetailsNarrative">
        <link:definition>870037 - Disclosure - OTHER LIABILITIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec" id="CommitmentsAndContingenciesDetailsNarrativec">
        <link:definition>870038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrativec)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/StockOptionsAndWarrantsDetails" id="StockOptionsAndWarrantsDetails">
        <link:definition>870039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative" id="StockOptionsAndWarrantsDetailsNarrative">
        <link:definition>870040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/DisaggregationOfRevenueDetails" id="DisaggregationOfRevenueDetails">
        <link:definition>870041 - Disclosure - DISAGGREGATION OF REVENUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/SegmentReportingDetails" id="SegmentReportingDetails">
        <link:definition>870042 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cosm.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>870043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <element id="cosm_AmountAccountsReceivableRelatedPartiesCurrent" name="AmountAccountsReceivableRelatedPartiesCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" name="PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_LoansReceivableNoncurrent" name="LoansReceivableNoncurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_LoansReceivableRelatedPartyNoncurrent" name="LoansReceivableRelatedPartyNoncurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_AdvancesForBuildingsAcquisition" name="AdvancesForBuildingsAcquisition" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OtherAssetsRelatedParty" name="OtherAssetsRelatedParty" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" name="AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_NotesPayableRelatedPartiesCurrent" name="NotesPayableRelatedPartiesCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_LoansPayableRelatedPartiesCurrent" name="LoansPayableRelatedPartiesCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_GainLossOnSalesOfEquityInvestments" name="GainLossOnSalesOfEquityInvestments" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ForeignCurrencyTranslationAdjustmentNet" name="ForeignCurrencyTranslationAdjustmentNet" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" name="ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" name="ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_SharesIssuedInLieuOfCashAmount" name="SharesIssuedInLieuOfCashAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares" name="SharesIssuedPursuantToWarrantExchangeAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount" name="SharesIssuedPursuantToWarrantExchangeAgreementAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_StockBasedCompensation" name="StockBasedCompensation" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_DebtExchangesShares" name="DebtExchangesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_DebtExchangesAmount" name="DebtExchangesAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" name="IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_IncreaseDecreaseInOtherLiabilities" name="IncreaseDecreaseInOtherLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CashPaidDuringTheYearNewAbstract" name="CashPaidDuringTheYearNewAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ClosingOfAcquisitionOfCloudscreen" name="ClosingOfAcquisitionOfCloudscreen" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CommonStockIssuedToEmployees" name="CommonStockIssuedToEmployees" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CommonStockIssuedToConsultants" name="CommonStockIssuedToConsultants" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CapitalStructureTextBlock" name="CapitalStructureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_LineOfCreditFacilitiesDisclosureTextBlock" name="LineOfCreditFacilitiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_StockOptionsAndWarrantsDisclouserTextBlock" name="StockOptionsAndWarrantsDisclouserTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_DisaggregationOfRevenueDisclosureTextBlock" name="DisaggregationOfRevenueDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_AcquisitionAccountingPolicy" name="AcquisitionAccountingPolicy" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_EffectsOfWarInTheUkrainePolicyTextBlock" name="EffectsOfWarInTheUkrainePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CreditLossesPolicyTextBlock" name="CreditLossesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_TaxReceivablesPolicyTextBlock" name="TaxReceivablesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CustomerAdvancesPolicyTextBlock" name="CustomerAdvancesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock" name="ScheduleOfRelatedPartyLoansPayableTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ScheduleOfOutstandingDebtTableTextBlock" name="ScheduleOfOutstandingDebtTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock" name="ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance" name="ChangesInAllowanceForDoubtfulAccountsBeginningBalance" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance" name="ChangesInAllowanceForDoubtfulAccountsEndingBalance" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PropertyPlantAndEquipmentUsefulLifes" name="PropertyPlantAndEquipmentUsefulLifes" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PropertyPlantsAndEquipmentUsefulLife" name="PropertyPlantsAndEquipmentUsefulLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives" name="PropertyPlantsAndEquipmentEstimatedUsefulLives" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PotentiallyDilutiveCommonStockEquivalents" name="PotentiallyDilutiveCommonStockEquivalents" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PotentialCommonShares" name="PotentialCommonShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_InitialShareCapital" name="InitialShareCapital" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_InitialShareCapitalIncreased" name="InitialShareCapitalIncreased" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PharmacyLicenseValue" name="PharmacyLicenseValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_MaturityPeriodOfLicense" name="MaturityPeriodOfLicense" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_EquityMethodInvestmentsOwnershipPercentage" name="EquityMethodInvestmentsOwnershipPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CashContributedToLimitedPartner" name="CashContributedToLimitedPartner" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_EquityMethodInvestmentOwnershipRemainingPercentage" name="EquityMethodInvestmentOwnershipRemainingPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable" name="ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_DecriptionOfLoanPayment" name="DecriptionOfLoanPayment" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CorporateTaxRate" name="CorporateTaxRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CommonStocksSharesIssued" name="CommonStocksSharesIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CommonStockShareAuthorized" name="CommonStockShareAuthorized" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_AuthorizationToRepurchaseCommonStock" name="AuthorizationToRepurchaseCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CommonStockSharesValue" name="CommonStockSharesValue" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CommonStocksSharesOutstanding" name="CommonStocksSharesOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PreferredStockLiquidationPreference1" name="PreferredStockLiquidationPreference1" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OriginalWarrantsSharesIssued" name="OriginalWarrantsSharesIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_RemainingWarrantsSharesIssued" name="RemainingWarrantsSharesIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_SharesHeldInEscrow" name="SharesHeldInEscrow" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_NotesPayableRelatedParty" name="NotesPayableRelatedParty" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_LoansPayableRelatedParty" name="LoansPayableRelatedParty" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_LoanPayableSetOffs" name="LoanPayableSetOffs" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_DescriptionInterestOfSecuredPromissoryNote" name="DescriptionInterestOfSecuredPromissoryNote" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_UnpaidSalariesAndBonusesDues" name="UnpaidSalariesAndBonusesDues" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" name="SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PrepaymentOfInventory" name="PrepaymentOfInventory" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_AccountsPayableRelatedPartyCurrent" name="AccountsPayableRelatedPartyCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_AmountAccountsReceivableRelatedParties" name="AmountAccountsReceivableRelatedParties" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_NetSales" name="NetSales" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_AgreementTerminate" name="AgreementTerminate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PiecesPerProduct" name="PiecesPerProduct" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PurchaseOfInventory" name="PurchaseOfInventory" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PurchaseOfPharmaceuticalsMedicine" name="PurchaseOfPharmaceuticalsMedicine" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PaymentReceivedFromInstallment" name="PaymentReceivedFromInstallment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_LineOfCreditBorrowingsLoanDescription" name="LineOfCreditBorrowingsLoanDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OutstandingDebtBalance" name="OutstandingDebtBalance" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ProceedFromDebt" name="ProceedFromDebt" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PaymentsOfDebt" name="PaymentsOfDebt" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ForeignCurrencyTranslation" name="ForeignCurrencyTranslation" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_CommonStockIssuedAsConsiderationFairValue" name="CommonStockIssuedAsConsiderationFairValue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_BusinessCombinationContingentConsiderationArrangementLiability" name="BusinessCombinationContingentConsiderationArrangementLiability" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_DebtAmountReceivedFromRelatedParty" name="DebtAmountReceivedFromRelatedParty" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OperatingLeaseLiabilityLessImputedInterest" name="OperatingLeaseLiabilityLessImputedInterest" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" name="FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" name="FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OperatingLeaseTermOfAgreements" name="OperatingLeaseTermOfAgreements" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OperatingLeaseCashFlowsUsedInFinanceLease" name="OperatingLeaseCashFlowsUsedInFinanceLease" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OperatingLeaseWeightedAverageDiscountRate" name="OperatingLeaseWeightedAverageDiscountRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm" name="OperatingLeaseWeightedAverageRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm" name="FinanceLeaseWeightedAverageRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_FinanceLeaseWeightedAverageDiscountRate" name="FinanceLeaseWeightedAverageDiscountRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_FinanceLeaseAmortizationExpense" name="FinanceLeaseAmortizationExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_TaxLiabilitiesPayable" name="TaxLiabilitiesPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PayrollTaxRelatedCurrentLiabilities" name="PayrollTaxRelatedCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ProvisionForStaffLeavingCompensation" name="ProvisionForStaffLeavingCompensation" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PaymentTax" name="PaymentTax" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ProjectCosts" name="ProjectCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_StockIssuedDuringPeriodSharesAwarded" name="StockIssuedDuringPeriodSharesAwarded" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_AdditionalStockConsideration" name="AdditionalStockConsideration" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ComplementaryCompensationShares" name="ComplementaryCompensationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_PurchasePriceAmount" name="PurchasePriceAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_WeightedAverageRemainingContractualTermOutstandingBeginning" name="WeightedAverageRemainingContractualTermOutstandingBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_WeightedAverageRemainingContractualTermOutstandingEnding" name="WeightedAverageRemainingContractualTermOutstandingEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_WeightedAverageRemainingContractualTermExercisable" name="WeightedAverageRemainingContractualTermExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_DiscriptionOfIncentiveStockAwards" name="DiscriptionOfIncentiveStockAwards" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_WarrantExpirationDateDescription" name="WarrantExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_NetFinanceCosts" name="NetFinanceCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_SegmentProfitLoss" name="SegmentProfitLoss" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OtherIncomeAndExpenses" name="OtherIncomeAndExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_InsiderTradingArrangementsAbstract" name="InsiderTradingArrangementsAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_OrganizationAndNatureOfTheBusinessAbstract" name="OrganizationAndNatureOfTheBusinessAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_LoanReceivableabstract" name="LoanReceivableabstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_IncomeTaxAbstract" name="IncomeTaxAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cosm_StockOptionsAndWarrantsAbstract" name="StockOptionsAndWarrantsAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="CANAPharmaceuticalLaboratoriesSACanaMember" id="cosm_CANAPharmaceuticalLaboratoriesSACanaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MachineryMember" id="cosm_MachineryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LeaseholdImprovementsAndTechnicalWorksMember" id="cosm_LeaseholdImprovementsAndTechnicalWorksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ZipDoctorIncMember" id="cosm_ZipDoctorIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="GreeceMember" id="cosm_GreeceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PancretaBankMember" id="cosm_PancretaBankMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BuildingAcquisionMember" id="cosm_BuildingAcquisionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TradeNameMarkMember" id="cosm_TradeNameMarkMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnitedKingdomMember" id="cosm_UnitedKingdomMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SoftwareMember" id="cosm_SoftwareMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UkMember" id="cosm_UkMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OtherMember" id="cosm_OtherMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DebtAgreementJulyMember" id="cosm_DebtAgreementJulyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TotalSegmentMember" id="cosm_TotalSegmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TopMember" id="cosm_TopMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BuildingsMember" id="cosm_BuildingsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BottomMember" id="cosm_BottomMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantInducementLetterMember" id="cosm_WarrantInducementLetterMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TreasuryStocksOneMember" id="cosm_TreasuryStocksOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantExchangeMember" id="cosm_WarrantExchangeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AtticaBankMember" id="cosm_AtticaBankMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EFGMember" id="cosm_EFGMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwentySevenTwoThousandTwentyFiveMember" id="cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AlbaniaMember" id="cosm_AlbaniaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CommonStockShareMember" id="cosm_CommonStockShareMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SubscriptionReceivableMember" id="cosm_SubscriptionReceivableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PhaseOneMember" id="cosm_PhaseOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CloudscreenMember" id="cosm_CloudscreenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantsMember" id="cosm_WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NotesPayableRelatedPartyMember" id="cosm_NotesPayableRelatedPartyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LoansPayableRelatedPartyMember" id="cosm_LoansPayableRelatedPartyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="GrigoriosSiokasMember" id="cosm_GrigoriosSiokasMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CanaHoldingsLaboratoriesHoldingLimitedMember" id="cosm_CanaHoldingsLaboratoriesHoldingLimitedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DocPharmaSaMember" id="cosm_DocPharmaSaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DimitriosGoulielmosMember" id="cosm_DimitriosGoulielmosMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PanagiotisKozarisMember" id="cosm_PanagiotisKozarisMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MariaKozariMember" id="cosm_MariaKozariMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="InventoriesRelatedAgreementMember" id="cosm_InventoriesRelatedAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="GeorgeTerzisMember" id="cosm_GeorgeTerzisMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="KanarogloySiaEpeMember" id="cosm_KanarogloySiaEpeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NationalMember" id="cosm_NationalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AlphaMember" id="cosm_AlphaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PancretaMember" id="cosm_PancretaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NationalBankOfGreeceOneMember" id="cosm_NationalBankOfGreeceOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NationalBankOfGreeceTwoMember" id="cosm_NationalBankOfGreeceTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AlphaBankOfGreeceMember" id="cosm_AlphaBankOfGreeceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PancretaOfGreeceMember" id="cosm_PancretaOfGreeceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TradeFacilityAgreementsMember" id="cosm_TradeFacilityAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ThirdPartyMember" id="cosm_ThirdPartyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="COVIDLoansMember" id="cosm_COVIDLoansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OperatingLeaseMember" id="cosm_OperatingLeaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FinanceLeaseMember" id="cosm_FinanceLeaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NationalMedicinesAgencyMember" id="cosm_NationalMedicinesAgencyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DebtExchangeAgreementMember" id="cosm_DebtExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JuneTwentyThreeTwoThousandTwentyMember" id="cosm_JuneTwentyThreeTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NationalBankOfGreeceSAMember" id="cosm_NationalBankOfGreeceSAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DebtAgreementJuneOneMember" id="cosm_DebtAgreementJuneOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JulyFourteenTwoThousandTwentyThreeMember" id="cosm_JulyFourteenTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PromissoryNotesMember" id="cosm_PromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CroatiaMember" id="cosm_CroatiaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CyprusMember" id="cosm_CyprusMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BulgariaMember" id="cosm_BulgariaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ShareExchangeAgreementMember" id="cosm_ShareExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IccMember" id="cosm_IccMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CosmoFarmacyLPMember" id="cosm_CosmoFarmacyLPMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JulyTwentyNineTwentyTwentyFourMember" id="cosm_JulyTwentyNineTwentyTwentyFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DeemberTwentyTwentyFourMember" id="cosm_DeemberTwentyTwentyFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CovidNinteenMember" id="cosm_CovidNinteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MayTwelveTwentyTwentyMember" id="cosm_MayTwelveTwentyTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JuneTwentyFourTwentyTwentyMember" id="cosm_JuneTwentyFourTwentyTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BasothoInvestmentLimitedMember" id="cosm_BasothoInvestmentLimitedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WholesaleMember" id="cosm_WholesaleMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PhaseTwoMember" id="cosm_PhaseTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FourThirdPartyConsultantsMember" id="cosm_FourThirdPartyConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BoardOfDirectorsMember" id="cosm_BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoZeroTwentyTwoPlanMember" id="cosm_TwoZeroTwentyTwoPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoZeroTwentyThreePlanMember" id="cosm_TwoZeroTwentyThreePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PharmamanufacturingMember" id="cosm_PharmamanufacturingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NutraceuticalsAndPharmaceuticalsMember" id="cosm_NutraceuticalsAndPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwentythreeTwoThousandTwentyFourMember" id="cosm_JanuaryTwentythreeTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>cosm-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address Country</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_ded99a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_ded99a" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_1afea8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_1afea8" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_3e967e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_3e967e" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_f82bd0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_f82bd0" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl_4fdbb1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl_4fdbb1" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AmountAccountsReceivableRelatedPartiesCurrent" xlink:label="cosm_AmountAccountsReceivableRelatedPartiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AmountAccountsReceivableRelatedPartiesCurrent" xlink:to="cosm_AmountAccountsReceivableRelatedPartiesCurrent_lbl_aab70b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AmountAccountsReceivableRelatedPartiesCurrent_lbl_aab70b" xml:lang="en-US">Accounts receivable - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl_ff78d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl_ff78d4" xml:lang="en-US">Marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_3986b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl_3986b0" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl_3f5906" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl_3f5906" xml:lang="en-US">Loans receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl_c23510" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl_c23510" xml:lang="en-US">Loans receivable - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_2f8ea3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_2f8ea3" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" xlink:label="cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" xlink:to="cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent_lbl_f2b35f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent_lbl_f2b35f" xml:lang="en-US">Prepaid expenses and other current assets - related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_93f513" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_93f513" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_13" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_38fa5e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_38fa5e" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl_6b06a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl_6b06a1" xml:lang="en-US">Goodwill and intangible assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansReceivableNoncurrent" xlink:label="cosm_LoansReceivableNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LoansReceivableNoncurrent" xlink:to="cosm_LoansReceivableNoncurrent_lbl_84d2a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LoansReceivableNoncurrent_lbl_84d2a9" xml:lang="en-US">Loans receivable - long term portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansReceivableRelatedPartyNoncurrent" xlink:label="cosm_LoansReceivableRelatedPartyNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LoansReceivableRelatedPartyNoncurrent" xlink:to="cosm_LoansReceivableRelatedPartyNoncurrent_lbl_8197af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LoansReceivableRelatedPartyNoncurrent_lbl_8197af" xml:lang="en-US">Loans receivable - related party - long term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_3924e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_3924e6" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_9af2f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_9af2f6" xml:lang="en-US">Financing lease right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AdvancesForBuildingsAcquisition" xlink:label="cosm_AdvancesForBuildingsAcquisition" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AdvancesForBuildingsAcquisition" xlink:to="cosm_AdvancesForBuildingsAcquisition_lbl_200a8a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AdvancesForBuildingsAcquisition_lbl_200a8a" xml:lang="en-US">Advances for building's acquisition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl_786f40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl_786f40" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OtherAssetsRelatedParty" xlink:label="cosm_OtherAssetsRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OtherAssetsRelatedParty" xlink:to="cosm_OtherAssetsRelatedParty_lbl_5bdf9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OtherAssetsRelatedParty_lbl_5bdf9a" xml:lang="en-US">Other assets - related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_0b5414" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_0b5414" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_23" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_974bda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_974bda" xml:lang="en-US">LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_0704a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_0704a0" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl_474f1f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl_474f1f" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:label="cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:to="cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl_f9c431" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl_f9c431" xml:lang="en-US">Accounts payable and accrued expenses - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl_90cc48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl_90cc48" xml:lang="en-US">Accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl_01a96d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl_01a96d" xml:lang="en-US">Lines of credit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl_8e5693" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl_8e5693" xml:lang="en-US">Notes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedPartiesCurrent" xlink:label="cosm_NotesPayableRelatedPartiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NotesPayableRelatedPartiesCurrent" xlink:to="cosm_NotesPayableRelatedPartiesCurrent_lbl_c3d035" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NotesPayableRelatedPartiesCurrent_lbl_c3d035" xml:lang="en-US">Notes payable - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedPartiesCurrent" xlink:label="cosm_LoansPayableRelatedPartiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LoansPayableRelatedPartiesCurrent" xlink:to="cosm_LoansPayableRelatedPartiesCurrent_lbl_d0f8a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LoansPayableRelatedPartiesCurrent_lbl_d0f8a4" xml:lang="en-US">Loans payable - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_e41709" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_e41709" xml:lang="en-US">Operating lease liability, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_c63aa0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_c63aa0" xml:lang="en-US">Financing lease liability, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl_97d6ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl_97d6ee" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_b47d3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_b47d3a" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_36" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl_0a6a6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl_0a6a6a" xml:lang="en-US">Notes payable - long term portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_7b7df3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_7b7df3" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_4366f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_4366f8" xml:lang="en-US">Financing lease liability, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_0a97af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_0a97af" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_cbbb8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_cbbb8f" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_41" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl_9f4480" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl_9f4480" xml:lang="en-US">Commitments and Contingencies (see Note 14)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_0e6179" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_0e6179" xml:lang="en-US">STOCKHOLDERS' EQUITY:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_ad1e3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_ad1e3a" xml:lang="en-US">Common stock, $0.001 par value; 300,000,000 shares authorized; 27,284,633 and 23,689,135 shares issued and 27,198,136 and 23,602,638 outstanding as of March 31, 2025 and December 31, 2024, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_1a4648" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_1a4648" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl_d4bde1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl_d4bde1" xml:lang="en-US">Subscription receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl_46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl_46" xml:lang="en-US">[Common Stock, Share Subscribed but Unissued, Subscriptions Receivable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl_9ac8b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockCommonValue_lbl_9ac8b4" xml:lang="en-US">Treasury stock, at cost, 86,497 shares as of March 31, 2025 and December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl_47" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonValue_lbl_47" xml:lang="en-US">[Treasury Stock, Common, Value]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_1e2de2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_1e2de2" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_89e46c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_89e46c" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_49" xml:lang="en-US">[Accumulated Other Comprehensive Income (Loss), Net of Tax]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_34552d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_34552d" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_50" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_50" xml:lang="en-US">[Equity, Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_f63890" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_f63890" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_51" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_6d01f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_6d01f5" xml:lang="en-US">Common stock, shares par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_4fb216" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_4fb216" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_1a0771" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_1a0771" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_8134be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_8134be" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl_13c338" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl_13c338" xml:lang="en-US">Treasury stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_27d1f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_27d1f5" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_d19201" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl_d19201" xml:lang="en-US">REVENUE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl_df294d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl_df294d" xml:lang="en-US">COST OF GOODS SOLD</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl_ddcff3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl_ddcff3" xml:lang="en-US">GROSS PROFIT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl_4" xml:lang="en-US">[Gross Profit]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_c903f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_c903f4" xml:lang="en-US">OPERATING EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_ab8a59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_ab8a59" xml:lang="en-US">General and administrative expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl_6d0f9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl_6d0f9c" xml:lang="en-US">Salaries and wages</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl_0e673f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl_0e673f" xml:lang="en-US">Sales and marketing expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_cd5f6f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_cd5f6f" xml:lang="en-US">Research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_abaf00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_abaf00" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_6b285a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_6b285a" xml:lang="en-US">TOTAL OPERATING EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_11" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_457884" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_457884" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_12" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_4aaf2c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_4aaf2c" xml:lang="en-US">OTHER INCOME (EXPENSE)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_c60b10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_c60b10" xml:lang="en-US">Other income (expense), net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_421f27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl_421f27" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl_15" xml:lang="en-US">[Interest Expense, Operating and Nonoperating]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl_8f6d2a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl_8f6d2a" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GainLossOnSalesOfEquityInvestments" xlink:label="cosm_GainLossOnSalesOfEquityInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_GainLossOnSalesOfEquityInvestments" xlink:to="cosm_GainLossOnSalesOfEquityInvestments_lbl_8c5eb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_GainLossOnSalesOfEquityInvestments_lbl_8c5eb3" xml:lang="en-US">Gain on equity investments, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl_f2be6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl_f2be6a" xml:lang="en-US">Foreign currency transaction, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_07f365" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_07f365" xml:lang="en-US">TOTAL OTHER INCOME (EXPENSE), NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_19" xml:lang="en-US">[Nonoperating Income (Expense)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_921397" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_921397" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_20" xml:lang="en-US">[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl_cb7b2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl_cb7b2b" xml:lang="en-US">INCOME TAX EXPENSE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_fc8fae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_fc8fae" xml:lang="en-US">NET LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_22" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_951dc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_951dc5" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_23" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl_798f7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl_798f7a" xml:lang="en-US">OTHER COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl_3521a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl_3521a9" xml:lang="en-US">Foreign currency translation adjustment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl_eeb85b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl_eeb85b" xml:lang="en-US">TOTAL COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl_26" xml:lang="en-US">[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl_28f981" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl_28f981" xml:lang="en-US">BASIC NET LOSS PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_c034f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_c034f2" xml:lang="en-US">DILUTED NET LOSS PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl_8c330f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl_8c330f" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl_5e4e9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl_5e4e9e" xml:lang="en-US">Basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:label="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:to="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_lbl_b89a9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_lbl_b89a9d" xml:lang="en-US">Diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_6e88bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_6e88bd" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_2b7832" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_2b7832" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_ca5653" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_ca5653" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_e14919" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_e14919" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl_a5d874" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl_a5d874" xml:lang="en-US">Treasury Stocks</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockShareMember" xlink:label="cosm_CommonStockShareMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStockShareMember" xlink:to="cosm_CommonStockShareMember_lbl_15fe40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CommonStockShareMember_lbl_15fe40" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_9feb8c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_9feb8c" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SubscriptionReceivableMember" xlink:label="cosm_SubscriptionReceivableMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_SubscriptionReceivableMember" xlink:to="cosm_SubscriptionReceivableMember_lbl_848a52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_SubscriptionReceivableMember_lbl_848a52" xml:lang="en-US">Subscription Receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_06703d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_06703d" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl_8a33d5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl_8a33d5" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl_27" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_23684d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_23684d" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl_10ed56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl_10ed56" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl_3" xml:lang="en-US">[Equity, Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ForeignCurrencyTranslationAdjustmentNet" xlink:to="cosm_ForeignCurrencyTranslationAdjustmentNet_lbl_9109a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_ForeignCurrencyTranslationAdjustmentNet_lbl_9109a3" xml:lang="en-US">Foreign currency translation adjustment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ForeignCurrencyTranslationAdjustmentNet" xlink:label="cosm_ForeignCurrencyTranslationAdjustmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ForeignCurrencyTranslationAdjustmentNet" xlink:to="cosm_ForeignCurrencyTranslationAdjustmentNet_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ForeignCurrencyTranslationAdjustmentNet_lbl_4" xml:lang="en-US">[Foreign currency translation adjustment, net]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" xlink:label="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" xlink:to="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares_lbl_3bcf5e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares_lbl_3bcf5e" xml:lang="en-US">Proceeds from sale of common stock, net of financing fees of $19,467, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" xlink:label="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" xlink:to="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount_lbl_cf461c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount_lbl_cf461c" xml:lang="en-US">Proceeds from sale of common stock, net of financing fees of $19,467, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesIssuedInLieuOfCashAmount" xlink:label="cosm_SharesIssuedInLieuOfCashAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_SharesIssuedInLieuOfCashAmount" xlink:to="cosm_SharesIssuedInLieuOfCashAmount_lbl_ee4f8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_SharesIssuedInLieuOfCashAmount_lbl_ee4f8f" xml:lang="en-US">Shares issued in lieu of cash</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares" xlink:label="cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares" xlink:to="cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares_lbl_99c358" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares_lbl_99c358" xml:lang="en-US">Shares issued pursuant to warrant exchange agreement, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount" xlink:label="cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount" xlink:to="cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount_lbl_f9bc81" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount_lbl_f9bc81" xml:lang="en-US">Shares issued pursuant to warrant exchange agreement, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockBasedCompensation" xlink:label="cosm_StockBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_StockBasedCompensation" xlink:to="cosm_StockBasedCompensation_lbl_da1b2a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_StockBasedCompensation_lbl_da1b2a" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_9876c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_9876c9" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtExchangesShares" xlink:label="cosm_DebtExchangesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DebtExchangesShares" xlink:to="cosm_DebtExchangesShares_lbl_83fe7b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DebtExchangesShares_lbl_83fe7b" xml:lang="en-US">Debt exchanges, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtExchangesAmount" xlink:label="cosm_DebtExchangesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DebtExchangesAmount" xlink:to="cosm_DebtExchangesAmount_lbl_10857b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DebtExchangesAmount_lbl_10857b" xml:lang="en-US">Debt exchanges, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_393641" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_393641" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl_ca770e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl_ca770e" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_b1ed27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_b1ed27" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e656d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e656d8" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_8013c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_8013c3" xml:lang="en-US">Net Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_997e43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_997e43" xml:lang="en-US">Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl_514ccb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl_514ccb" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl_5" xml:lang="en-US">[Other Depreciation and Amortization]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_605881" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_605881" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl_f53d37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl_f53d37" xml:lang="en-US">Bad debt expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl_ecb128" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl_ecb128" xml:lang="en-US">Lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl_d57a3b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl_d57a3b" xml:lang="en-US">Interest on finance leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_710a54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_710a54" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_10" xml:lang="en-US">[Share-Based Payment Arrangement, Noncash Expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl_d74a22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl_d74a22" xml:lang="en-US">Deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl_f6e228" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl_f6e228" xml:lang="en-US">Gain on net change in fair value of equity investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl_12" xml:lang="en-US">[Gain (Loss) on Investments]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_6b81ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_6b81ae" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_8d6c06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_8d6c06" xml:lang="en-US">Accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_14" xml:lang="en-US">[Increase (Decrease) in Accounts Receivable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl_89df9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl_89df9c" xml:lang="en-US">Accounts receivable - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl_15" xml:lang="en-US">[Increase (Decrease) in Accounts Receivable, Related Parties]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_db4638" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_db4638" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_16" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl_321cd7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl_321cd7" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl_17" xml:lang="en-US">[Increase (Decrease) in Prepaid Expenses, Other]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" xlink:to="cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty_lbl_f38c7e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty_lbl_f38c7e" xml:lang="en-US">Prepaid expenses and other current assets - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" xlink:label="cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" xlink:to="cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty_lbl_18" xml:lang="en-US">[Prepaid expenses and other current assets - related party]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_b27350" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_b27350" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_19" xml:lang="en-US">[Increase (Decrease) in Accounts Payable and Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" xlink:to="cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties_lbl_e1fed7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties_lbl_e1fed7" xml:lang="en-US">Accounts payable and accrued expenses - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" xlink:label="cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" xlink:to="cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties_lbl_20" xml:lang="en-US">[Accounts payable and accrued expenses - related party]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl_5861b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl_5861b0" xml:lang="en-US">Accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl_21" xml:lang="en-US">[Increase (Decrease) in Interest Payable, Net]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_90cd70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_90cd70" xml:lang="en-US">Lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_a17d34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_a17d34" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_23" xml:lang="en-US">[Increase (Decrease) in Other Current Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_IncreaseDecreaseInOtherLiabilities" xlink:to="cosm_IncreaseDecreaseInOtherLiabilities_lbl_7831ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_IncreaseDecreaseInOtherLiabilities_lbl_7831ac" xml:lang="en-US">Other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncreaseDecreaseInOtherLiabilities" xlink:label="cosm_IncreaseDecreaseInOtherLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_IncreaseDecreaseInOtherLiabilities" xlink:to="cosm_IncreaseDecreaseInOtherLiabilities_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_IncreaseDecreaseInOtherLiabilities_lbl_24" xml:lang="en-US">[Other liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_54add1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_54add1" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_25" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_0efe20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_0efe20" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfLoansReceivable" xlink:label="us-gaap_ProceedsFromSaleOfLoansReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfLoansReceivable" xlink:to="us-gaap_ProceedsFromSaleOfLoansReceivable_lbl_d35197" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfLoansReceivable_lbl_d35197" xml:lang="en-US">Proceeds from loan receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_768692" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_768692" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_28" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl_e6651c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl_e6651c" xml:lang="en-US">Sale of intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_fe8bdf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_fe8bdf" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_30" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_aadf9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_aadf9b" xml:lang="en-US">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_31" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_d8209b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_d8209b" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl_4ed370" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl_4ed370" xml:lang="en-US">Payment of note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl_33" xml:lang="en-US">[Repayments of Notes Payable]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl_e5ce28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl_e5ce28" xml:lang="en-US">Proceeds from note payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_116f4b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_116f4b" xml:lang="en-US">Payment of related party loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_35" xml:lang="en-US">[Repayments of Related Party Debt]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl_5301f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl_5301f3" xml:lang="en-US">Payment of lines of credit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl_36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl_36" xml:lang="en-US">[Repayments of Lines of Credit]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl_654e75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl_654e75" xml:lang="en-US">Proceeds from lines of credit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_996e0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_996e0e" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl_bbe89a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl_bbe89a" xml:lang="en-US">Payments of financing fees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl_39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl_39" xml:lang="en-US">[Payments of Financing Costs]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_3f34b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_3f34b4" xml:lang="en-US">Payments of finance lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_40" xml:lang="en-US">[Finance Lease, Principal Payments]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_9a8813" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_9a8813" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_41" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_a12c67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_a12c67" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_58ce24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_58ce24" xml:lang="en-US">NET CHANGE IN CASH</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_43" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_9af3c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_9af3c0" xml:lang="en-US">CASH AT BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_6ac551" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_6ac551" xml:lang="en-US">CASH AT END OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_841e56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_841e56" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CashPaidDuringTheYearNewAbstract" xlink:label="cosm_CashPaidDuringTheYearNewAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CashPaidDuringTheYearNewAbstract" xlink:to="cosm_CashPaidDuringTheYearNewAbstract_lbl_b76ba7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CashPaidDuringTheYearNewAbstract_lbl_b76ba7" xml:lang="en-US">Cash paid during the year:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_94b409" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_94b409" xml:lang="en-US">Interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_8b7368" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_8b7368" xml:lang="en-US">Supplemental Disclosure of Non-Cash Investing and Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ClosingOfAcquisitionOfCloudscreen" xlink:label="cosm_ClosingOfAcquisitionOfCloudscreen" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ClosingOfAcquisitionOfCloudscreen" xlink:to="cosm_ClosingOfAcquisitionOfCloudscreen_lbl_1c2772" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ClosingOfAcquisitionOfCloudscreen_lbl_1c2772" xml:lang="en-US">Closing of acquisition of Cloudscreen</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockIssuedToEmployees" xlink:label="cosm_CommonStockIssuedToEmployees" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStockIssuedToEmployees" xlink:to="cosm_CommonStockIssuedToEmployees_lbl_4fc662" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CommonStockIssuedToEmployees_lbl_4fc662" xml:lang="en-US">Common stock issued to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockIssuedToConsultants" xlink:label="cosm_CommonStockIssuedToConsultants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStockIssuedToConsultants" xlink:to="cosm_CommonStockIssuedToConsultants_lbl_7e3fc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CommonStockIssuedToConsultants_lbl_7e3fc2" xml:lang="en-US">Common stock issued to consultants</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InsiderTradingArrangementsAbstract" xlink:label="cosm_InsiderTradingArrangementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_InsiderTradingArrangementsAbstract" xlink:to="cosm_InsiderTradingArrangementsAbstract_lbl_2c4935" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_InsiderTradingArrangementsAbstract_lbl_2c4935" xml:lang="en-US">Insider Trading Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl_d48b7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl_d48b7a" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl_67b5c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl_67b5c0" xml:lang="en-US">Rule 10b5-1 Arrangements Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl_e371ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl_e371ce" xml:lang="en-US">Rule 10b5-1 Arrangements Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl_1c19c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl_1c19c3" xml:lang="en-US">Non Rule 10b5-1 Arrangements Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl_9961f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl_9961f8" xml:lang="en-US">Non Rule 10b5-1 Arrangements Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BasisOfPresentationAbstract" xlink:label="cosm_BasisOfPresentationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BasisOfPresentationAbstract" xlink:to="cosm_BasisOfPresentationAbstract_lbl_e585c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_BasisOfPresentationAbstract_lbl_e585c6" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl_43a5f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl_43a5f7" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl_2" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="cosm_OrganizationAndNatureOfTheBusinessAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:to="cosm_OrganizationAndNatureOfTheBusinessAbstract_lbl_c2315a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OrganizationAndNatureOfTheBusinessAbstract_lbl_c2315a" xml:lang="en-US">ORGANIZATION AND NATURE OF BUSINESS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl_bb9067" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl_bb9067" xml:lang="en-US">ORGANIZATION AND NATURE OF BUSINESS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl_0612b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAbstract_lbl_0612b9" xml:lang="en-US">EQUITY METHOD INVESTMENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl_379698" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl_379698" xml:lang="en-US">EQUITY METHOD INVESTMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl_2" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_dfe239" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_dfe239" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_1092d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_1092d6" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl_ec0c45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl_ec0c45" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl_00ed17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl_00ed17" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl_2" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoanReceivableabstract" xlink:label="cosm_LoanReceivableabstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LoanReceivableabstract" xlink:to="cosm_LoanReceivableabstract_lbl_a47652" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LoanReceivableabstract_lbl_a47652" xml:lang="en-US">LOAN RECEIVABLE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl_9edcd4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl_9edcd4" xml:lang="en-US">LOAN RECEIVABLE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl_2" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncomeTaxAbstract" xlink:label="cosm_IncomeTaxAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_IncomeTaxAbstract" xlink:to="cosm_IncomeTaxAbstract_lbl_a9ae98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_IncomeTaxAbstract_lbl_a9ae98" xml:lang="en-US">INCOME TAXES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_d88abd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_d88abd" xml:lang="en-US">INCOME TAXES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_6f197b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_6f197b" xml:lang="en-US">CAPITAL STRUCTURE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CapitalStructureTextBlock" xlink:to="cosm_CapitalStructureTextBlock_lbl_674701" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_CapitalStructureTextBlock_lbl_674701" xml:lang="en-US">CAPITAL STRUCTURE</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CapitalStructureTextBlock" xlink:label="cosm_CapitalStructureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CapitalStructureTextBlock" xlink:to="cosm_CapitalStructureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CapitalStructureTextBlock_lbl_2" xml:lang="en-US">[CAPITAL STRUCTURE]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_2ef43c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_2ef43c" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_00c99a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_00c99a" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract_lbl_4b270e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAbstract_lbl_4b270e" xml:lang="en-US">LINES OF CREDIT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LineOfCreditFacilitiesDisclosureTextBlock" xlink:to="cosm_LineOfCreditFacilitiesDisclosureTextBlock_lbl_4e2637" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_LineOfCreditFacilitiesDisclosureTextBlock_lbl_4e2637" xml:lang="en-US">LINES OF CREDIT</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LineOfCreditFacilitiesDisclosureTextBlock" xlink:label="cosm_LineOfCreditFacilitiesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LineOfCreditFacilitiesDisclosureTextBlock" xlink:to="cosm_LineOfCreditFacilitiesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LineOfCreditFacilitiesDisclosureTextBlock_lbl_2" xml:lang="en-US">[LINES OF CREDIT]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl_63b494" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl_63b494" xml:lang="en-US">NOTES PAYABLE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl_14dc00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl_14dc00" xml:lang="en-US">NOTES PAYABLE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl_2" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl_57ef35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl_57ef35" xml:lang="en-US">LEASES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl_b9cc9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl_b9cc9f" xml:lang="en-US">LEASES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl_2" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="us-gaap_OtherLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesAbstract_lbl_49c9ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesAbstract_lbl_49c9ab" xml:lang="en-US">OTHER LIABILITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl_bea393" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl_bea393" xml:lang="en-US">OTHER LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl_2" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_ce75cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_ce75cd" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_37f87d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_37f87d" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockOptionsAndWarrantsAbstract" xlink:label="cosm_StockOptionsAndWarrantsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_StockOptionsAndWarrantsAbstract" xlink:to="cosm_StockOptionsAndWarrantsAbstract_lbl_793dff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_StockOptionsAndWarrantsAbstract_lbl_793dff" xml:lang="en-US">STOCK OPTIONS AND WARRANTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_StockOptionsAndWarrantsDisclouserTextBlock" xlink:to="cosm_StockOptionsAndWarrantsDisclouserTextBlock_lbl_e286f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_StockOptionsAndWarrantsDisclouserTextBlock_lbl_e286f4" xml:lang="en-US">STOCK OPTIONS AND WARRANTS</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockOptionsAndWarrantsDisclouserTextBlock" xlink:label="cosm_StockOptionsAndWarrantsDisclouserTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_StockOptionsAndWarrantsDisclouserTextBlock" xlink:to="cosm_StockOptionsAndWarrantsDisclouserTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_StockOptionsAndWarrantsDisclouserTextBlock_lbl_2" xml:lang="en-US">[STOCK OPTIONS AND WARRANTS]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl_9b3e11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl_9b3e11" xml:lang="en-US">DISAGGREGATION OF REVENUE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DisaggregationOfRevenueDisclosureTextBlock" xlink:to="cosm_DisaggregationOfRevenueDisclosureTextBlock_lbl_b307d5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_DisaggregationOfRevenueDisclosureTextBlock_lbl_b307d5" xml:lang="en-US">DISAGGREGATION OF REVENUE</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DisaggregationOfRevenueDisclosureTextBlock" xlink:label="cosm_DisaggregationOfRevenueDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DisaggregationOfRevenueDisclosureTextBlock" xlink:to="cosm_DisaggregationOfRevenueDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DisaggregationOfRevenueDisclosureTextBlock_lbl_2" xml:lang="en-US">[DISAGGREGATION OF REVENUE]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl_f4e3f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl_f4e3f7" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl_046d7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl_046d7a" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl_2" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_4d13a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_4d13a6" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_810d4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_810d4d" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_df7877" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_df7877" xml:lang="en-US">Basis of Financial Statement Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AcquisitionAccountingPolicy" xlink:label="cosm_AcquisitionAccountingPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AcquisitionAccountingPolicy" xlink:to="cosm_AcquisitionAccountingPolicy_lbl_e8d66c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AcquisitionAccountingPolicy_lbl_e8d66c" xml:lang="en-US">Acquisition Accounting</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl_c40976" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl_c40976" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_e6220c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_e6220c" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EffectsOfWarInTheUkrainePolicyTextBlock" xlink:label="cosm_EffectsOfWarInTheUkrainePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_EffectsOfWarInTheUkrainePolicyTextBlock" xlink:to="cosm_EffectsOfWarInTheUkrainePolicyTextBlock_lbl_512dc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_EffectsOfWarInTheUkrainePolicyTextBlock_lbl_512dc2" xml:lang="en-US">The Effects of War in the Ukraine</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CreditLossesPolicyTextBlock" xlink:label="cosm_CreditLossesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CreditLossesPolicyTextBlock" xlink:to="cosm_CreditLossesPolicyTextBlock_lbl_414634" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CreditLossesPolicyTextBlock_lbl_414634" xml:lang="en-US">Credit Losses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_58d74d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_58d74d" xml:lang="en-US">Transactions in and Translations of Foreign Currency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_0082e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_0082e6" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl_20e4d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl_20e4d8" xml:lang="en-US">Accounts Receivable, net</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TaxReceivablesPolicyTextBlock" xlink:label="cosm_TaxReceivablesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TaxReceivablesPolicyTextBlock" xlink:to="cosm_TaxReceivablesPolicyTextBlock_lbl_c4b2c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_TaxReceivablesPolicyTextBlock_lbl_c4b2c3" xml:lang="en-US">Tax Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_f21269" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_f21269" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_5f67e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_5f67e6" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_005f58" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_005f58" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl_6fa0ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl_6fa0ed" xml:lang="en-US">Intangibles, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl_81b72e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl_81b72e" xml:lang="en-US">Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl_bb8ae2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl_bb8ae2" xml:lang="en-US">Investments in Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl_d2baf6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl_d2baf6" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CustomerAdvancesPolicyTextBlock" xlink:label="cosm_CustomerAdvancesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CustomerAdvancesPolicyTextBlock" xlink:to="cosm_CustomerAdvancesPolicyTextBlock_lbl_8761f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CustomerAdvancesPolicyTextBlock_lbl_8761f7" xml:lang="en-US">Customer Advances</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDeferredRevenue" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue_lbl_7abade" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl_7abade" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl_a2aeaa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl_a2aeaa" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_f4e6a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_f4e6a5" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl_e6a883" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl_e6a883" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitPlansPolicy" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl_80fef6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl_80fef6" xml:lang="en-US">Retirement and Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_bb1c93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_bb1c93" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f6661c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f6661c" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl_d20bb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl_d20bb4" xml:lang="en-US">Schedule of Accounts Receivable &amp; Allowance for Doubtful Accounts</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl_962da7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl_962da7" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl_a0842b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl_a0842b" xml:lang="en-US">Schedule of Property and Equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl_de9a13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl_de9a13" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_8ddfac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_8ddfac" xml:lang="en-US">Schedule of potential shares of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_d86fc8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_d86fc8" xml:lang="en-US">Schedule of Property and Equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_2" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl_6e6a82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl_6e6a82" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_4e9fcf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_4e9fcf" xml:lang="en-US">Schedule of amortization expense for intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl_62832b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl_62832b" xml:lang="en-US">Schedule of Related Party Notes Payable activity</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock" xlink:label="cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock" xlink:to="cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock_lbl_5c6a0c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock_lbl_5c6a0c" xml:lang="en-US">Schedule of Related Party Loans Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl_7f54a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl_7f54a6" xml:lang="en-US">Schedule of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl_2b53df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl_2b53df" xml:lang="en-US">Summary of roll forward of the third party Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ScheduleOfOutstandingDebtTableTextBlock" xlink:label="cosm_ScheduleOfOutstandingDebtTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ScheduleOfOutstandingDebtTableTextBlock" xlink:to="cosm_ScheduleOfOutstandingDebtTableTextBlock_lbl_ef378f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ScheduleOfOutstandingDebtTableTextBlock_lbl_ef378f" xml:lang="en-US">Summary of Outstanding Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_fc87d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_fc87d1" xml:lang="en-US">Schedule of maturity of Operating Lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_4ac909" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_4ac909" xml:lang="en-US">Schedule of maturity of finance lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_68c86b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_68c86b" xml:lang="en-US">Schedule of option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl_543e98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl_543e98" xml:lang="en-US">Schedule of Revenue Disaggregation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl_96d8c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl_96d8c8" xml:lang="en-US">Schedule of Segment Reporting Information</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock" xlink:label="cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock" xlink:to="cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock_lbl_8f85cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock_lbl_8f85cc" xml:lang="en-US">Schedule of describes the operations of each reportable segment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl_1d7c39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl_1d7c39" xml:lang="en-US">Net cash used in operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_540d5e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl_540d5e" xml:lang="en-US">Stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_abfbea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_abfbea" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WorkingCapital" xlink:label="cosm_WorkingCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_WorkingCapital" xlink:to="cosm_WorkingCapital_lbl_f126f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_WorkingCapital_lbl_f126f4" xml:lang="en-US">Working capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_8b438d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl_8b438d" xml:lang="en-US">Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_c445e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl_c445e6" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl_ba7019" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl_ba7019" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CANAPharmaceuticalLaboratoriesSACanaMember" xlink:label="cosm_CANAPharmaceuticalLaboratoriesSACanaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CANAPharmaceuticalLaboratoriesSACanaMember" xlink:to="cosm_CANAPharmaceuticalLaboratoriesSACanaMember_lbl_e48e9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CANAPharmaceuticalLaboratoriesSACanaMember_lbl_e48e9e" xml:lang="en-US">CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl_89d197" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl_89d197" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl_4f5c92" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl_4f5c92" xml:lang="en-US">Fair value of common stock issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl_6c49b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl_6c49b0" xml:lang="en-US">Fair value of total consideration transferred</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_577426" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Assets_lbl_577426" xml:lang="en-US">Financial assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl_34f99a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl_34f99a" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl_6" xml:lang="en-US">[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl_38fdfe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl_38fdfe" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl_2c4dbb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl_2c4dbb" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_lbl_8738f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_lbl_8738f0" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl_137d8a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl_137d8a" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl_ea8f6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl_ea8f6a" xml:lang="en-US">Bargain purchase gain</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance" xlink:label="cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance" xlink:to="cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance_lbl_cb7ff8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance_lbl_cb7ff8" xml:lang="en-US">Balance as of January 1st, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="us-gaap_ProvisionForOtherCreditLosses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl_86cf21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl_86cf21" xml:lang="en-US">Provisions for credit losses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl_20d499" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl_20d499" xml:lang="en-US">Write-offs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl_96bd4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl_96bd4d" xml:lang="en-US">Foreign exchange adjustments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl_70da80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl_70da80" xml:lang="en-US">Other adjustments</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance" xlink:label="cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance" xlink:to="cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance_lbl_720714" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance_lbl_720714" xml:lang="en-US">Balance as of March 31, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl_43d887" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl_43d887" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_ca4db7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_ca4db7" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl_6034f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl_6034f5" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MachineryMember" xlink:label="cosm_MachineryMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_MachineryMember" xlink:to="cosm_MachineryMember_lbl_4ca7ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_MachineryMember_lbl_4ca7ee" xml:lang="en-US">Machinery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LeaseholdImprovementsAndTechnicalWorksMember" xlink:label="cosm_LeaseholdImprovementsAndTechnicalWorksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LeaseholdImprovementsAndTechnicalWorksMember" xlink:to="cosm_LeaseholdImprovementsAndTechnicalWorksMember_lbl_48dba4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LeaseholdImprovementsAndTechnicalWorksMember_lbl_48dba4" xml:lang="en-US">Leasehold improvements and technical works [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl_b72213" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl_b72213" xml:lang="en-US">Furniture, fixtures and equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TopMember" xlink:label="cosm_TopMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TopMember" xlink:to="cosm_TopMember_lbl_13b071" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_TopMember_lbl_13b071" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BuildingsMember" xlink:label="cosm_BuildingsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BuildingsMember" xlink:to="cosm_BuildingsMember_lbl_bfb600" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_BuildingsMember_lbl_bfb600" xml:lang="en-US">Buildings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BottomMember" xlink:label="cosm_BottomMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BottomMember" xlink:to="cosm_BottomMember_lbl_531120" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_BottomMember_lbl_531120" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl_0f50ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl_0f50ec" xml:lang="en-US">Computers and software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PropertyPlantAndEquipmentUsefulLifes" xlink:label="cosm_PropertyPlantAndEquipmentUsefulLifes" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PropertyPlantAndEquipmentUsefulLifes" xlink:to="cosm_PropertyPlantAndEquipmentUsefulLifes_lbl_717fc7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PropertyPlantAndEquipmentUsefulLifes_lbl_717fc7" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PropertyPlantsAndEquipmentUsefulLife" xlink:to="cosm_PropertyPlantsAndEquipmentUsefulLife_lbl_1930a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_PropertyPlantsAndEquipmentUsefulLife_lbl_1930a9" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PropertyPlantsAndEquipmentUsefulLife" xlink:label="cosm_PropertyPlantsAndEquipmentUsefulLife" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PropertyPlantsAndEquipmentUsefulLife" xlink:to="cosm_PropertyPlantsAndEquipmentUsefulLife_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PropertyPlantsAndEquipmentUsefulLife_lbl_3" xml:lang="en-US">[Estimated Useful Life]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives" xlink:label="cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives" xlink:to="cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives_lbl_1f560c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives_lbl_1f560c" xml:lang="en-US">Estimated useful life, description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_c40b7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_c40b7a" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PotentiallyDilutiveCommonStockEquivalents" xlink:label="cosm_PotentiallyDilutiveCommonStockEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PotentiallyDilutiveCommonStockEquivalents" xlink:to="cosm_PotentiallyDilutiveCommonStockEquivalents_lbl_c78b01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PotentiallyDilutiveCommonStockEquivalents_lbl_c78b01" xml:lang="en-US">Potentially dilutive common stock equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_61a915" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_61a915" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl_2cf7c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl_2cf7c1" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PotentialCommonShares" xlink:to="cosm_PotentialCommonShares_lbl_fda22e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_PotentialCommonShares_lbl_fda22e" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PotentialCommonShares" xlink:label="cosm_PotentialCommonShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PotentialCommonShares" xlink:to="cosm_PotentialCommonShares_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PotentialCommonShares_lbl_3" xml:lang="en-US">[Total]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl_146816" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl_146816" xml:lang="en-US">Income Tax Authority Name Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_7ce8a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_7ce8a2" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ZipDoctorIncMember" xlink:label="cosm_ZipDoctorIncMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ZipDoctorIncMember" xlink:to="cosm_ZipDoctorIncMember_lbl_de1f9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ZipDoctorIncMember_lbl_de1f9c" xml:lang="en-US">Zip Doctor Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GreeceMember" xlink:label="cosm_GreeceMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_GreeceMember" xlink:to="cosm_GreeceMember_lbl_615f1f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_GreeceMember_lbl_615f1f" xml:lang="en-US">Greece [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PancretaBankMember" xlink:label="cosm_PancretaBankMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PancretaBankMember" xlink:to="cosm_PancretaBankMember_lbl_bc307c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PancretaBankMember_lbl_bc307c" xml:lang="en-US">Pancreta Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BuildingAcquisionMember" xlink:label="cosm_BuildingAcquisionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BuildingAcquisionMember" xlink:to="cosm_BuildingAcquisionMember_lbl_90c406" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_BuildingAcquisionMember_lbl_90c406" xml:lang="en-US">Building Acquision [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UnitedKingdomMember" xlink:label="cosm_UnitedKingdomMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_UnitedKingdomMember" xlink:to="cosm_UnitedKingdomMember_lbl_3e6abd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_UnitedKingdomMember_lbl_3e6abd" xml:lang="en-US">United Kingdom [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CloudscreenMember" xlink:label="cosm_CloudscreenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CloudscreenMember" xlink:to="cosm_CloudscreenMember_lbl_91c6a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CloudscreenMember_lbl_91c6a8" xml:lang="en-US">Cloudscreen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl_8edc01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl_8edc01" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_799c4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_799c4d" xml:lang="en-US">Corporate income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl_1693cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl_1693cf" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl_e5e032" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl_e5e032" xml:lang="en-US">Net receivable balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_8e6b07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_8e6b07" xml:lang="en-US">Amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:label="us-gaap_OtherInvestmentsAndSecuritiesAtCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:to="us-gaap_OtherInvestmentsAndSecuritiesAtCost_lbl_e854f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInvestmentsAndSecuritiesAtCost_lbl_e854f3" xml:lang="en-US">Investments in debt and equity securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_8ab203" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl_8ab203" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_lbl_c070fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_lbl_c070fb" xml:lang="en-US">Recurring Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedLoss_lbl_b50b09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss_lbl_b50b09" xml:lang="en-US">Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl_fd0721" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl_fd0721" xml:lang="en-US">Other Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl_feb854" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl_feb854" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl_12" xml:lang="en-US">[Payments to Acquire Productive Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCosts" xlink:to="us-gaap_AcquisitionCosts_lbl_fead4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquisitionCosts_lbl_fead4c" xml:lang="en-US">Payment of fees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl_dcbce5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl_dcbce5" xml:lang="en-US">Intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl_f26af8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl_f26af8" xml:lang="en-US">Impairment charge</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:to="us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_lbl_aa6dd4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_lbl_aa6dd4" xml:lang="en-US">Total purchase price amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl_220680" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl_220680" xml:lang="en-US">Shares of common stock issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_lbl_ad305f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_lbl_ad305f" xml:lang="en-US">Shares of common fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl_3a0936" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl_3a0936" xml:lang="en-US">Equity method investment aggregate cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl_e5d9eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl_e5d9eb" xml:lang="en-US">Issuable stock amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" xlink:label="cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" xlink:to="cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares_lbl_64d942" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares_lbl_64d942" xml:lang="en-US">Shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_lbl_bb9f4f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_lbl_bb9f4f" xml:lang="en-US">Asset acquision</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSecuredNotesPayable" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable_lbl_d7ebd7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable_lbl_d7ebd7" xml:lang="en-US">Secured Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:to="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl_4913d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl_4913d0" xml:lang="en-US">Asset acquisition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl_f7b754" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl_f7b754" xml:lang="en-US">Related Party Transaction Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareExchangeAgreementMember" xlink:label="cosm_ShareExchangeAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ShareExchangeAgreementMember" xlink:to="cosm_ShareExchangeAgreementMember_lbl_e80a5e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ShareExchangeAgreementMember_lbl_e80a5e" xml:lang="en-US">Share Exchange Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IccMember" xlink:label="cosm_IccMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_IccMember" xlink:to="cosm_IccMember_lbl_9c6609" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_IccMember_lbl_9c6609" xml:lang="en-US">ICC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CosmoFarmacyLPMember" xlink:label="cosm_CosmoFarmacyLPMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CosmoFarmacyLPMember" xlink:to="cosm_CosmoFarmacyLPMember_lbl_941045" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CosmoFarmacyLPMember_lbl_941045" xml:lang="en-US">Cosmo Farmacy LP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl_dca297" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl_dca297" xml:lang="en-US">Investement</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InitialShareCapital" xlink:label="cosm_InitialShareCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_InitialShareCapital" xlink:to="cosm_InitialShareCapital_lbl_fe5807" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_InitialShareCapital_lbl_fe5807" xml:lang="en-US">Initial share capital</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InitialShareCapitalIncreased" xlink:label="cosm_InitialShareCapitalIncreased" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_InitialShareCapitalIncreased" xlink:to="cosm_InitialShareCapitalIncreased_lbl_0d4210" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_InitialShareCapitalIncreased_lbl_0d4210" xml:lang="en-US">Initial share capital increased</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PharmacyLicenseValue" xlink:label="cosm_PharmacyLicenseValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PharmacyLicenseValue" xlink:to="cosm_PharmacyLicenseValue_lbl_6a5979" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PharmacyLicenseValue_lbl_6a5979" xml:lang="en-US">Pharmacy license value</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MaturityPeriodOfLicense" xlink:label="cosm_MaturityPeriodOfLicense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_MaturityPeriodOfLicense" xlink:to="cosm_MaturityPeriodOfLicense_lbl_c10a88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_MaturityPeriodOfLicense_lbl_c10a88" xml:lang="en-US">Maturity period of license</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EquityMethodInvestmentsOwnershipPercentage" xlink:label="cosm_EquityMethodInvestmentsOwnershipPercentage" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_EquityMethodInvestmentsOwnershipPercentage" xlink:to="cosm_EquityMethodInvestmentsOwnershipPercentage_lbl_ecd2d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_EquityMethodInvestmentsOwnershipPercentage_lbl_ecd2d2" xml:lang="en-US">Ownership equity</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CashContributedToLimitedPartner" xlink:label="cosm_CashContributedToLimitedPartner" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CashContributedToLimitedPartner" xlink:to="cosm_CashContributedToLimitedPartner_lbl_f05e3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CashContributedToLimitedPartner_lbl_f05e3a" xml:lang="en-US">Cash contributed to limited partner</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EquityMethodInvestmentOwnershipRemainingPercentage" xlink:label="cosm_EquityMethodInvestmentOwnershipRemainingPercentage" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_EquityMethodInvestmentOwnershipRemainingPercentage" xlink:to="cosm_EquityMethodInvestmentOwnershipRemainingPercentage_lbl_3f7c4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_EquityMethodInvestmentOwnershipRemainingPercentage_lbl_3f7c4d" xml:lang="en-US">Equity ownership remaining</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl_921453" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl_921453" xml:lang="en-US">Major Property Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl_08fa43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl_08fa43" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl_68f994" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl_68f994" xml:lang="en-US">Furniture, fixtures and equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl_c3c074" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl_c3c074" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl_aa6ccc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl_aa6ccc" xml:lang="en-US">Building And Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl_c49018" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl_c49018" xml:lang="en-US">Property plant and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_0ed76a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_0ed76a" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_3" xml:lang="en-US">[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_703c62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_703c62" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl_935506" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl_935506" xml:lang="en-US">Indefinite Lived Intangible Assets By Major Class Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_f40c1a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_f40c1a" xml:lang="en-US">Finite Lived Intangible Assets By Major Class Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl_aa3d8c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl_aa3d8c" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TradeNameMarkMember" xlink:label="cosm_TradeNameMarkMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TradeNameMarkMember" xlink:to="cosm_TradeNameMarkMember_lbl_a17d42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_TradeNameMarkMember_lbl_a17d42" xml:lang="en-US">Trade name / mark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerListsMember" xlink:label="us-gaap_CustomerListsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerListsMember" xlink:to="us-gaap_CustomerListsMember_lbl_a944f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerListsMember_lbl_a944f5" xml:lang="en-US">Customer Base [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SoftwareMember" xlink:label="cosm_SoftwareMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_SoftwareMember" xlink:to="cosm_SoftwareMember_lbl_3cf788" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_SoftwareMember_lbl_3cf788" xml:lang="en-US">Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_OtherFiniteLivedIntangibleAssetsGross_lbl_5f6dbf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross_lbl_5f6dbf" xml:lang="en-US">Goodwill and intangible assets, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_805874" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_805874" xml:lang="en-US">Less: Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_3" xml:lang="en-US">[Finite-Lived Intangible Assets, Accumulated Amortization]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl_7fce22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl_7fce22" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl_31d512" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl_31d512" xml:lang="en-US">Goodwill</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl_95e2e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl_95e2e5" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_d40927" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_d40927" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_bfe4c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_bfe4c7" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_faa7ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_faa7ce" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_7758d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_7758d1" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_33fa5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_33fa5f" xml:lang="en-US">2030</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl_43e733" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl_43e733" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_71ac6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_71ac6c" xml:lang="en-US">Total amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="us-gaap_PaymentsOfLoanCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfLoanCosts" xlink:to="us-gaap_PaymentsOfLoanCosts_lbl_73c6e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfLoanCosts_lbl_73c6e5" xml:lang="en-US">Prepayments of loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtInterestRateIncrease" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease_lbl_552937" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease_lbl_552937" xml:lang="en-US">Interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl_75b19f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl_75b19f" xml:lang="en-US">Accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl_4" xml:lang="en-US">[Increase (Decrease) in Accrued Interest Receivable, Net]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable" xlink:label="cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable" xlink:to="cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable_lbl_67dc30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable_lbl_67dc30" xml:lang="en-US">Loan receivables term</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DecriptionOfLoanPayment" xlink:label="cosm_DecriptionOfLoanPayment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DecriptionOfLoanPayment" xlink:to="cosm_DecriptionOfLoanPayment_lbl_e1fbaa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DecriptionOfLoanPayment_lbl_e1fbaa" xml:lang="en-US">Decription of loan payment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_GreeceMember" xlink:to="cosm_GreeceMember_lbl_56fc46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_GreeceMember_lbl_56fc46" xml:lang="en-US">Greece [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_UnitedKingdomMember" xlink:to="cosm_UnitedKingdomMember_lbl_b48560" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_UnitedKingdomMember_lbl_b48560" xml:lang="en-US">United Kingdom [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CorporateTaxRate" xlink:label="cosm_CorporateTaxRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CorporateTaxRate" xlink:to="cosm_CorporateTaxRate_lbl_c463d5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CorporateTaxRate_lbl_c463d5" xml:lang="en-US">Corporate tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl_260989" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl_260989" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_82e34b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_82e34b" xml:lang="en-US">Award Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl_bc804f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl_bc804f" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantInducementLetterMember" xlink:label="cosm_WarrantInducementLetterMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_WarrantInducementLetterMember" xlink:to="cosm_WarrantInducementLetterMember_lbl_a19b99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_WarrantInducementLetterMember_lbl_a19b99" xml:lang="en-US">Warrant Inducement Letter [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TreasuryStocksOneMember" xlink:label="cosm_TreasuryStocksOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TreasuryStocksOneMember" xlink:to="cosm_TreasuryStocksOneMember_lbl_0193a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_TreasuryStocksOneMember_lbl_0193a1" xml:lang="en-US">Treasury Stocks One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantExchangeMember" xlink:label="cosm_WarrantExchangeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_WarrantExchangeMember" xlink:to="cosm_WarrantExchangeMember_lbl_9bf5ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_WarrantExchangeMember_lbl_9bf5ea" xml:lang="en-US">Warrant Exchange [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BottomMember" xlink:to="cosm_BottomMember_lbl_332543" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_BottomMember_lbl_332543" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TopMember" xlink:to="cosm_TopMember_lbl_bec896" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_TopMember_lbl_bec896" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_ec97ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_ec97ee" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStocksSharesIssued" xlink:to="cosm_CommonStocksSharesIssued_lbl_f3d309" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_CommonStocksSharesIssued_lbl_f3d309" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStocksSharesIssued" xlink:label="cosm_CommonStocksSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStocksSharesIssued" xlink:to="cosm_CommonStocksSharesIssued_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CommonStocksSharesIssued_lbl_3" xml:lang="en-US">[Common stock, shares issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStockShareAuthorized" xlink:to="cosm_CommonStockShareAuthorized_lbl_e82509" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_CommonStockShareAuthorized_lbl_e82509" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockShareAuthorized" xlink:label="cosm_CommonStockShareAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStockShareAuthorized" xlink:to="cosm_CommonStockShareAuthorized_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CommonStockShareAuthorized_lbl_4" xml:lang="en-US">[Common stock, shares authorized]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_b6d3dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_b6d3dd" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AuthorizationToRepurchaseCommonStock" xlink:label="cosm_AuthorizationToRepurchaseCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AuthorizationToRepurchaseCommonStock" xlink:to="cosm_AuthorizationToRepurchaseCommonStock_lbl_7150ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AuthorizationToRepurchaseCommonStock_lbl_7150ff" xml:lang="en-US">Common stock, authorization to purchase</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockSharesValue" xlink:label="cosm_CommonStockSharesValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStockSharesValue" xlink:to="cosm_CommonStockSharesValue_lbl_be505c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CommonStockSharesValue_lbl_be505c" xml:lang="en-US">Common stock shares value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl_afd293" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl_afd293" xml:lang="en-US">Pre-funded warrants issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_ca60de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_ca60de" xml:lang="en-US">Warrants exercise price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStocksSharesOutstanding" xlink:to="cosm_CommonStocksSharesOutstanding_lbl_f36136" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_CommonStocksSharesOutstanding_lbl_f36136" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStocksSharesOutstanding" xlink:label="cosm_CommonStocksSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStocksSharesOutstanding" xlink:to="cosm_CommonStocksSharesOutstanding_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CommonStocksSharesOutstanding_lbl_10" xml:lang="en-US">[Common stock, shares outstanding]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PreferredStockLiquidationPreference1" xlink:label="cosm_PreferredStockLiquidationPreference1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PreferredStockLiquidationPreference1" xlink:to="cosm_PreferredStockLiquidationPreference1_lbl_88e574" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PreferredStockLiquidationPreference1_lbl_88e574" xml:lang="en-US">Preferred stock, Liquidation Preference</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_19ccab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_19ccab" xml:lang="en-US">Gross cash proceeds from warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OriginalWarrantsSharesIssued" xlink:label="cosm_OriginalWarrantsSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OriginalWarrantsSharesIssued" xlink:to="cosm_OriginalWarrantsSharesIssued_lbl_4f1b6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OriginalWarrantsSharesIssued_lbl_4f1b6b" xml:lang="en-US">Original Warrants Shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_RemainingWarrantsSharesIssued" xlink:label="cosm_RemainingWarrantsSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_RemainingWarrantsSharesIssued" xlink:to="cosm_RemainingWarrantsSharesIssued_lbl_b17295" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_RemainingWarrantsSharesIssued_lbl_b17295" xml:lang="en-US">Remaining Warrants Shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesHeldInEscrow" xlink:label="cosm_SharesHeldInEscrow" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_SharesHeldInEscrow" xlink:to="cosm_SharesHeldInEscrow_lbl_a8cc0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_SharesHeldInEscrow_lbl_a8cc0f" xml:lang="en-US">Shares held in escrow</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_d0dbf9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_d0dbf9" xml:lang="en-US">Term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl_a7c98e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl_a7c98e" xml:lang="en-US">Short Term Debt Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedPartyMember" xlink:label="cosm_NotesPayableRelatedPartyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NotesPayableRelatedPartyMember" xlink:to="cosm_NotesPayableRelatedPartyMember_lbl_49aa67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NotesPayableRelatedPartyMember_lbl_49aa67" xml:lang="en-US">Notes Payable - Related Party [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NotesPayableRelatedParty" xlink:to="cosm_NotesPayableRelatedParty_lbl_fc2096" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cosm_NotesPayableRelatedParty_lbl_fc2096" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedParty" xlink:label="cosm_NotesPayableRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NotesPayableRelatedParty" xlink:to="cosm_NotesPayableRelatedParty_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NotesPayableRelatedParty_lbl_2" xml:lang="en-US">[Beginning balance]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLoans" xlink:to="us-gaap_PaymentsForLoans_lbl_03a12f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForLoans_lbl_03a12f" xml:lang="en-US">Payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLoans" xlink:label="us-gaap_PaymentsForLoans" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLoans" xlink:to="us-gaap_PaymentsForLoans_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLoans_lbl_3" xml:lang="en-US">[Payments for Loans]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl_2cce06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl_2cce06" xml:lang="en-US">Foreign currency translation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NotesPayableRelatedParty" xlink:to="cosm_NotesPayableRelatedParty_lbl_628edd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cosm_NotesPayableRelatedParty_lbl_628edd" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedPartyMember" xlink:label="cosm_LoansPayableRelatedPartyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LoansPayableRelatedPartyMember" xlink:to="cosm_LoansPayableRelatedPartyMember_lbl_ecd751" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LoansPayableRelatedPartyMember_lbl_ecd751" xml:lang="en-US">Loans Payable - Related Party [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LoansPayableRelatedParty" xlink:to="cosm_LoansPayableRelatedParty_lbl_439a2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cosm_LoansPayableRelatedParty_lbl_439a2d" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedParty" xlink:label="cosm_LoansPayableRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LoansPayableRelatedParty" xlink:to="cosm_LoansPayableRelatedParty_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LoansPayableRelatedParty_lbl_2" xml:lang="en-US">[Beginning balance 1]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl_e62070" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl_e62070" xml:lang="en-US">Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoanPayableSetOffs" xlink:label="cosm_LoanPayableSetOffs" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LoanPayableSetOffs" xlink:to="cosm_LoanPayableSetOffs_lbl_7d374d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LoanPayableSetOffs_lbl_7d374d" xml:lang="en-US">Loan payable Set-offs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl_078a82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl_078a82" xml:lang="en-US">Foreign currency translation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl_6" xml:lang="en-US">[Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LoansPayableRelatedParty" xlink:to="cosm_LoansPayableRelatedParty_lbl_c7d87d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cosm_LoansPayableRelatedParty_lbl_c7d87d" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl_da0f4e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl_da0f4e" xml:lang="en-US">Long Term Purchase Commitment By Category Of Item Purchased Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GrigoriosSiokasMember" xlink:label="cosm_GrigoriosSiokasMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_GrigoriosSiokasMember" xlink:to="cosm_GrigoriosSiokasMember_lbl_e49e40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_GrigoriosSiokasMember_lbl_e49e40" xml:lang="en-US">Grigorios Siokas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CanaHoldingsLaboratoriesHoldingLimitedMember" xlink:label="cosm_CanaHoldingsLaboratoriesHoldingLimitedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CanaHoldingsLaboratoriesHoldingLimitedMember" xlink:to="cosm_CanaHoldingsLaboratoriesHoldingLimitedMember_lbl_5013bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CanaHoldingsLaboratoriesHoldingLimitedMember_lbl_5013bf" xml:lang="en-US">Cana Holdings Laboratories Holding Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DocPharmaSaMember" xlink:label="cosm_DocPharmaSaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DocPharmaSaMember" xlink:to="cosm_DocPharmaSaMember_lbl_dba86e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DocPharmaSaMember_lbl_dba86e" xml:lang="en-US">DOC Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DimitriosGoulielmosMember" xlink:label="cosm_DimitriosGoulielmosMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DimitriosGoulielmosMember" xlink:to="cosm_DimitriosGoulielmosMember_lbl_6f5fbb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DimitriosGoulielmosMember_lbl_6f5fbb" xml:lang="en-US">Dimitrios Goulielmos [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PanagiotisKozarisMember" xlink:label="cosm_PanagiotisKozarisMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PanagiotisKozarisMember" xlink:to="cosm_PanagiotisKozarisMember_lbl_8df27a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PanagiotisKozarisMember_lbl_8df27a" xml:lang="en-US">Panagiotis Kozaris [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MariaKozariMember" xlink:label="cosm_MariaKozariMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_MariaKozariMember" xlink:to="cosm_MariaKozariMember_lbl_e6e2fc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_MariaKozariMember_lbl_e6e2fc" xml:lang="en-US">Maria Kozari [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InventoriesRelatedAgreementMember" xlink:label="cosm_InventoriesRelatedAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_InventoriesRelatedAgreementMember" xlink:to="cosm_InventoriesRelatedAgreementMember_lbl_82af33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_InventoriesRelatedAgreementMember_lbl_82af33" xml:lang="en-US">Inventories Related Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GeorgeTerzisMember" xlink:label="cosm_GeorgeTerzisMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_GeorgeTerzisMember" xlink:to="cosm_GeorgeTerzisMember_lbl_da63ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_GeorgeTerzisMember_lbl_da63ba" xml:lang="en-US">George Terzis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_KanarogloySiaEpeMember" xlink:label="cosm_KanarogloySiaEpeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_KanarogloySiaEpeMember" xlink:to="cosm_KanarogloySiaEpeMember_lbl_e1ae39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_KanarogloySiaEpeMember_lbl_e1ae39" xml:lang="en-US">Kanarogloy &amp; Sia Epe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BasothoInvestmentLimitedMember" xlink:label="cosm_BasothoInvestmentLimitedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BasothoInvestmentLimitedMember" xlink:to="cosm_BasothoInvestmentLimitedMember_lbl_2787a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_BasothoInvestmentLimitedMember_lbl_2787a1" xml:lang="en-US">Basotho Investment Limited [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSecuredNotesPayable" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable_lbl_28fc66" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable_lbl_28fc66" xml:lang="en-US">Secured promissory note</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DescriptionInterestOfSecuredPromissoryNote" xlink:label="cosm_DescriptionInterestOfSecuredPromissoryNote" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DescriptionInterestOfSecuredPromissoryNote" xlink:to="cosm_DescriptionInterestOfSecuredPromissoryNote_lbl_a25040" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DescriptionInterestOfSecuredPromissoryNote_lbl_a25040" xml:lang="en-US">Description related to interest on principal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl_b4fd8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl_b4fd8d" xml:lang="en-US">Unpaid salaries and bonuses</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UnpaidSalariesAndBonusesDues" xlink:label="cosm_UnpaidSalariesAndBonusesDues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_UnpaidSalariesAndBonusesDues" xlink:to="cosm_UnpaidSalariesAndBonusesDues_lbl_956389" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_UnpaidSalariesAndBonusesDues_lbl_956389" xml:lang="en-US">Unpaid salaries and bonuses dues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl_d672cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeOther_lbl_d672cb" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl_b24ad3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl_b24ad3" xml:lang="en-US">Outstanding principal balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl_ad8174" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl_ad8174" xml:lang="en-US">Foreign curreny translation</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" xlink:label="cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" xlink:to="cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement_lbl_a4aa97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement_lbl_a4aa97" xml:lang="en-US">Shares owned</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl_0a4ede" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl_0a4ede" xml:lang="en-US">Prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl_045341" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl_045341" xml:lang="en-US">General and administrative expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl_11" xml:lang="en-US">[Other General and Administrative Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_40462c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_40462c" xml:lang="en-US">Common stock share issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl_103a3b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl_103a3b" xml:lang="en-US">Interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl_13" xml:lang="en-US">[Line of Credit Facility, Interest Rate During Period]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PrepaymentOfInventory" xlink:label="cosm_PrepaymentOfInventory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PrepaymentOfInventory" xlink:to="cosm_PrepaymentOfInventory_lbl_b0795f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PrepaymentOfInventory_lbl_b0795f" xml:lang="en-US">Prepayment relates to purchases of inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl_d1d815" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl_d1d815" xml:lang="en-US">Loan term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl_3d8af4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl_3d8af4" xml:lang="en-US">Maturity date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AccountsPayableRelatedPartyCurrent" xlink:to="cosm_AccountsPayableRelatedPartyCurrent_lbl_a62fed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_AccountsPayableRelatedPartyCurrent_lbl_a62fed" xml:lang="en-US">Accounts payable and accrued expenses - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AccountsPayableRelatedPartyCurrent" xlink:label="cosm_AccountsPayableRelatedPartyCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AccountsPayableRelatedPartyCurrent" xlink:to="cosm_AccountsPayableRelatedPartyCurrent_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AccountsPayableRelatedPartyCurrent_lbl_17" xml:lang="en-US">[Accounts payable and accrued expenses - related party 1]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInterest" xlink:label="us-gaap_PrepaidInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInterest" xlink:to="us-gaap_PrepaidInterest_lbl_582a03" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInterest_lbl_582a03" xml:lang="en-US">Prepaid balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AmountAccountsReceivableRelatedParties" xlink:to="cosm_AmountAccountsReceivableRelatedParties_lbl_35af56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_AmountAccountsReceivableRelatedParties_lbl_35af56" xml:lang="en-US">Accounts receivable - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AmountAccountsReceivableRelatedParties" xlink:label="cosm_AmountAccountsReceivableRelatedParties" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AmountAccountsReceivableRelatedParties" xlink:to="cosm_AmountAccountsReceivableRelatedParties_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AmountAccountsReceivableRelatedParties_lbl_19" xml:lang="en-US">[Accounts receivable - related party]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl_3f4118" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl_3f4118" xml:lang="en-US">Other expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl_6585bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl_6585bc" xml:lang="en-US">Accounts receivable balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl_56406d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl_56406d" xml:lang="en-US">Cumulative allowance for doubtful accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_89cc51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_89cc51" xml:lang="en-US">Prepaid expenses and other current assets - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NetSales" xlink:label="cosm_NetSales" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NetSales" xlink:to="cosm_NetSales_lbl_fe7217" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NetSales_lbl_fe7217" xml:lang="en-US">Net sales</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AgreementTerminate" xlink:label="cosm_AgreementTerminate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AgreementTerminate" xlink:to="cosm_AgreementTerminate_lbl_e0fd1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AgreementTerminate_lbl_e0fd1e" xml:lang="en-US">Agreement terminate</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PiecesPerProduct" xlink:label="cosm_PiecesPerProduct" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PiecesPerProduct" xlink:to="cosm_PiecesPerProduct_lbl_553c3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PiecesPerProduct_lbl_553c3c" xml:lang="en-US">Pieces per product</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases_lbl_e14a11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases_lbl_e14a11" xml:lang="en-US">Purchased of additional licenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl_50df0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl_50df0e" xml:lang="en-US">Impairment charge</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_117f68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl_117f68" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl_b35509" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl_b35509" xml:lang="en-US">Current portion of Royalty Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl_5ae12f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl_5ae12f" xml:lang="en-US">Non-current portion of Royalty Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PurchaseOfInventory" xlink:label="cosm_PurchaseOfInventory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PurchaseOfInventory" xlink:to="cosm_PurchaseOfInventory_lbl_681851" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PurchaseOfInventory_lbl_681851" xml:lang="en-US">Inventroy purchase</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PurchaseOfPharmaceuticalsMedicine" xlink:label="cosm_PurchaseOfPharmaceuticalsMedicine" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PurchaseOfPharmaceuticalsMedicine" xlink:to="cosm_PurchaseOfPharmaceuticalsMedicine_lbl_66670b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PurchaseOfPharmaceuticalsMedicine_lbl_66670b" xml:lang="en-US">Purchase of branded pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementFeeDescription" xlink:label="us-gaap_ManagementFeeDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeDescription" xlink:to="us-gaap_ManagementFeeDescription_lbl_f79b44" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeeDescription_lbl_f79b44" xml:lang="en-US">Description of research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl_eca5f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl_eca5f5" xml:lang="en-US">Loans receivable - related party current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl_362db4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl_362db4" xml:lang="en-US">Loans receivable - related party noncurrent portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PaymentReceivedFromInstallment" xlink:label="cosm_PaymentReceivedFromInstallment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PaymentReceivedFromInstallment" xlink:to="cosm_PaymentReceivedFromInstallment_lbl_445286" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PaymentReceivedFromInstallment_lbl_445286" xml:lang="en-US">Monthly basis instalments</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AtticaBankMember" xlink:label="cosm_AtticaBankMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AtticaBankMember" xlink:to="cosm_AtticaBankMember_lbl_3b636e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AtticaBankMember_lbl_3b636e" xml:lang="en-US">Attica Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EFGMember" xlink:label="cosm_EFGMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_EFGMember" xlink:to="cosm_EFGMember_lbl_2d06b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_EFGMember_lbl_2d06b6" xml:lang="en-US">EFG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalMember" xlink:label="cosm_NationalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NationalMember" xlink:to="cosm_NationalMember_lbl_90da1a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NationalMember_lbl_90da1a" xml:lang="en-US">National [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AlphaMember" xlink:label="cosm_AlphaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AlphaMember" xlink:to="cosm_AlphaMember_lbl_e63f74" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AlphaMember_lbl_e63f74" xml:lang="en-US">Alpha [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PancretaMember" xlink:label="cosm_PancretaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PancretaMember" xlink:to="cosm_PancretaMember_lbl_9c1052" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PancretaMember_lbl_9c1052" xml:lang="en-US">Pancreta [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl_ebdf91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCredit_lbl_ebdf91" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl_2" xml:lang="en-US">[Long-Term Line of Credit]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_37780b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_37780b" xml:lang="en-US">Title Of Individual Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalBankOfGreeceOneMember" xlink:label="cosm_NationalBankOfGreeceOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NationalBankOfGreeceOneMember" xlink:to="cosm_NationalBankOfGreeceOneMember_lbl_0fa6d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NationalBankOfGreeceOneMember_lbl_0fa6d3" xml:lang="en-US">National Bank of Greece One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl_14a213" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl_14a213" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalBankOfGreeceTwoMember" xlink:label="cosm_NationalBankOfGreeceTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NationalBankOfGreeceTwoMember" xlink:to="cosm_NationalBankOfGreeceTwoMember_lbl_eef852" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NationalBankOfGreeceTwoMember_lbl_eef852" xml:lang="en-US">National Bank of Greece Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AlphaBankOfGreeceMember" xlink:label="cosm_AlphaBankOfGreeceMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AlphaBankOfGreeceMember" xlink:to="cosm_AlphaBankOfGreeceMember_lbl_038c66" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AlphaBankOfGreeceMember_lbl_038c66" xml:lang="en-US">Alpha Bank of Greece [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PancretaOfGreeceMember" xlink:label="cosm_PancretaOfGreeceMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PancretaOfGreeceMember" xlink:to="cosm_PancretaOfGreeceMember_lbl_548dc8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PancretaOfGreeceMember_lbl_548dc8" xml:lang="en-US">Pancreta Bank of Greece [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_EFGMember" xlink:to="cosm_EFGMember_lbl_16e158" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_EFGMember_lbl_16e158" xml:lang="en-US">EGF [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl_348c5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl_348c5c" xml:lang="en-US">Line of credit facility outstanding balance</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LineOfCreditBorrowingsLoanDescription" xlink:label="cosm_LineOfCreditBorrowingsLoanDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_LineOfCreditBorrowingsLoanDescription" xlink:to="cosm_LineOfCreditBorrowingsLoanDescription_lbl_e9f41b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_LineOfCreditBorrowingsLoanDescription_lbl_e9f41b" xml:lang="en-US">Borrowings loan Description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:to="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements_lbl_4f0537" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements_lbl_4f0537" xml:lang="en-US">Borrowing</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OutstandingDebtBalance" xlink:label="cosm_OutstandingDebtBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OutstandingDebtBalance" xlink:to="cosm_OutstandingDebtBalance_lbl_47a602" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OutstandingDebtBalance_lbl_47a602" xml:lang="en-US">Outstanding debt balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl_75d83e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl_75d83e" xml:lang="en-US">Deferred Revenue Arrangement Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl_d08387" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl_d08387" xml:lang="en-US">Debt Instrument Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TradeFacilityAgreementsMember" xlink:label="cosm_TradeFacilityAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TradeFacilityAgreementsMember" xlink:to="cosm_TradeFacilityAgreementsMember_lbl_665a8a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_TradeFacilityAgreementsMember_lbl_665a8a" xml:lang="en-US">Trade Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ThirdPartyMember" xlink:label="cosm_ThirdPartyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ThirdPartyMember" xlink:to="cosm_ThirdPartyMember_lbl_2e3b63" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ThirdPartyMember_lbl_2e3b63" xml:lang="en-US">Third Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_COVIDLoansMember" xlink:label="cosm_COVIDLoansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_COVIDLoansMember" xlink:to="cosm_COVIDLoansMember_lbl_0f0c06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_COVIDLoansMember_lbl_0f0c06" xml:lang="en-US">COVID Loans [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl_4dba88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_NotesPayable_lbl_4dba88" xml:lang="en-US">Beginning balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ProceedFromDebt" xlink:to="cosm_ProceedFromDebt_lbl_3c8460" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_ProceedFromDebt_lbl_3c8460" xml:lang="en-US">Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProceedFromDebt" xlink:label="cosm_ProceedFromDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ProceedFromDebt" xlink:to="cosm_ProceedFromDebt_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ProceedFromDebt_lbl_3" xml:lang="en-US">[Proceeds]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PaymentsOfDebt" xlink:to="cosm_PaymentsOfDebt_lbl_655025" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_PaymentsOfDebt_lbl_655025" xml:lang="en-US">Payments</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PaymentsOfDebt" xlink:label="cosm_PaymentsOfDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PaymentsOfDebt" xlink:to="cosm_PaymentsOfDebt_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PaymentsOfDebt_lbl_4" xml:lang="en-US">[Payments]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ForeignCurrencyTranslation" xlink:to="cosm_ForeignCurrencyTranslation_lbl_7be420" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_ForeignCurrencyTranslation_lbl_7be420" xml:lang="en-US">Foreign currency translation</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ForeignCurrencyTranslation" xlink:label="cosm_ForeignCurrencyTranslation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ForeignCurrencyTranslation" xlink:to="cosm_ForeignCurrencyTranslation_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ForeignCurrencyTranslation_lbl_5" xml:lang="en-US">[Foreign currency translation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl_9e5cf7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_NotesPayable_lbl_9e5cf7" xml:lang="en-US">Ending balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl_a9d689" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl_a9d689" xml:lang="en-US">Notes payable - long-term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl_8cf7d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl_8cf7d3" xml:lang="en-US">Notes payable - short-term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl_643ed5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl_643ed5" xml:lang="en-US">Notes payable - long-term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl_1a03e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl_1a03e3" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl_2" xml:lang="en-US">[Long-Term Debt, Maturity, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl_c9ff13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl_c9ff13" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl_3" xml:lang="en-US">[Long-Term Debt, Maturity, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl_09981c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl_09981c" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl_4" xml:lang="en-US">[Long-Term Debt, Maturity, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl_65a5ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl_65a5ff" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl_5" xml:lang="en-US">[Long-Term Debt, Maturity, Year Four]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl_ed6552" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl_ed6552" xml:lang="en-US">2030 and thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl_dc9e6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl_dc9e6c" xml:lang="en-US">Total Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl_8fa05f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl_8fa05f" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl_e9fadd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl_e9fadd" xml:lang="en-US">Notes payable - long term portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_939da1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_939da1" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl_fda3ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl_fda3ac" xml:lang="en-US">Longterm Debt Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtAgreementJulyMember" xlink:label="cosm_DebtAgreementJulyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DebtAgreementJulyMember" xlink:to="cosm_DebtAgreementJulyMember_lbl_62d038" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DebtAgreementJulyMember_lbl_62d038" xml:lang="en-US">July 30, 2021 Debt Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" xlink:label="cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" xlink:to="cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember_lbl_c0a75a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember_lbl_c0a75a" xml:lang="en-US">January 27 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtExchangeAgreementMember" xlink:label="cosm_DebtExchangeAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DebtExchangeAgreementMember" xlink:to="cosm_DebtExchangeAgreementMember_lbl_296439" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DebtExchangeAgreementMember_lbl_296439" xml:lang="en-US">Debt Exchange Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JuneTwentyThreeTwoThousandTwentyMember" xlink:label="cosm_JuneTwentyThreeTwoThousandTwentyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_JuneTwentyThreeTwoThousandTwentyMember" xlink:to="cosm_JuneTwentyThreeTwoThousandTwentyMember_lbl_81e80d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_JuneTwentyThreeTwoThousandTwentyMember_lbl_81e80d" xml:lang="en-US">June 23, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalBankOfGreeceSAMember" xlink:label="cosm_NationalBankOfGreeceSAMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NationalBankOfGreeceSAMember" xlink:to="cosm_NationalBankOfGreeceSAMember_lbl_c193fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NationalBankOfGreeceSAMember_lbl_c193fb" xml:lang="en-US">National Bank of Greece SA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtAgreementJuneOneMember" xlink:label="cosm_DebtAgreementJuneOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DebtAgreementJuneOneMember" xlink:to="cosm_DebtAgreementJuneOneMember_lbl_d26937" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DebtAgreementJuneOneMember_lbl_d26937" xml:lang="en-US">June 9, 2022 Debt Agreement One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JulyFourteenTwoThousandTwentyThreeMember" xlink:label="cosm_JulyFourteenTwoThousandTwentyThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_JulyFourteenTwoThousandTwentyThreeMember" xlink:to="cosm_JulyFourteenTwoThousandTwentyThreeMember_lbl_9a7a34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_JulyFourteenTwoThousandTwentyThreeMember_lbl_9a7a34" xml:lang="en-US">July 14, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PromissoryNotesMember" xlink:label="cosm_PromissoryNotesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PromissoryNotesMember" xlink:to="cosm_PromissoryNotesMember_lbl_dfd683" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PromissoryNotesMember_lbl_dfd683" xml:lang="en-US">Promissory Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JulyTwentyNineTwentyTwentyFourMember" xlink:label="cosm_JulyTwentyNineTwentyTwentyFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_JulyTwentyNineTwentyTwentyFourMember" xlink:to="cosm_JulyTwentyNineTwentyTwentyFourMember_lbl_0be1cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_JulyTwentyNineTwentyTwentyFourMember_lbl_0be1cf" xml:lang="en-US">July 29, 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DeemberTwentyTwentyFourMember" xlink:label="cosm_DeemberTwentyTwentyFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DeemberTwentyTwentyFourMember" xlink:to="cosm_DeemberTwentyTwentyFourMember_lbl_65bc89" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DeemberTwentyTwentyFourMember_lbl_65bc89" xml:lang="en-US">December 20, 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CovidNinteenMember" xlink:label="cosm_CovidNinteenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CovidNinteenMember" xlink:to="cosm_CovidNinteenMember_lbl_4e01ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CovidNinteenMember_lbl_4e01ef" xml:lang="en-US">Covid Ninteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MayTwelveTwentyTwentyMember" xlink:label="cosm_MayTwelveTwentyTwentyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_MayTwelveTwentyTwentyMember" xlink:to="cosm_MayTwelveTwentyTwentyMember_lbl_218152" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_MayTwelveTwentyTwentyMember_lbl_218152" xml:lang="en-US">May 12, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JuneTwentyFourTwentyTwentyMember" xlink:label="cosm_JuneTwentyFourTwentyTwentyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_JuneTwentyFourTwentyTwentyMember" xlink:to="cosm_JuneTwentyFourTwentyTwentyMember_lbl_d829c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_JuneTwentyFourTwentyTwentyMember_lbl_d829c9" xml:lang="en-US">June 24, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JanuaryTwentythreeTwoThousandTwentyFourMember" xlink:label="cosm_JanuaryTwentythreeTwoThousandTwentyFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_JanuaryTwentythreeTwoThousandTwentyFourMember" xlink:to="cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_lbl_b6a463" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_lbl_b6a463" xml:lang="en-US">January 23, 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl_3e7d25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_lbl_3e7d25" xml:lang="en-US">Outstanding principal loan balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_f389d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_f389d3" xml:lang="en-US">Repayment of related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl_ac4d35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtDescription_lbl_ac4d35" xml:lang="en-US">Long-term Debt, Description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl_12cbf7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl_12cbf7" xml:lang="en-US">Outstanding principal amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl_7090da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl_7090da" xml:lang="en-US">Total purchase price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl_fb90b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl_fb90b5" xml:lang="en-US">Common stock issued as consideration</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockIssuedAsConsiderationFairValue" xlink:label="cosm_CommonStockIssuedAsConsiderationFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CommonStockIssuedAsConsiderationFairValue" xlink:to="cosm_CommonStockIssuedAsConsiderationFairValue_lbl_513964" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CommonStockIssuedAsConsiderationFairValue_lbl_513964" xml:lang="en-US">Common stock issued as consideration Fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BusinessCombinationContingentConsiderationArrangementLiability" xlink:label="cosm_BusinessCombinationContingentConsiderationArrangementLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BusinessCombinationContingentConsiderationArrangementLiability" xlink:to="cosm_BusinessCombinationContingentConsiderationArrangementLiability_lbl_b96a2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_BusinessCombinationContingentConsiderationArrangementLiability_lbl_b96a2f" xml:lang="en-US">Cash Consideration Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl_69a607" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl_69a607" xml:lang="en-US">Accrued interest expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl_f709da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl_f709da" xml:lang="en-US">Interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl_12" xml:lang="en-US">[Subordinated Borrowing, Interest Rate]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl_6932d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl_6932d8" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:label="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_lbl_8f7290" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_lbl_8f7290" xml:lang="en-US">Additional principal repayment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl_8b606c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl_8b606c" xml:lang="en-US">Loan from Related Party Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_3fa0a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_3fa0a5" xml:lang="en-US">Payment of the principal balance</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtAmountReceivedFromRelatedParty" xlink:label="cosm_DebtAmountReceivedFromRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DebtAmountReceivedFromRelatedParty" xlink:to="cosm_DebtAmountReceivedFromRelatedParty_lbl_ce19e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DebtAmountReceivedFromRelatedParty_lbl_ce19e1" xml:lang="en-US">Debt amount received from related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl_529af0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl_529af0" xml:lang="en-US">Accured interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl_bf8e48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl_bf8e48" xml:lang="en-US">Notes payable long term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl_374111" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl_374111" xml:lang="en-US">Property Subject To Or Available For Operating Lease Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseMember" xlink:label="cosm_OperatingLeaseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OperatingLeaseMember" xlink:to="cosm_OperatingLeaseMember_lbl_ee6a39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OperatingLeaseMember_lbl_ee6a39" xml:lang="en-US">Operating Lease [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_ba4dd0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_ba4dd0" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_2" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_f1ded2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_f1ded2" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_83ff49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_83ff49" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_b412b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_b412b8" xml:lang="en-US">2029 and Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_007805" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_007805" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OperatingLeaseLiabilityLessImputedInterest" xlink:to="cosm_OperatingLeaseLiabilityLessImputedInterest_lbl_866f5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cosm_OperatingLeaseLiabilityLessImputedInterest_lbl_866f5f" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseLiabilityLessImputedInterest" xlink:label="cosm_OperatingLeaseLiabilityLessImputedInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OperatingLeaseLiabilityLessImputedInterest" xlink:to="cosm_OperatingLeaseLiabilityLessImputedInterest_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OperatingLeaseLiabilityLessImputedInterest_lbl_7" xml:lang="en-US">[Less: Imputed interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_d364b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_d364b8" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseMember" xlink:label="cosm_FinanceLeaseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_FinanceLeaseMember" xlink:to="cosm_FinanceLeaseMember_lbl_6e08a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_FinanceLeaseMember_lbl_6e08a2" xml:lang="en-US">Finance Lease [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_523540" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_523540" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_2" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Two]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" xlink:label="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" xlink:to="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments_lbl_2bf494" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments_lbl_2bf494" xml:lang="en-US">Total undiscounted finance lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" xlink:to="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest_lbl_6317b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest_lbl_6317b2" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" xlink:label="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" xlink:to="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest_lbl_4" xml:lang="en-US">[Less: Imputed interest 1]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_5c26d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_5c26d2" xml:lang="en-US">Present value of finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl_ca59d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl_ca59d8" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl_452116" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl_452116" xml:lang="en-US">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl_0630d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl_0630d6" xml:lang="en-US">Interest expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseTermOfAgreements" xlink:label="cosm_OperatingLeaseTermOfAgreements" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OperatingLeaseTermOfAgreements" xlink:to="cosm_OperatingLeaseTermOfAgreements_lbl_babe18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OperatingLeaseTermOfAgreements_lbl_babe18" xml:lang="en-US">Operating lease, term of agreements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_dce89b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_dce89b" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseCashFlowsUsedInFinanceLease" xlink:label="cosm_OperatingLeaseCashFlowsUsedInFinanceLease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OperatingLeaseCashFlowsUsedInFinanceLease" xlink:to="cosm_OperatingLeaseCashFlowsUsedInFinanceLease_lbl_a7c5a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OperatingLeaseCashFlowsUsedInFinanceLease_lbl_a7c5a1" xml:lang="en-US">Operating lease cash flows used in finance lease</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseWeightedAverageDiscountRate" xlink:label="cosm_OperatingLeaseWeightedAverageDiscountRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OperatingLeaseWeightedAverageDiscountRate" xlink:to="cosm_OperatingLeaseWeightedAverageDiscountRate_lbl_e4d37c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OperatingLeaseWeightedAverageDiscountRate_lbl_e4d37c" xml:lang="en-US">Operating lease, weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:label="cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:to="cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm_lbl_2638a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm_lbl_2638a7" xml:lang="en-US">Operating lease Weighted-average remaining lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm" xlink:label="cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm" xlink:to="cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm_lbl_fe7431" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm_lbl_fe7431" xml:lang="en-US">Finance lease, weighted average remaining lease term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl_36f367" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl_36f367" xml:lang="en-US">Finance lease, interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseWeightedAverageDiscountRate" xlink:label="cosm_FinanceLeaseWeightedAverageDiscountRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_FinanceLeaseWeightedAverageDiscountRate" xlink:to="cosm_FinanceLeaseWeightedAverageDiscountRate_lbl_d0638e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_FinanceLeaseWeightedAverageDiscountRate_lbl_d0638e" xml:lang="en-US">Finance lease, weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseAmortizationExpense" xlink:label="cosm_FinanceLeaseAmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_FinanceLeaseAmortizationExpense" xlink:to="cosm_FinanceLeaseAmortizationExpense_lbl_a5c903" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_FinanceLeaseAmortizationExpense_lbl_a5c903" xml:lang="en-US">Finance lease, amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TaxLiabilitiesPayable" xlink:label="cosm_TaxLiabilitiesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TaxLiabilitiesPayable" xlink:to="cosm_TaxLiabilitiesPayable_lbl_77c457" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_TaxLiabilitiesPayable_lbl_77c457" xml:lang="en-US">Tax liabilities payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PayrollTaxRelatedCurrentLiabilities" xlink:label="cosm_PayrollTaxRelatedCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PayrollTaxRelatedCurrentLiabilities" xlink:to="cosm_PayrollTaxRelatedCurrentLiabilities_lbl_094639" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PayrollTaxRelatedCurrentLiabilities_lbl_094639" xml:lang="en-US">Payroll tax related current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl_d722df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl_d722df" xml:lang="en-US">Unaudited tax</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProvisionForStaffLeavingCompensation" xlink:label="cosm_ProvisionForStaffLeavingCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ProvisionForStaffLeavingCompensation" xlink:to="cosm_ProvisionForStaffLeavingCompensation_lbl_c5c17c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ProvisionForStaffLeavingCompensation_lbl_c5c17c" xml:lang="en-US">Provision for staff leaving compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomersForProgressPayments" xlink:label="us-gaap_ProceedsFromCustomersForProgressPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomersForProgressPayments" xlink:to="us-gaap_ProceedsFromCustomersForProgressPayments_lbl_ddfb96" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCustomersForProgressPayments_lbl_ddfb96" xml:lang="en-US">Received prepayments from customers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl_12f080" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl_12f080" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PhaseOneMember" xlink:label="cosm_PhaseOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PhaseOneMember" xlink:to="cosm_PhaseOneMember_lbl_5d2d55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PhaseOneMember_lbl_5d2d55" xml:lang="en-US">Phase 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl_91b4cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl_91b4cb" xml:lang="en-US">General and administrative expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalMedicinesAgencyMember" xlink:label="cosm_NationalMedicinesAgencyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NationalMedicinesAgencyMember" xlink:to="cosm_NationalMedicinesAgencyMember_lbl_471a30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NationalMedicinesAgencyMember_lbl_471a30" xml:lang="en-US">National Medicines Agency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PhaseTwoMember" xlink:label="cosm_PhaseTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PhaseTwoMember" xlink:to="cosm_PhaseTwoMember_lbl_effc88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PhaseTwoMember_lbl_effc88" xml:lang="en-US">Phase 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FourThirdPartyConsultantsMember" xlink:label="cosm_FourThirdPartyConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_FourThirdPartyConsultantsMember" xlink:to="cosm_FourThirdPartyConsultantsMember_lbl_37c31b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_FourThirdPartyConsultantsMember_lbl_37c31b" xml:lang="en-US">Four Third Party Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl_a3c6c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl_a3c6c3" xml:lang="en-US">Stock based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PaymentTax" xlink:label="cosm_PaymentTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PaymentTax" xlink:to="cosm_PaymentTax_lbl_238b58" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PaymentTax_lbl_238b58" xml:lang="en-US">Payment of additional tax</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProjectCosts" xlink:label="cosm_ProjectCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ProjectCosts" xlink:to="cosm_ProjectCosts_lbl_f491b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ProjectCosts_lbl_f491b6" xml:lang="en-US">Project cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_ede2d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_ede2d3" xml:lang="en-US">Research and Development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockIssuedDuringPeriodSharesAwarded" xlink:label="cosm_StockIssuedDuringPeriodSharesAwarded" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_StockIssuedDuringPeriodSharesAwarded" xlink:to="cosm_StockIssuedDuringPeriodSharesAwarded_lbl_af909a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_StockIssuedDuringPeriodSharesAwarded_lbl_af909a" xml:lang="en-US">Awarded shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl_7869f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl_7869f1" xml:lang="en-US">Awarded share value</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AdditionalStockConsideration" xlink:label="cosm_AdditionalStockConsideration" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AdditionalStockConsideration" xlink:to="cosm_AdditionalStockConsideration_lbl_e5a71a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AdditionalStockConsideration_lbl_e5a71a" xml:lang="en-US">Additional stock consideration</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:to="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_lbl_260909" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_lbl_260909" xml:lang="en-US">Settelment amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ComplementaryCompensationShares" xlink:label="cosm_ComplementaryCompensationShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ComplementaryCompensationShares" xlink:to="cosm_ComplementaryCompensationShares_lbl_782f7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ComplementaryCompensationShares_lbl_782f7a" xml:lang="en-US">Complementary compensation Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PurchasePriceAmount" xlink:label="cosm_PurchasePriceAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PurchasePriceAmount" xlink:to="cosm_PurchasePriceAmount_lbl_fd4773" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PurchasePriceAmount_lbl_fd4773" xml:lang="en-US">Purchase price</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantsMember" xlink:label="cosm_WarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_WarrantsMember" xlink:to="cosm_WarrantsMember_lbl_e2a9e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_WarrantsMember_lbl_e2a9e1" xml:lang="en-US">Warrants [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_f15707" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_f15707" xml:lang="en-US">Number of Shares Outstanding, Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_c5974f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_c5974f" xml:lang="en-US">Number of Shares Outstanding, Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_e67ef9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_e67ef9" xml:lang="en-US">Number of Shares Outstanding, Forfeited</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_301e11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_301e11" xml:lang="en-US">Number of Shares Outstanding, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_5" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl_b4e8ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl_b4e8ec" xml:lang="en-US">Number of Shares Outstanding, Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl_6" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_dead67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_dead67" xml:lang="en-US">Number of Shares Outstanding, Ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" xlink:label="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" xlink:to="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod_lbl_935c99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod_lbl_935c99" xml:lang="en-US">Number of Shares Outstanding, Exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_e90f20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_e90f20" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_9" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_d36bbd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_d36bbd" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_8fd4fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_8fd4fe" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" xlink:label="cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" xlink:to="cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92_lbl_700862" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92_lbl_700862" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WeightedAverageRemainingContractualTermOutstandingBeginning" xlink:label="cosm_WeightedAverageRemainingContractualTermOutstandingBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_WeightedAverageRemainingContractualTermOutstandingBeginning" xlink:to="cosm_WeightedAverageRemainingContractualTermOutstandingBeginning_lbl_8fe1ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_WeightedAverageRemainingContractualTermOutstandingBeginning_lbl_8fe1ad" xml:lang="en-US">Weighted Average Remaining Contractual Term Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WeightedAverageRemainingContractualTermOutstandingEnding" xlink:label="cosm_WeightedAverageRemainingContractualTermOutstandingEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_WeightedAverageRemainingContractualTermOutstandingEnding" xlink:to="cosm_WeightedAverageRemainingContractualTermOutstandingEnding_lbl_ff736f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_WeightedAverageRemainingContractualTermOutstandingEnding_lbl_ff736f" xml:lang="en-US">Weighted Average Remaining Contractual Term Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WeightedAverageRemainingContractualTermExercisable" xlink:label="cosm_WeightedAverageRemainingContractualTermExercisable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_WeightedAverageRemainingContractualTermExercisable" xlink:to="cosm_WeightedAverageRemainingContractualTermExercisable_lbl_ebb655" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_WeightedAverageRemainingContractualTermExercisable_lbl_ebb655" xml:lang="en-US">Weighted Average Remaining Contractual Term Exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl_336a49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl_336a49" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl_16" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl_9ba579" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl_9ba579" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" xlink:label="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" xlink:to="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue_lbl_7cbd3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue_lbl_7cbd3a" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BoardOfDirectorsMember" xlink:label="cosm_BoardOfDirectorsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BoardOfDirectorsMember" xlink:to="cosm_BoardOfDirectorsMember_lbl_e8b52f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_BoardOfDirectorsMember_lbl_e8b52f" xml:lang="en-US">Board of Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TwoZeroTwentyTwoPlanMember" xlink:label="cosm_TwoZeroTwentyTwoPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TwoZeroTwentyTwoPlanMember" xlink:to="cosm_TwoZeroTwentyTwoPlanMember_lbl_1d8b3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_TwoZeroTwentyTwoPlanMember_lbl_1d8b3d" xml:lang="en-US">2022 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TwoZeroTwentyThreePlanMember" xlink:label="cosm_TwoZeroTwentyThreePlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TwoZeroTwentyThreePlanMember" xlink:to="cosm_TwoZeroTwentyThreePlanMember_lbl_31dbfb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_TwoZeroTwentyThreePlanMember_lbl_31dbfb" xml:lang="en-US">2023 Plan [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl_6696e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl_6696e6" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DiscriptionOfIncentiveStockAwards" xlink:label="cosm_DiscriptionOfIncentiveStockAwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_DiscriptionOfIncentiveStockAwards" xlink:to="cosm_DiscriptionOfIncentiveStockAwards_lbl_12464f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_DiscriptionOfIncentiveStockAwards_lbl_12464f" xml:lang="en-US">Discription of incentive stock awards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl_1fe722" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl_1fe722" xml:lang="en-US">Share reserv for issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" xlink:label="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" xlink:to="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber_lbl_0499d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber_lbl_0499d8" xml:lang="en-US">Number of Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl_05dca9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl_05dca9" xml:lang="en-US">Warrant otstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantExpirationDateDescription" xlink:label="cosm_WarrantExpirationDateDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_WarrantExpirationDateDescription" xlink:to="cosm_WarrantExpirationDateDescription_lbl_a87c4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_WarrantExpirationDateDescription_lbl_a87c4c" xml:lang="en-US">Warrant expiration date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl_978886" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl_978886" xml:lang="en-US">Warrant with no expiration</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UkMember" xlink:label="cosm_UkMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_UkMember" xlink:to="cosm_UkMember_lbl_e30d2a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_UkMember_lbl_e30d2a" xml:lang="en-US">UK [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AlbaniaMember" xlink:label="cosm_AlbaniaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_AlbaniaMember" xlink:to="cosm_AlbaniaMember_lbl_f87e6f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_AlbaniaMember_lbl_f87e6f" xml:lang="en-US">Albania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CroatiaMember" xlink:label="cosm_CroatiaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CroatiaMember" xlink:to="cosm_CroatiaMember_lbl_fed4ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CroatiaMember_lbl_fed4ad" xml:lang="en-US">Croatia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CyprusMember" xlink:label="cosm_CyprusMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_CyprusMember" xlink:to="cosm_CyprusMember_lbl_a507f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_CyprusMember_lbl_a507f2" xml:lang="en-US">Cyprus [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BulgariaMember" xlink:label="cosm_BulgariaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_BulgariaMember" xlink:to="cosm_BulgariaMember_lbl_fa1535" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_BulgariaMember_lbl_fa1535" xml:lang="en-US">Bulgaria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl_c37722" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl_c37722" xml:lang="en-US">Statement Business Segments Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OtherMember" xlink:label="cosm_OtherMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OtherMember" xlink:to="cosm_OtherMember_lbl_170e11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OtherMember_lbl_170e11" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TotalSegmentMember" xlink:label="cosm_TotalSegmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_TotalSegmentMember" xlink:to="cosm_TotalSegmentMember_lbl_5cc2e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_TotalSegmentMember_lbl_5cc2e6" xml:lang="en-US">Total Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WholesaleMember" xlink:label="cosm_WholesaleMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_WholesaleMember" xlink:to="cosm_WholesaleMember_lbl_3b8547" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_WholesaleMember_lbl_3b8547" xml:lang="en-US">Wholesale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PharmamanufacturingMember" xlink:label="cosm_PharmamanufacturingMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_PharmamanufacturingMember" xlink:to="cosm_PharmamanufacturingMember_lbl_624e33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_PharmamanufacturingMember_lbl_624e33" xml:lang="en-US">Pharma manufacturing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NutraceuticalsAndPharmaceuticalsMember" xlink:label="cosm_NutraceuticalsAndPharmaceuticalsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NutraceuticalsAndPharmaceuticalsMember" xlink:to="cosm_NutraceuticalsAndPharmaceuticalsMember_lbl_48cb1a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NutraceuticalsAndPharmaceuticalsMember_lbl_48cb1a" xml:lang="en-US">Nutraceuticals and Pharmaceuticals [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl_80e03c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl_80e03c" xml:lang="en-US">Cost of Sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl_3808da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrossProfit_lbl_3808da" xml:lang="en-US">GROSS PROFIT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_10d7f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_10d7f3" xml:lang="en-US">General and administrative expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl_b1a17d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SalariesAndWages_lbl_b1a17d" xml:lang="en-US">Salaries</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl_3962f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl_3962f6" xml:lang="en-US">Sales and marketing expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl_54c52e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl_54c52e" xml:lang="en-US">Research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl_8" xml:lang="en-US">[Research and Development Expense (Excluding Acquired in Process Cost)]</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NetFinanceCosts" xlink:label="cosm_NetFinanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_NetFinanceCosts" xlink:to="cosm_NetFinanceCosts_lbl_d6056a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_NetFinanceCosts_lbl_d6056a" xml:lang="en-US">Net finance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SegmentProfitLoss" xlink:label="cosm_SegmentProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_SegmentProfitLoss" xlink:to="cosm_SegmentProfitLoss_lbl_9e6cbc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_SegmentProfitLoss_lbl_9e6cbc" xml:lang="en-US">Segment profit / (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_9f3b09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl_9f3b09" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_f1c5d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_f1c5d2" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl_9c3cce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl_9c3cce" xml:lang="en-US">Foreign currency transaction, net</link:label>
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OtherIncomeAndExpenses" xlink:label="cosm_OtherIncomeAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_OtherIncomeAndExpenses" xlink:to="cosm_OtherIncomeAndExpenses_lbl_a899fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cosm_OtherIncomeAndExpenses_lbl_a899fb" xml:lang="en-US">Other income and expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_1fb434" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_1fb434" xml:lang="en-US">Net profit/(loss) before Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl_01a38e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl_01a38e" xml:lang="en-US">Research and development costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl_453244" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl_453244" xml:lang="en-US">Cost of Sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl_b785fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl_b785fe" xml:lang="en-US">Sales and marketing expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_36ecff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_36ecff" xml:lang="en-US">Subsequent Event Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_ddd6b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_ddd6b9" xml:lang="en-US">Subsequent Events [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cosm_GrigoriosSiokasMember" xlink:to="cosm_GrigoriosSiokasMember_lbl_3fae81" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cosm_GrigoriosSiokasMember_lbl_3fae81" xml:lang="en-US">Grigorios Siokas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_609d9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_609d9d" xml:lang="en-US">Issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:label="us-gaap_AssetRetirementObligationLiabilitiesSettled" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:to="us-gaap_AssetRetirementObligationLiabilitiesSettled_lbl_93510e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationLiabilitiesSettled_lbl_93510e" xml:lang="en-US">Equity issued in settlement of liabilities</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cosm-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20250331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cosm-20250331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="cosm-20250331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:href="cosm-20250331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="cosm-20250331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cosm-20250331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/InsiderTradingArrangements" xlink:href="cosm-20250331.xsd#InsiderTradingArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/BasisOfPresentation" xlink:href="cosm-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusiness" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/EquityMethodInvestments" xlink:href="cosm-20250331.xsd#EquityMethodInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/PropertyAndEquipmentNet" xlink:href="cosm-20250331.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssets" xlink:href="cosm-20250331.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LoanReceivable" xlink:href="cosm-20250331.xsd#LoanReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IncomeTaxes" xlink:href="cosm-20250331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CapitalStructure" xlink:href="cosm-20250331.xsd#CapitalStructure" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactions" xlink:href="cosm-20250331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCredit" xlink:href="cosm-20250331.xsd#LinesOfCredit" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayable" xlink:href="cosm-20250331.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LEASES" xlink:href="cosm-20250331.xsd#LEASES" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OtherLiabilities" xlink:href="cosm-20250331.xsd#OtherLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CommitmentsAndContingencies" xlink:href="cosm-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrants" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrants" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/DisaggregationOfRevenue" xlink:href="cosm-20250331.xsd#DisaggregationOfRevenue" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SegmentReporting" xlink:href="cosm-20250331.xsd#SegmentReporting" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SubsequentEvents" xlink:href="cosm-20250331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessTables" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/PropertyAndEquipmentNetTables" xlink:href="cosm-20250331.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssetsTables" xlink:href="cosm-20250331.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsTables" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCreditTables" xlink:href="cosm-20250331.xsd#LinesOfCreditTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableTables" xlink:href="cosm-20250331.xsd#NotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesTables" xlink:href="cosm-20250331.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrantsTables" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/DisaggregationOfRevenueTables" xlink:href="cosm-20250331.xsd#DisaggregationOfRevenueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SegmentReportingTables" xlink:href="cosm-20250331.xsd#SegmentReportingTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/BasisOfPresentationDetailsNarrative" xlink:href="cosm-20250331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative" xlink:href="cosm-20250331.xsd#EquityMethodInvestmentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/PropertyPlantAndEquipmentDetails" xlink:href="cosm-20250331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssetsNetDetails" xlink:href="cosm-20250331.xsd#IntangibleAssetsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssetsNetDetails1" xlink:href="cosm-20250331.xsd#IntangibleAssetsNetDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LoanReceivableDetailsNarrative" xlink:href="cosm-20250331.xsd#LoanReceivableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cosm-20250331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CapitalStructureDetailsNarrative" xlink:href="cosm-20250331.xsd#CapitalStructureDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsDetails" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsDetails1" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCreditDetails" xlink:href="cosm-20250331.xsd#LinesOfCreditDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCreditDetailsNarrative" xlink:href="cosm-20250331.xsd#LinesOfCreditDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableDetails" xlink:href="cosm-20250331.xsd#NotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableDetails1" xlink:href="cosm-20250331.xsd#NotesPayableDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableDetailsNarrative" xlink:href="cosm-20250331.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesDetails" xlink:href="cosm-20250331.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesDetails1" xlink:href="cosm-20250331.xsd#LeasesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesDetailsNarrative" xlink:href="cosm-20250331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OtherLiabilitiesDetailsNarrative" xlink:href="cosm-20250331.xsd#OtherLiabilitiesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec" xlink:href="cosm-20250331.xsd#CommitmentsAndContingenciesDetailsNarrativec" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrantsDetails" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrantsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/DisaggregationOfRevenueDetails" xlink:href="cosm-20250331.xsd#DisaggregationOfRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SegmentReportingDetails" xlink:href="cosm-20250331.xsd#SegmentReportingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cosm-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedBalanceSheets" xlink:title="110200 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AmountAccountsReceivableRelatedPartiesCurrent" xlink:label="loc_cosmAmountAccountsReceivableRelatedPartiesCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cosmAmountAccountsReceivableRelatedPartiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="loc_us-gaapLoansAndLeasesReceivableRelatedParties" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapLoansAndLeasesReceivableRelatedParties" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" xlink:label="loc_cosmPrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cosmPrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwill" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetIncludingGoodwill" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansReceivableNoncurrent" xlink:label="loc_cosmLoansReceivableNoncurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cosmLoansReceivableNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansReceivableRelatedPartyNoncurrent" xlink:label="loc_cosmLoansReceivableRelatedPartyNoncurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cosmLoansReceivableRelatedPartyNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AdvancesForBuildingsAcquisition" xlink:label="loc_cosmAdvancesForBuildingsAcquisition" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cosmAdvancesForBuildingsAcquisition" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OtherAssetsRelatedParty" xlink:label="loc_cosmOtherAssetsRelatedParty" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cosmOtherAssetsRelatedParty" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:label="loc_cosmAccountsPayableAndAccruedExpensesRelatedPartiesCurrent" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cosmAccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedPartiesCurrent" xlink:label="loc_cosmNotesPayableRelatedPartiesCurrent" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cosmNotesPayableRelatedPartiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedPartiesCurrent" xlink:label="loc_cosmLoansPayableRelatedPartiesCurrent" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cosmLoansPayableRelatedPartiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
    <link:calculationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
    <link:calculationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
    <link:calculationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaapTreasuryStockCommonValue" />
    <link:calculationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockCommonValue" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="110201 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:title="124100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GainLossOnSalesOfEquityInvestments" xlink:label="loc_cosmGainLossOnSalesOfEquityInvestments" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_cosmGainLossOnSalesOfEquityInvestments" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossRealized" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossRealized" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:title="148600 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="170000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivableRelatedParties" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" xlink:label="loc_cosmIncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cosmIncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" xlink:label="loc_cosmIncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cosmIncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncreaseDecreaseInOtherLiabilities" xlink:label="loc_cosmIncreaseDecreaseInOtherLiabilities" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cosmIncreaseDecreaseInOtherLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="loc_us-gaapOtherDepreciationAndAmortization" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfLoansReceivable" xlink:label="loc_us-gaapProceedsFromSaleOfLoansReceivable" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfLoansReceivable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaapProceedsFromSaleOfIntangibleAssets" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfIntangibleAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
    <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
    <link:calculationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
    <link:calculationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
    <link:calculationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:calculationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/InsiderTradingArrangements" xlink:title="170001 - Disclosure - Insider Trading Arrangements" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/BasisOfPresentation" xlink:title="170002 - Disclosure - BASIS OF PRESENTATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusiness" xlink:title="170003 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/EquityMethodInvestments" xlink:title="170004 - Disclosure - EQUITY METHOD INVESTMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/PropertyAndEquipmentNet" xlink:title="360000 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssets" xlink:title="370000 - Disclosure - INTANGIBLE ASSETS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LoanReceivable" xlink:title="370001 - Disclosure - LOAN RECEIVABLE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/IncomeTaxes" xlink:title="370002 - Disclosure - INCOME TAXES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/CapitalStructure" xlink:title="500000 - Disclosure - CAPITAL STRUCTURE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactions" xlink:title="845000 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCredit" xlink:title="845001 - Disclosure - LINES OF CREDIT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayable" xlink:title="845002 - Disclosure - NOTES PAYABLE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LEASES" xlink:title="845003 - Disclosure - LEASES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OtherLiabilities" xlink:title="845004 - Disclosure - OTHER LIABILITIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/CommitmentsAndContingencies" xlink:title="845005 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrants" xlink:title="845006 - Disclosure - STOCK OPTIONS AND WARRANTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/DisaggregationOfRevenue" xlink:title="845007 - Disclosure - DISAGGREGATION OF REVENUE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/SegmentReporting" xlink:title="845008 - Disclosure - SEGMENT REPORTING" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/SubsequentEvents" xlink:title="870000 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies" xlink:title="870001 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessTables" xlink:title="870002 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/PropertyAndEquipmentNetTables" xlink:title="870003 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssetsTables" xlink:title="870004 - Disclosure - INTANGIBLE ASSETS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsTables" xlink:title="870005 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCreditTables" xlink:title="870006 - Disclosure - LINES OF CREDIT (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableTables" xlink:title="870007 - Disclosure - NOTES PAYABLE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesTables" xlink:title="870008 - Disclosure - LEASES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrantsTables" xlink:title="870009 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/DisaggregationOfRevenueTables" xlink:title="870010 - Disclosure - DISAGGREGATION OF REVENUE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/SegmentReportingTables" xlink:title="870011 - Disclosure - SEGMENT REPORTING (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/BasisOfPresentationDetailsNarrative" xlink:title="870012 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails" xlink:title="870013 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1" xlink:title="870014 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2" xlink:title="870015 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3" xlink:title="870016 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4" xlink:title="870017 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative" xlink:title="870018 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative" xlink:title="870019 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/PropertyPlantAndEquipmentDetails" xlink:title="870020 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssetsNetDetails" xlink:title="870021 - Disclosure - INTANGIBLE ASSETS NET (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssetsNetDetails1" xlink:title="870022 - Disclosure - INTANGIBLE ASSETS NET (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LoanReceivableDetailsNarrative" xlink:title="870023 - Disclosure - LOAN RECEIVABLE (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/IncomeTaxesDetailsNarrative" xlink:title="870024 - Disclosure - INCOME TAXES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/CapitalStructureDetailsNarrative" xlink:title="870025 - Disclosure - CAPITAL STRUCTURE (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsDetails" xlink:title="870026 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsDetails1" xlink:title="870027 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="870028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCreditDetails" xlink:title="870029 - Disclosure - LINES OF CREDIT (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCreditDetailsNarrative" xlink:title="870030 - Disclosure - LINES OF CREDIT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableDetails" xlink:title="870031 - Disclosure - NOTES PAYABLE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableDetails1" xlink:title="870032 - Disclosure - NOTES PAYABLE (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableDetailsNarrative" xlink:title="870033 - Disclosure - NOTES PAYABLE (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesDetails" xlink:title="870034 - Disclosure - LEASES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesDetails1" xlink:title="870035 - Disclosure - LEASES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesDetailsNarrative" xlink:title="870036 - Disclosure - LEASES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/OtherLiabilitiesDetailsNarrative" xlink:title="870037 - Disclosure - OTHER LIABILITIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec" xlink:title="870038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrativec)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrantsDetails" xlink:title="870039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:title="870040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/DisaggregationOfRevenueDetails" xlink:title="870041 - Disclosure - DISAGGREGATION OF REVENUE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/SegmentReportingDetails" xlink:title="870042 - Disclosure - SEGMENT REPORTING (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/SubsequentEventsDetailsNarrative" xlink:title="870043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cosm-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20250331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cosm-20250331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="cosm-20250331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:href="cosm-20250331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="cosm-20250331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cosm-20250331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/InsiderTradingArrangements" xlink:href="cosm-20250331.xsd#InsiderTradingArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/BasisOfPresentation" xlink:href="cosm-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusiness" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/EquityMethodInvestments" xlink:href="cosm-20250331.xsd#EquityMethodInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/PropertyAndEquipmentNet" xlink:href="cosm-20250331.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssets" xlink:href="cosm-20250331.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LoanReceivable" xlink:href="cosm-20250331.xsd#LoanReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IncomeTaxes" xlink:href="cosm-20250331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CapitalStructure" xlink:href="cosm-20250331.xsd#CapitalStructure" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactions" xlink:href="cosm-20250331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCredit" xlink:href="cosm-20250331.xsd#LinesOfCredit" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayable" xlink:href="cosm-20250331.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LEASES" xlink:href="cosm-20250331.xsd#LEASES" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OtherLiabilities" xlink:href="cosm-20250331.xsd#OtherLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CommitmentsAndContingencies" xlink:href="cosm-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrants" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrants" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/DisaggregationOfRevenue" xlink:href="cosm-20250331.xsd#DisaggregationOfRevenue" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SegmentReporting" xlink:href="cosm-20250331.xsd#SegmentReporting" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SubsequentEvents" xlink:href="cosm-20250331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessTables" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/PropertyAndEquipmentNetTables" xlink:href="cosm-20250331.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssetsTables" xlink:href="cosm-20250331.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsTables" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCreditTables" xlink:href="cosm-20250331.xsd#LinesOfCreditTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableTables" xlink:href="cosm-20250331.xsd#NotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesTables" xlink:href="cosm-20250331.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrantsTables" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/DisaggregationOfRevenueTables" xlink:href="cosm-20250331.xsd#DisaggregationOfRevenueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SegmentReportingTables" xlink:href="cosm-20250331.xsd#SegmentReportingTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/BasisOfPresentationDetailsNarrative" xlink:href="cosm-20250331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative" xlink:href="cosm-20250331.xsd#EquityMethodInvestmentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/PropertyPlantAndEquipmentDetails" xlink:href="cosm-20250331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssetsNetDetails" xlink:href="cosm-20250331.xsd#IntangibleAssetsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssetsNetDetails1" xlink:href="cosm-20250331.xsd#IntangibleAssetsNetDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LoanReceivableDetailsNarrative" xlink:href="cosm-20250331.xsd#LoanReceivableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cosm-20250331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CapitalStructureDetailsNarrative" xlink:href="cosm-20250331.xsd#CapitalStructureDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsDetails" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsDetails1" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCreditDetails" xlink:href="cosm-20250331.xsd#LinesOfCreditDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCreditDetailsNarrative" xlink:href="cosm-20250331.xsd#LinesOfCreditDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableDetails" xlink:href="cosm-20250331.xsd#NotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableDetails1" xlink:href="cosm-20250331.xsd#NotesPayableDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableDetailsNarrative" xlink:href="cosm-20250331.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesDetails" xlink:href="cosm-20250331.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesDetails1" xlink:href="cosm-20250331.xsd#LeasesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesDetailsNarrative" xlink:href="cosm-20250331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OtherLiabilitiesDetailsNarrative" xlink:href="cosm-20250331.xsd#OtherLiabilitiesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec" xlink:href="cosm-20250331.xsd#CommitmentsAndContingenciesDetailsNarrativec" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrantsDetails" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrantsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/DisaggregationOfRevenueDetails" xlink:href="cosm-20250331.xsd#DisaggregationOfRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SegmentReportingDetails" xlink:href="cosm-20250331.xsd#SegmentReportingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cosm-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedBalanceSheets" xlink:title="110200 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_73d5a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapAssetsAbstract_73d5a3" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_246f3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapAssetsCurrentAbstract_246f3b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96ee00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96ee00" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_e97921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_e97921" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AmountAccountsReceivableRelatedPartiesCurrent" xlink:label="loc_cosmAmountAccountsReceivableRelatedPartiesCurrent_2978d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_cosmAmountAccountsReceivableRelatedPartiesCurrent_2978d0" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_ae8f5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_ae8f5a" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_1577f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapInventoryNet_1577f2" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent_2d476b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent_2d476b" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="loc_us-gaapLoansAndLeasesReceivableRelatedParties_0e8259" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapLoansAndLeasesReceivableRelatedParties_0e8259" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_337150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_337150" order="10" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent" xlink:label="loc_cosmPrepaidExpenseAndOtherAssetsRelatedPartiesCurrent_2ee8bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_cosmPrepaidExpenseAndOtherAssetsRelatedPartiesCurrent_2ee8bd" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_52e3c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapAssetsCurrent_52e3c5" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_c017ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_c017ac" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwill_5b78f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapIntangibleAssetsNetIncludingGoodwill_5b78f9" order="14" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansReceivableNoncurrent" xlink:label="loc_cosmLoansReceivableNoncurrent_4d1166" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_cosmLoansReceivableNoncurrent_4d1166" order="15" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansReceivableRelatedPartyNoncurrent" xlink:label="loc_cosmLoansReceivableRelatedPartyNoncurrent_6ccc0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_cosmLoansReceivableRelatedPartyNoncurrent_6ccc0c" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_33e67c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_33e67c" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_947f7d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_947f7d" order="18" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AdvancesForBuildingsAcquisition" xlink:label="loc_cosmAdvancesForBuildingsAcquisition_7a2071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_cosmAdvancesForBuildingsAcquisition_7a2071" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_868a6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapOtherAssets_868a6d" order="20" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OtherAssetsRelatedParty" xlink:label="loc_cosmOtherAssetsRelatedParty_96e915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_cosmOtherAssetsRelatedParty_96e915" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_1b42d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapAssets_1b42d3" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_326134" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_326134" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_1eafea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_1eafea" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent_26a5d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent_26a5d8" order="25" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:label="loc_cosmAccountsPayableAndAccruedExpensesRelatedPartiesCurrent_0fe942" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_cosmAccountsPayableAndAccruedExpensesRelatedPartiesCurrent_0fe942" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_f942fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapInterestPayableCurrent_f942fa" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent_b6dde6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapLinesOfCreditCurrent_b6dde6" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_6fde04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapNotesPayableCurrent_6fde04" order="29" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedPartiesCurrent" xlink:label="loc_cosmNotesPayableRelatedPartiesCurrent_d3ffdb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_cosmNotesPayableRelatedPartiesCurrent_d3ffdb" order="30" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedPartiesCurrent" xlink:label="loc_cosmLoansPayableRelatedPartiesCurrent_fd5b81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_cosmLoansPayableRelatedPartiesCurrent_fd5b81" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_5b8648" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_5b8648" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_e69d23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_e69d23" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_276d5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_276d5d" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_325070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapLiabilitiesCurrent_325070" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_eb6577" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapLongTermNotesPayable_eb6577" order="36" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_9a1fc0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_9a1fc0" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_62c9d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_62c9d9" order="38" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_ea050d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_ea050d" order="39" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_c90cc0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapLiabilities_c90cc0" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_befb24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapCommitmentsAndContingencies_befb24" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_c0f7cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapStockholdersEquityAbstract_c0f7cb" order="42" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_e6206e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c0f7cb" xlink:to="loc_us-gaapCommonStockValue_e6206e" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_df757e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c0f7cb" xlink:to="loc_us-gaapAdditionalPaidInCapital_df757e" order="44" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable_0a99a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c0f7cb" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable_0a99a5" order="45" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaapTreasuryStockCommonValue_2dae00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c0f7cb" xlink:to="loc_us-gaapTreasuryStockCommonValue_2dae00" order="46" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_d2d9f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c0f7cb" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_d2d9f9" order="47" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_9b9611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c0f7cb" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_9b9611" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_b77757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c0f7cb" xlink:to="loc_us-gaapStockholdersEquity_b77757" order="49" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_d815c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3cba6c" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_d815c1" order="50" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="110201 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_34c210" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_0a20f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_34c210" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_0a20f5" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_e0fd68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_34c210" xlink:to="loc_us-gaapCommonStockSharesAuthorized_e0fd68" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_3c1467" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_34c210" xlink:to="loc_us-gaapCommonStockSharesIssued_3c1467" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_45fbf9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_34c210" xlink:to="loc_us-gaapCommonStockSharesOutstanding_45fbf9" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares_c55233" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_34c210" xlink:to="loc_us-gaapTreasuryStockCommonShares_c55233" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:title="124100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_9abaeb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_74a4c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapRevenues_74a4c2" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_dc9f63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_dc9f63" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_c93ad8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapGrossProfit_c93ad8" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_09127c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapOperatingExpensesAbstract_09127c" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_5a86f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_09127c" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_5a86f3" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_4c9294" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapSalariesAndWages_4c9294" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense_760ac2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapSellingAndMarketingExpense_760ac2" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_fc5cc7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_fc5cc7" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_143593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapDepreciationAndAmortization_143593" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_e857df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapOperatingExpenses_e857df" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_d681f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapOperatingIncomeLoss_d681f6" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4bf408" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4bf408" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_decc95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4bf408" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_decc95" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_50f238" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4bf408" xlink:to="loc_us-gaapInterestExpense_50f238" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_37ff07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapInterestIncomeOther_37ff07" order="15" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GainLossOnSalesOfEquityInvestments" xlink:label="loc_cosmGainLossOnSalesOfEquityInvestments_e00013" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_cosmGainLossOnSalesOfEquityInvestments_e00013" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossRealized_eca1e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossRealized_eca1e5" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_20cf16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapNonoperatingIncomeExpense_20cf16" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_445808" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_445808" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_d7d1c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_d7d1c3" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_a9df2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapNetIncomeLoss_a9df2c" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_6b8207" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_6b8207" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract_19b8c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract_19b8c5" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bf4470" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract_19b8c5" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bf4470" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_e5622d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_e5622d" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_fbd389" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapEarningsPerShareBasic_fbd389" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_fc55dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapEarningsPerShareDiluted_fc55dc" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_b341b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_b341b3" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesIssuedBasic_8ba2e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesIssuedBasic_8ba2e6" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:label="loc_us-gaapWeightedAverageLimitedPartnershipUnitsOutstandingDiluted_2aadbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_9abaeb" xlink:to="loc_us-gaapWeightedAverageLimitedPartnershipUnitsOutstandingDiluted_2aadbc" order="30" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:title="148600 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_22c1cc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0fdba5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_22c1cc" xlink:to="loc_us-gaapStatementTable_0fdba5" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0acca9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0fdba5" xlink:to="loc_us-gaapStatementLineItems_0acca9" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_ef68fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0fdba5" xlink:to="loc_us-gaapStatementEquityComponentsAxis_ef68fb" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_7229af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_ef68fb" xlink:to="loc_us-gaapEquityComponentDomain_7229af" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_7fafc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_7229af" xlink:to="loc_us-gaapTreasuryStockCommonMember_7fafc2" order="21" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockShareMember" xlink:label="loc_cosmCommonStockShareMember_3e33b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_7229af" xlink:to="loc_cosmCommonStockShareMember_3e33b7" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_3fecdf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_7229af" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_3fecdf" order="23" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SubscriptionReceivableMember" xlink:label="loc_cosmSubscriptionReceivableMember_ee73bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_7229af" xlink:to="loc_cosmSubscriptionReceivableMember_ee73bc" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_c9a639" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_7229af" xlink:to="loc_us-gaapRetainedEarningsMember_c9a639" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_367d62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_7229af" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_367d62" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_8aa442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_us-gaapSharesIssued_8aa442" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64909e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64909e" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ForeignCurrencyTranslationAdjustmentNet" xlink:label="loc_cosmForeignCurrencyTranslationAdjustmentNet_6ab921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_cosmForeignCurrencyTranslationAdjustmentNet_6ab921" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" xlink:label="loc_cosmProceedsFromSaleOfCommonStockNetOfFinancingFeesShares_e3e671" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_cosmProceedsFromSaleOfCommonStockNetOfFinancingFeesShares_e3e671" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" xlink:label="loc_cosmProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount_708cff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_cosmProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount_708cff" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesIssuedInLieuOfCashAmount" xlink:label="loc_cosmSharesIssuedInLieuOfCashAmount_8298a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_cosmSharesIssuedInLieuOfCashAmount_8298a2" order="6" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares" xlink:label="loc_cosmSharesIssuedPursuantToWarrantExchangeAgreementShares_56ad2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_cosmSharesIssuedPursuantToWarrantExchangeAgreementShares_56ad2b" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount" xlink:label="loc_cosmSharesIssuedPursuantToWarrantExchangeAgreementAmount_c5272e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_cosmSharesIssuedPursuantToWarrantExchangeAgreementAmount_c5272e" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockBasedCompensation" xlink:label="loc_cosmStockBasedCompensation_9df91d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_cosmStockBasedCompensation_9df91d" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_63a5ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_us-gaapProfitLoss_63a5ce" order="10" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtExchangesShares" xlink:label="loc_cosmDebtExchangesShares_ccf928" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_cosmDebtExchangesShares_ccf928" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtExchangesAmount" xlink:label="loc_cosmDebtExchangesAmount_8247f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_cosmDebtExchangesAmount_8247f2" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_c5f43e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_us-gaapSharesIssued_c5f43e" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c6196" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acca9" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c6196" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="170000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_72094b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_400738" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_400738" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_7a6576" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapNetIncomeLoss_7a6576" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b87911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b87911" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="loc_us-gaapOtherDepreciationAndAmortization_873529" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b87911" xlink:to="loc_us-gaapOtherDepreciationAndAmortization_873529" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_e74921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b87911" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_e74921" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts_552175" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b87911" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts_552175" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_cc32cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapLeaseAndRentalExpense_cc32cd" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_207c0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_207c0b" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_9c74e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapShareBasedCompensation_9c74e6" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits_f581f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits_f581f2" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_284677" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapGainLossOnInvestments_284677" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_37313a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_37313a" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivableRelatedParties_f89713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivableRelatedParties_f89713" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_bebb5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_bebb5f" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther_6231d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther_6231d4" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty" xlink:label="loc_cosmIncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty_7b03ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_cosmIncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty_7b03ab" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0015b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0015b9" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties" xlink:label="loc_cosmIncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties_ed2a9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_cosmIncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties_ed2a9a" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet_f21b03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet_f21b03" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_cddf91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_cddf91" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_480741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_480741" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncreaseDecreaseInOtherLiabilities" xlink:label="loc_cosmIncreaseDecreaseInOtherLiabilities_dc0158" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_cosmIncreaseDecreaseInOtherLiabilities_dc0158" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_f131a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_962c84" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_f131a2" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_547077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_547077" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfLoansReceivable" xlink:label="loc_us-gaapProceedsFromSaleOfLoansReceivable_d5f160" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_547077" xlink:to="loc_us-gaapProceedsFromSaleOfLoansReceivable_d5f160" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_bc2b80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_547077" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_bc2b80" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaapProceedsFromSaleOfIntangibleAssets_2ae1e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_547077" xlink:to="loc_us-gaapProceedsFromSaleOfIntangibleAssets_2ae1e2" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_d0e787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_547077" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_d0e787" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_8cb67b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_547077" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_8cb67b" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_515762" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_515762" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_8ec89b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" xlink:to="loc_us-gaapProceedsFromNotesPayable_8ec89b" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_aed9c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_aed9c4" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit_edd5c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit_edd5c4" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_d3cf93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_d3cf93" order="36" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_53fda8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_53fda8" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts_5c498d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" xlink:to="loc_us-gaapPaymentsOfFinancingCosts_5c498d" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_c48d88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_c48d88" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_e6df00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f67f5d" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_e6df00" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7386fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7386fd" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c245e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c245e1" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9b228b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9b228b" order="43" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a41dd4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a41dd4" order="44" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_3a198e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_3a198e" order="45" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CashPaidDuringTheYearNewAbstract" xlink:label="loc_cosmCashPaidDuringTheYearNewAbstract_e825e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_3a198e" xlink:to="loc_cosmCashPaidDuringTheYearNewAbstract_e825e6" order="46" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_bc1faa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmCashPaidDuringTheYearNewAbstract_e825e6" xlink:to="loc_us-gaapInterestPaidNet_bc1faa" order="47" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3d5cea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_72094b" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3d5cea" order="48" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ClosingOfAcquisitionOfCloudscreen" xlink:label="loc_cosmClosingOfAcquisitionOfCloudscreen_3a2796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3d5cea" xlink:to="loc_cosmClosingOfAcquisitionOfCloudscreen_3a2796" order="49" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockIssuedToEmployees" xlink:label="loc_cosmCommonStockIssuedToEmployees_f927e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3d5cea" xlink:to="loc_cosmCommonStockIssuedToEmployees_f927e4" order="50" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockIssuedToConsultants" xlink:label="loc_cosmCommonStockIssuedToConsultants_755891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3d5cea" xlink:to="loc_cosmCommonStockIssuedToConsultants_755891" order="51" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/InsiderTradingArrangements" xlink:title="170001 - Disclosure - Insider Trading Arrangements">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InsiderTradingArrangementsAbstract" xlink:label="loc_cosmInsiderTradingArrangementsAbstract_b006cc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems_d0913b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag_0f8012" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_d0913b" xlink:to="loc_ecdRule10b51ArrAdoptedFlag_0f8012" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag_dfdb80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_d0913b" xlink:to="loc_ecdRule10b51ArrTrmntdFlag_dfdb80" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag_08c0b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_d0913b" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag_08c0b1" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag_571430" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_d0913b" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag_571430" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/BasisOfPresentation" xlink:title="170002 - Disclosure - BASIS OF PRESENTATION">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BasisOfPresentationAbstract" xlink:label="loc_cosmBasisOfPresentationAbstract_783bae" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock_2bc66b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmBasisOfPresentationAbstract_783bae" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock_2bc66b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusiness" xlink:title="170003 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_194b79" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_2743d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_194b79" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_2743d9" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/EquityMethodInvestments" xlink:title="170004 - Disclosure - EQUITY METHOD INVESTMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAbstract_6a8c0c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaapEquityMethodInvestmentsDisclosureTextBlock_1e5a73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAbstract_6a8c0c" xlink:to="loc_us-gaapEquityMethodInvestmentsDisclosureTextBlock_1e5a73" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/PropertyAndEquipmentNet" xlink:title="360000 - Disclosure - PROPERTY AND EQUIPMENT, NET">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_0bbfa3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_b38913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_0bbfa3" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_b38913" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssets" xlink:title="370000 - Disclosure - INTANGIBLE ASSETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_19fdea" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock_efe7f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_19fdea" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock_efe7f3" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LoanReceivable" xlink:title="370001 - Disclosure - LOAN RECEIVABLE">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoanReceivableabstract" xlink:label="loc_cosmLoanReceivableabstract_df7d82" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock_c6c5f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmLoanReceivableabstract_df7d82" xlink:to="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock_c6c5f6" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/IncomeTaxes" xlink:title="370002 - Disclosure - INCOME TAXES">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncomeTaxAbstract" xlink:label="loc_cosmIncomeTaxAbstract_79e965" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock_b4ee82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmIncomeTaxAbstract_79e965" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock_b4ee82" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/CapitalStructure" xlink:title="500000 - Disclosure - CAPITAL STRUCTURE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_f11d72" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CapitalStructureTextBlock" xlink:label="loc_cosmCapitalStructureTextBlock_2805cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_f11d72" xlink:to="loc_cosmCapitalStructureTextBlock_2805cc" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactions" xlink:title="845000 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_2f9bc4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_68ebe6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_2f9bc4" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_68ebe6" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCredit" xlink:title="845001 - Disclosure - LINES OF CREDIT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="loc_us-gaapLineOfCreditFacilityAbstract_c20057" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LineOfCreditFacilitiesDisclosureTextBlock" xlink:label="loc_cosmLineOfCreditFacilitiesDisclosureTextBlock_1eb0e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_c20057" xlink:to="loc_cosmLineOfCreditFacilitiesDisclosureTextBlock_1eb0e5" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayable" xlink:title="845002 - Disclosure - NOTES PAYABLE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_73472b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock_0bab50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_73472b" xlink:to="loc_us-gaapDebtDisclosureTextBlock_0bab50" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LEASES" xlink:title="845003 - Disclosure - LEASES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_3a871a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock_20026a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_3a871a" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock_20026a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OtherLiabilities" xlink:title="845004 - Disclosure - OTHER LIABILITIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaapOtherLiabilitiesAbstract_9c0d6b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock_8fbd78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesAbstract_9c0d6b" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock_8fbd78" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/CommitmentsAndContingencies" xlink:title="845005 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_43c672" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_588786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_43c672" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_588786" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrants" xlink:title="845006 - Disclosure - STOCK OPTIONS AND WARRANTS">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockOptionsAndWarrantsAbstract" xlink:label="loc_cosmStockOptionsAndWarrantsAbstract_f25cc7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockOptionsAndWarrantsDisclouserTextBlock" xlink:label="loc_cosmStockOptionsAndWarrantsDisclouserTextBlock_970b2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmStockOptionsAndWarrantsAbstract_f25cc7" xlink:to="loc_cosmStockOptionsAndWarrantsDisclouserTextBlock_970b2b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/DisaggregationOfRevenue" xlink:title="845007 - Disclosure - DISAGGREGATION OF REVENUE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract_0b4ffa" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DisaggregationOfRevenueDisclosureTextBlock" xlink:label="loc_cosmDisaggregationOfRevenueDisclosureTextBlock_706450" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract_0b4ffa" xlink:to="loc_cosmDisaggregationOfRevenueDisclosureTextBlock_706450" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/SegmentReporting" xlink:title="845008 - Disclosure - SEGMENT REPORTING">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_92bfc0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock_987c8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_92bfc0" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock_987c8e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/SubsequentEvents" xlink:title="870000 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_171649" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_12524b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_171649" xlink:to="loc_us-gaapSubsequentEventsTextBlock_12524b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies" xlink:title="870001 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Policies)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_4d2e6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_4d2e6a" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AcquisitionAccountingPolicy" xlink:label="loc_cosmAcquisitionAccountingPolicy_dd6ac7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_cosmAcquisitionAccountingPolicy_dd6ac7" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock_60fc03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapConsolidationPolicyTextBlock_60fc03" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_c86793" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapUseOfEstimates_c86793" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EffectsOfWarInTheUkrainePolicyTextBlock" xlink:label="loc_cosmEffectsOfWarInTheUkrainePolicyTextBlock_754280" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_cosmEffectsOfWarInTheUkrainePolicyTextBlock_754280" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CreditLossesPolicyTextBlock" xlink:label="loc_cosmCreditLossesPolicyTextBlock_f43826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_cosmCreditLossesPolicyTextBlock_f43826" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_37b01a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_37b01a" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_334432" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_334432" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy_0f1040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy_0f1040" order="9" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TaxReceivablesPolicyTextBlock" xlink:label="loc_cosmTaxReceivablesPolicyTextBlock_53aa7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_cosmTaxReceivablesPolicyTextBlock_53aa7f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_a4fdef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapInventoryPolicyTextBlock_a4fdef" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_0f6309" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_0f6309" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_29095b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_29095b" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock_7ba2de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock_7ba2de" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy_1dab16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy_1dab16" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock_c5b4e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapInvestmentPolicyTextBlock_c5b4e7" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_a2497b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_a2497b" order="17" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CustomerAdvancesPolicyTextBlock" xlink:label="loc_cosmCustomerAdvancesPolicyTextBlock_f38268" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_cosmCustomerAdvancesPolicyTextBlock_f38268" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="loc_us-gaapRevenueRecognitionDeferredRevenue_831a3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapRevenueRecognitionDeferredRevenue_831a3a" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock_34d154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock_34d154" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_d4b8c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_d4b8c8" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="loc_us-gaapLessorLeasesPolicyTextBlock_fae7db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapLessorLeasesPolicyTextBlock_fae7db" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitPlansPolicy" xlink:label="loc_us-gaapPostemploymentBenefitPlansPolicy_dae102" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapPostemploymentBenefitPlansPolicy_dae102" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_7ca93d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_7ca93d" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_db6e72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8bd791" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_db6e72" order="25" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessTables" xlink:title="870002 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Tables)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_5ee3d3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock_a46653" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_5ee3d3" xlink:to="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock_a46653" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_cfdae6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_5ee3d3" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_cfdae6" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_022725" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_5ee3d3" xlink:to="loc_us-gaapScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_022725" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2bdb0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_5ee3d3" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2bdb0e" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9d7f17" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_5ee3d3" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9d7f17" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/PropertyAndEquipmentNetTables" xlink:title="870003 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_c9a539" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock_6c3f95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_c9a539" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock_6c3f95" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssetsTables" xlink:title="870004 - Disclosure - INTANGIBLE ASSETS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_1f5ae4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_c69d5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_1f5ae4" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_c69d5d" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c51cb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_1f5ae4" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c51cb8" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsTables" xlink:title="870005 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_b742e8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock_9e0e81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_b742e8" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock_9e0e81" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock" xlink:label="loc_cosmScheduleOfRelatedPartyLoansPayableTableTextBlock_e14630" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_b742e8" xlink:to="loc_cosmScheduleOfRelatedPartyLoansPayableTableTextBlock_e14630" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCreditTables" xlink:title="870006 - Disclosure - LINES OF CREDIT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="loc_us-gaapLineOfCreditFacilityAbstract_e14821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="loc_us-gaapScheduleOfLineOfCreditFacilitiesTextBlock_9357e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_e14821" xlink:to="loc_us-gaapScheduleOfLineOfCreditFacilitiesTextBlock_9357e4" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableTables" xlink:title="870007 - Disclosure - NOTES PAYABLE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_4730d3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock_e1024f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_4730d3" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock_e1024f" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ScheduleOfOutstandingDebtTableTextBlock" xlink:label="loc_cosmScheduleOfOutstandingDebtTableTextBlock_131cd2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_4730d3" xlink:to="loc_cosmScheduleOfOutstandingDebtTableTextBlock_131cd2" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesTables" xlink:title="870008 - Disclosure - LEASES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_5413a4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_3914b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_5413a4" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_3914b4" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_4a79a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_5413a4" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_4a79a7" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrantsTables" xlink:title="870009 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockOptionsAndWarrantsAbstract" xlink:label="loc_cosmStockOptionsAndWarrantsAbstract_6e832b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_927b40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmStockOptionsAndWarrantsAbstract_6e832b" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_927b40" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/DisaggregationOfRevenueTables" xlink:title="870010 - Disclosure - DISAGGREGATION OF REVENUE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract_3ac451" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock_8aec51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract_3ac451" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock_8aec51" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/SegmentReportingTables" xlink:title="870011 - Disclosure - SEGMENT REPORTING (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_e5537e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_cbafe2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_e5537e" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_cbafe2" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock" xlink:label="loc_cosmScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock_fef537" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_e5537e" xlink:to="loc_cosmScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock_fef537" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/BasisOfPresentationDetailsNarrative" xlink:title="870012 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BasisOfPresentationAbstract" xlink:label="loc_cosmBasisOfPresentationAbstract_478cb3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInContinuingOperations_5d984e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmBasisOfPresentationAbstract_478cb3" xlink:to="loc_us-gaapNetCashProvidedByUsedInContinuingOperations_5d984e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_9626e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmBasisOfPresentationAbstract_478cb3" xlink:to="loc_us-gaapStockholdersEquity_9626e1" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_3530cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmBasisOfPresentationAbstract_478cb3" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_3530cb" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WorkingCapital" xlink:label="loc_cosmWorkingCapital_2479b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmBasisOfPresentationAbstract_478cb3" xlink:to="loc_cosmWorkingCapital_2479b4" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_d87d0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmBasisOfPresentationAbstract_478cb3" xlink:to="loc_us-gaapRevenues_d87d0a" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_e71c00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmBasisOfPresentationAbstract_478cb3" xlink:to="loc_us-gaapProfitLoss_e71c00" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails" xlink:title="870013 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_fb75a8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5684c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_fb75a8" xlink:to="loc_us-gaapStatementTable_5684c3" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b70533" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5684c3" xlink:to="loc_us-gaapStatementLineItems_b70533" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis_a7d9e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5684c3" xlink:to="loc_us-gaapBusinessAcquisitionAxis_a7d9e1" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_eb14cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis_a7d9e1" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_eb14cf" order="20" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CANAPharmaceuticalLaboratoriesSACanaMember" xlink:label="loc_cosmCANAPharmaceuticalLaboratoriesSACanaMember_911b97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain_eb14cf" xlink:to="loc_cosmCANAPharmaceuticalLaboratoriesSACanaMember_911b97" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross_b8f8d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross_b8f8d7" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_569b03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_569b03" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_71dc66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_71dc66" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_975078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapAssets_975078" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_aca57f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_aca57f" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_005655" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_005655" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_337ca6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_337ca6" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_84f980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_84f980" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6df39b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6df39b" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_23d22c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b70533" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_23d22c" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1" xlink:title="870014 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_0acd22" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance" xlink:label="loc_cosmChangesInAllowanceForDoubtfulAccountsBeginningBalance_db2397" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_0acd22" xlink:to="loc_cosmChangesInAllowanceForDoubtfulAccountsBeginningBalance_db2397" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaapProvisionForOtherCreditLosses_f5fae2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_0acd22" xlink:to="loc_us-gaapProvisionForOtherCreditLosses_f5fae2" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs_4bf90d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_0acd22" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs_4bf90d" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:label="loc_us-gaapTemporaryEquityForeignCurrencyTranslationAdjustments_cd546f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_0acd22" xlink:to="loc_us-gaapTemporaryEquityForeignCurrencyTranslationAdjustments_cd546f" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="loc_us-gaapOtherPreferredStockDividendsAndAdjustments_aa70f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_0acd22" xlink:to="loc_us-gaapOtherPreferredStockDividendsAndAdjustments_aa70f8" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance" xlink:label="loc_cosmChangesInAllowanceForDoubtfulAccountsEndingBalance_e16d4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_0acd22" xlink:to="loc_cosmChangesInAllowanceForDoubtfulAccountsEndingBalance_e16d4d" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2" xlink:title="870015 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 2)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_62042b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e25a45" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_62042b" xlink:to="loc_us-gaapStatementTable_e25a45" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_531cf1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e25a45" xlink:to="loc_us-gaapStatementLineItems_531cf1" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_1a9c22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e25a45" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_1a9c22" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_d67fad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_1a9c22" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_d67fad" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_f8bf3d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e25a45" xlink:to="loc_us-gaapPlanNameAxis_f8bf3d" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_fded9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_f8bf3d" xlink:to="loc_us-gaapPlanNameDomain_fded9e" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_b6d221" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_d67fad" xlink:to="loc_us-gaapVehiclesMember_b6d221" order="41" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MachineryMember" xlink:label="loc_cosmMachineryMember_9a012b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_d67fad" xlink:to="loc_cosmMachineryMember_9a012b" order="42" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LeaseholdImprovementsAndTechnicalWorksMember" xlink:label="loc_cosmLeaseholdImprovementsAndTechnicalWorksMember_2d77ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_d67fad" xlink:to="loc_cosmLeaseholdImprovementsAndTechnicalWorksMember_2d77ce" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_b7110f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_d67fad" xlink:to="loc_us-gaapFurnitureAndFixturesMember_b7110f" order="44" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TopMember" xlink:label="loc_cosmTopMember_3855bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_fded9e" xlink:to="loc_cosmTopMember_3855bf" order="45" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BuildingsMember" xlink:label="loc_cosmBuildingsMember_df9d51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_d67fad" xlink:to="loc_cosmBuildingsMember_df9d51" order="46" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BottomMember" xlink:label="loc_cosmBottomMember_0d10aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_fded9e" xlink:to="loc_cosmBottomMember_0d10aa" order="47" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_bc14c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_d67fad" xlink:to="loc_us-gaapComputerEquipmentMember_bc14c7" order="48" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PropertyPlantAndEquipmentUsefulLifes" xlink:label="loc_cosmPropertyPlantAndEquipmentUsefulLifes_afc71a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_531cf1" xlink:to="loc_cosmPropertyPlantAndEquipmentUsefulLifes_afc71a" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PropertyPlantsAndEquipmentUsefulLife" xlink:label="loc_cosmPropertyPlantsAndEquipmentUsefulLife_d9e591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_531cf1" xlink:to="loc_cosmPropertyPlantsAndEquipmentUsefulLife_d9e591" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives" xlink:label="loc_cosmPropertyPlantsAndEquipmentEstimatedUsefulLives_ff8e38" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_531cf1" xlink:to="loc_cosmPropertyPlantsAndEquipmentEstimatedUsefulLives_ff8e38" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3" xlink:title="870016 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 3)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_4ccdf4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_756802" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_4ccdf4" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_756802" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PotentiallyDilutiveCommonStockEquivalents" xlink:label="loc_cosmPotentiallyDilutiveCommonStockEquivalents_754b50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_4ccdf4" xlink:to="loc_cosmPotentiallyDilutiveCommonStockEquivalents_754b50" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_b27533" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_4ccdf4" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_b27533" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4" xlink:title="870017 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 4)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_c24521" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants_85e626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_c24521" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants_85e626" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PotentialCommonShares" xlink:label="loc_cosmPotentialCommonShares_b4062d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_c24521" xlink:to="loc_cosmPotentialCommonShares_b4062d" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative" xlink:title="870018 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OrganizationAndNatureOfTheBusinessAbstract" xlink:label="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8b7ef4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_d771f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmOrganizationAndNatureOfTheBusinessAbstract_8b7ef4" xlink:to="loc_us-gaapStatementTable_d771f1" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_348baa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d771f1" xlink:to="loc_us-gaapStatementLineItems_348baa" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis_a2a08b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d771f1" xlink:to="loc_us-gaapBusinessAcquisitionAxis_a2a08b" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_80792e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis_a2a08b" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_80792e" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis_dca9d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d771f1" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis_dca9d3" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_1d7603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis_dca9d3" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_1d7603" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fce17c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d771f1" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fce17c" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_d627ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fce17c" xlink:to="loc_us-gaapRelatedPartyDomain_d627ad" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_f12916" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d771f1" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_f12916" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_727194" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_f12916" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_727194" order="60" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CANAPharmaceuticalLaboratoriesSACanaMember" xlink:label="loc_cosmCANAPharmaceuticalLaboratoriesSACanaMember_e62bdd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain_80792e" xlink:to="loc_cosmCANAPharmaceuticalLaboratoriesSACanaMember_e62bdd" order="61" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ZipDoctorIncMember" xlink:label="loc_cosmZipDoctorIncMember_802ea7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain_80792e" xlink:to="loc_cosmZipDoctorIncMember_802ea7" order="62" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GreeceMember" xlink:label="loc_cosmGreeceMember_9a9d1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_1d7603" xlink:to="loc_cosmGreeceMember_9a9d1c" order="63" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PancretaBankMember" xlink:label="loc_cosmPancretaBankMember_d60998" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_d627ad" xlink:to="loc_cosmPancretaBankMember_d60998" order="64" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BuildingAcquisionMember" xlink:label="loc_cosmBuildingAcquisionMember_d6925f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_727194" xlink:to="loc_cosmBuildingAcquisionMember_d6925f" order="65" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UnitedKingdomMember" xlink:label="loc_cosmUnitedKingdomMember_9e2336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_1d7603" xlink:to="loc_cosmUnitedKingdomMember_9e2336" order="66" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CloudscreenMember" xlink:label="loc_cosmCloudscreenMember_323c7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain_80792e" xlink:to="loc_cosmCloudscreenMember_323c7a" order="67" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="loc_us-gaapDepreciationExpenseOnReclassifiedAssets_2e7fae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapDepreciationExpenseOnReclassifiedAssets_2e7fae" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_d6c2ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_d6c2ce" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_d067d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_d067d3" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent_59ccdc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapReceivablesNetCurrent_59ccdc" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_91c41c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_91c41c" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:label="loc_us-gaapOtherInvestmentsAndSecuritiesAtCost_0805c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapOtherInvestmentsAndSecuritiesAtCost_0805c9" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_cb242a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapSharePrice_cb242a" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_00240c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues_00240c" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedLoss_3cf07b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedLoss_3cf07b" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_315f93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapOtherLiabilities_315f93" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_c18048" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_c18048" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionCosts" xlink:label="loc_us-gaapAcquisitionCosts_3482e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapAcquisitionCosts_3482e5" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3a35d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3a35d0" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_865105" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapAssetImpairmentCharges_865105" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaapAcceleratedShareRepurchasesAdjustmentToRecordedAmount_e6fd28" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapAcceleratedShareRepurchasesAdjustmentToRecordedAmount_e6fd28" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_00f1f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_00f1f6" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_d62b9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualFairValueOfSharesIssued_d62b9a" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaapEquityMethodInvestmentAggregateCost_7d5c66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapEquityMethodInvestmentAggregateCost_7d5c66" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4213a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4213a4" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" xlink:label="loc_cosmBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares_247879" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_cosmBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares_247879" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets_698f07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets_698f07" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromSecuredNotesPayable_fba77a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapProceedsFromSecuredNotesPayable_fba77a" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:label="loc_us-gaapAssetAcquisitionPriceOfAcquisitionExpected_b25c70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_348baa" xlink:to="loc_us-gaapAssetAcquisitionPriceOfAcquisitionExpected_b25c70" order="23" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative" xlink:title="870019 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAbstract_80843e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_48a23f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAbstract_80843e" xlink:to="loc_us-gaapStatementTable_48a23f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_7146b2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_48a23f" xlink:to="loc_us-gaapStatementLineItems_7146b2" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_bb51e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_48a23f" xlink:to="loc_us-gaapPlanNameAxis_bb51e0" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_30707f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_bb51e0" xlink:to="loc_us-gaapPlanNameDomain_30707f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_438e0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_48a23f" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_438e0d" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_917d25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_438e0d" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_917d25" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_371699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_48a23f" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_371699" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_c5e851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_371699" xlink:to="loc_us-gaapRelatedPartyDomain_c5e851" order="40" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareExchangeAgreementMember" xlink:label="loc_cosmShareExchangeAgreementMember_f0d401" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_30707f" xlink:to="loc_cosmShareExchangeAgreementMember_f0d401" order="41" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IccMember" xlink:label="loc_cosmIccMember_e41062" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_917d25" xlink:to="loc_cosmIccMember_e41062" order="42" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CosmoFarmacyLPMember" xlink:label="loc_cosmCosmoFarmacyLPMember_ca200b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_c5e851" xlink:to="loc_cosmCosmoFarmacyLPMember_ca200b" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_4573e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7146b2" xlink:to="loc_us-gaapInvestments_4573e8" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InitialShareCapital" xlink:label="loc_cosmInitialShareCapital_c73f0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7146b2" xlink:to="loc_cosmInitialShareCapital_c73f0e" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InitialShareCapitalIncreased" xlink:label="loc_cosmInitialShareCapitalIncreased_8901ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7146b2" xlink:to="loc_cosmInitialShareCapitalIncreased_8901ec" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PharmacyLicenseValue" xlink:label="loc_cosmPharmacyLicenseValue_9a3043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7146b2" xlink:to="loc_cosmPharmacyLicenseValue_9a3043" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MaturityPeriodOfLicense" xlink:label="loc_cosmMaturityPeriodOfLicense_7bcdd3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7146b2" xlink:to="loc_cosmMaturityPeriodOfLicense_7bcdd3" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EquityMethodInvestmentsOwnershipPercentage" xlink:label="loc_cosmEquityMethodInvestmentsOwnershipPercentage_8d9df6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7146b2" xlink:to="loc_cosmEquityMethodInvestmentsOwnershipPercentage_8d9df6" order="6" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CashContributedToLimitedPartner" xlink:label="loc_cosmCashContributedToLimitedPartner_781031" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7146b2" xlink:to="loc_cosmCashContributedToLimitedPartner_781031" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EquityMethodInvestmentOwnershipRemainingPercentage" xlink:label="loc_cosmEquityMethodInvestmentOwnershipRemainingPercentage_3fe56c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7146b2" xlink:to="loc_cosmEquityMethodInvestmentOwnershipRemainingPercentage_3fe56c" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/PropertyPlantAndEquipmentDetails" xlink:title="870020 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_65f781" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c6e470" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_65f781" xlink:to="loc_us-gaapStatementTable_c6e470" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ec67d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c6e470" xlink:to="loc_us-gaapStatementLineItems_ec67d0" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_777a68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c6e470" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_777a68" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_ba5aaf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_777a68" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_ba5aaf" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis_e75fd8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c6e470" xlink:to="loc_srtProductOrServiceAxis_e75fd8" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_d72922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis_e75fd8" xlink:to="loc_srtProductsAndServicesDomain_d72922" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_a90e05" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_ba5aaf" xlink:to="loc_us-gaapVehiclesMember_a90e05" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_c4ce34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_ba5aaf" xlink:to="loc_us-gaapLeaseholdImprovementsMember_c4ce34" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_ee1c71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_ba5aaf" xlink:to="loc_us-gaapFurnitureAndFixturesMember_ee1c71" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember_5f61fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain_d72922" xlink:to="loc_us-gaapLandMember_5f61fd" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaapBuildingImprovementsMember_a1e076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_ba5aaf" xlink:to="loc_us-gaapBuildingImprovementsMember_a1e076" order="35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_9c6571" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ec67d0" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_9c6571" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_475ef1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ec67d0" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_475ef1" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_1cbc46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ec67d0" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_1cbc46" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssetsNetDetails" xlink:title="870021 - Disclosure - INTANGIBLE ASSETS NET (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_a5a394" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0efa35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_a5a394" xlink:to="loc_us-gaapStatementTable_0efa35" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_4d1d37" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0efa35" xlink:to="loc_us-gaapStatementLineItems_4d1d37" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis_018b17" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0efa35" xlink:to="loc_srtProductOrServiceAxis_018b17" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_91b20d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis_018b17" xlink:to="loc_srtProductsAndServicesDomain_91b20d" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_cdcd50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0efa35" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_cdcd50" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_664f80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_cdcd50" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_664f80" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_31ecf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0efa35" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_31ecf3" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_077fbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_31ecf3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_077fbe" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_f7509b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain_91b20d" xlink:to="loc_us-gaapLicenseMember_f7509b" order="51" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TradeNameMarkMember" xlink:label="loc_cosmTradeNameMarkMember_dc6fbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_664f80" xlink:to="loc_cosmTradeNameMarkMember_dc6fbe" order="52" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerListsMember" xlink:label="loc_us-gaapCustomerListsMember_f58ffe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_077fbe" xlink:to="loc_us-gaapCustomerListsMember_f58ffe" order="53" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SoftwareMember" xlink:label="loc_cosmSoftwareMember_ad1244" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain_91b20d" xlink:to="loc_cosmSoftwareMember_ad1244" order="54" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapOtherFiniteLivedIntangibleAssetsGross_5102c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d1d37" xlink:to="loc_us-gaapOtherFiniteLivedIntangibleAssetsGross_5102c2" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_51ee55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d1d37" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_51ee55" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_8fcf9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d1d37" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_8fcf9b" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2ead0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d1d37" xlink:to="loc_us-gaapGoodwill_2ead0b" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwill_d298fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d1d37" xlink:to="loc_us-gaapIntangibleAssetsNetIncludingGoodwill_d298fc" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssetsNetDetails1" xlink:title="870022 - Disclosure - INTANGIBLE ASSETS NET (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_decd09" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c7c864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_decd09" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c7c864" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_414813" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_decd09" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_414813" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_be415c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_decd09" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_be415c" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_666f27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_decd09" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_666f27" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a13a91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_decd09" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a13a91" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4ca73c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_decd09" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4ca73c" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_38d435" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_decd09" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_38d435" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LoanReceivableDetailsNarrative" xlink:title="870023 - Disclosure - LOAN RECEIVABLE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoanReceivableabstract" xlink:label="loc_cosmLoanReceivableabstract_eb8be2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="loc_us-gaapPaymentsOfLoanCosts_d8b4ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmLoanReceivableabstract_eb8be2" xlink:to="loc_us-gaapPaymentsOfLoanCosts_d8b4ec" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease_2446fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmLoanReceivableabstract_eb8be2" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease_2446fb" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet_2a9154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmLoanReceivableabstract_eb8be2" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet_2a9154" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable" xlink:label="loc_cosmThresholdPeriodPastDueForWriteoffsOfFinancingReceivable_33dae3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmLoanReceivableabstract_eb8be2" xlink:to="loc_cosmThresholdPeriodPastDueForWriteoffsOfFinancingReceivable_33dae3" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DecriptionOfLoanPayment" xlink:label="loc_cosmDecriptionOfLoanPayment_9bde96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmLoanReceivableabstract_eb8be2" xlink:to="loc_cosmDecriptionOfLoanPayment_9bde96" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/IncomeTaxesDetailsNarrative" xlink:title="870024 - Disclosure - INCOME TAXES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IncomeTaxAbstract" xlink:label="loc_cosmIncomeTaxAbstract_b805dc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ec694a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmIncomeTaxAbstract_b805dc" xlink:to="loc_us-gaapStatementTable_ec694a" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9889d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ec694a" xlink:to="loc_us-gaapStatementLineItems_9889d9" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis_f248c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ec694a" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis_f248c5" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_88411e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis_f248c5" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_88411e" order="10" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GreeceMember" xlink:label="loc_cosmGreeceMember_9022ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_88411e" xlink:to="loc_cosmGreeceMember_9022ce" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UnitedKingdomMember" xlink:label="loc_cosmUnitedKingdomMember_87fe90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_88411e" xlink:to="loc_cosmUnitedKingdomMember_87fe90" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CorporateTaxRate" xlink:label="loc_cosmCorporateTaxRate_e2f128" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9889d9" xlink:to="loc_cosmCorporateTaxRate_e2f128" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/CapitalStructureDetailsNarrative" xlink:title="870025 - Disclosure - CAPITAL STRUCTURE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_57175b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_55fdd8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_57175b" xlink:to="loc_us-gaapStatementTable_55fdd8" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_6b4e09" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_55fdd8" xlink:to="loc_us-gaapStatementLineItems_6b4e09" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_0abace" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_55fdd8" xlink:to="loc_us-gaapStatementClassOfStockAxis_0abace" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_7a8c2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_0abace" xlink:to="loc_us-gaapClassOfStockDomain_7a8c2d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_f389bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_55fdd8" xlink:to="loc_us-gaapPlanNameAxis_f389bc" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_5a285d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_f389bc" xlink:to="loc_us-gaapPlanNameDomain_5a285d" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_529354" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_55fdd8" xlink:to="loc_us-gaapAwardTypeAxis_529354" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6833b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_529354" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6833b8" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_a5b4cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_7a8c2d" xlink:to="loc_us-gaapSeriesAPreferredStockMember_a5b4cd" order="51" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantInducementLetterMember" xlink:label="loc_cosmWarrantInducementLetterMember_593f23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_5a285d" xlink:to="loc_cosmWarrantInducementLetterMember_593f23" order="52" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TreasuryStocksOneMember" xlink:label="loc_cosmTreasuryStocksOneMember_e68539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_7a8c2d" xlink:to="loc_cosmTreasuryStocksOneMember_e68539" order="53" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantExchangeMember" xlink:label="loc_cosmWarrantExchangeMember_207bb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6833b8" xlink:to="loc_cosmWarrantExchangeMember_207bb2" order="54" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BottomMember" xlink:label="loc_cosmBottomMember_9cca0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_5a285d" xlink:to="loc_cosmBottomMember_9cca0f" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TopMember" xlink:label="loc_cosmTopMember_282ccd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_5a285d" xlink:to="loc_cosmTopMember_282ccd" order="56" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_db1050" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_db1050" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStocksSharesIssued" xlink:label="loc_cosmCommonStocksSharesIssued_a02960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_cosmCommonStocksSharesIssued_a02960" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockShareAuthorized" xlink:label="loc_cosmCommonStockShareAuthorized_8512ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_cosmCommonStockShareAuthorized_8512ee" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_95a8e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_us-gaapCommonStockSharesIssued_95a8e5" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AuthorizationToRepurchaseCommonStock" xlink:label="loc_cosmAuthorizationToRepurchaseCommonStock_6326ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_cosmAuthorizationToRepurchaseCommonStock_6326ac" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockSharesValue" xlink:label="loc_cosmCommonStockSharesValue_abf473" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_cosmCommonStockSharesValue_abf473" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued_4dc482" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued_4dc482" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_920d16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_920d16" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStocksSharesOutstanding" xlink:label="loc_cosmCommonStocksSharesOutstanding_53f0a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_cosmCommonStocksSharesOutstanding_53f0a1" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PreferredStockLiquidationPreference1" xlink:label="loc_cosmPreferredStockLiquidationPreference1_d52a27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_cosmPreferredStockLiquidationPreference1_d52a27" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_3fd9b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_us-gaapProceedsFromWarrantExercises_3fd9b6" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OriginalWarrantsSharesIssued" xlink:label="loc_cosmOriginalWarrantsSharesIssued_51af0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_cosmOriginalWarrantsSharesIssued_51af0a" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_RemainingWarrantsSharesIssued" xlink:label="loc_cosmRemainingWarrantsSharesIssued_ca0ce1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_cosmRemainingWarrantsSharesIssued_ca0ce1" order="13" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesHeldInEscrow" xlink:label="loc_cosmSharesHeldInEscrow_8a00eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_cosmSharesHeldInEscrow_8a00eb" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e8299" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6b4e09" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e8299" order="15" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsDetails" xlink:title="870026 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_0c8d5f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_8d8dc6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_0c8d5f" xlink:to="loc_us-gaapStatementTable_8d8dc6" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_806e95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8d8dc6" xlink:to="loc_us-gaapStatementLineItems_806e95" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis_1a4bf5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8d8dc6" xlink:to="loc_us-gaapShortTermDebtTypeAxis_1a4bf5" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_201a83" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis_1a4bf5" xlink:to="loc_us-gaapShortTermDebtTypeDomain_201a83" order="20" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedPartyMember" xlink:label="loc_cosmNotesPayableRelatedPartyMember_241305" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain_201a83" xlink:to="loc_cosmNotesPayableRelatedPartyMember_241305" order="21" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedParty" xlink:label="loc_cosmNotesPayableRelatedParty_5f9ad8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_806e95" xlink:to="loc_cosmNotesPayableRelatedParty_5f9ad8" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLoans" xlink:label="loc_us-gaapPaymentsForLoans_bc403f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_806e95" xlink:to="loc_us-gaapPaymentsForLoans_bc403f" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_404efa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_806e95" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_404efa" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedParty" xlink:label="loc_cosmNotesPayableRelatedParty_245c81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_806e95" xlink:to="loc_cosmNotesPayableRelatedParty_245c81" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsDetails1" xlink:title="870027 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_4fade3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_78a332" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_4fade3" xlink:to="loc_us-gaapStatementTable_78a332" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0142b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_78a332" xlink:to="loc_us-gaapStatementLineItems_0142b6" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis_91f0d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_78a332" xlink:to="loc_us-gaapShortTermDebtTypeAxis_91f0d5" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_a35b3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis_91f0d5" xlink:to="loc_us-gaapShortTermDebtTypeDomain_a35b3f" order="10" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedPartyMember" xlink:label="loc_cosmLoansPayableRelatedPartyMember_68ab4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain_a35b3f" xlink:to="loc_cosmLoansPayableRelatedPartyMember_68ab4c" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedParty" xlink:label="loc_cosmLoansPayableRelatedParty_d9bee9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0142b6" xlink:to="loc_cosmLoansPayableRelatedParty_d9bee9" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans_150235" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0142b6" xlink:to="loc_us-gaapProceedsFromLoans_150235" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLoans" xlink:label="loc_us-gaapPaymentsForLoans_9d825b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0142b6" xlink:to="loc_us-gaapPaymentsForLoans_9d825b" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoanPayableSetOffs" xlink:label="loc_cosmLoanPayableSetOffs_2e2308" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0142b6" xlink:to="loc_cosmLoanPayableSetOffs_2e2308" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_219524" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0142b6" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_219524" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedParty" xlink:label="loc_cosmLoansPayableRelatedParty_878dd2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0142b6" xlink:to="loc_cosmLoansPayableRelatedParty_878dd2" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="870028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_32e9a6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_148cea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_32e9a6" xlink:to="loc_us-gaapStatementTable_148cea" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_80e084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_148cea" xlink:to="loc_us-gaapStatementLineItems_80e084" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_775ba2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_148cea" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_775ba2" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_69eac5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_775ba2" xlink:to="loc_us-gaapRelatedPartyDomain_69eac5" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_49506e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_148cea" xlink:to="loc_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_49506e" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaapLongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_bedd51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_49506e" xlink:to="loc_us-gaapLongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_bedd51" order="30" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GrigoriosSiokasMember" xlink:label="loc_cosmGrigoriosSiokasMember_ac3149" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_69eac5" xlink:to="loc_cosmGrigoriosSiokasMember_ac3149" order="31" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CanaHoldingsLaboratoriesHoldingLimitedMember" xlink:label="loc_cosmCanaHoldingsLaboratoriesHoldingLimitedMember_4dfbe5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_69eac5" xlink:to="loc_cosmCanaHoldingsLaboratoriesHoldingLimitedMember_4dfbe5" order="32" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DocPharmaSaMember" xlink:label="loc_cosmDocPharmaSaMember_04a213" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_69eac5" xlink:to="loc_cosmDocPharmaSaMember_04a213" order="33" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DimitriosGoulielmosMember" xlink:label="loc_cosmDimitriosGoulielmosMember_d80bfb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_69eac5" xlink:to="loc_cosmDimitriosGoulielmosMember_d80bfb" order="34" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PanagiotisKozarisMember" xlink:label="loc_cosmPanagiotisKozarisMember_040076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_69eac5" xlink:to="loc_cosmPanagiotisKozarisMember_040076" order="35" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MariaKozariMember" xlink:label="loc_cosmMariaKozariMember_18dccd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_69eac5" xlink:to="loc_cosmMariaKozariMember_18dccd" order="36" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InventoriesRelatedAgreementMember" xlink:label="loc_cosmInventoriesRelatedAgreementMember_bc87f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_bedd51" xlink:to="loc_cosmInventoriesRelatedAgreementMember_bc87f9" order="37" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GeorgeTerzisMember" xlink:label="loc_cosmGeorgeTerzisMember_d4bb9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_69eac5" xlink:to="loc_cosmGeorgeTerzisMember_d4bb9e" order="38" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_KanarogloySiaEpeMember" xlink:label="loc_cosmKanarogloySiaEpeMember_18de29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_69eac5" xlink:to="loc_cosmKanarogloySiaEpeMember_18de29" order="39" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BasothoInvestmentLimitedMember" xlink:label="loc_cosmBasothoInvestmentLimitedMember_101072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_69eac5" xlink:to="loc_cosmBasothoInvestmentLimitedMember_101072" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromSecuredNotesPayable_b4bd1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapProceedsFromSecuredNotesPayable_b4bd1d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DescriptionInterestOfSecuredPromissoryNote" xlink:label="loc_cosmDescriptionInterestOfSecuredPromissoryNote_bc3a8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmDescriptionInterestOfSecuredPromissoryNote_bc3a8e" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedSalariesCurrentAndNoncurrent_501a17" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapAccruedSalariesCurrentAndNoncurrent_501a17" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UnpaidSalariesAndBonusesDues" xlink:label="loc_cosmUnpaidSalariesAndBonusesDues_5e8079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmUnpaidSalariesAndBonusesDues_5e8079" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_b27ed1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapInterestIncomeOther_b27ed1" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_e100f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapNotesPayable_e100f1" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainBeforeTax_56156a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapForeignCurrencyTransactionGainBeforeTax_56156a" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" xlink:label="loc_cosmSharesOwnedAdditionalPaymentUnderStockPurchaseAgreement_73fcd2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmSharesOwnedAdditionalPaymentUnderStockPurchaseAgreement_73fcd2" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets_4eb7ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets_4eb7ee" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_881e19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_881e19" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_9bbdcc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapCommonStockSharesIssued_9bbdcc" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_477b16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_477b16" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PrepaymentOfInventory" xlink:label="loc_cosmPrepaymentOfInventory_1e4eee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmPrepaymentOfInventory_1e4eee" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_ad3be0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapDebtInstrumentTerm_ad3be0" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_308d36" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_308d36" order="15" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AccountsPayableRelatedPartyCurrent" xlink:label="loc_cosmAccountsPayableRelatedPartyCurrent_4ea36e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmAccountsPayableRelatedPartyCurrent_4ea36e" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInterest" xlink:label="loc_us-gaapPrepaidInterest_ed8002" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapPrepaidInterest_ed8002" order="17" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AmountAccountsReceivableRelatedParties" xlink:label="loc_cosmAmountAccountsReceivableRelatedParties_851751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmAmountAccountsReceivableRelatedParties_851751" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_245f4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapOtherExpenses_245f4d" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_8ae51f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_8ae51f" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableRecoveries_37122d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableRecoveries_37122d" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_1d3d27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_1d3d27" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NetSales" xlink:label="loc_cosmNetSales_a1a183" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmNetSales_a1a183" order="23" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AgreementTerminate" xlink:label="loc_cosmAgreementTerminate_330ad2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmAgreementTerminate_330ad2" order="24" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PiecesPerProduct" xlink:label="loc_cosmPiecesPerProduct_4e5e9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmPiecesPerProduct_4e5e9e" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationPurchases_fc1f7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationPurchases_fc1f7f" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_e75d86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapAssetImpairmentCharges_e75d86" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_0b6d33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapRevenues_0b6d33" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent_327142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent_327142" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent_4f3e3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent_4f3e3f" order="30" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PurchaseOfInventory" xlink:label="loc_cosmPurchaseOfInventory_da5756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmPurchaseOfInventory_da5756" order="31" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PurchaseOfPharmaceuticalsMedicine" xlink:label="loc_cosmPurchaseOfPharmaceuticalsMedicine_cc07c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmPurchaseOfPharmaceuticalsMedicine_cc07c5" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementFeeDescription" xlink:label="loc_us-gaapManagementFeeDescription_e21264" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapManagementFeeDescription_e21264" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent_1abf81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent_1abf81" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetNoncurrent_7a2f0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_us-gaapNotesAndLoansReceivableNetNoncurrent_7a2f0d" order="35" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PaymentReceivedFromInstallment" xlink:label="loc_cosmPaymentReceivedFromInstallment_8506f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_80e084" xlink:to="loc_cosmPaymentReceivedFromInstallment_8506f9" order="36" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCreditDetails" xlink:title="870029 - Disclosure - LINES OF CREDIT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="loc_us-gaapLineOfCreditFacilityAbstract_64b46e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_a4d0e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_64b46e" xlink:to="loc_us-gaapStatementTable_a4d0e6" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ae4b78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a4d0e6" xlink:to="loc_us-gaapStatementLineItems_ae4b78" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_588bc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a4d0e6" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_588bc3" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_2e13c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_588bc3" xlink:to="loc_us-gaapRelatedPartyDomain_2e13c7" order="10" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AtticaBankMember" xlink:label="loc_cosmAtticaBankMember_6ed06c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_2e13c7" xlink:to="loc_cosmAtticaBankMember_6ed06c" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EFGMember" xlink:label="loc_cosmEFGMember_88abb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_2e13c7" xlink:to="loc_cosmEFGMember_88abb9" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalMember" xlink:label="loc_cosmNationalMember_ad02d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_2e13c7" xlink:to="loc_cosmNationalMember_ad02d9" order="13" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AlphaMember" xlink:label="loc_cosmAlphaMember_0e2dbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_2e13c7" xlink:to="loc_cosmAlphaMember_0e2dbc" order="14" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PancretaMember" xlink:label="loc_cosmPancretaMember_02006d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_2e13c7" xlink:to="loc_cosmPancretaMember_02006d" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_df1843" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ae4b78" xlink:to="loc_us-gaapLineOfCredit_df1843" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCreditDetailsNarrative" xlink:title="870030 - Disclosure - LINES OF CREDIT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="loc_us-gaapLineOfCreditFacilityAbstract_db8066" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_1ae907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAbstract_db8066" xlink:to="loc_us-gaapStatementTable_1ae907" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5d1694" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1ae907" xlink:to="loc_us-gaapStatementLineItems_5d1694" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_0906ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1ae907" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_0906ce" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_a5b551" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_0906ce" xlink:to="loc_us-gaapRelatedPartyDomain_a5b551" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis_92e815" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1ae907" xlink:to="loc_us-gaapShortTermDebtTypeAxis_92e815" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_dc7824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis_92e815" xlink:to="loc_us-gaapShortTermDebtTypeDomain_dc7824" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_c87f0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1ae907" xlink:to="loc_srtTitleOfIndividualAxis_c87f0a" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_e3ca0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_c87f0a" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_e3ca0c" order="40" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalBankOfGreeceOneMember" xlink:label="loc_cosmNationalBankOfGreeceOneMember_59fe92" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_a5b551" xlink:to="loc_cosmNationalBankOfGreeceOneMember_59fe92" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember_9bfafa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain_dc7824" xlink:to="loc_us-gaapLineOfCreditMember_9bfafa" order="42" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalBankOfGreeceTwoMember" xlink:label="loc_cosmNationalBankOfGreeceTwoMember_369e04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_e3ca0c" xlink:to="loc_cosmNationalBankOfGreeceTwoMember_369e04" order="43" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AlphaBankOfGreeceMember" xlink:label="loc_cosmAlphaBankOfGreeceMember_9039e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_e3ca0c" xlink:to="loc_cosmAlphaBankOfGreeceMember_9039e0" order="44" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PancretaOfGreeceMember" xlink:label="loc_cosmPancretaOfGreeceMember_edd0c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_e3ca0c" xlink:to="loc_cosmPancretaOfGreeceMember_edd0c5" order="45" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EFGMember" xlink:label="loc_cosmEFGMember_d00137" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_a5b551" xlink:to="loc_cosmEFGMember_d00137" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaapLineOfCreditFacilityAverageOutstandingAmount_2f9cca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d1694" xlink:to="loc_us-gaapLineOfCreditFacilityAverageOutstandingAmount_2f9cca" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LineOfCreditBorrowingsLoanDescription" xlink:label="loc_cosmLineOfCreditBorrowingsLoanDescription_034a41" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d1694" xlink:to="loc_cosmLineOfCreditBorrowingsLoanDescription_034a41" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:label="loc_us-gaapBorrowingsUnderGuaranteedInvestmentAgreements_90f43b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d1694" xlink:to="loc_us-gaapBorrowingsUnderGuaranteedInvestmentAgreements_90f43b" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OutstandingDebtBalance" xlink:label="loc_cosmOutstandingDebtBalance_262a41" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d1694" xlink:to="loc_cosmOutstandingDebtBalance_262a41" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableDetails" xlink:title="870031 - Disclosure - NOTES PAYABLE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_23f64c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_689d05" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_23f64c" xlink:to="loc_us-gaapStatementTable_689d05" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_372fcd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_689d05" xlink:to="loc_us-gaapStatementLineItems_372fcd" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeAxis_7f8b26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_689d05" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeAxis_7f8b26" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeDomain_73a040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeAxis_7f8b26" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeDomain_73a040" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis_6711d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_689d05" xlink:to="loc_us-gaapDebtInstrumentAxis_6711d1" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_5ca160" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis_6711d1" xlink:to="loc_us-gaapDebtInstrumentNameDomain_5ca160" order="40" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TradeFacilityAgreementsMember" xlink:label="loc_cosmTradeFacilityAgreementsMember_2ff237" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeDomain_73a040" xlink:to="loc_cosmTradeFacilityAgreementsMember_2ff237" order="41" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ThirdPartyMember" xlink:label="loc_cosmThirdPartyMember_71a27c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain_5ca160" xlink:to="loc_cosmThirdPartyMember_71a27c" order="42" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_COVIDLoansMember" xlink:label="loc_cosmCOVIDLoansMember_e1b40b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeDomain_73a040" xlink:to="loc_cosmCOVIDLoansMember_e1b40b" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_3419dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_372fcd" xlink:to="loc_us-gaapNotesPayable_3419dd" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProceedFromDebt" xlink:label="loc_cosmProceedFromDebt_91b0cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_372fcd" xlink:to="loc_cosmProceedFromDebt_91b0cb" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PaymentsOfDebt" xlink:label="loc_cosmPaymentsOfDebt_ee880e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_372fcd" xlink:to="loc_cosmPaymentsOfDebt_ee880e" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ForeignCurrencyTranslation" xlink:label="loc_cosmForeignCurrencyTranslation_105970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_372fcd" xlink:to="loc_cosmForeignCurrencyTranslation_105970" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_0866d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_372fcd" xlink:to="loc_us-gaapNotesPayable_0866d2" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_c66155" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_372fcd" xlink:to="loc_us-gaapLongTermNotesPayable_c66155" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_cfd0df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_372fcd" xlink:to="loc_us-gaapNotesPayableCurrent_cfd0df" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_ad0497" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_372fcd" xlink:to="loc_us-gaapLongTermNotesPayable_ad0497" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableDetails1" xlink:title="870032 - Disclosure - NOTES PAYABLE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_58c902" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_469166" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_58c902" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_469166" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_93ddcf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_58c902" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_93ddcf" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_06f148" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_58c902" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_06f148" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_34fdef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_58c902" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_34fdef" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4f6b16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_58c902" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4f6b16" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_d0873e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_58c902" xlink:to="loc_us-gaapLongTermDebt_d0873e" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_c4b006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_58c902" xlink:to="loc_us-gaapNotesPayableCurrent_c4b006" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_714233" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_58c902" xlink:to="loc_us-gaapLongTermNotesPayable_714233" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableDetailsNarrative" xlink:title="870033 - Disclosure - NOTES PAYABLE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_220e78" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_50a92c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_220e78" xlink:to="loc_us-gaapStatementTable_50a92c" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_641b64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_50a92c" xlink:to="loc_us-gaapStatementLineItems_641b64" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_7082a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_50a92c" xlink:to="loc_us-gaapPlanNameAxis_7082a2" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_6e55c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_7082a2" xlink:to="loc_us-gaapPlanNameDomain_6e55c6" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_fc7b99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_50a92c" xlink:to="loc_us-gaapAwardDateAxis_fc7b99" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_668afb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_fc7b99" xlink:to="loc_us-gaapAwardDateDomain_668afb" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_7c0e78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_50a92c" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_7c0e78" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_b80b42" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_7c0e78" xlink:to="loc_us-gaapRelatedPartyDomain_b80b42" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis_65f0b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_50a92c" xlink:to="loc_us-gaapLongtermDebtTypeAxis_65f0b3" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_57d815" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis_65f0b3" xlink:to="loc_us-gaapLongtermDebtTypeDomain_57d815" order="60" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtAgreementJulyMember" xlink:label="loc_cosmDebtAgreementJulyMember_e53c01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_6e55c6" xlink:to="loc_cosmDebtAgreementJulyMember_e53c01" order="61" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" xlink:label="loc_cosmJanuaryTwentySevenTwoThousandTwentyFiveMember_e68305" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_668afb" xlink:to="loc_cosmJanuaryTwentySevenTwoThousandTwentyFiveMember_e68305" order="62" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtExchangeAgreementMember" xlink:label="loc_cosmDebtExchangeAgreementMember_03b7e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_6e55c6" xlink:to="loc_cosmDebtExchangeAgreementMember_03b7e1" order="63" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JuneTwentyThreeTwoThousandTwentyMember" xlink:label="loc_cosmJuneTwentyThreeTwoThousandTwentyMember_82059e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_668afb" xlink:to="loc_cosmJuneTwentyThreeTwoThousandTwentyMember_82059e" order="64" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalBankOfGreeceSAMember" xlink:label="loc_cosmNationalBankOfGreeceSAMember_7c21d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_b80b42" xlink:to="loc_cosmNationalBankOfGreeceSAMember_7c21d2" order="65" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtAgreementJuneOneMember" xlink:label="loc_cosmDebtAgreementJuneOneMember_26c116" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_6e55c6" xlink:to="loc_cosmDebtAgreementJuneOneMember_26c116" order="66" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JulyFourteenTwoThousandTwentyThreeMember" xlink:label="loc_cosmJulyFourteenTwoThousandTwentyThreeMember_e6e628" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_668afb" xlink:to="loc_cosmJulyFourteenTwoThousandTwentyThreeMember_e6e628" order="67" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PromissoryNotesMember" xlink:label="loc_cosmPromissoryNotesMember_208f2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain_57d815" xlink:to="loc_cosmPromissoryNotesMember_208f2d" order="68" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JulyTwentyNineTwentyTwentyFourMember" xlink:label="loc_cosmJulyTwentyNineTwentyTwentyFourMember_8f84b2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_668afb" xlink:to="loc_cosmJulyTwentyNineTwentyTwentyFourMember_8f84b2" order="69" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DeemberTwentyTwentyFourMember" xlink:label="loc_cosmDeemberTwentyTwentyFourMember_97483b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_668afb" xlink:to="loc_cosmDeemberTwentyTwentyFourMember_97483b" order="70" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CovidNinteenMember" xlink:label="loc_cosmCovidNinteenMember_9ccc7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_6e55c6" xlink:to="loc_cosmCovidNinteenMember_9ccc7c" order="71" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MayTwelveTwentyTwentyMember" xlink:label="loc_cosmMayTwelveTwentyTwentyMember_439332" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_668afb" xlink:to="loc_cosmMayTwelveTwentyTwentyMember_439332" order="72" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JuneTwentyFourTwentyTwentyMember" xlink:label="loc_cosmJuneTwentyFourTwentyTwentyMember_ce52d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_668afb" xlink:to="loc_cosmJuneTwentyFourTwentyTwentyMember_ce52d8" order="73" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JanuaryTwentythreeTwoThousandTwentyFourMember" xlink:label="loc_cosmJanuaryTwentythreeTwoThousandTwentyFourMember_e7c131" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_668afb" xlink:to="loc_cosmJanuaryTwentythreeTwoThousandTwentyFourMember_e7c131" order="74" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent_09e707" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapDebtCurrent_09e707" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_324490" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_324490" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtDescription" xlink:label="loc_us-gaapLongTermDebtDescription_86e2bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapLongTermDebtDescription_86e2bb" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:label="loc_us-gaapPrincipalAmountOutstandingOnLoansSecuritized_d00ba0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapPrincipalAmountOutstandingOnLoansSecuritized_d00ba0" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_c2700f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_c2700f" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_cd6e09" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_cd6e09" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockIssuedAsConsiderationFairValue" xlink:label="loc_cosmCommonStockIssuedAsConsiderationFairValue_09dfc0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_cosmCommonStockIssuedAsConsiderationFairValue_09dfc0" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BusinessCombinationContingentConsiderationArrangementLiability" xlink:label="loc_cosmBusinessCombinationContingentConsiderationArrangementLiability_bfd57e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_cosmBusinessCombinationContingentConsiderationArrangementLiability_bfd57e" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_781494" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapLongTermNotesPayable_781494" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_02766f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapInterestPayableCurrent_02766f" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="loc_us-gaapSubordinatedBorrowingInterestRate_18f000" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapSubordinatedBorrowingInterestRate_18f000" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_09a538" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapRepaymentsOfDebt_09a538" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:label="loc_us-gaapPaymentsToAcquireAdditionalInterestInSubsidiaries_9c4723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapPaymentsToAcquireAdditionalInterestInSubsidiaries_9c4723" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_50c6d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_50c6d1" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_9b49ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_9b49ac" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtAmountReceivedFromRelatedParty" xlink:label="loc_cosmDebtAmountReceivedFromRelatedParty_8ad9fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_cosmDebtAmountReceivedFromRelatedParty_8ad9fc" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_45e182" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_45e182" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_24ce40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_641b64" xlink:to="loc_us-gaapLongTermDebtNoncurrent_24ce40" order="18" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesDetails" xlink:title="870034 - Disclosure - LEASES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_05ea14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f9b649" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_05ea14" xlink:to="loc_us-gaapStatementTable_f9b649" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b03efc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f9b649" xlink:to="loc_us-gaapStatementLineItems_b03efc" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_53bb2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f9b649" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_53bb2d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_1d72bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_53bb2d" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_1d72bd" order="20" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseMember" xlink:label="loc_cosmOperatingLeaseMember_7a3281" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_1d72bd" xlink:to="loc_cosmOperatingLeaseMember_7a3281" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97c517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b03efc" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97c517" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_cbcc11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b03efc" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_cbcc11" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_6019e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b03efc" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_6019e3" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7c7523" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b03efc" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7c7523" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_014639" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b03efc" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_014639" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseLiabilityLessImputedInterest" xlink:label="loc_cosmOperatingLeaseLiabilityLessImputedInterest_866ae5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b03efc" xlink:to="loc_cosmOperatingLeaseLiabilityLessImputedInterest_866ae5" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_72a7f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b03efc" xlink:to="loc_us-gaapOperatingLeaseLiability_72a7f6" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesDetails1" xlink:title="870035 - Disclosure - LEASES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_7b7262" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_800256" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_7b7262" xlink:to="loc_us-gaapStatementTable_800256" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_7b1dba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_800256" xlink:to="loc_us-gaapStatementLineItems_7b1dba" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_c9d776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_800256" xlink:to="loc_us-gaapAwardTypeAxis_c9d776" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e53e74" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_c9d776" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e53e74" order="10" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseMember" xlink:label="loc_cosmFinanceLeaseMember_faa7e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e53e74" xlink:to="loc_cosmFinanceLeaseMember_faa7e3" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_fd24e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7b1dba" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_fd24e3" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" xlink:label="loc_cosmFinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments_31531a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7b1dba" xlink:to="loc_cosmFinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments_31531a" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" xlink:label="loc_cosmFinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest_422760" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7b1dba" xlink:to="loc_cosmFinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest_422760" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_ae530c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7b1dba" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_ae530c" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesDetailsNarrative" xlink:title="870036 - Disclosure - LEASES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_aeda94" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_d0c49d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_aeda94" xlink:to="loc_us-gaapStatementTable_d0c49d" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_46444b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d0c49d" xlink:to="loc_us-gaapStatementLineItems_46444b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis_469831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d0c49d" xlink:to="loc_us-gaapIncomeStatementLocationAxis_469831" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_ce8586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis_469831" xlink:to="loc_us-gaapIncomeStatementLocationDomain_ce8586" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_df40d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_ce8586" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_df40d6" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember_e6298c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_ce8586" xlink:to="loc_us-gaapInterestExpenseMember_e6298c" order="22" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseTermOfAgreements" xlink:label="loc_cosmOperatingLeaseTermOfAgreements_4a7f7e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46444b" xlink:to="loc_cosmOperatingLeaseTermOfAgreements_4a7f7e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_6eea81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46444b" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_6eea81" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseCashFlowsUsedInFinanceLease" xlink:label="loc_cosmOperatingLeaseCashFlowsUsedInFinanceLease_d9c038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46444b" xlink:to="loc_cosmOperatingLeaseCashFlowsUsedInFinanceLease_d9c038" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseWeightedAverageDiscountRate" xlink:label="loc_cosmOperatingLeaseWeightedAverageDiscountRate_4585c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46444b" xlink:to="loc_cosmOperatingLeaseWeightedAverageDiscountRate_4585c6" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:label="loc_cosmOperatingLeaseWeightedAverageRemainingLeaseTerm_4bb621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46444b" xlink:to="loc_cosmOperatingLeaseWeightedAverageRemainingLeaseTerm_4bb621" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm" xlink:label="loc_cosmFinanceLeaseWeightedAverageRemainingLeaseTerm_cd2040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46444b" xlink:to="loc_cosmFinanceLeaseWeightedAverageRemainingLeaseTerm_cd2040" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_dd0576" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46444b" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_dd0576" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseWeightedAverageDiscountRate" xlink:label="loc_cosmFinanceLeaseWeightedAverageDiscountRate_0e8021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46444b" xlink:to="loc_cosmFinanceLeaseWeightedAverageDiscountRate_0e8021" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseAmortizationExpense" xlink:label="loc_cosmFinanceLeaseAmortizationExpense_c05c9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46444b" xlink:to="loc_cosmFinanceLeaseAmortizationExpense_c05c9c" order="9" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/OtherLiabilitiesDetailsNarrative" xlink:title="870037 - Disclosure - OTHER LIABILITIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaapOtherLiabilitiesAbstract_a1831f" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TaxLiabilitiesPayable" xlink:label="loc_cosmTaxLiabilitiesPayable_17cb6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesAbstract_a1831f" xlink:to="loc_cosmTaxLiabilitiesPayable_17cb6c" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PayrollTaxRelatedCurrentLiabilities" xlink:label="loc_cosmPayrollTaxRelatedCurrentLiabilities_d2fb91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesAbstract_a1831f" xlink:to="loc_cosmPayrollTaxRelatedCurrentLiabilities_d2fb91" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_734f5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesAbstract_a1831f" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_734f5c" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProvisionForStaffLeavingCompensation" xlink:label="loc_cosmProvisionForStaffLeavingCompensation_c7faf6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesAbstract_a1831f" xlink:to="loc_cosmProvisionForStaffLeavingCompensation_c7faf6" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomersForProgressPayments" xlink:label="loc_us-gaapProceedsFromCustomersForProgressPayments_ddcb67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesAbstract_a1831f" xlink:to="loc_us-gaapProceedsFromCustomersForProgressPayments_ddcb67" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec" xlink:title="870038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrativec)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_0ead01" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0a7133" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_0ead01" xlink:to="loc_us-gaapStatementTable_0a7133" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0da149" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0a7133" xlink:to="loc_us-gaapStatementLineItems_0da149" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_84fb1f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0a7133" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_84fb1f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_9145d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_84fb1f" xlink:to="loc_us-gaapRelatedPartyDomain_9145d1" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis_6d6d3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0a7133" xlink:to="loc_us-gaapIncomeStatementLocationAxis_6d6d3f" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_532741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis_6d6d3f" xlink:to="loc_us-gaapIncomeStatementLocationDomain_532741" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis_3bad43" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0a7133" xlink:to="loc_srtLitigationCaseAxis_3bad43" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain_545e91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseAxis_3bad43" xlink:to="loc_srtLitigationCaseTypeDomain_545e91" order="40" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PhaseOneMember" xlink:label="loc_cosmPhaseOneMember_8023a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_9145d1" xlink:to="loc_cosmPhaseOneMember_8023a1" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_7d1efa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_532741" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_7d1efa" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalMedicinesAgencyMember" xlink:label="loc_cosmNationalMedicinesAgencyMember_f6789b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseTypeDomain_545e91" xlink:to="loc_cosmNationalMedicinesAgencyMember_f6789b" order="43" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PhaseTwoMember" xlink:label="loc_cosmPhaseTwoMember_ae29de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_9145d1" xlink:to="loc_cosmPhaseTwoMember_ae29de" order="44" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FourThirdPartyConsultantsMember" xlink:label="loc_cosmFourThirdPartyConsultantsMember_1ff00a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_9145d1" xlink:to="loc_cosmFourThirdPartyConsultantsMember_1ff00a" order="45" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_ab0a17" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_ab0a17" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PaymentTax" xlink:label="loc_cosmPaymentTax_156e5e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_cosmPaymentTax_156e5e" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProjectCosts" xlink:label="loc_cosmProjectCosts_d0c0b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_cosmProjectCosts_d0c0b7" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_0ee028" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_0ee028" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockIssuedDuringPeriodSharesAwarded" xlink:label="loc_cosmStockIssuedDuringPeriodSharesAwarded_4fefe3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_cosmStockIssuedDuringPeriodSharesAwarded_4fefe3" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1_cba8d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_us-gaapStockIssued1_cba8d6" order="6" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AdditionalStockConsideration" xlink:label="loc_cosmAdditionalStockConsideration_786e7e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_cosmAdditionalStockConsideration_786e7e" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaapLifeSettlementContractsFairValueMethodCarryingAmount_674a73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_us-gaapLifeSettlementContractsFairValueMethodCarryingAmount_674a73" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ComplementaryCompensationShares" xlink:label="loc_cosmComplementaryCompensationShares_708374" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_cosmComplementaryCompensationShares_708374" order="9" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PurchasePriceAmount" xlink:label="loc_cosmPurchasePriceAmount_b4b4a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0da149" xlink:to="loc_cosmPurchasePriceAmount_b4b4a9" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrantsDetails" xlink:title="870039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockOptionsAndWarrantsAbstract" xlink:label="loc_cosmStockOptionsAndWarrantsAbstract_ece8fb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e5182a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmStockOptionsAndWarrantsAbstract_ece8fb" xlink:to="loc_us-gaapStatementTable_e5182a" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_95f4aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e5182a" xlink:to="loc_us-gaapStatementLineItems_95f4aa" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_c8f290" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e5182a" xlink:to="loc_us-gaapAwardTypeAxis_c8f290" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_578299" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_c8f290" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_578299" order="10" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantsMember" xlink:label="loc_cosmWarrantsMember_ed79e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_578299" xlink:to="loc_cosmWarrantsMember_ed79e0" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_41e208" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_41e208" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ef7fe1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ef7fe1" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_454bba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_454bba" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_e2ff34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_e2ff34" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d1ad59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d1ad59" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aeee94" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aeee94" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" xlink:label="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod_931bdb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod_931bdb" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be6e83" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be6e83" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6edd33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6edd33" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a77ab8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a77ab8" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" xlink:label="loc_cosmShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92_0debf9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_cosmShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92_0debf9" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WeightedAverageRemainingContractualTermOutstandingBeginning" xlink:label="loc_cosmWeightedAverageRemainingContractualTermOutstandingBeginning_92ebc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_cosmWeightedAverageRemainingContractualTermOutstandingBeginning_92ebc3" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WeightedAverageRemainingContractualTermOutstandingEnding" xlink:label="loc_cosmWeightedAverageRemainingContractualTermOutstandingEnding_222c60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_cosmWeightedAverageRemainingContractualTermOutstandingEnding_222c60" order="13" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WeightedAverageRemainingContractualTermExercisable" xlink:label="loc_cosmWeightedAverageRemainingContractualTermExercisable_67d6cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_cosmWeightedAverageRemainingContractualTermExercisable_67d6cd" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a0b819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a0b819" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9834a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9834a3" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" xlink:label="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue_dfeaf5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_95f4aa" xlink:to="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue_dfeaf5" order="17" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:title="870040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockOptionsAndWarrantsAbstract" xlink:label="loc_cosmStockOptionsAndWarrantsAbstract_f18d13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_7a7243" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cosmStockOptionsAndWarrantsAbstract_f18d13" xlink:to="loc_us-gaapStatementTable_7a7243" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_a52ab4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7a7243" xlink:to="loc_us-gaapStatementLineItems_a52ab4" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_bff438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7a7243" xlink:to="loc_us-gaapAwardTypeAxis_bff438" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b07d66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_bff438" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b07d66" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_725946" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7a7243" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_725946" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_cb2f57" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_725946" xlink:to="loc_us-gaapRelatedPartyDomain_cb2f57" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_74e112" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7a7243" xlink:to="loc_us-gaapPlanNameAxis_74e112" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_b351b2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_74e112" xlink:to="loc_us-gaapPlanNameDomain_b351b2" order="30" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantsMember" xlink:label="loc_cosmWarrantsMember_a610fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b07d66" xlink:to="loc_cosmWarrantsMember_a610fe" order="31" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BoardOfDirectorsMember" xlink:label="loc_cosmBoardOfDirectorsMember_7cb6e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_cb2f57" xlink:to="loc_cosmBoardOfDirectorsMember_7cb6e5" order="32" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TwoZeroTwentyTwoPlanMember" xlink:label="loc_cosmTwoZeroTwentyTwoPlanMember_15d50d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_b351b2" xlink:to="loc_cosmTwoZeroTwentyTwoPlanMember_15d50d" order="33" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TwoZeroTwentyThreePlanMember" xlink:label="loc_cosmTwoZeroTwentyThreePlanMember_a68f4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_b351b2" xlink:to="loc_cosmTwoZeroTwentyThreePlanMember_a68f4d" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_99c081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a52ab4" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_99c081" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DiscriptionOfIncentiveStockAwards" xlink:label="loc_cosmDiscriptionOfIncentiveStockAwards_817319" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a52ab4" xlink:to="loc_cosmDiscriptionOfIncentiveStockAwards_817319" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_60b04f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a52ab4" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_60b04f" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" xlink:label="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber_bcc724" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a52ab4" xlink:to="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber_bcc724" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_7d849a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a52ab4" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_7d849a" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantExpirationDateDescription" xlink:label="loc_cosmWarrantExpirationDateDescription_8977af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a52ab4" xlink:to="loc_cosmWarrantExpirationDateDescription_8977af" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued_f512c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a52ab4" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued_f512c8" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/DisaggregationOfRevenueDetails" xlink:title="870041 - Disclosure - DISAGGREGATION OF REVENUE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract_407436" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_851b35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract_407436" xlink:to="loc_us-gaapStatementTable_851b35" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_2f8926" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_851b35" xlink:to="loc_us-gaapStatementLineItems_2f8926" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis_3dc879" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_851b35" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis_3dc879" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_27905f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis_3dc879" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_27905f" order="10" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GreeceMember" xlink:label="loc_cosmGreeceMember_886051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_27905f" xlink:to="loc_cosmGreeceMember_886051" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UkMember" xlink:label="loc_cosmUkMember_176b7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_27905f" xlink:to="loc_cosmUkMember_176b7f" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AlbaniaMember" xlink:label="loc_cosmAlbaniaMember_362e28" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_27905f" xlink:to="loc_cosmAlbaniaMember_362e28" order="13" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CroatiaMember" xlink:label="loc_cosmCroatiaMember_6c5eb6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_27905f" xlink:to="loc_cosmCroatiaMember_6c5eb6" order="14" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CyprusMember" xlink:label="loc_cosmCyprusMember_ef6d73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_27905f" xlink:to="loc_cosmCyprusMember_ef6d73" order="15" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BulgariaMember" xlink:label="loc_cosmBulgariaMember_cd9ba7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain_27905f" xlink:to="loc_cosmBulgariaMember_cd9ba7" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_49ebb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f8926" xlink:to="loc_us-gaapRevenues_49ebb2" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/SegmentReportingDetails" xlink:title="870042 - Disclosure - SEGMENT REPORTING (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_48c514" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ad3ed4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_48c514" xlink:to="loc_us-gaapStatementTable_ad3ed4" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_7aa797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ad3ed4" xlink:to="loc_us-gaapStatementLineItems_7aa797" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis_3244a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ad3ed4" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis_3244a5" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_7a5c1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis_3244a5" xlink:to="loc_us-gaapSegmentDomain_7a5c1a" order="20" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OtherMember" xlink:label="loc_cosmOtherMember_1529db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_7a5c1a" xlink:to="loc_cosmOtherMember_1529db" order="21" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TotalSegmentMember" xlink:label="loc_cosmTotalSegmentMember_fe8d3e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_7a5c1a" xlink:to="loc_cosmTotalSegmentMember_fe8d3e" order="22" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WholesaleMember" xlink:label="loc_cosmWholesaleMember_fc6f54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_7a5c1a" xlink:to="loc_cosmWholesaleMember_fc6f54" order="23" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PharmamanufacturingMember" xlink:label="loc_cosmPharmamanufacturingMember_ac2f8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_7a5c1a" xlink:to="loc_cosmPharmamanufacturingMember_ac2f8f" order="24" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NutraceuticalsAndPharmaceuticalsMember" xlink:label="loc_cosmNutraceuticalsAndPharmaceuticalsMember_51a258" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_7a5c1a" xlink:to="loc_cosmNutraceuticalsAndPharmaceuticalsMember_51a258" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_456172" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapRevenues_456172" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_58c1c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_58c1c7" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_4b3f3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapGrossProfit_4b3f3a" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_8b60f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_8b60f2" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_c982f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapSalariesAndWages_c982f0" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense_59567d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapSellingAndMarketingExpense_59567d" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4ef4af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4ef4af" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NetFinanceCosts" xlink:label="loc_cosmNetFinanceCosts_a2a4bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_cosmNetFinanceCosts_a2a4bf" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SegmentProfitLoss" xlink:label="loc_cosmSegmentProfitLoss_68a924" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_cosmSegmentProfitLoss_68a924" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_98b8eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapDepreciationAndAmortization_98b8eb" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_4d9aec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapShareBasedCompensation_4d9aec" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossRealized_195c20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossRealized_195c20" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OtherIncomeAndExpenses" xlink:label="loc_cosmOtherIncomeAndExpenses_86d932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_cosmOtherIncomeAndExpenses_86d932" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_320db0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_320db0" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e6e2b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e6e2b8" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_6dd7a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_6dd7a0" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense_495945" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7aa797" xlink:to="loc_us-gaapSellingAndMarketingExpense_495945" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/SubsequentEventsDetailsNarrative" xlink:title="870043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_776b79" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_d89ee5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_776b79" xlink:to="loc_us-gaapStatementTable_d89ee5" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b34bb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d89ee5" xlink:to="loc_us-gaapStatementLineItems_b34bb8" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_4deb5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d89ee5" xlink:to="loc_us-gaapSubsequentEventTypeAxis_4deb5d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_87c52a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_4deb5d" xlink:to="loc_us-gaapSubsequentEventTypeDomain_87c52a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_a1e487" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d89ee5" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_a1e487" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_4acf58" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_a1e487" xlink:to="loc_us-gaapRelatedPartyDomain_4acf58" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_018a3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_87c52a" xlink:to="loc_us-gaapSubsequentEventMember_018a3f" order="31" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GrigoriosSiokasMember" xlink:label="loc_cosmGrigoriosSiokasMember_c596ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_4acf58" xlink:to="loc_cosmGrigoriosSiokasMember_c596ba" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_ae5b63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b34bb8" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_ae5b63" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:label="loc_us-gaapAssetRetirementObligationLiabilitiesSettled_5d3a8c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b34bb8" xlink:to="loc_us-gaapAssetRetirementObligationLiabilitiesSettled_5d3a8c" order="2" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cosm-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20250331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cosm-20250331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="cosm-20250331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:href="cosm-20250331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="cosm-20250331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cosm-20250331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/InsiderTradingArrangements" xlink:href="cosm-20250331.xsd#InsiderTradingArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/BasisOfPresentation" xlink:href="cosm-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusiness" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/EquityMethodInvestments" xlink:href="cosm-20250331.xsd#EquityMethodInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/PropertyAndEquipmentNet" xlink:href="cosm-20250331.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssets" xlink:href="cosm-20250331.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LoanReceivable" xlink:href="cosm-20250331.xsd#LoanReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IncomeTaxes" xlink:href="cosm-20250331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CapitalStructure" xlink:href="cosm-20250331.xsd#CapitalStructure" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactions" xlink:href="cosm-20250331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCredit" xlink:href="cosm-20250331.xsd#LinesOfCredit" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayable" xlink:href="cosm-20250331.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LEASES" xlink:href="cosm-20250331.xsd#LEASES" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OtherLiabilities" xlink:href="cosm-20250331.xsd#OtherLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CommitmentsAndContingencies" xlink:href="cosm-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrants" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrants" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/DisaggregationOfRevenue" xlink:href="cosm-20250331.xsd#DisaggregationOfRevenue" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SegmentReporting" xlink:href="cosm-20250331.xsd#SegmentReporting" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SubsequentEvents" xlink:href="cosm-20250331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessTables" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/PropertyAndEquipmentNetTables" xlink:href="cosm-20250331.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssetsTables" xlink:href="cosm-20250331.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsTables" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCreditTables" xlink:href="cosm-20250331.xsd#LinesOfCreditTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableTables" xlink:href="cosm-20250331.xsd#NotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesTables" xlink:href="cosm-20250331.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrantsTables" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/DisaggregationOfRevenueTables" xlink:href="cosm-20250331.xsd#DisaggregationOfRevenueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SegmentReportingTables" xlink:href="cosm-20250331.xsd#SegmentReportingTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/BasisOfPresentationDetailsNarrative" xlink:href="cosm-20250331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative" xlink:href="cosm-20250331.xsd#OrganizationAndNatureOfBusinessDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative" xlink:href="cosm-20250331.xsd#EquityMethodInvestmentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/PropertyPlantAndEquipmentDetails" xlink:href="cosm-20250331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssetsNetDetails" xlink:href="cosm-20250331.xsd#IntangibleAssetsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IntangibleAssetsNetDetails1" xlink:href="cosm-20250331.xsd#IntangibleAssetsNetDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LoanReceivableDetailsNarrative" xlink:href="cosm-20250331.xsd#LoanReceivableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cosm-20250331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CapitalStructureDetailsNarrative" xlink:href="cosm-20250331.xsd#CapitalStructureDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsDetails" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsDetails1" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cosm-20250331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCreditDetails" xlink:href="cosm-20250331.xsd#LinesOfCreditDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LinesOfCreditDetailsNarrative" xlink:href="cosm-20250331.xsd#LinesOfCreditDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableDetails" xlink:href="cosm-20250331.xsd#NotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableDetails1" xlink:href="cosm-20250331.xsd#NotesPayableDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/NotesPayableDetailsNarrative" xlink:href="cosm-20250331.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesDetails" xlink:href="cosm-20250331.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesDetails1" xlink:href="cosm-20250331.xsd#LeasesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/LeasesDetailsNarrative" xlink:href="cosm-20250331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/OtherLiabilitiesDetailsNarrative" xlink:href="cosm-20250331.xsd#OtherLiabilitiesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec" xlink:href="cosm-20250331.xsd#CommitmentsAndContingenciesDetailsNarrativec" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrantsDetails" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:href="cosm-20250331.xsd#StockOptionsAndWarrantsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/DisaggregationOfRevenueDetails" xlink:href="cosm-20250331.xsd#DisaggregationOfRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SegmentReportingDetails" xlink:href="cosm-20250331.xsd#SegmentReportingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cosm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cosm-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedBalanceSheets" xlink:title="110200 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="110201 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" xlink:title="124100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:title="148600 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockShareMember" xlink:label="loc_cosmCommonStockShareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cosmCommonStockShareMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SubscriptionReceivableMember" xlink:label="loc_cosmSubscriptionReceivableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_cosmSubscriptionReceivableMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ForeignCurrencyTranslationAdjustmentNet" xlink:label="loc_cosmForeignCurrencyTranslationAdjustmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmForeignCurrencyTranslationAdjustmentNet" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" xlink:label="loc_cosmProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmProceedsFromSaleOfCommonStockNetOfFinancingFeesShares" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" xlink:label="loc_cosmProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesIssuedInLieuOfCashAmount" xlink:label="loc_cosmSharesIssuedInLieuOfCashAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmSharesIssuedInLieuOfCashAmount" order="6" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares" xlink:label="loc_cosmSharesIssuedPursuantToWarrantExchangeAgreementShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmSharesIssuedPursuantToWarrantExchangeAgreementShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount" xlink:label="loc_cosmSharesIssuedPursuantToWarrantExchangeAgreementAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmSharesIssuedPursuantToWarrantExchangeAgreementAmount" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockBasedCompensation" xlink:label="loc_cosmStockBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmStockBasedCompensation" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" order="10" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtExchangesShares" xlink:label="loc_cosmDebtExchangesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmDebtExchangesShares" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtExchangesAmount" xlink:label="loc_cosmDebtExchangesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmDebtExchangesAmount" order="12" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="170000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/InsiderTradingArrangements" xlink:title="170001 - Disclosure - Insider Trading Arrangements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/BasisOfPresentation" xlink:title="170002 - Disclosure - BASIS OF PRESENTATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusiness" xlink:title="170003 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/EquityMethodInvestments" xlink:title="170004 - Disclosure - EQUITY METHOD INVESTMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/PropertyAndEquipmentNet" xlink:title="360000 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssets" xlink:title="370000 - Disclosure - INTANGIBLE ASSETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LoanReceivable" xlink:title="370001 - Disclosure - LOAN RECEIVABLE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/IncomeTaxes" xlink:title="370002 - Disclosure - INCOME TAXES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/CapitalStructure" xlink:title="500000 - Disclosure - CAPITAL STRUCTURE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactions" xlink:title="845000 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCredit" xlink:title="845001 - Disclosure - LINES OF CREDIT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayable" xlink:title="845002 - Disclosure - NOTES PAYABLE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LEASES" xlink:title="845003 - Disclosure - LEASES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OtherLiabilities" xlink:title="845004 - Disclosure - OTHER LIABILITIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/CommitmentsAndContingencies" xlink:title="845005 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrants" xlink:title="845006 - Disclosure - STOCK OPTIONS AND WARRANTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/DisaggregationOfRevenue" xlink:title="845007 - Disclosure - DISAGGREGATION OF REVENUE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/SegmentReporting" xlink:title="845008 - Disclosure - SEGMENT REPORTING" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/SubsequentEvents" xlink:title="870000 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies" xlink:title="870001 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessTables" xlink:title="870002 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/PropertyAndEquipmentNetTables" xlink:title="870003 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssetsTables" xlink:title="870004 - Disclosure - INTANGIBLE ASSETS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsTables" xlink:title="870005 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCreditTables" xlink:title="870006 - Disclosure - LINES OF CREDIT (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableTables" xlink:title="870007 - Disclosure - NOTES PAYABLE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesTables" xlink:title="870008 - Disclosure - LEASES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrantsTables" xlink:title="870009 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/DisaggregationOfRevenueTables" xlink:title="870010 - Disclosure - DISAGGREGATION OF REVENUE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/SegmentReportingTables" xlink:title="870011 - Disclosure - SEGMENT REPORTING (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/BasisOfPresentationDetailsNarrative" xlink:title="870012 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails" xlink:title="870013 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CANAPharmaceuticalLaboratoriesSACanaMember" xlink:label="loc_cosmCANAPharmaceuticalLaboratoriesSACanaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cosmCANAPharmaceuticalLaboratoriesSACanaMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="10" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1" xlink:title="870014 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2" xlink:title="870015 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MachineryMember" xlink:label="loc_cosmMachineryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_cosmMachineryMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LeaseholdImprovementsAndTechnicalWorksMember" xlink:label="loc_cosmLeaseholdImprovementsAndTechnicalWorksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_cosmLeaseholdImprovementsAndTechnicalWorksMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" order="44" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TopMember" xlink:label="loc_cosmTopMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmTopMember" order="45" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BuildingsMember" xlink:label="loc_cosmBuildingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_cosmBuildingsMember" order="46" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BottomMember" xlink:label="loc_cosmBottomMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmBottomMember" order="47" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" order="48" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PropertyPlantAndEquipmentUsefulLifes" xlink:label="loc_cosmPropertyPlantAndEquipmentUsefulLifes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPropertyPlantAndEquipmentUsefulLifes" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PropertyPlantsAndEquipmentUsefulLife" xlink:label="loc_cosmPropertyPlantsAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPropertyPlantsAndEquipmentUsefulLife" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives" xlink:label="loc_cosmPropertyPlantsAndEquipmentEstimatedUsefulLives" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPropertyPlantsAndEquipmentEstimatedUsefulLives" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3" xlink:title="870016 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 3)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4" xlink:title="870017 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 4)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative" xlink:title="870018 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CANAPharmaceuticalLaboratoriesSACanaMember" xlink:label="loc_cosmCANAPharmaceuticalLaboratoriesSACanaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cosmCANAPharmaceuticalLaboratoriesSACanaMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ZipDoctorIncMember" xlink:label="loc_cosmZipDoctorIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cosmZipDoctorIncMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GreeceMember" xlink:label="loc_cosmGreeceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmGreeceMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PancretaBankMember" xlink:label="loc_cosmPancretaBankMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmPancretaBankMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BuildingAcquisionMember" xlink:label="loc_cosmBuildingAcquisionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_cosmBuildingAcquisionMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UnitedKingdomMember" xlink:label="loc_cosmUnitedKingdomMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmUnitedKingdomMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CloudscreenMember" xlink:label="loc_cosmCloudscreenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cosmCloudscreenMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="loc_us-gaapDepreciationExpenseOnReclassifiedAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationExpenseOnReclassifiedAssets" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapReceivablesNetCurrent" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:label="loc_us-gaapOtherInvestmentsAndSecuritiesAtCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherInvestmentsAndSecuritiesAtCost" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilities" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionCosts" xlink:label="loc_us-gaapAcquisitionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAcquisitionCosts" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaapAcceleratedShareRepurchasesAdjustmentToRecordedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAcceleratedShareRepurchasesAdjustmentToRecordedAmount" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaapEquityMethodInvestmentAggregateCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentAggregateCost" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="19" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" xlink:label="loc_cosmBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromSecuredNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromSecuredNotesPayable" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:label="loc_us-gaapAssetAcquisitionPriceOfAcquisitionExpected" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetAcquisitionPriceOfAcquisitionExpected" order="23" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative" xlink:title="870019 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareExchangeAgreementMember" xlink:label="loc_cosmShareExchangeAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmShareExchangeAgreementMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_IccMember" xlink:label="loc_cosmIccMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_cosmIccMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CosmoFarmacyLPMember" xlink:label="loc_cosmCosmoFarmacyLPMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmCosmoFarmacyLPMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestments" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InitialShareCapital" xlink:label="loc_cosmInitialShareCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmInitialShareCapital" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InitialShareCapitalIncreased" xlink:label="loc_cosmInitialShareCapitalIncreased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmInitialShareCapitalIncreased" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PharmacyLicenseValue" xlink:label="loc_cosmPharmacyLicenseValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPharmacyLicenseValue" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MaturityPeriodOfLicense" xlink:label="loc_cosmMaturityPeriodOfLicense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmMaturityPeriodOfLicense" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EquityMethodInvestmentsOwnershipPercentage" xlink:label="loc_cosmEquityMethodInvestmentsOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmEquityMethodInvestmentsOwnershipPercentage" order="6" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CashContributedToLimitedPartner" xlink:label="loc_cosmCashContributedToLimitedPartner" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmCashContributedToLimitedPartner" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EquityMethodInvestmentOwnershipRemainingPercentage" xlink:label="loc_cosmEquityMethodInvestmentOwnershipRemainingPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmEquityMethodInvestmentOwnershipRemainingPercentage" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/PropertyPlantAndEquipmentDetails" xlink:title="870020 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLandMember" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaapBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingImprovementsMember" order="35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssetsNetDetails" xlink:title="870021 - Disclosure - INTANGIBLE ASSETS NET (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" order="51" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TradeNameMarkMember" xlink:label="loc_cosmTradeNameMarkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_cosmTradeNameMarkMember" order="52" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerListsMember" xlink:label="loc_us-gaapCustomerListsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerListsMember" order="53" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SoftwareMember" xlink:label="loc_cosmSoftwareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_cosmSoftwareMember" order="54" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapOtherFiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherFiniteLivedIntangibleAssetsGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwill" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetIncludingGoodwill" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/IntangibleAssetsNetDetails1" xlink:title="870022 - Disclosure - INTANGIBLE ASSETS NET (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LoanReceivableDetailsNarrative" xlink:title="870023 - Disclosure - LOAN RECEIVABLE (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/IncomeTaxesDetailsNarrative" xlink:title="870024 - Disclosure - INCOME TAXES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GreeceMember" xlink:label="loc_cosmGreeceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmGreeceMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UnitedKingdomMember" xlink:label="loc_cosmUnitedKingdomMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmUnitedKingdomMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CorporateTaxRate" xlink:label="loc_cosmCorporateTaxRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmCorporateTaxRate" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/CapitalStructureDetailsNarrative" xlink:title="870025 - Disclosure - CAPITAL STRUCTURE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" order="51" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantInducementLetterMember" xlink:label="loc_cosmWarrantInducementLetterMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmWarrantInducementLetterMember" order="52" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TreasuryStocksOneMember" xlink:label="loc_cosmTreasuryStocksOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_cosmTreasuryStocksOneMember" order="53" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantExchangeMember" xlink:label="loc_cosmWarrantExchangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cosmWarrantExchangeMember" order="54" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BottomMember" xlink:label="loc_cosmBottomMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmBottomMember" order="55" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TopMember" xlink:label="loc_cosmTopMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmTopMember" order="56" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStocksSharesIssued" xlink:label="loc_cosmCommonStocksSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmCommonStocksSharesIssued" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockShareAuthorized" xlink:label="loc_cosmCommonStockShareAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmCommonStockShareAuthorized" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AuthorizationToRepurchaseCommonStock" xlink:label="loc_cosmAuthorizationToRepurchaseCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmAuthorizationToRepurchaseCommonStock" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockSharesValue" xlink:label="loc_cosmCommonStockSharesValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmCommonStockSharesValue" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStocksSharesOutstanding" xlink:label="loc_cosmCommonStocksSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmCommonStocksSharesOutstanding" order="9" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PreferredStockLiquidationPreference1" xlink:label="loc_cosmPreferredStockLiquidationPreference1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPreferredStockLiquidationPreference1" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OriginalWarrantsSharesIssued" xlink:label="loc_cosmOriginalWarrantsSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmOriginalWarrantsSharesIssued" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_RemainingWarrantsSharesIssued" xlink:label="loc_cosmRemainingWarrantsSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmRemainingWarrantsSharesIssued" order="13" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesHeldInEscrow" xlink:label="loc_cosmSharesHeldInEscrow" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmSharesHeldInEscrow" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="15" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsDetails" xlink:title="870026 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedPartyMember" xlink:label="loc_cosmNotesPayableRelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_cosmNotesPayableRelatedPartyMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NotesPayableRelatedParty" xlink:label="loc_cosmNotesPayableRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmNotesPayableRelatedParty" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLoans" xlink:label="loc_us-gaapPaymentsForLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForLoans" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsDetails1" xlink:title="870027 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedPartyMember" xlink:label="loc_cosmLoansPayableRelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_cosmLoansPayableRelatedPartyMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoansPayableRelatedParty" xlink:label="loc_cosmLoansPayableRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmLoansPayableRelatedParty" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromLoans" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLoans" xlink:label="loc_us-gaapPaymentsForLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForLoans" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LoanPayableSetOffs" xlink:label="loc_cosmLoanPayableSetOffs" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmLoanPayableSetOffs" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="870028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaapLongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapLongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaapLongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapLongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GrigoriosSiokasMember" xlink:label="loc_cosmGrigoriosSiokasMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmGrigoriosSiokasMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CanaHoldingsLaboratoriesHoldingLimitedMember" xlink:label="loc_cosmCanaHoldingsLaboratoriesHoldingLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmCanaHoldingsLaboratoriesHoldingLimitedMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DocPharmaSaMember" xlink:label="loc_cosmDocPharmaSaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmDocPharmaSaMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DimitriosGoulielmosMember" xlink:label="loc_cosmDimitriosGoulielmosMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmDimitriosGoulielmosMember" order="34" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PanagiotisKozarisMember" xlink:label="loc_cosmPanagiotisKozarisMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmPanagiotisKozarisMember" order="35" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MariaKozariMember" xlink:label="loc_cosmMariaKozariMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmMariaKozariMember" order="36" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_InventoriesRelatedAgreementMember" xlink:label="loc_cosmInventoriesRelatedAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="loc_cosmInventoriesRelatedAgreementMember" order="37" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GeorgeTerzisMember" xlink:label="loc_cosmGeorgeTerzisMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmGeorgeTerzisMember" order="38" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_KanarogloySiaEpeMember" xlink:label="loc_cosmKanarogloySiaEpeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmKanarogloySiaEpeMember" order="39" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BasothoInvestmentLimitedMember" xlink:label="loc_cosmBasothoInvestmentLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmBasothoInvestmentLimitedMember" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromSecuredNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromSecuredNotesPayable" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DescriptionInterestOfSecuredPromissoryNote" xlink:label="loc_cosmDescriptionInterestOfSecuredPromissoryNote" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmDescriptionInterestOfSecuredPromissoryNote" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedSalariesCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedSalariesCurrentAndNoncurrent" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UnpaidSalariesAndBonusesDues" xlink:label="loc_cosmUnpaidSalariesAndBonusesDues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmUnpaidSalariesAndBonusesDues" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeOther" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayable" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" xlink:label="loc_cosmSharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmSharesOwnedAdditionalPaymentUnderStockPurchaseAgreement" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PrepaymentOfInventory" xlink:label="loc_cosmPrepaymentOfInventory" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPrepaymentOfInventory" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" order="15" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AccountsPayableRelatedPartyCurrent" xlink:label="loc_cosmAccountsPayableRelatedPartyCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmAccountsPayableRelatedPartyCurrent" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInterest" xlink:label="loc_us-gaapPrepaidInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidInterest" order="17" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AmountAccountsReceivableRelatedParties" xlink:label="loc_cosmAmountAccountsReceivableRelatedParties" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmAmountAccountsReceivableRelatedParties" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableRecoveries" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableRecoveries" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" order="22" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NetSales" xlink:label="loc_cosmNetSales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmNetSales" order="23" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AgreementTerminate" xlink:label="loc_cosmAgreementTerminate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmAgreementTerminate" order="24" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PiecesPerProduct" xlink:label="loc_cosmPiecesPerProduct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPiecesPerProduct" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationPurchases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationPurchases" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent" order="30" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PurchaseOfInventory" xlink:label="loc_cosmPurchaseOfInventory" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPurchaseOfInventory" order="31" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PurchaseOfPharmaceuticalsMedicine" xlink:label="loc_cosmPurchaseOfPharmaceuticalsMedicine" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPurchaseOfPharmaceuticalsMedicine" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementFeeDescription" xlink:label="loc_us-gaapManagementFeeDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapManagementFeeDescription" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableNetNoncurrent" order="35" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PaymentReceivedFromInstallment" xlink:label="loc_cosmPaymentReceivedFromInstallment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPaymentReceivedFromInstallment" order="36" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCreditDetails" xlink:title="870029 - Disclosure - LINES OF CREDIT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AtticaBankMember" xlink:label="loc_cosmAtticaBankMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmAtticaBankMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EFGMember" xlink:label="loc_cosmEFGMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmEFGMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalMember" xlink:label="loc_cosmNationalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmNationalMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AlphaMember" xlink:label="loc_cosmAlphaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmAlphaMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PancretaMember" xlink:label="loc_cosmPancretaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmPancretaMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCredit" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LinesOfCreditDetailsNarrative" xlink:title="870030 - Disclosure - LINES OF CREDIT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalBankOfGreeceOneMember" xlink:label="loc_cosmNationalBankOfGreeceOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmNationalBankOfGreeceOneMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapLineOfCreditMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalBankOfGreeceTwoMember" xlink:label="loc_cosmNationalBankOfGreeceTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cosmNationalBankOfGreeceTwoMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AlphaBankOfGreeceMember" xlink:label="loc_cosmAlphaBankOfGreeceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cosmAlphaBankOfGreeceMember" order="44" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PancretaOfGreeceMember" xlink:label="loc_cosmPancretaOfGreeceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cosmPancretaOfGreeceMember" order="45" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_EFGMember" xlink:label="loc_cosmEFGMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmEFGMember" order="46" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaapLineOfCreditFacilityAverageOutstandingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityAverageOutstandingAmount" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_LineOfCreditBorrowingsLoanDescription" xlink:label="loc_cosmLineOfCreditBorrowingsLoanDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmLineOfCreditBorrowingsLoanDescription" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:label="loc_us-gaapBorrowingsUnderGuaranteedInvestmentAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBorrowingsUnderGuaranteedInvestmentAgreements" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OutstandingDebtBalance" xlink:label="loc_cosmOutstandingDebtBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmOutstandingDebtBalance" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableDetails" xlink:title="870031 - Disclosure - NOTES PAYABLE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TradeFacilityAgreementsMember" xlink:label="loc_cosmTradeFacilityAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeDomain" xlink:to="loc_cosmTradeFacilityAgreementsMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ThirdPartyMember" xlink:label="loc_cosmThirdPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_cosmThirdPartyMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_COVIDLoansMember" xlink:label="loc_cosmCOVIDLoansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeDomain" xlink:to="loc_cosmCOVIDLoansMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayable" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProceedFromDebt" xlink:label="loc_cosmProceedFromDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmProceedFromDebt" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PaymentsOfDebt" xlink:label="loc_cosmPaymentsOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPaymentsOfDebt" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ForeignCurrencyTranslation" xlink:label="loc_cosmForeignCurrencyTranslation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmForeignCurrencyTranslation" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermNotesPayable" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayableCurrent" order="7" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableDetails1" xlink:title="870032 - Disclosure - NOTES PAYABLE (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/NotesPayableDetailsNarrative" xlink:title="870033 - Disclosure - NOTES PAYABLE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtAgreementJulyMember" xlink:label="loc_cosmDebtAgreementJulyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmDebtAgreementJulyMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember" xlink:label="loc_cosmJanuaryTwentySevenTwoThousandTwentyFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cosmJanuaryTwentySevenTwoThousandTwentyFiveMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtExchangeAgreementMember" xlink:label="loc_cosmDebtExchangeAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmDebtExchangeAgreementMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JuneTwentyThreeTwoThousandTwentyMember" xlink:label="loc_cosmJuneTwentyThreeTwoThousandTwentyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cosmJuneTwentyThreeTwoThousandTwentyMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalBankOfGreeceSAMember" xlink:label="loc_cosmNationalBankOfGreeceSAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmNationalBankOfGreeceSAMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtAgreementJuneOneMember" xlink:label="loc_cosmDebtAgreementJuneOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmDebtAgreementJuneOneMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JulyFourteenTwoThousandTwentyThreeMember" xlink:label="loc_cosmJulyFourteenTwoThousandTwentyThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cosmJulyFourteenTwoThousandTwentyThreeMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PromissoryNotesMember" xlink:label="loc_cosmPromissoryNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_cosmPromissoryNotesMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JulyTwentyNineTwentyTwentyFourMember" xlink:label="loc_cosmJulyTwentyNineTwentyTwentyFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cosmJulyTwentyNineTwentyTwentyFourMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DeemberTwentyTwentyFourMember" xlink:label="loc_cosmDeemberTwentyTwentyFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cosmDeemberTwentyTwentyFourMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CovidNinteenMember" xlink:label="loc_cosmCovidNinteenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmCovidNinteenMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_MayTwelveTwentyTwentyMember" xlink:label="loc_cosmMayTwelveTwentyTwentyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cosmMayTwelveTwentyTwentyMember" order="72" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JuneTwentyFourTwentyTwentyMember" xlink:label="loc_cosmJuneTwentyFourTwentyTwentyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cosmJuneTwentyFourTwentyTwentyMember" order="73" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_JanuaryTwentythreeTwoThousandTwentyFourMember" xlink:label="loc_cosmJanuaryTwentythreeTwoThousandTwentyFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cosmJanuaryTwentythreeTwoThousandTwentyFourMember" order="74" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtCurrent" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtDescription" xlink:label="loc_us-gaapLongTermDebtDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtDescription" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:label="loc_us-gaapPrincipalAmountOutstandingOnLoansSecuritized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrincipalAmountOutstandingOnLoansSecuritized" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" order="6" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CommonStockIssuedAsConsiderationFairValue" xlink:label="loc_cosmCommonStockIssuedAsConsiderationFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmCommonStockIssuedAsConsiderationFairValue" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BusinessCombinationContingentConsiderationArrangementLiability" xlink:label="loc_cosmBusinessCombinationContingentConsiderationArrangementLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmBusinessCombinationContingentConsiderationArrangementLiability" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermNotesPayable" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="loc_us-gaapSubordinatedBorrowingInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubordinatedBorrowingInterestRate" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:label="loc_us-gaapPaymentsToAcquireAdditionalInterestInSubsidiaries" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireAdditionalInterestInSubsidiaries" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" order="15" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DebtAmountReceivedFromRelatedParty" xlink:label="loc_cosmDebtAmountReceivedFromRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmDebtAmountReceivedFromRelatedParty" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent" order="18" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesDetails" xlink:title="870034 - Disclosure - LEASES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseMember" xlink:label="loc_cosmOperatingLeaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_cosmOperatingLeaseMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseLiabilityLessImputedInterest" xlink:label="loc_cosmOperatingLeaseLiabilityLessImputedInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmOperatingLeaseLiabilityLessImputedInterest" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="7" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesDetails1" xlink:title="870035 - Disclosure - LEASES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseMember" xlink:label="loc_cosmFinanceLeaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cosmFinanceLeaseMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" xlink:label="loc_cosmFinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmFinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" xlink:label="loc_cosmFinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmFinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/LeasesDetailsNarrative" xlink:title="870036 - Disclosure - LEASES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapInterestExpenseMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseTermOfAgreements" xlink:label="loc_cosmOperatingLeaseTermOfAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmOperatingLeaseTermOfAgreements" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseCashFlowsUsedInFinanceLease" xlink:label="loc_cosmOperatingLeaseCashFlowsUsedInFinanceLease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmOperatingLeaseCashFlowsUsedInFinanceLease" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseWeightedAverageDiscountRate" xlink:label="loc_cosmOperatingLeaseWeightedAverageDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmOperatingLeaseWeightedAverageDiscountRate" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:label="loc_cosmOperatingLeaseWeightedAverageRemainingLeaseTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmOperatingLeaseWeightedAverageRemainingLeaseTerm" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm" xlink:label="loc_cosmFinanceLeaseWeightedAverageRemainingLeaseTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmFinanceLeaseWeightedAverageRemainingLeaseTerm" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseWeightedAverageDiscountRate" xlink:label="loc_cosmFinanceLeaseWeightedAverageDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmFinanceLeaseWeightedAverageDiscountRate" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FinanceLeaseAmortizationExpense" xlink:label="loc_cosmFinanceLeaseAmortizationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmFinanceLeaseAmortizationExpense" order="9" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/OtherLiabilitiesDetailsNarrative" xlink:title="870037 - Disclosure - OTHER LIABILITIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec" xlink:title="870038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrativec)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtLitigationCaseAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PhaseOneMember" xlink:label="loc_cosmPhaseOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmPhaseOneMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NationalMedicinesAgencyMember" xlink:label="loc_cosmNationalMedicinesAgencyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_cosmNationalMedicinesAgencyMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PhaseTwoMember" xlink:label="loc_cosmPhaseTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmPhaseTwoMember" order="44" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_FourThirdPartyConsultantsMember" xlink:label="loc_cosmFourThirdPartyConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmFourThirdPartyConsultantsMember" order="45" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PaymentTax" xlink:label="loc_cosmPaymentTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPaymentTax" order="2" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ProjectCosts" xlink:label="loc_cosmProjectCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmProjectCosts" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="4" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_StockIssuedDuringPeriodSharesAwarded" xlink:label="loc_cosmStockIssuedDuringPeriodSharesAwarded" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmStockIssuedDuringPeriodSharesAwarded" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssued1" order="6" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AdditionalStockConsideration" xlink:label="loc_cosmAdditionalStockConsideration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmAdditionalStockConsideration" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaapLifeSettlementContractsFairValueMethodCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLifeSettlementContractsFairValueMethodCarryingAmount" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ComplementaryCompensationShares" xlink:label="loc_cosmComplementaryCompensationShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmComplementaryCompensationShares" order="9" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PurchasePriceAmount" xlink:label="loc_cosmPurchasePriceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmPurchasePriceAmount" order="10" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrantsDetails" xlink:title="870039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantsMember" xlink:label="loc_cosmWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cosmWarrantsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" xlink:label="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" xlink:label="loc_cosmShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WeightedAverageRemainingContractualTermOutstandingBeginning" xlink:label="loc_cosmWeightedAverageRemainingContractualTermOutstandingBeginning" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmWeightedAverageRemainingContractualTermOutstandingBeginning" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WeightedAverageRemainingContractualTermOutstandingEnding" xlink:label="loc_cosmWeightedAverageRemainingContractualTermOutstandingEnding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmWeightedAverageRemainingContractualTermOutstandingEnding" order="13" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WeightedAverageRemainingContractualTermExercisable" xlink:label="loc_cosmWeightedAverageRemainingContractualTermExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmWeightedAverageRemainingContractualTermExercisable" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="15" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" xlink:label="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue" order="17" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:title="870040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantsMember" xlink:label="loc_cosmWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cosmWarrantsMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BoardOfDirectorsMember" xlink:label="loc_cosmBoardOfDirectorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmBoardOfDirectorsMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TwoZeroTwentyTwoPlanMember" xlink:label="loc_cosmTwoZeroTwentyTwoPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmTwoZeroTwentyTwoPlanMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TwoZeroTwentyThreePlanMember" xlink:label="loc_cosmTwoZeroTwentyThreePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cosmTwoZeroTwentyThreePlanMember" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" order="1" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_DiscriptionOfIncentiveStockAwards" xlink:label="loc_cosmDiscriptionOfIncentiveStockAwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmDiscriptionOfIncentiveStockAwards" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" order="3" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" xlink:label="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" order="5" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WarrantExpirationDateDescription" xlink:label="loc_cosmWarrantExpirationDateDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmWarrantExpirationDateDescription" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued" order="7" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/DisaggregationOfRevenueDetails" xlink:title="870041 - Disclosure - DISAGGREGATION OF REVENUE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GreeceMember" xlink:label="loc_cosmGreeceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmGreeceMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_UkMember" xlink:label="loc_cosmUkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmUkMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_AlbaniaMember" xlink:label="loc_cosmAlbaniaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmAlbaniaMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CroatiaMember" xlink:label="loc_cosmCroatiaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmCroatiaMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_CyprusMember" xlink:label="loc_cosmCyprusMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmCyprusMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_BulgariaMember" xlink:label="loc_cosmBulgariaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_cosmBulgariaMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/SegmentReportingDetails" xlink:title="870042 - Disclosure - SEGMENT REPORTING (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OtherMember" xlink:label="loc_cosmOtherMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cosmOtherMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_TotalSegmentMember" xlink:label="loc_cosmTotalSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cosmTotalSegmentMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_WholesaleMember" xlink:label="loc_cosmWholesaleMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cosmWholesaleMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_PharmamanufacturingMember" xlink:label="loc_cosmPharmamanufacturingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cosmPharmamanufacturingMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NutraceuticalsAndPharmaceuticalsMember" xlink:label="loc_cosmNutraceuticalsAndPharmaceuticalsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cosmNutraceuticalsAndPharmaceuticalsMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingAndMarketingExpense" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="7" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_NetFinanceCosts" xlink:label="loc_cosmNetFinanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmNetFinanceCosts" order="8" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_SegmentProfitLoss" xlink:label="loc_cosmSegmentProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmSegmentProfitLoss" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossRealized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossRealized" order="12" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_OtherIncomeAndExpenses" xlink:label="loc_cosmOtherIncomeAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cosmOtherIncomeAndExpenses" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/SubsequentEventsDetailsNarrative" xlink:title="870043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="cosm-20250331.xsd#cosm_GrigoriosSiokasMember" xlink:label="loc_cosmGrigoriosSiokasMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cosmGrigoriosSiokasMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:label="loc_us-gaapAssetRetirementObligationLiabilitiesSettled" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetRetirementObligationLiabilitiesSettled" order="2" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 15, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COSMOS HEALTH INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001474167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,751,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-54436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0611758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">5 Agiou Georgiou Str<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Pilea<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Thessaloniki<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">GR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">55438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">536-3102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COSM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 742,881<span></span>
</td>
<td class="nump">$ 315,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">14,251,895<span></span>
</td>
<td class="nump">13,478,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AmountAccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable - related party</a></td>
<td class="nump">1,422,015<span></span>
</td>
<td class="nump">1,230,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">25,278<span></span>
</td>
<td class="nump">21,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">4,736,222<span></span>
</td>
<td class="nump">4,355,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loans receivable</a></td>
<td class="nump">666,225<span></span>
</td>
<td class="nump">614,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedParties', window );">Loans receivable - related party</a></td>
<td class="nump">768,891<span></span>
</td>
<td class="nump">557,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,383,105<span></span>
</td>
<td class="nump">1,310,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent', window );">Prepaid expenses and other current assets - related party</a></td>
<td class="nump">3,848,487<span></span>
</td>
<td class="nump">3,578,825<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">27,844,999<span></span>
</td>
<td class="nump">25,461,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,016,068<span></span>
</td>
<td class="nump">9,689,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and intangible assets, net</a></td>
<td class="nump">7,802,529<span></span>
</td>
<td class="nump">7,756,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LoansReceivableNoncurrent', window );">Loans receivable - long term portion</a></td>
<td class="nump">2,927,994<span></span>
</td>
<td class="nump">2,876,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LoansReceivableRelatedPartyNoncurrent', window );">Loans receivable - related party - long term</a></td>
<td class="nump">2,875,384<span></span>
</td>
<td class="nump">2,898,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">671,605<span></span>
</td>
<td class="nump">696,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Financing lease right-of-use asset</a></td>
<td class="nump">9,451<span></span>
</td>
<td class="nump">13,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AdvancesForBuildingsAcquisition', window );">Advances for building's acquisition</a></td>
<td class="nump">2,000,020<span></span>
</td>
<td class="nump">2,000,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">1,154,594<span></span>
</td>
<td class="nump">1,108,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OtherAssetsRelatedParty', window );">Other assets - related party</a></td>
<td class="nump">1,889,300<span></span>
</td>
<td class="nump">1,811,425<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">57,191,944<span></span>
</td>
<td class="nump">54,311,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">11,672,962<span></span>
</td>
<td class="nump">11,157,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent', window );">Accounts payable and accrued expenses - related party</a></td>
<td class="nump">614,554<span></span>
</td>
<td class="nump">1,269,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">255,192<span></span>
</td>
<td class="nump">221,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Lines of credit</a></td>
<td class="nump">7,305,377<span></span>
</td>
<td class="nump">6,985,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">2,763,723<span></span>
</td>
<td class="nump">2,548,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_NotesPayableRelatedPartiesCurrent', window );">Notes payable - related party</a></td>
<td class="nump">11,012<span></span>
</td>
<td class="nump">10,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LoansPayableRelatedPartiesCurrent', window );">Loans payable - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">203,601<span></span>
</td>
<td class="nump">196,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease liability, current portion</a></td>
<td class="nump">8,376<span></span>
</td>
<td class="nump">11,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">3,751,190<span></span>
</td>
<td class="nump">3,350,173<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">26,585,987<span></span>
</td>
<td class="nump">25,757,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long term portion</a></td>
<td class="nump">2,088,540<span></span>
</td>
<td class="nump">1,560,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">466,909<span></span>
</td>
<td class="nump">498,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liability, net of current portion</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">3,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">2,097,008<span></span>
</td>
<td class="nump">1,959,193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">31,240,232<span></span>
</td>
<td class="nump">29,778,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (see Note 14)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 300,000,000 shares authorized; 27,284,633 and 23,689,135 shares issued and 27,198,136 and 23,602,638 outstanding as of March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">27,285<span></span>
</td>
<td class="nump">23,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">142,785,641<span></span>
</td>
<td class="nump">141,583,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 86,497 shares as of March 31, 2025 and December 31, 2024</a></td>
<td class="num">(917,159)<span></span>
</td>
<td class="num">(917,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(114,840,372)<span></span>
</td>
<td class="num">(114,022,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,103,663)<span></span>
</td>
<td class="num">(2,134,931)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">25,951,712<span></span>
</td>
<td class="nump">24,532,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 57,191,944<span></span>
</td>
<td class="nump">$ 54,311,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_AdvancesForBuildingsAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_AdvancesForBuildingsAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_AmountAccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_AmountAccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_LoansPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_LoansPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_LoansReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_LoansReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_LoansReceivableRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_LoansReceivableRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_NotesPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_NotesPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OtherAssetsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OtherAssetsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, shares par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,284,633<span></span>
</td>
<td class="nump">23,689,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,198,136<span></span>
</td>
<td class="nump">23,602,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock</a></td>
<td class="nump">86,497<span></span>
</td>
<td class="nump">86,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUE</a></td>
<td class="nump">$ 13,712,528<span></span>
</td>
<td class="nump">$ 14,584,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF GOODS SOLD</a></td>
<td class="nump">11,662,729<span></span>
</td>
<td class="nump">13,250,847<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">2,049,799<span></span>
</td>
<td class="nump">1,333,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,478,702<span></span>
</td>
<td class="nump">1,418,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and wages</a></td>
<td class="nump">1,040,019<span></span>
</td>
<td class="nump">1,258,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">28,155<span></span>
</td>
<td class="nump">173,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">15,629<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">320,439<span></span>
</td>
<td class="nump">319,787<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">2,882,944<span></span>
</td>
<td class="nump">3,169,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(833,145)<span></span>
</td>
<td class="num">(1,836,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(68,137)<span></span>
</td>
<td class="nump">191,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(187,107)<span></span>
</td>
<td class="num">(168,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">91,326<span></span>
</td>
<td class="nump">105,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_GainLossOnSalesOfEquityInvestments', window );">Gain on equity investments, net</a></td>
<td class="nump">3,142<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction, net</a></td>
<td class="nump">175,824<span></span>
</td>
<td class="num">(161,254)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME (EXPENSE), NET</a></td>
<td class="nump">15,048<span></span>
</td>
<td class="num">(30,582)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(818,097)<span></span>
</td>
<td class="num">(1,866,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX EXPENSE</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(818,097)<span></span>
</td>
<td class="num">(1,866,690)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">(818,097)<span></span>
</td>
<td class="num">(1,866,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>OTHER COMPREHENSIVE INCOME (LOSS)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment, net</a></td>
<td class="nump">1,031,268<span></span>
</td>
<td class="num">(599,276)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">TOTAL COMPREHENSIVE INCOME (LOSS)</a></td>
<td class="nump">$ 213,171<span></span>
</td>
<td class="num">$ (2,465,966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC NET LOSS PER SHARE</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED NET LOSS PER SHARE</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Basic</a></td>
<td class="nump">26,037,608<span></span>
</td>
<td class="nump">16,851,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted', window );">Diluted</a></td>
<td class="nump">26,037,608<span></span>
</td>
<td class="nump">16,851,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_GainLossOnSalesOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_GainLossOnSalesOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of limited partnership units outstanding determined by relating the portion of time within a reporting period that limited partnership units have been outstanding to the total time in that period. Used in the calculation of diluted net income or loss per limited partnership unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Treasury Stocks</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Subscription Receivable</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,497<span></span>
</td>
<td class="nump">15,982,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">$ 36,043,028<span></span>
</td>
<td class="num">$ (917,159)<span></span>
</td>
<td class="nump">$ 15,983<span></span>
</td>
<td class="nump">$ 129,008,301<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">$ (91,644,233)<span></span>
</td>
<td class="num">$ (419,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ForeignCurrencyTranslationAdjustmentNet', window );">Foreign currency translation adjustment, net</a></td>
<td class="num">(1,715,087)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(599,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares', window );">Proceeds from sale of common stock, net of financing fees of $19,467, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount', window );">Proceeds from sale of common stock, net of financing fees of $19,467, amount</a></td>
<td class="nump">629,426<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">628,525<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SharesIssuedInLieuOfCashAmount', window );">Shares issued in lieu of cash</a></td>
<td class="nump">695,405<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">108,297<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares', window );">Shares issued pursuant to warrant exchange agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount', window );">Shares issued pursuant to warrant exchange agreement, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
<td class="num">(950)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_StockBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">994,307<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">231,897<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">3,868,868<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,866,690)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,497<span></span>
</td>
<td class="nump">17,834,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Mar. 31, 2024</a></td>
<td class="nump">40,515,948<span></span>
</td>
<td class="num">$ (917,159)<span></span>
</td>
<td class="nump">$ 17,834<span></span>
</td>
<td class="nump">129,976,070<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(93,510,923)<span></span>
</td>
<td class="num">(1,019,120)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,497<span></span>
</td>
<td class="nump">23,689,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Dec. 31, 2024</a></td>
<td class="nump">24,532,930<span></span>
</td>
<td class="num">$ (917,159)<span></span>
</td>
<td class="nump">$ 23,689<span></span>
</td>
<td class="nump">141,583,625<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(114,022,275)<span></span>
</td>
<td class="num">(2,134,931)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ForeignCurrencyTranslationAdjustmentNet', window );">Foreign currency translation adjustment, net</a></td>
<td class="nump">1,031,268<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,031,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares', window );">Shares issued pursuant to warrant exchange agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,542,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount', window );">Shares issued pursuant to warrant exchange agreement, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,542<span></span>
</td>
<td class="num">(2,542)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_StockBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">556,611<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">556,611<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(818,097)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(818,097)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_DebtExchangesShares', window );">Debt exchanges, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_DebtExchangesAmount', window );">Debt exchanges, amount</a></td>
<td class="nump">649,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,053<span></span>
</td>
<td class="nump">647,947<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,497<span></span>
</td>
<td class="nump">27,284,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Mar. 31, 2025</a></td>
<td class="nump">$ 25,951,712<span></span>
</td>
<td class="num">$ (917,159)<span></span>
</td>
<td class="nump">$ 27,284<span></span>
</td>
<td class="nump">$ 142,785,641<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">$ (114,840,372)<span></span>
</td>
<td class="num">$ (1,103,663)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_DebtExchangesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_DebtExchangesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_DebtExchangesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_DebtExchangesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ForeignCurrencyTranslationAdjustmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ForeignCurrencyTranslationAdjustmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_SharesIssuedInLieuOfCashAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_SharesIssuedInLieuOfCashAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_StockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_StockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (818,097)<span></span>
</td>
<td class="num">$ (1,866,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">315,836<span></span>
</td>
<td class="nump">312,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">7,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="num">(18,687)<span></span>
</td>
<td class="num">(31,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease expense</a></td>
<td class="nump">63,236<span></span>
</td>
<td class="nump">77,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance leases</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">556,611<span></span>
</td>
<td class="nump">340,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="nump">7,392<span></span>
</td>
<td class="num">(4,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on net change in fair value of equity investments</a></td>
<td class="num">(3,142)<span></span>
</td>
<td class="num">(1,755)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(170,948)<span></span>
</td>
<td class="nump">238,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable - related party</a></td>
<td class="num">(134,483)<span></span>
</td>
<td class="num">(348,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(192,792)<span></span>
</td>
<td class="num">(196,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other assets</a></td>
<td class="nump">92,249<span></span>
</td>
<td class="num">(106,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty', window );">Prepaid expenses and other current assets - related party</a></td>
<td class="num">(134,754)<span></span>
</td>
<td class="num">(974,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">83,627<span></span>
</td>
<td class="num">(599,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties', window );">Accounts payable and accrued expenses - related party</a></td>
<td class="num">(18,934)<span></span>
</td>
<td class="nump">319,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="nump">23,308<span></span>
</td>
<td class="num">(62,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(63,238)<span></span>
</td>
<td class="num">(76,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">169,429<span></span>
</td>
<td class="nump">261,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_IncreaseDecreaseInOtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">52,272<span></span>
</td>
<td class="num">(701,821)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(186,316)<span></span>
</td>
<td class="num">(3,412,103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfLoansReceivable', window );">Proceeds from loan receivable</a></td>
<td class="nump">6,734<span></span>
</td>
<td class="nump">207,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(1,273)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Sale of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(12,530)<span></span>
</td>
<td class="num">(82,662)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</a></td>
<td class="num">(7,069)<span></span>
</td>
<td class="nump">126,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of note payable</a></td>
<td class="num">(184,153)<span></span>
</td>
<td class="num">(364,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from note payable</a></td>
<td class="nump">737,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payment of related party loan</a></td>
<td class="num">(6,302)<span></span>
</td>
<td class="num">(7,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payment of lines of credit</a></td>
<td class="num">(6,756,201)<span></span>
</td>
<td class="num">(5,974,114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">6,775,739<span></span>
</td>
<td class="nump">5,932,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">649,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments of finance lease liability</a></td>
<td class="num">(5,398)<span></span>
</td>
<td class="num">(8,787)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">560,862<span></span>
</td>
<td class="nump">206,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">60,299<span></span>
</td>
<td class="nump">110,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH</a></td>
<td class="nump">427,776<span></span>
</td>
<td class="num">(2,968,096)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AT BEGINNING OF PERIOD</a></td>
<td class="nump">315,105<span></span>
</td>
<td class="nump">3,833,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AT END OF PERIOD</a></td>
<td class="nump">742,881<span></span>
</td>
<td class="nump">865,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CashPaidDuringTheYearNewAbstract', window );"><strong>Cash paid during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">104,800<span></span>
</td>
<td class="nump">234,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ClosingOfAcquisitionOfCloudscreen', window );">Closing of acquisition of Cloudscreen</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">637,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CommonStockIssuedToEmployees', window );">Common stock issued to employees</a></td>
<td class="nump">311,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CommonStockIssuedToConsultants', window );">Common stock issued to consultants</a></td>
<td class="nump">$ 245,310<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CashPaidDuringTheYearNewAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CashPaidDuringTheYearNewAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ClosingOfAcquisitionOfCloudscreen">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ClosingOfAcquisitionOfCloudscreen</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CommonStockIssuedToConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CommonStockIssuedToConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CommonStockIssuedToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CommonStockIssuedToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_IncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_IncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of loans receivables arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangements Adopted [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangements Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non Rule 10b5-1 Arrangements Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non Rule 10b5-1 Arrangements Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_BasisOfPresentationAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 &#8211; BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The terms &#8220;COSM,&#8221; &#8220;we,&#8221; the &#8220;Company,&#8221; the &#8220;Group&#8221; and &#8220;us&#8221; as used in this report refer to Cosmos Health Inc. The accompanying unaudited condensed consolidated balance sheet as of March 31, 2025 and unaudited condensed consolidated statements of operations and comprehensive income&#160;(loss) for the three months ended March 31, 2025 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of the management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2025, are not necessarily indicative of the results that may be expected for the year ending December 31, 2025, or any other period. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2024, included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 (&#8220;Form 10-K&#8221;). The accompanying condensed consolidated balance sheet as of December 31, 2024 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes on the accompanying balance sheet. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s unaudited consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), which contemplates the continuation of the Company as a going concern. For the period ended March 31, 2025, the Company had revenue of $13,712,528, net loss of $818,097 and net cash used in operations of $186,316. Additionally, as of March 31, 2025, the Company had positive working capital of $1,259,012, an accumulated deficit of $114,840,372, and stockholders&#8217; equity of $25,951,712. It is management&#8217;s opinion that these conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of 12 months from the date of this filing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s revenues are not able to sustain its operations, and concerns exist regarding the Company&#8217;s ability to meet its obligations as they become due. The Company is subject to a number of risks to those of smaller commercial companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the need to obtain additional capital, competition from larger companies, and other pharmaceutical and health care companies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management evaluated the above conditions which raise substantial doubt about the Company&#8217;s ability to continue as a going concern to determine if it can meet its obligations for the subsequent 12 months from the date of this filing. Management considered its ability to access future capital, curtail expenses if needed, expand product lines, and acquire new products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management&#8217;s plans include expansion of brand name products to the market, expanding the current product portfolio, and evaluating acquisition targets to expand distribution. The exclusive distribution agreement signed for its Sky Premium Life products in the United Arab Emirates (&#8220;UAE&#8221;) and the significant orders already received, are expected to substantially strengthen its operating cash flow. Furthermore, the Company intends to vertically integrate the supply chain distribution network. On top of that, the Company plans to access the capital markets further in order to raise additional funds through equity and/or debt offerings. More specifically, commencing from August 2025, the Company will be eligible to utilize an S-3 registration statement, (12 months following the date that the Company had regained compliance with Listing Rule 5250(c)(1) (the &#8220;Filing Rule&#8221;)), to be in a position to raise equity capital more efficiently in conjunction with utilizing potential equity proceeds by its outstanding warrants. Management&#8217;s plans also include postponing certain debt repayments, through achieving favorable amendments to its debt facilities and in parallel intends to make substantial efforts to receive additional debt financing. Moreover, the Company&#8217;s management is considering of postponing certain repayments of suppliers and creditors. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Considering the above, management is of the view that substantial doubt exists for the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OrganizationAndNatureOfTheBusinessAbstract', window );"><strong>ORGANIZATION AND NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND NATURE OF BUSINESS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 2 &#8211; ORGANIZATION AND NATURE OF BUSINESS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cosmos Health Inc. and its subsidiaries (Nasdaq: COSM), (&#8220;us&#8221;, &#8220;we&#8221;, the &#8220;Group&#8221;, or the &#8220;Company&#8221;) are an international healthcare group headquartered in Chicago, Illinois. The Group is engaged in the nutraceuticals sector through its own proprietary lines of products &#8220;Sky Premium Life&#8221; and &#8220;Mediterranation&#8221;. The Company is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the Group is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK, serving retail pharmacies and wholesale distributors. The Company is strategically focusing on the research and development (&#8220;R&amp;D&#8221;) of novel patented nutraceuticals and specialized root extracts, as well as on the R&amp;D of proprietary complex generics and innovative OTC products. The Company has developed a global distribution platform and is currently expanding throughout Europe, Asia, the UAE and North America. The Company has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009. On November 14, 2013, we changed our name to Cosmos Holdings Inc., and on November 29, 2022, we changed our name to Cosmos Health Inc. Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (&#8220;SkyPharm&#8221;), a subsidiary that used to focus on the trading, sourcing and export of nutraceutical and pharmaceutical products. In February 2017, the Company acquired Decahedron Ltd., a UK Company (&#8220;Decahedron&#8221;) which is a fully licensed second-generation wholesaler specializing in imports and exports of generics and OTC pharmaceutical products within the EEA (European Economic Area) and distributor of Sky Premium Life nutraceutical products in the UK.&#160;On December 19, 2018, the Company acquired Cosmofarm&#160;S.A. (&#8220;Cosmofarm&#8221;), a pharmaceutical wholesaler specializing in the distribution and export of pharmaceutical products through its extensive pharmacies network. On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (&#8220;ZipDoctor&#8221;), a telehealth company, a direct-to-consumer subscription-based telemedicine platform. On June 30, 2023, the Company acquired&#160;Laboratories Holdings (Cyprus) Limited (&#8220;Cana&#8221;), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana&#160;S.A. (&#8220;Cana SA&#8221;), a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Acquisition Accounting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cloudscreen</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, Business Combinations, (&#8220;ASC 805&#8221;) and recorded $637,080 as &#8220;Other assets&#8221; related to the technology platform acquired. The total amount was reclassified to &#8220;Goodwill and intangible assets, net&#8221; in January 2024 with the closing of the agreement (refer to Note 5).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>ZipDoctor</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (&#8220;ZipDoctor&#8221;), a&#160;telehealth company for a total sum of $150,000 in cash and $8,788 in fees. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, <em>Business Combinations</em>, (&#8220;ASC 805&#8221;) and recorded $158,788 as an intangible asset related to the technology platform acquired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2024, the Company recognized an impairment charge of $131,032 related to the technology platform. This decision followed management&#8217;s assessment that the asset&#8217;s recoverability was no longer supportable due to changes in market conditions and a shift in strategic priorities. Specifically, the telehealth platform was no longer in use and did not generate revenues, as the Company elected not to focus on the telehealth business segment. As a result, the unamortized balance of the intangible asset was effectively written off. The impairment charge was recorded within &#8220;Other income (expense), net&#8221; in the Consolidated Statement of Operations for the year ended December 31, 2024.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Bikas</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 15, 2023, Cosmos Health Inc. entered into an Assignment and Assumption Agreement (the &#8220;Agreement&#8221;) with Ioannis Bikas O.E., a Greek Company (&#8220;Bikas&#8221;). Bikas is owner of a pharmaceutical distribution network in Greece and agreed to sell to the Company their distribution network and customer base. The purchase price of the network was &#8364;100,000 ($109,330) of cash, and &#8364;300,000 ($316,081) of the Company&#8217;s stock. The Company issued 99,710 shares of common stock related to the acquisition of the customer base, based on the fair value of the stock on the acquisition date. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded $425,411 as an intangible asset related to the customer base acquired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Buildings Acquisitions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 24, 2023, the Company purchased a building for a total sum of $1,054,872 in cash.&#160;The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded the cost of the building as &#8220;Property, plant and equipment&#8221; on the consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 6, 2023, the Company agreed to purchase land and building located in Montreal, Canada from a third-party vendor. The total purchase price amounts to $3,950,000 and the closing date of the agreement based on the amendment signed on July 19, 2023, was December 31, 2023. Pursuant to the last amendment signed on December 31, 2024 the closing date was extended to December 31, 2025. As of March 31, 2025, the Company has made prepayments of $2,000,020 classified as &#8220;Advances for building&#8217;s acquisition&#8221; on the Company&#8217;s condensed consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cana </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 30, 2023, the Company acquired Cana Laboratories Holding (Cyprus) Limited (&#8220;Cana&#8221;), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana&#160;S.A. (&#8220;Cana SA&#8221;) for &#8364;800,000 ($873,600) in cash and 46,377 shares of common stock, with fair value of $138,667 as of the date of acquisition. Moreover, on February 28,<sup style="vertical-align:super"> </sup>2023, the Company had signed a Secured Promissory Note with Cana, whereby Cana borrowed the sum of &#8364;4,100,000 ($4,457,520), included in the total consideration of $5,469,787. The Company accounted for the acquisition as a business acquisition in accordance with ASC 805. The fair value of Cana assets acquired, and liabilities assumed was based upon management&#8217;s estimates assisted by an independent third-party valuation firm. The fixed assets of Cana (which included land, building &amp; machinery) were valued as of December 31, 2022 and the Company believes that nothing has materially changed between such date and the acquisition date (June 30, 2023). The following table summarizes the preliminary allocation of purchase price of the acquisition:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Consideration </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,331,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Fair value of common stock issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">138,667</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fair value of total consideration transferred</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>5,469,787</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recognized amounts of identifiable assets acquired</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,796,911</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297,340</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property, plant and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,488,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identifiable intangible assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">562,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,235,233 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total identifiable net assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,910,036</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Bargain purchase gain</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,440,249</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the prior year period, Cana had minimal operations as it was in financial difficulties and seeking for an investor. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis of Financial Statement Presentation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Principles of Consolidation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our consolidated accounts include our accounts and the accounts of our wholly owned subsidiaries, SkyPharm S.A., Decahedron Ltd., Cosmofarm S.A., Cana Laboratories Holdings (Cyprus) Limited and ZipDoctor Inc. The Group&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;). The consolidated financial statements reflect the consolidation of all entities in which the Company has control, as determined by the ability to direct the activities that significantly affect the entities&#8217; economic performance. All significant intercompany balances and transactions have been eliminated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Transactions in and Translations of Foreign Currency</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The functional currency for the Greek subsidiaries of the Company (CANA Laboratories, Cosmofarm S.A. and SkyPharm SA) is Euro (&#8364;) and for the UK subsidiary (Decahedron Ltd) is GBP (&#163;). ZipDoctor Inc. is a U.S. based entity. As a result, the financial statements of the subsidiaries (except for ZipDoctor Inc.) have been translated from the local currency into U.S. dollars using (i) year-end exchange rates for balance sheet accounts, and (ii) average exchange rates for the reporting period for all income statements accounts. Foreign currency translations gains and losses are reported as a separate component of the condensed consolidated statements of changes in stockholders&#8217; equity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Use of Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The Effects of War in the Ukraine</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company and, as such, is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Credit Losses</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which amends the requirement on the measurement and recognition of expected credit losses for financial assets held. Furthermore, amendments ASU 2019-10 and ASU 2019-11 provided additional clarification for implementing ASU 2016-13. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early adoption permitted. The Company adopted the standard on January 1, 2023, and the standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. The Company is exposed to credit losses primarily through sales to its customers and the loans that it has provided. The Company assesses each customer&#8217;s/ borrower&#8217;s ability to pay, and a credit loss estimate by conducting a credit review which includes consideration of established credit rating, or an internal assessment of the customer&#8217;s creditworthiness based on an analysis of their payment history when a credit rating is not available. The Company monitors credit exposure through active review of customer balances. In accordance with ASC 326 and the Current Expected Credit Loss (CECL) framework, the Company has elected to apply the practical expedient available for its trade receivables, which are short-term in nature and do not contain a significant financing component. The Company applies a loss-rate method for calculating expected credit losses (&#8220;ECL&#8221;) on accounts receivable, based on a combination of historical experience, industry data, and adjustments for current conditions and reasonable and supportable forecasts. Receivables are grouped into four aging buckets, with loss rates applied as follows: 1% for receivables aged 0&#8211;30 days, 2% for receivables aged 31&#8211;60 days, 3% for receivables aged 61&#8211;90 days, and 5% for receivables aged over 90 days. These loss rates are based on management&#8217;s expectations, which are further supported by external benchmarks, due to the Company&#8217;s limited history of actual write-offs. The resulting provision for expected credit losses is recognized in net income and is included in &#8220;General and administrative expenses&#8221;. Receivables that are deemed uncollectible are written off against the allowance when it is determined that they are no longer recoverable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cash and Cash Equivalents</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Accounts Receivable, net</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable, prepaid expenses and other current assets and other assets reflects the best estimate of probable losses inherent in the receivables&#8217; portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of March 31, 2025 and December 31, 2024, the Company&#8217;s allowance for doubtful accounts was $23,658,962 and $22,799,219, respectively. Below is the summary of changes in the allowance for doubtful accounts:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Balance as of January 1st, 2025 </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,799,219</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Provisions for credit losses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Write-offs </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Foreign exchange adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">878,430</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(18,687 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Balance as of March 31, 2025</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,658,962</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Tax Receivables</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company pays Value Added Tax (&#8220;VAT&#8221;) or similar taxes (&#8220;input VAT&#8221;), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (&#8220;output VAT&#8221;) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of March 31, 2025 and December 31, 2024, the Company had a VAT net receivable balance of $528,203 and $534,263 respectively, recorded in the condensed consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Inventory </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company writes down inventories to net realizable value based on physical condition, expiration date, and current market conditions, as well as forecasted demand. The Company&#8217;s inventories are not highly susceptible to obsolescence. Many of the Company&#8217;s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. No significant judgments have been applied in estimating the selling price of our inventory.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Property and Equipment, net </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Estimated</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Useful Life</strong></p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:77%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Leasehold improvements and technical works</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:1%;"></td><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Lesser of lease term or 25 years</p></td><td style="width:1%;"></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">25-30 years</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vehicles</p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6 years</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Machinery</p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20 years</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Furniture, fixtures and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5&#8211;10 years</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Computers and software</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3-5 years</p></td><td></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Depreciation expense was $97,539 and $112,874 for the three months ended March 31, 2025 and 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment additions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and Equipment additions are recognized as assets when it is probable that future economic benefits associated with the asset will flow to the entity and the cost of the asset can be measured reliably. Additions are initially measured at cost, which includes all costs directly attributable to bringing the asset to its working condition and location for its intended use. This may include purchase price, freight, installation, and any directly attributable professional fees. They are capitalized if their cost exceeds a certain threshold. The threshold is determined based on materiality considerations. Costs below the threshold are typically expensed as incurred. After initial recognition, additions are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is calculated systematically over the estimated useful life of the asset. They are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying amount exceeds the recoverable amount, an impairment loss is recognized, and the carrying amount of the asset is adjusted accordingly. Borrowing costs directly attributable to the acquisition, construction, or production of qualifying assets, including Property and Equipment additions, are capitalized as part of the cost of those assets. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Intangibles, net</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license and a useful life of 10 years for the pharmaceutical and nutraceutical products licenses included in Note 4 as &#8220;Licenses&#8221;. A useful life of 10 years is also used for the platforms included in Note 4 as &#8220;Software&#8221; and the customer bases. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset&#8217;s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2025 and December 31, 2024, no revision to the remaining amortization period of the intangible assets was made.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amortization expense was $208,833 and $189,855 for the three months ended March 31, 2025 and 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Impairment of Long-Lived Assets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. For the three months ended March 31, 2025, and 2024, the Company has recorded no impairment charge.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Equity Method Investment</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in &#8220;Equity earnings of affiliate&#8221; in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Investments in Equity Securities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for sale in current operations are reported as a component of current assets on the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets on the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, investments consisted of 16,666 shares which traded at a closing price of $0.95 per share or value of $15,749 of National Bank of Greece. Additionally, the Company has $7,665 in equity securities of Pancreta Bank, which are revalued annually. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fair Value Measurement</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company applies ASC 820, Fair Value Measurements and Disclosures, (&#8220;ASC 820&#8221;), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1:&#160;Observable inputs such as quoted prices (unadjusted)&#160;in active markets for identical assets or liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2:&#160;Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3:&#160;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, ASC 825-10-25, Fair Value Option, (&#8220;ASC 825-10-25&#8221;), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our financials also included the following financial instruments as of March 31, 2025 and December 31, 2024: cash, accounts receivable, inventory, prepaid expenses, loans receivable, accounts payable, notes payable and lines of credit. Except for the loans receivable which carry fixed interest rates, the carrying value of the remaining instruments, approximates fair value due to their short-term nature.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Customer Advances</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company&#8217;s products. The Company records these receipts as current liabilities until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer&#160;advances balance and credit the Company&#8217;s revenues.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Revenue Recognition</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 606,&#160;<em>Revenue from Contracts with Customers</em>&#160;(&#8220;ASC 606&#8221;), the Company uses a five-step model for recognizing revenue by applying the following steps: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identification of the Contract: The Company identifies a contract with a customer when it enters into an agreement that creates enforceable rights and obligations.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identification of Performance Obligations: The Company identifies distinct performance obligations within each contract, which represent promises to transfer goods or services to the customer.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Determination of Transaction Price: The Company determines the transaction price, which represents the amount of consideration to which it expects to be entitled in exchange for transferring promised goods or services to the customer, excluding any amounts collected on behalf of third parties.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Allocation of Transaction Price: The Company allocates the transaction price to each distinct performance obligation based on its standalone selling price. If the standalone selling price is not observable, the Company estimates it using an appropriate method.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Recognition of Revenue: Revenue is recognized when (or as) the Company satisfies a performance obligation by transferring a promised good or service to the customer. This typically occurs at a point in time or over time, depending on the nature of the performance obligation.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Wholesale revenue and sales of own branded nutraceutical and pharmaceutical products</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has contracts or signed partnership forms (usual in the wholesale sector of the pharma industry) with its customers, stipulating the enforceable rights and obligations. The Company is responsible for transferring the goods to the customer&#8217;s location, which represents its sole performance obligation. Thus, the transaction price, which is predetermined in most of the products sold, is exclusively allocated to this performance obligation. Revenue is recognized at a single point in time, which is upon issuance of the corresponding sales invoice. The Company has assessed the impact of the items invoiced but not delivered to the customer&#8217;s location as of March 31, 2025 and December 31, 2024 and deemed that it had no material effect. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Pharma manufacturing</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has active contracts with its customers, stipulating the enforceable rights and obligations. The Company is responsible for the manufacturing and the packaging of specific products assigned by its customers, which represents its performance obligations to which the Company allocates the transaction price determined. The customers are responsible for providing the raw materials to the Company. Revenue is recognized over a period of time, which is during the production and packaging period of the respective products. As of March 31, 2025 and 2024&#160;&#160;there were no products or batches of products for which the production or packaging phase was in progress. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Medihelm SA </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective January 1, 2023, and pursuant to the distribution agreement with Medihelm SA (&#8220;Medihelm&#8221;), the exclusive distributor of the Company&#8217;s proprietary line of nutraceutical products, the Company determined that the transaction price for sales to Medihelm was variable in nature. In accordance with ASC 606, <em>Revenue from Contracts with Customers</em>, and specifically ASC 606-10-32-5, the Company applied the &#8220;expected value&#8221; method to estimate the transaction price, subject to the constraint on variable consideration. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This approach was necessitated by the existence of significant overdue receivables from Medihelm, which raised substantial doubt regarding full collectability of the contractual amounts. The Company reassessed the estimate of the transaction price at each reporting date, considering changes in facts and circumstances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There was no impact on revenue recognition for the three-month period ended March 31, 2025 and no further adjustments to variable consideration were necessary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stock-based Compensation</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (&#8220;ASC 718&#8221;) and Staff Accounting Bulletin No. 107 (&#8220;SAB 107&#8221;) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, &#8220;Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.&#8221;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Income Taxes</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 25% in the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At March 31, 2025, we believe our United Kingdom and Greece deferred tax assets will not be realized, as such, we did not record a reversal on the full valuation approach we followed during the year ended December 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Leases</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for leases in accordance with ASC 842. For all leases, the Company recognizes a right-of-use (ROU) asset and a lease liability on the balance sheet. The ROU asset represents the Company's right to use the underlying asset for the lease term, and the lease liability represents the obligation to make lease payments arising from the lease, both measured at the present value of future lease payments. Lease payments are recognized as an operating expense on a straight-line basis over the lease term. The interest on the lease liability and the amortization of the ROU asset are recognized separately in the income statement. Initial direct costs incurred by the Company in negotiating and securing leases are capitalized and amortized over the lease term on a straight-line basis. The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company&#8217;s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company&#8217;s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt on the date of inception.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Retirement and Termination Benefits</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee&#8217;s work experience and remuneration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of March 31, 2025 and December 31, 2024, was $398,838 and $377,264, respectively, and has been recorded as a long-term liability within the consolidated balance sheets (&#8220;Other liabilities&#8221;). The Company engaged an actuarial expert for the first time, during the period ended December 31, 2023. Management did not engage an actuarial expert since then, since there were no circumstances indicating that there would be a significant change to the liability recorded and thus the movement compared to 2023, solely relates to the foreign exchange effect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basic and Diluted Net Loss per Common Share</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic income per share is calculated by dividing the income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average number of common shares outstanding Basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,037,608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,851,747</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Potentially dilutive common stock equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average number of common and equivalent shares outstanding &#8211; Diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,037,608</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,851,747</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes potential common shares that were excluded as their effect is anti-dilutive:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,558,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,558,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recent Accounting Pronouncements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no new material accounting standards issued in the first fiscal quarter of 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OrganizationAndNatureOfTheBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OrganizationAndNatureOfTheBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY METHOD INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>EQUITY METHOD INVESTMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">EQUITY METHOD INVESTMENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 3 &#8211; EQUITY METHOD INVESTMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>CosmoFarmacy LP</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a&#160;30-year term through May 31, 2049. The unaffiliated third party is the general partner (the &#8220;GP&#8221;) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR&#160;150,000&#160;($163,080) which was later increased to EUR&#160;500,000&#160;($543,600). The GP contributed the pharmacy license (the &#8220;License&#8221;) valued at EUR&#160;350,000&#160;(30-year term) to operate the business of CosmoFarmacy in exchange for a&#160;70% equity ownership. The Company is a limited partner and contributed cash of EUR&#160;150,000&#160;($163,080) for the remaining&#160;30% equity ownership. CosmoFarmacy is not publicly traded, and the Company&#8217;s investment has been recorded using the equity method of accounting. &#160;During the 12-month period ended December 31, 2024, the Company determined that its investment in CosmoFarmacy LP was fully impaired. As the entity is currently dormant and has not published or provided any financial statements, whether audited or unaudited, to substantiate the carrying value of the investment, management concluded that there was no reasonable expectation of recovery. Accordingly, the Company recognized a full impairment loss on the investment, writing off its entire carrying amount. As a result, the Company has determined that the investment no longer holds any recoverable value. The value of the investment as of March 31, 2025 and December 31, 2024, was $0.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 4 &#8211; PROPERTY AND EQUIPMENT, NET </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and equipment, net consists of the following at March 31, 2025 and December 31, 2024:&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Land</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,465,629</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,322,780</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Buildings and improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,713,642</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,526,432</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,552</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,405</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vehicles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,896</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">265,261</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture, fixtures and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,973,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,846,657</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,434,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,964,535</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,418,032 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,275,030 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,016,068</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,689,505</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE&#160;5 &#8211; INTANGIBLE ASSETS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Goodwill and intangible, net assets consist of the following at March 31, 2025 and December 31, 2024: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">License</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,585,857</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,257,938</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Trade name / mark</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">392,197</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">390,188</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer base</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">626,397</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">626,397</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,053,554</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,113,840</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,658,005</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,388,363</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated amortization &amp; impairment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">License</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,311,124 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,117,341 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Trade name / mark</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,997 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,997 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer base</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(189,526 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(174,279 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(367,526 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(352,909 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Subtotal</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,752,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,706,837</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Goodwill</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">49,697</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">49,697</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,802,529</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,756,534</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At March 31, 2025, the estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal years is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">881,066</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">877,344</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">879,895</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">878,532</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">871,974</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,008,821</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,397,632</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOAN RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LoanReceivableabstract', window );"><strong>LOAN RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">LOAN RECEIVABLE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 6 &#8211; LOAN RECEIVABLE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 30, 2021, the Company entered into an agreement for a ten-year loan with Medihelm SA to memorialize &#8364;4,284,521 ($4,849,221) in prepayments the Company had made. The prepayments to Medihelm SA had been made in accordance with the parallel export business, through which Medihelm supplied and would supply SkyPharm SA with branded pharmaceuticals. This business is no longer in place for the Company and thus the Company entered into this agreement with Medihelm SA in order for the outstanding amount to be settled. Interest is calculated at a rate of 5.5% per annum on a 360-day basis. Under the terms of the agreement, the Company is to receive 120 equal payments over the term of the loan. During the three-month period ended March 31, 2025, the Company accrued interest income of &#8364;43,179 ($45,472) in connection with the note receivable governed by this agreement. No principal or interest payments were received during the period. The Note is considered fully recoverable as of March 31, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_LoanReceivableabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_LoanReceivableabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_IncomeTaxAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 7 &#8211; INCOME TAXES </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company had no U.S. taxable income for the three months ended March 31, 2025, and 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s Greek subsidiaries are governed by the income tax laws of Greece. The corporate tax rate in Greece is 22% on income reported in the statutory financial statements after appropriate tax adjustments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s United Kingdom subsidiaries are governed by the income tax laws of the United Kingdom. The corporate tax rate in the United Kingdom is 25% on income reported in the statutory financial statements after appropriate tax adjustments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, and 2024, the Company&#8217;s effective tax rate differs from the U.S. federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in in the United States and the United Kingdom. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. As of March 31, 2025, and December 31, 2024, the Company has maintained a valuation allowance against all net deferred tax assets in the United States, Greece, and the UK.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended March 31, 2025, and 2024, the Company has not recorded any tax benefits/expenses in any jurisdiction where it is subject to income tax.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_IncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_IncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STRUCTURE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>CAPITAL STRUCTURE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CapitalStructureTextBlock', window );">CAPITAL STRUCTURE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE&#160;8 &#8211; CAPITAL STRUCTURE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Preferred Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is authorized to issue 100 million shares of preferred stock, of which 6,000,000 are designated as Series A convertible preferred stock. The preferred stock has a&#160;liquidation preference over the common stock and&#160;is non-voting. As of March 31, 2025 and December 31, 2024, no preferred shares were issued and outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Treasury stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 and December 31, 2024, the Company held 86,497 and 86,497, respectively, shares of our common stock at a cost of $917,159 and $917,159, respectively. Shares of our common stock that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. The Company repurchased no shares of our common stock during the three months ended March 31, 2025. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 24, 2023 the Company announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $3 million of its common stock. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is authorized to issue 300 million shares of common stock. As of March 31, 2025 and December 31, 2024, the Company had 27,284,633 and 23,689,135 shares of our common stock issued, respectively, and 27,198,136 and 23,602,638 shares outstanding, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Issuance of Common Stock</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Between January 13, 2025, and March 4, 2025, the Company issued an aggregate of 1,053,372 shares of common stock to Mr. Grigorios Siokas, the Company&#8217;s Chief Executive Officer, in settlement of outstanding obligations totalling $649,000. The liabilities settled pertained to unpaid salaries and performance-related bonuses previously accrued by the Company and owed to Mr. Siokas. The shares were issued at the respective fair market value of the Company&#8217;s common stock on the dates of issuance. The transaction was accounted for as a non-cash settlement of related party debt.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 26, 2024, the Company had entered into a Warrant Inducement Letter (the &#8220;Letter&#8221;) with an investor pursuant to which the Company issued 9,748,252 new warrants (the &#8220;New Warrants&#8221;) and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977 (the &#8220;Original Warrants&#8221;). Of the 9,748,252 warrants 4,874,126 of them have a term of 5 years (&#8220;Series A Warrants&#8221;) and the remaining 4,874,126 have a term of 1.5 years (&#8220;Series B Warrants&#8221;). The Company issued 2,332,000 shares of common stock, held 2,542,126 shares in escrow until the investor&#8217;s beneficial ownership limitation allows for the transfer of the escrow shares. The 2,542,126 shares were issued on January 28, 2025, but were already valued in the year ended December 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Warrant Classification</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company determines the classification of its warrants upon issuance by identifying the instrument issued to determine if it is debt or equity classified. The Company determined its warrants meet the scope exception in ASC 815-10 and are equity classified because, (a) the warrant is indexed to the Company&#8217;s own stock, (b) require settlement in equity shares, and (c) the Company has enough authorized and unissued shares.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CapitalStructureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CapitalStructureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 9 &#8211; RELATED PARTY TRANSACTIONS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Doc Pharma S.A.</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Doc Pharma S.A. is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the son of Grigorios Siokas, the Company&#8217;s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Prepaid expenses and other current assets &#8211; related party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 and December 31, 2024, the Company had a prepaid balance of $3,549,574 and $3,284,052, respectively, to Doc Pharma. For the year ended March 31, 2025 the prepayment of approximately $2.9 million relates to purchases of inventory pursuant to the CMO agreement signed between the Company and Doc Pharma SA on October 10, 2020, $310k concern the purchase of pharmaceutical and nutraceutical licenses according to the May 17, 2021 R&amp;D agreement and the remaining $378k relate to the current portion of the Royalty Agreement signed on December 31, 2024 between the and DocPharma SA (refer to &#8220;Research and Development&#8221; section of the MD&amp;A). The non-current portion of the Royalty Agreement of $1,889,300 is included in &#8220;Other Assets &#8211; Related Party&#8221; in the Company&#8217;s Consolidated Balance Sheets as of March 31, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accounts payable and accrued expenses - related party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 and December 31, 2024, the Company had an accounts payable balance to Doc Pharma of $345,702&#160;and $249,768, respectively. The March 31, 2025 balance mostly concerns a checks payable balance that our subsidiary, Skypharm SA, owes to Doc Pharma SA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accounts receivable - related party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, the Company had a receivable balance of $2,469,234&#160;and $2,295,706&#160;from Doc Pharma S.A. as of March 31, 2025 and December 31, 2024, respectively, which concerns trading receivables balances with the Company&#8217;s Greek and UK subsidiaries. As of March 31, 2025, a cumulative allowance for doubtful accounts of approximately $1.4 million has been recognized, effectively offsetting this balance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Sales and Purchases</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended March 31, 2025 and 2024, the Company purchased a total of $300,208 and $189,048&#160;of products from Doc Pharma S.A., respectively. During the three months ended March 31, 2025, and 2024, the Company sold&#160; $130,362 and $384,321&#160;of products to Doc Pharma, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Other Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 10, 2020, the Company entered into a contract manufacturer outsourcing (&#8220;CMO&#8221;) agreement with Doc Pharma whereby Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company&#8217;s specifications based on strict pharmaceutical standards and good manufacturing practice (&#8220;GMP&#8221;) protocols as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named &#8220;Sky Premium Life<sup style="vertical-align:super">&#174;</sup>&#8221;. The duration of the agreement is for five years, however, either party may terminate the agreement at any time giving six-month advance notice. Doc Pharma is exclusively responsible for supplying the raw materials and packaging required to manufacture the final product. However, it is not responsible for potential delays that may arise, concerning their import. Doc Pharma is also obligated to store the raw and packaging materials. The delivery of raw and packaging materials should be purchased at least 30 and 25 days, respectively, before the delivery date of the final product. The Manufacturer solely delivers the finished product to the Company. There is a minimum order quantity (&#8220;MoQ&#8221;) of&#160;1,000 pieces&#160;per product code. Both parties have agreed that the Company will deposit 60% of the total cost upon agreement and assignment and 40% of the total cost including VAT charge upon the delivery date. The prices are indicative and are subject to amendments if the cost of the raw material or the production cost change.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended March 31, 2025 and 2024, the Company has purchased &#8364;208,568 ($219,645) and &#8364;65,161 ($68,621) respectively, in inventory related to this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 17, 2021, Doc Pharma and the Company entered into a Research and Development (&#8220;R&amp;D&#8221;) agreement whereby Doc Pharma will be responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life<sup style="vertical-align:super">&#174;</sup>. These products will be sold in Greece and abroad.&#160;The total cost of this project will be &#8364;1,425,000 plus VAT and will be done over three phases as follows: Design &amp; Development (&#8364;725,000); Control and Product Manufacturing (&#8364;250,000) and Clinical Study and Research (&#8364;450,000). SkyPharm has bought a total of as of 81 licenses at value of &#8364;554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022. During the year ended December 31, 2023, 24 additional licenses were purchased at value of &#8364;475,014 ($525,461) and during the year ended December 31, 2024, 60 additional Sky Premium Life licenses were purchased for &#8364;710,000 ($734,921). During the three months ended March 31, 2025, no additional licenses were purchased. The agreement will terminate on&#160;December 31, 2025.&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Purchase of branded pharmaceuticals</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2023, the Company approved the purchase of five proprietary and innovative branded pharmaceuticals with significant market presence and material profit contribution from Zakalia Ltd., the parent company of Doc Pharma, for &#8364;1,800,000 ($1,965,600). The transaction was settled on a non-cash basis through the reduction, of an equivalent amount, of prepaid expense balances the Company held with Doc Pharma. The purchased branded pharmaceuticals are presented in &#8220;Goodwill and intangible assets, net&#8221; on the accompanying consolidated balance sheets. During the year ended December 31, 2024, the Company recognized an impairment charge of $160,947 related to two licenses that are no longer expected to be commercialized. The impairment was recorded after management&#8217;s assessment determined that the recoverability of these assets was no longer supportable due to changes in market conditions and strategic priorities. No additional impairment charge was recorded within the three-month period ended March 31, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 29, 2023, the Company approved the purchase of additional 19 generic licenses from Doc Pharma, of a total value of &#8364;3,200,000 ($3,539,840). This transaction was also settled on a non-cash basis through the reduction, of an equivalent amount, of prepaid expense balances the Company held with Doc Pharma.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Loans receivable - related party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The balance of prepaid expenses due Doc Pharma as of December 31, 2022, had increased to &#8364;7,103,706 ($7,599,545), which was mainly attributable to the prepayments SkyPharm S.A. made in accordance with the CMO agreement and the extensive orders and sales of the SPL products the Company expected to achieve within 2023, mainly through its Amazon channels in the UK, Singapore, Canada and other countries. However, as the benefit from a significant portion of the prepaid balance would not have been realized within a 12-month period, the Company opted to secure a portion of the outstanding prepaid balance through a loan agreement. SkyPharm S.A. (the &#8220;Lender&#8221;) entered into a loan agreement with Doc Pharma (the &#8220;Borrower&#8221;) for &#8364;4,000,000 ($4,279,200), all of which was financed through the outstanding prepaid balance. The duration of the loan is for a&#160;10-year period up to&#160;December 31, 2032&#160;(the &#8220;Maturity Date&#8221;). The loan bears a fixed interest rate of&#160;5.5% payable on a monthly basis and will be repayable in 120 equal instalments of &#8364;33,333.33 ($37,150). The loan may be prepaid anytime during its duration in full or partially based on the Company&#8217;s product requirements and other factors, without Doc Pharma incurring any prepayment penalty. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 and December 31, 2024, the loan had a current portion of &#8364;712,200 ($768,891) and &#8364;500,000 ($517,550), and a non-current portion of &#8364;2,663,379 ($2,875,384), and &#8364;2,800,000 ($2,898,280), respectively, which is classified as &#8220;Loans receivable &#8211; related party&#8221; on the accompanying consolidated balance sheets. During the three-month period ended March 31, 2025, the Company received no principal repayments or interest repayments. Additionally, during the three months ended ended March 31, 2025 and 2024, the Company recorded &#8364;43,179 ($45,472) and &#8364;49,041 ($53,235) as interest income relating to this loan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Cana Laboratories Holding Limited&#160;</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cana was considered a related party as the Company had signed a binding letter of intent and an SPA for the acquisition of Cana. The acquisition was completed on June 30, 2023 according to the SPA signed on May 31, 2023. Thus, all balances between the Company and Cana were eliminated upon consolidation as of December 31, 2023. The Secured Promissory Note discussed below was included in consideration transferred upon acquisition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Loans receivable - Related Party - Long Term</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 28,<sup style="vertical-align:super">&#160;</sup>2023 (Issue Date), the Company signed a Secured Promissory Note with Cana Laboratories Holdings (Cyprus) Limited (the &#8220;Holder&#8221;), whereby the Holder borrowed the sum of &#8364;4,100,000 ($4,457,520) from the Company.&#160;Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023). The maturity date (&#8220;Maturity Date&#8221;) of this Note shall be five (5) years from the Issue Date. The Principal Amount, as well as all accrued interest shall be due and payable on the Maturity Date. Following the completion of Cana&#8217;s acquisition on June 30, 2023 the balance of the Note was eliminated on a consolidated level.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Panagiotis Kozaris</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Panagiotis Kozaris is considered a related party due to the fact that he is a former General operational manager and current employee of Cosmofarm S.A.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Prepaid Expenses and Other Current Assets - Related Party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time-to-time the Company purchases back shares that Panagiotis Kozaris owns and records them as treasury shares. The Company pays Panagiotis Kozaris in advance for the shares owned and obtains the shares upon execution of a cumulative stock-purchase agreement (&#8220;SPA&#8221;). During the years ended December 31, 2023 and 2022, the Company paid Panagiotis Kozaris an additional sum of $51,159&#160;and $143,056&#160;respectively for shares owned, however, no SPA for these funds has been executed as of December 31, 2024. The Company intends to execute a cumulative SPA for these amounts within 2025. The total balances owed of $194,215&#160;and $194,215 are included in &#8220;Prepaid expenses and other current assets - related party&#8221;, on the accompanying consolidated balance sheets as of March 31, 2025 and December 31, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Basotho Investment Limited</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basotho Investment Limited is considered a related party once Panagiotis Kozaris (former general operational manager and current employee of Cosmofarm SA) is one of its directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>General and administrative expenses</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 21, 2023, the Company issued 120,000 shares of common stock to Basotho Investment Limited for services rendered. The amortization of the fair value of these shares for the three-month period ended March 31, 2025 and 2024 was $0 and $30,900, which was recorded as general and administrative expense. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Maria Kozari</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Maria Kozari is considered a related party to the Company due to the fact that she is the daughter of Panagiotis Kozaris, a former Operational General Manager and current employee of Cosmofarm S.A.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accounts Receivable - Related Party</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During 2021, the Company, through its subsidiary, Cosmofarm SA, commenced a partnership with a pharmacy called &#8220;Pharmacy &amp; More&#8221;, owned by Maria Kozari. The transactions with the respective pharmacy were in Cosmofarm&#8217;s normal course of business, however, a more flexible credit policy was allowed as the pharmacy was new and needed to be established in the market. During the three-month peirod ended March 31, 2025 and 2024 the Company&#8217;s net sales to Pharmacy &amp; More amounted to $100,870&#160;and $86,678, respectively. As of March 31, 2025 and December 31, 2024 the Company&#8217;s outstanding receivable balance due from the pharmacy amounted to $1,188,908 and $1,183,429, respectively, and are included in &#8220;Accounts receivable - related party&#8221;, on the accompanying consolidated balance sheets. As of March 31, 2025 and December 31, 2024, a cumulative allowance for doubtful accounts of approximately $773,051 and $735,000, respectively, has been recognized, effectively offsetting this balance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company plans to acquire Pharmacy &amp; More within fiscal year 2025. Upon acquisition, the Company intends to offset the outstanding receivable balance with the corresponding purchase price and additionally plans to make Pharmacy &amp; More the&#160;first shop-in-shop of its own branded line of nutraceutical products, Sky Premium Life&#174; (SPL).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Other Related Parties</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, the Company has the following material related-party balances as of March 31, 2025: a) a balance of $76,865 relating to unpaid salaries and bonuses due to Grigorios Siokas, the CEO of the Company, classified as &#8220;Accounts payable and accrued expenses - related party&#8221;&#160;in the Company&#8217;s consolidated balance sheets, b) a balance of $168,000&#160;relating to unpaid salaries and bonuses due to George Terzis, the CFO of the Company, classified as &#8220;Accounts payable and accrued expenses - related party&#8221;&#160;in the Company&#8217;s consolidated balance sheets c) a balance of $15,000&#160;relating to unpaid salaries and bonuses due to Nikolaos Bardakis, the COO of the Company, classified as &#8220;Accounts payable and accrued expenses - related party&#8221;&#160;in the Company&#8217;s consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Notes Payable &#8211; Related Party</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s related party notes payable as of March 31, 2025 and December 31, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Beginning Balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,558</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,283</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Payments </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(725</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ending Balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,012</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,558</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Dimitrios Goulielmos</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dimitris Goulielmos was the Company&#8217;s former CEO and a Director of the Company. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of March 31, 2025 and December 31, 2024, the Company had a principal balance of &#8364;10,200 ($11,012) and &#8364;10,200 ($10,558), respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2025, the Company recorded a foreign currency translation loss of $454.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Loans Payable &#8211; Related Party</span></em><span style="text-decoration:underline"> </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s related party loans payable as of March 31, 2025 and December 31, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,194</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,257</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(108,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,210 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Set-offs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,039</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">267</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(853 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,194</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Grigorios Siokas</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of March 31, 2025 and December 31, 2024 the Company had an outstanding principal balance under these loans of $0 and $6,194, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2025, the Company recorded a loss of $267.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LINES OF CREDIT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>LINES OF CREDIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LineOfCreditFacilitiesDisclosureTextBlock', window );">LINES OF CREDIT</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 10 &#8211; LINES OF CREDIT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s lines of credit as of March 31, 2025 and December 31, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">National</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">3,816,515</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">4,012,642</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Alpha</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">769,867</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">960,867</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pancreta</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,437,670</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,583,291</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Attica Bank</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">849,483</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">EFG</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">431,840</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">428,252</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">7,305,376</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">6,985,052</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has three lines of credit with the National Bank of Greece, which are renewed annually. The three lines have interest rates of 6.00% (the "National Bank LOC"), 3.6% (the "COSME 2 Facility"), and 3.6% plus the six-month Euribor rate and any contributions currently in force by law on certain lines of credit (the "COSME 1 Facility").</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The maximum borrowing allowed for the 6% line of credit was $5,398,000 and $5,175,000 as of March 31, 2025 and December 31, 2024, respectively. The outstanding balance of the facility was $2,975,052 and $3,165,058, as of March 31, 2025 and December 31, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The cumulative maximum borrowing allowed for the COSME 1 Facility and COSME 2 Facility (collectively, the "Facilities") was $1,079,600 and $1,035,100 as of March 31, 2025 and December 31, 2024, respectively. The outstanding balance of the Facilities was $895,406 and $895,987 as of March 31, 2025 and December 31, 2024, respectively.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains a line of credit with Alpha Bank of Greece ("Alpha LOC"), which is renewed annually and has a current interest rate of 6.00%. The maximum borrowing allowed was $1,079,600 and $1,035,100 as of March 31, 2025 and December 31, 2024, respectively. The outstanding balance of the Alpha LOC was $769,868 and $960,868, as of March 31, 2025 and December 31, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company holds a line of credit with Pancreta Bank ("Pancreta LOC"), which is renewed annually and has a current interest rate of 4.10%. The maximum borrowing allowed as of March 31, 2025 and December 31, 2024 was $1,619,400 and $1,552,650, respectively. The outstanding balance of the Pancreta LOC as of March 31, 2025 and December 31, 2024, was $1,437,670 and $1,583,291, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains a line of credit with EGF ("EGF LOC"), which is renewed annually and has a current interest rate of 4.49% plus 3-month Euribor. The maximum borrowing allowed as of March 31, 2025 and December 31, 2024, was $431,840 and $414,040, respectively. The outstanding balance of the EGF LOC as of March 31, 2025 and December 31, 2024 was $431,840 and $428,251, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 27, 2025, the Company entered into a bond loan agreement with Attica Bank, providing for maximum borrowings of up to &#8364;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#8364;700,000 ($749,600), which were classified as Notes Payable in the Company&#8217;s consolidated financial statements. The remaining borrowing capacity of &#8364;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral. These subsequent drawdowns are classified as Lines of Credit due to their secured and contingent nature. The facility bears interest at a floating rate of 2.95% plus the applicable 6-month Euribor, recalculated periodically in accordance with market conditions. The loan agreement includes standard covenants and collateral arrangements customary for this type of facility.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the aforementioned line of credit agreements, the Company is required to maintain certain financial ratios and covenants. As of March 31, 2025, and December 31, 2024, the Company was in compliance with these ratios and covenants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All lines of credit are guaranteed by customer receivable checks, which are a type of factoring in which postponed customer checks are assigned by the Company to the bank, in order to be financed at an agreed upon rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Interest expense on the Company&#8217;s outstanding lines of credit balances for the three months ended March 31, 2025 and 2024, was $61,035 and $44,568, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_LineOfCreditFacilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_LineOfCreditFacilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>NOTES PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 11 &#8211; NOTES PAYABLE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s third-party debt as of and for the nine&#160;months ended March 31, 2025, and the year ended December 31, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>March 31, 2025</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trade </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Facility </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Third </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Party</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COVID </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Loans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance, December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,397,385</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,557,023</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,505</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,108,913</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">755,720</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">755,720</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(183,455 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,060 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(188,515 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">60,075</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">110,051</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,019</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">176,145</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance, March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,457,460</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,239,339</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">155,464</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,852,263</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - long-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,968,180 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(120,360 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,088,540 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - short-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,457,460</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,271,159</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">35,104</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,763,723</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trade </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Facility </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Third </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Party</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COVID </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Loans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance, December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,908,195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,511,148</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">186,884</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,606,227</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">828,080</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">828,080</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(388,163 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(634,653 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(22,806 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,045,622 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(122,647 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(147,552 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,573 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(279,772 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance, December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,397,385</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,557,023</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">154,505</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,108,913</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable &#8211; long-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,437,798 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(122,635 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,560,433 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - short-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,397,385</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,119,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,870</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,548,480</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="5" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Our outstanding debt as of March 31, 2025&#160;is repayable as follows:</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,763,723</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">819,335</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">666,070</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">378,706</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030 and thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">224,429</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total debt</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>4,852,263</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: notes payable - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,763,723 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,088,540</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Trade Facility Agreements</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the &#8220;TFF&#8221;) with Synthesis Structured Commodity Trade Finance Limited (the &#8220;Lender&#8221;) as amended on November 16, 2017, and May 16, 2018. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No principal repayments were made during the three-month period ended March 31, 2025. As of March 31, 2025, the Company had an outstanding principal balance of &#8364;1,350,000 ($1,457,460), which is fully classified as &#8220;Notes Payable&#8221; in the Company&#8217;s consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">June 23, 2020 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 23, 2020, the Company&#8217;s subsidiary, Cosmofarm, entered into an agreement with the National Bank of Greece S.A. (the &#8220;Bank&#8221;) to borrow a maximum of &#8364;500,000 ($611,500).&#160; The outstanding balance was &#8364;58,824 ($63,506) and &#8364;88,235 ($91,232) as of March 31, 2025 and December 31, 2024, respectively, of which $63,506 and $91,232 was classified as&#160;&#8220;Notes payable &#8211; long-term portion&#8221;&#160;respectively,&#160;on the&#160;accompanying consolidated balance sheets. During the three-month period ended March 31, 2025, the Company repaid &#8364;29,412 ($31,753) of the principal balance.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">November 19, 2020 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of &#8364;500,000 ($611,500). During the three-month period ended March 31, 2025 the Company repaid &#8364;27,778 ($29,999) of the principal and as of March 31, 2025 the Company has accrued interest of &#8364;4,372 ($4,720) related to this note and a principal balance of &#8364;83,333 ($89,967), all of which is classified as &#8220;Notes payable&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">July 30, 2021 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of &#8364;500,000 ($578,850). During the three-month period ended March 31, 2025, the Company repaid &#8364;28,434 ($30,697) of the principal. As of March 31, 2025 the Company had accrued interest of &#8364;16,677 ($18,004), principal of &#8364;177,909 ($192,071), of which $66,896 is classified as &#8220;Notes payable &#8211; long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">June 9, 2022 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 9, 2022 the Company entered into an agreement with a third-party lender in the principal amount of &#8364;320,000 ($335,008), the &#8220;Note&#8221;. During the three-month period ended March 31, 2025 the Company repaid &#8364;20,000 ($21,592) of the principal. As of March 31, 2025 and December 31, 2024 the Company has accrued interest of &#8364;4,337 ($4,682) and &#8364;8,352 ($8,645), respectively, and an outstanding balance of &#8364;160,000 ($172,736) and &#8364;180,000 ($186,318), respectively, of which $86,368 and $103,510, are classified as &#8220;Notes payable &#8211; long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">July 14, 2023 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 14, 2023, the Company entered into an agreement with a third-party lender in the principal amount of &#8364;1,000,000 ($1,123,700), the &#8220;Note&#8221;. During the three-month period ended March 31, 2025 the Company repaid &#8364;54,317 ($58,640) of the principal. As of March 31, 2025 and December 31, 2024 the Company has accrued interest of &#8364;3,403 ($3,674) and &#8364;16,735 ($17,322), respectively, and an outstanding balance of &#8364;760,433 ($820,964) and &#8364;814,750 ($843,348), of which $586,571 and $618,616, respectively, are classified as &#8220;Notes payable &#8211; long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Cloudscreen Promissory Note</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. During the three-month period ended March 31, 2025 the Company repaid $10,782 of the principal. As of March 31, 2025, and December 31, 2024, the Company had an outstanding balance of $280,696 and $279,348 all of which is classified as &#8220;Notes payable&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">July 29, 2024 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 29, 2024 the Company entered into an agreement with a third-party lender in the principal amount of &#8364;400,000 ($432,760), the &#8220;Note&#8221;. During the 3-month period ended March 31, 2025, the Company repaid no principal. As of March 31, 2025, and December 31, 2024 the Company has accrued interest of &#8364;1,358 ($1,466) and &#8364;1,527 ($1,581), respectively, and an outstanding balance of &#8364;400,000 ($431,840) and &#8364;400,000 ($414,040), of which $335,876 and $345,033 is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">December 20, 2024 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 20, 2024 the Company entered into an agreement with a third-party lender in the principal amount of &#8364;400,000 ($414,040), the &#8220;Note&#8221;. During the 3-month period ended March 31, 2025, the Company repaid no principal. As of March 31, 2025, and December 31, 2024 the Company has accrued interest of &#8364;6,509 ($7,027) and &#8364;794 ($821), respectively, and an outstanding balance of &#8364;400,000 ($431,840) and &#8364;400,000 ($414,040), of which $287,893 and $276,027 is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">January 27, 2025 Debt Agreement</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 27, 2025, the Company entered into a bond loan agreement with Attica Bank, providing for maximum borrowings of up to &#8364;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#8364;700,000 ($749,600), which were classified as Notes Payable in the Company&#8217;s consolidated financial statements. The remaining borrowing capacity of &#8364;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral. These subsequent drawdowns are classified as Lines of Credit due to their secured and contingent nature. The facility bears interest at a floating rate of 2.95% plus the applicable 6-month Euribor (2.331% as of March 31, 2025). The Note Payable portion of the facility is to be repaid in 10 equal semiannual installments of &#8364;70,000 commencing on July 27, 2026. During the 3-month period ended March 31, 2025, the Company repaid no principal. As of March 31, 2025, and December 31, 2024 the Company has accrued interest of &#8364;3,488 ($3,766) and &#8364;0 ($0), respectively, and an outstanding balance of &#8364;700,000 ($755,720) and &#8364;0 ($0), of which $604,576 and $0 is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">COVID-19 Loans</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 12, 2020, the Company&#8217;s wholly owned subsidiary, SkyPharm SA, was granted a loan from the Greek government in the amount of &#8364;300,000 (approximately $366,900). During the three-month period ended March 31, 2025, an additional principal repayment of &#8364;4,688 (approximately $5,061) was made. As of March 31, 2025, and December 31, 2024 the Company has an outstanding balance of &#8364;98,438 ($106,273) and &#8364;103,125 ($106,745), of which $86,031 and $87,337 is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 24, 2020, the Company&#8217;s subsidiary, Decahedron, received a loan &#163;50,000 ($68,310) from the&#160;UK government. As of March 31, 2025, and December 31, 2024 the Company has an outstanding balance of &#163; 38,144 ($49,191) and &#163; 38,144 ($47,761), of which $34,329 and $35,299 is classified as &#8220;Notes payable - long term portion&#8221; on the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None of the above loans were made by any related parties.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 12 &#8211; LEASES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has various operating and finance lease agreements with terms up to 10 years, for various types of property and equipment (such as office space and vehicles) etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Operating Leases</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s weighted-average remaining lease term relating to its operating leases is 3.71 years, with a weighted-average discount rate of 6.74%.<span style="text-decoration:underline"> </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s operating leases as of March 31, 2025:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Maturity of Operating Lease Liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">181,753</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218,637</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">156,745</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2029 and thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">202,251</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total undiscounted operating lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">759,386</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Less: Imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(88,876 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Present value of operating lease liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">670,510</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company incurred lease expense, due to amortization of operating lease right-of-use assets, of&#160;$60,668 and $77,167, which was included in &#8220;General and administrative expenses,&#8221; for the&#160;three ended March 31, 2025 and 2024, respectively.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Finance Leases </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s weighted-average remaining lease term relating to its finance leases is 1.07 years, with a weighted-average discount rate of 6.74%. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s finance leases as of March 31, 2025:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Maturity of Lease Liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,357</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total undiscounted finance lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,357</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Less: Imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(373 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Present value of finance lease liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,164</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company had financing cash flows used in finances leases of $5,533 and $8,737 for the three ended March 31, 2025 and 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company incurred interest expense on its finance leases of $195 and $725 which was included in &#8220;Interest expense&#8221;, for the three months ended March 31, 2025 and 2024, respectively. The Company incurred amortization expense on its finance leases of $4,603 and $7,489 which was included in &#8220;Depreciation and amortization expense,&#8221; for the three months ended March 31, 2025 and 2024, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/840/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>OTHER LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER LIABILITIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 13 &#8211; OTHER LIABILITIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025 the Company&#8217;s other liabilities primarily consist of obligations to local tax authorities, payroll taxes, fines, and other miscellaneous liabilities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The significant components of other liabilities are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s Greek subsidiaries have $2,819,815 and $2,552,488 in settled tax liabilities as March 31, 2025 and December 31, 2024, respectively, which are payable in installments to the tax authorities.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Payroll and other tax-related current liabilities amount to $1,350,825 and $1,191,315 as of March 31, 2025 and December 31, 2024, respectively, and represent obligations due to tax authorities within the next 12 months.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A provision of $624,588 has been recorded for potential tax liabilities related to the unaudited tax years of SkyPharm S.A., in accordance with ASC 450-20, as the Company has assessed that a loss is probable and reasonably estimable.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A provision of $398,838 has been recognized for staff leaving compensation, based on actuarial valuations performed in accordance with ASC 715-30 (Defined Benefit Plans &#8211; Pension).</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Customer prepayments totaling $447,872 and $363,708 as of March 31, 2025 and December 31, 2024, respectively, are included in &#8220;Other Current Liabilities&#8221;, in accordance with ASC 606-10-45-2 (Revenue Recognition &#8211; Contract Liabilities).</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Liabilities that are due within 12 months from the balance sheet date are classified under &#8220;Other Current Liabilities. &#8220;Obligations that extend beyond 12 months are classified as &#8220;Other Non-Current Liabilities.&#8221;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 14 &#8211; COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Legal Matters</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, the Company may be involved in litigation relating to claims arising out of the Company&#8217;s operations in the normal course of business. As of March 31, 2025, the following litigations were pending. None of the below is expected to have a material financial or operational impact. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Tax Audit-Related Fine &#8211; Cosmofarm</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A payment request was issued by the Greek court in relation to a fine arising from a tax audit of Cosmofarm for the financial year 2014. The fine was imposed under Law No. 483/16.12.2020. Cosmofarm appealed the decision under Law No. 11541/09.03.2021; however, the appeal was dismissed 120 days after its submission. The Company settled additional taxes and fines related to this matter in the amount of &#8364;91,652 ($99,644) but has filed a claim to recover the amount through appeal. As of March 31, 2025, the trial remains pending.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Criminal Cases Related to Dishonored Checks</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 25, 2023, a criminal case involving dishonored checks issued by Cosmofarm&#8217;s customer, Filippou, was heard at the Z&#8217; Three-Member Misdemeanor Court of Athens. The case was postponed to November 27, 2023, when the defendant was tried and found guilty.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 23, 2023, a criminal case involving dishonored checks issued by Cosmofarm&#8217;s customer, Kafantaris, was heard at the Sixth Single-Member Misdemeanor Court of Athens. The case was postponed to January 26, 2024, when the defendant was convicted under Decision No. 1599/2024.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Appeal Against Decision 1389/2021 &#8211; Eleutheria Drakopoulou</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 26, 2023, the Company&#8217;s appeal against Eleutheria Drakopoulou and Decision No. 1389/2021 of the Single-Member Court of First Instance of Athens was heard at the Athens Court of Appeal. The appeal was partially accepted. The Court ordered the return of the fee to the appellants, dismissed the action against the third defendant (Kozaris), and accepted the action against the first and second defendants (Kastrantas &amp; Cosmofarm).&#160;The case was settled in two equal installments by Cosmofarm SA, of &#8364;35,000 ($37,880) on July 31, 2024 and of &#8364;35,000 ($37,993) on October 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Pending Lawsuits Against Euaggelismos &amp; Pananikolaou Hospitals</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s subsidiary, Cana Laboratories, has two pending lawsuits against Euaggelismos Hospital for unpaid bills totaling &#8364;526,436. A court date has been scheduled for one of the lawsuits on December 11, 2024, while the other remains unscheduled. The matter is currently pending a court decision. Based on legal counsel&#8217;s assessment, it is considered highly probable that the losing party will appeal the decision once it is rendered. However, counsel has also indicated that the collection of the full amount awarded to the Company is considered highly probable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There is also an unasserted claim against Papanikolaou Hospital, for a total sum of &#8364;89,300 due to unpaid bills, which will be asserted through a lawsuit. Court date is not set yet. The opinion of our legal advisor is that the success of the case and the collection of the aforementioned amount is probable and as of now negotiations are taking place in the direction of out-of-court settlement.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Both claims have been classified under &#8220;Other assets&#8221; within non-current assets in the Company&#8217;s consolidated balance sheets as of March 31, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employment Dispute &#8211; Cana Laboratories</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A lawsuit filed on April 5, 2018, by a former employee against the Company&#8217;s subsidiary, Cana, before the Athens Court of First Instance, sought the nullification of the termination of employment and compensation for unpaid wages and moral damages. Following multiple appeals, Judgment No. 1192/2024 was issued on September 26, 2023, requiring Cana to reinstate the former employee, with a penalty of &#8364;200 per day for non-compliance. According to the Company&#8217;s legal counsel, for the penalty to be enforceable, the former employee must file a new lawsuit requesting reinstatement. As of the date of this report, no such lawsuit or request for reinstatement has been received.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Lease Dispute</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A lawsuit has been filed against the Company&#8217;s subsidiary, Cana, seeking restitution of a leased property, payment of approximately &#8364;13,190 in outstanding rent, and &#8364;8,488 in compensation for use of the property. The Company has settled the monetary claims in full, rendering that portion of the case moot. However, the claim for restitution of the leased property remains pending and is expected to be accepted by the court.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Claims for Recovery of Receivables</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s subsidiary, Cosmofarm SA, is in the process of initiating legal action to recover approximately &#8364;20,301 in unpaid invoices from a certain customer. The hearing is expected to be scheduled in 2026. Based on legal counsel&#8217;s assessment, the claim is anticipated to be upheld. In addition, Cosmofarm SA is preparing to file two further lawsuits for the recovery of &#8364;15,143 and &#8364;15,255, respectively, related to unpaid invoices concerning two customers. Both hearings are expected to be scheduled in 2026, and legal counsel similarly anticipates favorable outcomes in both cases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Advisory Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 21, 2023, the Company entered into certain consulting agreements with four third-party consultants for the provision of a variety of services such as digital marketing, advisory services relating to target acquisitions and M&amp;As and other additional services as described in the respective agreements. The agreements have duration from ten to 18 months and the consultants will solely receive stock consideration for the services rendered. More precisely, they have been awarded a total of 970,000 shares of the Company&#8217;s common stock valued at a total of $999,100 based on the fair value of the Company&#8217;s common stock as of the agreements&#8217; date. On September 17, 2024 the terms of two out of the four aforementioned consulting agreements were extended and the consultants received additional 440,000 shares as complementary compensation for the extended services to be provided. The additional stock based consideration was valued at a total of $501,600 based on the fair value of the Company&#8217;s common stock as of the agreements&#8217; date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 1, 2024 the Company entered into a consulting agreement with a third-party consultant for the provision of a variety of services such as preparation of press releases and other publications, relationship management and other additional services as described in the respective agreement. The agreement has a duration of 16 months and the consultant will solely receive stock consideration for the services rendered. More precisely, they have been awarded a total of 240,000 shares of the Company&#8217;s common stock valued at a total of $264,000 based on the fair value of the Company&#8217;s common stock as of the agreements&#8217; date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The corresponding stock-based compensation expense is accrued evenly over the term of the agreements. For the three-month periods ended March 31, 2025 and 2024 the Company has recorded $245,310 and $231,750, respectively, as stock based compensation for the above agreements, respectively, classified as &#8220;General and administrative expenses&#8221; in the Company&#8217;s consolidated statements of operations and comprehensive Income (loss).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Research and Development Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company entered into a Research &amp; Development agreement with Doc Pharma S.A. on May 17, 2021. Under this agreement, Doc Pharma is responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life&#174;. More specifically, Doc Pharma is responsible for the product development and the Company has added 165 of such products codes in its portfolio as of March 31, 2025. The licenses purchased by Doc Pharma SA are capitalized and included in &#8220;Goodwill and intangible assets, net&#8221; of the Company&#8217;s Consolidated Balance Sheets as of March 31, 2025. Thus, no relevant R&amp;D expense had been charged to the Company&#8217;s Consolidated Statements of Operations and Comprehensive income (Loss), concerning this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 25, 2022, the Company signed a research and development (&#8220;R&amp;D&#8221;) agreement with a third party(CloudPharm PC), through which the Company assigned to the third party the development of new products and services in the field of health, focusing on the human intestinal microbiome. The project includes two phases. Phase 1 has a 20-month duration and its cost amounts to EUR 758,000 ($838,450) and phase 2, has a 22-month duration and a cost of EUR 820,000 ($907,084). The amount will be due and payable upon completion of the corresponding phases. The Company records the corresponding R&amp;D expense based on the project&#8217;s progress, which is invoiced by the third party in the relevant period. For the 3-month periods ended March 31, 2025 and 2024, the Company has not incurred any costs relating to this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 incorporating both cash and stock consideration the platform is included in &#8220;Goodwill and intangible assets, net&#8221; in the Company&#8217;s Consolidated Balance Sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 3, 2024, the Company and the National Hellenic Research Foundation (NHRF) (Contractor) signed a Research Study Agreement. NHRF will conduct an in vitro study to support modifications to an invention, pursuant to the prior agreement involving CloudPharm PC (signed on June 15, 2022). NHRF ensures scientific rigor, provides updates, and maintains confidentiality. Cosmos Health provides necessary support and documentation. Rights to the research protocol belong to CloudPharm PC, NHRF, and Cosmos Health, while NHRF retains control over its methodologies. NHRF cannot publish findings without Cosmos Health&#8217;s approval and cannot use the study for other purposes. The total fee to by paid by the Company amounts to &#8364;60,000 plus VAT, payable in three installments. For the 3-month period ended March 31, 2025, the Company incurred EUR 15,000 ($15,629) concerning this agreement, which were included in &#8220;Research and Development costs&#8221; in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss).&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 6, 2024, the Company signed an Independent Contractor Agreement with a third-party contractor (the &#8220;Contractor&#8221;). The Contractor will provide oncology research and development services exclusively to the Company. The contract lasts three years (December 5, 2024 &#8211; December 5, 2027) and may be extended by mutual agreement. The Company may terminate the contract immediately for specific causes, including felony conviction, fraud, or loss of medical license. Either party may terminate the contract with 30 days' written notice. Certain compensation obligations will remain even after termination. The monthly consideration to be paid to the Contractor is based on the commencement of the Clinical Trials and New Drugs Applications and additional cash and stock consideration is payable based on certain milestones. None of the milestones were met as of March 31, 2025, and thus the Company has incurred no expenses as of the end of the period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 31, 2024, the Company signed an agreement with a related party, DocPharma SA (the &#8220;Licensor&#8221;), through which the Company obtained a royalty-bearing, exclusive worldwide license to actively commercialize the patents owned by the Licensor, through research and preclinical and clinical trials for the useful life of the patents, or for 20 years, whichever is longer. The patents, filed in 2016 and 2017 respectively, cover innovative treatments for cancer.&#160;The terms of the agreement include an initial payment of EUR 500,000 due by the end of 2024, followed by fixed annual payments of EUR 350,000 during the five-year Start-Up Term from 2025 to 2030. After the Start-Up Term, the Company will pay a 1.5% royalty on annual net sales of licensed products covered by an issued patent. Moreover, the Company retains an optional buy-out right for a total amount of EUR 7,500,000, which can be exercised with 60 days' notice and a 60-day close period. The Company also has the right to sublicense the patents. For the 3-month period ended March 31, 2025, the Company incurred no royalties concerning this agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_StockOptionsAndWarrantsAbstract', window );"><strong>STOCK OPTIONS AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_StockOptionsAndWarrantsDisclouserTextBlock', window );">STOCK OPTIONS AND WARRANTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 15&#160;&#8211; STOCK OPTIONS AND WARRANTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Omnibus Equity Incentive Plan</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 19, 2022, the Company held a Board of Directors meeting, whereas, the Board of Directors had elected to adopt an Omnibus Equity Incentive Plan (the &#8220;2022 Plan&#8221;), that includes reserving 200,000 shares of common stock eligible for issuance under the 2022 Plan to be registered on a Form S-8 Registration Statement with the SEC. The 2022 Plan is designed to enable the flexibility to grant equity awards to the Company&#8217;s officers, employees, non-employee directors and consultants and to ensure that it can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. According to the Proxy Statement filed with the SEC on October 20, 2022 the 2022 Plan received final approval by the Company&#8217;s stockholders&#160;at the Annual Meeting of Stockholders held on December 2, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 3, 2023, the Company approved incentive stock awards for the CFO, certain officers and directors and other employees of the Company. The awards are in the form of restricted stock and will vest in two parts: 50% on October 2, 2023 and 50% on October 2, 2024. For the three-month periods ended March 31, 2025 and 2024, the Company recorded share-based compensation expense of $0 and $108,297, respectively, in connection with the &#8220;2022 Plan.&#8221;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 21, 2023, the Board adopted, subject to stockholder approval, the Cosmos Health Inc. 2023 Omnibus Equity Incentive Plan (the &#8220;2023 Plan&#8221;). The 2023 Plan is designed to enable the flexibility to grant equity awards to our officers, employees, non-employee directors and consultants and to ensure that we can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. Subject to certain adjustments (as provided in Section 4.2 of the 2023 Plan) and exception (as provided in Section 5.6(b) of the 2023 Plan), the maximum number of shares reserved for issuance under the Plan (including incentive share options) is 2,500,000 shares. The 2023 Plan was approved by the Company&#8217;s stockholders at the Annual Meeting of Stockholders held on September 18, 2023. As of March 31, 2025, no shares remained reserved and available for future issuance under the Company's 2023 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 16, 2024, the Company&#8217;s Board of Directors approved incentive stock awards for the CEO, the CFO, certain officers and directors and other key employees of the Company pursuant to the 2023 Plan. The awards are in the form of restricted stock and will vest in two parts: 50% on September 16, 2025 and 50% on September 16, 2026. A total of 2,500,000 shares were awarded. For the three-month periods ended March 31, 2025 and 2024, the Company recorded share-based compensation expense of $311,301 and $0, respectively, in connection with the &#8220;2023 Plan.&#8221; The expense was recorded in accordance with ASC 718 (Compensation&#8212;Stock Compensation) and is included in the Company&#8217;s Consolidated Statement of Operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Warrant Anti-Dilution Adjustment and Deemed Dividend</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, there were 12,926,506 warrants outstanding and 12,913,172 warrants exercisable with 12,913,172 warrants having expiration dates from May 2026 through October 2029 and 13,334 warrants with no expiration date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the Company&#8217;s warrant activity for the nine months ended March 31, 2025 and the year ending December 31, 2024 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Intrinsic</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance Outstanding, January 1, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,561,476</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.91</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.64</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,801</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,748,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.95</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,874,126 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(509,096 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance Outstanding, December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.63</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,920</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance Outstanding, March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.63</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.99</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,814</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Exercisable, March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,913,172</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.63</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_StockOptionsAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_StockOptionsAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_StockOptionsAndWarrantsDisclouserTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_StockOptionsAndWarrantsDisclouserTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISAGGREGATION OF REVENUE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>DISAGGREGATION OF REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_DisaggregationOfRevenueDisclosureTextBlock', window );">DISAGGREGATION OF REVENUE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 16 &#8211; DISAGGREGATION OF REVENUE</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity&#8217;s revenue is disaggregated depends on the facts and circumstances that pertain to the entity&#8217;s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table presents our revenue disaggregated by country for the three months ended:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Country</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Croatia</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,093</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,344</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cyprus</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,562</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,737</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bulgaria</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,183</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,651</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Greece</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,322,494</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,225,572</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Albania</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,332</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">UK</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">285,864</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">312,569</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>13,712,528</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>14,584,473</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_DisaggregationOfRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_DisaggregationOfRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT REPORTING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 17 &#8211; SEGMENT REPORTING</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A. Basis for segmentation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Group operates through various operating segments, which include the wholesale sector, the pharmaceutical manufacturing sector, the nutraceuticals and pharmaceuticals sector and other, with only the first three of them being reportable segments based on the criteria (quantitative thresholds) of ASC 280. The financial information utilized by our Chief Operating Decision Maker (&#8220;CODM&#8221;), which is our CEO, for resource allocation and performance evaluation is included within the operating segments described above.&#160;The reconciling items presented in the tables below are excluded from the segment data provided to the Chief Operating Decision Maker (&#8220;CODM&#8221;). The &#8220;Other&#8221; category primarily consists of corporate expenses incurred by the Group&#8217;s parent entity, including, but not limited to, costs related to SEC legal and compliance matters, executive compensation, audit and review fees, and other corporate overhead expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>B. Information about reportable segments</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The table below presents information about the Company's reportable segments for the three-month period ended March 31, 2025. The accounting policies followed in the preparation of the reportable segments are the same with those followed in the preparation of the Company's condensed consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Three-month period ended March 31, 2025</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Wholesale </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Pharma</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>manufacturing </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nutraceuticals &amp; Pharmaceuticals</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,504,562</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">268,557</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">939,409</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,712,528</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,320,936 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,975 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(270,818 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,662,729 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Gross Profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1,183,626</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>197,582</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>668,591</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>2,049,799</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General and Administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(162,269 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(155,454 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(243,227 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(361,140 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(922,090 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Salaries</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(378,595 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(363,670 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(297,499 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(255 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,040,019 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Sales and Marketing expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(715 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(428 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(27,012 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28,155 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and Development costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,629 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,629 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net finance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(149,274 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53,493</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(95,781 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Segment profit / (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">492,773</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(321,970 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,346</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(377,024 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(51,875 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Reconciling items:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,880 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(131,974 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(99,807 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(35,778 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(320,439 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(556,613 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(556,613 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">59,428</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,454</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">175,825</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income and expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,556</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,341</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">88,701</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(193,593 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(64,995 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net profit/(loss) before Income Taxes</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">526,877</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(441,603 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">253,184</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,156,555 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(818,097 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following summary describes the operations of each reportable segment:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:41%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Reportable segments</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:54%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Operations</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Wholesale </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Distribution and export of pharmaceutical products </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pharma manufacturing</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Production of pharmaceutical products</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nutraceutical and pharmaceuticals </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Trade of owned nutraceutical &amp; pharmaceutical products</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 18 &#8211; SUBSEQUENT EVENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Between April 21, 2025, and April 24, 2025, the Company issued an aggregate of 1,466,764 shares of common stock to Mr. Grigorios Siokas, the Company&#8217;s Chief Executive Officer, in settlement of outstanding obligations totalling $526,000. The liabilities settled pertained to unpaid salaries and performance-related bonuses previously accrued by the Company and owed to Mr. Siokas. The shares were issued at the respective fair market value of the Company&#8217;s common stock on the dates of issuance. The transaction was accounted for as a non-cash settlement of related party debt.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 6, 2025, the Company received a notice from the Nasdaq Stock Market LLC indicating that it had not regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) by the initial deadline of May 5, 2025. However, the Company was granted an additional 180-day compliance period, through November 3, 2025, to meet the requirement. The extension was granted based on the Company&#8217;s continued compliance with all other initial listing standards for the Nasdaq Capital Market and its intent to cure the deficiency, including through a potential reverse stock split if necessary.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF BUSINESS (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OrganizationAndNatureOfTheBusinessAbstract', window );"><strong>ORGANIZATION AND NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Financial Statement Presentation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AcquisitionAccountingPolicy', window );">Acquisition Accounting</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cloudscreen</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, Business Combinations, (&#8220;ASC 805&#8221;) and recorded $637,080 as &#8220;Other assets&#8221; related to the technology platform acquired. The total amount was reclassified to &#8220;Goodwill and intangible assets, net&#8221; in January 2024 with the closing of the agreement (refer to Note 5).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>ZipDoctor</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (&#8220;ZipDoctor&#8221;), a&#160;telehealth company for a total sum of $150,000 in cash and $8,788 in fees. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, <em>Business Combinations</em>, (&#8220;ASC 805&#8221;) and recorded $158,788 as an intangible asset related to the technology platform acquired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2024, the Company recognized an impairment charge of $131,032 related to the technology platform. This decision followed management&#8217;s assessment that the asset&#8217;s recoverability was no longer supportable due to changes in market conditions and a shift in strategic priorities. Specifically, the telehealth platform was no longer in use and did not generate revenues, as the Company elected not to focus on the telehealth business segment. As a result, the unamortized balance of the intangible asset was effectively written off. The impairment charge was recorded within &#8220;Other income (expense), net&#8221; in the Consolidated Statement of Operations for the year ended December 31, 2024.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Bikas</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 15, 2023, Cosmos Health Inc. entered into an Assignment and Assumption Agreement (the &#8220;Agreement&#8221;) with Ioannis Bikas O.E., a Greek Company (&#8220;Bikas&#8221;). Bikas is owner of a pharmaceutical distribution network in Greece and agreed to sell to the Company their distribution network and customer base. The purchase price of the network was &#8364;100,000 ($109,330) of cash, and &#8364;300,000 ($316,081) of the Company&#8217;s stock. The Company issued 99,710 shares of common stock related to the acquisition of the customer base, based on the fair value of the stock on the acquisition date. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded $425,411 as an intangible asset related to the customer base acquired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Buildings Acquisitions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 24, 2023, the Company purchased a building for a total sum of $1,054,872 in cash.&#160;The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded the cost of the building as &#8220;Property, plant and equipment&#8221; on the consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 6, 2023, the Company agreed to purchase land and building located in Montreal, Canada from a third-party vendor. The total purchase price amounts to $3,950,000 and the closing date of the agreement based on the amendment signed on July 19, 2023, was December 31, 2023. Pursuant to the last amendment signed on December 31, 2024 the closing date was extended to December 31, 2025. As of March 31, 2025, the Company has made prepayments of $2,000,020 classified as &#8220;Advances for building&#8217;s acquisition&#8221; on the Company&#8217;s condensed consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cana </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 30, 2023, the Company acquired Cana Laboratories Holding (Cyprus) Limited (&#8220;Cana&#8221;), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana&#160;S.A. (&#8220;Cana SA&#8221;) for &#8364;800,000 ($873,600) in cash and 46,377 shares of common stock, with fair value of $138,667 as of the date of acquisition. Moreover, on February 28,<sup style="vertical-align:super"> </sup>2023, the Company had signed a Secured Promissory Note with Cana, whereby Cana borrowed the sum of &#8364;4,100,000 ($4,457,520), included in the total consideration of $5,469,787. The Company accounted for the acquisition as a business acquisition in accordance with ASC 805. The fair value of Cana assets acquired, and liabilities assumed was based upon management&#8217;s estimates assisted by an independent third-party valuation firm. The fixed assets of Cana (which included land, building &amp; machinery) were valued as of December 31, 2022 and the Company believes that nothing has materially changed between such date and the acquisition date (June 30, 2023). The following table summarizes the preliminary allocation of purchase price of the acquisition:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Consideration </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,331,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Fair value of common stock issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">138,667</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fair value of total consideration transferred</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>5,469,787</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recognized amounts of identifiable assets acquired</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,796,911</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297,340</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property, plant and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,488,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identifiable intangible assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">562,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,235,233 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total identifiable net assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,910,036</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Bargain purchase gain</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,440,249</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the prior year period, Cana had minimal operations as it was in financial difficulties and seeking for an investor. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our consolidated accounts include our accounts and the accounts of our wholly owned subsidiaries, SkyPharm S.A., Decahedron Ltd., Cosmofarm S.A., Cana Laboratories Holdings (Cyprus) Limited and ZipDoctor Inc. The Group&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;). The consolidated financial statements reflect the consolidation of all entities in which the Company has control, as determined by the ability to direct the activities that significantly affect the entities&#8217; economic performance. All significant intercompany balances and transactions have been eliminated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_EffectsOfWarInTheUkrainePolicyTextBlock', window );">The Effects of War in the Ukraine</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company and, as such, is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CreditLossesPolicyTextBlock', window );">Credit Losses</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which amends the requirement on the measurement and recognition of expected credit losses for financial assets held. Furthermore, amendments ASU 2019-10 and ASU 2019-11 provided additional clarification for implementing ASU 2016-13. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early adoption permitted. The Company adopted the standard on January 1, 2023, and the standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. The Company is exposed to credit losses primarily through sales to its customers and the loans that it has provided. The Company assesses each customer&#8217;s/ borrower&#8217;s ability to pay, and a credit loss estimate by conducting a credit review which includes consideration of established credit rating, or an internal assessment of the customer&#8217;s creditworthiness based on an analysis of their payment history when a credit rating is not available. The Company monitors credit exposure through active review of customer balances. In accordance with ASC 326 and the Current Expected Credit Loss (CECL) framework, the Company has elected to apply the practical expedient available for its trade receivables, which are short-term in nature and do not contain a significant financing component. The Company applies a loss-rate method for calculating expected credit losses (&#8220;ECL&#8221;) on accounts receivable, based on a combination of historical experience, industry data, and adjustments for current conditions and reasonable and supportable forecasts. Receivables are grouped into four aging buckets, with loss rates applied as follows: 1% for receivables aged 0&#8211;30 days, 2% for receivables aged 31&#8211;60 days, 3% for receivables aged 61&#8211;90 days, and 5% for receivables aged over 90 days. These loss rates are based on management&#8217;s expectations, which are further supported by external benchmarks, due to the Company&#8217;s limited history of actual write-offs. The resulting provision for expected credit losses is recognized in net income and is included in &#8220;General and administrative expenses&#8221;. Receivables that are deemed uncollectible are written off against the allowance when it is determined that they are no longer recoverable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Transactions in and Translations of Foreign Currency</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The functional currency for the Greek subsidiaries of the Company (CANA Laboratories, Cosmofarm S.A. and SkyPharm SA) is Euro (&#8364;) and for the UK subsidiary (Decahedron Ltd) is GBP (&#163;). ZipDoctor Inc. is a U.S. based entity. As a result, the financial statements of the subsidiaries (except for ZipDoctor Inc.) have been translated from the local currency into U.S. dollars using (i) year-end exchange rates for balance sheet accounts, and (ii) average exchange rates for the reporting period for all income statements accounts. Foreign currency translations gains and losses are reported as a separate component of the condensed consolidated statements of changes in stockholders&#8217; equity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, net</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable, prepaid expenses and other current assets and other assets reflects the best estimate of probable losses inherent in the receivables&#8217; portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of March 31, 2025 and December 31, 2024, the Company&#8217;s allowance for doubtful accounts was $23,658,962 and $22,799,219, respectively. Below is the summary of changes in the allowance for doubtful accounts:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Balance as of January 1st, 2025 </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,799,219</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Provisions for credit losses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Write-offs </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Foreign exchange adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">878,430</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(18,687 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Balance as of March 31, 2025</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,658,962</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_TaxReceivablesPolicyTextBlock', window );">Tax Receivables</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company pays Value Added Tax (&#8220;VAT&#8221;) or similar taxes (&#8220;input VAT&#8221;), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (&#8220;output VAT&#8221;) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of March 31, 2025 and December 31, 2024, the Company had a VAT net receivable balance of $528,203 and $534,263 respectively, recorded in the condensed consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company writes down inventories to net realizable value based on physical condition, expiration date, and current market conditions, as well as forecasted demand. The Company&#8217;s inventories are not highly susceptible to obsolescence. Many of the Company&#8217;s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. No significant judgments have been applied in estimating the selling price of our inventory.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Estimated</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Useful Life</strong></p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:77%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Leasehold improvements and technical works</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:1%;"></td><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Lesser of lease term or 25 years</p></td><td style="width:1%;"></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">25-30 years</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vehicles</p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6 years</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Machinery</p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20 years</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Furniture, fixtures and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5&#8211;10 years</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Computers and software</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3-5 years</p></td><td></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Depreciation expense was $97,539 and $112,874 for the three months ended March 31, 2025 and 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment additions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and Equipment additions are recognized as assets when it is probable that future economic benefits associated with the asset will flow to the entity and the cost of the asset can be measured reliably. Additions are initially measured at cost, which includes all costs directly attributable to bringing the asset to its working condition and location for its intended use. This may include purchase price, freight, installation, and any directly attributable professional fees. They are capitalized if their cost exceeds a certain threshold. The threshold is determined based on materiality considerations. Costs below the threshold are typically expensed as incurred. After initial recognition, additions are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is calculated systematically over the estimated useful life of the asset. They are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying amount exceeds the recoverable amount, an impairment loss is recognized, and the carrying amount of the asset is adjusted accordingly. Borrowing costs directly attributable to the acquisition, construction, or production of qualifying assets, including Property and Equipment additions, are capitalized as part of the cost of those assets. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. For the three months ended March 31, 2025, and 2024, the Company has recorded no impairment charge.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangibles, net</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license and a useful life of 10 years for the pharmaceutical and nutraceutical products licenses included in Note 4 as &#8220;Licenses&#8221;. A useful life of 10 years is also used for the platforms included in Note 4 as &#8220;Software&#8221; and the customer bases. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset&#8217;s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2025 and December 31, 2024, no revision to the remaining amortization period of the intangible assets was made.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amortization expense was $208,833 and $189,855 for the three months ended March 31, 2025 and 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in &#8220;Equity earnings of affiliate&#8221; in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in Equity Securities</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for sale in current operations are reported as a component of current assets on the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets on the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2025, investments consisted of 16,666 shares which traded at a closing price of $0.95 per share or value of $15,749 of National Bank of Greece. Additionally, the Company has $7,665 in equity securities of Pancreta Bank, which are revalued annually. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company applies ASC 820, Fair Value Measurements and Disclosures, (&#8220;ASC 820&#8221;), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1:&#160;Observable inputs such as quoted prices (unadjusted)&#160;in active markets for identical assets or liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2:&#160;Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3:&#160;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, ASC 825-10-25, Fair Value Option, (&#8220;ASC 825-10-25&#8221;), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our financials also included the following financial instruments as of March 31, 2025 and December 31, 2024: cash, accounts receivable, inventory, prepaid expenses, loans receivable, accounts payable, notes payable and lines of credit. Except for the loans receivable which carry fixed interest rates, the carrying value of the remaining instruments, approximates fair value due to their short-term nature.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CustomerAdvancesPolicyTextBlock', window );">Customer Advances</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company&#8217;s products. The Company records these receipts as current liabilities until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer&#160;advances balance and credit the Company&#8217;s revenues.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDeferredRevenue', window );">Revenue Recognition</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 606,&#160;<em>Revenue from Contracts with Customers</em>&#160;(&#8220;ASC 606&#8221;), the Company uses a five-step model for recognizing revenue by applying the following steps: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identification of the Contract: The Company identifies a contract with a customer when it enters into an agreement that creates enforceable rights and obligations.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identification of Performance Obligations: The Company identifies distinct performance obligations within each contract, which represent promises to transfer goods or services to the customer.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Determination of Transaction Price: The Company determines the transaction price, which represents the amount of consideration to which it expects to be entitled in exchange for transferring promised goods or services to the customer, excluding any amounts collected on behalf of third parties.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Allocation of Transaction Price: The Company allocates the transaction price to each distinct performance obligation based on its standalone selling price. If the standalone selling price is not observable, the Company estimates it using an appropriate method.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Recognition of Revenue: Revenue is recognized when (or as) the Company satisfies a performance obligation by transferring a promised good or service to the customer. This typically occurs at a point in time or over time, depending on the nature of the performance obligation.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Wholesale revenue and sales of own branded nutraceutical and pharmaceutical products</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has contracts or signed partnership forms (usual in the wholesale sector of the pharma industry) with its customers, stipulating the enforceable rights and obligations. The Company is responsible for transferring the goods to the customer&#8217;s location, which represents its sole performance obligation. Thus, the transaction price, which is predetermined in most of the products sold, is exclusively allocated to this performance obligation. Revenue is recognized at a single point in time, which is upon issuance of the corresponding sales invoice. The Company has assessed the impact of the items invoiced but not delivered to the customer&#8217;s location as of March 31, 2025 and December 31, 2024 and deemed that it had no material effect. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Pharma manufacturing</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has active contracts with its customers, stipulating the enforceable rights and obligations. The Company is responsible for the manufacturing and the packaging of specific products assigned by its customers, which represents its performance obligations to which the Company allocates the transaction price determined. The customers are responsible for providing the raw materials to the Company. Revenue is recognized over a period of time, which is during the production and packaging period of the respective products. As of March 31, 2025 and 2024&#160;&#160;there were no products or batches of products for which the production or packaging phase was in progress. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Medihelm SA </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective January 1, 2023, and pursuant to the distribution agreement with Medihelm SA (&#8220;Medihelm&#8221;), the exclusive distributor of the Company&#8217;s proprietary line of nutraceutical products, the Company determined that the transaction price for sales to Medihelm was variable in nature. In accordance with ASC 606, <em>Revenue from Contracts with Customers</em>, and specifically ASC 606-10-32-5, the Company applied the &#8220;expected value&#8221; method to estimate the transaction price, subject to the constraint on variable consideration. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This approach was necessitated by the existence of significant overdue receivables from Medihelm, which raised substantial doubt regarding full collectability of the contractual amounts. The Company reassessed the estimate of the transaction price at each reporting date, considering changes in facts and circumstances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There was no impact on revenue recognition for the three-month period ended March 31, 2025 and no further adjustments to variable consideration were necessary.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (&#8220;ASC 718&#8221;) and Staff Accounting Bulletin No. 107 (&#8220;SAB 107&#8221;) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, &#8220;Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.&#8221;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 25% in the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At March 31, 2025, we believe our United Kingdom and Greece deferred tax assets will not be realized, as such, we did not record a reversal on the full valuation approach we followed during the year ended December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for leases in accordance with ASC 842. For all leases, the Company recognizes a right-of-use (ROU) asset and a lease liability on the balance sheet. The ROU asset represents the Company's right to use the underlying asset for the lease term, and the lease liability represents the obligation to make lease payments arising from the lease, both measured at the present value of future lease payments. Lease payments are recognized as an operating expense on a straight-line basis over the lease term. The interest on the lease liability and the amortization of the ROU asset are recognized separately in the income statement. Initial direct costs incurred by the Company in negotiating and securing leases are capitalized and amortized over the lease term on a straight-line basis. The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company&#8217;s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company&#8217;s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt on the date of inception.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitPlansPolicy', window );">Retirement and Termination Benefits</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee&#8217;s work experience and remuneration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of March 31, 2025 and December 31, 2024, was $398,838 and $377,264, respectively, and has been recorded as a long-term liability within the consolidated balance sheets (&#8220;Other liabilities&#8221;). The Company engaged an actuarial expert for the first time, during the period ended December 31, 2023. Management did not engage an actuarial expert since then, since there were no circumstances indicating that there would be a significant change to the liability recorded and thus the movement compared to 2023, solely relates to the foreign exchange effect.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic income per share is calculated by dividing the income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average number of common shares outstanding Basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,037,608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,851,747</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Potentially dilutive common stock equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average number of common and equivalent shares outstanding &#8211; Diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,037,608</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,851,747</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes potential common shares that were excluded as their effect is anti-dilutive:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,558,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,558,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no new material accounting standards issued in the first fiscal quarter of 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_AcquisitionAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_AcquisitionAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CreditLossesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CreditLossesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CustomerAdvancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CustomerAdvancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_EffectsOfWarInTheUkrainePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_EffectsOfWarInTheUkrainePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OrganizationAndNatureOfTheBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OrganizationAndNatureOfTheBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_TaxReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_TaxReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF BUSINESS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OrganizationAndNatureOfTheBusinessAbstract', window );"><strong>ORGANIZATION AND NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Accounts Receivable &amp; Allowance for Doubtful Accounts</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Balance as of January 1st, 2025 </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,799,219</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Provisions for credit losses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Write-offs </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Foreign exchange adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">878,430</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(18,687 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Balance as of March 31, 2025</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,658,962</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Consideration </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,331,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Fair value of common stock issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">138,667</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fair value of total consideration transferred</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>5,469,787</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recognized amounts of identifiable assets acquired</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,796,911</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297,340</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property, plant and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,488,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identifiable intangible assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">562,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,235,233 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total identifiable net assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,910,036</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Bargain purchase gain</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,440,249</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, net</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Estimated</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Useful Life</strong></p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:77%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Leasehold improvements and technical works</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:1%;"></td><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Lesser of lease term or 25 years</p></td><td style="width:1%;"></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">25-30 years</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vehicles</p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6 years</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Machinery</p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20 years</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Furniture, fixtures and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5&#8211;10 years</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Computers and software</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3-5 years</p></td><td></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average number of common shares outstanding Basic</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,037,608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,851,747</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Potentially dilutive common stock equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average number of common and equivalent shares outstanding &#8211; Diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,037,608</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,851,747</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potential shares of common stock</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,558,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,558,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OrganizationAndNatureOfTheBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OrganizationAndNatureOfTheBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481834/980-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, net</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Land</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,465,629</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,322,780</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Buildings and improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,713,642</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,526,432</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,552</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,405</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vehicles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,896</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">265,261</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture, fixtures and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,973,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,846,657</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,434,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,964,535</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,418,032 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,275,030 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,016,068</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,689,505</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">License</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,585,857</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,257,938</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Trade name / mark</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">392,197</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">390,188</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer base</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">626,397</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">626,397</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,053,554</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,113,840</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,658,005</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,388,363</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated amortization &amp; impairment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">License</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,311,124 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,117,341 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Trade name / mark</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,997 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,997 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer base</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(189,526 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(174,279 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(367,526 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(352,909 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Subtotal</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,752,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,706,837</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Goodwill</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">49,697</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">49,697</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,802,529</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,756,534</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of amortization expense for intangible assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">881,066</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">877,344</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">879,895</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">878,532</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">871,974</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,008,821</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,397,632</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Notes Payable activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Beginning Balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,558</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,283</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Payments </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(725</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ending Balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,012</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,558</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock', window );">Schedule of Related Party Loans Payable</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,194</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,257</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(108,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,210 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Set-offs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,039</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">267</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(853 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,194</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LINES OF CREDIT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>LINES OF CREDIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Lines of Credit</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">National</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">3,816,515</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">4,012,642</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Alpha</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">769,867</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">960,867</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pancreta</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,437,670</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,583,291</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Attica Bank</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">849,483</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">EFG</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">431,840</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">428,252</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">7,305,376</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">6,985,052</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>NOTES PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of roll forward of the third party Debt</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>March 31, 2025</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trade </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Facility </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Third </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Party</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COVID </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Loans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance, December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,397,385</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,557,023</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,505</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,108,913</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">755,720</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">755,720</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(183,455 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,060 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(188,515 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">60,075</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">110,051</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,019</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">176,145</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance, March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,457,460</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,239,339</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">155,464</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,852,263</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - long-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,968,180 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(120,360 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,088,540 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - short-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,457,460</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,271,159</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">35,104</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,763,723</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trade </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Facility </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Third </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Party</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COVID </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Loans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance, December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,908,195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,511,148</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">186,884</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,606,227</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">828,080</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">828,080</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(388,163 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(634,653 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(22,806 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,045,622 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(122,647 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(147,552 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,573 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(279,772 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance, December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,397,385</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,557,023</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">154,505</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,108,913</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable &#8211; long-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,437,798 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(122,635 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,560,433 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - short-term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,397,385</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,119,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,870</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,548,480</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ScheduleOfOutstandingDebtTableTextBlock', window );">Summary of Outstanding Debt</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="5" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Our outstanding debt as of March 31, 2025&#160;is repayable as follows:</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,763,723</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">819,335</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">666,070</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">378,706</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030 and thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">224,429</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total debt</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>4,852,263</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: notes payable - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,763,723 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Notes payable - long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,088,540</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ScheduleOfOutstandingDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ScheduleOfOutstandingDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of Operating Lease liability</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Maturity of Operating Lease Liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">181,753</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218,637</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">156,745</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2029 and thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">202,251</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total undiscounted operating lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">759,386</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Less: Imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(88,876 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Present value of operating lease liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">670,510</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of finance lease liability</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Maturity of Lease Liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,357</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total undiscounted finance lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,357</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Less: Imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(373 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Present value of finance lease liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,164</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_StockOptionsAndWarrantsAbstract', window );"><strong>STOCK OPTIONS AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Intrinsic</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance Outstanding, January 1, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,561,476</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.91</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.64</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,801</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,748,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.95</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,874,126 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(509,096 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance Outstanding, December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.63</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,920</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance Outstanding, March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,926,506</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.63</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.99</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,814</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Exercisable, March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,913,172</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.63</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_StockOptionsAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_StockOptionsAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISAGGREGATION OF REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>DISAGGREGATION OF REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue Disaggregation</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Country</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, 2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Croatia</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,093</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,344</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cyprus</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,562</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,737</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bulgaria</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,183</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,651</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Greece</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,322,494</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,225,572</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Albania</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,332</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">UK</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">285,864</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">312,569</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>13,712,528</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>14,584,473</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT REPORTING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Wholesale </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Pharma</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>manufacturing </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nutraceuticals &amp; Pharmaceuticals</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,504,562</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">268,557</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">939,409</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,712,528</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,320,936 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,975 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(270,818 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,662,729 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Gross Profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1,183,626</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>197,582</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>668,591</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>2,049,799</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General and Administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(162,269 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(155,454 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(243,227 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(361,140 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(922,090 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Salaries</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(378,595 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(363,670 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(297,499 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(255 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,040,019 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Sales and Marketing expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(715 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(428 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(27,012 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28,155 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and Development costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,629 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,629 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net finance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(149,274 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53,493</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(95,781 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Segment profit / (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">492,773</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(321,970 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,346</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(377,024 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(51,875 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Reconciling items:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,880 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(131,974 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(99,807 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(35,778 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(320,439 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(556,613 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(556,613 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Foreign currency adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">59,428</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,454</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">175,825</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income and expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,556</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,341</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">88,701</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(193,593 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(64,995 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net profit/(loss) before Income Taxes</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">526,877</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(441,603 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">253,184</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,156,555 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(818,097 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock', window );">Schedule of describes the operations of each reportable segment</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:41%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Reportable segments</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:54%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Operations</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Wholesale </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Distribution and export of pharmaceutical products </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pharma manufacturing</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Production of pharmaceutical products</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nutraceutical and pharmaceuticals </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Trade of owned nutraceutical &amp; pharmaceutical products</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_BasisOfPresentationAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Net cash used in operations</a></td>
<td class="nump">$ 186,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">25,951,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,532,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(114,840,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (114,022,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_WorkingCapital', window );">Working capital</a></td>
<td class="nump">1,259,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">13,712,528<span></span>
</td>
<td class="nump">$ 14,584,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (818,097)<span></span>
</td>
<td class="nump">$ 3,868,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF BUSINESS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,311,892<span></span>
</td>
<td class="nump">$ 57,191,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cosm_CANAPharmaceuticalLaboratoriesSACanaMember', window );">CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of common stock issued</a></td>
<td class="nump">$ 138,667<span></span>
</td>
<td class="nump">138,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,469,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,796,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,488,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,235,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,910,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Bargain purchase gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,440,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cosm_CANAPharmaceuticalLaboratoriesSACanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cosm_CANAPharmaceuticalLaboratoriesSACanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF BUSINESS (Details 1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OrganizationAndNatureOfTheBusinessAbstract', window );"><strong>ORGANIZATION AND NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance', window );">Balance as of January 1st, 2025</a></td>
<td class="nump">$ 22,799,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Provisions for credit losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign exchange adjustments</a></td>
<td class="nump">878,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPreferredStockDividendsAndAdjustments', window );">Other adjustments</a></td>
<td class="num">(18,687)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance', window );">Balance as of March 31, 2025</a></td>
<td class="nump">$ 23,658,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OrganizationAndNatureOfTheBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OrganizationAndNatureOfTheBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPreferredStockDividendsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred stock dividends and adjustments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 5.Q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPreferredStockDividendsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to temporary equity resulting from foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF BUSINESS (Details 2)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PropertyPlantAndEquipmentUsefulLifes', window );">Estimated Useful Life</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_MachineryMember', window );">Machinery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PropertyPlantsAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_LeaseholdImprovementsAndTechnicalWorksMember', window );">Leasehold improvements and technical works [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives', window );">Estimated useful life, description</a></td>
<td class="text">Lesser of lease term or 25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PropertyPlantsAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PropertyPlantsAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_BuildingsMember', window );">Buildings [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PropertyPlantsAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_BuildingsMember', window );">Buildings [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PropertyPlantAndEquipmentUsefulLifes', window );">Estimated Useful Life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PropertyPlantAndEquipmentUsefulLifes', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PropertyPlantsAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PropertyPlantAndEquipmentUsefulLifes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PropertyPlantAndEquipmentUsefulLifes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PropertyPlantsAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PropertyPlantsAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_LeaseholdImprovementsAndTechnicalWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_LeaseholdImprovementsAndTechnicalWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_TopMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_TopMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_BottomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_BottomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF BUSINESS (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OrganizationAndNatureOfTheBusinessAbstract', window );"><strong>ORGANIZATION AND NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic</a></td>
<td class="nump">26,037,608<span></span>
</td>
<td class="nump">16,851,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">26,037,608<span></span>
</td>
<td class="nump">16,851,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OrganizationAndNatureOfTheBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OrganizationAndNatureOfTheBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF BUSINESS (Details 4) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OrganizationAndNatureOfTheBusinessAbstract', window );"><strong>ORGANIZATION AND NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Common Stock Warrants</a></td>
<td class="nump">12,926,506<span></span>
</td>
<td class="nump">8,558,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PotentialCommonShares', window );">Total</a></td>
<td class="nump">12,926,506<span></span>
</td>
<td class="nump">8,558,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OrganizationAndNatureOfTheBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OrganizationAndNatureOfTheBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PotentialCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PotentialCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Jan. 06, 2023</div></th>
<th class="th"><div>Jan. 23, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 15, 2023</div></th>
<th class="th"><div>Apr. 24, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExpenseOnReclassifiedAssets', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,539<span></span>
</td>
<td class="nump">$ 112,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,658,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,799,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Net receivable balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,833<span></span>
</td>
<td class="nump">$ 189,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_BuildingAcquisionMember', window );">Building Acquision [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,054,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment aggregate cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PancretaBankMember', window );">Pancreta Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost', window );">Investments in debt and equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues', window );">Recurring Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedLoss', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_GreeceMember', window );">Greece [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Issuable stock amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_UnitedKingdomMember', window );">United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cosm_CANAPharmaceuticalLaboratoriesSACanaMember', window );">CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 873,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Issuable stock amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets', window );">Asset acquision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,469,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredNotesPayable', window );">Secured Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,457,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cosm_ZipDoctorIncMember', window );">Zip Doctor Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Payment of fees</a></td>
<td class="nump">8,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 158,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cosm_CloudscreenMember', window );">Cloudscreen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount', window );">Total purchase price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued', window );">Shares of common fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected', window );">Asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment needed to reconcile previously recorded amounts to the actual aggregate amount paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized acquisition cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes exploration and development costs and capitalized interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477385/932-360-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionPriceOfAcquisitionExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total fair value of shares issued during the period under a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationExpenseOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-44<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationExpenseOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes other investments and securities that are not at fair value as of the balance sheet date and those that are not accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentsAndSecuritiesAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_BuildingAcquisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cosm_BuildingAcquisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PancretaBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PancretaBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_GreeceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_GreeceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_UnitedKingdomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_UnitedKingdomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cosm_CANAPharmaceuticalLaboratoriesSACanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cosm_CANAPharmaceuticalLaboratoriesSACanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cosm_ZipDoctorIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cosm_ZipDoctorIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cosm_CloudscreenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cosm_CloudscreenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY METHOD INVESTMENTS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_CosmoFarmacyLPMember', window );">Cosmo Farmacy LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_InitialShareCapital', window );">Initial share capital</a></td>
<td class="nump">&#8364; 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_InitialShareCapitalIncreased', window );">Initial share capital increased</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PharmacyLicenseValue', window );">Pharmacy license value</a></td>
<td class="nump">&#8364; 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_MaturityPeriodOfLicense', window );">Maturity period of license</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_EquityMethodInvestmentsOwnershipPercentage', window );">Ownership equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CashContributedToLimitedPartner', window );">Cash contributed to limited partner</a></td>
<td class="nump">&#8364; 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_EquityMethodInvestmentOwnershipRemainingPercentage', window );">Equity ownership remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_ShareExchangeAgreementMember', window );">Share Exchange Agreement [Member] | ICC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CashContributedToLimitedPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CashContributedToLimitedPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_EquityMethodInvestmentOwnershipRemainingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_EquityMethodInvestmentOwnershipRemainingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_EquityMethodInvestmentsOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_EquityMethodInvestmentsOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_InitialShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_InitialShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_InitialShareCapitalIncreased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_InitialShareCapitalIncreased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_MaturityPeriodOfLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_MaturityPeriodOfLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PharmacyLicenseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PharmacyLicenseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_CosmoFarmacyLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_CosmoFarmacyLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_ShareExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_ShareExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cosm_IccMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cosm_IccMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment</a></td>
<td class="nump">$ 11,434,100<span></span>
</td>
<td class="nump">$ 10,964,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(1,418,032)<span></span>
</td>
<td class="num">(1,275,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">10,016,068<span></span>
</td>
<td class="nump">9,689,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment</a></td>
<td class="nump">3,465,629<span></span>
</td>
<td class="nump">3,322,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment</a></td>
<td class="nump">277,896<span></span>
</td>
<td class="nump">265,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment</a></td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">3,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment</a></td>
<td class="nump">2,973,291<span></span>
</td>
<td class="nump">2,846,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building And Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment</a></td>
<td class="nump">$ 4,713,642<span></span>
</td>
<td class="nump">$ 4,526,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS NET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Goodwill and intangible assets, gross</a></td>
<td class="nump">$ 9,658,005<span></span>
</td>
<td class="nump">$ 9,388,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Subtotal</a></td>
<td class="nump">7,752,832<span></span>
</td>
<td class="nump">7,706,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">49,697<span></span>
</td>
<td class="nump">49,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total</a></td>
<td class="nump">7,802,529<span></span>
</td>
<td class="nump">7,756,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember', window );">Customer Base [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Goodwill and intangible assets, gross</a></td>
<td class="nump">626,397<span></span>
</td>
<td class="nump">626,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated Amortization</a></td>
<td class="nump">189,526<span></span>
</td>
<td class="nump">174,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cosm_TradeNameMarkMember', window );">Trade name / mark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Goodwill and intangible assets, gross</a></td>
<td class="nump">392,197<span></span>
</td>
<td class="nump">390,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated Amortization</a></td>
<td class="nump">36,997<span></span>
</td>
<td class="nump">36,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Goodwill and intangible assets, gross</a></td>
<td class="nump">7,585,857<span></span>
</td>
<td class="nump">7,257,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated Amortization</a></td>
<td class="nump">1,311,124<span></span>
</td>
<td class="nump">1,117,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cosm_SoftwareMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Goodwill and intangible assets, gross</a></td>
<td class="nump">1,053,554<span></span>
</td>
<td class="nump">1,113,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated Amortization</a></td>
<td class="nump">$ 367,526<span></span>
</td>
<td class="nump">$ 352,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of finite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherFiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cosm_TradeNameMarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cosm_TradeNameMarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cosm_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cosm_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS NET (Details 1)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 881,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">877,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">879,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">878,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">871,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,008,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">$ 7,397,632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOAN RECEIVABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LoanReceivableabstract', window );"><strong>LOAN RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfLoanCosts', window );">Prepayments of loan</a></td>
<td class="nump">$ 4,849,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtInterestRateIncrease', window );">Interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable', window );">Loan receivables term</a></td>
<td class="text">360 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_DecriptionOfLoanPayment', window );">Decription of loan payment</a></td>
<td class="text">the Company is to receive 120 equal payments over the term of the loan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_DecriptionOfLoanPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_DecriptionOfLoanPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_LoanReceivableabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_LoanReceivableabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfLoanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan origination associated cost which is usually collected through escrow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfLoanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the stated interest rate on a short-term debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_GreeceMember', window );">Greece [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CorporateTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_UnitedKingdomMember', window );">United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CorporateTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CorporateTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CorporateTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_GreeceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_GreeceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_UnitedKingdomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_UnitedKingdomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STRUCTURE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2024</div></th>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 04, 2025</div></th>
<th class="th"><div>Jan. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CommonStocksSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CommonStockShareAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,284,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,689,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CommonStocksSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,198,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,602,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OriginalWarrantsSharesIssued', window );">Original Warrants Shares issued</a></td>
<td class="nump">9,748,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_RemainingWarrantsSharesIssued', window );">Remaining Warrants Shares issued</a></td>
<td class="nump">4,874,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cosm_WarrantExchangeMember', window );">Warrant Exchange [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Pre-funded warrants issued</a></td>
<td class="nump">4,874,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross cash proceeds from warrants exercised</a></td>
<td class="nump">$ 4,240,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SharesHeldInEscrow', window );">Shares held in escrow</a></td>
<td class="nump">2,542,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_WarrantInducementLetterMember', window );">Warrant Inducement Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Pre-funded warrants issued</a></td>
<td class="nump">9,748,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,542,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross cash proceeds from warrants exercised</a></td>
<td class="nump">$ 649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_BottomMember', window );">Minimum [Member] | Warrant Exchange [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.8701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_TopMember', window );">Maximum [Member] | Warrant Exchange [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PreferredStockLiquidationPreference1', window );">Preferred stock, Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OriginalWarrantsSharesIssued', window );">Original Warrants Shares issued</a></td>
<td class="nump">4,874,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cosm_TreasuryStocksOneMember', window );">Treasury Stocks One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AuthorizationToRepurchaseCommonStock', window );">Common stock, authorization to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CommonStockSharesValue', window );">Common stock shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_AuthorizationToRepurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_AuthorizationToRepurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CommonStockShareAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CommonStockShareAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CommonStockSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CommonStockSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CommonStocksSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CommonStocksSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CommonStocksSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CommonStocksSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OriginalWarrantsSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OriginalWarrantsSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PreferredStockLiquidationPreference1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PreferredStockLiquidationPreference1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_RemainingWarrantsSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_RemainingWarrantsSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_SharesHeldInEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_SharesHeldInEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cosm_WarrantExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cosm_WarrantExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_WarrantInducementLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_WarrantInducementLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_BottomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_BottomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_TopMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_TopMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cosm_TreasuryStocksOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cosm_TreasuryStocksOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - Notes Payable - Related Party [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_NotesPayableRelatedParty', window );">Beginning balance</a></td>
<td class="nump">$ 10,558<span></span>
</td>
<td class="nump">$ 11,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLoans', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation</a></td>
<td class="nump">454<span></span>
</td>
<td class="num">(725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_NotesPayableRelatedParty', window );">Ending balance</a></td>
<td class="nump">$ 11,012<span></span>
</td>
<td class="nump">$ 10,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_NotesPayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_NotesPayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments for and related to principal collection on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=cosm_NotesPayableRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=cosm_NotesPayableRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details 1) - Loans Payable - Related Party [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LoansPayableRelatedParty', window );">Beginning balance</a></td>
<td class="nump">$ 6,194<span></span>
</td>
<td class="nump">$ 13,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLoans', window );">Payments</a></td>
<td class="num">(108,500)<span></span>
</td>
<td class="num">(6,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LoanPayableSetOffs', window );">Loan payable Set-offs</a></td>
<td class="nump">102,039<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">267<span></span>
</td>
<td class="num">(853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LoansPayableRelatedParty', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_LoanPayableSetOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_LoanPayableSetOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_LoansPayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_LoansPayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments for and related to principal collection on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=cosm_LoansPayableRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=cosm_LoansPayableRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2023</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>May 17, 2021</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,326<span></span>
</td>
<td class="nump">$ 105,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,852,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,108,913<span></span>
</td>
<td class="nump">$ 4,606,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,284,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,689,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,251,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,478,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,310,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,712,528<span></span>
</td>
<td class="nump">14,584,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loans receivable - related party current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_GrigoriosSiokasMember', window );">Grigorios Siokas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Foreign curreny translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_CanaHoldingsLaboratoriesHoldingLimitedMember', window );">Cana Holdings Laboratories Holding Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredNotesPayable', window );">Secured promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,457,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_DescriptionInterestOfSecuredPromissoryNote', window );">Description related to interest on principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_DocPharmaSaMember', window );">DOC Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,472<span></span>
</td>
<td class="nump">53,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PrepaymentOfInventory', window );">Prepayment relates to purchases of inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AccountsPayableRelatedPartyCurrent', window );">Accounts payable and accrued expenses - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInterest', window );">Prepaid balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,279,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AmountAccountsReceivableRelatedParties', window );">Accounts receivable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,295,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,599,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Cumulative allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,549,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,284,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AgreementTerminate', window );">Agreement terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PiecesPerProduct', window );">Pieces per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1,000 pieces<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases', window );">Purchased of additional licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,461<span></span>
</td>
<td class="nump">734,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,362<span></span>
</td>
<td class="nump">384,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Current portion of Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Non-current portion of Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,889,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PurchaseOfInventory', window );">Inventroy purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,208<span></span>
</td>
<td class="nump">189,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PurchaseOfPharmaceuticalsMedicine', window );">Purchase of branded pharmaceuticals</a></td>
<td class="nump">$ 3,539,840<span></span>
</td>
<td class="nump">$ 1,965,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeDescription', window );">Description of research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The total cost of this project will be &#8364;1,425,000 plus VAT and will be done over three phases as follows: Design & Development (&#8364;725,000); Control and Product Manufacturing (&#8364;250,000) and Clinical Study and Research (&#8364;450,000). SkyPharm has bought a total of as of 81 licenses at value of &#8364;554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loans receivable - related party current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loans receivable - related party noncurrent portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,875,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,898,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PaymentReceivedFromInstallment', window );">Monthly basis instalments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_DocPharmaSaMember', window );">DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PurchaseOfInventory', window );">Inventroy purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,645<span></span>
</td>
<td class="nump">68,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_DimitriosGoulielmosMember', window );">Dimitrios Goulielmos [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Foreign curreny translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PanagiotisKozarisMember', window );">Panagiotis Kozaris [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement', window );">Shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,159<span></span>
</td>
<td class="nump">$ 143,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_MariaKozariMember', window );">Maria Kozari [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,188,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Cumulative allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_NetSales', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,870<span></span>
</td>
<td class="nump">86,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_GeorgeTerzisMember', window );">George Terzis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Unpaid salaries and bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_UnpaidSalariesAndBonusesDues', window );">Unpaid salaries and bonuses dues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_KanarogloySiaEpeMember', window );">Kanarogloy &amp; Sia Epe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AccountsPayableRelatedPartyCurrent', window );">Accounts payable and accrued expenses - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_BasothoInvestmentLimitedMember', window );">Basotho Investment Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_AccountsPayableRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_AccountsPayableRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_AgreementTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_AgreementTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_AmountAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_AmountAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_DescriptionInterestOfSecuredPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_DescriptionInterestOfSecuredPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_NetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_NetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PaymentReceivedFromInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PaymentReceivedFromInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PiecesPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PiecesPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PrepaymentOfInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PrepaymentOfInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PurchaseOfInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PurchaseOfInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PurchaseOfPharmaceuticalsMedicine">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PurchaseOfPharmaceuticalsMedicine</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_UnpaidSalariesAndBonusesDues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_UnpaidSalariesAndBonusesDues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature of payments to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP), including the fee rate, basis of calculation, relevant accounting period, whether the fee is paid to an entity other than the managing member or general partner, or whether the fee is waived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount purchased during the period under an unrecorded unconditional purchase obligation (for example, under the take-or-pay or throughput contract).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_GrigoriosSiokasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_GrigoriosSiokasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_CanaHoldingsLaboratoriesHoldingLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_CanaHoldingsLaboratoriesHoldingLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_DocPharmaSaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_DocPharmaSaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cosm_InventoriesRelatedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cosm_InventoriesRelatedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_DimitriosGoulielmosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_DimitriosGoulielmosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PanagiotisKozarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PanagiotisKozarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_MariaKozariMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_MariaKozariMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_GeorgeTerzisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_GeorgeTerzisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_KanarogloySiaEpeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_KanarogloySiaEpeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_BasothoInvestmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_BasothoInvestmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LINES OF CREDIT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Subtotal</a></td>
<td class="nump">$ 7,305,376<span></span>
</td>
<td class="nump">$ 6,985,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_AtticaBankMember', window );">Attica Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Subtotal</a></td>
<td class="nump">849,483<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_EFGMember', window );">EFG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Subtotal</a></td>
<td class="nump">431,840<span></span>
</td>
<td class="nump">428,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_NationalMember', window );">National [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Subtotal</a></td>
<td class="nump">3,816,515<span></span>
</td>
<td class="nump">4,012,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_AlphaMember', window );">Alpha [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Subtotal</a></td>
<td class="nump">769,867<span></span>
</td>
<td class="nump">960,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PancretaMember', window );">Pancreta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Subtotal</a></td>
<td class="nump">$ 1,437,670<span></span>
</td>
<td class="nump">$ 1,583,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_AtticaBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_AtticaBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_EFGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_EFGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_NationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_NationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_AlphaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_AlphaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PancretaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PancretaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LINES OF CREDIT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 27, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Line of credit facility outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,035<span></span>
</td>
<td class="nump">$ 44,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_LineOfCreditBorrowingsLoanDescription', window );">Borrowings loan Description</a></td>
<td class="text">providing for maximum borrowings of up to &#8364;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#8364;700,000 ($749,600), which were classified as Notes Payable in the Company&#8217;s consolidated financial statements. The remaining borrowing capacity of &#8364;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | National Bank of Greece Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements', window );">Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OutstandingDebtBalance', window );">Outstanding debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">895,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">895,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Alpha Bank of Greece [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements', window );">Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OutstandingDebtBalance', window );">Outstanding debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Pancreta Bank of Greece [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements', window );">Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,619,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,552,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OutstandingDebtBalance', window );">Outstanding debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_NationalBankOfGreeceOneMember', window );">National Bank of Greece One [Member] | Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements', window );">Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,398,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OutstandingDebtBalance', window );">Outstanding debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,975,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,165,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_EFGMember', window );">EGF [Member] | Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements', window );">Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OutstandingDebtBalance', window );">Outstanding debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 428,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_LineOfCreditBorrowingsLoanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_LineOfCreditBorrowingsLoanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OutstandingDebtBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OutstandingDebtBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the sum of the obligations to contract holders to provide to them an agreed upon rate of return pursuant to the terms of the underlying contract. These contracts represent lending by the contract holders to the entity in return for a guaranteed (primarily fixed) interest rate until maturity, unless called earlier if the contracts provide that option to the contract holders (usually institutions). There is little or no insurance risk for the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cosm_NationalBankOfGreeceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cosm_NationalBankOfGreeceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cosm_AlphaBankOfGreeceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cosm_AlphaBankOfGreeceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cosm_PancretaOfGreeceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cosm_PancretaOfGreeceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_NationalBankOfGreeceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_NationalBankOfGreeceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_EFGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_EFGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Beginning balance</a></td>
<td class="nump">$ 4,108,913<span></span>
</td>
<td class="nump">$ 4,606,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ProceedFromDebt', window );">Proceeds</a></td>
<td class="nump">755,720<span></span>
</td>
<td class="nump">828,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PaymentsOfDebt', window );">Payments</a></td>
<td class="num">(188,515)<span></span>
</td>
<td class="num">(1,045,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ForeignCurrencyTranslation', window );">Foreign currency translation</a></td>
<td class="nump">176,145<span></span>
</td>
<td class="num">(279,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Ending balance</a></td>
<td class="nump">4,852,263<span></span>
</td>
<td class="nump">4,108,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long-term</a></td>
<td class="num">(2,088,540)<span></span>
</td>
<td class="num">(1,560,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable - short-term</a></td>
<td class="nump">2,763,723<span></span>
</td>
<td class="nump">2,548,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long-term</a></td>
<td class="nump">2,088,540<span></span>
</td>
<td class="nump">1,560,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cosm_ThirdPartyMember', window );">Third Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Beginning balance</a></td>
<td class="nump">2,557,023<span></span>
</td>
<td class="nump">2,511,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ProceedFromDebt', window );">Proceeds</a></td>
<td class="nump">755,720<span></span>
</td>
<td class="nump">828,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PaymentsOfDebt', window );">Payments</a></td>
<td class="num">(183,455)<span></span>
</td>
<td class="num">(634,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ForeignCurrencyTranslation', window );">Foreign currency translation</a></td>
<td class="nump">110,051<span></span>
</td>
<td class="num">(147,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Ending balance</a></td>
<td class="nump">3,239,339<span></span>
</td>
<td class="nump">2,557,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long-term</a></td>
<td class="num">(1,968,180)<span></span>
</td>
<td class="num">(1,437,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable - short-term</a></td>
<td class="nump">1,271,159<span></span>
</td>
<td class="nump">1,119,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long-term</a></td>
<td class="nump">1,968,180<span></span>
</td>
<td class="nump">1,437,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=cosm_TradeFacilityAgreementsMember', window );">Trade Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Beginning balance</a></td>
<td class="nump">1,397,385<span></span>
</td>
<td class="nump">1,908,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ProceedFromDebt', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PaymentsOfDebt', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(388,163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ForeignCurrencyTranslation', window );">Foreign currency translation</a></td>
<td class="nump">60,075<span></span>
</td>
<td class="num">(122,647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Ending balance</a></td>
<td class="nump">1,457,460<span></span>
</td>
<td class="nump">1,397,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable - short-term</a></td>
<td class="nump">1,457,460<span></span>
</td>
<td class="nump">1,397,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=cosm_COVIDLoansMember', window );">COVID Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Beginning balance</a></td>
<td class="nump">154,505<span></span>
</td>
<td class="nump">186,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ProceedFromDebt', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PaymentsOfDebt', window );">Payments</a></td>
<td class="num">(5,060)<span></span>
</td>
<td class="num">(22,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ForeignCurrencyTranslation', window );">Foreign currency translation</a></td>
<td class="nump">6,019<span></span>
</td>
<td class="num">(9,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Ending balance</a></td>
<td class="nump">155,464<span></span>
</td>
<td class="nump">154,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long-term</a></td>
<td class="num">(120,360)<span></span>
</td>
<td class="num">(122,635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable - short-term</a></td>
<td class="nump">35,104<span></span>
</td>
<td class="nump">31,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long-term</a></td>
<td class="nump">$ 120,360<span></span>
</td>
<td class="nump">$ 122,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ProceedFromDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ProceedFromDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cosm_ThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cosm_ThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=cosm_TradeFacilityAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=cosm_TradeFacilityAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=cosm_COVIDLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=cosm_COVIDLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTES PAYABLE (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>NOTES PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 2,763,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">819,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">666,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">378,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2030 and thereafter</a></td>
<td class="nump">224,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Debt</a></td>
<td class="nump">4,852,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes Payable, Current</a></td>
<td class="num">(2,763,723)<span></span>
</td>
<td class="num">$ (2,548,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long term portion</a></td>
<td class="nump">$ 2,088,540<span></span>
</td>
<td class="nump">$ 1,560,433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 12, 2020</div></th>
<th class="th"><div>Jan. 23, 2024</div></th>
<th class="th"><div>Jun. 24, 2020</div></th>
<th class="th"><div>Jun. 23, 2020</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
<th class="th"><div>Nov. 19, 2020</div></th>
<th class="th"><div>May 12, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,302<span></span>
</td>
<td class="nump">$ 7,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,088,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,560,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of the principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,398<span></span>
</td>
<td class="nump">$ 8,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember', window );">January 27 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 755,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-term Debt, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered into a bond loan agreement with Attica Bank, providing for maximum borrowings of up to &#8364;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#8364;700,000 ($749,600), which were classified as Notes Payable in the Company&#8217;s consolidated financial statements. The remaining borrowing capacity of &#8364;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 604,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=cosm_JuneTwentyThreeTwoThousandTwentyMember', window );">June 23, 2020 [Member] | National Bank of Greece SA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of the principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_DebtAmountReceivedFromRelatedParty', window );">Debt amount received from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 611,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=cosm_JulyFourteenTwoThousandTwentyThreeMember', window );">July 14, 2023 [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">820,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">843,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,123,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=cosm_JulyTwentyNineTwentyTwentyFourMember', window );">July 29, 2024 [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=cosm_DeemberTwentyTwentyFourMember', window );">December 20, 2024 [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=cosm_JanuaryTwentythreeTwoThousandTwentyFourMember', window );">January 23, 2024 [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common stock issued as consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_CommonStockIssuedAsConsiderationFairValue', window );">Common stock issued as consideration Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_BusinessCombinationContingentConsiderationArrangementLiability', window );">Cash Consideration Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of the principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_DebtAgreementJulyMember', window );">July 30, 2021 Debt Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 578,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,457,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - long term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_DebtExchangeAgreementMember', window );">Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 611,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_DebtAgreementJuneOneMember', window );">June 9, 2022 Debt Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accured interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_CovidNinteenMember', window );">Covid Ninteen [Member] | May 12, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Additional principal repayment</a></td>
<td class="nump">$ 5,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Loan from Related Party Debt</a></td>
<td class="nump">$ 366,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_CovidNinteenMember', window );">Covid Ninteen [Member] | June 24, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Outstanding principal loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Loan from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_BusinessCombinationContingentConsiderationArrangementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_BusinessCombinationContingentConsiderationArrangementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_CommonStockIssuedAsConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_CommonStockIssuedAsConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_DebtAmountReceivedFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_DebtAmountReceivedFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the principal amount outstanding for securitized loans only (across all types of loans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)<br> -Paragraph 4<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOnLoansSecuritized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cosm_JuneTwentyThreeTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cosm_JuneTwentyThreeTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_NationalBankOfGreeceSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_NationalBankOfGreeceSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cosm_JulyFourteenTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cosm_JulyFourteenTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cosm_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cosm_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cosm_JulyTwentyNineTwentyTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cosm_JulyTwentyNineTwentyTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cosm_DeemberTwentyTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cosm_DeemberTwentyTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cosm_JanuaryTwentythreeTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cosm_JanuaryTwentythreeTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_DebtAgreementJulyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_DebtAgreementJulyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_DebtExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_DebtExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_DebtAgreementJuneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_DebtAgreementJuneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_CovidNinteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_CovidNinteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cosm_MayTwelveTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cosm_MayTwelveTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cosm_JuneTwentyFourTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cosm_JuneTwentyFourTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details) - Operating Lease [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">$ 181,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">218,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">156,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2029 and Thereafter</a></td>
<td class="nump">202,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">759,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OperatingLeaseLiabilityLessImputedInterest', window );">Less: Imputed interest</a></td>
<td class="num">(88,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 670,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OperatingLeaseLiabilityLessImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OperatingLeaseLiabilityLessImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=cosm_OperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=cosm_OperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details 1) - Finance Lease [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">$ 10,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments', window );">Total undiscounted finance lease payments</a></td>
<td class="nump">10,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest', window );">Less: Imputed interest</a></td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Present value of finance lease liabilities</a></td>
<td class="nump">$ 10,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cosm_FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cosm_FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OperatingLeaseTermOfAgreements', window );">Operating lease, term of agreements</a></td>
<td class="text">The Company has various operating and finance lease agreements with terms up to 10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 4,603<span></span>
</td>
<td class="nump">$ 7,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OperatingLeaseCashFlowsUsedInFinanceLease', window );">Operating lease cash flows used in finance lease</a></td>
<td class="nump">$ 5,533<span></span>
</td>
<td class="nump">8,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OperatingLeaseWeightedAverageDiscountRate', window );">Operating lease, weighted average discount rate</a></td>
<td class="nump">6.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm', window );">Operating lease Weighted-average remaining lease term</a></td>
<td class="text">3 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm', window );">Finance lease, weighted average remaining lease term</a></td>
<td class="text">1 year 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease, interest expense</a></td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_FinanceLeaseWeightedAverageDiscountRate', window );">Finance lease, weighted average discount rate</a></td>
<td class="nump">6.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_FinanceLeaseAmortizationExpense', window );">Finance lease, amortization expense</a></td>
<td class="nump">$ 4,603<span></span>
</td>
<td class="nump">7,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General And Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">60,668<span></span>
</td>
<td class="nump">77,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease, interest expense</a></td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_FinanceLeaseAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_FinanceLeaseAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_FinanceLeaseWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_FinanceLeaseWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OperatingLeaseCashFlowsUsedInFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OperatingLeaseCashFlowsUsedInFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OperatingLeaseTermOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OperatingLeaseTermOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OperatingLeaseWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OperatingLeaseWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER LIABILITIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>OTHER LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_TaxLiabilitiesPayable', window );">Tax liabilities payable</a></td>
<td class="nump">$ 2,819,815<span></span>
</td>
<td class="nump">$ 2,552,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PayrollTaxRelatedCurrentLiabilities', window );">Payroll tax related current liabilities</a></td>
<td class="nump">1,350,825<span></span>
</td>
<td class="nump">1,191,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unaudited tax</a></td>
<td class="nump">624,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ProvisionForStaffLeavingCompensation', window );">Provision for staff leaving compensation</a></td>
<td class="nump">398,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomersForProgressPayments', window );">Received prepayments from customers</a></td>
<td class="nump">$ 447,872<span></span>
</td>
<td class="nump">$ 363,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PayrollTaxRelatedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PayrollTaxRelatedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ProvisionForStaffLeavingCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ProvisionForStaffLeavingCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_TaxLiabilitiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_TaxLiabilitiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomersForProgressPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from customers as progress payments on projects that have been partially completed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomersForProgressPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrativec) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Jan. 23, 2024</div></th>
<th class="th"><div>Nov. 21, 2023</div></th>
<th class="th"><div>Jun. 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PaymentTax', window );">Payment of additional tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and Development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_StockIssuedDuringPeriodSharesAwarded', window );">Awarded shares</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_AdditionalStockConsideration', window );">Additional stock consideration</a></td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Settelment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,993<span></span>
</td>
<td class="nump">$ 37,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ComplementaryCompensationShares', window );">Complementary compensation Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_PurchasePriceAmount', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member] | National Medicines Agency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,310<span></span>
</td>
<td class="nump">$ 231,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PhaseOneMember', window );">Phase 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ProjectCosts', window );">Project cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 838,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PhaseTwoMember', window );">Phase 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ProjectCosts', window );">Project cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 907,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_FourThirdPartyConsultantsMember', window );">Four Third Party Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_StockIssuedDuringPeriodSharesAwarded', window );">Awarded shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Awarded share value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_AdditionalStockConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_AdditionalStockConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ComplementaryCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ComplementaryCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PaymentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PaymentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ProjectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ProjectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_PurchasePriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_PurchasePriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_StockIssuedDuringPeriodSharesAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_StockIssuedDuringPeriodSharesAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of life settlement contracts accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 325<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481493/325-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 325<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481463/325-30-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cosm_NationalMedicinesAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cosm_NationalMedicinesAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PhaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PhaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_FourThirdPartyConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_FourThirdPartyConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS (Details) - Warrants [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning balance</a></td>
<td class="nump">12,926,506<span></span>
</td>
<td class="nump">8,561,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Shares Outstanding, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,748,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Outstanding, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,874,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Shares Outstanding, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(509,096)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending balance</a></td>
<td class="nump">12,926,506<span></span>
</td>
<td class="nump">12,926,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod', window );">Number of Shares Outstanding, Exercisable</a></td>
<td class="nump">12,913,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning balance</a></td>
<td class="nump">$ 2.63<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">2.63<span></span>
</td>
<td class="nump">$ 2.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 2.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_WeightedAverageRemainingContractualTermOutstandingBeginning', window );">Weighted Average Remaining Contractual Term Outstanding, Beginning</a></td>
<td class="text">3 years 2 months 26 days<span></span>
</td>
<td class="text">4 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_WeightedAverageRemainingContractualTermOutstandingEnding', window );">Weighted Average Remaining Contractual Term Outstanding, Ending</a></td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
<td class="text">3 years 2 months 27 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_WeightedAverageRemainingContractualTermExercisable', window );">Weighted Average Remaining Contractual Term Exercisable</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Beginning balance</a></td>
<td class="nump">$ 8,920<span></span>
</td>
<td class="nump">$ 18,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending balance</a></td>
<td class="nump">5,814<span></span>
</td>
<td class="nump">$ 8,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_WeightedAverageRemainingContractualTermExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_WeightedAverageRemainingContractualTermExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_WeightedAverageRemainingContractualTermOutstandingBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_WeightedAverageRemainingContractualTermOutstandingBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_WeightedAverageRemainingContractualTermOutstandingEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_WeightedAverageRemainingContractualTermOutstandingEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cosm_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cosm_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Aug. 21, 2023</div></th>
<th class="th"><div>Sep. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_DiscriptionOfIncentiveStockAwards', window );">Discription of incentive stock awards</a></td>
<td class="text">The awards are in the form of restricted stock and will vest in two parts: 50% on September 16, 2025 and 50% on September 16, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_TwoZeroTwentyTwoPlanMember', window );">2022 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share reserv for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cosm_TwoZeroTwentyThreePlanMember', window );">2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share reserv for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_BoardOfDirectorsMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,301<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share reserv for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cosm_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber', window );">Number of Warrants Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,913,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant otstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,926,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_WarrantExpirationDateDescription', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">expiration dates from May 2026 through October 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrant with no expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_DiscriptionOfIncentiveStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_DiscriptionOfIncentiveStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_WarrantExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_WarrantExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_TwoZeroTwentyTwoPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_TwoZeroTwentyTwoPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cosm_TwoZeroTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cosm_TwoZeroTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cosm_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cosm_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISAGGREGATION OF REVENUE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 13,712,528<span></span>
</td>
<td class="nump">$ 14,584,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_GreeceMember', window );">Greece [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">13,322,494<span></span>
</td>
<td class="nump">14,225,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_UkMember', window );">UK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">285,864<span></span>
</td>
<td class="nump">312,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_AlbaniaMember', window );">Albania [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">36,332<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_CroatiaMember', window );">Croatia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,093<span></span>
</td>
<td class="nump">19,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_CyprusMember', window );">Cyprus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">52,562<span></span>
</td>
<td class="nump">22,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_BulgariaMember', window );">Bulgaria [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 12,183<span></span>
</td>
<td class="nump">$ 4,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_GreeceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_GreeceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_UkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_UkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_AlbaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_AlbaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_CroatiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_CroatiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_CyprusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_CyprusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=cosm_BulgariaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=cosm_BulgariaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 13,712,528<span></span>
</td>
<td class="nump">$ 14,584,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="num">(11,662,729)<span></span>
</td>
<td class="num">(13,250,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">2,049,799<span></span>
</td>
<td class="nump">1,333,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(1,478,702)<span></span>
</td>
<td class="num">(1,418,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="num">(1,040,019)<span></span>
</td>
<td class="num">(1,258,179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="num">(28,155)<span></span>
</td>
<td class="num">(173,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(320,439)<span></span>
</td>
<td class="num">(319,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">556,611<span></span>
</td>
<td class="nump">340,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction, net</a></td>
<td class="nump">175,824<span></span>
</td>
<td class="num">(161,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net profit/(loss) before Income Taxes</a></td>
<td class="num">(818,097)<span></span>
</td>
<td class="num">(1,866,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="nump">11,662,729<span></span>
</td>
<td class="nump">13,250,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">28,155<span></span>
</td>
<td class="nump">$ 173,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cosm_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(361,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="num">(255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="num">(15,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_NetFinanceCosts', window );">Net finance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SegmentProfitLoss', window );">Segment profit / (loss)</a></td>
<td class="num">(377,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(35,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="num">(556,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction, net</a></td>
<td class="nump">6,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OtherIncomeAndExpenses', window );">Other income and expenses</a></td>
<td class="num">(193,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net profit/(loss) before Income Taxes</a></td>
<td class="num">(1,156,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">15,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cosm_TotalSegmentMember', window );">Total Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">13,712,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="num">(11,662,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">2,049,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(922,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="num">(1,040,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="num">(28,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="num">(15,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_NetFinanceCosts', window );">Net finance costs</a></td>
<td class="num">(95,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SegmentProfitLoss', window );">Segment profit / (loss)</a></td>
<td class="num">(51,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(320,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="num">(556,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction, net</a></td>
<td class="nump">175,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OtherIncomeAndExpenses', window );">Other income and expenses</a></td>
<td class="num">(64,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net profit/(loss) before Income Taxes</a></td>
<td class="num">(818,097)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">15,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="nump">11,662,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">28,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cosm_WholesaleMember', window );">Wholesale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">12,504,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="num">(11,320,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">1,183,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(162,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="num">(378,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="num">(715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_NetFinanceCosts', window );">Net finance costs</a></td>
<td class="num">(149,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SegmentProfitLoss', window );">Segment profit / (loss)</a></td>
<td class="nump">492,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(52,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction, net</a></td>
<td class="nump">59,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OtherIncomeAndExpenses', window );">Other income and expenses</a></td>
<td class="nump">27,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net profit/(loss) before Income Taxes</a></td>
<td class="nump">526,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="nump">11,320,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cosm_PharmamanufacturingMember', window );">Pharma manufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">268,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="num">(70,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">197,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(155,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="num">(363,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="num">(428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_NetFinanceCosts', window );">Net finance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SegmentProfitLoss', window );">Segment profit / (loss)</a></td>
<td class="num">(321,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(131,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OtherIncomeAndExpenses', window );">Other income and expenses</a></td>
<td class="nump">12,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net profit/(loss) before Income Taxes</a></td>
<td class="num">(441,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="nump">70,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cosm_NutraceuticalsAndPharmaceuticalsMember', window );">Nutraceuticals and Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">939,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="num">(270,818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">668,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(243,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="num">(297,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="num">(27,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_NetFinanceCosts', window );">Net finance costs</a></td>
<td class="nump">53,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_SegmentProfitLoss', window );">Segment profit / (loss)</a></td>
<td class="nump">154,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(99,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction, net</a></td>
<td class="nump">109,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cosm_OtherIncomeAndExpenses', window );">Other income and expenses</a></td>
<td class="nump">88,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net profit/(loss) before Income Taxes</a></td>
<td class="nump">253,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="nump">270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">$ 27,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_NetFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_NetFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_OtherIncomeAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_OtherIncomeAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cosm_SegmentProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cosm_SegmentProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cosm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cosm_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cosm_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cosm_TotalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cosm_TotalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cosm_WholesaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cosm_WholesaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cosm_PharmamanufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cosm_PharmamanufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cosm_NutraceuticalsAndPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cosm_NutraceuticalsAndPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - Subsequent Events [Member] - Grigorios Siokas [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 24, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock | shares</a></td>
<td class="nump">1,466,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationLiabilitiesSettled', window );">Equity issued in settlement of liabilities | $</a></td>
<td class="nump">$ 526,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationLiabilitiesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset retirement obligations settled, or otherwise disposed of, during the period. This may include asset retirement obligations transferred to third parties associated with the sale of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationLiabilitiesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_GrigoriosSiokasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_GrigoriosSiokasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )%*KUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( )%*KUH(^:>4\0   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL].PS ,AU\%Y=ZZ:54.4=?+$">0D)@$XA8E
MWA;1_%%BU.[M2<O6@> !.,;^Y?-GR9T*0OF(3]$'C&0PW4QV<$FHL&%'HB
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M]G!AXKDI&P/X_J& 7&%[TKR9M'L3[?3_4$L#!!0    ( )%*KUK$.3)5K (
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MBL(E"ZW],M]N-BF7T3Q*T2@IXS0OMT7-RFF>=>MNF]3?E62GR:73U0%-ZI
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M!)K(A4D_M&I"L>#E,,N>9_K(CMM+Y%9=38%C(VLVXXISZFS&88J8D +K!UI
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MHAK42(A4PF'R=Z=3Z(,-@;JP:FABG)^=I\>DL;7$-/CET>(\/3T_2PY&D(W
M?I@$F/N<?8O412@#R$;NDK]Q .6B@#;"8&M=_>WBL[>N2-62MB3QE/39M\ $
M*^OMT"?!T-0J.AZ7!C0E#P;M)C7("4[_T'8N@N-B"R@)#(I&^(3:*.]"V)5(
M@NG&938H^0Z\>03 UFB/DZJ_Q]B.[64J>YO"[>QO2">S:\8&>O9-R1_;FI"A
MJFT[8&$74337E5EGU<INQ(=:'!*;H1]AD2GH.U!SMP+Y%S*MGP-$98R&(]SY
MI!+GRB&HV?C&2#I_WIMBS8/FIG7/1[/ZQ2:G#62W2UB$<P.%&$<80I/HT')]
M_ZJLK*7.NKJZ<P)NA3IUEV\6H+O(E DD)[M<S15094-\K[\@N#I40=TBZ;TV
M.Z0?<NB!PRN4*K5R["G'JZ8;78/T*ML\-A^5.J=(BC"Q/2SC7/R@[14M"F'O
M*P=^.]?Y+-SBVK!(!\,V%J$JG8]_6/QR3E[.2!2H.Z>@#O7AR?(\7<Z/1.:>
M'!VGR].C2-ZFOK:K=#59WZVF23B \7LTJ],&ED[URQ9!/SO%6!7X2@O_%_<3
M!P9$@A+GEH3QH=2E3=L3FD/#^%N^0 +/:SY,'-9P-6W:".,\A,P5S'B$/ZZ;
MII!=;;/\J[AX-C8% W%F9JG^9/8V);J(P6U+7J"-%:D?CH_.6*<SP.$0I6@R
MA:R TL':W1&Y;8 6:P"*![68S_\DDG868X^.K<K0J&,GXYQ\[PU($0M;,G6&
MC2_.7/.!Q5&'#3K/8 ]U:ZEU&74&0TV2-0T+Q0)<"@M-GI'S'K?KNTX;O&H;
M^"8:*34:!8),M9Y6"&VGX#SJ\K8>.Z)]ACS3..;F[)@01'&2>NNP=$.'Y&ZI
M I8D$B1 ;CA!_PY[W5-CZ\^)4+&1>4U52MF/>-DL,S'I(#YP5>+TV8LC%CO4
M*D<EFS FS;X(7$\.PI'\88BM)]PWZ00>;<)NA$K=+7'"+'G?1#$@G[OQ66P;
MMB!:49/8,A<4F=9]B 3"KAP29JY2BN%X;4NDQ%^(?O/E4['+ "9/Q>TCZ3%L
M!HWBHO4Y+]6B?15\XM9ZC4-9G01G'$+@D"]A4,UTH]WI0V=@2%;ES2BK7Z$)
M;,W,N$'L0(/)/I+A@+#!$A9/B.>VECYXCH3C<,UHN95QE=I6;@91(9NZ+I#+
MQ@/<I/MV&B06+>@/D0Y:7#Q$0RT<,0RD;%!5T 5ER\N30S)9Y=N_&=H>]-ZI
M?O$NRQ&SY9XD_>H7HN 2$<649.0W;L <G>&)QID6]A'PR=!;J=<UJY[SCT>'
M%IKH"%4_B"?QY"P].7HB&FVQ6*;G9\<N<1&%!Z2H=4*Q2B_#-"FZG$KW_0%2
MS>"+"UW.,@C!.#>1 S"2WO6%/E>F-BM-=C9*.:[+2[M&T"N&P(JU[*14Q9<<
M!X:U/$%LBWB(IJHXTX$*052W1*"7R%NQ\'=#'8.-L@&(W>"'3NN<X$SV8O18
MH_,*N7\K!@00S8: _B2&' HA+LQVN2J.4V@9\B"M$:S1[EPI75R'3936LAZ'
M#"3I4%7!G0>0Q]-PTFFLB \D9>9ZS$3-YMFV[&WWJ<T\,':MN9PE.=&#:$BB
M<?"=5HK;CZ.@6Q .%>L !Q=E5E"6S'B]8J^WCR8#5/W=5C6T,@'3&2$%F@]E
M%:N>VX#X*,-T9#HBU/$9WR]#'1[# 4%_DKC"]TI:,4RR7L%W M$X21:(OHB"
M@T,A^\&V,@2K@[\,YN/Z! X$!M&!L%:ALYV_QD5 ?;F!-FN"RJ#]KDP<#7VS
MFAP>.D_!>/TY'37R<8 \"B+[/.=XYHB+4:'&X0*-ZK20S1P?X12@,-2]'-G'
MO1\I4U[?#KE\0D17C I-HOPV$(&N!"!M1G7VQ7>%8;K#0W 1LC9P^JV<0IF/
M+ #+U!9!2^MK\(43II"'A8'UW8^TLQ7 [+Z, VF\()-QRX>C77K?-0"(ZR=(
M]&:<'A[8Y1G3L%5?MM*9+_1XK'=2Z*4@FJ,=/>E4H]5E$Y<+[+F30^>-,Q'<
M 'P<=%N\U5$N\7"Q%P30'L(A?"V+@T<;,+^SS*7J\O"JK3 'S$)QA$L#^Y^#
M#L)4\$2XQCN&;[=B/JOKP;HO3NY"/+ ;JM*!'85()A!\+=?I^U(DY1>_ME),
M9BL;N(A-14(8!Y;(2@Q8T$,[M17(2;GO)QTMND<B[+:2PBBX"LF:B,%[SI:6
M,\GN=VP$3$#R^X(/=?/[T+4/>HD(HV&(U@\?B\R\Y?P\/3_2R,7B_$EZ?G+R
M!^R\G9""%\T$WMNFOCY\6^+ZM L!;5^*_W1^B%L1^($J>(#O7YIT6Z;:^U5B
MH<3@7ZW5N)1/R66?AOL4MWC#-_#[4X@EN89B)=X2BP289M:<N+J3=#S)^K*;
MJ.F; ,<:LE[*(C#JVA;%1O8)Q:AVDF"Q_=V^#%^,ACWZ.ES9ZNZP0O%[RX\U
MND8%X\2PA426O+H+V@GNU?*A,;';&6NU9-#[5(:-%(&IZ>-;L01RN--]!3L-
M,(P(M810>)44!C"NGBV#181D?OE1#DP#%AQ7N3B=32)E![,S-B^('-])(<D;
MER76Q1N^J,6GCKDD.V@<XXCP(6*^4JX:=Y7MZ_1@U/EB*O,-A;:=&;5>K @[
M'%NUUJSOZ(O+'U%@F@>=$ *P,6GPB?=4NL2E2@1_3YY4K[OX9*@Q!8-"R-S/
M9Z.WI+]K=N)'Z]Y3K*#H#I_,5BO"!#''Z"J!Z4K\N YT3T&;N'ANV]@I!XL/
M28+5AS01K@]$G"P6B/]MPG"$]@W,OPFA&%9U_M-T4]8\:K/8,A_/J?YN#[!M
M9-(S]2R@9-Z$XOW2Y(/<@#$>H.??^0%LRD;4DH5+B+X*\!3\M+>*Y1$V=>"X
M;K1:W+@;E)$A( 9EP1^BSF:M+K-5(L%\8@H22!I'=MRV04[!HLRS5!CLG +0
ME<M8617'ISE%4];CB7WH)FQ$B?I/1@D,=S=!T']X;ZOQ/:!JM1V' ,PXHJYW
M4$T +.7V5_="[<_CC\(- ;M+=4Q5;/WM:H2 Q&(Y;R21FL4ETY7>''S#'FK(
M'%]4[+'OX4;%<^I4W8CQNG%@N [%2%CWITQC.<37@G%N4Q.-$BA"_#HL.0C[
M+=APX]Y;^&%!GCB$:22 12RZ6])[]JYXQ#X$E=I5S]5I* =VB0._S+[V_!"0
MZ JRQ6EZ>GIJ>\!5%:)RE -#F;L=P 7P'\YG3TY@T:N>::+V\)/T[/@)_GQO
MKX-^@>(C^D)RK#[FZ"_U";7NPS,"YV1:V-$D'XDZ<?4PSQH6#;;L,@)H]0#5
M2)("B+ !(%)&6J[*5ULLR9R??D:OH_6%X:.KQ99S7R'!,GBZT2J,N(6V7<U^
M)WB<:T,1?)A9D((R:V5OF"X:_;#1TF RL8AM/H;M%KW8;J+==KHO5]U$Z>/1
MC 2G._TJFQ W,82NEEG+'#"0&<H_K2FG#'5C0;-:=H5KC=&$M&\ICQ5& "J>
M@ED[K0XIXXZD*UM 8/PE/<[^1\P+.6NY2Y=O"T#M<FE5$7?5)%P_4-V%/$_3
M]K=(?:F9C,A6B4MZ5?J,^5BNKHEIWV[&=0D&R)8 " L&SMO\-MB3V63?2+C\
M,SJ:0%!Q48?0'C?HCT8.]<Y86[IKGVR-NX2+/1D$HI\F;W'M9;)XFGS868N/
MC-#_V]#T''G@*I9'0VUE[($TA;,0LVU'L<B<[.V:Z:++IV0(\4I:;$12>+28
MTZ9^=ZEM@'/Q4+WV43[Y74LZ(9YO%<CPZ;ZSW1T!Y;NS3*J%O5/:N2+K0-:Q
MV#AZ2JIQ]\"='T.3]16+Y;JQU(ER=Y$$4HW;&J3 @ZM,Q5O<WY(:77HZN')M
MWU#?=,ITV01'*"=R'B=J7A,..#E<S ^AI +I^V$K(V(YJR.]M+5BI.%2\:%6
MVTITZ3Z!%=U-X1M3N7Z#.Y8Z?Q$ WV/7\.X:.PN*V>^"*4K?-":Q14T*";5J
MGC^V_$,E9)N:C+N;(%0.6V]A:%D!X M"\Y-PS/@N"O>3AF^=K\>+<"9Y[PS3
MU8>3D<"G]M*QJ7I;E^O?+;U-M0LJ'#XN"T*4$0095@FYMSM(&299USXG+P5
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M3/!.VI4&?)29T&E-IX"C^ _ GY6BW)E50WX-O.T0RH)XFJ) _G984KB,O;W
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MCQFMTVA9@+XOC/'M"SO8+.CC?P!02P,$%     @ D4JO6K [B8@, P  F 8
M !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULK55M;]LX#/XKA'<8-D"H
M;?DE3I8$:-8,&[!VN2[;X3ZJ-A,+LRU/DION?OU1=N+K=EV  ?L2DS3Y\*$4
M/IX?E/YB2D0+#W75F(576MO.?-_D)=;"7*@6&WJS4[H6EER]]TVK411]45WY
M/ A2OQ:R\9;S/K;1R[GJ;"4;W&@P75T+_6V%E3HLO- [!6[EOK0NX"_GK=CC
M1[2?VHTFSQ]1"EEC8Z1J0.-NX5V&LU7L\ON$SQ(/YI$-;I([I;XXYUVQ\ )'
M""O,K4,0]+C'UUA5#HAH?#UB>F-+5_C8/J&_Z6>G6>Z$P=>J^DL6MEQXF0<%
M[D17V5MU>(O'>1*'EZO*]+]P&'(Y)>>=L:H^%A.#6C;#4SP<S^%101;\I( ?
M"WC/>VC4L[P25BSG6AU NVQ"<T8_:E]-Y&3C+N6CU?164IU=;FX_;-:WV[_A
M\N8*UG]^>K>Y7M]L&=RLMW/?4@.7YN='L-4 QG\"%L&U:FQI8-T46'Q?[Q.Q
MD1T_L5OQLX#70E] %#+@ 4_.X$7CM%&/%_V>:0>P^&DPMRXSTXH<%Q[M@T%]
MC][R^;,P#5Z=H1J/5.-SZ+]*]2S8TU1O/FS7$,/S9QD/PU=PIB%L-*F MM]
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M4)TWD1.=3<K<*-H5Y&>FM_>+V?W'VZN[&YC-YS>+^=@W!&LW_>H <=5#1#^
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M/^#U_[_"!F#P:P"^%N>N$AE.(JI[A_8)H^F'=\FH=_$&O4%+;_ 6^G^A]S;
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MS,C)7 HK"92P"'.S0*LI6KH*>3:H08EE* I[9MA&[6L8+,* :ME:<,7&XU^
MCIDNBD4RWJJWH^HUWM@5%%(+G4DJ(:\A'7">\!0>+8B:"EE;N4XB\A]T @2+
MW<RZK?DB]3PWU4]1W!)#%V8?W9?6@?K1_TO]/"!];=,'VX+J2X-%@>'$W^#/
M):U9DJ@EV($)JVXMZ W,WH'PT$TEU0KR!KD5!"R$:D1[GRBZT(@.$Z9BL2S%
MG&Y!YT'394HW UI+BX&-<^BY$7>W'S/9M0_?.?:\4<(2!(L+ON1VQ65D-'*A
MM:2%VG@J'->9[FDE_^H 4Q8DEJF2KGR%"O<<[UYH9:JY:ZCDFRR4M\DP8,V$
MM2L"&L*0-@I84H4--;,G[="E354%&0Z0E+N7U*CD(RH6HM#!C 8^Q-K%:2F5
M8L^6 >8QW#9V7012FFIRJAQV) A':GQ)V)T,F_XKQO-X ,XT-FL/N.>GR[M0
M#HUSL6U..TF%@U+2O<NGH0)EN+#O*!$1TH&[8(*-(GV3XK*605?G5"KI5YR-
M\NZBM4_+'RAYE5+5NN7GPJ:3T@&_LCS]L=9V[M]:@;2R3X4O)#CH#K+!1HM?
M8OCXWT_@EYAYIS<=HMOV2E%C(;U+\(F>EU1A1L4??S16NERV3[9EB20;$M'S
M"VESBL6[KN%DZS5$E]H\O/D<[YGV[<.H7^V?E>?M:VICWKY)B>6<Z@D*"W(=
MQL='$=CVG==.O*G#VXK$1R^U,"SI:8R6#>A[8:@5NPDGZ!_;L[\!4$L#!!0
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MW$B%#MSXFFVM0F;W,I@D/.J_Q \,?A,8]T$7NUES>%J[_%"/BCYND#R;88)
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M#W7GF^D^A/C+M$_ ;I0637"@5++8=1;AH(/<VOIM$-],1TP(0E8M;%U7%7@
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MZ*#_4JH-_=1NH<I2Y?1Q+3CX%#X ]Y<*[6"_X 3U;R]?_R]02P,$%     @
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MR+(]# A*7KE?^JWE87!@&MQS(&H/1!:W4V11OJ:&'A\JN28*=X,TO+"FVM,
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MTM#G@QM6]+V&RAK0\U)*,T[L!MLOP,7?4$L#!!0    ( )%*KUI$$H]JNP0
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M\&&M 2$8H^&]_+<?CI,!9@^OU&8!LUQIFZN-DE@+@@G%,,4YQI?6G2$K1L*
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M!:&#!V@+5$K$>&\$XA)%-K)J45"HL@-/$#?G28\UI_-D/!Z#-:<GR>GI^$!
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M?>8P%E<BQR[5RH!=74(N8=%&?F5,%)).W4<T77>KH%HX-,M#!U#'4K0>( K
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M\#R_[!JT3[.Z46GKQMD*W['5@Z\R,VL-]UG,X_WU7<15@PLK<#?A28-?F>I
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MO6'B@>[>L<ZPJF[?CH6R=$3;84%//VKG0.M+I>S6< EV?R:F_P-02P,$%
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M=&RKH)7!>P>^*@KA=C/4=CMI]5K[C>]JG0?>Z$['I5CC$L-C>>_HJ7M D:I
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MO3B]Q#_?9Y)??8WYAO %)Q5X#[-O^A8J $\O )RS?F8'DWP$ZJQ-D]&L82E
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M)<G.>N:[:H/WPFMA)R6?H#IQ(OU"@FG2"% **P6XR3QV#*9WX7>GXY^\'S'
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M6ZIY^C8+(ROWW'R0!A^O[K/ _Q:HL@)XGDO,;[NP#KK_/V;_ E!+ P04
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M0H.+4>*![G=2KUC5='M@HRQME4XL:(VC=@YTOU7*'A678/@QS/\#4$L#!!0
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M::B@G+BA^8G*&M#Y2DIS5.P%PT2>_ !02P,$%     @ D4JO6C?*UH+/ @
MX 8  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULI55_;]HP$/TJIVR:
MF)0VOX%V$ G:3JO4=@C8IOUID@N)FMC,-J5\^YT3"-U$F;8)B9SMNW?O7GR7
MP4;(1Y4C:GBN2JZ&5J[UZM)Q5))CQ=2Y6"&GDTS(BFE:RJ6C5A)96@=5I>.[
M;M>I6,&M>%#O360\$&M=%APG$M2ZJIC<CK$4FZ'E6?N-:;',M=EPXL&*+7&&
M^LMJ(FGEM"AI42%7A> @,1M:(^]R'!G_VN%K@1OUP@93R4*(1[.X38>6:PAA
MB8DV"(P>3WB%96F B,:/':;5IC2!+^T]^L>Z=JIEP11>B?);D>I\:/4M2#%C
MZU)/Q>83[NJI"2:B5/4_;!K?\,*"9*VTJ';!Q* J>/-DSSL=7@3TW5<"_%V
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MR]NBBCN^Z\9.Q<K:2D=M;"'3D=AJ7M:XD*"V5<7D[RERL1M;GG4(/):;0IN
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M <SPB!D63F_#PV&I'9XA0=S@W:>,5\#Y2FOWN/ .#B_)V;]02P,$%     @
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M3V703@:H9D(U"ZK94,V!:BY4HU#-@VH^2FL'L6EXD,4-#Z<VBHO+1H<*VN,
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M.5C>;[+(/7!1QN<G>M\:"RVA<RQ*VO!TS36W,?_W30)38RI=LT_.%5)@V^)
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M!.#\6F!1:3IF@?;+E?X%4$L#!!0    ( )%*KUJ'H%]-\ (  "8(   9
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M)3C(O-_\%Y[?H.@^>-XE26")4NNZ@R41^:V4=Q3?9,:^X JOB:RYQHL<A [
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MR?,+-^EJ7=4OG%V<;^F*W;+JC^UU(7X[.U"6Z8;E9<IS4K#[3R>7^L?$T>J
MYHB_I^RQ//J9U&_ECO.?]2_Q\M.)5I\1R]BBJA%4_// KEB6U21Q'O]HH2>'
MG'7@\<_/]+!Y\^+-W-&27?'L/])EM?YTXIV0);NGNZRZX8\1:]^07?,6/"N;
M_Y/'_;&.<T(6N[+BFS98G,$FS??_TC_;"W$4(#CR *,-,(8!U@L!9AM@#@(\
M[84 JPVPWAI@MP'V6]^#TP8X;WT/;AO@#@->NJQ>&^"]-<.L#9B]-4#7GC^Y
M1I)G^X^\T8M/*WIQ7O!'4M3'"U[]0R.Z)E[(),WK]G%;%>*OJ8BK+FZ"+Y<_
M I]<7][\^$_RX^;RV^WEU8_X^[=;\LYG%4VSDGRC14%K&;\GOY$_;GWR[J_O
MS\\JD;UFG"W:3)_WF8P7,NGD*\^K=4F"?,F6DOA0'6^^%A^]DM]0 ,[$93M<
M.^/YVGTVE$2?+4Z),?M #,TP)2=TI0Y/=KD(]UX,]]7A(;M3A@?J\*_TB>AN
M$ZW+/HS7HHM38NI-N"T)G[\]W))]E&^X\(KP^.WALBN7O#W<4,C(/#1!L^%9
M+_#BO&(%*RN2Y@N^8;*6I0347Z$?RRU=L$\GXCNR9,4#.[GX]2^ZH_TN4R42
MYB-A 1(6[F%. ZNKA(>+F6X:SOG9P[%.QT?IFNTZ=O^P"'EF,1*6@& ]Y5H'
MY5I*Y7[?565%\V6:K\BV$/)-MS03Y4I&\X54QTK<5!TC83X2%B!AH352J.79
MAN&8 R4CDT:2I+KFB0;43QI+CG,TQS#<_G$)Z.1Z*K4/*K65*KWBFXVHQ$4Q
MM?A)RC4M&$G+<B>M(3XK45,5BH3Y2%B A(5[F'TD L,U/,LQAQ)%9HTD64VG
MENB@[XZ161,0K"=DYR!D1RGDR\6"[_*J%/>E"Y8^T+N,J3I;)6RJE)$P'PD+
MD+#0&9<#EF'KWFP@JCDR:R3):EJN-^KC8V36! 3K2=D]2-E52OFZ8%N:+@G[
M<\ORDI5$5!&$5VM6B-O>HF!Y16A9,J'UWX3:,UJQ)=G2HGJ2"5V9:JK0D3 ?
M"0N0L- =]9ZZZ9FB]AWH')DTDB75-=/S!C)')DU L)[,O8/,/:7,;]@#RW?2
MWED9.%6T2)B/A 5(6.A)]./JAFT,!#27'&C9GF6Y@PXU0IY>C(0E(%A/MK.#
M;&=*V7[A-.]5&8-.^-!';WE1CW++]*W,,%7?2)B/A 5(6#@;R=9QQ,W4L$]&
MYHPD.?5Q0XF1.1,0K*=M7>M&O#6ENN=%NN)%RDMRF_*?M"3_]95M[ECQW](Q
M;25KJHZA-!]*"Z"T$$J;0VD1E!9#:0F*UF\;1VZ0CAW14_,FMP\DS8?2 B@M
M;&G'_:XVZ.:A":.6YO0Z^IDUZ.:A.1,4K2]FHQ.SH11SR N6KO*V6GDB52'*
M&E'&O%"QJ&F3I8RD^5!: *6%+:TW$N>X0S$C4T906@RE)2A:7_2=F:BKW<0K
MFE,2\:SNPDORA=[Q@E:BW&'E\ZOD2[I)ZUI>6?= +4<HS8?2 B@MA-+F4%H$
MI<506H*B]5M-9V3J:B?SEHDOB?KVMN";M"QY\41R7LDK'JB)":7YNL2/LVS7
M-@:U10!-&T)I<R@M@M)B*"U!T?JB[WQ176V,^JQ<%.FVVD]UW(_O5)RDS_-1
MQ,N'>P!I2X":I5":_\I;CX_>8[5FY/IPKW.YJ3TVLLN7K!!_2DOR370$M6^<
M980N%L6.$5H12L37*B/L'SL1(RY:F#X("BL6];#8._N7]V2;[4JBDTT]YXQ\
MB3]_OR%;@:1YOMN((TXM]Q="2\+OB<\6S1?Q84Z2;'9= +T^(90VA](B*"V&
MTA(4K=]D.P=85UO _O<K<KVFQ8:2V]/+4W4)!S6 H30?2@N@M!!*FT-I$906
M0VD)BM9O&IVCK*LMY3=,HU03)K<(J%4,I0506JB/C5O+MEQC>(\_/LPVC>%\
MG AZ;C&4EJ!H?0UW=K&N]HL/&JZ+"ZF"H;8QE.9#:0&4%D)I<R@M:FFZ?CP6
M?*K9PWELT*P)BM97>N<PZVJ+N9D ]+2IJ^7]K4=95]';7;%8TWH^D"B+T_Q!
M_%G<BDL; M1?AM)\*"V TD)][/<:,ZW^;]B90UUF*"V&TA(4K;^&J+.C#;4=
M74^V(*+;W\ADKHZ=*G,HS8?2 B@MA-+F4%KTBAYTC3PQ6I0RX4-/)$'1^L+O
MO&9#[35_I=6N2*LGLGRAV%''3Q8_U%N&T@(H+832YE!:](HF#FOKB*&9AK0)
M0!UJ%*W?!#J'VE [U(<9_:(6:B;:U=.@]X.,1W.CWS %6IUG<E.!>M=06@"E
MA<;8NS8MV]6&M[;0K%%+.[9I#&OF.L-YT-"L"8K6UWIG3!MJ8_IYRK]B,I&:
M,%G%4-,92@N@M+"E]<9G#'=FC(IZ:-H(2HNAM 1%ZXN]\Y,-M9\L6ZKUEFX<
MZBU#:3Z4%D!I84OKW=5:SLPPK6$#@'K+LK3&3'Q].,..'&H;HVA];7>VL:'V
M3K\WR[2>JQ.IC*'&,)3F0VD!E!9":7,H+8+28B@M:6G']91KSV:VU0VA]K7>
M^:V&VF^]VFUV6;/W#:%9QA_KRH7<\X(L^>ZNNM\U4P*:GE[:#J .+)3F0VD!
ME!:VM/[Z+=D@)31M!*7%4%J"HO7;06>N&O^/ZW75N28W"Z@-"Z4%4%K8THZ[
M.=.V1+TQJG*@JW9E:0W/TFQC6.5 K5@4K:_XSHHUU%;LY:I@K/&GZK'Y-']I
MC!)JR$)I/I060&DAE#:'TJ)7E'$\1BG=_"R&GDZ"HO4;0N?4&J\XM:FXA2V;
MN8O;@B]WBTK:#J!^+)3F0VD!E!:^<O'U#Z+H(=OF(Y *'^K20FDQE):@:/TM
M^CJ7UE2[<M?MS(1E/3.!+I=I/6N:9B1+%R_>!JN14]L$E.9#:0&4%D)I<R@M
M:FG'Q9!MV):C#VJA]KCC6QC7M&;&X+@$=79]67<>K*GVV^*-*.N+ILP1\BY6
M\MTGH3XLE.9#:0&4%D)I<R@M,L?KC\6A,\L=ZAAJMZ)H?;5W=JNIMEL5V_&H
M(R=K'&J@0FD!E!::8RM3-S73&1JHIL1H]2QSV!]&T+.+H;0$1>NK]VB;X%=6
M]O8WW:D+D1O^1+/JB1QN5J72QNX>C-T^&+M_,'8#X;&K:KK>>! 2FC6"TF(H
M+4'1^@V@,U5-M:GZC>>_+?ZOC0#JK$)I/I060&FA.;8X=<^;F>-6 '56H;08
M2DM0M'XKZ.Q7\[6EJ_6T^((_'6;+2_4.M6"A-!]*"Z"TT!QO*RRT;FC#'08E
MQ^G>3+.\83T#M4VAM 1%ZPNY\U9-M;?Z/*12]^%W!:T?RD&VS=K6!=M5Z8)F
M\E&5\6ZYIFW./&O0(UU)#M1GCNT,NRY??9Z3]0BU0J&T.90606DQE):@:'UM
M=WZIJ?9+C[=6$/*N4U"A]L8V78J[T(QO7ZQ4H.XHE.9#:<$KU_#'FI&*5S0C
M"U[OU'"_WXYA6_#_88N*/*991NX8^?4OGNE8O^L?+,/>CY;7&R_\_?)'<[&?
MCUKR7'0T#\V>#J),K#N:QL8NR3VO)W:4'XGXS.K=PGZEF^WOXI?#AT3>M2G<
M?8+WOY,K7G\#9TV&Z[TI0K[2?'=/%_6:AGQUB#%LK8EI#KT2;['NU\AMM5L^
M-2_=/"OC.<!J T[)[<^G9JD_$:=*[OANM:ZWG=A?D7H0NEDDY^F'(>AZ6XH'
MFNV:#K6EV;;UP1;7Y-U?[9GYP="L]^1QG8ITXD*:WNE,_V5_78^O](<7MJ60
M3<</H8J80VD1E!9#:0F*UN^?.G?;5'N8B!U^U2DF=U10ZQM*"Z"TT!SO3NTZ
MXIY*'Y:84%-;DM767=O6A@.^4.\:1>O+O/.NS7]S(^N<YV]1.M3<AM)\*"V
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M'LA(63D#E@M!\V*,FE(AA[+B="GG9LQ4@;P_IU2\+-1D5D_BT3]02P,$%
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MGLOJ+UIO^H9>#Z5+J7A1@V$$!2LWG^1'+40+,'2. -P:X.X!(' WP*L!WC[
M/P+P:X#_4D!0 ZJI#S9SKX2+B2+C2\'72.C>P*:_5.I7:-"+E7JAW"L!OS+
MJ?'O'S\E]^CS>S3YDL0?OZ*W,56$Y1)](D(0G<0S] OZ=A^CMS^?70X4A-3
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M4RP>K]+U[O_D6_-&'!3HYI$"HRDPN@7VD0*S*3"[!=:1 JLIL%Y;8#<%=J?
MTXX4.$V!\UH%MREPNP7.D0*O*?!>JS!I"B:O+="UYT].>^U'I^\_[-U!MSM*
MZD/,3\KD\B+/'DE>O5[PJE_JX[2N%T=6NJXL]:7,Q5]345=>?OKM]^ +N;GZ
MU]6'7P/RH\_+)%T6Y%.2YTEUL/]$?B9_?/')C]__='%>"L&J['S6P*]W<.,(
M7"<?LW6Y*$BPGO/Y0#U5UYLOU8<OZ!L*P+EXI_9OE_'\=GTPE,2/R1/1C5-B
M:(8V]'ZHJ^-D?48,LRZW!LK]%\JW5;EU5#UX3;EYM)R^M.OY&3'UNMP>*)^^
MOGQHWT-UN<]GRO+HI7U?BG*M+M<'RF-U^:?LX8SHDZ-O'7OM4:.[BH/0W'O6
MK''6$=QGODF>1+-6DNQ.-&O+I.1SLDGR\FE@TSXH656+_:[8)#/^_D0TR07/
M'_C)Y0_?Z8[VR]#QC83Y2%B A-$=S*EA5:?DX=(Q->/B_.'P>.^_R+4G$_E%
M(7*S(B0L1L(8"";9P=K;P5+:X5-6\D(<_T_)[9*+YFJ9K>])R?,5V61YU6\;
M<H42.=852)B/A 5(&-W![(,#WM \S[:TCC&0HJ'5<YEN.YIEFK)HA!2-D3 &
M@DG>L/?>L)7>N)K-\JUH'=*U, 0O2L*_B<%8P8LA3RA18SV!A/E(6("$4;OO
M"=O6)]VV JD9#F@:NF=T;!@A-6,DC(%@DB.<O2,<I2-NVJY3N>!DDZ?K6;I)
MEF)@ODS6,SYD#"5QK#&0,!\)"Y PZO0.4MN<>!U;.+TO=\_UW$X7"KE9$1(6
M(V$,!)-,X>Y-X2I-(0:FVR1_(H9;C^[(OS_RU2W/_S-D!B5IK!F0,!\)"Y P
MBH1-D; 0"8N0L!@)8R"89"YO;RY/::[?MF51)NMY*H8E;7.SS)*UJLU1,L?:
M# GSD;  ":/>P(C<=KL=HRE2,_1Z[5RW'X:4BY$P!H))KICL73%1NN)7,4K_
MN1ZE^_RV/!4_BUF>;HZ-UY6PL79 PGPD+$#"J/H#J'J_U]EJDZR?"*^'A_4P
M,2,)N<W6\]T75'*?<U[WEQ_3<D&NRC*=)>1#LOYZ*K[+LH>T_E:[R_+JI$2Z
MVJY$;2Z.!/%L476QMQLBB#]\YYF.]8MQ:FC:J:9IY,?OC5/3=D]U0_OIC/RQ
MGO.\[HU7QT/QW#6_2V;I,BV?3LGAIN9\QM.'>EO3,A5?I&(S9IS/Z[)&R-W+
MN-;DU-&TGT[)XR*=+<BCV$TR6R9%D=ZE I(49#=]=--,'Z7K0S7!,W3WEX+,
MLG61+=-Y/=5ZEZ[%MW:E+;[7R_KM*<[([Z(LY]59S.HMV;\-9):(3TSLQL'V
MZ:?V?@OU4T>?G%IB&TE:D.0A29?UAHBW[7"WJ[./ O^0+1]J?%*DQ2DIMK?_
MY;/R^<7U)U*?[!1:?VZ397KW5&_"@L^^%LU;5].3:I>6U<QQGBR'.AG( S%$
MPB(D+$;"& @F?9WJ6GLB3\--]:A98[]/H30?2@N@--K0#KL8INLXG0X&5#-L
M:*HN!E0PAM(8BB;;XN#\MJZT1?1LAUQ\V0U:05D_V@I(F@^E!5 :;6BZ?GA<
MGFG&Q.ZZ 2D;0FD1E!9#:0Q%DXUCM,8Q1IQ6VY]4&[20DC3:0DB:#Z4%4!IM
M:-)Y9LVRW5Y[@E0-&YJR/4$*QE :0]%D6[39"UT=OHBW:[Y/T>PG2LG_R*>D
M&KN*04$U.JHZX%,Q=)IQ\N5*.9VJEAOM'6A  TH+H#0*I4VAM!!*BZ"T&$IC
M*)ILQC;YH:NC'V^;6E5#1UL.FOZ T@(HC>K] (ACVEJOM8+F/P9$)[IA&MT6
M"YK_@-(8BB:;I(V Z.H,R%O.>*N1HRT"#8- :4%#DT;TNFMWXD44*CJ%TD(H
M+8+28BB-H6BRD]KHB*[.CE1G*DBRRK;"3?MYZ+L\6[V<PE631QL*&B*!T@*]
M'^IP=-W6M*ZCD*I3*"V$TB(H+8;2&(HF.ZK-G>CJX,F8209H\ 1*\Z&T $JC
M#>W%7ALT5C(@.MAK@R9&H#2&HLG.:$,CNCHU$F^73T3?7>QC'LXSW(CV)BV*
M+'^J3UVJ)Q>@*1(HS8?2 BB-0FE3*"V$TB(H+8;2&(HF.[ -J.CJ@,0;)Q>@
M214HS8?2 BB--K3#%L,SM(EC==LI:#)A2-4R3<OK-E30U &4QE T^8+8-G=@
MJ','PS;9C9*&#*+&C34(E.9#:0&41HU^#$ 772JW.[":0F5#*"V"TF(HC:%H
MLH_:H(*A#BJ,RN^H6:--! TM0&D!E$8;VJ&)3,?MMC%0S7! 4W=-HSL6@HK&
M4!I#T61KM%$$0QU%V%_P7H<\JUFX04] 4PA0F@^E!5 :-?IY -MS>E?U0D5#
M*"V"TF(HC:%HLG?:O(*ASBN,F&%3DT8;"!I%@-("*(TVM(Z!;%?O.@@:,AA0
M=73/T9UNNP*-#T!I#$63O='&!PQU?*">8S-VR[I8;YUC4VN,=@TT30"E!5 :
MA=*F4%H(I4506@RE,11-=F";33#4V82WS;&IH:,M!TTG0&D!E$:-_LH1EJE[
M_:X>-)XPI*I;6E<U@JK&4!I#T62;M,$#0QT\&#W'!DT;0&D^E!9 :=3HKUIA
MF8;K] P"31M :1&4%D-I#$63;=2F#0QUVF#<%!LT;P"E^5!: *51HW_J7[=Z
ME\A!-<,A3=O3NPT,-&T I3$4379&FS8PU&F#,;,$T$P!E.9#:0&41HW^2A&F
M:7N]BWV@JN&0JF5KO>7SH*HQE,90--D;;0[ 4.< ?#ZK1__$T/[B3 $T&@"E
M^5!: *51*&T*I8506@2EQ5 :0]'D)8_;F('YEIC!2S,%:NA8RT%I/I060&G4
M[(<-!F<*H*KAD.K03 %4-8;2&(HFVZ1-$9CJ%,'8F0(U;K1!H$$"*"V TJC9
M/ZD_=*A.H:HAE!9!:3&4QE TV49MXL!4)PY&S12H6:,]! T>0&D!E$;-?O#
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MPQ(_ B#-!EPOA- ?$].8^L]*]@Y02P,$%     @ D4JO6KX8PWPP @  _P0
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M=( T ?A\(80^3$R"ZC,F_@-02P,$%     @ D4JO6H..D^D8!@  V#,  !D
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MO(SH*M<WAO91N1"T=A$4K6W ?>;'4*=^'JH%@J$>14%S/J T%Y3F@=)\4%H
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MIEPW4.<7C,G=CNZ@6I:>_ ]02P,$%     @ D4JO6@N<<^U4 P  P0T  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULK5=K;]HP%/TK5C9-G;0UB?."
M#I!XE553'X+1?9CVP< %HB8QLPVT_WYV$@*!D [$%["=>T[.O4?.M6MKRE[X
M'$"@US"(>%V;"[&XT74^GD-(^#5=0"2?3"D+B9!3-M/Y@@&9Q* PT+%AN'I(
M_$AKU.*U)]:HT:4(_ B>&.++,"3LK04!7=<U4]LL]/W97*@%O5%;D!D,0 P7
M3TS.](QEXH<0<9]&B,&TKC7-F[;I*$ <\>S#FN^,D4IE1.F+FMQ-ZIJA%$$
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MR -\/)S+.Q8P%2"?3RD5FXEZ079K:_P#4$L#!!0    ( )%*KUK#J/9W#PL
M &Q6   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;+6<6W/;N!7'OPI'
M[72R,^N(N .I[9G<-IN')![;VWWH](&68$L3B71).L[VTQ>D9($BH ,3%E\2
M209PSI\7G-_![?2Q*+]7"ZWKY.=ZE5=GDT5=W[^93JO90J^SZG5QKW/SE]NB
M7&>U^5K>3:O[4F?SMM)Z-<5IRJ?K;)E/SD_;WR[*\]/BH5XM<WU1)M7#>IV5
M?[W3J^+Q;((F3S]<+N\6=?/#]/ST/KO35[K^X_ZB--^FNU;FR[7.JV61)Z6^
M/9N\16_>HY0V-=HB_UKJQZKS.6FTW!3%]^;+Y_G9)&U<TBL]JYLV,O/?#_U>
MKU9-4\:1_VY;G>R,-A6[GY]:_ZU5;]3<9)5^7ZS^7,[KQ=E$3I*YOLT>5O5E
M\?B[WBIB37NS8E6U_R:/F[*43I+90U47ZVUEX\%ZF6_^SWYNKT2G@FG'7P%O
M*^!^A4,6R+8":85N/&ME?<CJ[/RT+!Z3LBEM6FL^M->FK6W4+//F/E[5I?GK
MTM2KSZ\^?OKR\>MU<OGQXMOE]>>OGY)7'W2=+5?5+\E)\L?5A^35WW\YG=;&
M5%-A.MLV^V[3+#[0+$F^%'F]J)*/^5S/]^M/C8L[/_&3G^\PV."7K'R=$/1K
M@E/,//Z\?WYU"KA#=I>-M.W1 ^U=ZA\Z?]"^"[.IR-N*S5OTXQP1@3##\G3Z
MH^NQIR!EDE)!=@7W?*,[WRCHV_NBJI/B-KG*5KKR>;BISCJ&3Q#B' NL>B[Z
M2A+,4DF%WT>V\Y&!/GZZ_'9UE5Q<?OOM\[7/1>88QBE50O4==,LA0@C'W.\>
MW[G'8?=TKLMLE63Y/,GFYK5;5G69-1U.HG^:+K3R7UCNN5Q42)'BGMO>@D@B
M(OU^BYW? O3;W/*L7/J=$QZ;*4U3U+^FOH*82224WSFY<TZ&G--5>TE-Q/BN
MZV5^!UY-Z?J!)6*LYZZG&!*$D]3OK=IYJT!O/V@3%V?+;!-LFN=@793U\G_M
M#SYWE>L',0\MZ5]>7SFDS%/B]Q>EMB=/X>M;%[/O)TU,FR>S8MU<V(/.;IOJ
M>L$8YPCUG/64(]0\,O2 LYVP@T!G30PV$38W(:XL=3[[*S'OE_&WC>V_)KFN
MO5XC]W473&+:]]HM=X*X>8@/N8VMVQAT^ZLAJ_NRN%W6TU>KHC)!\D8;F-+)
MY]Q<<IU<9S_]#_.VW3V7))*I$GW?/061Y)RK P\TLC$+P4$K&!BV]?>NKS\P
M^$J"@0'9Z(7@\#6TFT!ND/)U$]MB>^$6Z":0C60(#F7?ZH4NDW]_T>L;7?['
MZR'80$/J;ZK[;*;/)J;+J73Y0T_.__$WQ--_^D#G6*WMR[61$<&A$2 ?Y(:U
MM'\7P,9CG;?A$<'Q,?P&N,'/D0":B)5@@RB"HVB(G) ;#QT%H(58!3:P(CBR
M1L(5\@5.$[&H(P\T'RD/VS", V$88##LAM,3['15L(%8 38T8S@T#^V L1MM
M^[<$MABKR$9M#$?M2]-F5LX6K:BYZ<!6Q?U:Y[7!I*KV:_)%8<:=. @;CA5F
M(SJ&(WJ#([?+/,MG&M#BQFKG_H!F8F78D(\#(5_?M;=C0U;)--FPE5>,)R4E
M0J0. \(F8R59*L P%0Q.'[";RIX0)D1_U "V&ZO+AG\,A_\A20;VI+EMED'Z
MFL:@ FRI ,-4$)6+8)<4.&7.4S@&+& +"QB&A0V;+C>Y2?,4@OVX+Y-6A"GG
M=HW!#]CR X;Y(3H'PQZ"0*979VX$'@,AB$4( B/$\'A%7+#PA2O8;JPN2Q8$
M)HL@?I,P2L F8B58E" P2@R%(^*"A*-H#(8@G9%LF"&NB]K ^%,(AO)8N*&A
M>>RQ6MN7;9F#P,P!C>"[C'%H"'\,R" 6,@@,&>'WR0,5!T9T8%.Q4BQ7D,"(
M>R"M)2Y+^&<$8#NQ.BQ+$)@E(I-;XAET5QBGRNDLQ@ *8H&"!,?P#R:WQ,</
MWAD&V$BL" L0! :(P7VXAQM\0XRPV4A9U%(#/38U4,]PA \;8,.QPBPV4!@;
MGI7E4L^8OV)"]F<T8%NQ6BP_T  _/#_5I9XQ"(:DZ#]VL,58198?*,P/@S-=
MZHY'^&?*8,.QPCK3Z(%1B0&I+O4,2WA37=AFK"9+#!0FAJA4EWIFV9MI-^=!
M' ,AJ$4("B/$H&27>L8F.%7*T30&3E"+$Q3&B>A<EWJ PCO?"#L0*] "!86!
M(B)HN9CAC5EC, :UC$%AQ@@OPG&AXM BG#&P@EFL8,'YC$&TQ%RH\,$2;#56
ME64*!C/%GXO"R#+2P(P7;F1HQGNLUO8E6_1@H5F0@QDO<U'#I+LI->]5_[:-
M 1O,P@9[X1(&YH$+A Q>*,+[4L; "V;Q@L%X$5P"YQF%0')O;=M6QQA(P3HK
M^0)+^>(R7N8;FN 8<V>)WQA4P2Q5L,"$!Y#Q,@]$$"&90Q&PC5@-EB)8<%G@
ML"[< P\".:+&( =FR8$=FQQ8>&D$;#-6DZ4&%I[:"&:ZS#>-0146_<DGV%BD
M&&[!@0? X?FI+G>9H1$D^MD3;#%6D84&#D/#X%27>P8E&):R_]C!=F-U63+@
M@4&) 9DN#T]HP-9BU5A&X# C1.6XW.4&IJ@SX ^;CI5FF8'#S# HQ>6>A9&"
ML3X^P"9C)5E\X# ^1&>XW 4(AKD4_007MA^KK[.3(+1><FB8XN%EE+#-6$V6
M)_@+EU%R%R .0#AL*5:)A0A^W#T)W$4(%XQ@F[&:+$1P&"(N%EFYSHR@_.'6
M]'H/92,*RG+A]H9FN<=J;7\#C*4.$9H%.9CE"L_(!)>,]7L,V$*L DL9XH6K
M)(2'*D2JG(D!V$ZL#DL5 J:*4((K/(,.JAE7[LL8 R>$Q0D!XT1D?BM\ Q&,
MN4O$8/.Q\BQ2B, L![1ES+?8DA,N^O$(MA&KP3*$@!EB:"\N/&,/+NO!1F-%
M67 0QP8'$08'V&:LIL[VQ/!T1C"_%>$]&+"96!F6&D2 &IZ?V0K/H@B"33_G
M2!H#&H2%!G'D[8["-PK1;&1T^K<Q>$!:'I#'VQ4I74#HWR;86JP:RP9RA&V3
M,KRJ$C8;*\NB@H1185!>*WV3%83V%WK )F,E66R0X:T947FM]( #I<:O_F 8
M[$"L0 L.,K2 <FA\DBY..,_A&" A+4C(%RZHE"XY^,@;-A,KPZ*##,Y9#-MI
M[X*#BT.PS5A-%AUD !T>3%<WTP_U<I:M-N(VB:[]#<IQX=:'YKC':FW_6G0.
M4@A-?1S,<:7+&XHHFO9GU6 +L0HL;L@7+H^0OC67(I7(>2S'P ME\4+!>!%*
M<I6+%)Q+IOK1"C83*\-RA8*Y(C+)59Z1"$P)QOTA%=A\K#S+%RJX:^-@DJL\
MRRRQP5AG93EL(U:#!0H% \703EUY.,*\0:@_O *;C95E,4(=&R-4&"-@F[&:
M+$:H\)Q&,,U5GOD+0IW-=K"I6"D6)50 )9Z?ZBJ7(A"CA/:'_&&+L8HL2"@8
M)(8?[./;FZ%DZO1Q8T"!LE"@ H,2 Q)=%5X) 5N+5=,Y?0D&A*A$5WG65*9*
M4>>=&H,94-H]J0FFAD'Y[E-C75E2FI[<.:MI#(9 :>=,IS2\42/N=*34!0G,
M")+.R4ZP!]$:<4?CL<^2>&H1/)(%MAJMJW,V5/K2PZ%2%RB\1!ZP%*VE<X)4
M&IS3&':$U+8]OB_-0:6 W:'*IIUC.]>ZO&M/,ZW,@_20UYN3,7>_;HY,?=<<
MF=H<^]G[_2UZ\[8]/W1JF]F<P_HE*^^6>96L]*UI,GW=S&F4FY---U_JXKX]
M'/2FJ.MBW7Y<Z&RNRZ: ^?MM4=1/7QH#NP-FS_\/4$L#!!0    ( )%*KUHP
MT'^C7 (  -H$   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;'V444_;
M,!#'O\HIX@&DC:2A+1M*(U'H-AZ*&%G9P[0'-[DV5NTXV$X+TC[\SDX:N@EX
M<6S?W=^_L^^2[)3>F!+1PI,4E9D$I;7U11B:O$3)S*FJL2++2FG)+"WU.C2U
M1E;X("G".(K&H62\"M+$[]WI-%&-%;S".PVFD9+IYRD*M9L$@V"_<<_7I74;
M89K4;(T9VD5]IVD5]BH%EU@9KBK0N)H$EX.+Z=#Y>X<'CCMS, >7R5*IC5O<
M%),@<D H,+=.@=%GBU<HA!,BC,=.,^B/=(&'\[WZ%Y\[Y;)D!J^4^,D+6TZ"
M3P$4N&*-L/=J]PV[?$9.+U?"^!%VG6\40-X8JV073 225^V7/77W<! 0?WXC
M(.X"8L_='N0IKYEE::+5#K3S)C4W\:GZ:(+CE7N4S&JR<HJS:;:89K/OB]GM
M#Y@]T)C!\35:QH6!6Z8U<W=V A\A:Y8&'QNL+,RV-!KX-4>Y1/V;C%\U7RO-
ME8&,JPU[L26A)49W4IAW/-.6)WZ#9P!S5=G2P*PJL/@W/J3<^@3C?8+3^%W!
MRUJ?0CS\ '$4CV"17</QT0F8DFDT[\B?]?=WYN6';\C?&-.P*D=0*\B5E%1H
M]&;Y!OZ\>D9+W$J.O*3KFFTZ&(['Y^-A$FY?81GV+,-W66:/#;?/P D)"^!$
M@M8*E.[1"$]PMN2"6XZ&Z(Y> VOUQP=@HW@<1=%_7.%!O4G4:]]5AO)O*MN6
M7K_;-^YE6Z\O[FW7SYE>\\J P!6%1J?G="NZ[:1V857MJW>I+/6"GY;T\T'M
M',B^4LKN%^Z _G>6_@502P,$%     @ D4JO6@;V_E%4 P  \!0   T   !X
M;"]S='EL97,N>&ULW5A1;]HP$/XK4;I.K30U0$H@*R!M2)4F;5.E]F%OE2$.
M6'+LS#$=]'&_9[]JOV2^."1 ?8CU82T#M;'O\WWW^>Z2N!T4>L7I[9Q2[2TS
M+HJA/]<Z?Q\$Q71.,U)<R)P*@Z12942;J9H%1:XH20IPRGC0:;6B("-,^*.!
M6&37F2Z\J5P(/?1[M<FSET_)T&]'E[YGZ<8RH4/__NSM]X745V\\>SUY=W+2
MNC^_VK6?E<"Y'SA)NP>07K1:.#& &'ET&/D^;HRZMTU=+C\U1-;Q%'/KNQ7]
M_OD+R6*#[,]C[-!CY#>28((X]UH'%F%_%:RVH&JFT2"5HNFIT+<&$Y]DU'L@
M?.B/"6<3Q< K)1GC*VON@&$JN52>-LUL!+7!4CQ:N&UGT.<53\:$5&5L&\'^
MGE3+=X#U# 0RSFN!'=\:1H.<:$V5N#:3<G%I? )YU?ANE1N%,T56[4[7;QS*
MBPDRD2JAJ@[3]M>FT8#3%.0H-IO#5<L\ %!KF9E!PLA,"E)J6'M4 T,[I9S?
MPD/@6[K%O4PW*EO65=1#(Z@:6AH[ ?Y--LN]27OY+%XO9P]2?UR8[8AR#NU"
M;Q1-V;*<+]-: ,;>QME)GO/5!\YF(J-V\P<'' W(VL^;2\4>331HE:DQ4.5[
M#U1I-MVT_% DOZ-+O6ZG98IK[ARAYG^;YQD55!&^*=KT_FO.\K,5A[V7DEP^
M578%.S56;_;7+K)[#"*C8Q!Y%#W9/P:1\1&([+W84_-PD>'K3&10G80VCEM;
MAZW:ZL&A=NA_A4,T;X)ZDP7CFHEJ-F=)0L63,Y>AUV1B_IS;XC?K$YJ2!==W
M-3CTF_$7FK!%%M>K;B 1U:IF_!FVUX[J$[6)Q41"ES095U,UFY1#SPQ,U.H#
M#KO(=?EQ(YB/Q=P(8%@<3 'F8[VP./_3?OKH?BR&:>L[D3[JTT=]K)<+&9=?
M+([;)S8?]T[C. RC",OH>.Q4,,;R%D7PXV;#M($'%@<B_5VN\6KC';*_#[":
M[NL0;*=X)V([Q7,-B#MOX!''[FIC<< #JP+6.Q#?'0=ZRNT3AE!53!MV!^-(
M'&,(]**[1Z,(R4X$7W=]L+LD#./8C0#F5A"&& )W(XY@"D #AH1A^1[<>1\%
MZ_=4T/R/<_0'4$L#!!0    ( )%*KUJ7BKL<P    !,"   +    7W)E;',O
M+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +
M&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P
M6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,
M-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4
M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ D4JO6HU,V5DV!0  ERP   \
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M%!M9*4=EO NHB0D)QD86S(&2>^\WY!8;V2V]+1]R-A=U)O/*[.;:D%ML9+?
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MPP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ D4JO6IE<G",0!@
MG"<  !,              ( !XP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "12J]:JOMT$,P%  "+'P  &               @($D"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ D4JO6G9_HR3#"
ME28  !@              ("!)@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( )%*KUK$.3)5K (  -8'   8              " @1\7
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "12J]:*TAC
M&WP&  #L&@  &               @($!&@  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ D4JO6IA7,T6W!P  %"X  !@
M ("!LR   'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( )%*
MKUJJX3W>.@D  !HI   8              " @: H  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " "12J]:RJFX'T@"  "O!@  &
M        @($0,@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ D4JO6F",>MPF"@  _!D  !@              ("!CC0  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( )%*KUIY.Y(DO"L  (V'   8
M              " @>H^  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " "12J]:552!^2<%  "L"P  &0              @('<:@  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( )%*KUJP.XF(# ,
M )@&   9              " @3IP  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ D4JO6H7/ _BS P  ^ <  !D              ("!
M?7,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "12J]:
M2'O!O>H#  "6"   &0              @(%G=P  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( )%*KUK[C7)RC00  '@+   9
M      " @8A[  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ D4JO6EN/)DU3!P  C!(  !D              ("!3(   'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "12J]:!JX@<6P2  "'.0
M&0              @('6AP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( )%*KUJ18<>M#P<  "(4   9              " @7F:  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ D4JO6HUY+5?_
M"P  \"D  !D              ("!OZ$  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " "12J]: QYR1C@%   -#@  &0
M@('UK0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( )%*
MKUI$$H]JNP0   D+   9              " @62S  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ D4JO6N *YC,*%   FS<  !D
M         ("!5K@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " "12J]:!B?I2'P'  #-%   &0              @(&7S   >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( )%*KUJ=/QM%VP,  %@(
M   9              " @4K4  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ D4JO6OV+=*3B!@  40\  !D              ("!7-@
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "12J]:?_;L
M#5H$  !>"0  &0              @(%UWP  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( )%*KUJ%;J'!2RT  "B3   9
M  " @0;D  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MD4JO6NCE8#,#!0  BPP  !D              ("!B!$! 'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " "12J]:M*)/*_4"   D!@  &0
M            @('"%@$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( )%*KUHUIPVE:@,  )T'   9              " @>X9 0!X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ D4JO6C?*UH+/ @
MX 8  !D              ("!CQT! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " "12J]:25IW*(L"  !L!0  &0              @(&5
M( $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( )%*KUKX
MR:V51@0  #\*   9              " @5<C 0!X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ D4JO6G.4;#3% @  !@<  !D
M     ("!U"<! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )%*KUJ@ZHXX/@0   82   9              "
M@5XY 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ D4JO
M6B_(\X7" @  -P<  !D              ("!TST! 'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " "12J]:?"XSE7H#  !K#P  &0
M        @(',0 $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( )%*KUK*%T"KB (  )T&   9              " @7U$ 0!X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ D4JO6F?8Y/YO @  2P8
M !D              ("!/$<! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " "12J]:P\$])Q,+   V@P  &0              @('B20$
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( )%*KUH^9P3\
M] ,  %83   9              " @2Q5 0!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ D4JO6IR6R/"  P  K T  !D
M ("!5UD! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "1
M2J]:3#71&K@#  !6#P  &0              @($.70$ >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( )%*KUH204-Q9 (  )\&   9
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M970U,2YX;6Q02P$"% ,4    " "12J]:AZ!?3? "   F"   &0
M    @(%/<P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M )%*KUKV8,:HP1   %ZT   9              " @79V 0!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ D4JO6BCU:^OU @  E0L  !D
M             ("!;H<! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    " "12J]:#$+NL;8%  "T'@  &0              @(&:B@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( )%*KUK^<HR-AP4
M -,;   9              " @8>0 0!X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ D4JO6NH/_Q/H @  %PH  !D              ("!
M198! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " "12J]:
MUK3+XJH0  !ZSP  &0              @(%DF0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    ( )%*KUJ&N,XO@ (  &(&   9
M      " @46J 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @ D4JO6KX8PWPP @  _P0  !D              ("!_*P! 'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " "12J]:JH_#,/T#  !+#P
M&0              @(%CKP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    ( )%*KUJ><OQO P,  -((   9              " @9>S 0!X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ D4JO6H..D^D8
M!@  V#,  !D              ("!T;8! 'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    " "12J]:?[S12BH$  !0$@  &0
M@($@O0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( )%*
MKUK 2NG#ZP0  *(>   9              " @8'! 0!X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @ D4JO6@N<<^U4 P  P0T  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "12J]:EXJ[',     3 @  "P
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52P4&     $P 3 #+%   5>8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>266</ContextCount>
  <ElementCount>429</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>110200 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>110201 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>124100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>148600 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>170000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>170001 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>170002 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>170003 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OrganizationAndNatureOfBusiness</Role>
      <ShortName>ORGANIZATION AND NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>170004 - Disclosure - EQUITY METHOD INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/EquityMethodInvestments</Role>
      <ShortName>EQUITY METHOD INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>360000 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>370000 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>370001 - Disclosure - LOAN RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LoanReceivable</Role>
      <ShortName>LOAN RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>370002 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>500000 - Disclosure - CAPITAL STRUCTURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/CapitalStructure</Role>
      <ShortName>CAPITAL STRUCTURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>845000 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>845001 - Disclosure - LINES OF CREDIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LinesOfCredit</Role>
      <ShortName>LINES OF CREDIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>845002 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cosm.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>845003 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>845004 - Disclosure - OTHER LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OtherLiabilities</Role>
      <ShortName>OTHER LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>845005 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>845006 - Disclosure - STOCK OPTIONS AND WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/StockOptionsAndWarrants</Role>
      <ShortName>STOCK OPTIONS AND WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>845007 - Disclosure - DISAGGREGATION OF REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/DisaggregationOfRevenue</Role>
      <ShortName>DISAGGREGATION OF REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>845008 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>870000 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>870001 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies</Role>
      <ShortName>ORGANIZATION AND NATURE OF BUSINESS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>870002 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OrganizationAndNatureOfBusinessTables</Role>
      <ShortName>ORGANIZATION AND NATURE OF BUSINESS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/OrganizationAndNatureOfBusiness</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>870003 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>870004 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/IntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>870005 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>870006 - Disclosure - LINES OF CREDIT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LinesOfCreditTables</Role>
      <ShortName>LINES OF CREDIT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/LinesOfCredit</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>870007 - Disclosure - NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cosm.com/role/NotesPayableTables</Role>
      <ShortName>NOTES PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/NotesPayable</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>870008 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/LEASES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>870009 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/StockOptionsAndWarrantsTables</Role>
      <ShortName>STOCK OPTIONS AND WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/StockOptionsAndWarrants</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>870010 - Disclosure - DISAGGREGATION OF REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/DisaggregationOfRevenueTables</Role>
      <ShortName>DISAGGREGATION OF REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/DisaggregationOfRevenue</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>870011 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/SegmentReportingTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cosm.com/role/SegmentReporting</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>870012 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/BasisOfPresentation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>870013 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OrganizationAndNatureOfBusinessDetails</Role>
      <ShortName>ORGANIZATION AND NATURE OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/OrganizationAndNatureOfBusinessTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>870014 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1</Role>
      <ShortName>ORGANIZATION AND NATURE OF BUSINESS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/OrganizationAndNatureOfBusinessTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>870015 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2</Role>
      <ShortName>ORGANIZATION AND NATURE OF BUSINESS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/OrganizationAndNatureOfBusinessTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>870016 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3</Role>
      <ShortName>ORGANIZATION AND NATURE OF BUSINESS (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/OrganizationAndNatureOfBusinessTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>870017 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4</Role>
      <ShortName>ORGANIZATION AND NATURE OF BUSINESS (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/OrganizationAndNatureOfBusinessTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>870018 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND NATURE OF BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/OrganizationAndNatureOfBusinessTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>870019 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative</Role>
      <ShortName>EQUITY METHOD INVESTMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/EquityMethodInvestments</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>870020 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>PROPERTY PLANT AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>870021 - Disclosure - INTANGIBLE ASSETS NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>INTANGIBLE ASSETS NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/IntangibleAssetsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>870022 - Disclosure - INTANGIBLE ASSETS NET (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/IntangibleAssetsNetDetails1</Role>
      <ShortName>INTANGIBLE ASSETS NET (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/IntangibleAssetsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>870023 - Disclosure - LOAN RECEIVABLE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LoanReceivableDetailsNarrative</Role>
      <ShortName>LOAN RECEIVABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/LoanReceivable</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>870024 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>870025 - Disclosure - CAPITAL STRUCTURE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/CapitalStructureDetailsNarrative</Role>
      <ShortName>CAPITAL STRUCTURE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/CapitalStructure</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>870026 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>870027 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/RelatedPartyTransactionsDetails1</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>870028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>870029 - Disclosure - LINES OF CREDIT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LinesOfCreditDetails</Role>
      <ShortName>LINES OF CREDIT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/LinesOfCreditTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>870030 - Disclosure - LINES OF CREDIT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LinesOfCreditDetailsNarrative</Role>
      <ShortName>LINES OF CREDIT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/LinesOfCreditTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>870031 - Disclosure - NOTES PAYABLE (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cosm.com/role/NotesPayableDetails</Role>
      <ShortName>NOTES PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/NotesPayableTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>870032 - Disclosure - NOTES PAYABLE (Details 1)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cosm.com/role/NotesPayableDetails1</Role>
      <ShortName>NOTES PAYABLE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/NotesPayableTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>870033 - Disclosure - NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cosm.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/NotesPayableTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>870034 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/LeasesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>870035 - Disclosure - LEASES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LeasesDetails1</Role>
      <ShortName>LEASES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/LeasesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>870036 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/LeasesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>870037 - Disclosure - OTHER LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/OtherLiabilitiesDetailsNarrative</Role>
      <ShortName>OTHER LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/OtherLiabilities</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>870038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrativec)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrativec)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>870039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/StockOptionsAndWarrantsDetails</Role>
      <ShortName>STOCK OPTIONS AND WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/StockOptionsAndWarrantsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>870040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative</Role>
      <ShortName>STOCK OPTIONS AND WARRANTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/StockOptionsAndWarrantsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>870041 - Disclosure - DISAGGREGATION OF REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/DisaggregationOfRevenueDetails</Role>
      <ShortName>DISAGGREGATION OF REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/DisaggregationOfRevenueTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>870042 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/SegmentReportingDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/SegmentReportingTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="cosm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>870043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cosm.com/role/SubsequentEvents</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cosm-20250331.xsd</File>
    <File>cosm-20250331_cal.xml</File>
    <File>cosm-20250331_def.xml</File>
    <File>cosm-20250331_lab.xml</File>
    <File>cosm-20250331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="cosm_10q.htm">cosm_10q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="728">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cosm_10q.htm": {
   "nsprefix": "cosm",
   "nsuri": "http://cosm.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "cosm-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cosm-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cosm-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cosm-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cosm-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cosm_10q.htm"
     ]
    }
   },
   "keyStandard": 311,
   "keyCustom": 118,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 17,
   "memberCustom": 80,
   "hidden": {
    "total": 16,
    "http://fasb.org/us-gaap/2024": 4,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://cosm.com/20250331": 2
   },
   "contextCount": 266,
   "entityCount": 1,
   "segmentCount": 97,
   "elementCount": 619,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 728,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://cosm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "110200 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "cosm:AmountAccountsReceivableRelatedPartiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "110201 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
     "longName": "124100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "cosm:DisaggregationOfRevenueDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
     "longName": "148600 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_TreasuryStockCommonMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_TreasuryStockCommonMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "170000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cosm.com/role/InsiderTradingArrangements",
     "longName": "170001 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://cosm.com/role/BasisOfPresentation",
     "longName": "170002 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cosm.com/role/OrganizationAndNatureOfBusiness",
     "longName": "170003 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS",
     "shortName": "ORGANIZATION AND NATURE OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cosm.com/role/EquityMethodInvestments",
     "longName": "170004 - Disclosure - EQUITY METHOD INVESTMENTS",
     "shortName": "EQUITY METHOD INVESTMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cosm.com/role/PropertyAndEquipmentNet",
     "longName": "360000 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cosm.com/role/IntangibleAssets",
     "longName": "370000 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cosm.com/role/LoanReceivable",
     "longName": "370001 - Disclosure - LOAN RECEIVABLE",
     "shortName": "LOAN RECEIVABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cosm.com/role/IncomeTaxes",
     "longName": "370002 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cosm.com/role/CapitalStructure",
     "longName": "500000 - Disclosure - CAPITAL STRUCTURE",
     "shortName": "CAPITAL STRUCTURE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:CapitalStructureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:CapitalStructureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cosm.com/role/RelatedPartyTransactions",
     "longName": "845000 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cosm.com/role/LinesOfCredit",
     "longName": "845001 - Disclosure - LINES OF CREDIT",
     "shortName": "LINES OF CREDIT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:LineOfCreditFacilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:LineOfCreditFacilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cosm.com/role/NotesPayable",
     "longName": "845002 - Disclosure - NOTES PAYABLE",
     "shortName": "NOTES PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cosm.com/role/LEASES",
     "longName": "845003 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cosm.com/role/OtherLiabilities",
     "longName": "845004 - Disclosure - OTHER LIABILITIES",
     "shortName": "OTHER LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cosm.com/role/CommitmentsAndContingencies",
     "longName": "845005 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cosm.com/role/StockOptionsAndWarrants",
     "longName": "845006 - Disclosure - STOCK OPTIONS AND WARRANTS",
     "shortName": "STOCK OPTIONS AND WARRANTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:StockOptionsAndWarrantsDisclouserTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:StockOptionsAndWarrantsDisclouserTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cosm.com/role/DisaggregationOfRevenue",
     "longName": "845007 - Disclosure - DISAGGREGATION OF REVENUE",
     "shortName": "DISAGGREGATION OF REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:DisaggregationOfRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:DisaggregationOfRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cosm.com/role/SegmentReporting",
     "longName": "845008 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cosm.com/role/SubsequentEvents",
     "longName": "870000 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies",
     "longName": "870001 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Policies)",
     "shortName": "ORGANIZATION AND NATURE OF BUSINESS (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cosm.com/role/OrganizationAndNatureOfBusinessTables",
     "longName": "870002 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Tables)",
     "shortName": "ORGANIZATION AND NATURE OF BUSINESS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cosm.com/role/PropertyAndEquipmentNetTables",
     "longName": "870003 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cosm.com/role/IntangibleAssetsTables",
     "longName": "870004 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cosm.com/role/RelatedPartyTransactionsTables",
     "longName": "870005 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cosm.com/role/LinesOfCreditTables",
     "longName": "870006 - Disclosure - LINES OF CREDIT (Tables)",
     "shortName": "LINES OF CREDIT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cosm:LineOfCreditFacilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cosm:LineOfCreditFacilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cosm.com/role/NotesPayableTables",
     "longName": "870007 - Disclosure - NOTES PAYABLE (Tables)",
     "shortName": "NOTES PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cosm.com/role/LeasesTables",
     "longName": "870008 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cosm.com/role/StockOptionsAndWarrantsTables",
     "longName": "870009 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)",
     "shortName": "STOCK OPTIONS AND WARRANTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cosm.com/role/DisaggregationOfRevenueTables",
     "longName": "870010 - Disclosure - DISAGGREGATION OF REVENUE (Tables)",
     "shortName": "DISAGGREGATION OF REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cosm:DisaggregationOfRevenueDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cosm:DisaggregationOfRevenueDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cosm.com/role/SegmentReportingTables",
     "longName": "870011 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cosm.com/role/BasisOfPresentationDetailsNarrative",
     "longName": "870012 - Disclosure - BASIS OF PRESENTATION (Details Narrative)",
     "shortName": "BASIS OF PRESENTATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetCashProvidedByUsedInContinuingOperations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:NetCashProvidedByUsedInContinuingOperations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails",
     "longName": "870013 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details)",
     "shortName": "ORGANIZATION AND NATURE OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Assets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1",
     "longName": "870014 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 1)",
     "shortName": "ORGANIZATION AND NATURE OF BUSINESS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:ChangesInAllowanceForDoubtfulAccountsBeginningBalance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:ChangesInAllowanceForDoubtfulAccountsBeginningBalance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2",
     "longName": "870015 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 2)",
     "shortName": "ORGANIZATION AND NATURE OF BUSINESS (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31_us-gaap_VehiclesMember",
      "name": "cosm:PropertyPlantAndEquipmentUsefulLifes",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31_us-gaap_VehiclesMember",
      "name": "cosm:PropertyPlantAndEquipmentUsefulLifes",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3",
     "longName": "870016 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 3)",
     "shortName": "ORGANIZATION AND NATURE OF BUSINESS (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4",
     "longName": "870017 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details 4)",
     "shortName": "ORGANIZATION AND NATURE OF BUSINESS (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative",
     "longName": "870018 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS (Details Narrative)",
     "shortName": "ORGANIZATION AND NATURE OF BUSINESS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative",
     "longName": "870019 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative)",
     "shortName": "EQUITY METHOD INVESTMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember",
      "name": "cosm:InitialShareCapital",
      "unitRef": "EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember",
      "name": "cosm:InitialShareCapital",
      "unitRef": "EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://cosm.com/role/PropertyPlantAndEquipmentDetails",
     "longName": "870020 - Disclosure - PROPERTY PLANT AND EQUIPMENT (Details)",
     "shortName": "PROPERTY PLANT AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://cosm.com/role/IntangibleAssetsNetDetails",
     "longName": "870021 - Disclosure - INTANGIBLE ASSETS NET (Details)",
     "shortName": "INTANGIBLE ASSETS NET (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:OtherFiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:OtherFiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://cosm.com/role/IntangibleAssetsNetDetails1",
     "longName": "870022 - Disclosure - INTANGIBLE ASSETS NET (Details 1)",
     "shortName": "INTANGIBLE ASSETS NET (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://cosm.com/role/LoanReceivableDetailsNarrative",
     "longName": "870023 - Disclosure - LOAN RECEIVABLE (Details Narrative)",
     "shortName": "LOAN RECEIVABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2021-10-01to2021-10-30",
      "name": "us-gaap:PaymentsOfLoanCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-10-01to2021-10-30",
      "name": "us-gaap:PaymentsOfLoanCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://cosm.com/role/IncomeTaxesDetailsNarrative",
     "longName": "870024 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31_cosm_GreeceMember",
      "name": "cosm:CorporateTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31_cosm_GreeceMember",
      "name": "cosm:CorporateTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://cosm.com/role/CapitalStructureDetailsNarrative",
     "longName": "870025 - Disclosure - CAPITAL STRUCTURE (Details Narrative)",
     "shortName": "CAPITAL STRUCTURE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "cosm:CapitalStructureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "cosm:CapitalStructureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://cosm.com/role/RelatedPartyTransactionsDetails",
     "longName": "870026 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_cosm_NotesPayableRelatedPartyMember",
      "name": "cosm:NotesPayableRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_cosm_NotesPayableRelatedPartyMember",
      "name": "cosm:NotesPayableRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://cosm.com/role/RelatedPartyTransactionsDetails1",
     "longName": "870027 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_cosm_LoansPayableRelatedPartyMember",
      "name": "cosm:LoansPayableRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cosm:ScheduleOfRelatedPartyLoansPayableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_cosm_LoansPayableRelatedPartyMember",
      "name": "cosm:LoansPayableRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cosm:ScheduleOfRelatedPartyLoansPayableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "870028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:InterestIncomeOther",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_cosm_GrigoriosSiokasMember",
      "name": "us-gaap:NotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://cosm.com/role/LinesOfCreditDetails",
     "longName": "870029 - Disclosure - LINES OF CREDIT (Details)",
     "shortName": "LINES OF CREDIT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "cosm:LineOfCreditFacilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "cosm:LineOfCreditFacilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://cosm.com/role/LinesOfCreditDetailsNarrative",
     "longName": "870030 - Disclosure - LINES OF CREDIT (Details Narrative)",
     "shortName": "LINES OF CREDIT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LineOfCreditFacilityAverageOutstandingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:LineOfCreditFacilityAverageOutstandingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://cosm.com/role/NotesPayableDetails",
     "longName": "870031 - Disclosure - NOTES PAYABLE (Details)",
     "shortName": "NOTES PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:NotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:ProceedFromDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://cosm.com/role/NotesPayableDetails1",
     "longName": "870032 - Disclosure - NOTES PAYABLE (Details 1)",
     "shortName": "NOTES PAYABLE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cosm:ScheduleOfOutstandingDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cosm:ScheduleOfOutstandingDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://cosm.com/role/NotesPayableDetailsNarrative",
     "longName": "870033 - Disclosure - NOTES PAYABLE (Details Narrative)",
     "shortName": "NOTES PAYABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:RepaymentsOfRelatedPartyDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember",
      "name": "us-gaap:DebtCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://cosm.com/role/LeasesDetails",
     "longName": "870034 - Disclosure - LEASES (Details)",
     "shortName": "LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_cosm_OperatingLeaseMember",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_cosm_OperatingLeaseMember",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://cosm.com/role/LeasesDetails1",
     "longName": "870035 - Disclosure - LEASES (Details 1)",
     "shortName": "LEASES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_cosm_FinanceLeaseMember",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_cosm_FinanceLeaseMember",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://cosm.com/role/LeasesDetailsNarrative",
     "longName": "870036 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:OperatingLeaseTermOfAgreements",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:OperatingLeaseTermOfAgreements",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://cosm.com/role/OtherLiabilitiesDetailsNarrative",
     "longName": "870037 - Disclosure - OTHER LIABILITIES (Details Narrative)",
     "shortName": "OTHER LIABILITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:TaxLiabilitiesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:TaxLiabilitiesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec",
     "longName": "870038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrativec)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrativec)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "cosm:StockOptionsAndWarrantsDisclouserTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "cosm:PaymentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://cosm.com/role/StockOptionsAndWarrantsDetails",
     "longName": "870039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)",
     "shortName": "STOCK OPTIONS AND WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_cosm_WarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_cosm_WarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative",
     "longName": "870040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)",
     "shortName": "STOCK OPTIONS AND WARRANTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "cosm:StockOptionsAndWarrantsDisclouserTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-04-03",
      "name": "cosm:DiscriptionOfIncentiveStockAwards",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://cosm.com/role/DisaggregationOfRevenueDetails",
     "longName": "870041 - Disclosure - DISAGGREGATION OF REVENUE (Details)",
     "shortName": "DISAGGREGATION OF REVENUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "cosm:DisaggregationOfRevenueDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31_cosm_GreeceMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "cosm:DisaggregationOfRevenueDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://cosm.com/role/SegmentReportingDetails",
     "longName": "870042 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "cosm:DisaggregationOfRevenueDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31_cosm_OtherMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://cosm.com/role/SubsequentEventsDetailsNarrative",
     "longName": "870043 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2025-04-24_us-gaap_SubsequentEventMember_cosm_GrigoriosSiokasMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesOther",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2025-04-24_us-gaap_SubsequentEventMember_cosm_GrigoriosSiokasMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesOther",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcceleratedShareRepurchasesAdjustmentToRecordedAmount",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total purchase price amount",
        "documentation": "The adjustment needed to reconcile previously recorded amounts to the actual aggregate amount paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AccountsPayableAndAccruedExpensesRelatedPartiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses - related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_AccountsPayableRelatedPartyCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AccountsPayableRelatedPartyCurrent",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses - related party",
        "label": "[Accounts payable and accrued expenses - related party 1]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Receivable &amp; Allowance for Doubtful Accounts",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable balance",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of Royalty Agreement",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r665"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current portion of Royalty Agreement",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_AccruedSalariesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid salaries and bonuses",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r173",
      "r528"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 41.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "[Accumulated Other Comprehensive Income (Loss), Net of Tax]",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r87",
      "r184",
      "r523",
      "r563",
      "r564"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r15",
      "r23",
      "r454",
      "r457",
      "r494",
      "r559",
      "r560",
      "r731",
      "r732",
      "r733",
      "r743",
      "r744",
      "r745",
      "r746"
     ]
    },
    "cosm_AcquisitionAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AcquisitionAccountingPolicy",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Accounting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquisitionCosts",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of fees",
        "documentation": "Amount of capitalized acquisition cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes exploration and development costs and capitalized interest."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 37.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r700",
      "r877"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r743",
      "r744",
      "r745",
      "r746",
      "r825",
      "r880"
     ]
    },
    "cosm_AdditionalStockConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AdditionalStockConsideration",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional stock consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_AdvancesForBuildingsAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AdvancesForBuildingsAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances for building's acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_AgreementTerminate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AgreementTerminate",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement terminate"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_AlbaniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AlbaniaMember",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Albania [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "verboseLabel": "Share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for doubtful accounts",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r280",
      "r289",
      "r290",
      "r294",
      "r845"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative allowance for doubtful accounts",
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Write-offs",
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "cosm_AlphaBankOfGreeceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AlphaBankOfGreeceMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alpha Bank of Greece [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_AlphaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AlphaMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alpha [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r310",
      "r317",
      "r682"
     ]
    },
    "cosm_AmountAccountsReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AmountAccountsReceivableRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable - related party",
        "label": "[Accounts receivable - related party]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_AmountAccountsReceivableRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AmountAccountsReceivableRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable - related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset acquision",
        "documentation": "Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_AssetAcquisitionPriceOfAcquisitionExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionPriceOfAcquisitionExpected",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset acquisition",
        "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charge",
        "verboseLabel": "Impairment charge",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r46"
     ]
    },
    "us-gaap_AssetRetirementObligationLiabilitiesSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligationLiabilitiesSettled",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity issued in settlement of liabilities",
        "documentation": "Amount of asset retirement obligations settled, or otherwise disposed of, during the period. This may include asset retirement obligations transferred to third parties associated with the sale of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "[Assets]",
        "verboseLabel": "Financial assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r143",
      "r177",
      "r209",
      "r241",
      "r249",
      "r268",
      "r272",
      "r283",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r447",
      "r451",
      "r466",
      "r518",
      "r614",
      "r675",
      "r676",
      "r700",
      "r712",
      "r787",
      "r788",
      "r836"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "label": "[Assets, Current]",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r188",
      "r209",
      "r283",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r447",
      "r451",
      "r466",
      "r700",
      "r787",
      "r788",
      "r836"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_AtticaBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AtticaBankMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attica Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_AuthorizationToRepurchaseCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "AuthorizationToRepurchaseCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, authorization to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/LeasesDetails1",
      "http://cosm.com/role/StockOptionsAndWarrantsDetails",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type Axis",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Financial Statement Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_BasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "BasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_BasothoInvestmentLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "BasothoInvestmentLimitedMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basotho Investment Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BorrowingsUnderGuaranteedInvestmentAgreements",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing",
        "documentation": "Carrying value as of the balance sheet date of the sum of the obligations to contract holders to provide to them an agreed upon rate of return pursuant to the terms of the underlying contract. These contracts represent lending by the contract holders to the entity in return for a guaranteed (primarily fixed) interest rate until maturity, unless called earlier if the contracts provide that option to the contract holders (usually institutions). There is little or no insurance risk for the entity."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "cosm_BottomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "BottomMember",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_BuildingAcquisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "BuildingAcquisionMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building Acquision [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building And Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "cosm_BuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "BuildingsMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Buildings [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_BulgariaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "BulgariaMember",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bulgaria [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r442",
      "r689",
      "r690"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r442",
      "r689",
      "r690"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of total consideration transferred",
        "verboseLabel": "Total purchase price",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r14"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of common stock issued",
        "verboseLabel": "Issuable stock amount",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2"
     ]
    },
    "cosm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_BusinessCombinationContingentConsiderationArrangementLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "BusinessCombinationContingentConsiderationArrangementLiability",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Consideration Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "documentation": "The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory]",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total identifiable net assets",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Identifiable intangible assets",
        "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bargain purchase gain",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://cosm.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIS OF PRESENTATION",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r109",
      "r111"
     ]
    },
    "cosm_CANAPharmaceuticalLaboratoriesSACanaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CANAPharmaceuticalLaboratoriesSACanaMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANA Pharmaceutical Laboratories, S.A. (\"Cana\") [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_COVIDLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "COVIDLoansMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COVID Loans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CanaHoldingsLaboratoriesHoldingLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CanaHoldingsLaboratoriesHoldingLimitedMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cana Holdings Laboratories Holding Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CapitalStructureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CapitalStructureTextBlock",
     "presentation": [
      "http://cosm.com/role/CapitalStructure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CAPITAL STRUCTURE",
        "label": "[CAPITAL STRUCTURE]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AT BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AT END OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r104",
      "r207"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CHANGE IN CASH",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r104"
     ]
    },
    "cosm_CashContributedToLimitedPartner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CashContributedToLimitedPartner",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash contributed to limited partner"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosure of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CashPaidDuringTheYearNewAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CashPaidDuringTheYearNewAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the year:"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_ChangesInAllowanceForDoubtfulAccountsBeginningBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ChangesInAllowanceForDoubtfulAccountsBeginningBalance",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance as of January 1st, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_ChangesInAllowanceForDoubtfulAccountsEndingBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ChangesInAllowanceForDoubtfulAccountsEndingBalance",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance as of March 31, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r181",
      "r182",
      "r183",
      "r209",
      "r229",
      "r233",
      "r236",
      "r238",
      "r243",
      "r244",
      "r283",
      "r341",
      "r343",
      "r344",
      "r345",
      "r348",
      "r349",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r466",
      "r570",
      "r571",
      "r572",
      "r573",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r601",
      "r624",
      "r645",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r722",
      "r740",
      "r747"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant otstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrants issued",
        "verboseLabel": "Warrant with no expiration",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_ClosingOfAcquisitionOfCloudscreen": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ClosingOfAcquisitionOfCloudscreen",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Closing of acquisition of Cloudscreen"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CloudscreenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CloudscreenMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cloudscreen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (see Note 14)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r133",
      "r521",
      "r600"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r336",
      "r337",
      "r660",
      "r780",
      "r784"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share reserv for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "cosm_CommonStockIssuedAsConsiderationFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CommonStockIssuedAsConsiderationFairValue",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued as consideration Fair value"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CommonStockIssuedToConsultants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CommonStockIssuedToConsultants",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued to consultants"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CommonStockIssuedToEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CommonStockIssuedToEmployees",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued to employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "cosm_CommonStockShareAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CommonStockShareAuthorized",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized",
        "label": "[Common stock, shares authorized]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CommonStockShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CommonStockShareMember",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 38.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Subscription receivable",
        "label": "[Common Stock, Share Subscribed but Unissued, Subscriptions Receivable]",
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r609",
      "r650"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r601"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares issued",
        "terseLabel": "Common stock share issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r601",
      "r620",
      "r880",
      "r881"
     ]
    },
    "cosm_CommonStockSharesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CommonStockSharesValue",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 300,000,000 shares authorized; 27,284,633 and 23,689,135 shares issued and 27,198,136 and 23,602,638 outstanding as of March 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r522",
      "r700"
     ]
    },
    "cosm_CommonStocksSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CommonStocksSharesIssued",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued",
        "label": "[Common stock, shares issued]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CommonStocksSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CommonStocksSharesOutstanding",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares outstanding",
        "label": "[Common stock, shares outstanding]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r124"
     ]
    },
    "cosm_ComplementaryCompensationShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ComplementaryCompensationShares",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Complementary compensation Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL COMPREHENSIVE INCOME (LOSS)",
        "label": "[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r190",
      "r192",
      "r198",
      "r511",
      "r534",
      "r535"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER COMPREHENSIVE INCOME (LOSS)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers and software [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r666"
     ]
    },
    "cosm_CorporateTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CorporateTaxRate",
     "presentation": [
      "http://cosm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CosmoFarmacyLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CosmoFarmacyLPMember",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cosmo Farmacy LP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COST OF GOODS SOLD",
        "negatedLabel": "Cost of Sales",
        "verboseLabel": "Cost of Sales",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r506"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CovidNinteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CovidNinteenMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Covid Ninteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CreditLossesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CreditLossesPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Losses"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CroatiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CroatiaMember",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Croatia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_CustomerAdvancesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CustomerAdvancesPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Advances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerListsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerListsMember",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Base [Member]",
        "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r777",
      "r778"
     ]
    },
    "cosm_CyprusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "CyprusMember",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cyprus [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DebtAgreementJulyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DebtAgreementJulyMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 30, 2021 Debt Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DebtAgreementJuneOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DebtAgreementJuneOneMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 9, 2022 Debt Agreement One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DebtAmountReceivedFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DebtAmountReceivedFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt amount received from related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding principal loan balance",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NOTES PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "NOTES PAYABLE",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r208",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r339",
      "r340",
      "r350",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r366",
      "r373",
      "r374",
      "r375",
      "r481"
     ]
    },
    "cosm_DebtExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DebtExchangeAgreementMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DebtExchangesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DebtExchangesAmount",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt exchanges, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DebtExchangesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DebtExchangesShares",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt exchanges, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Axis",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r72",
      "r73",
      "r129",
      "r132",
      "r211",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r698",
      "r741",
      "r781",
      "r782",
      "r783",
      "r831",
      "r832"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r683",
      "r826",
      "r827"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r211",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r698",
      "r741",
      "r781",
      "r782",
      "r783",
      "r831",
      "r832"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DecriptionOfLoanPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DecriptionOfLoanPayment",
     "presentation": [
      "http://cosm.com/role/LoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decription of loan payment"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DeemberTwentyTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DeemberTwentyTwentyFourMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 20, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of common fair value",
        "documentation": "The total fair value of shares issued during the period under a deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueArrangementTypeAxis",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Arrangement Type Axis",
        "documentation": "Information by type of deferred revenue arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueArrangementTypeDomain",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization expense",
        "negatedLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48"
     ]
    },
    "us-gaap_DepreciationExpenseOnReclassifiedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationExpenseOnReclassifiedAssets",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47"
     ]
    },
    "cosm_DescriptionInterestOfSecuredPromissoryNote": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DescriptionInterestOfSecuredPromissoryNote",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description related to interest on principal"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DimitriosGoulielmosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DimitriosGoulielmosMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dimitrios Goulielmos [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DisaggregationOfRevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DisaggregationOfRevenueDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "DISAGGREGATION OF REVENUE",
        "label": "[DISAGGREGATION OF REVENUE]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue Disaggregation",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "cosm_DiscriptionOfIncentiveStockAwards": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DiscriptionOfIncentiveStockAwards",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discription of incentive stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_DocPharmaSaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "DocPharmaSaMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DOC Pharma S.A. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_EFGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "EFGMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetails",
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EFG [Member]",
        "verboseLabel": "EGF [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC NET LOSS PER SHARE",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r226",
      "r229",
      "r236",
      "r237",
      "r238",
      "r240",
      "r440",
      "r445",
      "r460",
      "r461",
      "r512",
      "r536",
      "r668"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DILUTED NET LOSS PER SHARE",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r229",
      "r236",
      "r237",
      "r238",
      "r240",
      "r440",
      "r445",
      "r460",
      "r461",
      "r512",
      "r536",
      "r668"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Net Loss per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r239"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 37.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r692"
     ]
    },
    "cosm_EffectsOfWarInTheUkrainePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "EffectsOfWarInTheUkrainePolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Effects of War in the Ukraine"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL STRUCTURE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r165",
      "r194",
      "r195",
      "r196",
      "r212",
      "r213",
      "r214",
      "r216",
      "r221",
      "r223",
      "r225",
      "r242",
      "r287",
      "r288",
      "r323",
      "r383",
      "r430",
      "r431",
      "r437",
      "r438",
      "r439",
      "r441",
      "r444",
      "r445",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r482",
      "r484",
      "r494",
      "r533",
      "r559",
      "r560",
      "r561",
      "r581",
      "r645"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity method investment aggregate cost",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "cosm_EquityMethodInvestmentOwnershipRemainingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "EquityMethodInvestmentOwnershipRemainingPercentage",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity ownership remaining"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "EQUITY METHOD INVESTMENTS",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r282",
      "r284",
      "r723"
     ]
    },
    "cosm_EquityMethodInvestmentsOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "EquityMethodInvestmentsOwnershipPercentage",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r64",
      "r281"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities",
        "documentation": "Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recurring Fair Value",
        "documentation": "Amount of issuances of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r465",
      "r696"
     ]
    },
    "cosm_FinanceLeaseAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "FinanceLeaseAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease, amortization expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on finance leases",
        "verboseLabel": "Finance lease, interest expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r489",
      "r699"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease liability, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cosm.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturity of finance lease liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of finance lease liabilities",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "cosm_FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "[Less: Imputed interest 1]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted finance lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Finance Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "cosm_FinanceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "FinanceLeaseMember",
     "presentation": [
      "http://cosm.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of finance lease liability",
        "label": "[Finance Lease, Principal Payments]",
        "verboseLabel": "Payment of the principal balance",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r490"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease right-of-use asset",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "cosm_FinanceLeaseWeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "FinanceLeaseWeightedAverageDiscountRate",
     "presentation": [
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease, weighted average discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_FinanceLeaseWeightedAverageRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm",
     "presentation": [
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease, weighted average remaining lease term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated Amortization",
        "label": "[Finite-Lived Intangible Assets, Accumulated Amortization]",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r298",
      "r316",
      "r682"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r882"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r661",
      "r682"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2030",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r661",
      "r682"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r661",
      "r682"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r661",
      "r682"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r661",
      "r682"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets By Major Class Axis",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r320",
      "r321",
      "r507",
      "r508",
      "r661"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r320",
      "r321",
      "r661"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total amortization",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r774"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign curreny translation",
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r830"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r471",
      "r642"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency transaction, net",
        "verboseLabel": "Foreign currency transaction, net",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r710",
      "r829",
      "r830",
      "r879"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions in and Translations of Foreign Currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "cosm_ForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ForeignCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation",
        "label": "[Foreign currency translation]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_ForeignCurrencyTranslationAdjustmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ForeignCurrencyTranslationAdjustmentNet",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation adjustment, net",
        "label": "[Foreign currency translation adjustment, net]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_FourThirdPartyConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "FourThirdPartyConsultantsMember",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Third Party Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2",
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture, fixtures and equipment [Member]",
        "verboseLabel": "Furniture, fixtures and equipment [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on net change in fair value of equity investments",
        "label": "[Gain (Loss) on Investments]",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99",
      "r721"
     ]
    },
    "cosm_GainLossOnSalesOfEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "GainLossOnSalesOfEquityInvestments",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on equity investments, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "negatedLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r626"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec",
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative Expense [Member]",
        "verboseLabel": "General and administrative expenses [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "cosm_GeorgeTerzisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "GeorgeTerzisMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "George Terzis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r299",
      "r509",
      "r676",
      "r681",
      "r695",
      "r700",
      "r766",
      "r767"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INTANGIBLE ASSETS",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangibles, net",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768"
     ]
    },
    "cosm_GreeceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "GreeceMember",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenueDetails",
      "http://cosm.com/role/IncomeTaxesDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Greece [Member]",
        "verboseLabel": "Greece [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_GrigoriosSiokasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "GrigoriosSiokasMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grigorios Siokas [Member]",
        "verboseLabel": "Grigorios Siokas [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "GROSS PROFIT",
        "label": "[Gross Profit]",
        "verboseLabel": "GROSS PROFIT",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r92",
      "r142",
      "r209",
      "r283",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r466",
      "r670",
      "r675",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r787"
     ]
    },
    "cosm_IccMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "IccMember",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r115"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]",
        "verboseLabel": "Net profit/(loss) before Income Taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r138",
      "r142",
      "r513",
      "r530",
      "r670",
      "r675",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec",
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r331",
      "r333",
      "r462",
      "r464",
      "r465",
      "r557",
      "r558",
      "r629",
      "r661",
      "r697",
      "r847"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec",
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r333",
      "r462",
      "r464",
      "r465",
      "r557",
      "r558",
      "r629",
      "r661",
      "r697",
      "r847"
     ]
    },
    "cosm_IncomeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "IncomeTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenueDetails",
      "http://cosm.com/role/IncomeTaxesDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority Name Axis",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r820"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenueDetails",
      "http://cosm.com/role/IncomeTaxesDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r820"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r415",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r428",
      "r432",
      "r434",
      "r435",
      "r436",
      "r575",
      "r692"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAX EXPENSE",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r162",
      "r224",
      "r225",
      "r241",
      "r257",
      "r272",
      "r418",
      "r419",
      "r433",
      "r538",
      "r692"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r416",
      "r417",
      "r425",
      "r426",
      "r427",
      "r429",
      "r569"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses",
        "label": "[Increase (Decrease) in Accounts Payable and Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "cosm_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses - related party",
        "label": "[Accounts payable and accrued expenses - related party]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "[Increase (Decrease) in Accounts Receivable]",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable - related party",
        "label": "[Increase (Decrease) in Accounts Receivable, Related Parties]",
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued interest",
        "label": "[Increase (Decrease) in Accrued Interest Receivable, Net]",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued interest",
        "label": "[Increase (Decrease) in Interest Payable, Net]",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "[Increase (Decrease) in Inventories]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r738"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "[Increase (Decrease) in Other Current Liabilities]",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "cosm_IncreaseDecreaseInOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "IncreaseDecreaseInOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other liabilities",
        "label": "[Other liabilities]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets - related party",
        "label": "[Prepaid expenses and other current assets - related party]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "[Increase (Decrease) in Prepaid Expenses, Other]",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r238"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite Lived Intangible Assets By Major Class Axis",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r314",
      "r319",
      "r682"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r314",
      "r319",
      "r682"
     ]
    },
    "cosm_InitialShareCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "InitialShareCapital",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial share capital"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_InitialShareCapitalIncreased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "InitialShareCapitalIncreased",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial share capital increased"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subtotal",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r774",
      "r776"
     ]
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and intangible assets, net",
        "verboseLabel": "Total",
        "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "[Interest Expense, Operating and Nonoperating]",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r249",
      "r253",
      "r259",
      "r272",
      "r480",
      "r675",
      "r676"
     ]
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense [Member]",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "verboseLabel": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r205",
      "r206"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "verboseLabel": "Accrued interest expenses",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accured interest expense",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r841"
     ]
    },
    "cosm_InventoriesRelatedAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "InventoriesRelatedAgreementMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories Related Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r663",
      "r700"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r171",
      "r186",
      "r295",
      "r296",
      "r297",
      "r505",
      "r667"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Equity Securities",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r565",
      "r566",
      "r567",
      "r568",
      "r652",
      "r653"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Investments",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investement",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r706",
      "r708"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY METHOD INVESTMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "JanuaryTwentySevenTwoThousandTwentyFiveMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 27 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_JanuaryTwentythreeTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "JanuaryTwentythreeTwoThousandTwentyFourMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 23, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_JulyFourteenTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "JulyFourteenTwoThousandTwentyThreeMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 14, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_JulyTwentyNineTwentyTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "JulyTwentyNineTwentyTwentyFourMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 29, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_JuneTwentyFourTwentyTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "JuneTwentyFourTwentyTwentyMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 24, 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_JuneTwentyThreeTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "JuneTwentyThreeTwoThousandTwentyMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 23, 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_KanarogloySiaEpeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "KanarogloySiaEpeMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kanarogloy &amp; Sia Epe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_LeaseAndRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAndRentalExpense",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expense",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_LeaseholdImprovementsAndTechnicalWorksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LeaseholdImprovementsAndTechnicalWorksMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements and technical works [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r492"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LEASES",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cosm.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturity of Operating Lease liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029 and Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted operating lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorLeasesPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r493"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 42.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "[Liabilities]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r72",
      "r73",
      "r74",
      "r76",
      "r77",
      "r78",
      "r79",
      "r209",
      "r283",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r448",
      "r451",
      "r452",
      "r466",
      "r599",
      "r669",
      "r712",
      "r787",
      "r836",
      "r837"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r134",
      "r525",
      "r700",
      "r742",
      "r761",
      "r828"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "[Liabilities, Current]",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r170",
      "r209",
      "r283",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r448",
      "r451",
      "r452",
      "r466",
      "r700",
      "r787",
      "r836",
      "r837"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LifeSettlementContractsFairValueMethodCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settelment amount",
        "documentation": "Fair value amount of life settlement contracts accounted for under the fair value method."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Subtotal",
        "label": "[Long-Term Line of Credit]",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r132",
      "r842"
     ]
    },
    "cosm_LineOfCreditBorrowingsLoanDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LineOfCreditBorrowingsLoanDescription",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings loan Description"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_LineOfCreditFacilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LineOfCreditFacilitiesDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/LinesOfCredit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LINES OF CREDIT",
        "label": "[LINES OF CREDIT]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LINES OF CREDIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAverageOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit facility outstanding balance",
        "documentation": "Average amount borrowed under the credit facility during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate",
        "label": "[Line of Credit Facility, Interest Rate During Period]",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r75"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lines of credit",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r129"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "auth_ref": []
    },
    "cosm_LoanPayableSetOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LoanPayableSetOffs",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan payable Set-offs"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_LoanReceivableabstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LoanReceivableabstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LOAN RECEIVABLE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansAndLeasesReceivableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans receivable - related party",
        "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r136"
     ]
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/LoanReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LOAN RECEIVABLE",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r754"
     ]
    },
    "cosm_LoansPayableRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LoansPayableRelatedPartiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans payable - related party"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_LoansPayableRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LoansPayableRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "label": "[Beginning balance 1]",
        "periodEndLabel": "Ending balance"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_LoansPayableRelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LoansPayableRelatedPartyMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable - Related Party [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_LoansReceivableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LoansReceivableNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans receivable - long term portion"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_LoansReceivableRelatedPartyNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "LoansReceivableRelatedPartyNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans receivable - related party - long term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r132",
      "r363",
      "r376",
      "r684",
      "r685",
      "r698",
      "r842"
     ]
    },
    "us-gaap_LongTermDebtDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtDescription",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Description",
        "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r51"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2030 and thereafter",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r211",
      "r789"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Long-Term Debt, Maturity, Year One]",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r211",
      "r368"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Long-Term Debt, Maturity, Year Four]",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r211",
      "r368"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Long-Term Debt, Maturity, Year Three]",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r211",
      "r368"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Long-Term Debt, Maturity, Year Two]",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r211",
      "r368"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable long term",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/NotesPayableDetails",
      "http://cosm.com/role/NotesPayableDetails1",
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable - long term portion",
        "negatedLabel": "Notes payable - long-term",
        "verboseLabel": "Notes payable - long-term",
        "terseLabel": "Notes payable - long term portion",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Purchase Commitment By Category Of Item Purchased Axis",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Longterm Debt Type Axis",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r50",
      "r781",
      "r782",
      "r783"
     ]
    },
    "cosm_MachineryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "MachineryMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementFeeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManagementFeeDescription",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of research and development",
        "documentation": "Description of the nature of payments to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP), including the fee rate, basis of calculation, relevant accounting period, whether the fee is paid to an entity other than the managing member or general partner, or whether the fee is waived."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "cosm_MariaKozariMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "MariaKozariMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maria Kozari [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "cosm_MaturityPeriodOfLicense": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "MaturityPeriodOfLicense",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity period of license"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_MayTwelveTwentyTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "MayTwelveTwentyTwentyMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 12, 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_NationalBankOfGreeceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NationalBankOfGreeceOneMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "National Bank of Greece One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_NationalBankOfGreeceSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NationalBankOfGreeceSAMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "National Bank of Greece SA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_NationalBankOfGreeceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NationalBankOfGreeceTwoMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "National Bank of Greece Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_NationalMedicinesAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NationalMedicinesAgencyMember",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "National Medicines Agency [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_NationalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NationalMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "National [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInContinuingOperations",
     "presentation": [
      "http://cosm.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in operations",
        "documentation": "The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r108"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_NetFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NetFinanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net finance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 20.0
      },
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net Loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r108",
      "r139",
      "r168",
      "r189",
      "r191",
      "r196",
      "r209",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r224",
      "r225",
      "r234",
      "r283",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r440",
      "r445",
      "r461",
      "r466",
      "r532",
      "r623",
      "r643",
      "r644",
      "r710",
      "r787"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r217",
      "r218",
      "r219",
      "r220",
      "r226",
      "r227",
      "r235",
      "r238",
      "r445"
     ]
    },
    "cosm_NetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NetSales",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://cosm.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10b5-1 Arrangements Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://cosm.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10b5-1 Arrangements Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OTHER INCOME (EXPENSE), NET",
        "label": "[Nonoperating Income (Expense)]",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans receivable",
        "verboseLabel": "Loans receivable - related party current portion",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r756"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans receivable - related party noncurrent portion",
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding principal balance",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r132",
      "r842",
      "r844"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/NotesPayableDetails",
      "http://cosm.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "verboseLabel": "Notes payable - short-term",
        "negatedLabel": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "cosm_NotesPayableRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NotesPayableRelatedPartiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable - related party"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_NotesPayableRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NotesPayableRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "label": "[Beginning balance]",
        "periodEndLabel": "Ending balance"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_NotesPayableRelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NotesPayableRelatedPartyMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable - Related Party [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_NutraceuticalsAndPharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "NutraceuticalsAndPharmaceuticalsMember",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nutraceuticals and Pharmaceuticals [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OPERATING EXPENSES",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r670",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "cosm_OperatingLeaseCashFlowsUsedInFinanceLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OperatingLeaseCashFlowsUsedInFinanceLease",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cash flows used in finance lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "cosm_OperatingLeaseLiabilityLessImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OperatingLeaseLiabilityLessImputedInterest",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "[Less: Imputed interest]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "cosm_OperatingLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OperatingLeaseMember",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right-of-use assets",
        "verboseLabel": "Amortization of right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "cosm_OperatingLeaseTermOfAgreements": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OperatingLeaseTermOfAgreements",
     "presentation": [
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, term of agreements"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_OperatingLeaseWeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OperatingLeaseWeightedAverageDiscountRate",
     "presentation": [
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, weighted average discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_OperatingLeaseWeightedAverageRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm",
     "presentation": [
      "http://cosm.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease Weighted-average remaining lease term"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_OrganizationAndNatureOfTheBusinessAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OrganizationAndNatureOfTheBusinessAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND NATURE OF BUSINESS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ORGANIZATION AND NATURE OF BUSINESS",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r125"
     ]
    },
    "cosm_OriginalWarrantsSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OriginalWarrantsSharesIssued",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original Warrants Shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r176",
      "r517",
      "r676",
      "r712"
     ]
    },
    "cosm_OtherAssetsRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OtherAssetsRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets - related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation",
        "label": "[Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent]",
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r15",
      "r126"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment, net",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r533"
     ]
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization expense",
        "label": "[Other Depreciation and Amortization]",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r94"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96"
     ]
    },
    "us-gaap_OtherFiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherFiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and intangible assets, gross",
        "documentation": "Amount before accumulated amortization of finite-lived intangible assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r725",
      "r774"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative expenses",
        "label": "[Other General and Administrative Expense]",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r878"
     ]
    },
    "cosm_OtherIncomeAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OtherIncomeAndExpenses",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income and expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInvestmentsAndSecuritiesAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherInvestmentsAndSecuritiesAtCost",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in debt and equity securities",
        "documentation": "Includes other investments and securities that are not at fair value as of the balance sheet date and those that are not accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r726"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r519",
      "r595",
      "r596",
      "r712",
      "r844",
      "r876"
     ]
    },
    "us-gaap_OtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r700"
     ]
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/OtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "OTHER LIABILITIES",
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r77",
      "r779"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "cosm_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OtherMember",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSE)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPreferredStockDividendsAndAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPreferredStockDividendsAndAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other adjustments",
        "documentation": "Amount of preferred stock dividends and adjustments classified as other."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r120"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development costs",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "cosm_OutstandingDebtBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "OutstandingDebtBalance",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding debt balance"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PanagiotisKozarisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PanagiotisKozarisMember",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Panagiotis Kozaris [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PancretaBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PancretaBankMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pancreta Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PancretaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PancretaMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pancreta [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PancretaOfGreeceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PancretaOfGreeceMember",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pancreta Bank of Greece [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PaymentReceivedFromInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PaymentReceivedFromInstallment",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly basis instalments"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PaymentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PaymentTax",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of additional tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLoans",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetails",
      "http://cosm.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "[Payments for Loans]",
        "documentation": "Cash payments for and related to principal collection on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "cosm_PaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payments",
        "label": "[Payments]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of financing fees",
        "label": "[Payments of Financing Costs]",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsOfLoanCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfLoanCosts",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/LoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments of loan",
        "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional principal repayment",
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r443"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets",
        "label": "[Payments to Acquire Intangible Assets]",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "[Payments to Acquire Productive Assets]",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "cosm_PayrollTaxRelatedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PayrollTaxRelatedCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OtherLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll tax related current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PharmacyLicenseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PharmacyLicenseValue",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pharmacy license value"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PharmamanufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PharmamanufacturingMember",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pharma manufacturing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PhaseOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PhaseOneMember",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PhaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PhaseTwoMember",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PiecesPerProduct": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PiecesPerProduct",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pieces per product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative",
      "http://cosm.com/role/NotesPayableDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative",
      "http://cosm.com/role/NotesPayableDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_PostemploymentBenefitPlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PostemploymentBenefitPlansPolicy",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement and Termination Benefits",
        "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "cosm_PotentialCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PotentialCommonShares",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Total]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PotentiallyDilutiveCommonStockEquivalents": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PotentiallyDilutiveCommonStockEquivalents",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potentially dilutive common stock equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PreferredStockLiquidationPreference1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PreferredStockLiquidationPreference1",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, Liquidation Preference"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r601"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets - related party",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "cosm_PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets - related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInterest",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid balance",
        "documentation": "Amount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r680",
      "r763"
     ]
    },
    "cosm_PrepaymentOfInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PrepaymentOfInventory",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment relates to purchases of inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrincipalAmountOutstandingOnLoansSecuritized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrincipalAmountOutstandingOnLoansSecuritized",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding principal amount",
        "documentation": "This is the principal amount outstanding for securitized loans only (across all types of loans)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "cosm_ProceedFromDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ProceedFromDebt",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds",
        "label": "[Proceeds]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCustomersForProgressPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromCustomersForProgressPayments",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OtherLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Received prepayments from customers",
        "documentation": "Cash received from customers as progress payments on projects that have been partially completed."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r504"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from lines of credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r741"
     ]
    },
    "us-gaap_ProceedsFromLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLoans",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds",
        "documentation": "Cash received from principal payments made on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from note payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock, net of financing fees of $19,467, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock, net of financing fees of $19,467, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of intangible assets",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ProceedsFromSaleOfLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfLoansReceivable",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from loan receivable",
        "documentation": "The cash inflow associated with the sale of loans receivables arising from the financing of goods and services."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ProceedsFromSecuredNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSecuredNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Promissory Note",
        "verboseLabel": "Secured promissory note",
        "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross cash proceeds from warrants exercised",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails",
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Property Class [Axis]"
       }
      }
     },
     "auth_ref": [
      "r275",
      "r506",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r662",
      "r688",
      "r701",
      "r702",
      "r703",
      "r705",
      "r707",
      "r785",
      "r786",
      "r791",
      "r846",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails",
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "auth_ref": [
      "r275",
      "r506",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r662",
      "r688",
      "r701",
      "r702",
      "r703",
      "r705",
      "r707",
      "r785",
      "r786",
      "r791",
      "r846",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/BasisOfPresentationDetailsNarrative",
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r189",
      "r191",
      "r203",
      "r209",
      "r215",
      "r221",
      "r224",
      "r225",
      "r283",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r440",
      "r445",
      "r446",
      "r449",
      "r450",
      "r461",
      "r466",
      "r513",
      "r531",
      "r580",
      "r623",
      "r643",
      "r644",
      "r693",
      "r694",
      "r711",
      "r733",
      "r787"
     ]
    },
    "cosm_ProjectCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ProjectCosts",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project cost"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PromissoryNotesMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative",
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r492"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r154",
      "r160",
      "r161"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property plant and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r172",
      "r529"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets",
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "verboseLabel": "Total",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r492",
      "r514",
      "r529",
      "r700"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r154",
      "r160",
      "r527"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cosm.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Property and Equipment, net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative",
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r492"
     ]
    },
    "cosm_PropertyPlantAndEquipmentUsefulLifes": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PropertyPlantAndEquipmentUsefulLifes",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PropertyPlantsAndEquipmentEstimatedUsefulLives": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PropertyPlantsAndEquipmentEstimatedUsefulLives",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful life, description"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PropertyPlantsAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PropertyPlantsAndEquipmentUsefulLife",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated Useful Life",
        "label": "[Estimated Useful Life]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Subject To Or Available For Operating Lease Axis",
        "documentation": "Information by property that could be leased or is available for lease."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "presentation": [
      "http://cosm.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bad debt expense",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r291"
     ]
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions for credit losses",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r137"
     ]
    },
    "cosm_ProvisionForStaffLeavingCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ProvisionForStaffLeavingCompensation",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OtherLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for staff leaving compensation"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PurchaseOfInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PurchaseOfInventory",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventroy purchase"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PurchaseOfPharmaceuticalsMedicine": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PurchaseOfPharmaceuticalsMedicine",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of branded pharmaceuticals"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_PurchasePriceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "PurchasePriceAmount",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net receivable balance",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec",
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative",
      "http://cosm.com/role/LinesOfCreditDetails",
      "http://cosm.com/role/LinesOfCreditDetailsNarrative",
      "http://cosm.com/role/NotesPayableDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative",
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r385",
      "r498",
      "r499",
      "r520",
      "r526",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r619",
      "r621",
      "r651"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction Axis",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499",
      "r835"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec",
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative",
      "http://cosm.com/role/LinesOfCreditDetails",
      "http://cosm.com/role/LinesOfCreditDetailsNarrative",
      "http://cosm.com/role/NotesPayableDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative",
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r385",
      "r498",
      "r499",
      "r520",
      "r526",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r619",
      "r621",
      "r651",
      "r835"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r576",
      "r577",
      "r578",
      "r627",
      "r628",
      "r629",
      "r648",
      "r649"
     ]
    },
    "cosm_RemainingWarrantsSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "RemainingWarrantsSharesIssued",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Warrants Shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of lines of credit",
        "label": "[Repayments of Lines of Credit]",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r741"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of note payable",
        "label": "[Repayments of Notes Payable]",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of related party loan",
        "label": "[Repayments of Related Party Debt]",
        "verboseLabel": "Repayment of related party",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r661",
      "r675",
      "r838"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development costs",
        "label": "[Research and Development Expense (Excluding Acquired in Process Cost)]",
        "verboseLabel": "Research and development costs",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cosm.com/role/BasisOfPresentationDetailsNarrative",
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r118",
      "r524",
      "r562",
      "r564",
      "r574",
      "r602",
      "r700"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r212",
      "r213",
      "r214",
      "r216",
      "r221",
      "r223",
      "r225",
      "r287",
      "r288",
      "r323",
      "r430",
      "r431",
      "r437",
      "r438",
      "r439",
      "r441",
      "r444",
      "r445",
      "r453",
      "r455",
      "r456",
      "r458",
      "r459",
      "r482",
      "r484",
      "r559",
      "r561",
      "r581",
      "r880"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DISAGGREGATION OF REVENUE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionDeferredRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionDeferredRevenue",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cosm.com/role/BasisOfPresentationDetailsNarrative",
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/DisaggregationOfRevenueDetails",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE",
        "verboseLabel": "Revenue",
        "terseLabel": "Revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r197",
      "r209",
      "r241",
      "r250",
      "r251",
      "r266",
      "r272",
      "r275",
      "r277",
      "r278",
      "r283",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r466",
      "r513",
      "r675",
      "r787"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://cosm.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangements Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://cosm.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangements Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries and wages",
        "negatedLabel": "Salaries",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of potential shares of common stock",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://cosm.com/role/NotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of roll forward of the third party Debt",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768"
     ]
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lines of Credit",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r75"
     ]
    },
    "cosm_ScheduleOfOutstandingDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ScheduleOfOutstandingDebtTableTextBlock",
     "presentation": [
      "http://cosm.com/role/NotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Outstanding Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment, net",
        "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "cosm_ScheduleOfRelatedPartyLoansPayableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ScheduleOfRelatedPartyLoansPayableTableTextBlock",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Loans Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Notes Payable activity",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://cosm.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r122"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of amortization expense for intangible assets",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r775"
     ]
    },
    "cosm_ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock",
     "presentation": [
      "http://cosm.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of describes the operations of each reportable segment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r241",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r278",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r322",
      "r334",
      "r335",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r672",
      "r675",
      "r676",
      "r681",
      "r704",
      "r846",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ]
    },
    "cosm_SegmentProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "SegmentProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment profit / (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://cosm.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r241",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r262",
      "r264",
      "r265",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r671",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing expenses",
        "negatedLabel": "Sales and marketing expenses",
        "verboseLabel": "Sales and marketing expenses",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r790"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "[Share-Based Payment Arrangement, Noncash Expense]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares Outstanding, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares Outstanding, Expired",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period]",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares Outstanding, Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares Outstanding, Granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "cosm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Outstanding, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding, Beginning balance",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value]",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares Outstanding, Beginning balance",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]",
        "periodEndLabel": "Number of Shares Outstanding, Ending balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning balance",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/LeasesDetails1",
      "http://cosm.com/role/StockOptionsAndWarrantsDetails",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411"
     ]
    },
    "cosm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "cosm_ShareExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ShareExchangeAgreementMember",
     "presentation": [
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "cosm_SharesHeldInEscrow": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "SharesHeldInEscrow",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares held in escrow"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "cosm_SharesIssuedInLieuOfCashAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "SharesIssuedInLieuOfCashAmount",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in lieu of cash"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_SharesIssuedPursuantToWarrantExchangeAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "SharesIssuedPursuantToWarrantExchangeAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to warrant exchange agreement, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_SharesIssuedPursuantToWarrantExchangeAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "SharesIssuedPursuantToWarrantExchangeAgreementShares",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to warrant exchange agreement, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares owned"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtInterestRateIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtInterestRateIncrease",
     "presentation": [
      "http://cosm.com/role/LoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative",
      "http://cosm.com/role/RelatedPartyTransactionsDetails",
      "http://cosm.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Debt Type Axis",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative",
      "http://cosm.com/role/RelatedPartyTransactionsDetails",
      "http://cosm.com/role/RelatedPartyTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r781",
      "r782",
      "r783"
     ]
    },
    "cosm_SoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "SoftwareMember",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Business Segments Axis",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r167",
      "r241",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r278",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r322",
      "r325",
      "r334",
      "r335",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r672",
      "r675",
      "r676",
      "r681",
      "r704",
      "r846",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r181",
      "r182",
      "r183",
      "r209",
      "r229",
      "r233",
      "r236",
      "r238",
      "r243",
      "r244",
      "r283",
      "r341",
      "r343",
      "r344",
      "r345",
      "r348",
      "r349",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r466",
      "r570",
      "r571",
      "r572",
      "r573",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r601",
      "r624",
      "r645",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r722",
      "r740",
      "r747"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r84",
      "r85",
      "r165",
      "r194",
      "r195",
      "r196",
      "r212",
      "r213",
      "r214",
      "r216",
      "r221",
      "r223",
      "r225",
      "r242",
      "r287",
      "r288",
      "r323",
      "r383",
      "r430",
      "r431",
      "r437",
      "r438",
      "r439",
      "r441",
      "r444",
      "r445",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r482",
      "r484",
      "r494",
      "r533",
      "r559",
      "r560",
      "r561",
      "r581",
      "r645"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec",
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
      "http://cosm.com/role/DisaggregationOfRevenueDetails",
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative",
      "http://cosm.com/role/IncomeTaxesDetailsNarrative",
      "http://cosm.com/role/IntangibleAssetsNetDetails",
      "http://cosm.com/role/LeasesDetails",
      "http://cosm.com/role/LeasesDetails1",
      "http://cosm.com/role/LeasesDetailsNarrative",
      "http://cosm.com/role/LinesOfCreditDetails",
      "http://cosm.com/role/LinesOfCreditDetailsNarrative",
      "http://cosm.com/role/NotesPayableDetails",
      "http://cosm.com/role/NotesPayableDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative",
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails",
      "http://cosm.com/role/RelatedPartyTransactionsDetails",
      "http://cosm.com/role/RelatedPartyTransactionsDetails1",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cosm.com/role/SegmentReportingDetails",
      "http://cosm.com/role/StockOptionsAndWarrantsDetails",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative",
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r242",
      "r484",
      "r506",
      "r565",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r621",
      "r625",
      "r626",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r645",
      "r709"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec",
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
      "http://cosm.com/role/DisaggregationOfRevenueDetails",
      "http://cosm.com/role/EquityMethodInvestmentsDetailsNarrative",
      "http://cosm.com/role/IncomeTaxesDetailsNarrative",
      "http://cosm.com/role/IntangibleAssetsNetDetails",
      "http://cosm.com/role/LeasesDetails",
      "http://cosm.com/role/LeasesDetails1",
      "http://cosm.com/role/LeasesDetailsNarrative",
      "http://cosm.com/role/LinesOfCreditDetails",
      "http://cosm.com/role/LinesOfCreditDetailsNarrative",
      "http://cosm.com/role/NotesPayableDetails",
      "http://cosm.com/role/NotesPayableDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative",
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails",
      "http://cosm.com/role/RelatedPartyTransactionsDetails",
      "http://cosm.com/role/RelatedPartyTransactionsDetails1",
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cosm.com/role/SegmentReportingDetails",
      "http://cosm.com/role/StockOptionsAndWarrantsDetails",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative",
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r242",
      "r279",
      "r484",
      "r506",
      "r565",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r621",
      "r625",
      "r626",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r645",
      "r709"
     ]
    },
    "cosm_StockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "StockBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awarded share value",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of common stock issued",
        "verboseLabel": "Common stock issued as consideration",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r118"
     ]
    },
    "cosm_StockIssuedDuringPeriodSharesAwarded": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesAwarded",
     "presentation": [
      "http://cosm.com/role/CommitmentsAndContingenciesDetailsNarrativec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awarded shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares Outstanding, Exercised",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period]",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r80",
      "r81",
      "r118",
      "r394"
     ]
    },
    "cosm_StockOptionsAndWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "StockOptionsAndWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK OPTIONS AND WARRANTS"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_StockOptionsAndWarrantsDisclouserTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "StockOptionsAndWarrantsDisclouserTextBlock",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCK OPTIONS AND WARRANTS",
        "label": "[STOCK OPTIONS AND WARRANTS]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 43.0
      }
     },
     "presentation": [
      "http://cosm.com/role/BasisOfPresentationDetailsNarrative",
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY",
        "label": "[Equity, Attributable to Parent]",
        "verboseLabel": "Stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r84",
      "r85",
      "r112",
      "r603",
      "r620",
      "r646",
      "r647",
      "r700",
      "r712",
      "r742",
      "r761",
      "r828",
      "r880"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, amount",
        "label": "[Equity, Including Portion Attributable to Noncontrolling Interest]",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r63",
      "r165",
      "r166",
      "r195",
      "r212",
      "r213",
      "r214",
      "r216",
      "r221",
      "r223",
      "r287",
      "r288",
      "r323",
      "r383",
      "r430",
      "r431",
      "r437",
      "r438",
      "r439",
      "r441",
      "r444",
      "r445",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r473",
      "r474",
      "r478",
      "r483",
      "r494",
      "r560",
      "r561",
      "r579",
      "r603",
      "r620",
      "r646",
      "r647",
      "r659",
      "r711",
      "r742",
      "r761",
      "r828",
      "r880"
     ]
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingInterestRate",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate",
        "label": "[Subordinated Borrowing, Interest Rate]",
        "documentation": "Stated interest rate of the subordinated debt."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_SubscriptionReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "SubscriptionReceivableMember",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r502"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type Axis",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r502"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cosm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r502"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cosm.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r503"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosure of Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_TaxLiabilitiesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "TaxLiabilitiesPayable",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OtherLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax liabilities payable"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_TaxReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "TaxReceivablesPolicyTextBlock",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange adjustments",
        "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_ThirdPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ThirdPartyMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Party [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable",
     "presentation": [
      "http://cosm.com/role/LoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan receivables term"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual Axis"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r834"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://cosm.com/role/LinesOfCreditDetailsNarrative"
     ],
     "auth_ref": []
    },
    "cosm_TopMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "TopMember",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_TotalSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "TotalSegmentMember",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Segment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, net",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r757",
      "r758",
      "r759"
     ]
    },
    "cosm_TradeFacilityAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "TradeFacilityAgreementsMember",
     "presentation": [
      "http://cosm.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_TradeNameMarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "TradeNameMarkMember",
     "presentation": [
      "http://cosm.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade name / mark [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stocks",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 39.0
      }
     },
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 86,497 shares as of March 31, 2025 and December 31, 2024",
        "label": "[Treasury Stock, Common, Value]",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r84"
     ]
    },
    "cosm_TreasuryStocksOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "TreasuryStocksOneMember",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stocks One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_TwoZeroTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "TwoZeroTwentyThreePlanMember",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_TwoZeroTwentyTwoPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "TwoZeroTwentyTwoPlanMember",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_UkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "UkMember",
     "presentation": [
      "http://cosm.com/role/DisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UK [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_UnitedKingdomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "UnitedKingdomMember",
     "presentation": [
      "http://cosm.com/role/IncomeTaxesDetailsNarrative",
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom [Member]",
        "verboseLabel": "United Kingdom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_UnpaidSalariesAndBonusesDues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "UnpaidSalariesAndBonusesDues",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid salaries and bonuses dues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/OtherLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited tax",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r691"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationPurchases",
     "crdr": "debit",
     "presentation": [
      "http://cosm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased of additional licenses",
        "documentation": "The amount purchased during the period under an unrecorded unconditional purchase obligation (for example, under the take-or-pay or throughput contract)."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r152",
      "r153",
      "r155",
      "r156"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VehiclesMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails2",
      "http://cosm.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "cosm_WarrantExchangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "WarrantExchangeMember",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exchange [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_WarrantExpirationDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "WarrantExpirationDateDescription",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_WarrantInducementLetterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "WarrantInducementLetterMember",
     "presentation": [
      "http://cosm.com/role/CapitalStructureDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Inducement Letter [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "WarrantsMember",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails",
      "http://cosm.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageLimitedPartnershipUnitsOutstandingDiluted",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted",
        "documentation": "Weighted average number of limited partnership units outstanding determined by relating the portion of time within a reporting period that limited partnership units have been outstanding to the total time in that period. Used in the calculation of diluted net income or loss per limited partnership unit."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r238"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r36"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://cosm.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r238"
     ]
    },
    "cosm_WeightedAverageRemainingContractualTermExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "WeightedAverageRemainingContractualTermExercisable",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_WeightedAverageRemainingContractualTermOutstandingBeginning": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "WeightedAverageRemainingContractualTermOutstandingBeginning",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Outstanding, Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_WeightedAverageRemainingContractualTermOutstandingEnding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "WeightedAverageRemainingContractualTermOutstandingEnding",
     "presentation": [
      "http://cosm.com/role/StockOptionsAndWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Outstanding, Ending"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_WholesaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "WholesaleMember",
     "presentation": [
      "http://cosm.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wholesale [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://cosm.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital"
       }
      }
     },
     "auth_ref": []
    },
    "cosm_ZipDoctorIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cosm.com/20250331",
     "localname": "ZipDoctorIncMember",
     "presentation": [
      "http://cosm.com/role/OrganizationAndNatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zip Doctor Inc [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)",
   "Paragraph": "4",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "44",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-44"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-7"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "980",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481834/980-20-45-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 5.Q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/840/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-14"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "325",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481493/325-30-45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "325",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481463/325-30-50-8"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001477932-25-003730-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001477932-25-003730-xbrl.zip
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M>:O 8#&:B"!Y;O/9=+6PITO[2F3/>C#2,9W[\+/-E8_7)/9DBH^T9I='=.[
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MO*KG,N!$ 8HK1BF=,E!YQ3C![#?MYZ!/OD#J13(J\,"7'XCP(9_.@083B"A
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M@_-D0<97_>@/,+Y8=WW6J/)(A7"3A_+Y(2FS]6U2S%C^XB01 [&D.CO 695
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M#/9B48%!>(W$H3122OWHJ0?82(71^SB$LG,1;.^@G^S6290#<>4G/R27)2N
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MQG ERHRM0*H?"N64R@K2U(H:5X$@9']:!0(NJ9$0<*5I(WD__\O#,();DL.
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M,,]*"]\"YQAWO"U?VH] ):_]NP]%=5],;X:#I?7/89_*OH^,*=J:#D?&E%I
M]M/$BJ--0'*^R!/;BVB,<B^(!-'\KIK-FMQ3**+JA)] /N"40.K(R^GF8>K0
M[7ZC4)T@&H=S;W:- -[!"&_-CIOHW_"J#*OLU=DQ__6JVG.T>$LN"]Q?\48:
MBR!4)K.E>3IEBE&O<#TW32K:!:2&,F9NCO^/H]=B,_U*5<RF5> \?TEXFB/8
M/OWB F^W'/),4.5@\#%_,+BP9J.E-1XLEO/;B^7MG'VBZ4\'_>G _-/!08K$
M%S9=)?7!Q8<# 8E19P.!')KWG%F&9#M-5MM.' .D(ROO9F4(HCG(MQX.'=KG
MU\<BN[G_T-&PG&^S:)^NR?&-%NW3%6_^;1?MZVITM_5@(U>>N3+7S"BCD^-=
M<PQVDF3_G&36OPBV.RR?G2H.D8HQ22*,\Z?G-C/[B?PN$>%9#M]5G4SM?*T3
M%I Y<O,[Y%;$UQS4;?X(ZI!1US6*3(@27P $06C-<&\ (> FNVE9)*V02/]M
M(/]$E ==)$<KP>2_D:LY/QKY;NRD%S@@B@ 27F1+:/3K6UXR32)"O2AR;MP^
ML,,8/26@AE-?['KAMM:O7OEP%@K02A#X'E!:!4]E_.;;ZE=LFXLL8_3G%5 O
ML)P#S'D011+'V'$3_3#(%7C,,=5;H]5_EL%.;!^>_VZ"QC+L4G55J\O30*ZN
M[.*:3*=P[_K\BUERC<HHH=./0HE\76)1VJ@;B"W:-O#3Q2#]XB@,8VZ-.WYS
M$_0LEJ"-,H*9KR4?$X[H''L% @-57)!!;WA_GC/^8*=[*AZ!"5C(9&BC\B#%
M.MDB+8,YV,4(;V="D.&",_352$U0O+HT;10H+. MJJC):VR*FGG\URHRV)2O
M=;^AGZ(Y7&^B6Q_*K(V8S 1,U"2I58ZP'72&CP Y, 0S!!UP^&.X_^OSHQ=%
MU.3=F8ZF7,)\'<-V]JO3. HCVR=OII0WK4<T)@"A(,9>VS\UJ>WC$\D8_AE#
M=Y_RF?P!^ Y@38RDV+$2J2FZ5Y-&?W$[!P WO,(R'NZ2TDDJ3E8OH#(!("5!
M6HDRGR*XAK[M4>.G<((6DYB@;KD4K82='TKEEE"VA,84;4O$H.IN-GU+\HG/
MP'-'_C#$,CUP=,QJ:(IB6;Q3;6IZ(I^P="=P-NQ]#7=Y7\.5#5%R^+'PL-CN
M"%4X?-P!AQ0$!V@KV,&V^4T3AL()U$!'U8E?\<]!DA6%U(%_6F(Y0MM)N!/4
M7/B4?T$R'XZMY?!R,+-(8>_EW)HLK(OE:#I9](47^@<D+^L!R29 $9FQE^ N
MDD="<IH;%1')D4'SHY$"5_+0- Y!)^(3A>-*!DA'WH\T!4F' OX:@.4$3TDX
M&_1)$($0[T+(W,XN\\+P!!E1!W9KXF&6W;W+A*$VK-$C/^^C)17>"54KG9'X
M$NA-G;C?@(=7 2)IGT0W7(66)NB>R[S>I(:8#P#7_D6,R*UG]E!QC<4>!V%X
M#E:XS=)^Y"-2JA.#P"HEEYX"?)(3(3.YVP\5CH0DPUM_*.P/A?VA\,4="G7Y
MM_I#(?=0:/HY_>4>"D^;/"S9(I8]%,J(.K !4S\4RH1IQ0_,^VA)A7="U4J'
M0KX$F@^%F1@ V:FPV-0$[?.YUUQK_1L_CC?J?"==[V?7 D33U8JE3CH/\PU-
MT":/=[WIZ9.2(<3WB\"&[!;N09J%D7^LMWPW^<E+7<7NO^,P2CS%])@_(^4H
M\%^B",&[."+"+@-L*M,C#F>&G)H/$T:,)M7H2;XON:019H#\L<IE39\*LK^T
M>5&7-KP9=/Z4_8OX)J=,'T9=[Y013/.=3Y8AV=T"JVTG;GK*#T8!8!VY^:D'
M3(?N>UH YP3W/_7+O@;^FMRHS#+/$F&Z,7JZP/*L _0T79&%@K9PQ=:R<H=&
MF<[*4FJ.WN'SS>%:-J<K=]@)BUQS]"L/"HDN-*?A[,J@Z-!JT(F!<8)DH=SB
M(Q!S!8-P 8.O-K]4<EK%@]E6_V4"?VMR7(2$R3ZUT\UF6;%]^W/@D8>:X=B^
M(\4E I)2;O^[,=R2XAU";9?KPA00RDE%L6GT7=EEX,PV-MK:"UL( *.=*5IF
ML$Y5V>BU]26!BTRIZR#V(/"V@=B""-H;HUJ^"%3%C>97F>$)LX9!!,-?@[]L
M!,4*YK8V1;U< :AR&\V<<H._8*<?$JJ5T<X4A3)8IZJLEBN%H\J1?X^W)HDM
MWS-FK1%(-BY"U2K0Z5=US7US%@\%>2D^U;*E\#9Z (L/L!!_24P(JZ%^!!2W
M> S>J38;S4KR*S93*%A[P=,"VL.=.,\IK[$I6N7Q3S7;: :2<SL,HDU IDGJ
MME/9*\N(3-&T3 [=53PR,2@+X,0(N-G'(FJA-TQ"_0!5"L1ARM)&ULY+$#H(
M)@_-1WX$$!X>T]7^ZYBA+0Q#O @1/G@[[Q(=F !&69GTQDI9CH-BX"YLSR8+
M?QJT$%D^'CF^D_[ GSQ*Q"9@5D:>-H*L;OV=#0_?Q1\\#_PX!.%ES$R71&C$
M)"8H72Z%WA L.G/3J)XDVH<_%9B-34!!Q'^ME*"U]:^V@!N[6C.79DU)0L6/
M!6N_HGR)+RB+KR<;/13OLRH^^/@4[KJ)BFQO'_%[Z^/O)=G_Z*G^<%#G+!:5
M>S,!KEH"UDH,VD2E ;+^D01-?D@J<R2&UPI#$ F?"XBH3(!,29!:642;"<"^
M!CY MH<YL]PMUF,8I:&I>X[Y$*E1&P25FD":(_3ZG/JL7(R:WC\1OJ>K"WSB
MA=&5[4 /1D]TESG'LEW&"/KK&4 P$"!4KA>#8"LG6"MI3!/SFRR1TQ6]_.>]
M$^2T-4'A O;KI2NM/47($]*1CZUHG,3Z ;3E3P166Q.T+V!?<WK38Y9N[ C/
MN.CITF;>5#+%.*8Q%HUC,0KI09LP-9;C!+$?L=[I7G!O&9/:)0J$)BA>51:J
M?7VES\B.G"Y$TC/(<T,30.#Q3I7>Z G>VA*P*>9SX !XGX,=<F]W58E-T'H9
M>2@2FL[CR2EG?YH1',!SS4P @<TY5;>F,W9Q/$Q Q%\/GKTT BJ#P! +HOE1
ME>5YP8/M.^0Y\V40WT6KV&/-7R>X3TI2"_ JW9-)&)86KEXJT%:O'*533XG8
M(/24Y*& -7KVQC-]87O<]?_YSR9H\YACJJ]&/>2'*WMR=(0^^Y"6[#08#4W1
M(8MWJLUF0[<A-DWA#* 9"MS8X1V^BLU,T621<ZI'3<[L6Q_A-0#SX-[Z3N ?
M7%1[C]3TSH/KM(K7_C>"!;5*7R8 5T,\BJZF8W.R8HRV>"U!2>CUQD9KX9:(
MT]X@E'@B4"0T%=2<@WO@LZ.F#O&NM(5!VGYFFNI7TPEY'R(W#YYL+WJ.D1.>
MUM@$!FF?*P,%0]_YF<57N>A-";7Y,''B-ZN=JWD;*KHXR1UIK)8F*)G+?"O/
ME)^_E#X7=4 <0<?VPAO@0@?S*%4OE\X\97-%J?<*N;;]N2%/(A-!K@#(Q+SS
M;0Z?P@14I$+4>\K<3,0L-G=).M!REZH*I 8AI"!-O2?1+4*ELG2K4;\(P%A+
M=Z.NZ7V4:/I1X)+'4\0U;GN>(*!61F2"ZE7D*#S(/DW24<)S2*.C! 5"?\HG
M&!V/)L/%8'HUN)@/+T?+OBIHGTN4PW"?2[3/)=KG$NUSB?:Y1)7!T5=+QHK(
MR??<]K\*DRT4F^G?AZFE5RARWDIQF.'5M5"!F;^;HKD,RZT$R4_LU/TDKF6;
M:V2*\O)\UXN'YTU>;[<1Y[,[:F&*[HZ8KA?*SD^PYB!\?I'E53MJ9(KZ\GS7
M"SMO]+42?\4_;J5?U95>&Q7SP.@[U(O*A[Q_JWJZ[VN&].?\_IS?G_/[<WY_
MSN_/^2:<\_M*V.7-GK@2MNEEESMBZYJLA*VKP$I?"5M6"?O#*:U:B*(,:OBG
M9\3P#W\LR8F'!%2Y\!ZZL>UQ+!ENRVEJAA7C\]]&[MBR2O\-1IMD)21KYP;N
MEL'0CZ!@;\ 21]:)7@O'!T .E$RR3(68EPQA%RQB>S!F+>2GD_IWZ#TT<8!,
M5]<(  =,?7'N<@F-_LNY<E?P'#&H;>Q $B<N&HP[QNZ@(-D,">Y)\Q"TXE;*
MPKY\"$J/^ R-1EU763+4ID)&/HI#\\ZI[ ?ECBI6:^-USY6,:KT5SY:2TGF-
MC=<Y3S"J\D;#7+\)U_\'3>\_L\L&3>9GW0-DK\$TCL+(]DD)N30)CMH"*N]%
M/TJU<AWR!6NC2D66@_, H> A*?,7V+[XV0HA5J0U 8\2XN@M2_',6)*]^3JV
MD8U/(<!]+D!S2)8@N/8MV8T)$%:3K(VB%9FI2_;6Y[9'\N!P)A&OL0DJ%_&?
M+U%QFE"*;.T _O.(]V?Y (K)=#E<#&;6[];Y>-@_CNB#)EY4T,0E6 &$U[5]
ML@0+89.8OM.4.PA5:,VX9R\AD&;7H9A%F=-*C;H33D7U@5D*Q(ZX&]N'L0O7
M[J> 4IN+LA3:V=31,J-:;&N8$2T*H+G2Y3%+$WNK,,-X%!TQCKP!)00C*T<;
MWD<MD'3*T-6$19\W<8EL%QSNF0ZG8.'UIX1&_S&US"J;/;A*!*OG7^0!L($H
MO;P5Z[S0K MJ%L_E(]46^&_%57@Q_3*Z3!)C"+59;-8%;58;M$59ZCG_^EJ4
M%6I1-IO/*ZU-31*,D"G&<_7E6YF@0R;CM:[/Q9EJPNE*I,)<(V,TF..[C1MK
M5D7/U&'+4::(P!3%BF306V!Y'/AK$IFC9ES9K4U 02B WL*_65[4<L3E&QL$
M )/_?/%>;0Z<,Y8'YYV:!V=P]K<#_^UR*7RP^UZ1V_ZY;N]Y>E&>IYEG^^2L
M*+X./6YEU$7H,>N:']529F2W;/EVG;CN9 T5CK([\E2VFKH[=)596N4F/("U
M'FSDDHJ=8IN3:V:4T<GQKMG->>!&-@\*#3MA=YCCA:?PG.71Y>NJJO(.V9X*
M:L]:GX\=M3Y]?I)F\Y/HFF%]?A*>9)I]RGU^$K7\)"UYEANYVXR4TY.P6QME
M]-@B9%#J @JRF<1KWPDS)QI2$C!R1NT'H^'HD'&K#4G6E/UXTB 9PL<A'.3O
ML2<.U>"VUG_]S[Z>R'K N,Q3Z]2HI_OOMA_;Z&GY@#_VM""!#\N'8+D)XM#V
MW?2W5_!>_.2U9!_Z0>"<U+(HE)2)8M.H!YV,A.&CLR%1*(<1(1WX7 K]>E<;
M_%P!J)(;];+_/?9!BN<2MP,%E,4C7Y%8O^I5AKRB,!2&1M_8L[(I+*S2"2:>
M2?2KO'I&E6<IJ*X;?5R?6V%\:?(:$8%^/9=>4GU&RII/U4(:N$;%>[H*8A0!
MQKJ1S"Z)65$EUZ]])<.B*@X%HUHY9GXPWQ:&88">D@@!<?8.=EO]:A8?1G+!
M?2P1J&JK56(6C/,4Q@D\+![IY@CC+1WC<E+]BE<<WW)1* #5JB]S37G2>RG-
M2VB,4+E$AGHW![S(]N >NAAA8L;$L>V,AOJU*E\F67Q3339ZZ+RQ"6;>_=%<
M$:I42*%?MPHC5B@!U7*CQ\?G_3R9&LJJEI,9H6^Y&%3IS1XGL_<&$?,<)5\:
MR_5A!ASE9*+8:(KU)KLL:8#Q42/]("@',1[Q7>OU3 -^P]WA(<71<9G]8N1P
ML!91&82$6!"].:UH_#_A19QU+/=@H$!@$"!<&6J][ZD?TXB@[\"=[:5)YS+9
MG:9^\NYP 9P88:7^]1PHSXAX+-6+0:B5$TSO*Z+S."2%Q<*+8'L'_>3N[R+P
M0XAY2GY(@@[29ZAG?"C+]6(0E.4$HU$ONEXY!,[741C&P+W$P\M?SP""@;O8
MV B$EO-G#,-$S<('&\I=& 1B":EJO2?CGM.WV\#/,&&%1V/HRH;HB^W%O.1_
M)>A- *6D2/D79DT@PI[5$1X9F/$C1C)O[L?0ODO20'!@JMNI*=C5E9/&:_2O
M9G6_FJUV\UL;@I$? 6QX(]6'L[SV!L' $T'S4[!%?(<Y(),8N(>4N)37.?ZM
M8*<@)S4('P5IZE64;_1F0OTVPN@;B*-;AXIEZ>L?=??L+(-DHXB Y;HPC9"@
MXV/DX^&#5SUH(PA$#UC+=V40<A6DH]!JN\5(LLZ$).V,^F6?F,HDP(2"4&PT
M74M<85OL.V ,[! <KE/H$..#(R$S"!V))!2>YN.PDBNK.7  O$\S,F7'AB@>
M2T)H@NY59:':UY1VAKV;M'QW$OA.M=UTCM@$L,K(0P&K=HO0J.]"!2->>X-@
MX8E D3@<_T^3,2BQHZ&@V,.'?/*=\=!:#!=]E8<^UPZ'84-S[:!@!_ BAG?B
M_P9.M RFR+K' YS(=!6@Z2ZYN_/7R821).0IWY51;S(KR*<[UTP9CJ4)::IT
MUHFGGI7'>)T!T)%R$KJ'0(>>EVH<!B<H1<$K*W;$C3"LC]U4_QZSQA ^JCG&
M%(]::%T5H4$8 G#,VL$W1H_WES'X'=AH^1 (C@AE.]*/J_K9H:QL>H,&2[%+
M(DT;0C7MZJ7BFDJG.>:P!,,D6K@98-.>7BBNJ7!ZPQ=5^;56$4 )TYF,O=6Q
MS77W @'.2:@Y/[J(Z5O?A:%#;GF!.WQT<%-I>>EJW;T4E/D2U@IZ5-K%'I@@
M'(ZVNS@BA7K3:U^EO:VX Q,@*BN3WKSX'$[YDXM+8 (V,AGTY,@_NO%F9L?_
M*+GR)FGQ^TOO_M+;_$OOY#V@/(]@KIE1E]4YWG4'%I+0^G-L@-R+8+O#\N7C
M@</SI^<V^QUD(L*S'+ZKFCJ]G:]UXBJ;.7+S<[05\36[,LP?01VZ"=<UBDY0
M"8!7JRP3/B6\!&<U[,"FL\71?U3=C"&]YD#G+$N5;L:5.^@ S%6B =N["5>8
M2]QK/7@/ED%D>]E[@J,81G[L9GX@-O -$Z!M0>PVRF:JLJAV+U.YMY>&*._&
M1M.5N(SMZN;6#.B4A<G?:6NXS!$6$?PDN]3IJP?VESLOZG)GY.-I IZ%)A\A
M6A9>]0B)C+KX$4JB^1#/X4UV&I>0=>)B1F'4J0'5D;C!-J#JT U(PW"=(+ZO
M-J+7P ?(]BS?M=PM5GH8I>O^\)%<*/!O1?;TBN3Z-W=*(S<'KJ)PFH,%Z>%
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M"C7X_&?SM/?,>ROOXBSOSO:A+51?KHUY.LP)T,H#M0L4X"V]6)&Y-N8I,B=
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M@%8-4(7, JV1(Q,:H)P\/>R8N3Z+8!#[))2N43UX4LW7:@*HW!5;A<XB#1%
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MW7CJF3ZUGHB]LZ:JVU1=EPJ-EPETY$N\BQGJ,BI)H:-#\TU"&1\7;+/9KNY
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M.7<R!B,ZJI!])Z9FZ\A\,($V["E5<8KR\ H::#H9+TL6>( ?Q(>8AW X3G1
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MJLN_K6\__Y$H\^K7]>/J\QK<?_URB=5Y<\,T^@ELOFZ?MJO[Z]O[SS:K-RL
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MU/KD*&"F;P(.Y^[8HFRKCNBK\[@IN<>4YM.4O9'/;-?78]C>]*6N(QN*!'6
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MLO=<>/4(ZY:HN;G#D%[(Z3WTR"U+RFE'8+7R++9])5KM1W^J:$4%N190^7C
ME)<4ADZYP9$=,'[3VS3>.*JJH0*CR75,21$;N=)."+.IT8[67?%RY<[2GM4M
M3*%.VX&'AP\RR<<#!IVL I<T!7HC)$I&1,C-HM?18N?VWA#ZA(5-$;YLA7M+
M1= H$93QFS8PK6>Y\YLRNO#UJ;QC&\YX73 KK8F9G M )5U0]<V%6>5EK3G0
MGG:<9[>CT/66NNJ;=O6R-H(7>EE_E[I9?P\>'C>_WE[COUS^N?9(_\.XK$Y^
M=7:ZJ,Z@RV,; J.Z8&[K<\V%V>]S966+S^!SE0HRKM *PU10;(D4YB=:C ;:
MC'4')5?&W^1SO;F]7]U?V=#6[1&]I=N&C7<?)BB+K:Z;51$M'?L$N>/^H^#4
M#P%J8+DM?UIG&._X \R4Q88;MCU-DZ0X=)UVY&QZ-;8AVJD9(;?$'5F(,E&F
M+.K7]%)6='4HJ).8W(P/JDF=1+3,?S-UD!W>3R64\@L3-1.EZ2LO9G*3CNU-
M7WJ5GN4]#F?>I/<=0+=51 Y8LI*4,HCH+9=%ZXEHVEJ\"%/KREDT;FQ#((L:
MRH8UIEBV[@,05C/^G>)@[OP X?]<T>+Z3?-3(F9A9N/!T.M] ]#-'$C02FS!
MGG"1/SB4SR)#4#M5JN,W90).U*^Q#>7J%" V?/EWF5(Q/IOVERI:):$WL\-L
MU"HA,:O2/IV@N0W+BB+,AJ@<JRQ6<4BW<7P@[;[PJ,+7US"@':<47H6 SXRN
M20<ATKE:IK3']@P-;.ALT!*N7 >3%P3\5 A512H&Q$2.T?OUC9?[!*_"6!Z2
M4Z5EE8UV:+&$]NQPU, *-CC43'@9'_"0\5S#IGE2'+V)V^^356ML0PVD9H3B
M>VRL3#D3H%QF#C3%UI0/D8_QO,%]AK)N6J0,;.3>>++K/6=+_;-O@;CYVT_[
M;^;Y7*:+="O-7YL78JK?ZYF4;V)#R(LB3,XZI'R ,EZ G#5K$6E7ZF#-C>%I
M]Z5LUP07BZ&N>Y&N02V-X(5!+<50EKJ;TA\F$N#D%V;GS?\9-'AB<2B+%'/;
M4);C!L:>4):UYR$GV7CK[ZQGYB/>'6P",@CR_R0Z\!WN$>VS$B>1[^"] _F!
M-GLO_D.!4O"&>WF2OD^BQQ=5_'9Z>$Q:&6;DS&S($NM]@-6ODCV0=G]-'PDB
M_,RT1VQ,.GJ2SM%&=@HG#?L!17[H\K46G/W!Q4:F^(+9.ZC3-[T(TCI]#M)6
MHZ)QQV+R!=3N>OZXNO^\)M42R/['\.I@1C^-SI#.->6_Y><_L2&(R]2XN2TC
M$7W!-HV%)Y"^<]G# 2,AR1J5?RQS,%2@II#6!<BQ@0P<(.@ @V?FE'SVK=/I
M>X@E],:.+H?(&YVOIP1&26_K4WE4M9'(JRVX7'^^O;\GY^K-#7A8/]YNKO]_
MC6#O;@:=Z537^91IQ#J0>F?/.":1/JSOKU4T0<L.Y.GP]K9'Q)D']V0P-_OP
MVVW@A=$K3/PP:,BO4.;6M^:W'%!1G15965/?R1!-;8AHZ02:2Z@N" '7?NSL
MP_@0T>M?NA 2H: @M9>2@]0_!'WW^A#AE73[@OZ,8'2/O@ET4)%'4[E!5?!Y
ML<$F!G8)/)_MH$FO0@>HG-4C"D0;2KF4GP88?& )I@L?'8N,^ZZL)'R%2F>=
MVUJ Y6JV)1*V'YGL)@,;[J.EX/@NPU8T#\A,Z#V>'OS'8ZIEX-;XJH^FLF&A
M/%VLWE/S.5Y!=:=XBDRV?.WFXYD-^23G'4V+Q1@_\!.UI\>L77)NK;OXZ&>)
MQE#P8S8>K7D0^V0OL/'POQ[<&!^&45"[?#0SZ5JD5>$?5^DF#I:8XHSF\]ZK
MC34NT^VP<NLT8R=J!H\"Z!;P**(?K3H&*I+H1>1NP_7KVS[\0/55IN7TNG1)
M ?11C23$S'GE.;.9>0U2ALDI3R%(E$:/(I>41D$9MRZ]N0J#^+!/(']-JL1A
M3G=J@,NTIT#.*@>BL>?8J#]"H(H:Y!SY>ZIS'_LNBK81).[;5101YRV-;9(=
M.U6XM-6Y5QU H<Y]$PNK!NA,ED8S]CJ!Y<\5E!^D D!1PAG/&C%R?GX.WW]!
MCIL>,QSW>+K ?^$'<N<'Z#9!KU5+U43<OV*IP27Z)*=DA3HF>*?;>]2]1(W:
M8&RC/> O1 B@4LX99M2L2H^'/1H.=M,AAK-RP[<$N3=[^%PS;B&E'B5J )II
MD(",>=/GNZFV.R.1^B@!K.H.80*$Z].PK#>I!/ 7(L.<YFRCUR!149PBH7Z]
MX6'6J<V1BA5U&,^'CLG4+%5\RDJS1=$K/N8;TIO[,% W.C)B/?K3##?3(3%E
M>EH>+AV3 15M,'+A3G@_;:,1JHQ':H<DM$9426R-A(19\N70,^F[; &QE1Z=
MV2X)CFF7,/;CC?> WP;QBTJNIIO)-1W,%"#G)S();5JC:#%U3-XVMT-95:#+
MU=/M$PUY>%P_K>^WJ^WMYMY(",SE(28I]O$UBIW(?Z-#"-R:@6W1]^1R+T@/
M;R\EC5"#4T_7;:Y"[]-3AW'B-&NYS^L^X2>_+)UW=D;UVJ3?\0S0.35.18&"
M+'K-1J61"Y&B// 7(A%0D?VL?9OH&0;^WV$ZIGN8'"*T\;8O*$,J6PK;<&M:
M&=L/*%\HU5GI]#JC\7!JTO=T$FBN\^OCY]7][;]3LPI6]]?@?K7]^K@F%O?R
MZ]/M_?I)DJ[9H_$ICH_X^\.][]*_U'Q^]=_IRG'"0T#NLQ\PL^.C6&JG>GU@
M6GUC.="6SJ6P5&L<\5FU3LL:KT7_=$Z(SIW#?\&/UX;]B)Y1<M]JX:D7H/3<
MB_KM"_YGT7;G" !D",ZXV3E#^"8)@9)=U4HI=89Q"H&60SDY,M9<=#8<[>P(
MYVP R&4&_^O7V^V?P9?U]H^;Z[11RA=\+C2S2R%I&LG'%Y2\D-RR?"C' #NI
MU5+G9A5\YLO94I>[3V'_T!7^&:943YF%UI/;^05I+8J@4V=M6#8[0.94E(H
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M'I5 <A6+:K+YP5\(WXE)'J*2S*O[U<,+C%ZA@PZ)[\ ]_@3""+(634^K*QC
M+^AUAZ(ZT]Z&6U>AYM8#.M9L5F9E 023!5J:K*5[$FBNDC.6 \J"0%'2!7CZ
M>?4S^-U/1.!/OP=_84)-IQX]0%J8+MZ&](.)4/8!H?AS5%AGJK:\D4UC(ISB
M$$I+90,/VP(LW>'2A@(H[=#6-5&U9"V]"E]W:0'#*WQT]]WT$$]CUEGY:G8
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MD:GRZ2/@'#5,!$#?';K/ /#(:5C#Z1+S@&71X"::M'CMDSS4P"5E]IOUNHT
M?=K<?EA%'5;G9K5,!RY<V.".[(J[JJ]4SOF4])0#UIK613SU=%618M/1JG:
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MW7T)_ [(WW^(TG&"EZ/*;%NAN#H%5>-DGMS9<NR8/,2?@KFJF+D,6M703:4
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M_ ")'E5H--9 J@-7*F14)&!).",TGNPLT!$)-,[#04@!H;6AI,$3/C6@>/6
MI='.UE19I2G,4@Z-EJ89>,G6B,G95L!9#*QH0:X,E&__3!C!"N2LF>7I<_?R
M&XPB&"2W@7MPJ)&\0PD^+(J3GQL8-.UKE&#GFQPI=5JS8+E;&F]OU )G57M2
M5G#D!8RY[T(;",:'Z(-J:KP))%GS0E)M!3>D4 M%-VKI6+W&X7(,34:7J2/D
MBV\P)F948H#9M%B6K"EOHT6I$NJU)/4PJQ:D3,6R9';>%!GW""G@$UF,O&NR
M.4?%99@D0@]%\<<TE&PTU=:?H,DU(4;'-;[P __UH.*,Z,T"AF\BFY?]PK8H
MR%DL;?&W":#Q;46^*[Y=386\B]L_VL8R7AV2ES#R_\ZU$E5ETEG(6P5^N>ZH
MC"-MB[:<%[(83!;R5L=:$RR3;LYCPGS!^HS& .;\^K_KJ_#U-0S8NLY&<QO'
MAYKFKR)"EDDQ=L?:VL(W??5J2'D?(.&JS(Q/&7MR_<I?O,J(-+J"SZ$E)L-S
MU=!Q=_P2K3"P"!?P4_CU9K6!E-FH!=9'"S]8*5:E3U;%F)[GLQ5,@=K(3'RZ
M)^J,R=@=57QJ'_!11\P49J\.I,::-I"R#>W,';NZ&D$JQ (J836][F9*0^/;
MM^$C>L-OX@7&J("^3OG4^#1]U&T&D7_>*DQI@L!TX)GTAW>$*U<M6)1'VN!F
M\K2L$S'M-Z]BU3)*0^M#&:AP;6!DZ;EZ.IB:S'U1!BA3D,STO!,VTS6%V65S
MZF7;1(_^\TOR-?#K#@B*/!KK#*N +RUQ,@9V<^&YHZ4-R7TMH-8<_C]YA\#%
MI_]OC/T\RUP_RK;^CB+'C]%#Y#LH_S%.?XV';=Y/LRS#RJDZV$:E;1+$HI#@
M;.#:X,HZPQ $]P(Q0*D8\$;DV.#6VAR2.($!J52FX+4H4*=NH]EP;(M;NP5<
MI=UV>.36Y.JJF0SE 1IT>IVF0T/C^0**&-4.T06MZ><2N.QJO_/_\^"[:5,W
M\@/"LU==AUKP:5*B-H/(=4F%B06:+=#4:%OFCG ;;T8*0L!1BO&+N=!!R(UO
M\/3FE^9LG9/TUY6P:.VNVPB]T@I02,\,Q=)QH W1E^I(^1R+,(Z! ^,7O$MA
M0@!Y:\?]>;:+Z<<3M8G\9S^ ^VS3U'0+)*?79,]40.=V3$;,7+;><#<SJ44M
M8595*.,$^<;WJ7<'YB-ZA7Z 5UU5O6E@T*0X2K!SS9%2,Z?.<#Y:&L\S:8&S
MJCLYJT[E84_X(]J[M\$ZQC/WK6Y4=52Z&A4) 1Z;%7$DS/.R<)R!<:]U$S@N
M<IM-^0MF(,GCB+*8S@L@F'80KWMXXT_*5-%]V(HHZ3,-#[[\.)*D^:,TL^$&
M^A%UNZZP!K_2?-&8%+IR$N222A\BMU&?#]19M*7OUU:N]M+7TU@-ZX&[\ZS(
MP-(T3B[F^>2L]_.6,FK(W!+0&BI9),ODJB5D1G+N+!<V>$85(/)V'+, P@,(
MT[ERO 3+^'V8H!@K.RG0\(AH^YT'&"4?XD#Y)@Y-R[L:\'RIEY.SO?D2PIG)
M>E:M@595A_*"E!E\ BD_H (,AGR+QJ0\2\P5[8P&V@+"WV@=E*<$/UWH/5=#
M6YVD2X0/>G2WOH/XAU-]42V_ZS;C,/XMM],/XZV(&]%Q[G!.%\Q$D67%&F_"
MB!1RD5:<S&A8GM<8#D>]GY34NS#*07*^XI3:M#-8\/8;QF:B*FEK!;$AU$((
MC/L<,TK@A1&@M*8S>#!FY#\'5X>(7%M\;/%9)88..8%\AGYP%\;Q)<)@27$2
MP>A;2=!8.[G]P$J%E-79F?5U'#30M7>0*6-GX%5E304!)Y4$$B)JWU!LV>X5
M?#9:(&UAR&R'MPYJ%Y066*L3LZ87V;UN[JAI:G5H:^+0M-%3 YXKBYP\39%S
MYU/CN?!M@-952;3QT"8:D_(LI4T(EG"D]Y.6']K4T)HYM#6]<I5Q&/^6V^F'
M\4-;([KF0QL8FMXF%D,7I&<(GLY,Y(CX%%$E8L9S-AK,30:]*<+CHY$8>6_6
M(E7<)Y1L/*\ZZT(JC1:B'F#)-I1)6"*..YY/=*T:4M,@ U=;[_@M7<@QQR=2
M-]F(0V>3O*"(W')%Z 4%L?].6B&$KTA\^E@%[O9X@%BY_W&($WHGEIU&'D@O
M%_Q+DD3^[I"0,6Y#;"DKM8O-(&!^GOD"+G2M)PI)C"9?P7E.BUK6+C.Z:G2N
M=*ZZ_RU-@0V>'D/#YK:K% <H 0$,"?@=\3?]_@)DUB'#! J@  Q<4( %CK@N
MP(XB QC:!4C!@2(ZDAS+\/VP!UAG[B[F]OBDU+#VZ9,ZV>#?A<$S"6]X*&1A
M^TS1/Z[P@)[#Z&/CW28HIW EX2J=I>DSP2<.N&A+.XIB 4IPX$UL"(HYRR#X
MS3=6<!HUDS&!HUQP^0$RR6#C 2([IW/[BZ[Y'/GXD7X8/_GAWV L]L\*"#4=
MU*0P"QTQ:JC8^7>R1!/C.6D*^/C$C90%,)Z>>S3  /XQW!-3'&,#3_H$A*3:
M<OIO=_XKZ1<A5I)V_+IR&SL,ZICJV(*9M3D9#,<[XZ'9W6%S6;18$LA$@:*L
M[%]!*JU?U;P.G8<7&+W")RC6OQHB74V31/".[9*J%&RUV,'%S.22IX*-:Y&T
MN0*,'CS]O/JYYXDGVD4LX.?PL/?1_C64K%(28EV*T 3WJ! B2G92\J;>SGBZ
MF")&3D$R-G#DZU=+'K"9>O;#Q(__%/X=1KY$1X2DNM*DY5"/F='U="R[V/5&
M<^/5M)40\C%M&1-(N?K5C"_X$9 ]2:P3-42:M$$(+]<#CB*]T4$CSW@EJ@9L
M?/5I3)Y.>[^S?AN\XU,5W:>D3HC5<X1H$HU8"Q28-&F%,OQ<2QHYTFX]T!L;
MKTW;$BO?#CMGSV-1<@']JM5GA(>(\"'^[[(5IHY*UT%9"/!X2N9(4K_%;+PS
MOJ0T@>/.QY0>,(9^Y_Y/>.&*PN=]^/'DP_6;I%.'B%*3#LB!YGI03Y8V1X5H
M;+S-CPK JCX<><#_@J]O_P@P*\"\_:K&)8S#Y"4DAHE=/#1Z2IHX-*F*&O!C
MCQ$I.0M(FB_FYEO_M '*1=(Q7G!D;N'AT!2=](2<0X3<8OQO4ZQ2#0M[#PO/
MF5E0[JT39KXY'&4@16Y>_3@FSO0@/+7%J<@Q00H8L$[1MT&"\.M(-EX*X"%_
M/L%>>[)NP:VM\7?; 15Z@:NRLM1B_"[-N^.[@N8[AN=R0)3N1Y,0^*E,@/_Y
M+?(#QW^#>].-41TG.B#W">XAV3ZSZ_1D%>!/+&"1-Z+X$R5.C4U4U0=2:JW:
MS)9VS/;<A<GPOLZ ^1;?;]!W09P*H,$2NS XQ*B?"T7VO PO!GK)'G9]X K'
M*=!KLGPJH NMX,7$K)7<=#8VVM&Y)<P6*@/<@TQO>OS@,PO- H-HR%#=!UY#
MQ@Z0L_G(T>5.5]CE-.+DG1[I:N)3#L/K2-W&LS+",HF^E:%I3\QM)G>C"71M
M2 ,6(^-J\1WKT1ZW%I8$3\GS1T]+!K8P$?B$).!R'BUT%T.C]6U/ BT/YSYC
M-+>TV-_F6X#<E>OZY#EPGV;+?PU<%-%ZO5E 5>XMKELX.XO26C:P\U KM05;
MRV'S/H%P:;P2T5E&(*A2&!*IQI/F$-F)D4IN <8?N'2?L(ICE(CSYV0L6CNC
M-D*O]$45TK/$$3A!5K224$=:4_F;;JP18S68>/49!2B">PQ^Y;[Z@1]C\YSX
M[R@=5-T$J?"QX4^FXXDN![!JDE,KX/P=$V6FYR!88E>82GT92HJ3VN'U:,\&
MZE,_AR8O)[JA%63,%/6R+ &D(G[HEH^3P60VTA7A@@_7W1L^YDB;FZXU%KSN
M<5[N_ !MO*L(X:W2#73\O9]\9&Z%1YB@ZP,^2CX_T R?NLEJPY]V6!G#L45.
ME^X#$'IC\/=F^L#=95I/>#%:\Y*T:ZP-?J!NJ+E%@H@!H0>8()!)N@"Y\A)A
M@$D#3%QOW8W>V*ELXV7!6[4E8P2$^OH7B6$6&Q;Q5,Q=-Y@OI\93/Q3PU1Y,
M*$MZ?QD7>\;&1(G\3))A8T<*3M\&>)]S('!)-IW@(ZHCU&>XQ#"+YHFG8G<
M0W<Q--GN0Q5?;7F1Q'PQ^3+N+S#!)B[YN(9<)(8*@RFEJ8,M5IXB-2L?ZBZ@
M9X,[614G'RO.*($KW6+UM1BL'"<\!$E=)OL5'U^@R,(\C[.1ARQH9=\)<W66
M,OZ\JA!UDK"@A=P[ C[E<3%O1'(_S>Z5)ZS=^/4UNN]-XX;&/?5M@'(;V4XZ
M9D/).^KNS7;;<G?RD4J[C[X*L,8MGY&P5.'%" YL."=)P8F<[XV7Y+U]WJ]$
MB3-=?D0.\M\KWX)?$VVDQL:6TBGTIA9$\G;&+5Q<HIQ=SU+2:JK:CUK?DM*[
MS@V-Q[FU!2M>7L1:9GHIH?[^U*<ONOFMT&B^L:F"XZYF,@+VQ7N3X7!AP1(B
M@<;%7-$[%Z-WM[R2WZ.D9F^H0L\2^*>+Z4[7%8N"@UX=L,I284<\W&J_#[\1
M'#=A=!T>=HEWV-=9*R?$+XA?5KJ+T1B,WW&()5UM*8/M]F:3P<R*,/V3T'/7
MAH?7PYY=Y,),,.WXXJ:BR>F'RC:4B":.@)%8(P4VEO>]=!QM#1.4$M):XFZ*
M^Z'GUY N)VD*!X!4FI;-+;:H3W!?OWT]_J:KKUH%S+$+2_H#ZU2'YB/S/HQZ
M2%R'0Y20S(F>LFOR&$;BC/<#WJ,MI-)UXA "/)XN.!*6TCWPW*'Q2EA-X+A]
M1UYW(LD8^KE"]?$J$C^@Z"$*W8-3Z\OD:71=G K '>],*P1L^9N.G;'Q"C9R
M:)PII]3@#9ON-T9O>'?Y-< ;WC!RD?LUP-.4!T&G=[>;W=Y_IE'WV;^(]I==
M!.G;878?9G$'TEY*6FQB JV(&CP5/Z?->7W9T ,PCZ '>]\Q>,@E6Z';5[QC
MBHA=O7J!T;/@R%!+F9:S=+V!KL5$Y6"K )6+,<O)@4/IC4S'(WI'P:%^ K+?
MTDC5N3?3Y=-I#->LAU9]Q2F5:0\!N\IZ##_@/CDF>8M])/74VI/O18!K$NZK
MI"P>:3R=#DSZCUN!Y _I[.CVEG85P":4"?@X%B.S4[%:E'MH8#6N<JH%'Z1\
MS Q#I*%1='=EE"#FCJ!A\,GI73M%!Y5L,](0Z5E'INNX(H9X/+'P-,P!O1@N
MS'?S;$177S(Q"C_RJ,Z>)Y^5AW;0(?$=N(^_(-=W_*#66Z' I%TQ&N#7J(F
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MX8).RD73T\PF/H1I5O,-=BQQK"/G;>;R2.[]44F3(\$<X/R^&QKAAUZ:VI&
MA5!#=RWMA VUFV2]F%O?S,_@6Y:%)+.BW134D(^^=KUN<\_7P*&<<17,5PZU
M"]?FMV4!A^T%U=V8M!V_M%'M&Q#ET4L3#VYR$[H_$(>-AISCKN9B_$-760R%
M#T$FN1#%@JZUN#]TX.&FMO2V$^O#1SMQVJ)3N.S>&-.*W>&7+Z?(9=Z%3R2=
M!-"0UBC9+'1%" 6E#6MOL;1^K-;@KY&=A5_*H>5C@[I1=($R1/G?TT?F;4'S
M;HPEGD52::$9TI,.(A1:HX$#48OM8F6_Q5=G;@7M@1D!E%'-.K9NS3LD.I3$
M\"-*B!??1VRX(97U XE($&8I1,3I'[Z1".\9GQ>1+SD)UPZ79U$T%P$<0/#R
M%> ,<G (6L]FOLTY4(,+4O\>?D3XX(?L*Z!?Q#AV-8F?PY2-8HN3VPP' 3TB
M/-/;Y,?XD?&'!:-_.^"9LJP=A#B95@TD2(%9>E/[;MGN[ KZ;@(%%,0)2AD-
M=J1C1)!7HF*_K6PQ"^#C(<WH)Y2D5&CZ]WOZ1E-)&4)W=#N#&W1$D@UQ4.&"
M(?&#W=:%_(I^7#<GXN2]W)^2TVP<WM?=.](<0UG3)"LI*OW724GI/_[UA9Y!
M[F'>'Q8V-I8!C:]P:O:86HDA\FE6P61CL^^Z#F^- H$"'GWD99H#)!_*MDHV
MQ/@F4A3GUB%,;7]"QDX;7>5G2"3V9_[29F^15L8:FQ>?(#VU6X9K( ]S.]TM
M/(<R8WIP+DO'9-V,<#4=\S@^<]Q<NJ\8IE']1OS08S-;+^Y)Y+W*O^,6!$.?
MM1;;Q5>NA(9\V?44SVW:]ZY\-L8@Y*BHP$6 /*[Z<--S]RMNL?LE")-VO\%8
MU>X7/T.V1A!X&^NIE"K&Q'9_-NX*L^:!=P]A K.&V-SEPS[#]+"IZ,/1AF(J
M9*''^BEDH8;/)S=X\ZFI/4@>LNC":2-D09$1Q\[GP97P74G^O]ASNL2_?< )
M^4#UW"]?YM4>0UUD<Y?<;N*43T=ZF!"CFGLKSX4>S7UXKBOI;19[/]&.X0[H
M@)$'4-C]^0Z_2#SWQ:_FPB$UALI1C_PGR-Z:;W9+^[N6A"G%B$-\&H0ZHO^6
MS=#Y&*?BJI#J[^;\L0VFRG[7XD=(?5K0JX--IU4+6P(_*A];1-%L#[.]R1Y(
M\IVDA+ZO!WI'NR3/9!\_,?U3;Q\ZB 8;T&F+4:D\:<6"HZ5/9KX+6T97?IO>
M4$#E%^D2,E?$<2I*^ YUG:8'XE\>DC"Z_T:2,(8]+[WXA1.?^**/20_/D#7J
M(D1AI7208'</MI,MMFV]NK/;*%H"()1R%,MVK23.5/(U54',V2H1:V6K5/X=
MTF<VJVW@PA@_.6=*78"F$J.8E].@>,X;NZ.%/D_(%P>=U?"&S(D.TX4940&#
MM5_B]=2Z^=!GLZ$JIR-NRJ\S7AG7=LOZ,""W),OVO,:62I4EV,O2*QPF_V1*
M_1O)'F+_(TZ25VHRU1WK>Y$RV+#^#%$K_>I[T,E+;"9T9W' S)TO0>.>3JF1
M/3]JP9#Q48PA<Q\ SSAY+?L28!,7?;:M*(9,HB;KA55L@<\WIUFPMFX8.W%:
MUYL*<L7#@VX'.&7)/ )4>.8T_Y:$'A':-#F8*?^ G,63FZ ) ]=R?[%>6\^G
M;^6NX33($= 3PQAEX7^G)DT=M*A#&%IN,6/%2E=_AN/&#&^)]2H^%6/U]3W"
MVDU0$#NC+QAK]]P0?7@]@>2.2G[8OWEB@.G-(4LS'/ET8_QZD"4S#/Z0?.CF
M<CTQ507Q!+=C:I<S5?+#R)(VXML<ACF.87M )?QWZ .Y#R->Z+G#>U:/8_N.
M/I:NC;T(1KT%;_>#=*$KYGB2-;JW<CKO.2%4?A@J/0WM7E$9[ACJX8]D POY
M0]]5OUMXL.U@\[EO\C/?W:XC\"N.M%SUA[R=[U3\>H;\2*M/R#/]M^N%"_4O
M8\K6;9/DE(C_QC^VJS@)2)@=J'@C?W'")[V=ST[QHH;\]@2/@=O :DT"%WQ>
MHPO8[2O,R:F^0S,1FF8LC/^82_WIA21>F!*QSG2F AEIDRF9CGYS;1_),)08
MW1:^(&+; /=6@;-?GZ58I'E-=V$T[1FLCWH!.#XN9?T6@:>WZ1 J;0P7D?_I
MY2F$P)ZI[5;\T'QT-MF0T<MR.UA:LU)W-<R4G'VS;$H;32_-&STSN_9)NU"Y
M;$[247>@$AL\7[#$R%O?DRSZ1'V"?6--"2%(\2D:===ID;/C+L/_=YCXA"PC
M=>#/DY_36-<JR19BZJ&F<F%-O;Y3(NW83X3BX_G2VUKO?V58UEYW<W6'MK=A
M]FO=,8^W+9Z,,?)FH'HTN,RVDV!FJLK:?!Q;7_Y&AL2Q%6F.6ER2$4?^MPEV
MZRBOG?5[2[>8-V(-_@K!@:[RF@NMMY@4YV/N::>XZ!B&8T@.'#(>P[_83@9D
MN,?#;6R^VNW\MV!)QA*\XUE"(P_@/UO;N:9^$_B+P%33?-.^$'WISSKFNN P
M:?MF!==0U=O9SGK=C$?@PA67RF@O6-_',C@+4/@RF6Q6-M-$G1"^\]ZDY8@Y
MIPY$,G#H6 IWP'L^OO1DB(K;MK *XAQRIBI,SA?Y5([2GU:^,Y IMGE:&U:*
M5O4N2*,2;<2(2UPZCB@][+W#O+LC+6?5O2KL&;H.A*".)5C/5S;3CP<483 M
M!^(V5;RTO9SQOBI4W%)K@8!=%;I$ IS6N]W*?C_D<YD_1XG_0M&A:RI:&*6A
MQ\O]1[XF5Q\&N;/S%5Z8<OR:CP"I)&YT![F_3WCF'"JP$$?[MXGVB)71U.HX
MY91].U_P]*^0B*8AHKE(3>WS?_.)9[8U=+O#R[79/<:<\U4E;\\=Q@5'J_X+
MJ'BD%/N'P>>ZXDP=\"4.EJ*F\U#P&7H[?VZ]IY%Y<?M^M",[2C_$3*C@,DR(
M1W$4C7-DD(:^"C6CA1Z+P>".N-DM9]9]-3H,UG6%X["<Q@)KW%D0=[_B_R5)
M?/>+:OTK_<<WRHU<,530IL8/MS)\FD$L!84SH;_9S:U[KG69K"L*7<H98L F
M]8."DBX:4H>WHB-BIB5:4@6&Z_[4WP76YX/HLRG0E+FNIHQX'3$R,&.UVJZ(
MJ>NLQCRQ/JPW^G'RV^>.WSXK717''$9_&:9>$O(3T$UP31<W8A/,>(TQ/QP)
M&W1J(!FR -KL%V:@%2,?S+A86>U!TX?7ND*5T-E)(SP2R%L:8T["LD^2?B6/
M<03MF?%3F.$]%'FPJ0#),_&OXN3JP$I'6#D\N^1*/L >=,SY$'L+6;:.G8F
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M<X+E)J7RLR%[(F"I,":EW\ 3O9X8Z(#=9DFD7-67F ..G#(0,R<^Z(TB44
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MV2N")@HL0)QR+'XSI3J\/Y%KJ'#Y#U_H_Z-_//Z)_H>YT__[_P%02P,$%
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MXXTMSJ!?'*AM\VGK-WB%D#T"'P,IPIM_ZP)I:CQT!G=)CK 6]<ZS0IO:#J;
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MW?!<KBFGS^7W#\O[^</J;Q?WM[.[55'>A[R@WY,G\_V+N9!W<BJ\]E?SUJ[
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M*)[P>MZ]*-X*J:3\J!E,[[&4/45)'F5_3?X!TXA-=TIKO#@4Q9;$R:<3U=L
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M)-%].Q&T#J$29#.B6P?<OBLRR7G<",! T8(ITI2"8UA,#&T'6+\^LQ.\5EH
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M"Y[3PC4?]SQ>+?E!=^+7U=-'\;OE:OYX<3_[V^SR=B[6A9\0]#"W]B?PYO9
MTT/+J-FHI'[\MAPW4$2KX'Q493^T'L.9^+.W;FNA++6%*11F<Z,.1?BS]_7N
MEK!+3C%+\2FV#35M?WUK[POLT/'J.6/D9UD':(+?Y=@S;7NDX^D-;!TJ=9.[
MJ-V0FS$]&'L"6#AKJXG#VV3QM"VP;%65KNH=E^Q1H0@NNGL\LSOXPB%?S3V
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M;JE>BDN>,05V&/HQ,QA(O*C^AF"Z^IZ,M)9VHP%7#P)?DD/\[$OH%+0P\X2
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M<GS__8#%U/ Q8)B&)UW1J0]:42QZB'V79#[R5*_)\Q\H]:.L\2VL_BS!.19
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MOO,6EGH2$#A.]=QE;Q1*B)]XL*(<HV55&#JSSLKBW#_AXAD_XZQ*9$4BV<)
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MMQ\G"&JW'UW=-= M^?M_)?'/]UBZ/U[[GWW\OY7*O:5B)IDNN+,1=)$&1G-
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M?L/XV"XQ:&Y775Q\;_6W93>UT*,*-6/6_[+X?='(]=IT[)Z=:FAVJA6Y^M]
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M#GU@HY\T9<Q)V]]UW#)Q!<@ +")2;[I#K0H3FJH.#6*?D=07\C"IGZ!!6W,
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MGG]TG^S^M$UHS!V=FE,KHA(F^ZXM>>8%.9[ATD?Z,^1G.SN9L[;.:9L%:Y2
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M;MX7M:-(_G/[_K[;^QP>\8?RB%ZA4+]'JG\9> !\E57@+ZE?%@G-F5-N/#Y
MVZ=9T'>5;LS(Q.0.DMP/_=*E(@[798>666X/!M2FWG;1$J<9E^UR3#I?5,N
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M&D5H5IM"M=F(40H'%ATHTWI1>K'9P>YZ"NP^-[E>J#6P0WU D)0%9B=0!+1
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MFY'KM>H7Z5WS-",I(BEUS(MK,])R%JR+;$J>P+IS3?%676A(W!9/0*5O7I'
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MZ<D1YE9-J(KL)5ZQGX>^'F&>>;;C0=,%K@6^0]LF/Z(?Z@2:KPC 5QLA<EZ
M$9(76KR:XE;Q>@Y &EJ_^1!U H3:"X#82#NOB8)8YU69&6DY"\[*9W"6@:SS
MVA'5<<M F?R3===!N>;VK:'$V9IF@#Y4F?(8 O-3FRQISNW;0NEH3AZ'+V;+
M/ Z?[Y:ST#7;=_=26_=X=+Z +6?!U>U[1JEQE<?LB]9R%D3=OHV4GC/!(_G%
M;SD+[F[?;TJ:NX5@8@[2QHF951E!!VFDI,P,JP2_;#DCI,Z_.''_*-_X[5*'
M&QN;1)8^$5&Z"TD23Q4O=\L9\+ E)LG#5%/$9442FCQ%G)66LR"GE+B2Y"'I
M8K;,3:Y\MYR%-I'36.IXT+F +6?!1B4--O*P<M%:SH**U51\ !XX+G[+6;"S
MEB [3\[::U4%163/]V0_];N'7&!8CL,(88,7?NJ_W'=>*I_ZPV'_Z09(N+>.
M9>C:!V9D:$\/S_)IGMOW]]W>Y_#++S%PSH(L6;!+Q49N&WZVK;'N/F*Y938&
MS4G,2;Q&XD8")+[<-9J<SIS.:W1N)J63,P]Y<RJ7D,K<R.0LV*W06@FNS]E&
MW3F52TCE':?ZJJ*8()</B=F?= =>LUX7ZJW]I_5VTCNG)_A*1=5=3)62](HN
M&M+G6IA3>XW:\OG4/G4_0,'*M4G^EPO6LI]+_M%Q;<M\O?T$#6BJ"$ 7/$%;
MG0!%$@"!Z^-U\ 33LJC@\6B6A]UK9H4QTL6DI%'9E,;P$8]U>6P[_7'JE6&D
MAM!4JH(H[R\.LRFC"E]9RL[F6H3-A)D3R]"0[73^]'1WC@T>P].PQ?YLV?2J
M:]>U]9'GDNC:T.I9)J&\;1D&?J2+R8\IZJ8K!S%EM:D0< '@ G"L $2V!#,0
M@'0KS,LMH=6H"V+C>(^8RT,IY&%GR">RO9C5BG#X_LT)42+Y3&$H1GBHZ,3>
MQ>OJR7;[D<'XHZSW9EVH'G#6BROJ4O)YIZ*.;)QG:+F<*0J[RNYA4UZJM;BV
M+CF[([NH&;([I9VJEB+4)%%HG1NIX>S..[NER+YJEE[G:;M;)VW-BE)+D+CM
M70:^[Z)[9',V?;J?&CZIBEA)UX16]?@MKTL8Y73+Z]H=6=J<_$MF*ZE&_/I&
M])6+]XTL&R-&1X5AN!'#/##0V&^!M@4VWQ],C"C^':.&.3B#&D&;SOG'H/^Q
M6W=TARY5;R9K(9QHNX3P;R+]STF[R2HBDO&!R(6!!X2U<#T\DH=^;U@9=/_3
MN0%T*(!^\-!^ZC[^?A-!##RU7SYW>S=@8Q?S XAI<;FSZ3L#@ HXV+V;F<Z\
M+SJRF'\V>[!!A25>\@F'"U<89(KT*GK-<4X"Y]+,R>5[4 9%O C1^*J8520N
MWP,NH2SVH #K(W6N69W?R_>@  @/+1<:3,[O]DS(A-RI7'(LN;3=Z/HN9TV^
MGO4>6&/@[RKN!" V-9>KGF+2XE=H>(C3@=/!'RA)+*OH)@A2RS@Q.#'"XP[G
M7&U$<2[0FU76U^Z($B=JB8C*[1Q."V[GY)D.9PXIE*^0^ JUFV/W:*RKNLM9
ME@>69;2YN4J5N:"Y]$@+37)6<E:2@8:3:?YQ05;ZB3RL\/+PP^'I9Y@PFN\5
MP_>$U_#M<\)"O0".$$>((\01X@AQA#A"'"&.$$>((\01*BM"[-^R$E,_[7^A
MZ4%[#OP":C5&"Z@Q0_ED#W9%2A,>4%1!DM,KAB8K0KW9$B2EQMP51B5M.0L6
M1DM[I'F\,"'^QEW\3,C+B;NKY6/. O^4*0FSK:3GDS#=0F)52:@U,2=EKDP9
MYN3..@/95K<+:<9+%_/*>_& @J[4IQ3/75=U%RS"52HVY$C)95NQ,%$Z)E (
MJS":CF&&95MJ;9UA:5V;(I&:X;(@-XZP[CC%4J-8MO7.-MR'S"I"R8*D5(66
M(G'.7=QCE;,M0D8I=W)HI"K4%!D3YPC+G\6@^44N'7FP;-PI$ZB>;2-3G0/7
MAJ9CT OE =3^\!QWBDQ7P*]R&;4^\^<%1>Z)+-4LYA^_78IS6<Z.A#IN O&Z
M"Z1KN!*N]E*V>FA#+097-=5"5S75+G3!>*GH46QBRJD2\W*7AI>**,6FJ)*^
M[LS\(O!2D23_].2F6;[QVZ5>JIFL@-E>RUTJDA2;GK5,Z'E(R)AS,T\M9\'-
M>C;.0\JQ9G+I@"()\@%7%I>*0<7F;B--[A:/B>PG>E/+JC*"#L($PBH"ZP<8
M%*EB@M3Y%R?N!>4;OUWJL+FF#JDL?2*B=!>2)!Z/+G?+6?"PE20/4TUVKM7J
M0ETZ(BVA#!0I-#D5,7$ER0//Q6R9FUSY;CD+;2*EL=3Q.',!6\Z"C7(:;.1A
MY:*UG 45E51\@-.BR)R=>6HY"W96$V1GT7Q/]C.;_=-\0*?'!\',LQT/FBYP
M+? =VC;Y$?U0)]!\10"^V@B1P#\CY"ZV6*WO<X</>3X'( VMWWR(.@%"[05
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M\AJCHZ$161O&B 0-'2S=>*3 P5-&)Y>:\G31\ ]54LW0]EXQ@V,L^N^Z8=#
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M9WA2L**A?PM$,4Q&_\V+8[H^X? Z:0NQ2U\H$HZ7H,5Z$\2\8X:]&C$UNH@
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M3J3J47EC4WEC?MCGU&M6J1?K,5.K .,8ONN$+EBF@9LF<95=.KHZUF[@=;
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MW=8B\-.<<CH?HZ&?@^-1"%O<*Q8,O40A+-%$((^["YL( @.ZP)%GP\6;B-4
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MSBRFI-(2E*%9%MLO4) 2R[ZA6$>^F]Y<HQ@A>,L(21GY?@&G)!2Q\]'QOY=
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M045J-CY7ME0^BMJ3 RJA['B(,!62E))I8_O5!.TO5VY+\3-;!/65']9AIUU
M3%U-;H6;S,3Y-']LZ5",?%?*&44U7GZ(EX>HC'G-Q#3>6,C*V(8<72K].'7F
MWNSA0_Z=<R>\\?P/#7S($E[26R\6-"?Q 2[9^]#)DI&L[X4J[N;B KRK"*:E
M831>LF&!,'4<Q'$P+XNI8;453,3_SW>M#>C?ZDC(EB,PQ;A+;DLO1I\^G9[]
M;J[IK]O;YKU<K2W"MGW!ZM15L*H#V[^.G<GWFQ \7_<0-BH(/_S;9"+  '_W
MFI1+?SS'&*$[K)H\NOG+*QSC[;]9GN?I-'.>5S^VE-/'L55'!=H%+T#MUXBW
MZXQVZWS*C:W/TSVB+5K=G%@E?%!LG@U&0:MG-]I]N]<HQCQJL$4_XYNW(9:%
M0/W+Q;)CB&7GQ6+9[-F#;M/N=_JU$\LGW1!3^K]7O2$NE%NIO#"F^#$\:JR1
MN'-FG.2KQ1E8S;:JP;%\W/K;Z *5&DH_D[+<"\K;$93=,ZT).*^59YFE39G;
MYJ\J*KD_->L^-6LQAPJIQ@IS2.YBP2JJEYU>A[.^%^\:B7>!!6(=XOUJ]GX=
MQ+L4J[AC^=?KDI1/E,QA6:A^(LU69>-,E".G3#HWT6"< 9>?R0);I$Z#KQXJ
M;^3#ZV> 6H4SDF: 1C!6-=0K@O0CQN%$S@Z/ R(<$JY(+":,]LFA?1!_GQS:
M)X?>J%SMDT-;\V"?.<H_)!ZD7M9W;8SL]=G2P\Z@@/(\38NM&(G&YNW(X'2Y
M#HZ=V8SYK**1[ZK]VH+7V&S90_ <NXU>[<+H/^F;MR"CA6C&NF5TO:[?P.YV
M!W9[T*B=B&XXT_/,45X'L(\UD>9R,Z<-9@ZR5,]$;4,MA2&NY^RE5$-(F/-!
MI][,8U<OM9^WIMK[8.%/+L+-9XKP:]T*=9#@GR$>>%P!&:""2,F[Y*JZ1[<*
MA:\@^%10Y\\>& 3/\'9+_!#AQ$,JB=!3['W(,A0R-91)40"[\5W$LBM!6DYH
M!")SB'M)7R'<G2Z6N62>*H.N^ )^'R22UJ-6U<*=O)UZ)N[3@6?'S<4R]2^9
MN<X4DN%7=6>T$NK1B-K"I:>&J]^F'K+F6?]*G##F=#-.9=_0H3:,&OT]H\:>
M46//J/%,J:AJ5M#K%BHFP<B('[Y2R=JI?R=D#YQ/H!]G 5*6U?DFT")R?GUB
MM340Z.2_OYU>_X_U]>3Z;^>?0&3_<7)U_174S=4KW,R;[75W#.Y#\)G:^SY8
M7RYVIMW=J6]=B47,)>BM1G.8:Q1/W%EXI2/_1:'#G8.<M<YTZLT\2=[@A=P"
MF BOT5Y6+,?9!3RZ.$I-V@0^$PG97U%6L2)-7"QNX$S-TVIX+-]/9FQT<#\'
MS?^-Q ^.-\,F7RX_JKP7,[,'G%\?4[TI?X88*3+CXY:->O"NG*W<D?(SWVP,
MN]F R5=LD@=G_H)L]O/I%Q@PZ-*GT12;X_IRH7B*#4_T,!*3#VX2(E_IN]_:
MC;Q5=4A$IL2)$-^&07)S:WUU'J3F[ R9U:!R%SVN[;\12,HR4]V=K?=&V[W?
M+W23$,VA,:?;P^P%C<M>TBS5V%WNQPL>$_9JF#O?)9MD,/'2+3!70_$I>FF5
ML2(DI U$GD38Y)-OEYE]*P,5=8:9C9-4B>3*'_,3U[QIE>$#&&T^_-5MV(U&
M,7+ DWK_EV:O;3<&C0/)AH<SQZ)PR9Q'5'HKKD*W\=@JG*I'OMYR=!O+EZ/;
M:=O@CDFVCM\ON&T@9@8DN8P\]-@[DXYC1I;E$=4"3?20Q"FYT@+FHDWR3?*A
M_\!GO=["M9?+4;N1*HH#E!@F?F1^US&6X"/Q-IGGAJ+T#/8./,[.XVO4SJQ1
MA55TKAC.07>BZ0<ZHH)QIC$\;#>6K=;*E.[]XMK\0J$AI,M-&==S30"<O+;C
M!I&&T$V<Z!87;B4)ZF16YQB^>IP^ZCKXPN^ZX%>] :6D+GE-K_KX$G17$! M
M'Y?JN5L4E/9J@I(]*!&SIB9C4#O(#H]VBIN2(N=I5ST]U1*JHY000[Y5]KC%
M)AYISR*+E_I3RBK2;)6UZRRALS)-P'S;8&[_I4<'&B!G&],5Q#P92.2%#6NH
M#S=W!8D]MBJ(=]B/L8R+>IC'FM9)KU-TRVU-)-6L2QVZ2OK&,'\N-Q>5?BM\
M*U%.K(W:+.TY&Y<2^TO+)9V8G3,\9438)$WB9JEX(0;$U2M[LVA^-=F;!0R5
M$;&3P-N0OJJ4PAM9S(B@GI>,WDH=:@*_,+![Q&Q2$WDF6,-%#46^>PZM.;+@
MH\F<?2NN<EDW:&-;86+(I05+BGPQW!Q-SH>F2JO&RK!B =?*G]8KU'@:E\4R
MZC0^\&3#G,B+:J1\&#[X_(G3R>0I&K%(7E;4":\8FJ^,2A2ZJUR$>,^#CS*#
MPS'R752W"UR<-QB7Z.BXQ,7E^<7)Y?7_6*.S3Q2DN,"HA&V=G5QO& &X9?==
M;9\NWEJPBL!65]2>)(HUAV8*?W?RS3G*C^6'K4QAE>1* <]>*;9[?/H>1[R;
M..(]0'V'!2NC>_<8]9ICU+_ =5DOP)=^<[F EX_G+UO#\0Z&)6SJ55?X[R'X
M/4MM>OF(?^(^O,QJ;]N=7M?NM8:U@^O^I&_>@B066*R>(8F2Z7JMDMANM>S^
M'CB^XB@_)M[,)6)7RBP9K;UK(LD[?88*:+<U:'.UHV:;]I>=J8[=;[;M7J?8
MD;8&N_0SOGD+DEG W:Q!NV]",KNMGMUIUT\R:VIQ8]89(]%[3;_5\S0HUHBN
MPVY7N[F^ ]6VN]WZ'::?],U;$,O5(\)/,.(W(9:=1K%3_&MO43TM^G^(6V\R
M$WNMOOGC,RRTB%B#5E?[][(3T^KW[<%P7^%?DS=O018+W=W7H,K7)(N]KMWJ
M-6LGB_6TT3\G(2QE@@UVIK#.22C1V3HM71.1WNG#M(DPN]Y8^/IGN;,O/%CV
ML-^V6\/Z':V?],U;D,Q-A-TW(9F#3L_N=7>'J7_')'6U5'\-#L\6Z'#!CE^'
M\?3"+K/-IMUI=^QF"1R\CFRW>^FMC_2NPPU]8=/A9L,>]CIVM_UXF*8.TEM/
MT_^+B*(/B')/YK(CJ2L6H<#*/4]V%G#F ;SY3_K%_C"^VF%\O\1"*X##C0W]
M9.PG_'LF\!]P0$?&ME8>WHW<.G:G.; ;)1DTZTGG]BF J8.]T-9.: O\D!L5
MVI=>-G:KWP6A+5I*&Q?:>L;\WR;]XSI!EMO@P8-CLGH:]TQL1E\W[$:S9S=Z
M3V_YLF=Q_*E9'$%Z5\_V5DGO"Q7WT.X-AG9WA5QN'81W)0+'5RE,_+FIU@9[
MJK4]U=J>:FU]Y<P%X__W('#OO=D,KH13/W;\&R0:&D61>(M$:[P"75W5?'IV
M/3K[_?3CEQ-K='5ULF,L:VKK&,^O-X]KF1W:0E72_/R*9NNUA;;7:!:"GFES
MKKS,@ABK92&=O:]NWA>A[JN;]]7-;TRP]M7-;RJ9PW1U]8J%U+_ N1!A.T>:
MJ,_(3RF^>'>B8) ^H5Z"=^1ER):^W1UT[4$-D2T_Z9NW().%N-GS9;)0++$>
MF6QU^_:P_7A,N-9Y]NVE2XC=&+?4^BLU#:F)*._R(2KZ:R]7[$0Y1YMY!D\&
MN_O["\N,ABV[.=QK]IJ\>0M"6<#]O5RSKU\H&W9S\,95^]:L[N,D BD 'VGL
MU-;VWJD35*B46)^]KO;R"](OONP0]5H]N[W7['5Y\Q;DLE GL3Z;_2>0RWK:
M[5?!-+YWPIKI]9\*0UA]XEH%W.N:#'RUZR\[:4V[T45VB\Z;P*?OY;H^<EW(
MCJ_)1UB77#>;;7O0>1M50\]U&O8G;(=/6'O]H:$7 !2[ [OQ#(#B_I;XN65X
M_9&DY\MP>S"PV[WVFY#A>GH:Q4H\L_#.^G=GOOC5Z#%3KR-9FY.G#]BN3?=G
M?///M,7UC&W7$E'R4]W_U164PU;!B%UR]QL7BUE$N344BQ7!K/[SW2&ZC^TF
MN)"M8EAD7__[,TEOP7Q=D_1N N]B2F^SV;?;G2(!UL]:"%QO9,O^N,GC5LB:
MKOFR6#,((3UQ[9X]+,E7[2^+GTEZ"[G5-5\6.R>]]?0G:HR5V1\U>=0*'6(V
MY%6L#]-@6&=8Z]\J<E#O+XN?28(+G60VY%EL1(+[';O5+W:UJ]>%L<??[$\:
MGK1"Z=0FG(JUH!9,BZR_OR-^>LDM%%AMPJ%8M^1V6_:P4?>[86O.Q%4RCNO'
M0E>;@[16;'/!*<B?D3,1G_R8S!+DDE#,%YN R_3M/IR"00W[[_VD;]Z"\!7L
M^6<+WPMQ+B!\C1X(WQX]O]HHU5[41%1_1AMHR;$JH.<WJ;<[0[NW0M5)'?!A
M>QFMCXQ6\L1M0KV_(1FMIT6^)X7>"JWNL%F(NY181*?^5LSQ0:-E=UM%I_2Q
M4[/GAOZYN:&'S4((YME"_'*SOMNSN^VG%^K5EB/ZC5.*CO*LH#;1A@KX^YRQ
M\3<WH;B!?V91\N+' K%>* <&$ZDB(8V2\?^)28SLO9EOX:>% V]3[*3>G8 /
MX[6)H@<_1R#JUH-PPLCR(GB<)#"-/M2 E;2 HU.LI,%T24SS<T+=]XQE..&U
MVRFZTD>-U7(]MH93JU@,_P>$9BF+X9Z<<L53H6\4N9@@NPG6P>P9(E<?)1S8
M7KW,H=K30[:?!)PLZM,S>-GUO9C=B:^P6+<;J2$=#)IVHU>_UNOUC$K">O=K
M>@A>V_)?Z\%Y$F:S>'#PYKR^#S9R7OH(X7_<W*_U>=GFI3&HB=3N]'EY$O"R
MXKS<AD)LYL0,[<'P<8Z"6I^8;=XPPYK([4Z?F"<!/<M/S.<@"3=S8 9VMX8H
MA;I>,=A9LQ9BN],'II#R?<:!@<]NYL T[6'_C=MDVZNZO!6AH,YR-1'>?=XZ
M<] *>>NG';01[NPF3UO;;C0&]J!5+&/>9[OWV>YZ9;O;3ZDRV% 3Y#YRYMJ]
M%0RZ-Y,BW'3*4#=T6J4?9&&+OP2.'U&S3:K*'?DNL9M=BHGP[G!";[ MI-73
M'2&_G(_.K,N3XY/3?XP^?CG9J7Z0Y[YU/HD#:AO6H/1MD].WQ\%\X?@/%@F&
MH%Z1@>7XEG,3"NJ/2IE8!Y[J'V*RU9J!$%CW7GQK?16N=RMF<^MJA.G;N8 [
MTX,7_REP2=N]SJ\=NS7HV-U6TWK_ERI=,NRVBPVIG0=JS7H^19$[#J(X*A6C
MYF&SH<2(_HT<DL_$F=F#SM!NE5R^![ FUB(4"SFHS++=.JXUA[-P9('UE_U4
MD%D@_.!8")\^C4]T)I,@=!U_(G@U\:D+)W1F,S'#G#G8']8XB3Q?1!%N%=RG
M-[<6**N)L?)1LEC,/,R]^ZYU'R0SEW_U8%U]?[BX=4)Z-SU_',)GX),+_"WH
MNH2N@ @'[D7Z39A*]P/89/]&A#3Q&7R69,"<-KXNODVB:A&*\:FI$!4$!AY-
M"6C]Z"")([@V*+GO4!H1EW L++A!XIEPCZQ3>GX4XQAAZ!-%R1>#>(8(.PBF
M5K64=8J=0F]AC:]%./\DQK%Z^"4\Z-2?@"$?B=5E3@O6!:@^4[).SS[#S0RC
MA?<>MM[]UCTJQNM^L1:P#HX/PFK!D!VK0B7#''0X$DN9/F!D,;H-9NX%?"YP
M+YPH_I2(ST'X1PA76C"=P@&2'8_]FU1+/^LH'49B\L%-0M0!6*_7R-]5AZ[S
M@!0"'HC4-Q]W%G<5%G4>*0R'%@=[R12[F2E^$I/06^ RL2Z0FF'E*?QF"JA'
MIS*DA1!6L]6PQ+\29V;I,QO<&<-6HT:%EY_LD?4I"5%2Z<,8X#V<8R81=Q)V
M HX"'K4RN(P^09,)7'-T6*10^Y-@3C*LE&?;;O:'2S1GLS'LE=0 L>SBPN%_
M3_T1OTD+N):#@EFV[')^IE;MVIU^T3XCE0IO]@7/2"M 'XP+N4&$5;G!'?%A
MF<8/.8UR9)T%H&]AU;P%;"%CBW@E]7;>P\]JNUW+37>,=XEU-MHSI%&P&[)+
M"FR:S$"#PA?Q[0Z#E7!CLOMYQ+;=:X"\E@-Y-@;<46"5Q?@V3,>SW!E<!OD9
MP]WRW?#VK>N3_W=]>'KVZ>3LFE>BS'1M#E=ZI[$5"^=&'([A.'P_I/#,!\N9
MW3L/T;O?5G%GY=/$_+?_<"PXZB#H_Q8'$_ U:1= +H[Q#%$G>0<>A!^LMO@W
M+1\;M"8+W6"/SZ^^GE]9?SL9?;G^FW5Z=GRTY7:TY(N@3O_F.XGKH34 >^%B
MM(;^16)%1H*\!D%37,7PBSEOUU8'F]4>K^!=5#IZ):!?O(NNG1]OT)_K:W\.
M!/+\ZXEU/?I_)U<;;I2\96_N.FO4H.D0@L- D@XW*UYQWWPZ#B3M='F-:-L=
M,MV]#.XV^]&I@-L$SDGL_*#HI[QH@SLO@I\B">,E6P4^ E^X=<"82ET;I^@@
M@4/Q[>CJB!Z)*E-^75G^9#]99#]%%983#AHQY4<[MGLDJOU?(^MW6(+ON"E@
M@WA.Z,$SG3!O_PACX:V9<T_[BM^<2/]3BP%]@OX!XL"?P$U?9DEF[>YC]210
M N@2K7KJF6.!WZ@8%E9VCEI%2_$7](CDK,&Y!H<M%7%P%^,D#L(':ZJU>Z2U
MNT57O>4L0';!3E2+XKBX$?2)(VM7I4F>Z+^#;><&\V>)E:%#Y&.6B5CQTX^)
M6V^-XL9OEB]^NM25>>0;E+I=$+I1B3^4:NF,IZN%4DRGZ.[=&9+C>O"[$.X4
M>#'+$%X3Z@9*5UI_ 99T#F(,WIF;"*H9L>Z<6<(E(PZ6?U! #5VWT*62%,?S
MP27T10P2 .]"]XXVA*M//+_\ON3X5O$$[,+>_8'K<Y/,G)"<W#L/OERV-KBZ
M\*^([G,OM!8!.CDH[N!)S52=#JX4.-UPKWO1;<5VX$6/AXCL!Y";* &Q2=\"
M[TTF@M9[XH3A WKI^!C0+%/PX2TWP+B =M M3T4&YP'HLIGW7<Q0C3D^?0S^
M$=.SRN:$U6KX39X!!A7/DU M@D=U;;"<0DX"QC$.,*@31!X)[GMQ='-D@[>:
MA!.VJK(FS0$MAX]%4,;',0+AQ]:M%X$P8]#5 I,:%O8 7@03\FGN#DX0X[?8
M3F3",Y#K//9F7OR ;X/WEDWKR*H^CY_@Y7,*^_.OLX<3S+,(S#8LR_+P/BC?
M/W6*X#?+3E+A&-G2]+#3\_3WG5!_GY]NN1:7'84U550^:[FQ\,74BZ._RJHY
M6EC\X_\EH1>YGHR7(=($ST'6D$^O\5>,355YF?U&]L9W%E[LS*[ .9S$:_ O
MZ5N>GPAW%.,K_/B?G>FTUQ]OS?/D-1AH]_-X='%Z/?IB75U??CN^_G:Y6PE%
MC(==A$H17,6P<S+T]?;GEG.OG22^!<7])RH\.&11!#?3,M.VD#?7ZT3+='4+
M)G@TT@]].32"GVC:N(<];>+VWOW6;!3;0EISN IQY!%]&:^/A=[.",=IX^\X
MWU@YVV8C;1E!QSH[U2_>OQ(,P,%W^ ]XV3578B*^$NBMC++/>PIG7W%1L-&R
MW6@T\'_%]4"_""Y_D 3.*D86#\$:X7 ),H,7?6Z1=-[7_"6I=X=%=98N@?P8
M7?@ZTP0:>XZ[0-^#RX*_15E8__ N0".D_'JONMW]P!P.;RXE0DAP.5-LY%JW
M<Q]O/#:=54S7F/I*P'&(=DHO/44,,M:& +MRB<8:% + QR25AKHZ)>%9I=D$
MKSQ]-3KWGT2S67ID!SV[4T;6C_->,J=A(=W_E#GE6A!L:4[H*D0+=I)G#[:A
MFM'PSVH*!#W Z&+\:W6&&#1_.Q=HR2W"/]#1VO"^EC2G;/;M9K>$-15W=>ET
M.L^=SOJV=/7I9#?TR+JJWE#R !W*5R_ NX0;!'4U_$Q)5V_J\9T49S2;!3X"
MLV$0<X251()6T/"H81*H&-#KEB\W<#9)Q'$MA:;!WPDG].&_$8%2Z#M'H$BB
M>8".XH,Q//5 #MYX<XK'\'\E6"E84%(@_ X^H_I65(9]<A#%-.&DMIB IQ/C
MQ4NA2+JN$&6(2QF'[ !%?.TJ_68N&5Q_2XZ-FT-M+//=9+1GG^#?=H*_U=@G
M^/<)_GV"_SFA%QD%<?2]N:U(R+EO_9<#+X:K"<U/6(%V#C'J!PDH?)=O.B^.
MK(^!$[IXO#YY(=R101BQXX2YDSL*1I(F-Z\<^,M-Z,SEK2%=:)XL"(G^6++
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MN;OVR6P8PK-$*;(Y-.>*)$<7<5= $G$K"Q<FO7*,F42\=@781OCH$:[&#=V
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MLG%=.2\[.B&66$=JIZ&T&JK&4WKQXAA^?P_MW4LV6QVYV<ZKBA>R! H@; [
M=Q3:]HSK)=;(@LT$) J(<MD@E%F!5*">]$92/7SGO8]K2T1%M('^F+' O]RO
M<#@(3M=EL7\/'29I.D%.D?! $X8BN.PYD"TPV<Q*Y4),^.' MX:6X<UD^)L_
M<4? AN4Y/NQ(1LQQB;/BG>YH8X$4/QC.#Z3#3W ) .KALG^9X:+X]YB'PNU
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M(D+S '_LF,XW+3IG:< ,ST_4<R/ - J (7Y) O["EF:E %WE@@4/(5:6868
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M_)XZM9N?)ES*6S,=E@8[K9ZL=_/57"=/@Q60GGC\[Z3;R30,4O6^IT:(9R1
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M<NT&&<PT&0J;&7PIQJW.\?#+#7QR!V%5@G[.]VF5VN;C!;5.C;%^%:I.HMP
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M$BAO0@PTHGH1#:.9\EV]W7S?4^5V2UL^4[Z=BR?A60*2]VT/]'IRNYFOF[H
M7A60*V-DT6YP1HA+1K=&-, PBOR-/3=\&HN]7\;= F)'O >4'S.T<R# N'C%
MPX9 L,@KRHK]EF %]*:Q"S(!:TC&S/QQ#(E;YT>]EORH>T?ZN^&$AC>3D/B
M!'49R3B"IXFUM%P!0HX_3,!I$CA3LB/FS[&N8PIS7P;1:EO3J1O*Q'''( >
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M?@#GA6:&.X#S%19%@,8A];'^\V+K5NWFB+;OP_V_L<#RZ!'W\2T_6\; LJW
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MVV)X&M%FB,_%^<Y_S(\K=S48"J".3PD:\]^(,3/W!]+JA[F/@>S@ZJ=9[H4
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MPAZE,Q(04RX]GP'U+/]YDY:S$B4 R(W1,Z9EEH<17X$T@ @$<&&V+@;*.\Z
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ME&/_8K_QGNC:G1=CJ,51<RZ'Y-0M3J;-H!T;Q%W)41E,6<:]LPY/CGX\4^<
M!^SH)#X\/0UZCJN_8W +:9#K6T*#K:-PC:!]1O_;WNE^_Q@K(,\"U.%;?=%^
M])A\F9);!(?<,:2__XM$\AKL#?V2DLT>D56VF/U]=>NXJ.BU^F//:$MFX&58
M1D]*X[S'%&I6:["4*:8IKZ29-@,-6([IS!S%/9V;G6^/XJ/CT_BX?[!K*L>S
MRHH,Y,[6UBS&T69([-Q6(/'VILC(X \B_\+N ER3G<Y%PK''3V[CYD@XW<]2
M-8\0T&T[U-PPIX),'U>3<W31AX.4<]!H[>@0W7 8<"4Y8VTJ5O@8:4?DJ<3
M%:C4T40C0!_(Z#+NRH!/X2I[!#;G6LH_J%APA#6Q];) I;[&+VR/.^Y/WA>_
M280.R9$]?B8C'+BM(=)=I,LY3)]S_X>$>487CL9G(D"P(C5MN:BU_8:R#-R
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M/OA:=3\Y8E#=**WNDJ51,$BP6=N1"3.HH ;81]&LO6!!0ZJV1H8M'!YJ$TQ
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M.7&K><19D$R!C_"&>4:F]T2NP$=Q[0MGY1V6F13^;0SU4R'I6%6E\8*2Q$R
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MR;0^LK!J16(PSCC/;A$79SV.RUP]<=<W64VQ? 'DRU.F8.%)<(<^B&6Q9^;
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MWA'0\%-4R?[AR.YQN191ZJLPR<9+:VZR1I]0O; POGYE976&%N-?PF_*Z@;
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MS$>8C6'ELI8JU\OIH,QYS&>'W@C\-,TC5_ 9$7O($IJ9(7*=WE2,Q129-%K
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MX=U!8SC(:YQ$"N-H]I6Z=J97?B8D8WSC/D7)B%HQX2)&8W@HECKW8-#*A_
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M4$L! A0#%     @ D4JO6G&VA^SAB   9^<& !4              ( !F&@
M &-O<VTM,C R-3 S,S%?;&%B+GAM;%!+ 0(4 Q0    ( )%*KUJKP?F$SFP
M &W<!0 5              "  :SQ  !C;W-M+3(P,C4P,S,Q7W!R92YX;6Q0
M2P$"% ,4    " "12J]:6=T+IR*7 0 AB!( #               @ &M7@$
M8V]S;5\Q,'$N:'1M4$L! A0#%     @ D4JO6GTM0F=T!P  3R4   X
M         ( !^?4" &-O<VU?97@S,3$N:'1M4$L! A0#%     @ D4JO6LI]
MNAUU!P  WR0   X              ( !F?T" &-O<VU?97@S,3(N:'1M4$L!
M A0#%     @ D4JO6I.\")Q'!   K@T   X              ( !.@4# &-O
M<VU?97@S,C$N:'1M4$L! A0#%     @ D4JO6E9_I%A0!   Y@P   X
M         ( !K0D# &-O<VU?97@S,C(N:'1M4$L%!@     *  H =0(  "D.
$ P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>cosm_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cosm="http://cosm.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cosm-20250331.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-01to2025-04-24_us-gaap_SubsequentEventMember_cosm_GrigoriosSiokasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GrigoriosSiokasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-24</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:NutraceuticalsAndPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:PharmamanufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_WholesaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_TotalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cosm:TotalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_UkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:UkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_UkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:UkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_GreeceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:GreeceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_BulgariaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:BulgariaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_BulgariaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:BulgariaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_CyprusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:CyprusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_CyprusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:CyprusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_CroatiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:CroatiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_CroatiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:CroatiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_AlbaniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:AlbaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_AlbaniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:AlbaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-21_cosm_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-21</instant>
        </period>
    </context>
    <context id="AsOf2023-08-21_cosm_TwoZeroTwentyThreePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TwoZeroTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-21</instant>
        </period>
    </context>
    <context id="AsOf2022-09-19_cosm_TwoZeroTwentyTwoPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TwoZeroTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-19</instant>
        </period>
    </context>
    <context id="From2023-04-01to2023-04-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_cosm_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-01-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2023-11-01to2023-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-21</endDate>
        </period>
    </context>
    <context id="From2023-11-01to2023-11-21_cosm_FourThirdPartyConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:FourThirdPartyConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-21</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-07-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="From2022-06-01to2022-06-25_cosm_PhaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PhaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-25</endDate>
        </period>
    </context>
    <context id="From2022-06-01to2022-06-25_cosm_PhaseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PhaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-25</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_cosm_NationalMedicinesAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cosm:NationalMedicinesAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_cosm_NationalMedicinesAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cosm:NationalMedicinesAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_InterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_InterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_FinanceLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_OperatingLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">cosm:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentythreeTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2020-06-01to2020-06-23_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyThreeTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-23</endDate>
        </period>
    </context>
    <context id="From2020-06-01to2020-06-24_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyFourTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-24</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_DebtAgreementJuneOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJuneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2020-05-01to2020-05-12_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-12</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyFourteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyFourTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:DeemberTwentyTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyTwentyNineTwentyTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyFourTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:MayTwelveTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:CovidNinteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyFourteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentythreeTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentythreeTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentythreeTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-30_cosm_DebtAgreementJulyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJulyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="AsOf2020-11-19_cosm_DebtExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyThreeTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JuneTwentyThreeTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_DebtAgreementJulyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJulyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2017-05-12_cosm_DebtAgreementJulyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJulyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentySevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_DebtAgreementJuneOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJuneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:DeemberTwentyTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyTwentyNineTwentyTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JulyFourteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cosm:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJuneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentySevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cosm:JanuaryTwentySevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_DebtAgreementJulyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtAgreementJulyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_DebtExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_DebtExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_COVIDLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_COVIDLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_COVIDLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_COVIDLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cosm_COVIDLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:COVIDLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cosm_ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cosm:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_TradeFacilityAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_TradeFacilityAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_TradeFacilityAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cosm_TradeFacilityAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">cosm:TradeFacilityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_EFGMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:EFGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_EFGMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:EFGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:PancretaOfGreeceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:PancretaOfGreeceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:AlphaBankOfGreeceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:AlphaBankOfGreeceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:NationalBankOfGreeceTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cosm:NationalBankOfGreeceTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalBankOfGreeceOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-01-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_PancretaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PancretaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_PancretaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PancretaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_AtticaBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:AtticaBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_AtticaBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:AtticaBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_EFGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:EFGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_EFGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:EFGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_AlphaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:AlphaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_AlphaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:AlphaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_NationalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_NationalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:NationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2021-05-01to2021-05-17_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-17</endDate>
        </period>
    </context>
    <context id="From2023-12-01to2023-12-29_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="From2023-06-01to2023-06-28_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-28</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_InventoriesRelatedAgreementMember_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cosm:InventoriesRelatedAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_InventoriesRelatedAgreementMember_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cosm:InventoriesRelatedAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-12-31_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_MariaKozariMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_MariaKozariMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_MariaKozariMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_MariaKozariMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_MariaKozariMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:MariaKozariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_KanarogloySiaEpeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:KanarogloySiaEpeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_BasothoInvestmentLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BasothoInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_BasothoInvestmentLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BasothoInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_BasothoInvestmentLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:BasothoInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_PanagiotisKozarisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PanagiotisKozarisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_PanagiotisKozarisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PanagiotisKozarisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_cosm_PanagiotisKozarisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PanagiotisKozarisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-12-31_cosm_PanagiotisKozarisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PanagiotisKozarisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_GrigoriosSiokasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GrigoriosSiokasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_DimitriosGoulielmosMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DimitriosGoulielmosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_GrigoriosSiokasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GrigoriosSiokasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_GrigoriosSiokasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GrigoriosSiokasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_DimitriosGoulielmosMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DimitriosGoulielmosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_DimitriosGoulielmosMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DimitriosGoulielmosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:DocPharmaSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_GeorgeTerzisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:GeorgeTerzisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-02-01to2023-02-28_cosm_CanaHoldingsLaboratoriesHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:CanaHoldingsLaboratoriesHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_LoansPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_LoansPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_LoansPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cosm_LoansPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:LoansPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_NotesPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_NotesPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_NotesPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_NotesPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cosm_NotesPayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cosm:NotesPayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-09-01to2024-09-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="From2024-09-01to2024-09-26_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="From2024-09-01to2024-09-26_cosm_WarrantExchangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="From2024-09-01to2024-09-26_cosm_WarrantInducementLetterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:WarrantInducementLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-26_cosm_WarrantExchangeMember_cosm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:BottomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="AsOf2024-09-26_cosm_WarrantExchangeMember_cosm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TopMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="AsOf2024-09-26_cosm_WarrantExchangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="AsOf2024-09-26_cosm_WarrantInducementLetterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:WarrantInducementLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="AsOf2025-01-28_cosm_WarrantInducementLetterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:WarrantInducementLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-28</instant>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-24_cosm_TreasuryStocksOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cosm:TreasuryStocksOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-04_cosm_WarrantExchangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cosm:WarrantExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_TreasuryStocksOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cosm:TreasuryStocksOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_TreasuryStocksOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cosm:TreasuryStocksOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-10-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CustomerListsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CustomerListsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_TradeNameMarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cosm:TradeNameMarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_TradeNameMarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cosm:TradeNameMarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cosm:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cosm:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cosm_CosmoFarmacyLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:CosmoFarmacyLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:CosmoFarmacyLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_ShareExchangeAgreementMember_cosm_IccMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:ShareExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cosm:IccMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_ShareExchangeAgreementMember_cosm_IccMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:ShareExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cosm:IccMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-06-01to2023-06-30_cosm_CANAPharmaceuticalLaboratoriesSACanaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CANAPharmaceuticalLaboratoriesSACanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-06_cosm_BuildingAcquisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingAcquisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="From2023-02-01to2023-02-28_cosm_CANAPharmaceuticalLaboratoriesSACanaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CANAPharmaceuticalLaboratoriesSACanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-04-24_cosm_BuildingAcquisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingAcquisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-15_cosm_GreeceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:GreeceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="From2023-06-01to2023-06-15_cosm_GreeceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:GreeceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_BuildingAcquisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingAcquisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-01-23_cosm_CloudscreenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CloudscreenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-23</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_ZipDoctorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:ZipDoctorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-03_cosm_ZipDoctorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:ZipDoctorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-03</instant>
        </period>
    </context>
    <context id="From2023-04-01to2023-04-03_cosm_ZipDoctorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:ZipDoctorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_UnitedKingdomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:UnitedKingdomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_PancretaBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PancretaBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_PancretaBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cosm:PancretaBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_GreeceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">cosm:GreeceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_LeaseholdImprovementsAndTechnicalWorksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:LeaseholdImprovementsAndTechnicalWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_ComputerEquipmentMember_cosm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_FurnitureAndFixturesMember_cosm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_FurnitureAndFixturesMember_cosm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_TopMember_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_BuildingsMember_cosm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_BuildingsMember_cosm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cosm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cosm:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CANAPharmaceuticalLaboratoriesSACanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cosm:CANAPharmaceuticalLaboratoriesSACanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_cosm_CommonStockShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_cosm_CommonStockShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cosm_CommonStockShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_cosm_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_cosm_CommonStockShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cosm_CommonStockShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cosm_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cosm_CommonStockShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cosm:CommonStockShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <instant>2025-05-15</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-03-31" id="ixv-11299">0001474167</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-03-31" id="ixv-11300">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-03-31" id="ixv-11301">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-03-31" id="ixv-11302">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-03-31" id="ixv-11303">2025</dei:DocumentFiscalYearFocus>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-03-31" id="ixv-11304">COSM</dei:TradingSymbol>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="ixv-11305"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="ixv-11306"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="ixv-11307"
      unitRef="Shares">86497</us-gaap:TreasuryStockCommonShares>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-03-31" id="ixv-11308">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-03-31" id="ixv-11309">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-03-31" id="ixv-11310">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-03-31" id="ixv-11311">false</ecd:NonRule10b51ArrTrmntdFlag>
    <us-gaap:Investments
      contextRef="AsOf2024-12-31_cosm_ShareExchangeAgreementMember_cosm_IccMember"
      decimals="0"
      id="ixv-11312"
      unitRef="USD">0</us-gaap:Investments>
    <cosm:CommonStockShareAuthorized
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="ixv-11313"
      unitRef="Shares">300000000</cosm:CommonStockShareAuthorized>
    <cosm:WeightedAverageRemainingContractualTermOutstandingEnding
      contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember"
      id="ixv-11314">P3Y2M27D</cosm:WeightedAverageRemainingContractualTermOutstandingEnding>
    <dei:DocumentType contextRef="From2025-01-01to2025-03-31" id="ixv-13325">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-01-01to2025-03-31" id="ixv-13326">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-03-31" id="ixv-13327">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-03-31" id="ixv-13328">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-03-31" id="ixv-13329">000-54436</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-03-31" id="ixv-13330">COSMOS HEALTH INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-03-31" id="ixv-13331">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-03-31" id="ixv-13332">27-0611758</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-03-31" id="ixv-13333">5 Agiou Georgiou Str</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-03-31" id="ixv-13334">Pilea</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-03-31" id="ixv-13335">Thessaloniki</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2025-01-01to2025-03-31" id="ixv-13336">GR</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-03-31" id="ixv-13337">55438</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-03-31" id="ixv-13338">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-03-31" id="ixv-13339">536-3102</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-03-31" id="ixv-13340">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-03-31" id="ixv-13341">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-03-31" id="ixv-13342">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-03-31" id="ixv-13343">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-03-31" id="ixv-13344">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-03-31" id="ixv-13345">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-03-31" id="ixv-13346">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-03-31" id="ixv-13347">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-05-15"
      decimals="INF"
      id="ixv-13348"
      unitRef="Shares">28751422</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11199"
      unitRef="USD">742881</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11200"
      unitRef="USD">315105</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11201"
      unitRef="USD">14251895</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11202"
      unitRef="USD">13478263</us-gaap:AccountsReceivableNetCurrent>
    <cosm:AmountAccountsReceivableRelatedPartiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11203"
      unitRef="USD">1422015</cosm:AmountAccountsReceivableRelatedPartiesCurrent>
    <cosm:AmountAccountsReceivableRelatedPartiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11204"
      unitRef="USD">1230308</cosm:AmountAccountsReceivableRelatedPartiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11205"
      unitRef="USD">25278</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11206"
      unitRef="USD">21148</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11207"
      unitRef="USD">4736222</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11208"
      unitRef="USD">4355365</us-gaap:InventoryNet>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11209"
      unitRef="USD">666225</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11210"
      unitRef="USD">614473</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:LoansAndLeasesReceivableRelatedParties
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11211"
      unitRef="USD">768891</us-gaap:LoansAndLeasesReceivableRelatedParties>
    <us-gaap:LoansAndLeasesReceivableRelatedParties
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11212"
      unitRef="USD">557473</us-gaap:LoansAndLeasesReceivableRelatedParties>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11213"
      unitRef="USD">1383105</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11214"
      unitRef="USD">1310388</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <cosm:PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11215"
      unitRef="USD">3848487</cosm:PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent>
    <cosm:PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11216"
      unitRef="USD">3578825</cosm:PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11217"
      unitRef="USD">27844999</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11218"
      unitRef="USD">25461347</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11219"
      unitRef="USD">10016068</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11220"
      unitRef="USD">9689505</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11221"
      unitRef="USD">7802529</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11222"
      unitRef="USD">7756534</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <cosm:LoansReceivableNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11223"
      unitRef="USD">2927994</cosm:LoansReceivableNoncurrent>
    <cosm:LoansReceivableNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11224"
      unitRef="USD">2876523</cosm:LoansReceivableNoncurrent>
    <cosm:LoansReceivableRelatedPartyNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11225"
      unitRef="USD">2875384</cosm:LoansReceivableRelatedPartyNoncurrent>
    <cosm:LoansReceivableRelatedPartyNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11226"
      unitRef="USD">2898280</cosm:LoansReceivableRelatedPartyNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11227"
      unitRef="USD">671605</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11228"
      unitRef="USD">696166</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11229"
      unitRef="USD">9451</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11230"
      unitRef="USD">13607</us-gaap:FinanceLeaseRightOfUseAsset>
    <cosm:AdvancesForBuildingsAcquisition
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11231"
      unitRef="USD">2000020</cosm:AdvancesForBuildingsAcquisition>
    <cosm:AdvancesForBuildingsAcquisition
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11232"
      unitRef="USD">2000020</cosm:AdvancesForBuildingsAcquisition>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11233"
      unitRef="USD">1154594</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11234"
      unitRef="USD">1108484</us-gaap:OtherAssets>
    <cosm:OtherAssetsRelatedParty
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11235"
      unitRef="USD">1889300</cosm:OtherAssetsRelatedParty>
    <cosm:OtherAssetsRelatedParty
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11236"
      unitRef="USD">1811425</cosm:OtherAssetsRelatedParty>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11237"
      unitRef="USD">57191944</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11238"
      unitRef="USD">54311892</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11241"
      unitRef="USD">11672962</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11242"
      unitRef="USD">11157658</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <cosm:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11243"
      unitRef="USD">614554</cosm:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <cosm:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11244"
      unitRef="USD">1269403</cosm:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11245"
      unitRef="USD">255192</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11246"
      unitRef="USD">221820</us-gaap:InterestPayableCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11247"
      unitRef="USD">7305377</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11248"
      unitRef="USD">6985052</us-gaap:LinesOfCreditCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11249"
      unitRef="USD">2763723</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11250"
      unitRef="USD">2548480</us-gaap:NotesPayableCurrent>
    <cosm:NotesPayableRelatedPartiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11251"
      unitRef="USD">11012</cosm:NotesPayableRelatedPartiesCurrent>
    <cosm:NotesPayableRelatedPartiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11252"
      unitRef="USD">10558</cosm:NotesPayableRelatedPartiesCurrent>
    <cosm:LoansPayableRelatedPartiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11253"
      unitRef="USD">0</cosm:LoansPayableRelatedPartiesCurrent>
    <cosm:LoansPayableRelatedPartiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11254"
      unitRef="USD">6194</cosm:LoansPayableRelatedPartiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11255"
      unitRef="USD">203601</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11256"
      unitRef="USD">196718</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11257"
      unitRef="USD">8376</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11258"
      unitRef="USD">11484</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11259"
      unitRef="USD">3751190</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11260"
      unitRef="USD">3350173</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11261"
      unitRef="USD">26585987</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11262"
      unitRef="USD">25757540</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11263"
      unitRef="USD">2088540</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11264"
      unitRef="USD">1560433</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11265"
      unitRef="USD">466909</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11266"
      unitRef="USD">498398</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11267"
      unitRef="USD">1788</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11268"
      unitRef="USD">3399</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11269"
      unitRef="USD">2097008</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11270"
      unitRef="USD">1959193</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11271"
      unitRef="USD">31240232</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11272"
      unitRef="USD">29778963</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11273"
      unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11274"
      unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="fid_8807"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8809"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8812"
      unitRef="Shares">27284633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_8811"
      unitRef="Shares">23689135</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8814"
      unitRef="Shares">27198136</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_8813"
      unitRef="Shares">23602638</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11276"
      unitRef="USD">27285</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11277"
      unitRef="USD">23689</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11278"
      unitRef="USD">142785641</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11279"
      unitRef="USD">141583625</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11280"
      unitRef="USD">20</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11281"
      unitRef="USD">20</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8815"
      unitRef="Shares">86497</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11282"
      unitRef="USD">917159</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11283"
      unitRef="USD">917159</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11284"
      unitRef="USD">-114840372</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11285"
      unitRef="USD">-114022275</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11286"
      unitRef="USD">-1103663</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11287"
      unitRef="USD">-2134931</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11288"
      unitRef="USD">25951712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11289"
      unitRef="USD">24532929</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11290"
      unitRef="USD">57191944</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11291"
      unitRef="USD">54311892</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11292"
      unitRef="USD">13712528</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11293"
      unitRef="USD">14584473</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11294"
      unitRef="USD">11662729</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11295"
      unitRef="USD">13250847</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11296"
      unitRef="USD">2049799</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11297"
      unitRef="USD">1333626</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11299"
      unitRef="USD">1478702</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11300"
      unitRef="USD">1418138</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11301"
      unitRef="USD">1040019</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11302"
      unitRef="USD">1258179</us-gaap:SalariesAndWages>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11303"
      unitRef="USD">28155</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11304"
      unitRef="USD">173630</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11305"
      unitRef="USD">15629</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11306"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11307"
      unitRef="USD">320439</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11308"
      unitRef="USD">319787</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11309"
      unitRef="USD">2882944</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11310"
      unitRef="USD">3169734</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11311"
      unitRef="USD">-833145</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11312"
      unitRef="USD">-1836108</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11314"
      unitRef="USD">-68137</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11315"
      unitRef="USD">191824</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11316"
      unitRef="USD">187107</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11317"
      unitRef="USD">168672</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11318"
      unitRef="USD">91326</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11319"
      unitRef="USD">105765</us-gaap:InterestIncomeOther>
    <cosm:GainLossOnSalesOfEquityInvestments
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11320"
      unitRef="USD">3142</cosm:GainLossOnSalesOfEquityInvestments>
    <cosm:GainLossOnSalesOfEquityInvestments
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11321"
      unitRef="USD">1755</cosm:GainLossOnSalesOfEquityInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11322"
      unitRef="USD">175824</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11323"
      unitRef="USD">-161254</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11324"
      unitRef="USD">15048</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11325"
      unitRef="USD">-30582</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11326"
      unitRef="USD">-818097</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11327"
      unitRef="USD">-1866690</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11328"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11329"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11330"
      unitRef="USD">-818097</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11331"
      unitRef="USD">-1866690</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11332"
      unitRef="USD">-818097</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11333"
      unitRef="USD">-1866690</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11335"
      unitRef="USD">1031268</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11336"
      unitRef="USD">-599276</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11337"
      unitRef="USD">213171</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11338"
      unitRef="USD">-2465966</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="fid_11339"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="fid_11340"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="fid_11341"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="fid_11342"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11344"
      unitRef="Shares">26037608</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11345"
      unitRef="Shares">16851747</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11346"
      unitRef="Shares">26037608</us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted>
    <us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11347"
      unitRef="Shares">16851747</us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11348"
      unitRef="Shares">15982472</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11350"
      unitRef="USD">15983</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11351"
      unitRef="USD">129008301</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11352"
      unitRef="USD">-20</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11349"
      unitRef="Shares">86497</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11353"
      unitRef="USD">-917159</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11354"
      unitRef="USD">-91644233</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11355"
      unitRef="USD">-419844</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_11356"
      unitRef="USD">36043028</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11357"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11358"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11359"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11360"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11361"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11362"
      unitRef="USD">-599276</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11363"
      unitRef="USD">-1715087</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares
      contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11364"
      unitRef="Shares">901488</cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesShares>
    <cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount
      contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11366"
      unitRef="USD">901</cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount>
    <cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11367"
      unitRef="USD">628525</cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount>
    <cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount
      contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11368"
      unitRef="USD">0</cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount>
    <cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11369"
      unitRef="USD">0</cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount>
    <cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11370"
      unitRef="USD">0</cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount>
    <cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11371"
      unitRef="USD">0</cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount>
    <cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11372"
      unitRef="USD">629426</cosm:ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount>
    <cosm:SharesIssuedInLieuOfCashAmount
      contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11373"
      unitRef="USD">0</cosm:SharesIssuedInLieuOfCashAmount>
    <cosm:SharesIssuedInLieuOfCashAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11374"
      unitRef="USD">108297</cosm:SharesIssuedInLieuOfCashAmount>
    <cosm:SharesIssuedInLieuOfCashAmount
      contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11375"
      unitRef="USD">0</cosm:SharesIssuedInLieuOfCashAmount>
    <cosm:SharesIssuedInLieuOfCashAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11376"
      unitRef="USD">0</cosm:SharesIssuedInLieuOfCashAmount>
    <cosm:SharesIssuedInLieuOfCashAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11377"
      unitRef="USD">0</cosm:SharesIssuedInLieuOfCashAmount>
    <cosm:SharesIssuedInLieuOfCashAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11378"
      unitRef="USD">0</cosm:SharesIssuedInLieuOfCashAmount>
    <cosm:SharesIssuedInLieuOfCashAmount
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11379"
      unitRef="USD">695405</cosm:SharesIssuedInLieuOfCashAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementShares
      contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11380"
      unitRef="Shares">950063</cosm:SharesIssuedPursuantToWarrantExchangeAgreementShares>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11382"
      unitRef="USD">950</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11383"
      unitRef="USD">-950</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11384"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11385"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11386"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11387"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11388"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:StockBasedCompensation
      contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11389"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11390"
      unitRef="USD">231897</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11391"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11392"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11393"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11394"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11395"
      unitRef="USD">994307</cosm:StockBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11396"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11397"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11398"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11399"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11400"
      unitRef="USD">-1866690</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11401"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11402"
      unitRef="USD">3868868</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11403"
      unitRef="Shares">17834023</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11405"
      unitRef="USD">17834</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11406"
      unitRef="USD">129976070</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11407"
      unitRef="USD">-20</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11404"
      unitRef="Shares">86497</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11408"
      unitRef="USD">-917159</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11409"
      unitRef="USD">-93510923</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11410"
      unitRef="USD">-1019120</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_11411"
      unitRef="USD">40515948</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11412"
      unitRef="Shares">23689135</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11414"
      unitRef="USD">23689</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11415"
      unitRef="USD">141583625</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11416"
      unitRef="USD">-20</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11413"
      unitRef="Shares">86497</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11417"
      unitRef="USD">-917159</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11418"
      unitRef="USD">-114022275</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11419"
      unitRef="USD">-2134931</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11420"
      unitRef="USD">24532930</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11421"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11422"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11423"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11424"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11425"
      unitRef="USD">0</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11426"
      unitRef="USD">1031268</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:ForeignCurrencyTranslationAdjustmentNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11427"
      unitRef="USD">1031268</cosm:ForeignCurrencyTranslationAdjustmentNet>
    <cosm:StockBasedCompensation
      contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11428"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11429"
      unitRef="USD">556611</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11430"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11431"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11432"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11433"
      unitRef="USD">0</cosm:StockBasedCompensation>
    <cosm:StockBasedCompensation
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11434"
      unitRef="USD">556611</cosm:StockBasedCompensation>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementShares
      contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11435"
      unitRef="Shares">2542126</cosm:SharesIssuedPursuantToWarrantExchangeAgreementShares>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11437"
      unitRef="USD">2542</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11438"
      unitRef="USD">-2542</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11439"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11440"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11441"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11442"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11443"
      unitRef="USD">0</cosm:SharesIssuedPursuantToWarrantExchangeAgreementAmount>
    <cosm:DebtExchangesShares
      contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11444"
      unitRef="Shares">1053372</cosm:DebtExchangesShares>
    <cosm:DebtExchangesAmount
      contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11446"
      unitRef="USD">1053</cosm:DebtExchangesAmount>
    <cosm:DebtExchangesAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11447"
      unitRef="USD">647947</cosm:DebtExchangesAmount>
    <cosm:DebtExchangesAmount
      contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11448"
      unitRef="USD">0</cosm:DebtExchangesAmount>
    <cosm:DebtExchangesAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11449"
      unitRef="USD">0</cosm:DebtExchangesAmount>
    <cosm:DebtExchangesAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11450"
      unitRef="USD">0</cosm:DebtExchangesAmount>
    <cosm:DebtExchangesAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11451"
      unitRef="USD">0</cosm:DebtExchangesAmount>
    <cosm:DebtExchangesAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11452"
      unitRef="USD">649000</cosm:DebtExchangesAmount>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11453"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11454"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11455"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11456"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11457"
      unitRef="USD">-818097</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11458"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11459"
      unitRef="USD">-818097</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11460"
      unitRef="Shares">27284633</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_cosm_CommonStockShareMember"
      decimals="0"
      id="fid_11462"
      unitRef="USD">27284</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_11463"
      unitRef="USD">142785641</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_cosm_SubscriptionReceivableMember"
      decimals="0"
      id="fid_11464"
      unitRef="USD">-20</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11461"
      unitRef="Shares">86497</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="fid_11465"
      unitRef="USD">-917159</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_11466"
      unitRef="USD">-114840372</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_11467"
      unitRef="USD">-1103663</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11468"
      unitRef="USD">25951712</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11470"
      unitRef="USD">-818097</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11471"
      unitRef="USD">-1866690</us-gaap:NetIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11473"
      unitRef="USD">315836</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11474"
      unitRef="USD">312298</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11475"
      unitRef="USD">4603</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11476"
      unitRef="USD">7489</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11477"
      unitRef="USD">-18687</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11478"
      unitRef="USD">-31071</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11479"
      unitRef="USD">63236</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11480"
      unitRef="USD">77167</us-gaap:LeaseAndRentalExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11481"
      unitRef="USD">195</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11482"
      unitRef="USD">725</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11483"
      unitRef="USD">556611</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11484"
      unitRef="USD">340194</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11485"
      unitRef="USD">7392</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11486"
      unitRef="USD">-4344</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11487"
      unitRef="USD">3142</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11488"
      unitRef="USD">1755</us-gaap:GainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11490"
      unitRef="USD">170948</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11491"
      unitRef="USD">-238025</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11492"
      unitRef="USD">134483</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11493"
      unitRef="USD">348639</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11494"
      unitRef="USD">192792</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11495"
      unitRef="USD">196020</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11496"
      unitRef="USD">-92249</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11497"
      unitRef="USD">106353</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <cosm:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11498"
      unitRef="USD">134754</cosm:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty>
    <cosm:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11499"
      unitRef="USD">974442</cosm:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11500"
      unitRef="USD">83627</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11501"
      unitRef="USD">-599161</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cosm:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11502"
      unitRef="USD">-18934</cosm:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties>
    <cosm:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11503"
      unitRef="USD">319713</cosm:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11504"
      unitRef="USD">23308</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11505"
      unitRef="USD">-62387</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11506"
      unitRef="USD">-63238</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11507"
      unitRef="USD">-76344</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11508"
      unitRef="USD">169429</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11509"
      unitRef="USD">261313</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <cosm:IncreaseDecreaseInOtherLiabilities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11510"
      unitRef="USD">52272</cosm:IncreaseDecreaseInOtherLiabilities>
    <cosm:IncreaseDecreaseInOtherLiabilities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11511"
      unitRef="USD">-701821</cosm:IncreaseDecreaseInOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11512"
      unitRef="USD">-186316</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11513"
      unitRef="USD">-3412103</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfLoansReceivable
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11515"
      unitRef="USD">6734</us-gaap:ProceedsFromSaleOfLoansReceivable>
    <us-gaap:ProceedsFromSaleOfLoansReceivable
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11516"
      unitRef="USD">207119</us-gaap:ProceedsFromSaleOfLoansReceivable>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11517"
      unitRef="USD">1273</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11518"
      unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11519"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11520"
      unitRef="USD">1997</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11521"
      unitRef="USD">12530</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11522"
      unitRef="USD">82662</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11523"
      unitRef="USD">-7069</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11524"
      unitRef="USD">126454</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11526"
      unitRef="USD">184153</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11527"
      unitRef="USD">364354</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11528"
      unitRef="USD">737177</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11529"
      unitRef="USD">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11530"
      unitRef="USD">6302</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11531"
      unitRef="USD">7599</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11532"
      unitRef="USD">6756201</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11533"
      unitRef="USD">5974114</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11534"
      unitRef="USD">6775739</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11535"
      unitRef="USD">5932222</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11536"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11537"
      unitRef="USD">649039</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11538"
      unitRef="USD">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11539"
      unitRef="USD">19465</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11540"
      unitRef="USD">5398</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11541"
      unitRef="USD">8787</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11542"
      unitRef="USD">560862</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11543"
      unitRef="USD">206942</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11544"
      unitRef="USD">60299</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11545"
      unitRef="USD">110611</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11546"
      unitRef="USD">427776</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11547"
      unitRef="USD">-2968096</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11548"
      unitRef="USD">315105</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_11549"
      unitRef="USD">3833195</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11550"
      unitRef="USD">742881</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_11551"
      unitRef="USD">865099</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11554"
      unitRef="USD">104800</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11555"
      unitRef="USD">234732</us-gaap:InterestPaidNet>
    <cosm:ClosingOfAcquisitionOfCloudscreen
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11557"
      unitRef="USD">0</cosm:ClosingOfAcquisitionOfCloudscreen>
    <cosm:ClosingOfAcquisitionOfCloudscreen
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11558"
      unitRef="USD">637080</cosm:ClosingOfAcquisitionOfCloudscreen>
    <cosm:CommonStockIssuedToEmployees
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11559"
      unitRef="USD">311301</cosm:CommonStockIssuedToEmployees>
    <cosm:CommonStockIssuedToEmployees
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11560"
      unitRef="USD">0</cosm:CommonStockIssuedToEmployees>
    <cosm:CommonStockIssuedToConsultants
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11561"
      unitRef="USD">245310</cosm:CommonStockIssuedToConsultants>
    <cosm:CommonStockIssuedToConsultants
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11562"
      unitRef="USD">0</cosm:CommonStockIssuedToConsultants>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5964">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 1 &#x2013; BASIS OF PRESENTATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The terms &#x201c;COSM,&#x201d; &#x201c;we,&#x201d; the &#x201c;Company,&#x201d; the &#x201c;Group&#x201d; and &#x201c;us&#x201d; as used in this report refer to Cosmos Health Inc. The accompanying unaudited condensed consolidated balance sheet as of March 31, 2025 and unaudited condensed consolidated statements of operations and comprehensive income&#160;(loss) for the three months ended March 31, 2025 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of the management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2025, are not necessarily indicative of the results that may be expected for the year ending December 31, 2025, or any other period. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2024, included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024 (&#x201c;Form 10-K&#x201d;). The accompanying condensed consolidated balance sheet as of December 31, 2024 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes on the accompanying balance sheet. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Going Concern&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s unaudited consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;), which contemplates the continuation of the Company as a going concern. For the period ended March 31, 2025, the Company had revenue of $13,712,528, net loss of $818,097 and net cash used in operations of $186,316. Additionally, as of March 31, 2025, the Company had positive working capital of $1,259,012, an accumulated deficit of $114,840,372, and stockholders&#x2019; equity of $25,951,712. It is management&#x2019;s opinion that these conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of 12 months from the date of this filing.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s revenues are not able to sustain its operations, and concerns exist regarding the Company&#x2019;s ability to meet its obligations as they become due. The Company is subject to a number of risks to those of smaller commercial companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the need to obtain additional capital, competition from larger companies, and other pharmaceutical and health care companies.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Management evaluated the above conditions which raise substantial doubt about the Company&#x2019;s ability to continue as a going concern to determine if it can meet its obligations for the subsequent 12 months from the date of this filing. Management considered its ability to access future capital, curtail expenses if needed, expand product lines, and acquire new products.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Management&#x2019;s plans include expansion of brand name products to the market, expanding the current product portfolio, and evaluating acquisition targets to expand distribution. The exclusive distribution agreement signed for its Sky Premium Life products in the United Arab Emirates (&#x201c;UAE&#x201d;) and the significant orders already received, are expected to substantially strengthen its operating cash flow. Furthermore, the Company intends to vertically integrate the supply chain distribution network. On top of that, the Company plans to access the capital markets further in order to raise additional funds through equity and/or debt offerings. More specifically, commencing from August 2025, the Company will be eligible to utilize an S-3 registration statement, (12 months following the date that the Company had regained compliance with Listing Rule 5250(c)(1) (the &#x201c;Filing Rule&#x201d;)), to be in a position to raise equity capital more efficiently in conjunction with utilizing potential equity proceeds by its outstanding warrants. Management&#x2019;s plans also include postponing certain debt repayments, through achieving favorable amendments to its debt facilities and in parallel intends to make substantial efforts to receive additional debt financing. Moreover, the Company&#x2019;s management is considering of postponing certain repayments of suppliers and creditors. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Considering the above, management is of the view that substantial doubt exists for the Company&#x2019;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10900"
      unitRef="USD">13712528</us-gaap:Revenues>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10901"
      unitRef="USD">-818097</us-gaap:ProfitLoss>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10902"
      unitRef="USD">186316</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <cosm:WorkingCapital
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10899"
      unitRef="USD">1259012</cosm:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10898"
      unitRef="USD">-114840372</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10897"
      unitRef="USD">25951712</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_11563">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 2 &#x2013; ORGANIZATION AND NATURE OF BUSINESS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cosmos Health Inc. and its subsidiaries (Nasdaq: COSM), (&#x201c;us&#x201d;, &#x201c;we&#x201d;, the &#x201c;Group&#x201d;, or the &#x201c;Company&#x201d;) are an international healthcare group headquartered in Chicago, Illinois. The Group is engaged in the nutraceuticals sector through its own proprietary lines of products &#x201c;Sky Premium Life&#x201d; and &#x201c;Mediterranation&#x201d;. The Company is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the Group is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK, serving retail pharmacies and wholesale distributors. The Company is strategically focusing on the research and development (&#x201c;R&amp;amp;D&#x201d;) of novel patented nutraceuticals and specialized root extracts, as well as on the R&amp;amp;D of proprietary complex generics and innovative OTC products. The Company has developed a global distribution platform and is currently expanding throughout Europe, Asia, the UAE and North America. The Company has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009. On November 14, 2013, we changed our name to Cosmos Holdings Inc., and on November 29, 2022, we changed our name to Cosmos Health Inc. Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (&#x201c;SkyPharm&#x201d;), a subsidiary that used to focus on the trading, sourcing and export of nutraceutical and pharmaceutical products. In February 2017, the Company acquired Decahedron Ltd., a UK Company (&#x201c;Decahedron&#x201d;) which is a fully licensed second-generation wholesaler specializing in imports and exports of generics and OTC pharmaceutical products within the EEA (European Economic Area) and distributor of Sky Premium Life nutraceutical products in the UK.&#160;On December 19, 2018, the Company acquired Cosmofarm&#160;S.A. (&#x201c;Cosmofarm&#x201d;), a pharmaceutical wholesaler specializing in the distribution and export of pharmaceutical products through its extensive pharmacies network. On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (&#x201c;ZipDoctor&#x201d;), a telehealth company, a direct-to-consumer subscription-based telemedicine platform. On June 30, 2023, the Company acquired&#160;Laboratories Holdings (Cyprus) Limited (&#x201c;Cana&#x201d;), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana&#160;S.A. (&#x201c;Cana SA&#x201d;), a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Acquisition Accounting&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cloudscreen&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 805, Business Combinations, (&#x201c;ASC 805&#x201d;) and recorded $637,080 as &#x201c;Other assets&#x201d; related to the technology platform acquired. The total amount was reclassified to &#x201c;Goodwill and intangible assets, net&#x201d; in January 2024 with the closing of the agreement (refer to Note 5).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;ZipDoctor&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (&#x201c;ZipDoctor&#x201d;), a&#160;telehealth company for a total sum of $150,000 in cash and $8,788 in fees. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 805, &lt;em&gt;Business Combinations&lt;/em&gt;, (&#x201c;ASC 805&#x201d;) and recorded $158,788 as an intangible asset related to the technology platform acquired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended December 31, 2024, the Company recognized an impairment charge of $131,032 related to the technology platform. This decision followed management&#x2019;s assessment that the asset&#x2019;s recoverability was no longer supportable due to changes in market conditions and a shift in strategic priorities. Specifically, the telehealth platform was no longer in use and did not generate revenues, as the Company elected not to focus on the telehealth business segment. As a result, the unamortized balance of the intangible asset was effectively written off. The impairment charge was recorded within &#x201c;Other income (expense), net&#x201d; in the Consolidated Statement of Operations for the year ended December 31, 2024.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Bikas&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 15, 2023, Cosmos Health Inc. entered into an Assignment and Assumption Agreement (the &#x201c;Agreement&#x201d;) with Ioannis Bikas O.E., a Greek Company (&#x201c;Bikas&#x201d;). Bikas is owner of a pharmaceutical distribution network in Greece and agreed to sell to the Company their distribution network and customer base. The purchase price of the network was &#x20ac;100,000 ($109,330) of cash, and &#x20ac;300,000 ($316,081) of the Company&#x2019;s stock. The Company issued 99,710 shares of common stock related to the acquisition of the customer base, based on the fair value of the stock on the acquisition date. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded $425,411 as an intangible asset related to the customer base acquired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Buildings Acquisitions&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 24, 2023, the Company purchased a building for a total sum of $1,054,872 in cash.&#160;The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded the cost of the building as &#x201c;Property, plant and equipment&#x201d; on the consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 6, 2023, the Company agreed to purchase land and building located in Montreal, Canada from a third-party vendor. The total purchase price amounts to $3,950,000 and the closing date of the agreement based on the amendment signed on July 19, 2023, was December 31, 2023. Pursuant to the last amendment signed on December 31, 2024 the closing date was extended to December 31, 2025. As of March 31, 2025, the Company has made prepayments of $2,000,020 classified as &#x201c;Advances for building&#x2019;s acquisition&#x201d; on the Company&#x2019;s condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cana &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 30, 2023, the Company acquired Cana Laboratories Holding (Cyprus) Limited (&#x201c;Cana&#x201d;), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana&#160;S.A. (&#x201c;Cana SA&#x201d;) for &#x20ac;800,000 ($873,600) in cash and 46,377 shares of common stock, with fair value of $138,667 as of the date of acquisition. Moreover, on February 28,&lt;sup style="vertical-align:super"&gt; &lt;/sup&gt;2023, the Company had signed a Secured Promissory Note with Cana, whereby Cana borrowed the sum of &#x20ac;4,100,000 ($4,457,520), included in the total consideration of $5,469,787. The Company accounted for the acquisition as a business acquisition in accordance with ASC 805. The fair value of Cana assets acquired, and liabilities assumed was based upon management&#x2019;s estimates assisted by an independent third-party valuation firm. The fixed assets of Cana (which included land, building &amp;amp; machinery) were valued as of December 31, 2022 and the Company believes that nothing has materially changed between such date and the acquisition date (June 30, 2023). The following table summarizes the preliminary allocation of purchase price of the acquisition:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Consideration &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,331,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Fair value of common stock issued&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;138,667&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Fair value of total consideration transferred&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;5,469,787&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Recognized amounts of identifiable assets acquired&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,796,911&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;297,340&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,488,818&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Identifiable intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;562,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Financial liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,235,233 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total identifiable net assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,910,036&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Bargain purchase gain&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;1,440,249&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the prior year period, Cana had minimal operations as it was in financial difficulties and seeking for an investor. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Basis of Financial Statement Presentation&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Principles of Consolidation&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Our consolidated accounts include our accounts and the accounts of our wholly owned subsidiaries, SkyPharm S.A., Decahedron Ltd., Cosmofarm S.A., Cana Laboratories Holdings (Cyprus) Limited and ZipDoctor Inc. The Group&#x2019;s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;). The consolidated financial statements reflect the consolidation of all entities in which the Company has control, as determined by the ability to direct the activities that significantly affect the entities&#x2019; economic performance. All significant intercompany balances and transactions have been eliminated.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Transactions in and Translations of Foreign Currency&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The functional currency for the Greek subsidiaries of the Company (CANA Laboratories, Cosmofarm S.A. and SkyPharm SA) is Euro (&#x20ac;) and for the UK subsidiary (Decahedron Ltd) is GBP (&#xa3;). ZipDoctor Inc. is a U.S. based entity. As a result, the financial statements of the subsidiaries (except for ZipDoctor Inc.) have been translated from the local currency into U.S. dollars using (i) year-end exchange rates for balance sheet accounts, and (ii) average exchange rates for the reporting period for all income statements accounts. Foreign currency translations gains and losses are reported as a separate component of the condensed consolidated statements of changes in stockholders&#x2019; equity.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Use of Estimates&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;The Effects of War in the Ukraine&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company and, as such, is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Credit Losses&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which amends the requirement on the measurement and recognition of expected credit losses for financial assets held. Furthermore, amendments ASU 2019-10 and ASU 2019-11 provided additional clarification for implementing ASU 2016-13. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early adoption permitted. The Company adopted the standard on January 1, 2023, and the standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. The Company is exposed to credit losses primarily through sales to its customers and the loans that it has provided. The Company assesses each customer&#x2019;s/ borrower&#x2019;s ability to pay, and a credit loss estimate by conducting a credit review which includes consideration of established credit rating, or an internal assessment of the customer&#x2019;s creditworthiness based on an analysis of their payment history when a credit rating is not available. The Company monitors credit exposure through active review of customer balances. In accordance with ASC 326 and the Current Expected Credit Loss (CECL) framework, the Company has elected to apply the practical expedient available for its trade receivables, which are short-term in nature and do not contain a significant financing component. The Company applies a loss-rate method for calculating expected credit losses (&#x201c;ECL&#x201d;) on accounts receivable, based on a combination of historical experience, industry data, and adjustments for current conditions and reasonable and supportable forecasts. Receivables are grouped into four aging buckets, with loss rates applied as follows: 1% for receivables aged 0&#x2013;30 days, 2% for receivables aged 31&#x2013;60 days, 3% for receivables aged 61&#x2013;90 days, and 5% for receivables aged over 90 days. These loss rates are based on management&#x2019;s expectations, which are further supported by external benchmarks, due to the Company&#x2019;s limited history of actual write-offs. The resulting provision for expected credit losses is recognized in net income and is included in &#x201c;General and administrative expenses&#x201d;. Receivables that are deemed uncollectible are written off against the allowance when it is determined that they are no longer recoverable.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Cash and Cash Equivalents&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Accounts Receivable, net&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable, prepaid expenses and other current assets and other assets reflects the best estimate of probable losses inherent in the receivables&#x2019; portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of March 31, 2025 and December 31, 2024, the Company&#x2019;s allowance for doubtful accounts was $23,658,962 and $22,799,219, respectively. Below is the summary of changes in the allowance for doubtful accounts:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, 2025 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Balance as of January 1st, 2025 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,799,219&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Provisions for credit losses &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Write-offs &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Foreign exchange adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;878,430&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(18,687 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Balance as of March 31, 2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,658,962&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Tax Receivables&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company pays Value Added Tax (&#x201c;VAT&#x201d;) or similar taxes (&#x201c;input VAT&#x201d;), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (&#x201c;output VAT&#x201d;) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of March 31, 2025 and December 31, 2024, the Company had a VAT net receivable balance of $528,203 and $534,263 respectively, recorded in the condensed consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Inventory &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company writes down inventories to net realizable value based on physical condition, expiration date, and current market conditions, as well as forecasted demand. The Company&#x2019;s inventories are not highly susceptible to obsolescence. Many of the Company&#x2019;s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. No significant judgments have been applied in estimating the selling price of our inventory.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Property and Equipment, net &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Estimated&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Useful Life&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:77%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Leasehold improvements and technical works&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;/td&gt;&lt;td style="width:20%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Lesser of lease term or 25 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;25-30 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Machinery&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;20 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Furniture, fixtures and equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;5&#x2013;10 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Depreciation expense was $97,539 and $112,874 for the three months ended March 31, 2025 and 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment additions&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Property and Equipment additions are recognized as assets when it is probable that future economic benefits associated with the asset will flow to the entity and the cost of the asset can be measured reliably. Additions are initially measured at cost, which includes all costs directly attributable to bringing the asset to its working condition and location for its intended use. This may include purchase price, freight, installation, and any directly attributable professional fees. They are capitalized if their cost exceeds a certain threshold. The threshold is determined based on materiality considerations. Costs below the threshold are typically expensed as incurred. After initial recognition, additions are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is calculated systematically over the estimated useful life of the asset. They are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying amount exceeds the recoverable amount, an impairment loss is recognized, and the carrying amount of the asset is adjusted accordingly. Borrowing costs directly attributable to the acquisition, construction, or production of qualifying assets, including Property and Equipment additions, are capitalized as part of the cost of those assets. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Intangibles, net&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license and a useful life of 10 years for the pharmaceutical and nutraceutical products licenses included in Note 4 as &#x201c;Licenses&#x201d;. A useful life of 10 years is also used for the platforms included in Note 4 as &#x201c;Software&#x201d; and the customer bases. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset&#x2019;s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2025 and December 31, 2024, no revision to the remaining amortization period of the intangible assets was made.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Amortization expense was $208,833 and $189,855 for the three months ended March 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Impairment of Long-Lived Assets&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily determinable. For the three months ended March 31, 2025, and 2024, the Company has recorded no impairment charge.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Equity Method Investment&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in &#x201c;Equity earnings of affiliate&#x201d; in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Investments in Equity Securities&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for sale in current operations are reported as a component of current assets on the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets on the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of March 31, 2025, investments consisted of 16,666 shares which traded at a closing price of $0.95 per share or value of $15,749 of National Bank of Greece. Additionally, the Company has $7,665 in equity securities of Pancreta Bank, which are revalued annually. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Fair Value Measurement&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company applies ASC 820, Fair Value Measurements and Disclosures, (&#x201c;ASC 820&#x201d;), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 1:&#160;Observable inputs such as quoted prices (unadjusted)&#160;in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 2:&#160;Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 3:&#160;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In addition, ASC 825-10-25, Fair Value Option, (&#x201c;ASC 825-10-25&#x201d;), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Our financials also included the following financial instruments as of March 31, 2025 and December 31, 2024: cash, accounts receivable, inventory, prepaid expenses, loans receivable, accounts payable, notes payable and lines of credit. Except for the loans receivable which carry fixed interest rates, the carrying value of the remaining instruments, approximates fair value due to their short-term nature.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Customer Advances&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company&#x2019;s products. The Company records these receipts as current liabilities until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer&#160;advances balance and credit the Company&#x2019;s revenues.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Revenue Recognition&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC Topic 606,&#160;&lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;&#160;(&#x201c;ASC 606&#x201d;), the Company uses a five-step model for recognizing revenue by applying the following steps: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Identification of the Contract: The Company identifies a contract with a customer when it enters into an agreement that creates enforceable rights and obligations.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Identification of Performance Obligations: The Company identifies distinct performance obligations within each contract, which represent promises to transfer goods or services to the customer.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Determination of Transaction Price: The Company determines the transaction price, which represents the amount of consideration to which it expects to be entitled in exchange for transferring promised goods or services to the customer, excluding any amounts collected on behalf of third parties.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Allocation of Transaction Price: The Company allocates the transaction price to each distinct performance obligation based on its standalone selling price. If the standalone selling price is not observable, the Company estimates it using an appropriate method.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Recognition of Revenue: Revenue is recognized when (or as) the Company satisfies a performance obligation by transferring a promised good or service to the customer. This typically occurs at a point in time or over time, depending on the nature of the performance obligation.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Wholesale revenue and sales of own branded nutraceutical and pharmaceutical products&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has contracts or signed partnership forms (usual in the wholesale sector of the pharma industry) with its customers, stipulating the enforceable rights and obligations. The Company is responsible for transferring the goods to the customer&#x2019;s location, which represents its sole performance obligation. Thus, the transaction price, which is predetermined in most of the products sold, is exclusively allocated to this performance obligation. Revenue is recognized at a single point in time, which is upon issuance of the corresponding sales invoice. The Company has assessed the impact of the items invoiced but not delivered to the customer&#x2019;s location as of March 31, 2025 and December 31, 2024 and deemed that it had no material effect. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Pharma manufacturing&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has active contracts with its customers, stipulating the enforceable rights and obligations. The Company is responsible for the manufacturing and the packaging of specific products assigned by its customers, which represents its performance obligations to which the Company allocates the transaction price determined. The customers are responsible for providing the raw materials to the Company. Revenue is recognized over a period of time, which is during the production and packaging period of the respective products. As of March 31, 2025 and 2024&#160;&#160;there were no products or batches of products for which the production or packaging phase was in progress. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Medihelm SA &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Effective January 1, 2023, and pursuant to the distribution agreement with Medihelm SA (&#x201c;Medihelm&#x201d;), the exclusive distributor of the Company&#x2019;s proprietary line of nutraceutical products, the Company determined that the transaction price for sales to Medihelm was variable in nature. In accordance with ASC 606, &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;, and specifically ASC 606-10-32-5, the Company applied the &#x201c;expected value&#x201d; method to estimate the transaction price, subject to the constraint on variable consideration. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;This approach was necessitated by the existence of significant overdue receivables from Medihelm, which raised substantial doubt regarding full collectability of the contractual amounts. The Company reassessed the estimate of the transaction price at each reporting date, considering changes in facts and circumstances.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;There was no impact on revenue recognition for the three-month period ended March 31, 2025 and no further adjustments to variable consideration were necessary.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Stock-based Compensation&lt;/strong&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (&#x201c;ASC 718&#x201d;) and Staff Accounting Bulletin No. 107 (&#x201c;SAB 107&#x201d;) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, &#x201c;Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.&#x201d;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Income Taxes&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 25% in the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At March 31, 2025, we believe our United Kingdom and Greece deferred tax assets will not be realized, as such, we did not record a reversal on the full valuation approach we followed during the year ended December 31, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Leases&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company accounts for leases in accordance with ASC 842. For all leases, the Company recognizes a right-of-use (ROU) asset and a lease liability on the balance sheet. The ROU asset represents the Company's right to use the underlying asset for the lease term, and the lease liability represents the obligation to make lease payments arising from the lease, both measured at the present value of future lease payments. Lease payments are recognized as an operating expense on a straight-line basis over the lease term. The interest on the lease liability and the amortization of the ROU asset are recognized separately in the income statement. Initial direct costs incurred by the Company in negotiating and securing leases are capitalized and amortized over the lease term on a straight-line basis. The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company&#x2019;s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company&#x2019;s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt on the date of inception.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Retirement and Termination Benefits&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee&#x2019;s work experience and remuneration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of March 31, 2025 and December 31, 2024, was $398,838 and $377,264, respectively, and has been recorded as a long-term liability within the consolidated balance sheets (&#x201c;Other liabilities&#x201d;). The Company engaged an actuarial expert for the first time, during the period ended December 31, 2023. Management did not engage an actuarial expert since then, since there were no circumstances indicating that there would be a significant change to the liability recorded and thus the movement compared to 2023, solely relates to the foreign exchange effect.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Basic and Diluted Net Loss per Common Share&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic income per share is calculated by dividing the income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average number of common shares outstanding Basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,037,608&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,851,747&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Potentially dilutive common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average number of common and equivalent shares outstanding &#x2013; Diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;26,037,608&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;16,851,747&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table summarizes potential common shares that were excluded as their effect is anti-dilutive:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,558,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8,558,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Recent Accounting Pronouncements&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;There were no new material accounting standards issued in the first fiscal quarter of 2025.&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <cosm:AcquisitionAccountingPolicy contextRef="From2025-01-01to2025-03-31" id="fid_11565">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cloudscreen&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 805, Business Combinations, (&#x201c;ASC 805&#x201d;) and recorded $637,080 as &#x201c;Other assets&#x201d; related to the technology platform acquired. The total amount was reclassified to &#x201c;Goodwill and intangible assets, net&#x201d; in January 2024 with the closing of the agreement (refer to Note 5).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;ZipDoctor&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 3, 2023, the Company completed the acquisition of ZipDoctor Inc. (&#x201c;ZipDoctor&#x201d;), a&#160;telehealth company for a total sum of $150,000 in cash and $8,788 in fees. The Company accounted for the acquisition as an asset acquisition in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 805, &lt;em&gt;Business Combinations&lt;/em&gt;, (&#x201c;ASC 805&#x201d;) and recorded $158,788 as an intangible asset related to the technology platform acquired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended December 31, 2024, the Company recognized an impairment charge of $131,032 related to the technology platform. This decision followed management&#x2019;s assessment that the asset&#x2019;s recoverability was no longer supportable due to changes in market conditions and a shift in strategic priorities. Specifically, the telehealth platform was no longer in use and did not generate revenues, as the Company elected not to focus on the telehealth business segment. As a result, the unamortized balance of the intangible asset was effectively written off. The impairment charge was recorded within &#x201c;Other income (expense), net&#x201d; in the Consolidated Statement of Operations for the year ended December 31, 2024.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Bikas&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 15, 2023, Cosmos Health Inc. entered into an Assignment and Assumption Agreement (the &#x201c;Agreement&#x201d;) with Ioannis Bikas O.E., a Greek Company (&#x201c;Bikas&#x201d;). Bikas is owner of a pharmaceutical distribution network in Greece and agreed to sell to the Company their distribution network and customer base. The purchase price of the network was &#x20ac;100,000 ($109,330) of cash, and &#x20ac;300,000 ($316,081) of the Company&#x2019;s stock. The Company issued 99,710 shares of common stock related to the acquisition of the customer base, based on the fair value of the stock on the acquisition date. The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded $425,411 as an intangible asset related to the customer base acquired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Buildings Acquisitions&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 24, 2023, the Company purchased a building for a total sum of $1,054,872 in cash.&#160;The Company accounted for the acquisition as an asset acquisition in accordance with ASC 805 and recorded the cost of the building as &#x201c;Property, plant and equipment&#x201d; on the consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 6, 2023, the Company agreed to purchase land and building located in Montreal, Canada from a third-party vendor. The total purchase price amounts to $3,950,000 and the closing date of the agreement based on the amendment signed on July 19, 2023, was December 31, 2023. Pursuant to the last amendment signed on December 31, 2024 the closing date was extended to December 31, 2025. As of March 31, 2025, the Company has made prepayments of $2,000,020 classified as &#x201c;Advances for building&#x2019;s acquisition&#x201d; on the Company&#x2019;s condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cana &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 30, 2023, the Company acquired Cana Laboratories Holding (Cyprus) Limited (&#x201c;Cana&#x201d;), which wholly owned an operating subsidiary, Pharmaceutical Laboratories Cana&#160;S.A. (&#x201c;Cana SA&#x201d;) for &#x20ac;800,000 ($873,600) in cash and 46,377 shares of common stock, with fair value of $138,667 as of the date of acquisition. Moreover, on February 28,&lt;sup style="vertical-align:super"&gt; &lt;/sup&gt;2023, the Company had signed a Secured Promissory Note with Cana, whereby Cana borrowed the sum of &#x20ac;4,100,000 ($4,457,520), included in the total consideration of $5,469,787. The Company accounted for the acquisition as a business acquisition in accordance with ASC 805. The fair value of Cana assets acquired, and liabilities assumed was based upon management&#x2019;s estimates assisted by an independent third-party valuation firm. The fixed assets of Cana (which included land, building &amp;amp; machinery) were valued as of December 31, 2022 and the Company believes that nothing has materially changed between such date and the acquisition date (June 30, 2023). The following table summarizes the preliminary allocation of purchase price of the acquisition:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Consideration &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,331,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Fair value of common stock issued&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;138,667&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Fair value of total consideration transferred&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;5,469,787&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Recognized amounts of identifiable assets acquired&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,796,911&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;297,340&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,488,818&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Identifiable intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;562,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Financial liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,235,233 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total identifiable net assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,910,036&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Bargain purchase gain&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;1,440,249&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the prior year period, Cana had minimal operations as it was in financial difficulties and seeking for an investor. &lt;/p&gt;</cosm:AcquisitionAccountingPolicy>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember"
      decimals="0"
      id="fid_8855"
      unitRef="USD">637080</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember"
      decimals="0"
      id="fid_8856"
      unitRef="Shares">280000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
      contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember"
      decimals="0"
      id="fid_8857"
      unitRef="USD">319200</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember"
      decimals="0"
      id="fid_8858"
      unitRef="USD">317880</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionPriceOfAcquisitionExpected
      contextRef="From2024-01-01to2024-01-23_cosm_CloudscreenMember"
      decimals="0"
      id="fid_8859"
      unitRef="USD">637080</us-gaap:AssetAcquisitionPriceOfAcquisitionExpected>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-04-01to2023-04-03_cosm_ZipDoctorIncMember"
      decimals="0"
      id="fid_8844"
      unitRef="USD">150000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AcquisitionCosts
      contextRef="From2023-04-01to2023-04-03_cosm_ZipDoctorIncMember"
      decimals="0"
      id="fid_8845"
      unitRef="USD">8788</us-gaap:AcquisitionCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="AsOf2023-04-03_cosm_ZipDoctorIncMember"
      decimals="0"
      id="fid_8846"
      unitRef="USD">158788</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2024-01-01to2024-12-31_cosm_ZipDoctorIncMember"
      decimals="0"
      id="fid_8869"
      unitRef="USD">131032</us-gaap:AssetImpairmentCharges>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-06-01to2023-06-15_cosm_GreeceMember"
      decimals="0"
      id="fid_8847"
      unitRef="USD">109330</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="From2023-06-01to2023-06-15_cosm_GreeceMember"
      decimals="0"
      id="fid_8848"
      unitRef="USD">316081</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <cosm:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares
      contextRef="From2023-06-01to2023-06-15_cosm_GreeceMember"
      decimals="0"
      id="fid_8849"
      unitRef="Shares">99710</cosm:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="AsOf2023-06-15_cosm_GreeceMember"
      decimals="0"
      id="fid_8850"
      unitRef="USD">425411</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-04-01to2023-04-24_cosm_BuildingAcquisionMember"
      decimals="0"
      id="fid_8851"
      unitRef="USD">1054872</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-01-01to2023-01-06_cosm_BuildingAcquisionMember"
      decimals="0"
      id="fid_8854"
      unitRef="USD">3950000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2025-03-31_cosm_BuildingAcquisionMember"
      decimals="0"
      id="fid_10904"
      unitRef="USD">2000020</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-06-01to2023-06-30_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8861"
      unitRef="USD">873600</us-gaap:PaymentsToAcquireProductiveAssets>
    <cosm:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares
      contextRef="From2023-06-01to2023-06-30_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8860"
      unitRef="Shares">46377</cosm:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="From2023-06-01to2023-06-30_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8862"
      unitRef="USD">138667</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="From2023-02-01to2023-02-28_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8853"
      unitRef="USD">4457520</us-gaap:ProceedsFromSecuredNotesPayable>
    <us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets
      contextRef="From2023-02-01to2023-02-28_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8852"
      unitRef="USD">5469787</us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_11564">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Consideration &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,331,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Fair value of common stock issued&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;138,667&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Fair value of total consideration transferred&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;5,469,787&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Recognized amounts of identifiable assets acquired&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,796,911&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;297,340&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,488,818&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Identifiable intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;562,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Financial liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,235,233 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total identifiable net assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,910,036&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Bargain purchase gain&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;1,440,249&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2024-01-01to2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8833"
      unitRef="USD">5331120</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="From2024-01-01to2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8839"
      unitRef="USD">138667</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2024-01-01to2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8832"
      unitRef="USD">5469787</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8840"
      unitRef="USD">1796911</us-gaap:Assets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8834"
      unitRef="USD">297340</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8835"
      unitRef="USD">7488818</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
      contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8836"
      unitRef="USD">562200</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities
      contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8837"
      unitRef="USD">-3235233</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8841"
      unitRef="USD">6910036</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="AsOf2024-12-31_cosm_CANAPharmaceuticalLaboratoriesSACanaMember"
      decimals="0"
      id="fid_8838"
      unitRef="USD">1440249</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6006">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5983">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Our consolidated accounts include our accounts and the accounts of our wholly owned subsidiaries, SkyPharm S.A., Decahedron Ltd., Cosmofarm S.A., Cana Laboratories Holdings (Cyprus) Limited and ZipDoctor Inc. The Group&#x2019;s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;). The consolidated financial statements reflect the consolidation of all entities in which the Company has control, as determined by the ability to direct the activities that significantly affect the entities&#x2019; economic performance. All significant intercompany balances and transactions have been eliminated.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5984">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The functional currency for the Greek subsidiaries of the Company (CANA Laboratories, Cosmofarm S.A. and SkyPharm SA) is Euro (&#x20ac;) and for the UK subsidiary (Decahedron Ltd) is GBP (&#xa3;). ZipDoctor Inc. is a U.S. based entity. As a result, the financial statements of the subsidiaries (except for ZipDoctor Inc.) have been translated from the local currency into U.S. dollars using (i) year-end exchange rates for balance sheet accounts, and (ii) average exchange rates for the reporting period for all income statements accounts. Foreign currency translations gains and losses are reported as a separate component of the condensed consolidated statements of changes in stockholders&#x2019; equity.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-03-31" id="fid_5985">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <cosm:EffectsOfWarInTheUkrainePolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5986">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company and, as such, is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition.&lt;/p&gt;</cosm:EffectsOfWarInTheUkrainePolicyTextBlock>
    <cosm:CreditLossesPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5987">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which amends the requirement on the measurement and recognition of expected credit losses for financial assets held. Furthermore, amendments ASU 2019-10 and ASU 2019-11 provided additional clarification for implementing ASU 2016-13. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early adoption permitted. The Company adopted the standard on January 1, 2023, and the standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. The Company is exposed to credit losses primarily through sales to its customers and the loans that it has provided. The Company assesses each customer&#x2019;s/ borrower&#x2019;s ability to pay, and a credit loss estimate by conducting a credit review which includes consideration of established credit rating, or an internal assessment of the customer&#x2019;s creditworthiness based on an analysis of their payment history when a credit rating is not available. The Company monitors credit exposure through active review of customer balances. In accordance with ASC 326 and the Current Expected Credit Loss (CECL) framework, the Company has elected to apply the practical expedient available for its trade receivables, which are short-term in nature and do not contain a significant financing component. The Company applies a loss-rate method for calculating expected credit losses (&#x201c;ECL&#x201d;) on accounts receivable, based on a combination of historical experience, industry data, and adjustments for current conditions and reasonable and supportable forecasts. Receivables are grouped into four aging buckets, with loss rates applied as follows: 1% for receivables aged 0&#x2013;30 days, 2% for receivables aged 31&#x2013;60 days, 3% for receivables aged 61&#x2013;90 days, and 5% for receivables aged over 90 days. These loss rates are based on management&#x2019;s expectations, which are further supported by external benchmarks, due to the Company&#x2019;s limited history of actual write-offs. The resulting provision for expected credit losses is recognized in net income and is included in &#x201c;General and administrative expenses&#x201d;. Receivables that are deemed uncollectible are written off against the allowance when it is determined that they are no longer recoverable.&lt;/p&gt;</cosm:CreditLossesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5988">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling).&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2025-01-01to2025-03-31" id="fid_5989">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable, prepaid expenses and other current assets and other assets reflects the best estimate of probable losses inherent in the receivables&#x2019; portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of March 31, 2025 and December 31, 2024, the Company&#x2019;s allowance for doubtful accounts was $23,658,962 and $22,799,219, respectively. Below is the summary of changes in the allowance for doubtful accounts:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, 2025 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Balance as of January 1st, 2025 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,799,219&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Provisions for credit losses &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Write-offs &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Foreign exchange adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;878,430&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(18,687 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Balance as of March 31, 2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,658,962&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10906"
      unitRef="USD">23658962</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_10907"
      unitRef="USD">22799219</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_9426">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, 2025 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Balance as of January 1st, 2025 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,799,219&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Provisions for credit losses &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Write-offs &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Foreign exchange adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;878,430&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(18,687 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Balance as of March 31, 2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,658,962&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <cosm:ChangesInAllowanceForDoubtfulAccountsBeginningBalance
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_9448"
      unitRef="USD">22799219</cosm:ChangesInAllowanceForDoubtfulAccountsBeginningBalance>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_9449"
      unitRef="USD">0</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_9450"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_9451"
      unitRef="USD">878430</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10929"
      unitRef="USD">-18687</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <cosm:ChangesInAllowanceForDoubtfulAccountsEndingBalance
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_9452"
      unitRef="USD">23658962</cosm:ChangesInAllowanceForDoubtfulAccountsEndingBalance>
    <cosm:TaxReceivablesPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5990">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company pays Value Added Tax (&#x201c;VAT&#x201d;) or similar taxes (&#x201c;input VAT&#x201d;), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (&#x201c;output VAT&#x201d;) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of March 31, 2025 and December 31, 2024, the Company had a VAT net receivable balance of $528,203 and $534,263 respectively, recorded in the condensed consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively.&lt;/p&gt;</cosm:TaxReceivablesPolicyTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10908"
      unitRef="USD">528203</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_10909"
      unitRef="USD">534263</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5991">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company writes down inventories to net realizable value based on physical condition, expiration date, and current market conditions, as well as forecasted demand. The Company&#x2019;s inventories are not highly susceptible to obsolescence. Many of the Company&#x2019;s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. No significant judgments have been applied in estimating the selling price of our inventory.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5992">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Estimated&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Useful Life&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:77%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Leasehold improvements and technical works&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;/td&gt;&lt;td style="width:20%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Lesser of lease term or 25 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;25-30 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Machinery&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;20 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Furniture, fixtures and equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;5&#x2013;10 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Depreciation expense was $97,539 and $112,874 for the three months ended March 31, 2025 and 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment additions&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Property and Equipment additions are recognized as assets when it is probable that future economic benefits associated with the asset will flow to the entity and the cost of the asset can be measured reliably. Additions are initially measured at cost, which includes all costs directly attributable to bringing the asset to its working condition and location for its intended use. This may include purchase price, freight, installation, and any directly attributable professional fees. They are capitalized if their cost exceeds a certain threshold. The threshold is determined based on materiality considerations. Costs below the threshold are typically expensed as incurred. After initial recognition, additions are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is calculated systematically over the estimated useful life of the asset. They are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the carrying amount exceeds the recoverable amount, an impairment loss is recognized, and the carrying amount of the asset is adjusted accordingly. Borrowing costs directly attributable to the acquisition, construction, or production of qualifying assets, including Property and Equipment additions, are capitalized as part of the cost of those assets. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_9427">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Estimated&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Useful Life&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:77%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Leasehold improvements and technical works&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;/td&gt;&lt;td style="width:20%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Lesser of lease term or 25 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;25-30 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Machinery&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;20 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Furniture, fixtures and equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;5&#x2013;10 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock>
    <cosm:PropertyPlantsAndEquipmentEstimatedUsefulLives
      contextRef="From2025-01-01to2025-03-31_cosm_LeaseholdImprovementsAndTechnicalWorksMember"
      id="fid_9458">Lesser of lease term or 25 years</cosm:PropertyPlantsAndEquipmentEstimatedUsefulLives>
    <cosm:PropertyPlantAndEquipmentUsefulLifes
      contextRef="From2025-01-01to2025-03-31_cosm_BuildingsMember_cosm_BottomMember"
      id="fid_9459">P25Y</cosm:PropertyPlantAndEquipmentUsefulLifes>
    <cosm:PropertyPlantsAndEquipmentUsefulLife
      contextRef="From2025-01-01to2025-03-31_cosm_BuildingsMember_cosm_TopMember"
      id="fid_9460">P30Y</cosm:PropertyPlantsAndEquipmentUsefulLife>
    <cosm:PropertyPlantAndEquipmentUsefulLifes
      contextRef="From2025-01-01to2025-03-31_us-gaap_VehiclesMember"
      id="fid_9453">P6Y</cosm:PropertyPlantAndEquipmentUsefulLifes>
    <cosm:PropertyPlantsAndEquipmentUsefulLife
      contextRef="From2025-01-01to2025-03-31_cosm_MachineryMember"
      id="fid_9454">P20Y</cosm:PropertyPlantsAndEquipmentUsefulLife>
    <cosm:PropertyPlantsAndEquipmentUsefulLife
      contextRef="From2025-01-01to2025-03-31_us-gaap_FurnitureAndFixturesMember_cosm_BottomMember"
      id="fid_9455">P5Y</cosm:PropertyPlantsAndEquipmentUsefulLife>
    <cosm:PropertyPlantsAndEquipmentUsefulLife
      contextRef="From2025-01-01to2025-03-31_us-gaap_FurnitureAndFixturesMember_cosm_TopMember"
      id="fid_9456">P10Y</cosm:PropertyPlantsAndEquipmentUsefulLife>
    <cosm:PropertyPlantsAndEquipmentUsefulLife
      contextRef="From2025-01-01to2025-03-31_us-gaap_ComputerEquipmentMember_cosm_BottomMember"
      id="fid_9457">P3Y</cosm:PropertyPlantsAndEquipmentUsefulLife>
    <cosm:PropertyPlantAndEquipmentUsefulLifes
      contextRef="From2025-01-01to2025-03-31_cosm_TopMember_us-gaap_ComputerEquipmentMember"
      id="fid_10931">P5Y</cosm:PropertyPlantAndEquipmentUsefulLifes>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10913"
      unitRef="USD">97539</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_10914"
      unitRef="USD">112874</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5993">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license and a useful life of 10 years for the pharmaceutical and nutraceutical products licenses included in Note 4 as &#x201c;Licenses&#x201d;. A useful life of 10 years is also used for the platforms included in Note 4 as &#x201c;Software&#x201d; and the customer bases. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset&#x2019;s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2025 and December 31, 2024, no revision to the remaining amortization period of the intangible assets was made.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Amortization expense was $208,833 and $189,855 for the three months ended March 31, 2025 and 2024, respectively.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10916"
      unitRef="USD">208833</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_10917"
      unitRef="USD">189855</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5994">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily determinable. For the three months ended March 31, 2025, and 2024, the Company has recorded no impairment charge.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2025-01-01to2025-03-31" id="fid_5995">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in &#x201c;Equity earnings of affiliate&#x201d; in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value.&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5996">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for sale in current operations are reported as a component of current assets on the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets on the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of March 31, 2025, investments consisted of 16,666 shares which traded at a closing price of $0.95 per share or value of $15,749 of National Bank of Greece. Additionally, the Company has $7,665 in equity securities of Pancreta Bank, which are revalued annually. &lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:OtherInvestmentsAndSecuritiesAtCost
      contextRef="AsOf2025-03-31_cosm_PancretaBankMember"
      decimals="0"
      id="fid_10918"
      unitRef="USD">16666</us-gaap:OtherInvestmentsAndSecuritiesAtCost>
    <us-gaap:SharePrice
      contextRef="AsOf2025-03-31_cosm_PancretaBankMember"
      decimals="INF"
      id="fid_10919"
      unitRef="USDPShares">0.95</us-gaap:SharePrice>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues
      contextRef="From2025-01-01to2025-03-31_cosm_PancretaBankMember"
      decimals="0"
      id="fid_10923"
      unitRef="USD">15749</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues>
    <us-gaap:EquitySecuritiesFvNiRealizedLoss
      contextRef="From2025-01-01to2025-03-31_cosm_PancretaBankMember"
      decimals="0"
      id="fid_10924"
      unitRef="USD">7665</us-gaap:EquitySecuritiesFvNiRealizedLoss>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5997">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company applies ASC 820, Fair Value Measurements and Disclosures, (&#x201c;ASC 820&#x201d;), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 1:&#160;Observable inputs such as quoted prices (unadjusted)&#160;in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 2:&#160;Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 3:&#160;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In addition, ASC 825-10-25, Fair Value Option, (&#x201c;ASC 825-10-25&#x201d;), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Our financials also included the following financial instruments as of March 31, 2025 and December 31, 2024: cash, accounts receivable, inventory, prepaid expenses, loans receivable, accounts payable, notes payable and lines of credit. Except for the loans receivable which carry fixed interest rates, the carrying value of the remaining instruments, approximates fair value due to their short-term nature.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <cosm:CustomerAdvancesPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5998">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company&#x2019;s products. The Company records these receipts as current liabilities until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer&#160;advances balance and credit the Company&#x2019;s revenues.&lt;/p&gt;</cosm:CustomerAdvancesPolicyTextBlock>
    <us-gaap:RevenueRecognitionDeferredRevenue contextRef="From2025-01-01to2025-03-31" id="fid_7889">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC Topic 606,&#160;&lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;&#160;(&#x201c;ASC 606&#x201d;), the Company uses a five-step model for recognizing revenue by applying the following steps: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Identification of the Contract: The Company identifies a contract with a customer when it enters into an agreement that creates enforceable rights and obligations.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Identification of Performance Obligations: The Company identifies distinct performance obligations within each contract, which represent promises to transfer goods or services to the customer.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Determination of Transaction Price: The Company determines the transaction price, which represents the amount of consideration to which it expects to be entitled in exchange for transferring promised goods or services to the customer, excluding any amounts collected on behalf of third parties.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Allocation of Transaction Price: The Company allocates the transaction price to each distinct performance obligation based on its standalone selling price. If the standalone selling price is not observable, the Company estimates it using an appropriate method.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Recognition of Revenue: Revenue is recognized when (or as) the Company satisfies a performance obligation by transferring a promised good or service to the customer. This typically occurs at a point in time or over time, depending on the nature of the performance obligation.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Wholesale revenue and sales of own branded nutraceutical and pharmaceutical products&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has contracts or signed partnership forms (usual in the wholesale sector of the pharma industry) with its customers, stipulating the enforceable rights and obligations. The Company is responsible for transferring the goods to the customer&#x2019;s location, which represents its sole performance obligation. Thus, the transaction price, which is predetermined in most of the products sold, is exclusively allocated to this performance obligation. Revenue is recognized at a single point in time, which is upon issuance of the corresponding sales invoice. The Company has assessed the impact of the items invoiced but not delivered to the customer&#x2019;s location as of March 31, 2025 and December 31, 2024 and deemed that it had no material effect. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Pharma manufacturing&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has active contracts with its customers, stipulating the enforceable rights and obligations. The Company is responsible for the manufacturing and the packaging of specific products assigned by its customers, which represents its performance obligations to which the Company allocates the transaction price determined. The customers are responsible for providing the raw materials to the Company. Revenue is recognized over a period of time, which is during the production and packaging period of the respective products. As of March 31, 2025 and 2024&#160;&#160;there were no products or batches of products for which the production or packaging phase was in progress. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Medihelm SA &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Effective January 1, 2023, and pursuant to the distribution agreement with Medihelm SA (&#x201c;Medihelm&#x201d;), the exclusive distributor of the Company&#x2019;s proprietary line of nutraceutical products, the Company determined that the transaction price for sales to Medihelm was variable in nature. In accordance with ASC 606, &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;, and specifically ASC 606-10-32-5, the Company applied the &#x201c;expected value&#x201d; method to estimate the transaction price, subject to the constraint on variable consideration. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;This approach was necessitated by the existence of significant overdue receivables from Medihelm, which raised substantial doubt regarding full collectability of the contractual amounts. The Company reassessed the estimate of the transaction price at each reporting date, considering changes in facts and circumstances.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;There was no impact on revenue recognition for the three-month period ended March 31, 2025 and no further adjustments to variable consideration were necessary.&lt;/p&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5999">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (&#x201c;ASC 718&#x201d;) and Staff Accounting Bulletin No. 107 (&#x201c;SAB 107&#x201d;) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, &#x201c;Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.&#x201d;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6000">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 25% in the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At March 31, 2025, we believe our United Kingdom and Greece deferred tax assets will not be realized, as such, we did not record a reversal on the full valuation approach we followed during the year ended December 31, 2024.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-01to2025-03-31_cosm_GreeceMember"
      decimals="INF"
      id="fid_11192"
      unitRef="Pure">0.22</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-01to2025-03-31_cosm_UnitedKingdomMember"
      decimals="INF"
      id="fid_10926"
      unitRef="Pure">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6001">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company accounts for leases in accordance with ASC 842. For all leases, the Company recognizes a right-of-use (ROU) asset and a lease liability on the balance sheet. The ROU asset represents the Company's right to use the underlying asset for the lease term, and the lease liability represents the obligation to make lease payments arising from the lease, both measured at the present value of future lease payments. Lease payments are recognized as an operating expense on a straight-line basis over the lease term. The interest on the lease liability and the amortization of the ROU asset are recognized separately in the income statement. Initial direct costs incurred by the Company in negotiating and securing leases are capitalized and amortized over the lease term on a straight-line basis. The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company&#x2019;s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company&#x2019;s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt on the date of inception.&#160;&lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:PostemploymentBenefitPlansPolicy contextRef="From2025-01-01to2025-03-31" id="fid_6002">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee&#x2019;s work experience and remuneration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of March 31, 2025 and December 31, 2024, was $398,838 and $377,264, respectively, and has been recorded as a long-term liability within the consolidated balance sheets (&#x201c;Other liabilities&#x201d;). The Company engaged an actuarial expert for the first time, during the period ended December 31, 2023. Management did not engage an actuarial expert since then, since there were no circumstances indicating that there would be a significant change to the liability recorded and thus the movement compared to 2023, solely relates to the foreign exchange effect.&lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10927"
      unitRef="USD">398838</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_10928"
      unitRef="USD">377264</us-gaap:OtherLiabilities>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6003">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic income per share is calculated by dividing the income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average number of common shares outstanding Basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,037,608&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,851,747&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Potentially dilutive common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average number of common and equivalent shares outstanding &#x2013; Diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;26,037,608&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;16,851,747&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table summarizes potential common shares that were excluded as their effect is anti-dilutive:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,558,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8,558,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_9430">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average number of common shares outstanding Basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,037,608&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,851,747&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Potentially dilutive common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average number of common and equivalent shares outstanding &#x2013; Diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;26,037,608&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;16,851,747&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10933"
      unitRef="Shares">26037608</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_10932"
      unitRef="Shares">16851747</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10937"
      unitRef="Shares">26037608</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_10939"
      unitRef="Shares">16851747</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_9429">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,558,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8,558,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_9488"
      unitRef="Shares">12926506</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_9487"
      unitRef="Shares">8558380</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <cosm:PotentialCommonShares
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_9492"
      unitRef="Shares">12926506</cosm:PotentialCommonShares>
    <cosm:PotentialCommonShares
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_9491"
      unitRef="Shares">8558380</cosm:PotentialCommonShares>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6004">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;There were no new material accounting standards issued in the first fiscal quarter of 2025.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5965">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 3 &#x2013; EQUITY METHOD INVESTMENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;CosmoFarmacy LP&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a&#160;30-year term through May 31, 2049. The unaffiliated third party is the general partner (the &#x201c;GP&#x201d;) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR&#160;150,000&#160;($163,080) which was later increased to EUR&#160;500,000&#160;($543,600). The GP contributed the pharmacy license (the &#x201c;License&#x201d;) valued at EUR&#160;350,000&#160;(30-year term) to operate the business of CosmoFarmacy in exchange for a&#160;70% equity ownership. The Company is a limited partner and contributed cash of EUR&#160;150,000&#160;($163,080) for the remaining&#160;30% equity ownership. CosmoFarmacy is not publicly traded, and the Company&#x2019;s investment has been recorded using the equity method of accounting. &#160;During the 12-month period ended December 31, 2024, the Company determined that its investment in CosmoFarmacy LP was fully impaired. As the entity is currently dormant and has not published or provided any financial statements, whether audited or unaudited, to substantiate the carrying value of the investment, management concluded that there was no reasonable expectation of recovery. Accordingly, the Company recognized a full impairment loss on the investment, writing off its entire carrying amount. As a result, the Company has determined that the investment no longer holds any recoverable value. The value of the investment as of March 31, 2025 and December 31, 2024, was $0.&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <cosm:MaturityPeriodOfLicense
      contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember"
      id="fid_10952">P30Y</cosm:MaturityPeriodOfLicense>
    <cosm:InitialShareCapital
      contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember"
      decimals="0"
      id="fid_10949"
      unitRef="EUR">150000</cosm:InitialShareCapital>
    <cosm:InitialShareCapitalIncreased
      contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember"
      decimals="0"
      id="fid_10950"
      unitRef="EUR">500000</cosm:InitialShareCapitalIncreased>
    <cosm:PharmacyLicenseValue
      contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember"
      decimals="0"
      id="fid_10951"
      unitRef="EUR">350000</cosm:PharmacyLicenseValue>
    <cosm:EquityMethodInvestmentsOwnershipPercentage
      contextRef="AsOf2024-09-30_cosm_CosmoFarmacyLPMember"
      decimals="INF"
      id="fid_10953"
      unitRef="Pure">0.70</cosm:EquityMethodInvestmentsOwnershipPercentage>
    <cosm:CashContributedToLimitedPartner
      contextRef="From2025-01-01to2025-03-31_cosm_CosmoFarmacyLPMember"
      decimals="0"
      id="fid_10954"
      unitRef="EUR">150000</cosm:CashContributedToLimitedPartner>
    <cosm:EquityMethodInvestmentOwnershipRemainingPercentage
      contextRef="AsOf2024-09-30_cosm_CosmoFarmacyLPMember"
      decimals="INF"
      id="fid_10955"
      unitRef="Pure">0.30</cosm:EquityMethodInvestmentOwnershipRemainingPercentage>
    <us-gaap:Investments
      contextRef="AsOf2025-03-31_cosm_ShareExchangeAgreementMember_cosm_IccMember"
      decimals="0"
      id="fid_10962"
      unitRef="USD">0</us-gaap:Investments>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5966">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 4 &#x2013; PROPERTY AND EQUIPMENT, NET &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Property and equipment, net consists of the following at March 31, 2025 and December 31, 2024:&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,465,629&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,322,780&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Buildings and improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,713,642&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,526,432&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,552&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,405&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,896&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;265,261&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Furniture, fixtures and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,973,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,846,657&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;11,434,100&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;10,964,535&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,418,032 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,275,030 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,016,068&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,689,505&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6009">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,465,629&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,322,780&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Buildings and improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,713,642&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,526,432&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,552&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,405&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,896&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;265,261&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Furniture, fixtures and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,973,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,846,657&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;11,434,100&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;10,964,535&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,418,032 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,275,030 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,016,068&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,689,505&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_us-gaap_LandMember"
      decimals="0"
      id="fid_8902"
      unitRef="USD">3465629</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LandMember"
      decimals="0"
      id="fid_8903"
      unitRef="USD">3322780</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="fid_8904"
      unitRef="USD">4713642</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="fid_8905"
      unitRef="USD">4526432</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="fid_8888"
      unitRef="USD">3552</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="fid_8889"
      unitRef="USD">3405</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_us-gaap_VehiclesMember"
      decimals="0"
      id="fid_8890"
      unitRef="USD">277896</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_VehiclesMember"
      decimals="0"
      id="fid_8891"
      unitRef="USD">265261</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="fid_8892"
      unitRef="USD">2973291</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="fid_8893"
      unitRef="USD">2846657</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8901"
      unitRef="USD">11434100</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_8900"
      unitRef="USD">10964535</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8896"
      unitRef="USD">1418032</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_8897"
      unitRef="USD">1275030</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8898"
      unitRef="USD">10016068</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_8899"
      unitRef="USD">9689505</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5967">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE&#160;5 &#x2013; INTANGIBLE ASSETS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Goodwill and intangible, net assets consist of the following at March 31, 2025 and December 31, 2024: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;License&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,585,857&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,257,938&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Trade name / mark&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;392,197&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;390,188&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Customer base&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;626,397&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;626,397&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,053,554&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,113,840&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,658,005&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,388,363&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: Accumulated amortization &amp;amp; impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;License&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,311,124 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,117,341 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Trade name / mark&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(36,997 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(36,997 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Customer base&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(189,526 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(174,279 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(367,526 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(352,909 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,752,832&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,706,837&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;49,697&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;49,697&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,802,529&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,756,534&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;At March 31, 2025, the estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal years is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Year&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;881,066&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;877,344&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;879,895&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;878,532&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;871,974&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,008,821&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,397,632&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6010">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;License&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,585,857&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,257,938&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Trade name / mark&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;392,197&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;390,188&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Customer base&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;626,397&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;626,397&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,053,554&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,113,840&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,658,005&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,388,363&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: Accumulated amortization &amp;amp; impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;License&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,311,124 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,117,341 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Trade name / mark&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(36,997 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(36,997 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Customer base&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(189,526 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(174,279 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(367,526 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(352,909 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,752,832&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,706,837&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;49,697&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;49,697&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,802,529&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,756,534&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-03-31_us-gaap_LicenseMember"
      decimals="0"
      id="fid_8908"
      unitRef="USD">7585857</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="fid_8909"
      unitRef="USD">7257938</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-03-31_cosm_TradeNameMarkMember"
      decimals="0"
      id="fid_8910"
      unitRef="USD">392197</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_cosm_TradeNameMarkMember"
      decimals="0"
      id="fid_8911"
      unitRef="USD">390188</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-03-31_us-gaap_CustomerListsMember"
      decimals="0"
      id="fid_8912"
      unitRef="USD">626397</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_CustomerListsMember"
      decimals="0"
      id="fid_8913"
      unitRef="USD">626397</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-03-31_cosm_SoftwareMember"
      decimals="0"
      id="fid_8926"
      unitRef="USD">1053554</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_cosm_SoftwareMember"
      decimals="0"
      id="fid_8927"
      unitRef="USD">1113840</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8930"
      unitRef="USD">9658005</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:OtherFiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_8931"
      unitRef="USD">9388363</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-03-31_us-gaap_LicenseMember"
      decimals="0"
      id="fid_8920"
      unitRef="USD">-1311124</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="fid_8921"
      unitRef="USD">-1117341</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-03-31_cosm_TradeNameMarkMember"
      decimals="0"
      id="fid_8922"
      unitRef="USD">-36997</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_cosm_TradeNameMarkMember"
      decimals="0"
      id="fid_8923"
      unitRef="USD">-36997</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-03-31_us-gaap_CustomerListsMember"
      decimals="0"
      id="fid_8924"
      unitRef="USD">-189526</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_CustomerListsMember"
      decimals="0"
      id="fid_8925"
      unitRef="USD">-174279</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-03-31_cosm_SoftwareMember"
      decimals="0"
      id="fid_8928"
      unitRef="USD">-367526</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_cosm_SoftwareMember"
      decimals="0"
      id="fid_8929"
      unitRef="USD">-352909</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8914"
      unitRef="USD">7752832</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_8915"
      unitRef="USD">7706837</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8916"
      unitRef="USD">49697</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_8917"
      unitRef="USD">49697</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8918"
      unitRef="USD">7802529</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_8919"
      unitRef="USD">7756534</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6011">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Year&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;881,066&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;877,344&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;879,895&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;878,532&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;871,974&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,008,821&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,397,632&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8932"
      unitRef="USD">881066</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8933"
      unitRef="USD">877344</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8934"
      unitRef="USD">879895</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8935"
      unitRef="USD">878532</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8936"
      unitRef="USD">871974</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8937"
      unitRef="USD">3008821</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_8938"
      unitRef="USD">7397632</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5968">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 6 &#x2013; LOAN RECEIVABLE&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On October 30, 2021, the Company entered into an agreement for a ten-year loan with Medihelm SA to memorialize &#x20ac;4,284,521 ($4,849,221) in prepayments the Company had made. The prepayments to Medihelm SA had been made in accordance with the parallel export business, through which Medihelm supplied and would supply SkyPharm SA with branded pharmaceuticals. This business is no longer in place for the Company and thus the Company entered into this agreement with Medihelm SA in order for the outstanding amount to be settled. Interest is calculated at a rate of 5.5% per annum on a 360-day basis. Under the terms of the agreement, the Company is to receive 120 equal payments over the term of the loan. During the three-month period ended March 31, 2025, the Company accrued interest income of &#x20ac;43,179 ($45,472) in connection with the note receivable governed by this agreement. No principal or interest payments were received during the period. The Note is considered fully recoverable as of March 31, 2025.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:PaymentsOfLoanCosts
      contextRef="From2021-10-01to2021-10-30"
      decimals="0"
      id="fid_9539"
      unitRef="USD">4849221</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:ShortTermDebtInterestRateIncrease
      contextRef="From2021-10-01to2021-10-30"
      decimals="INF"
      id="fid_9540"
      unitRef="Pure">0.055</us-gaap:ShortTermDebtInterestRateIncrease>
    <cosm:ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable contextRef="From2021-10-01to2021-10-30" id="fid_9544">P360Y</cosm:ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable>
    <cosm:DecriptionOfLoanPayment contextRef="From2021-10-01to2021-10-30" id="fid_9545">the Company is to receive 120 equal payments over the term of the loan</cosm:DecriptionOfLoanPayment>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10964"
      unitRef="USD">45472</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5969">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 7 &#x2013; INCOME TAXES &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company had no U.S. taxable income for the three months ended March 31, 2025, and 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s Greek subsidiaries are governed by the income tax laws of Greece. The corporate tax rate in Greece is 22% on income reported in the statutory financial statements after appropriate tax adjustments. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s United Kingdom subsidiaries are governed by the income tax laws of the United Kingdom. The corporate tax rate in the United Kingdom is 25% on income reported in the statutory financial statements after appropriate tax adjustments.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of March 31, 2025, and 2024, the Company&#x2019;s effective tax rate differs from the U.S. federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in in the United States and the United Kingdom. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. As of March 31, 2025, and December 31, 2024, the Company has maintained a valuation allowance against all net deferred tax assets in the United States, Greece, and the UK.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For the three months ended March 31, 2025, and 2024, the Company has not recorded any tax benefits/expenses in any jurisdiction where it is subject to income tax.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <cosm:CorporateTaxRate
      contextRef="From2025-01-01to2025-03-31_cosm_GreeceMember"
      decimals="INF"
      id="fid_10965"
      unitRef="Pure">0.22</cosm:CorporateTaxRate>
    <cosm:CorporateTaxRate
      contextRef="From2025-01-01to2025-03-31_cosm_UnitedKingdomMember"
      decimals="INF"
      id="fid_10966"
      unitRef="Pure">0.25</cosm:CorporateTaxRate>
    <cosm:CapitalStructureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5970">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE&#160;8 &#x2013; CAPITAL STRUCTURE&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Preferred Stock&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is authorized to issue 100 million shares of preferred stock, of which 6,000,000 are designated as Series A convertible preferred stock. The preferred stock has a&#160;liquidation preference over the common stock and&#160;is non-voting. As of March 31, 2025 and December 31, 2024, no preferred shares were issued and outstanding.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Treasury stock&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of March 31, 2025 and December 31, 2024, the Company held 86,497 and 86,497, respectively, shares of our common stock at a cost of $917,159 and $917,159, respectively. Shares of our common stock that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. The Company repurchased no shares of our common stock during the three months ended March 31, 2025. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 24, 2023 the Company announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $3 million of its common stock. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Common Stock&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is authorized to issue 300 million shares of common stock. As of March 31, 2025 and December 31, 2024, the Company had 27,284,633 and 23,689,135 shares of our common stock issued, respectively, and 27,198,136 and 23,602,638 shares outstanding, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Issuance of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Between January 13, 2025, and March 4, 2025, the Company issued an aggregate of 1,053,372 shares of common stock to Mr. Grigorios Siokas, the Company&#x2019;s Chief Executive Officer, in settlement of outstanding obligations totalling $649,000. The liabilities settled pertained to unpaid salaries and performance-related bonuses previously accrued by the Company and owed to Mr. Siokas. The shares were issued at the respective fair market value of the Company&#x2019;s common stock on the dates of issuance. The transaction was accounted for as a non-cash settlement of related party debt.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On September 26, 2024, the Company had entered into a Warrant Inducement Letter (the &#x201c;Letter&#x201d;) with an investor pursuant to which the Company issued 9,748,252 new warrants (the &#x201c;New Warrants&#x201d;) and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977 (the &#x201c;Original Warrants&#x201d;). Of the 9,748,252 warrants 4,874,126 of them have a term of 5 years (&#x201c;Series A Warrants&#x201d;) and the remaining 4,874,126 have a term of 1.5 years (&#x201c;Series B Warrants&#x201d;). The Company issued 2,332,000 shares of common stock, held 2,542,126 shares in escrow until the investor&#x2019;s beneficial ownership limitation allows for the transfer of the escrow shares. The 2,542,126 shares were issued on January 28, 2025, but were already valued in the year ended December 31, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Warrant Classification&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company determines the classification of its warrants upon issuance by identifying the instrument issued to determine if it is debt or equity classified. The Company determined its warrants meet the scope exception in ASC 815-10 and are equity classified because, (a) the warrant is indexed to the Company&#x2019;s own stock, (b) require settlement in equity shares, and (c) the Company has enough authorized and unissued shares.&#160;&lt;/p&gt;</cosm:CapitalStructureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="-6"
      id="fid_10968"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <cosm:PreferredStockLiquidationPreference1
      contextRef="AsOf2025-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="fid_11021"
      unitRef="Shares">6000000</cosm:PreferredStockLiquidationPreference1>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31_cosm_TreasuryStocksOneMember"
      decimals="0"
      id="fid_10989"
      unitRef="Shares">86497</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31_cosm_TreasuryStocksOneMember"
      decimals="0"
      id="fid_10990"
      unitRef="Shares">86497</us-gaap:CommonStockSharesIssued>
    <cosm:CommonStockSharesValue
      contextRef="AsOf2025-03-31_cosm_TreasuryStocksOneMember"
      decimals="0"
      id="fid_11003"
      unitRef="USD">917159</cosm:CommonStockSharesValue>
    <cosm:CommonStockSharesValue
      contextRef="AsOf2024-12-31_cosm_TreasuryStocksOneMember"
      decimals="0"
      id="fid_11004"
      unitRef="USD">917159</cosm:CommonStockSharesValue>
    <cosm:AuthorizationToRepurchaseCommonStock
      contextRef="From2023-01-01to2023-01-24_cosm_TreasuryStocksOneMember"
      decimals="-6"
      id="fid_10999"
      unitRef="USD">3000000</cosm:AuthorizationToRepurchaseCommonStock>
    <cosm:CommonStockShareAuthorized
      contextRef="AsOf2025-03-31"
      decimals="-6"
      id="fid_10985"
      unitRef="Shares">300000000</cosm:CommonStockShareAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10987"
      unitRef="Shares">27284633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_10988"
      unitRef="Shares">23689135</us-gaap:CommonStockSharesIssued>
    <cosm:CommonStocksSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_11014"
      unitRef="Shares">27198136</cosm:CommonStocksSharesOutstanding>
    <cosm:CommonStocksSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_11015"
      unitRef="Shares">23602638</cosm:CommonStocksSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-04_cosm_WarrantExchangeMember"
      decimals="0"
      id="fid_11194"
      unitRef="Shares">1053372</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-09-01to2024-09-26_cosm_WarrantInducementLetterMember"
      decimals="0"
      id="fid_11026"
      unitRef="USD">649000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2024-09-26_cosm_WarrantInducementLetterMember"
      decimals="0"
      id="fid_11006"
      unitRef="Shares">9748252</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2024-09-26_cosm_WarrantExchangeMember"
      decimals="0"
      id="fid_11009"
      unitRef="Shares">4874126</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-26_cosm_WarrantExchangeMember_cosm_TopMember"
      decimals="INF"
      id="fid_11012"
      unitRef="USDPShares">1.45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-26_cosm_WarrantExchangeMember_cosm_BottomMember"
      decimals="INF"
      id="fid_11013"
      unitRef="USDPShares">0.8701</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-09-01to2024-09-26_cosm_WarrantExchangeMember"
      decimals="0"
      id="fid_11028"
      unitRef="USD">4240977</us-gaap:ProceedsFromWarrantExercises>
    <cosm:OriginalWarrantsSharesIssued
      contextRef="From2024-09-01to2024-09-26"
      decimals="0"
      id="fid_11031"
      unitRef="Shares">9748252</cosm:OriginalWarrantsSharesIssued>
    <cosm:OriginalWarrantsSharesIssued
      contextRef="From2024-09-01to2024-09-26_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="fid_11195"
      unitRef="Shares">4874126</cosm:OriginalWarrantsSharesIssued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-09-01to2024-09-26_cosm_WarrantExchangeMember"
      id="fid_11036">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <cosm:RemainingWarrantsSharesIssued
      contextRef="From2024-09-01to2024-09-26"
      decimals="0"
      id="fid_11196"
      unitRef="Shares">4874126</cosm:RemainingWarrantsSharesIssued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-09-01to2024-09-26" id="fid_11037">P1Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <cosm:CommonStocksSharesIssued
      contextRef="AsOf2024-09-26"
      decimals="0"
      id="fid_10983"
      unitRef="Shares">2332000</cosm:CommonStocksSharesIssued>
    <cosm:SharesHeldInEscrow
      contextRef="From2024-09-01to2024-09-26_cosm_WarrantExchangeMember"
      decimals="0"
      id="fid_11033"
      unitRef="Shares">2542126</cosm:SharesHeldInEscrow>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-01-28_cosm_WarrantInducementLetterMember"
      decimals="0"
      id="fid_11040"
      unitRef="Shares">2542126</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5971">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 9 &#x2013; RELATED PARTY TRANSACTIONS &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Doc Pharma S.A.&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Doc Pharma S.A. is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the son of Grigorios Siokas, the Company&#x2019;s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Prepaid expenses and other current assets &#x2013; related party&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of March 31, 2025 and December 31, 2024, the Company had a prepaid balance of $3,549,574 and $3,284,052, respectively, to Doc Pharma. For the year ended March 31, 2025 the prepayment of approximately $2.9 million relates to purchases of inventory pursuant to the CMO agreement signed between the Company and Doc Pharma SA on October 10, 2020, $310k concern the purchase of pharmaceutical and nutraceutical licenses according to the May 17, 2021 R&amp;amp;D agreement and the remaining $378k relate to the current portion of the Royalty Agreement signed on December 31, 2024 between the and DocPharma SA (refer to &#x201c;Research and Development&#x201d; section of the MD&amp;amp;A). The non-current portion of the Royalty Agreement of $1,889,300 is included in &#x201c;Other Assets &#x2013; Related Party&#x201d; in the Company&#x2019;s Consolidated Balance Sheets as of March 31, 2025.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Accounts payable and accrued expenses - related party&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of March 31, 2025 and December 31, 2024, the Company had an accounts payable balance to Doc Pharma of $345,702&#160;and $249,768, respectively. The March 31, 2025 balance mostly concerns a checks payable balance that our subsidiary, Skypharm SA, owes to Doc Pharma SA.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Accounts receivable - related party&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Additionally, the Company had a receivable balance of $2,469,234&#160;and $2,295,706&#160;from Doc Pharma S.A. as of March 31, 2025 and December 31, 2024, respectively, which concerns trading receivables balances with the Company&#x2019;s Greek and UK subsidiaries. As of March 31, 2025, a cumulative allowance for doubtful accounts of approximately $1.4 million has been recognized, effectively offsetting this balance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Sales and Purchases&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the three months ended March 31, 2025 and 2024, the Company purchased a total of $300,208 and $189,048&#160;of products from Doc Pharma S.A., respectively. During the three months ended March 31, 2025, and 2024, the Company sold&#160; $130,362 and $384,321&#160;of products to Doc Pharma, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Other Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On October 10, 2020, the Company entered into a contract manufacturer outsourcing (&#x201c;CMO&#x201d;) agreement with Doc Pharma whereby Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company&#x2019;s specifications based on strict pharmaceutical standards and good manufacturing practice (&#x201c;GMP&#x201d;) protocols as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named &#x201c;Sky Premium Life&lt;sup style="vertical-align:super"&gt;&#xae;&lt;/sup&gt;&#x201d;. The duration of the agreement is for five years, however, either party may terminate the agreement at any time giving six-month advance notice. Doc Pharma is exclusively responsible for supplying the raw materials and packaging required to manufacture the final product. However, it is not responsible for potential delays that may arise, concerning their import. Doc Pharma is also obligated to store the raw and packaging materials. The delivery of raw and packaging materials should be purchased at least 30 and 25 days, respectively, before the delivery date of the final product. The Manufacturer solely delivers the finished product to the Company. There is a minimum order quantity (&#x201c;MoQ&#x201d;) of&#160;1,000 pieces&#160;per product code. Both parties have agreed that the Company will deposit 60% of the total cost upon agreement and assignment and 40% of the total cost including VAT charge upon the delivery date. The prices are indicative and are subject to amendments if the cost of the raw material or the production cost change.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For the three months ended March 31, 2025 and 2024, the Company has purchased &#x20ac;208,568 ($219,645) and &#x20ac;65,161 ($68,621) respectively, in inventory related to this agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 17, 2021, Doc Pharma and the Company entered into a Research and Development (&#x201c;R&amp;amp;D&#x201d;) agreement whereby Doc Pharma will be responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life&lt;sup style="vertical-align:super"&gt;&#xae;&lt;/sup&gt;. These products will be sold in Greece and abroad.&#160;The total cost of this project will be &#x20ac;1,425,000 plus VAT and will be done over three phases as follows: Design &amp;amp; Development (&#x20ac;725,000); Control and Product Manufacturing (&#x20ac;250,000) and Clinical Study and Research (&#x20ac;450,000). SkyPharm has bought a total of as of 81 licenses at value of &#x20ac;554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022. During the year ended December 31, 2023, 24 additional licenses were purchased at value of &#x20ac;475,014 ($525,461) and during the year ended December 31, 2024, 60 additional Sky Premium Life licenses were purchased for &#x20ac;710,000 ($734,921). During the three months ended March 31, 2025, no additional licenses were purchased. The agreement will terminate on&#160;December 31, 2025.&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Purchase of branded pharmaceuticals&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 28, 2023, the Company approved the purchase of five proprietary and innovative branded pharmaceuticals with significant market presence and material profit contribution from Zakalia Ltd., the parent company of Doc Pharma, for &#x20ac;1,800,000 ($1,965,600). The transaction was settled on a non-cash basis through the reduction, of an equivalent amount, of prepaid expense balances the Company held with Doc Pharma. The purchased branded pharmaceuticals are presented in &#x201c;Goodwill and intangible assets, net&#x201d; on the accompanying consolidated balance sheets. During the year ended December 31, 2024, the Company recognized an impairment charge of $160,947 related to two licenses that are no longer expected to be commercialized. The impairment was recorded after management&#x2019;s assessment determined that the recoverability of these assets was no longer supportable due to changes in market conditions and strategic priorities. No additional impairment charge was recorded within the three-month period ended March 31, 2025.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 29, 2023, the Company approved the purchase of additional 19 generic licenses from Doc Pharma, of a total value of &#x20ac;3,200,000 ($3,539,840). This transaction was also settled on a non-cash basis through the reduction, of an equivalent amount, of prepaid expense balances the Company held with Doc Pharma.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Loans receivable - related party&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The balance of prepaid expenses due Doc Pharma as of December 31, 2022, had increased to &#x20ac;7,103,706 ($7,599,545), which was mainly attributable to the prepayments SkyPharm S.A. made in accordance with the CMO agreement and the extensive orders and sales of the SPL products the Company expected to achieve within 2023, mainly through its Amazon channels in the UK, Singapore, Canada and other countries. However, as the benefit from a significant portion of the prepaid balance would not have been realized within a 12-month period, the Company opted to secure a portion of the outstanding prepaid balance through a loan agreement. SkyPharm S.A. (the &#x201c;Lender&#x201d;) entered into a loan agreement with Doc Pharma (the &#x201c;Borrower&#x201d;) for &#x20ac;4,000,000 ($4,279,200), all of which was financed through the outstanding prepaid balance. The duration of the loan is for a&#160;10-year period up to&#160;December 31, 2032&#160;(the &#x201c;Maturity Date&#x201d;). The loan bears a fixed interest rate of&#160;5.5% payable on a monthly basis and will be repayable in 120 equal instalments of &#x20ac;33,333.33 ($37,150). The loan may be prepaid anytime during its duration in full or partially based on the Company&#x2019;s product requirements and other factors, without Doc Pharma incurring any prepayment penalty. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of March 31, 2025 and December 31, 2024, the loan had a current portion of &#x20ac;712,200 ($768,891) and &#x20ac;500,000 ($517,550), and a non-current portion of &#x20ac;2,663,379 ($2,875,384), and &#x20ac;2,800,000 ($2,898,280), respectively, which is classified as &#x201c;Loans receivable &#x2013; related party&#x201d; on the accompanying consolidated balance sheets. During the three-month period ended March 31, 2025, the Company received no principal repayments or interest repayments. Additionally, during the three months ended ended March 31, 2025 and 2024, the Company recorded &#x20ac;43,179 ($45,472) and &#x20ac;49,041 ($53,235) as interest income relating to this loan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Cana Laboratories Holding Limited&#160;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cana was considered a related party as the Company had signed a binding letter of intent and an SPA for the acquisition of Cana. The acquisition was completed on June 30, 2023 according to the SPA signed on May 31, 2023. Thus, all balances between the Company and Cana were eliminated upon consolidation as of December 31, 2023. The Secured Promissory Note discussed below was included in consideration transferred upon acquisition.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Loans receivable - Related Party - Long Term&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On February 28,&lt;sup style="vertical-align:super"&gt;&#160;&lt;/sup&gt;2023 (Issue Date), the Company signed a Secured Promissory Note with Cana Laboratories Holdings (Cyprus) Limited (the &#x201c;Holder&#x201d;), whereby the Holder borrowed the sum of &#x20ac;4,100,000 ($4,457,520) from the Company.&#160;Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023). The maturity date (&#x201c;Maturity Date&#x201d;) of this Note shall be five (5) years from the Issue Date. The Principal Amount, as well as all accrued interest shall be due and payable on the Maturity Date. Following the completion of Cana&#x2019;s acquisition on June 30, 2023 the balance of the Note was eliminated on a consolidated level.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Panagiotis Kozaris&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Panagiotis Kozaris is considered a related party due to the fact that he is a former General operational manager and current employee of Cosmofarm S.A.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Prepaid Expenses and Other Current Assets - Related Party&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;From time-to-time the Company purchases back shares that Panagiotis Kozaris owns and records them as treasury shares. The Company pays Panagiotis Kozaris in advance for the shares owned and obtains the shares upon execution of a cumulative stock-purchase agreement (&#x201c;SPA&#x201d;). During the years ended December 31, 2023 and 2022, the Company paid Panagiotis Kozaris an additional sum of $51,159&#160;and $143,056&#160;respectively for shares owned, however, no SPA for these funds has been executed as of December 31, 2024. The Company intends to execute a cumulative SPA for these amounts within 2025. The total balances owed of $194,215&#160;and $194,215 are included in &#x201c;Prepaid expenses and other current assets - related party&#x201d;, on the accompanying consolidated balance sheets as of March 31, 2025 and December 31, 2024, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Basotho Investment Limited&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basotho Investment Limited is considered a related party once Panagiotis Kozaris (former general operational manager and current employee of Cosmofarm SA) is one of its directors.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;General and administrative expenses&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 21, 2023, the Company issued 120,000 shares of common stock to Basotho Investment Limited for services rendered. The amortization of the fair value of these shares for the three-month period ended March 31, 2025 and 2024 was $0 and $30,900, which was recorded as general and administrative expense. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Maria Kozari&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Maria Kozari is considered a related party to the Company due to the fact that she is the daughter of Panagiotis Kozaris, a former Operational General Manager and current employee of Cosmofarm S.A.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Accounts Receivable - Related Party&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During 2021, the Company, through its subsidiary, Cosmofarm SA, commenced a partnership with a pharmacy called &#x201c;Pharmacy &amp;amp; More&#x201d;, owned by Maria Kozari. The transactions with the respective pharmacy were in Cosmofarm&#x2019;s normal course of business, however, a more flexible credit policy was allowed as the pharmacy was new and needed to be established in the market. During the three-month peirod ended March 31, 2025 and 2024 the Company&#x2019;s net sales to Pharmacy &amp;amp; More amounted to $100,870&#160;and $86,678, respectively. As of March 31, 2025 and December 31, 2024 the Company&#x2019;s outstanding receivable balance due from the pharmacy amounted to $1,188,908 and $1,183,429, respectively, and are included in &#x201c;Accounts receivable - related party&#x201d;, on the accompanying consolidated balance sheets. As of March 31, 2025 and December 31, 2024, a cumulative allowance for doubtful accounts of approximately $773,051 and $735,000, respectively, has been recognized, effectively offsetting this balance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company plans to acquire Pharmacy &amp;amp; More within fiscal year 2025. Upon acquisition, the Company intends to offset the outstanding receivable balance with the corresponding purchase price and additionally plans to make Pharmacy &amp;amp; More the&#160;first shop-in-shop of its own branded line of nutraceutical products, Sky Premium Life&#xae; (SPL).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Other Related Parties&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Additionally, the Company has the following material related-party balances as of March 31, 2025: a) a balance of $76,865 relating to unpaid salaries and bonuses due to Grigorios Siokas, the CEO of the Company, classified as &#x201c;Accounts payable and accrued expenses - related party&#x201d;&#160;in the Company&#x2019;s consolidated balance sheets, b) a balance of $168,000&#160;relating to unpaid salaries and bonuses due to George Terzis, the CFO of the Company, classified as &#x201c;Accounts payable and accrued expenses - related party&#x201d;&#160;in the Company&#x2019;s consolidated balance sheets c) a balance of $15,000&#160;relating to unpaid salaries and bonuses due to Nikolaos Bardakis, the COO of the Company, classified as &#x201c;Accounts payable and accrued expenses - related party&#x201d;&#160;in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Notes Payable &#x2013; Related Party&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A summary of the Company&#x2019;s related party notes payable as of March 31, 2025 and December 31, 2024 is presented below:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Beginning Balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,558&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,283&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Payments &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;454&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(725&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Ending Balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;11,012&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,558&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Dimitrios Goulielmos&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Dimitris Goulielmos was the Company&#x2019;s former CEO and a Director of the Company. &#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of March 31, 2025 and December 31, 2024, the Company had a principal balance of &#x20ac;10,200 ($11,012) and &#x20ac;10,200 ($10,558), respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2025, the Company recorded a foreign currency translation loss of $454.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Loans Payable &#x2013; Related Party&lt;/span&gt;&lt;/em&gt;&lt;span style="text-decoration:underline"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A summary of the Company&#x2019;s related party loans payable as of March 31, 2025 and December 31, 2024 is presented below:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,194&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,257&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payments &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(108,500&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(6,210 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Set-offs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;102,039&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;267&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(853 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,194&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Grigorios Siokas&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of March 31, 2025 and December 31, 2024 the Company had an outstanding principal balance under these loans of $0 and $6,194, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2025, the Company recorded a loss of $267.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10458"
      unitRef="USD">3549574</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10457"
      unitRef="USD">3284052</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <cosm:PrepaymentOfInventory
      contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember"
      decimals="-5"
      id="fid_11045"
      unitRef="USD">2900000</cosm:PrepaymentOfInventory>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember"
      decimals="-3"
      id="fid_11046"
      unitRef="USD">378000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11047"
      unitRef="USD">1889300</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <cosm:AccountsPayableRelatedPartyCurrent
      contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10450"
      unitRef="USD">345702</cosm:AccountsPayableRelatedPartyCurrent>
    <cosm:AccountsPayableRelatedPartyCurrent
      contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10449"
      unitRef="USD">249768</cosm:AccountsPayableRelatedPartyCurrent>
    <cosm:AmountAccountsReceivableRelatedParties
      contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10454"
      unitRef="USD">2469234</cosm:AmountAccountsReceivableRelatedParties>
    <cosm:AmountAccountsReceivableRelatedParties
      contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10453"
      unitRef="USD">2295706</cosm:AmountAccountsReceivableRelatedParties>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember"
      decimals="-5"
      id="fid_11048"
      unitRef="USD">1400000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <cosm:PurchaseOfInventory
      contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11049"
      unitRef="USD">300208</cosm:PurchaseOfInventory>
    <cosm:PurchaseOfInventory
      contextRef="From2024-01-01to2024-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11051"
      unitRef="USD">189048</cosm:PurchaseOfInventory>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11052"
      unitRef="USD">130362</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11053"
      unitRef="USD">384321</us-gaap:Revenues>
    <cosm:PiecesPerProduct
      contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember"
      id="fid_11054">1,000 pieces</cosm:PiecesPerProduct>
    <cosm:PurchaseOfInventory
      contextRef="From2025-01-01to2025-03-31_cosm_InventoriesRelatedAgreementMember_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11055"
      unitRef="USD">219645</cosm:PurchaseOfInventory>
    <cosm:PurchaseOfInventory
      contextRef="From2024-01-01to2024-03-31_cosm_InventoriesRelatedAgreementMember_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11056"
      unitRef="USD">68621</cosm:PurchaseOfInventory>
    <us-gaap:ManagementFeeDescription
      contextRef="From2021-05-01to2021-05-17_cosm_DocPharmaSaMember"
      id="fid_10476">The total cost of this project will be &#x20ac;1,425,000 plus VAT and will be done over three phases as follows: Design &amp; Development (&#x20ac;725,000); Control and Product Manufacturing (&#x20ac;250,000) and Clinical Study and Research (&#x20ac;450,000). SkyPharm has bought a total of as of 81 licenses at value of &#x20ac;554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022</us-gaap:ManagementFeeDescription>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases
      contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10463"
      unitRef="USD">525461</us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases
      contextRef="From2023-01-01to2023-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10483"
      unitRef="USD">734921</us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases>
    <cosm:AgreementTerminate
      contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember"
      id="fid_10461">2025-12-31</cosm:AgreementTerminate>
    <cosm:PurchaseOfPharmaceuticalsMedicine
      contextRef="From2023-06-01to2023-06-28_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10474"
      unitRef="USD">1965600</cosm:PurchaseOfPharmaceuticalsMedicine>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10485"
      unitRef="USD">160947</us-gaap:AssetImpairmentCharges>
    <cosm:PurchaseOfPharmaceuticalsMedicine
      contextRef="From2023-12-01to2023-12-29_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10475"
      unitRef="USD">3539840</cosm:PurchaseOfPharmaceuticalsMedicine>
    <us-gaap:OtherExpenses
      contextRef="From2022-01-01to2022-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10486"
      unitRef="USD">7599545</us-gaap:OtherExpenses>
    <us-gaap:PrepaidInterest
      contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10452"
      unitRef="USD">4279200</us-gaap:PrepaidInterest>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember"
      id="fid_10447">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember"
      id="fid_10448">2032-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember"
      decimals="INF"
      id="fid_10446"
      unitRef="Pure">0.055</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <cosm:PaymentReceivedFromInstallment
      contextRef="From2024-01-01to2024-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_10477"
      unitRef="USD">37150</cosm:PaymentReceivedFromInstallment>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11058"
      unitRef="USD">768891</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11059"
      unitRef="USD">517550</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="AsOf2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11060"
      unitRef="USD">2875384</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="AsOf2024-12-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11061"
      unitRef="USD">2898280</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-01-01to2025-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11063"
      unitRef="USD">45472</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-01to2024-03-31_cosm_DocPharmaSaMember"
      decimals="0"
      id="fid_11064"
      unitRef="USD">53235</us-gaap:InterestIncomeOther>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="From2023-02-01to2023-02-28_cosm_CanaHoldingsLaboratoriesHoldingLimitedMember"
      decimals="0"
      id="fid_10428"
      unitRef="USD">4457520</us-gaap:ProceedsFromSecuredNotesPayable>
    <cosm:DescriptionInterestOfSecuredPromissoryNote
      contextRef="From2023-02-01to2023-02-28_cosm_CanaHoldingsLaboratoriesHoldingLimitedMember"
      id="fid_10429">Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023)</cosm:DescriptionInterestOfSecuredPromissoryNote>
    <cosm:SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement
      contextRef="From2023-01-01to2023-12-31_cosm_PanagiotisKozarisMember"
      decimals="0"
      id="fid_10488"
      unitRef="USD">51159</cosm:SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement>
    <cosm:SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement
      contextRef="From2022-01-01to2022-12-31_cosm_PanagiotisKozarisMember"
      decimals="0"
      id="fid_10489"
      unitRef="USD">143056</cosm:SharesOwnedAdditionalPaymentUnderStockPurchaseAgreement>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-12-31_cosm_PanagiotisKozarisMember"
      decimals="0"
      id="fid_10442"
      unitRef="USD">194215</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2025-03-31_cosm_PanagiotisKozarisMember"
      decimals="0"
      id="fid_10443"
      unitRef="USD">194215</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31_cosm_BasothoInvestmentLimitedMember"
      decimals="0"
      id="fid_10445"
      unitRef="Shares">120000</us-gaap:CommonStockSharesIssued>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31_cosm_BasothoInvestmentLimitedMember"
      decimals="0"
      id="fid_11065"
      unitRef="USD">0</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-03-31_cosm_BasothoInvestmentLimitedMember"
      decimals="0"
      id="fid_11066"
      unitRef="USD">30900</us-gaap:OtherGeneralAndAdministrativeExpense>
    <cosm:NetSales
      contextRef="From2025-01-01to2025-03-31_cosm_MariaKozariMember"
      decimals="0"
      id="fid_11067"
      unitRef="USD">100870</cosm:NetSales>
    <cosm:NetSales
      contextRef="From2024-01-01to2024-03-31_cosm_MariaKozariMember"
      decimals="0"
      id="fid_11068"
      unitRef="USD">86678</cosm:NetSales>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-03-31_cosm_MariaKozariMember"
      decimals="0"
      id="fid_10456"
      unitRef="USD">1188908</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31_cosm_MariaKozariMember"
      decimals="0"
      id="fid_10455"
      unitRef="USD">1183429</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="From2025-01-01to2025-03-31_cosm_MariaKozariMember"
      decimals="0"
      id="fid_11069"
      unitRef="USD">773051</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="From2024-01-01to2024-12-31_cosm_MariaKozariMember"
      decimals="0"
      id="fid_10491"
      unitRef="USD">735000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent
      contextRef="AsOf2025-03-31_cosm_GeorgeTerzisMember"
      decimals="0"
      id="fid_10431"
      unitRef="USD">76865</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <cosm:UnpaidSalariesAndBonusesDues
      contextRef="AsOf2025-03-31_cosm_GeorgeTerzisMember"
      decimals="0"
      id="fid_11070"
      unitRef="USD">168000</cosm:UnpaidSalariesAndBonusesDues>
    <cosm:AccountsPayableRelatedPartyCurrent
      contextRef="AsOf2025-03-31_cosm_KanarogloySiaEpeMember"
      decimals="0"
      id="fid_11071"
      unitRef="USD">15000</cosm:AccountsPayableRelatedPartyCurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6012">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Beginning Balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,558&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,283&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Payments &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;454&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(725&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Ending Balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;11,012&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,558&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <cosm:NotesPayableRelatedParty
      contextRef="AsOf2024-12-31_cosm_NotesPayableRelatedPartyMember"
      decimals="0"
      id="fid_10411"
      unitRef="USD">10558</cosm:NotesPayableRelatedParty>
    <cosm:NotesPayableRelatedParty
      contextRef="AsOf2023-12-31_cosm_NotesPayableRelatedPartyMember"
      decimals="0"
      id="fid_10410"
      unitRef="USD">11283</cosm:NotesPayableRelatedParty>
    <us-gaap:PaymentsForLoans
      contextRef="From2025-01-01to2025-03-31_cosm_NotesPayableRelatedPartyMember"
      decimals="0"
      id="fid_10413"
      unitRef="USD">0</us-gaap:PaymentsForLoans>
    <us-gaap:PaymentsForLoans
      contextRef="From2024-01-01to2024-12-31_cosm_NotesPayableRelatedPartyMember"
      decimals="0"
      id="fid_10412"
      unitRef="USD">0</us-gaap:PaymentsForLoans>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-01-01to2025-03-31_cosm_NotesPayableRelatedPartyMember"
      decimals="0"
      id="fid_10415"
      unitRef="USD">454</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-01to2024-12-31_cosm_NotesPayableRelatedPartyMember"
      decimals="0"
      id="fid_10414"
      unitRef="USD">-725</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <cosm:NotesPayableRelatedParty
      contextRef="AsOf2025-03-31_cosm_NotesPayableRelatedPartyMember"
      decimals="0"
      id="fid_10416"
      unitRef="USD">11012</cosm:NotesPayableRelatedParty>
    <cosm:NotesPayableRelatedParty
      contextRef="AsOf2024-12-31_cosm_NotesPayableRelatedPartyMember"
      decimals="0"
      id="fid_10417"
      unitRef="USD">10558</cosm:NotesPayableRelatedParty>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-03-31_cosm_DimitriosGoulielmosMember"
      decimals="0"
      id="fid_10437"
      unitRef="USD">11012</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_cosm_DimitriosGoulielmosMember"
      decimals="0"
      id="fid_10436"
      unitRef="USD">10558</us-gaap:NotesPayable>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax
      contextRef="From2025-01-01to2025-03-31_cosm_DimitriosGoulielmosMember"
      decimals="0"
      id="fid_11072"
      unitRef="USD">454</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <cosm:ScheduleOfRelatedPartyLoansPayableTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6013">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,194&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,257&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payments &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(108,500&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(6,210 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Set-offs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;102,039&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;267&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(853 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,194&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cosm:ScheduleOfRelatedPartyLoansPayableTableTextBlock>
    <cosm:LoansPayableRelatedParty
      contextRef="AsOf2024-12-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_10419"
      unitRef="USD">6194</cosm:LoansPayableRelatedParty>
    <cosm:LoansPayableRelatedParty
      contextRef="AsOf2023-12-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_10418"
      unitRef="USD">13257</cosm:LoansPayableRelatedParty>
    <us-gaap:ProceedsFromLoans
      contextRef="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_10420"
      unitRef="USD">0</us-gaap:ProceedsFromLoans>
    <us-gaap:PaymentsForLoans
      contextRef="From2025-01-01to2025-03-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_10423"
      unitRef="USD">108500</us-gaap:PaymentsForLoans>
    <us-gaap:PaymentsForLoans
      contextRef="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_10422"
      unitRef="USD">6210</us-gaap:PaymentsForLoans>
    <cosm:LoanPayableSetOffs
      contextRef="From2025-01-01to2025-03-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_11042"
      unitRef="USD">102039</cosm:LoanPayableSetOffs>
    <cosm:LoanPayableSetOffs
      contextRef="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_11043"
      unitRef="USD">0</cosm:LoanPayableSetOffs>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-01-01to2025-03-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_10425"
      unitRef="USD">267</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-01-01to2024-12-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_10424"
      unitRef="USD">-853</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <cosm:LoansPayableRelatedParty
      contextRef="AsOf2025-03-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_10426"
      unitRef="USD">0</cosm:LoansPayableRelatedParty>
    <cosm:LoansPayableRelatedParty
      contextRef="AsOf2024-12-31_cosm_LoansPayableRelatedPartyMember"
      decimals="0"
      id="fid_10427"
      unitRef="USD">6194</cosm:LoansPayableRelatedParty>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-03-31_cosm_GrigoriosSiokasMember"
      decimals="0"
      id="fid_10439"
      unitRef="USD">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_cosm_GrigoriosSiokasMember"
      decimals="0"
      id="fid_10438"
      unitRef="USD">6194</us-gaap:NotesPayable>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax
      contextRef="From2025-01-01to2025-03-31_cosm_GrigoriosSiokasMember"
      decimals="0"
      id="fid_11073"
      unitRef="USD">267</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <cosm:LineOfCreditFacilitiesDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5972">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 10 &#x2013; LINES OF CREDIT&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A summary of the Company&#x2019;s lines of credit as of March 31, 2025 and December 31, 2024 is presented below:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;National&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;3,816,515&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;4,012,642&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Alpha&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;769,867&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;960,867&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Pancreta&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,437,670&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,583,291&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Attica Bank&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;849,483&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;EFG&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;431,840&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;428,252&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;7,305,376&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;6,985,052&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has three lines of credit with the National Bank of Greece, which are renewed annually. The three lines have interest rates of 6.00% (the "National Bank LOC"), 3.6% (the "COSME 2 Facility"), and 3.6% plus the six-month Euribor rate and any contributions currently in force by law on certain lines of credit (the "COSME 1 Facility").&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The maximum borrowing allowed for the 6% line of credit was $5,398,000 and $5,175,000 as of March 31, 2025 and December 31, 2024, respectively. The outstanding balance of the facility was $2,975,052 and $3,165,058, as of March 31, 2025 and December 31, 2024, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The cumulative maximum borrowing allowed for the COSME 1 Facility and COSME 2 Facility (collectively, the "Facilities") was $1,079,600 and $1,035,100 as of March 31, 2025 and December 31, 2024, respectively. The outstanding balance of the Facilities was $895,406 and $895,987 as of March 31, 2025 and December 31, 2024, respectively.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company maintains a line of credit with Alpha Bank of Greece ("Alpha LOC"), which is renewed annually and has a current interest rate of 6.00%. The maximum borrowing allowed was $1,079,600 and $1,035,100 as of March 31, 2025 and December 31, 2024, respectively. The outstanding balance of the Alpha LOC was $769,868 and $960,868, as of March 31, 2025 and December 31, 2024, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company holds a line of credit with Pancreta Bank ("Pancreta LOC"), which is renewed annually and has a current interest rate of 4.10%. The maximum borrowing allowed as of March 31, 2025 and December 31, 2024 was $1,619,400 and $1,552,650, respectively. The outstanding balance of the Pancreta LOC as of March 31, 2025 and December 31, 2024, was $1,437,670 and $1,583,291, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company maintains a line of credit with EGF ("EGF LOC"), which is renewed annually and has a current interest rate of 4.49% plus 3-month Euribor. The maximum borrowing allowed as of March 31, 2025 and December 31, 2024, was $431,840 and $414,040, respectively. The outstanding balance of the EGF LOC as of March 31, 2025 and December 31, 2024 was $431,840 and $428,251, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 27, 2025, the Company entered into a bond loan agreement with Attica Bank, providing for maximum borrowings of up to &#x20ac;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#x20ac;700,000 ($749,600), which were classified as Notes Payable in the Company&#x2019;s consolidated financial statements. The remaining borrowing capacity of &#x20ac;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral. These subsequent drawdowns are classified as Lines of Credit due to their secured and contingent nature. The facility bears interest at a floating rate of 2.95% plus the applicable 6-month Euribor, recalculated periodically in accordance with market conditions. The loan agreement includes standard covenants and collateral arrangements customary for this type of facility.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Under the aforementioned line of credit agreements, the Company is required to maintain certain financial ratios and covenants. As of March 31, 2025, and December 31, 2024, the Company was in compliance with these ratios and covenants. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;All lines of credit are guaranteed by customer receivable checks, which are a type of factoring in which postponed customer checks are assigned by the Company to the bank, in order to be financed at an agreed upon rate. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Interest expense on the Company&#x2019;s outstanding lines of credit balances for the three months ended March 31, 2025 and 2024, was $61,035 and $44,568, respectively.&lt;/p&gt;</cosm:LineOfCreditFacilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6014">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;National&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;3,816,515&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;4,012,642&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Alpha&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;769,867&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;960,867&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Pancreta&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,437,670&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,583,291&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Attica Bank&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;849,483&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;EFG&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;431,840&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;428,252&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;7,305,376&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;6,985,052&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-03-31_cosm_NationalMember"
      decimals="0"
      id="fid_9929"
      unitRef="USD">3816515</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2024-12-31_cosm_NationalMember"
      decimals="0"
      id="fid_9964"
      unitRef="USD">4012642</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-03-31_cosm_AlphaMember"
      decimals="0"
      id="fid_9931"
      unitRef="USD">769867</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2024-12-31_cosm_AlphaMember"
      decimals="0"
      id="fid_9965"
      unitRef="USD">960867</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-03-31_cosm_PancretaMember"
      decimals="0"
      id="fid_9933"
      unitRef="USD">1437670</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2024-12-31_cosm_PancretaMember"
      decimals="0"
      id="fid_9966"
      unitRef="USD">1583291</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-03-31_cosm_AtticaBankMember"
      decimals="0"
      id="fid_11078"
      unitRef="USD">849483</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2024-12-31_cosm_AtticaBankMember"
      decimals="0"
      id="fid_11079"
      unitRef="USD">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-03-31_cosm_EFGMember"
      decimals="0"
      id="fid_11076"
      unitRef="USD">431840</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2024-12-31_cosm_EFGMember"
      decimals="0"
      id="fid_11077"
      unitRef="USD">428252</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_9963"
      unitRef="USD">7305376</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_9962"
      unitRef="USD">6985052</us-gaap:LineOfCredit>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2025-03-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9937"
      unitRef="USD">5398000</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2024-12-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9968"
      unitRef="USD">5175000</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2025-03-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9947"
      unitRef="USD">2975052</cosm:OutstandingDebtBalance>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2024-12-31_cosm_NationalBankOfGreeceOneMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9969"
      unitRef="USD">3165058</cosm:OutstandingDebtBalance>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2025-03-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9939"
      unitRef="USD">1079600</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2024-12-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9970"
      unitRef="USD">1035100</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2025-03-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9949"
      unitRef="USD">895406</cosm:OutstandingDebtBalance>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2024-12-31_cosm_NationalBankOfGreeceTwoMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9971"
      unitRef="USD">895987</cosm:OutstandingDebtBalance>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2025-03-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9941"
      unitRef="USD">1079600</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2024-12-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9972"
      unitRef="USD">1035100</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2025-03-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9951"
      unitRef="USD">769868</cosm:OutstandingDebtBalance>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2024-12-31_cosm_AlphaBankOfGreeceMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9973"
      unitRef="USD">960868</cosm:OutstandingDebtBalance>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2025-03-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9943"
      unitRef="USD">1619400</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2024-12-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9974"
      unitRef="USD">1552650</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2025-03-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9953"
      unitRef="USD">1437670</cosm:OutstandingDebtBalance>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2024-12-31_cosm_PancretaOfGreeceMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9975"
      unitRef="USD">1583291</cosm:OutstandingDebtBalance>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2025-03-31_cosm_EFGMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9945"
      unitRef="USD">431840</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements
      contextRef="AsOf2024-12-31_cosm_EFGMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9979"
      unitRef="USD">414040</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2025-03-31_cosm_EFGMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9977"
      unitRef="USD">431840</cosm:OutstandingDebtBalance>
    <cosm:OutstandingDebtBalance
      contextRef="AsOf2024-12-31_cosm_EFGMember_us-gaap_LineOfCreditMember"
      decimals="0"
      id="fid_9976"
      unitRef="USD">428251</cosm:OutstandingDebtBalance>
    <cosm:LineOfCreditBorrowingsLoanDescription contextRef="From2025-01-01to2025-01-27" id="fid_11082">providing for maximum borrowings of up to &#x20ac;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#x20ac;700,000 ($749,600), which were classified as Notes Payable in the Company&#x2019;s consolidated financial statements. The remaining borrowing capacity of &#x20ac;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral</cosm:LineOfCreditBorrowingsLoanDescription>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_9981"
      unitRef="USD">61035</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_9980"
      unitRef="USD">44568</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5973">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 11 &#x2013; NOTES PAYABLE&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A summary of the Company&#x2019;s third-party debt as of and for the nine&#160;months ended March 31, 2025, and the year ended December 31, 2024 is presented below:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;March 31, 2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Trade &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Facility &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Third &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Party&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;COVID &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Loans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Beginning balance, December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,397,385&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,557,023&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;154,505&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,108,913&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;755,720&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;755,720&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(183,455 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(5,060 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(188,515 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;60,075&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;110,051&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;6,019&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;176,145&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance, March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,457,460&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,239,339&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;155,464&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,852,263&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable - long-term&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,968,180 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(120,360 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,088,540 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable - short-term&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,457,460&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,271,159&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;35,104&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,763,723&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;December 31, 2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Trade &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Facility &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Third &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Party&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;COVID &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Loans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Beginning balance, December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,908,195&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,511,148&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;186,884&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,606,227&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;828,080&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;828,080&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(388,163 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(634,653 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(22,806 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,045,622 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(122,647 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(147,552 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(9,573 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(279,772 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance, December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,397,385&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,557,023&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;154,505&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,108,913&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable &#x2013; long-term&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,437,798 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(122,635 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,560,433 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable - short-term&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,397,385&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,119,225&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;31,870&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,548,480&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="5" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Our outstanding debt as of March 31, 2025&#160;is repayable as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,763,723&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;819,335&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;666,070&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;378,706&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;224,429&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Total debt&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;4,852,263&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: notes payable - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,763,723 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable - long term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,088,540&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Trade Facility Agreements&lt;/span&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the &#x201c;TFF&#x201d;) with Synthesis Structured Commodity Trade Finance Limited (the &#x201c;Lender&#x201d;) as amended on November 16, 2017, and May 16, 2018. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;No principal repayments were made during the three-month period ended March 31, 2025. As of March 31, 2025, the Company had an outstanding principal balance of &#x20ac;1,350,000 ($1,457,460), which is fully classified as &#x201c;Notes Payable&#x201d; in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;June 23, 2020 Debt Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 23, 2020, the Company&#x2019;s subsidiary, Cosmofarm, entered into an agreement with the National Bank of Greece S.A. (the &#x201c;Bank&#x201d;) to borrow a maximum of &#x20ac;500,000 ($611,500).&#160; The outstanding balance was &#x20ac;58,824 ($63,506) and &#x20ac;88,235 ($91,232) as of March 31, 2025 and December 31, 2024, respectively, of which $63,506 and $91,232 was classified as&#160;&#x201c;Notes payable &#x2013; long-term portion&#x201d;&#160;respectively,&#160;on the&#160;accompanying consolidated balance sheets. During the three-month period ended March 31, 2025, the Company repaid &#x20ac;29,412 ($31,753) of the principal balance.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;November 19, 2020 Debt Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of &#x20ac;500,000 ($611,500). During the three-month period ended March 31, 2025 the Company repaid &#x20ac;27,778 ($29,999) of the principal and as of March 31, 2025 the Company has accrued interest of &#x20ac;4,372 ($4,720) related to this note and a principal balance of &#x20ac;83,333 ($89,967), all of which is classified as &#x201c;Notes payable&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;July 30, 2021 Debt Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of &#x20ac;500,000 ($578,850). During the three-month period ended March 31, 2025, the Company repaid &#x20ac;28,434 ($30,697) of the principal. As of March 31, 2025 the Company had accrued interest of &#x20ac;16,677 ($18,004), principal of &#x20ac;177,909 ($192,071), of which $66,896 is classified as &#x201c;Notes payable &#x2013; long term portion&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;June 9, 2022 Debt Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 9, 2022 the Company entered into an agreement with a third-party lender in the principal amount of &#x20ac;320,000 ($335,008), the &#x201c;Note&#x201d;. During the three-month period ended March 31, 2025 the Company repaid &#x20ac;20,000 ($21,592) of the principal. As of March 31, 2025 and December 31, 2024 the Company has accrued interest of &#x20ac;4,337 ($4,682) and &#x20ac;8,352 ($8,645), respectively, and an outstanding balance of &#x20ac;160,000 ($172,736) and &#x20ac;180,000 ($186,318), respectively, of which $86,368 and $103,510, are classified as &#x201c;Notes payable &#x2013; long term portion&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;July 14, 2023 Debt Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On July 14, 2023, the Company entered into an agreement with a third-party lender in the principal amount of &#x20ac;1,000,000 ($1,123,700), the &#x201c;Note&#x201d;. During the three-month period ended March 31, 2025 the Company repaid &#x20ac;54,317 ($58,640) of the principal. As of March 31, 2025 and December 31, 2024 the Company has accrued interest of &#x20ac;3,403 ($3,674) and &#x20ac;16,735 ($17,322), respectively, and an outstanding balance of &#x20ac;760,433 ($820,964) and &#x20ac;814,750 ($843,348), of which $586,571 and $618,616, respectively, are classified as &#x201c;Notes payable &#x2013; long term portion&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Cloudscreen Promissory Note&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The total purchase price amounted to $637,080 and consisted of 280,000 shares of common stock with a fair value of $319,200 and an amount of $317,880 to be settled in cash during 2024 based on the Promissory Note signed on October 10, 2023. During the three-month period ended March 31, 2025 the Company repaid $10,782 of the principal. As of March 31, 2025, and December 31, 2024, the Company had an outstanding balance of $280,696 and $279,348 all of which is classified as &#x201c;Notes payable&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;July 29, 2024 Debt Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On July 29, 2024 the Company entered into an agreement with a third-party lender in the principal amount of &#x20ac;400,000 ($432,760), the &#x201c;Note&#x201d;. During the 3-month period ended March 31, 2025, the Company repaid no principal. As of March 31, 2025, and December 31, 2024 the Company has accrued interest of &#x20ac;1,358 ($1,466) and &#x20ac;1,527 ($1,581), respectively, and an outstanding balance of &#x20ac;400,000 ($431,840) and &#x20ac;400,000 ($414,040), of which $335,876 and $345,033 is classified as &#x201c;Notes payable - long term portion&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;December 20, 2024 Debt Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 20, 2024 the Company entered into an agreement with a third-party lender in the principal amount of &#x20ac;400,000 ($414,040), the &#x201c;Note&#x201d;. During the 3-month period ended March 31, 2025, the Company repaid no principal. As of March 31, 2025, and December 31, 2024 the Company has accrued interest of &#x20ac;6,509 ($7,027) and &#x20ac;794 ($821), respectively, and an outstanding balance of &#x20ac;400,000 ($431,840) and &#x20ac;400,000 ($414,040), of which $287,893 and $276,027 is classified as &#x201c;Notes payable - long term portion&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;January 27, 2025 Debt Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 27, 2025, the Company entered into a bond loan agreement with Attica Bank, providing for maximum borrowings of up to &#x20ac;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#x20ac;700,000 ($749,600), which were classified as Notes Payable in the Company&#x2019;s consolidated financial statements. The remaining borrowing capacity of &#x20ac;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral. These subsequent drawdowns are classified as Lines of Credit due to their secured and contingent nature. The facility bears interest at a floating rate of 2.95% plus the applicable 6-month Euribor (2.331% as of March 31, 2025). The Note Payable portion of the facility is to be repaid in 10 equal semiannual installments of &#x20ac;70,000 commencing on July 27, 2026. During the 3-month period ended March 31, 2025, the Company repaid no principal. As of March 31, 2025, and December 31, 2024 the Company has accrued interest of &#x20ac;3,488 ($3,766) and &#x20ac;0 ($0), respectively, and an outstanding balance of &#x20ac;700,000 ($755,720) and &#x20ac;0 ($0), of which $604,576 and $0 is classified as &#x201c;Notes payable - long term portion&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;COVID-19 Loans&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 12, 2020, the Company&#x2019;s wholly owned subsidiary, SkyPharm SA, was granted a loan from the Greek government in the amount of &#x20ac;300,000 (approximately $366,900). During the three-month period ended March 31, 2025, an additional principal repayment of &#x20ac;4,688 (approximately $5,061) was made. As of March 31, 2025, and December 31, 2024 the Company has an outstanding balance of &#x20ac;98,438 ($106,273) and &#x20ac;103,125 ($106,745), of which $86,031 and $87,337 is classified as &#x201c;Notes payable - long term portion&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 24, 2020, the Company&#x2019;s subsidiary, Decahedron, received a loan &#xa3;50,000 ($68,310) from the&#160;UK government. As of March 31, 2025, and December 31, 2024 the Company has an outstanding balance of &#xa3; 38,144 ($49,191) and &#xa3; 38,144 ($47,761), of which $34,329 and $35,299 is classified as &#x201c;Notes payable - long term portion&#x201d; on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;None of the above loans were made by any related parties.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6015">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;March 31, 2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Trade &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Facility &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Third &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Party&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;COVID &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Loans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Beginning balance, December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,397,385&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,557,023&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;154,505&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,108,913&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;755,720&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;755,720&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(183,455 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(5,060 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(188,515 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;60,075&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;110,051&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;6,019&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;176,145&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance, March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,457,460&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,239,339&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;155,464&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,852,263&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable - long-term&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,968,180 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(120,360 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,088,540 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable - short-term&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,457,460&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,271,159&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;35,104&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,763,723&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;December 31, 2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Trade &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Facility &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Third &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Party&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;COVID &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Loans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Beginning balance, December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,908,195&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,511,148&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;186,884&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,606,227&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;828,080&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;828,080&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(388,163 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(634,653 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(22,806 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,045,622 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(122,647 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(147,552 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(9,573 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(279,772 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance, December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,397,385&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,557,023&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;154,505&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,108,913&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable &#x2013; long-term&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,437,798 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(122,635 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,560,433 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable - short-term&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,397,385&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,119,225&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;31,870&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,548,480&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10164"
      unitRef="USD">1397385</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10087"
      unitRef="USD">2557023</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10167"
      unitRef="USD">154505</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_10202"
      unitRef="USD">4108913</us-gaap:NotesPayable>
    <cosm:ProceedFromDebt
      contextRef="From2025-01-01to2025-03-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10093"
      unitRef="USD">0</cosm:ProceedFromDebt>
    <cosm:ProceedFromDebt
      contextRef="From2025-01-01to2025-03-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10094"
      unitRef="USD">755720</cosm:ProceedFromDebt>
    <cosm:ProceedFromDebt
      contextRef="From2025-01-01to2025-03-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10095"
      unitRef="USD">0</cosm:ProceedFromDebt>
    <cosm:ProceedFromDebt
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10198"
      unitRef="USD">755720</cosm:ProceedFromDebt>
    <cosm:PaymentsOfDebt
      contextRef="From2025-01-01to2025-03-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10104"
      unitRef="USD">0</cosm:PaymentsOfDebt>
    <cosm:PaymentsOfDebt
      contextRef="From2025-01-01to2025-03-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10105"
      unitRef="USD">-183455</cosm:PaymentsOfDebt>
    <cosm:PaymentsOfDebt
      contextRef="From2025-01-01to2025-03-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10106"
      unitRef="USD">-5060</cosm:PaymentsOfDebt>
    <cosm:PaymentsOfDebt
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10200"
      unitRef="USD">-188515</cosm:PaymentsOfDebt>
    <cosm:ForeignCurrencyTranslation
      contextRef="From2025-01-01to2025-03-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10123"
      unitRef="USD">60075</cosm:ForeignCurrencyTranslation>
    <cosm:ForeignCurrencyTranslation
      contextRef="From2025-01-01to2025-03-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10124"
      unitRef="USD">110051</cosm:ForeignCurrencyTranslation>
    <cosm:ForeignCurrencyTranslation
      contextRef="From2025-01-01to2025-03-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10125"
      unitRef="USD">6019</cosm:ForeignCurrencyTranslation>
    <cosm:ForeignCurrencyTranslation
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10208"
      unitRef="USD">176145</cosm:ForeignCurrencyTranslation>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-03-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10859"
      unitRef="USD">1457460</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-03-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10131"
      unitRef="USD">3239339</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-03-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10132"
      unitRef="USD">155464</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10214"
      unitRef="USD">4852263</us-gaap:NotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-03-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10139"
      unitRef="USD">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-03-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10140"
      unitRef="USD">1968180</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-03-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10141"
      unitRef="USD">120360</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10137"
      unitRef="USD">2088540</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2025-03-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10860"
      unitRef="USD">1457460</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2025-03-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10148"
      unitRef="USD">1271159</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2025-03-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10149"
      unitRef="USD">35104</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10146"
      unitRef="USD">2763723</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_11083"
      unitRef="USD">1908195</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_11084"
      unitRef="USD">2511148</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_11085"
      unitRef="USD">186884</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_11086"
      unitRef="USD">4606227</us-gaap:NotesPayable>
    <cosm:ProceedFromDebt
      contextRef="From2024-01-01to2024-12-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10168"
      unitRef="USD">0</cosm:ProceedFromDebt>
    <cosm:ProceedFromDebt
      contextRef="From2024-01-01to2024-12-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10178"
      unitRef="USD">828080</cosm:ProceedFromDebt>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10175"
      unitRef="USD">0</us-gaap:LongTermNotesPayable>
    <cosm:ProceedFromDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="fid_10211"
      unitRef="USD">828080</cosm:ProceedFromDebt>
    <cosm:PaymentsOfDebt
      contextRef="From2024-01-01to2024-12-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10170"
      unitRef="USD">-388163</cosm:PaymentsOfDebt>
    <cosm:PaymentsOfDebt
      contextRef="From2024-01-01to2024-12-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10179"
      unitRef="USD">-634653</cosm:PaymentsOfDebt>
    <cosm:PaymentsOfDebt
      contextRef="From2024-01-01to2024-12-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10192"
      unitRef="USD">-22806</cosm:PaymentsOfDebt>
    <cosm:PaymentsOfDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="fid_10199"
      unitRef="USD">-1045622</cosm:PaymentsOfDebt>
    <cosm:ForeignCurrencyTranslation
      contextRef="From2024-01-01to2024-12-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10173"
      unitRef="USD">-122647</cosm:ForeignCurrencyTranslation>
    <cosm:ForeignCurrencyTranslation
      contextRef="From2024-01-01to2024-12-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10180"
      unitRef="USD">-147552</cosm:ForeignCurrencyTranslation>
    <cosm:ForeignCurrencyTranslation
      contextRef="From2024-01-01to2024-12-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10193"
      unitRef="USD">-9573</cosm:ForeignCurrencyTranslation>
    <cosm:ForeignCurrencyTranslation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="fid_10207"
      unitRef="USD">-279772</cosm:ForeignCurrencyTranslation>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10174"
      unitRef="USD">1397385</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10185"
      unitRef="USD">2557023</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10194"
      unitRef="USD">154505</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_10209"
      unitRef="USD">4108913</us-gaap:NotesPayable>
    <cosm:ProceedFromDebt
      contextRef="From2024-01-01to2024-12-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10189"
      unitRef="USD">0</cosm:ProceedFromDebt>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10857"
      unitRef="USD">1437798</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10195"
      unitRef="USD">122635</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_10212"
      unitRef="USD">1560433</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31_cosm_TradeFacilityAgreementsMember"
      decimals="0"
      id="fid_10176"
      unitRef="USD">1397385</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31_cosm_ThirdPartyMember"
      decimals="0"
      id="fid_10858"
      unitRef="USD">1119225</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31_cosm_COVIDLoansMember"
      decimals="0"
      id="fid_10196"
      unitRef="USD">31870</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_10213"
      unitRef="USD">2548480</us-gaap:NotesPayableCurrent>
    <cosm:ScheduleOfOutstandingDebtTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6016">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="5" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Our outstanding debt as of March 31, 2025&#160;is repayable as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,763,723&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;819,335&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;666,070&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;378,706&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;224,429&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Total debt&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;4,852,263&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: notes payable - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,763,723 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Notes payable - long term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,088,540&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cosm:ScheduleOfOutstandingDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10215"
      unitRef="USD">2763723</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10216"
      unitRef="USD">819335</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10217"
      unitRef="USD">666070</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10218"
      unitRef="USD">378706</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10219"
      unitRef="USD">224429</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10220"
      unitRef="USD">4852263</us-gaap:LongTermDebt>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10221"
      unitRef="USD">2763723</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_10222"
      unitRef="USD">2088540</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtCurrent
      contextRef="AsOf2017-05-12_cosm_DebtAgreementJulyMember"
      decimals="0"
      id="fid_11088"
      unitRef="USD">1457460</us-gaap:DebtCurrent>
    <cosm:DebtAmountReceivedFromRelatedParty
      contextRef="From2020-06-01to2020-06-23_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember"
      decimals="0"
      id="fid_10291"
      unitRef="USD">611500</cosm:DebtAmountReceivedFromRelatedParty>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember"
      decimals="0"
      id="fid_11090"
      unitRef="USD">63506</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2024-12-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember"
      decimals="0"
      id="fid_10346"
      unitRef="USD">91232</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-03-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember"
      decimals="0"
      id="fid_11091"
      unitRef="USD">63506</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember"
      decimals="0"
      id="fid_10347"
      unitRef="USD">91232</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2020-06-01to2020-06-23_cosm_JuneTwentyThreeTwoThousandTwentyMember_cosm_NationalBankOfGreeceSAMember"
      decimals="0"
      id="fid_11092"
      unitRef="USD">31753</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:DebtCurrent
      contextRef="AsOf2020-11-19_cosm_DebtExchangeAgreementMember"
      decimals="0"
      id="fid_10244"
      unitRef="USD">611500</us-gaap:DebtCurrent>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-01to2025-03-31_cosm_DebtExchangeAgreementMember"
      decimals="0"
      id="fid_11096"
      unitRef="USD">29999</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-03-31_cosm_DebtExchangeAgreementMember"
      decimals="0"
      id="fid_11094"
      unitRef="USD">4720</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_DebtExchangeAgreementMember"
      decimals="0"
      id="fid_11089"
      unitRef="USD">89967</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2021-07-30_cosm_DebtAgreementJulyMember"
      decimals="0"
      id="fid_10245"
      unitRef="USD">578850</us-gaap:DebtCurrent>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-01to2025-03-31_cosm_DebtAgreementJulyMember"
      decimals="0"
      id="fid_11098"
      unitRef="USD">30697</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-03-31_cosm_DebtAgreementJulyMember"
      decimals="0"
      id="fid_11100"
      unitRef="USD">18004</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_DebtAgreementJulyMember"
      decimals="0"
      id="fid_11101"
      unitRef="USD">192071</us-gaap:DebtCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-03-31_cosm_DebtAgreementJulyMember"
      decimals="0"
      id="fid_11103"
      unitRef="USD">66896</us-gaap:LongTermNotesPayable>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized
      contextRef="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember"
      decimals="0"
      id="fid_11117"
      unitRef="USD">335008</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-01-01to2025-03-31_cosm_DebtAgreementJuneOneMember"
      decimals="0"
      id="fid_11115"
      unitRef="USD">21592</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember"
      decimals="0"
      id="fid_11113"
      unitRef="USD">4682</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_cosm_DebtAgreementJuneOneMember"
      decimals="0"
      id="fid_10361"
      unitRef="USD">8645</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember"
      decimals="0"
      id="fid_11114"
      unitRef="USD">172736</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2024-12-31_cosm_DebtAgreementJuneOneMember"
      decimals="0"
      id="fid_10362"
      unitRef="USD">186318</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-03-31_cosm_DebtAgreementJuneOneMember"
      decimals="0"
      id="fid_11116"
      unitRef="USD">86368</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31_cosm_DebtAgreementJuneOneMember"
      decimals="0"
      id="fid_10363"
      unitRef="USD">103510</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized
      contextRef="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11122"
      unitRef="USD">1123700</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-01-01to2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11121"
      unitRef="USD">58640</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11118"
      unitRef="USD">3674</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10369"
      unitRef="USD">17322</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11119"
      unitRef="USD">820964</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2024-12-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10372"
      unitRef="USD">843348</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-03-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11120"
      unitRef="USD">586571</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31_cosm_JulyFourteenTwoThousandTwentyThreeMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10373"
      unitRef="USD">618616</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10872"
      unitRef="USD">637080</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10873"
      unitRef="Shares">280000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <cosm:CommonStockIssuedAsConsiderationFairValue
      contextRef="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10874"
      unitRef="USD">319200</cosm:CommonStockIssuedAsConsiderationFairValue>
    <cosm:BusinessCombinationContingentConsiderationArrangementLiability
      contextRef="From2024-01-01to2024-01-23_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10875"
      unitRef="USD">317880</cosm:BusinessCombinationContingentConsiderationArrangementLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2025-01-01to2025-03-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11125"
      unitRef="USD">10782</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11123"
      unitRef="USD">280696</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2024-12-31_cosm_JanuaryTwentythreeTwoThousandTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10870"
      unitRef="USD">279348</us-gaap:DebtCurrent>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized
      contextRef="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11129"
      unitRef="USD">432760</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11127"
      unitRef="USD">1466</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10383"
      unitRef="USD">1581</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11126"
      unitRef="USD">431840</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2024-12-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10382"
      unitRef="USD">414040</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-03-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11128"
      unitRef="USD">335876</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31_cosm_JulyTwentyNineTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10386"
      unitRef="USD">345033</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized
      contextRef="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11131"
      unitRef="USD">414040</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11132"
      unitRef="USD">7027</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11133"
      unitRef="USD">821</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11130"
      unitRef="USD">431840</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2024-12-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10395"
      unitRef="USD">414040</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-03-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_11134"
      unitRef="USD">287893</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31_cosm_DeemberTwentyTwentyFourMember_cosm_PromissoryNotesMember"
      decimals="0"
      id="fid_10392"
      unitRef="USD">276027</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtDescription
      contextRef="From2025-01-01to2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"
      id="fid_11147">the Company entered into a bond loan agreement with Attica Bank, providing for maximum borrowings of up to &#x20ac;2,200,000 ($2,357,120). Under the terms of the facility, the Company received initial proceeds of &#x20ac;700,000 ($749,600), which were classified as Notes Payable in the Company&#x2019;s consolidated financial statements. The remaining borrowing capacity of &#x20ac;1,500,000 ($1,619,400) is available to the Company on a revolving basis, subject to the provision of qualifying checks receivable as collateral</us-gaap:LongTermDebtDescription>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="From2025-01-01to2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"
      decimals="INF"
      id="fid_11149"
      unitRef="Pure">0.0295</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"
      decimals="0"
      id="fid_11137"
      unitRef="USD">3766</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"
      decimals="0"
      id="fid_11138"
      unitRef="USD">0</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"
      decimals="0"
      id="fid_11142"
      unitRef="USD">755720</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2024-12-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"
      decimals="0"
      id="fid_11143"
      unitRef="USD">0</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-03-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"
      decimals="0"
      id="fid_11150"
      unitRef="USD">604576</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31_cosm_JanuaryTwentySevenTwoThousandTwentyFiveMember"
      decimals="0"
      id="fid_11151"
      unitRef="USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2020-05-01to2020-05-12_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"
      decimals="0"
      id="fid_10290"
      unitRef="USD">366900</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="From2020-05-01to2020-05-12_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"
      decimals="0"
      id="fid_11153"
      unitRef="USD">5061</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"
      decimals="0"
      id="fid_11154"
      unitRef="USD">106273</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"
      decimals="0"
      id="fid_10400"
      unitRef="USD">106745</us-gaap:DebtCurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-01to2025-03-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"
      decimals="0"
      id="fid_11157"
      unitRef="USD">86031</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-01to2024-12-31_cosm_CovidNinteenMember_cosm_MayTwelveTwentyTwentyMember"
      decimals="0"
      id="fid_11156"
      unitRef="USD">87337</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2020-06-01to2020-06-24_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember"
      decimals="0"
      id="fid_10403"
      unitRef="USD">68310</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:DebtCurrent
      contextRef="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember"
      decimals="0"
      id="fid_11158"
      unitRef="USD">49191</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember"
      decimals="0"
      id="fid_10406"
      unitRef="USD">47761</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-03-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember"
      decimals="0"
      id="fid_11159"
      unitRef="USD">34329</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31_cosm_CovidNinteenMember_cosm_JuneTwentyFourTwentyTwentyMember"
      decimals="0"
      id="fid_11160"
      unitRef="USD">35299</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5974">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 12 &#x2013; LEASES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has various operating and finance lease agreements with terms up to 10 years, for various types of property and equipment (such as office space and vehicles) etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Operating Leases&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s weighted-average remaining lease term relating to its operating leases is 3.71 years, with a weighted-average discount rate of 6.74%.&lt;span style="text-decoration:underline"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#x2019;s operating leases as of March 31, 2025:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Maturity of Operating Lease Liability&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;181,753&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;218,637&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;156,745&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2029 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;202,251&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total undiscounted operating lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;759,386&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(88,876 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Present value of operating lease liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;670,510&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company incurred lease expense, due to amortization of operating lease right-of-use assets, of&#160;$60,668 and $77,167, which was included in &#x201c;General and administrative expenses,&#x201d; for the&#160;three ended March 31, 2025 and 2024, respectively.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Finance Leases &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s weighted-average remaining lease term relating to its finance leases is 1.07 years, with a weighted-average discount rate of 6.74%. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#x2019;s finance leases as of March 31, 2025:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Maturity of Lease Liability&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,357&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total undiscounted finance lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;10,357&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(373 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Present value of finance lease liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,164&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company had financing cash flows used in finances leases of $5,533 and $8,737 for the three ended March 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company incurred interest expense on its finance leases of $195 and $725 which was included in &#x201c;Interest expense&#x201d;, for the three months ended March 31, 2025 and 2024, respectively. The Company incurred amortization expense on its finance leases of $4,603 and $7,489 which was included in &#x201c;Depreciation and amortization expense,&#x201d; for the three months ended March 31, 2025 and 2024, respectively.&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <cosm:OperatingLeaseTermOfAgreements contextRef="From2025-01-01to2025-03-31" id="fid_10510">The Company has various operating and finance lease agreements with terms up to 10 years</cosm:OperatingLeaseTermOfAgreements>
    <cosm:OperatingLeaseWeightedAverageRemainingLeaseTerm contextRef="From2025-01-01to2025-03-31" id="fid_10516">P3Y8M15D</cosm:OperatingLeaseWeightedAverageRemainingLeaseTerm>
    <cosm:OperatingLeaseWeightedAverageDiscountRate
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="fid_10515"
      unitRef="Pure">0.0674</cosm:OperatingLeaseWeightedAverageDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6017">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Maturity of Operating Lease Liability&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;181,753&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;218,637&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;156,745&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2029 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;202,251&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total undiscounted operating lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;759,386&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(88,876 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Present value of operating lease liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;670,510&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember"
      decimals="0"
      id="fid_10497"
      unitRef="USD">181753</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember"
      decimals="0"
      id="fid_10498"
      unitRef="USD">218637</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember"
      decimals="0"
      id="fid_10499"
      unitRef="USD">156745</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember"
      decimals="0"
      id="fid_10500"
      unitRef="USD">202251</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember"
      decimals="0"
      id="fid_10501"
      unitRef="USD">759386</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <cosm:OperatingLeaseLiabilityLessImputedInterest
      contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember"
      decimals="0"
      id="fid_10502"
      unitRef="USD">88876</cosm:OperatingLeaseLiabilityLessImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-03-31_cosm_OperatingLeaseMember"
      decimals="0"
      id="fid_10503"
      unitRef="USD">670510</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2025-01-01to2025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="fid_10511"
      unitRef="USD">60668</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-01-01to2024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="fid_10512"
      unitRef="USD">77167</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <cosm:FinanceLeaseWeightedAverageRemainingLeaseTerm contextRef="From2025-01-01to2025-03-31" id="fid_10517">P1Y25D</cosm:FinanceLeaseWeightedAverageRemainingLeaseTerm>
    <cosm:FinanceLeaseWeightedAverageDiscountRate
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="fid_10520"
      unitRef="Pure">0.0674</cosm:FinanceLeaseWeightedAverageDiscountRate>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6018">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Maturity of Lease Liability&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,357&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total undiscounted finance lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;10,357&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(373 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Present value of finance lease liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,164&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-03-31_cosm_FinanceLeaseMember"
      decimals="0"
      id="fid_10506"
      unitRef="USD">10357</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <cosm:FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments
      contextRef="AsOf2025-03-31_cosm_FinanceLeaseMember"
      decimals="0"
      id="fid_10507"
      unitRef="USD">10357</cosm:FinanceLeaseLiabilityPaymentsDueYearFiveTotalUndiscountedFinanceLeasePayments>
    <cosm:FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest
      contextRef="AsOf2025-03-31_cosm_FinanceLeaseMember"
      decimals="0"
      id="fid_10508"
      unitRef="USD">-373</cosm:FinanceLeaseLiabilityPaymentsDueYearFiveImputedInterest>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-03-31_cosm_FinanceLeaseMember"
      decimals="0"
      id="fid_10509"
      unitRef="USD">10164</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <cosm:OperatingLeaseCashFlowsUsedInFinanceLease
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10513"
      unitRef="USD">5533</cosm:OperatingLeaseCashFlowsUsedInFinanceLease>
    <cosm:OperatingLeaseCashFlowsUsedInFinanceLease
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_10514"
      unitRef="USD">8737</cosm:OperatingLeaseCashFlowsUsedInFinanceLease>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2025-01-01to2025-03-31_us-gaap_InterestExpenseMember"
      decimals="0"
      id="fid_10518"
      unitRef="USD">195</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2024-01-01to2024-03-31_us-gaap_InterestExpenseMember"
      decimals="0"
      id="fid_10519"
      unitRef="USD">725</us-gaap:FinanceLeaseInterestExpense>
    <cosm:FinanceLeaseAmortizationExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10521"
      unitRef="USD">4603</cosm:FinanceLeaseAmortizationExpense>
    <cosm:FinanceLeaseAmortizationExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_10522"
      unitRef="USD">7489</cosm:FinanceLeaseAmortizationExpense>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5975">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 13 &#x2013; OTHER LIABILITIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of March 31, 2025 the Company&#x2019;s other liabilities primarily consist of obligations to local tax authorities, payroll taxes, fines, and other miscellaneous liabilities. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The significant components of other liabilities are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s Greek subsidiaries have $2,819,815 and $2,552,488 in settled tax liabilities as March 31, 2025 and December 31, 2024, respectively, which are payable in installments to the tax authorities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Payroll and other tax-related current liabilities amount to $1,350,825 and $1,191,315 as of March 31, 2025 and December 31, 2024, respectively, and represent obligations due to tax authorities within the next 12 months.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A provision of $624,588 has been recorded for potential tax liabilities related to the unaudited tax years of SkyPharm S.A., in accordance with ASC 450-20, as the Company has assessed that a loss is probable and reasonably estimable.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A provision of $398,838 has been recognized for staff leaving compensation, based on actuarial valuations performed in accordance with ASC 715-30 (Defined Benefit Plans &#x2013; Pension).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Customer prepayments totaling $447,872 and $363,708 as of March 31, 2025 and December 31, 2024, respectively, are included in &#x201c;Other Current Liabilities&#x201d;, in accordance with ASC 606-10-45-2 (Revenue Recognition &#x2013; Contract Liabilities).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Liabilities that are due within 12 months from the balance sheet date are classified under &#x201c;Other Current Liabilities. &#x201c;Obligations that extend beyond 12 months are classified as &#x201c;Other Non-Current Liabilities.&#x201d;&#160;&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <cosm:TaxLiabilitiesPayable
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10528"
      unitRef="USD">2819815</cosm:TaxLiabilitiesPayable>
    <cosm:TaxLiabilitiesPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="fid_10523"
      unitRef="USD">2552488</cosm:TaxLiabilitiesPayable>
    <cosm:PayrollTaxRelatedCurrentLiabilities
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10529"
      unitRef="USD">1350825</cosm:PayrollTaxRelatedCurrentLiabilities>
    <cosm:PayrollTaxRelatedCurrentLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="fid_10524"
      unitRef="USD">1191315</cosm:PayrollTaxRelatedCurrentLiabilities>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11161"
      unitRef="USD">624588</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <cosm:ProvisionForStaffLeavingCompensation
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11162"
      unitRef="USD">398838</cosm:ProvisionForStaffLeavingCompensation>
    <us-gaap:ProceedsFromCustomersForProgressPayments
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_10530"
      unitRef="USD">447872</us-gaap:ProceedsFromCustomersForProgressPayments>
    <us-gaap:ProceedsFromCustomersForProgressPayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="fid_10527"
      unitRef="USD">363708</us-gaap:ProceedsFromCustomersForProgressPayments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5976">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 14 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Legal Matters&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;From time to time, the Company may be involved in litigation relating to claims arising out of the Company&#x2019;s operations in the normal course of business. As of March 31, 2025, the following litigations were pending. None of the below is expected to have a material financial or operational impact. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Tax Audit-Related Fine &#x2013; Cosmofarm&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A payment request was issued by the Greek court in relation to a fine arising from a tax audit of Cosmofarm for the financial year 2014. The fine was imposed under Law No. 483/16.12.2020. Cosmofarm appealed the decision under Law No. 11541/09.03.2021; however, the appeal was dismissed 120 days after its submission. The Company settled additional taxes and fines related to this matter in the amount of &#x20ac;91,652 ($99,644) but has filed a claim to recover the amount through appeal. As of March 31, 2025, the trial remains pending.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Criminal Cases Related to Dishonored Checks&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 25, 2023, a criminal case involving dishonored checks issued by Cosmofarm&#x2019;s customer, Filippou, was heard at the Z&#x2019; Three-Member Misdemeanor Court of Athens. The case was postponed to November 27, 2023, when the defendant was tried and found guilty.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On October 23, 2023, a criminal case involving dishonored checks issued by Cosmofarm&#x2019;s customer, Kafantaris, was heard at the Sixth Single-Member Misdemeanor Court of Athens. The case was postponed to January 26, 2024, when the defendant was convicted under Decision No. 1599/2024.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Appeal Against Decision 1389/2021 &#x2013; Eleutheria Drakopoulou&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 26, 2023, the Company&#x2019;s appeal against Eleutheria Drakopoulou and Decision No. 1389/2021 of the Single-Member Court of First Instance of Athens was heard at the Athens Court of Appeal. The appeal was partially accepted. The Court ordered the return of the fee to the appellants, dismissed the action against the third defendant (Kozaris), and accepted the action against the first and second defendants (Kastrantas &amp;amp; Cosmofarm).&#160;The case was settled in two equal installments by Cosmofarm SA, of &#x20ac;35,000 ($37,880) on July 31, 2024 and of &#x20ac;35,000 ($37,993) on October 31, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Pending Lawsuits Against Euaggelismos &amp;amp; Pananikolaou Hospitals&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s subsidiary, Cana Laboratories, has two pending lawsuits against Euaggelismos Hospital for unpaid bills totaling &#x20ac;526,436. A court date has been scheduled for one of the lawsuits on December 11, 2024, while the other remains unscheduled. The matter is currently pending a court decision. Based on legal counsel&#x2019;s assessment, it is considered highly probable that the losing party will appeal the decision once it is rendered. However, counsel has also indicated that the collection of the full amount awarded to the Company is considered highly probable.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;There is also an unasserted claim against Papanikolaou Hospital, for a total sum of &#x20ac;89,300 due to unpaid bills, which will be asserted through a lawsuit. Court date is not set yet. The opinion of our legal advisor is that the success of the case and the collection of the aforementioned amount is probable and as of now negotiations are taking place in the direction of out-of-court settlement.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Both claims have been classified under &#x201c;Other assets&#x201d; within non-current assets in the Company&#x2019;s consolidated balance sheets as of March 31, 2025.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Employment Dispute &#x2013; Cana Laboratories&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A lawsuit filed on April 5, 2018, by a former employee against the Company&#x2019;s subsidiary, Cana, before the Athens Court of First Instance, sought the nullification of the termination of employment and compensation for unpaid wages and moral damages. Following multiple appeals, Judgment No. 1192/2024 was issued on September 26, 2023, requiring Cana to reinstate the former employee, with a penalty of &#x20ac;200 per day for non-compliance. According to the Company&#x2019;s legal counsel, for the penalty to be enforceable, the former employee must file a new lawsuit requesting reinstatement. As of the date of this report, no such lawsuit or request for reinstatement has been received.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Lease Dispute&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A lawsuit has been filed against the Company&#x2019;s subsidiary, Cana, seeking restitution of a leased property, payment of approximately &#x20ac;13,190 in outstanding rent, and &#x20ac;8,488 in compensation for use of the property. The Company has settled the monetary claims in full, rendering that portion of the case moot. However, the claim for restitution of the leased property remains pending and is expected to be accepted by the court.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Claims for Recovery of Receivables&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s subsidiary, Cosmofarm SA, is in the process of initiating legal action to recover approximately &#x20ac;20,301 in unpaid invoices from a certain customer. The hearing is expected to be scheduled in 2026. Based on legal counsel&#x2019;s assessment, the claim is anticipated to be upheld. In addition, Cosmofarm SA is preparing to file two further lawsuits for the recovery of &#x20ac;15,143 and &#x20ac;15,255, respectively, related to unpaid invoices concerning two customers. Both hearings are expected to be scheduled in 2026, and legal counsel similarly anticipates favorable outcomes in both cases.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Advisory Agreements&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 21, 2023, the Company entered into certain consulting agreements with four third-party consultants for the provision of a variety of services such as digital marketing, advisory services relating to target acquisitions and M&amp;amp;As and other additional services as described in the respective agreements. The agreements have duration from ten to 18 months and the consultants will solely receive stock consideration for the services rendered. More precisely, they have been awarded a total of 970,000 shares of the Company&#x2019;s common stock valued at a total of $999,100 based on the fair value of the Company&#x2019;s common stock as of the agreements&#x2019; date. On September 17, 2024 the terms of two out of the four aforementioned consulting agreements were extended and the consultants received additional 440,000 shares as complementary compensation for the extended services to be provided. The additional stock based consideration was valued at a total of $501,600 based on the fair value of the Company&#x2019;s common stock as of the agreements&#x2019; date. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On July 1, 2024 the Company entered into a consulting agreement with a third-party consultant for the provision of a variety of services such as preparation of press releases and other publications, relationship management and other additional services as described in the respective agreement. The agreement has a duration of 16 months and the consultant will solely receive stock consideration for the services rendered. More precisely, they have been awarded a total of 240,000 shares of the Company&#x2019;s common stock valued at a total of $264,000 based on the fair value of the Company&#x2019;s common stock as of the agreements&#x2019; date.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The corresponding stock-based compensation expense is accrued evenly over the term of the agreements. For the three-month periods ended March 31, 2025 and 2024 the Company has recorded $245,310 and $231,750, respectively, as stock based compensation for the above agreements, respectively, classified as &#x201c;General and administrative expenses&#x201d; in the Company&#x2019;s consolidated statements of operations and comprehensive Income (loss).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Research and Development Agreements&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company entered into a Research &amp;amp; Development agreement with Doc Pharma S.A. on May 17, 2021. Under this agreement, Doc Pharma is responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life&#xae;. More specifically, Doc Pharma is responsible for the product development and the Company has added 165 of such products codes in its portfolio as of March 31, 2025. The licenses purchased by Doc Pharma SA are capitalized and included in &#x201c;Goodwill and intangible assets, net&#x201d; of the Company&#x2019;s Consolidated Balance Sheets as of March 31, 2025. Thus, no relevant R&amp;amp;D expense had been charged to the Company&#x2019;s Consolidated Statements of Operations and Comprehensive income (Loss), concerning this agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 25, 2022, the Company signed a research and development (&#x201c;R&amp;amp;D&#x201d;) agreement with a third party(CloudPharm PC), through which the Company assigned to the third party the development of new products and services in the field of health, focusing on the human intestinal microbiome. The project includes two phases. Phase 1 has a 20-month duration and its cost amounts to EUR 758,000 ($838,450) and phase 2, has a 22-month duration and a cost of EUR 820,000 ($907,084). The amount will be due and payable upon completion of the corresponding phases. The Company records the corresponding R&amp;amp;D expense based on the project&#x2019;s progress, which is invoiced by the third party in the relevant period. For the 3-month periods ended March 31, 2025 and 2024, the Company has not incurred any costs relating to this agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 23, 2024, the Company completed the acquisition of Cloudscreen, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023. Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases. The total purchase price amounted to $637,080 incorporating both cash and stock consideration the platform is included in &#x201c;Goodwill and intangible assets, net&#x201d; in the Company&#x2019;s Consolidated Balance Sheets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 3, 2024, the Company and the National Hellenic Research Foundation (NHRF) (Contractor) signed a Research Study Agreement. NHRF will conduct an in vitro study to support modifications to an invention, pursuant to the prior agreement involving CloudPharm PC (signed on June 15, 2022). NHRF ensures scientific rigor, provides updates, and maintains confidentiality. Cosmos Health provides necessary support and documentation. Rights to the research protocol belong to CloudPharm PC, NHRF, and Cosmos Health, while NHRF retains control over its methodologies. NHRF cannot publish findings without Cosmos Health&#x2019;s approval and cannot use the study for other purposes. The total fee to by paid by the Company amounts to &#x20ac;60,000 plus VAT, payable in three installments. For the 3-month period ended March 31, 2025, the Company incurred EUR 15,000 ($15,629) concerning this agreement, which were included in &#x201c;Research and Development costs&#x201d; in the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss).&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 6, 2024, the Company signed an Independent Contractor Agreement with a third-party contractor (the &#x201c;Contractor&#x201d;). The Contractor will provide oncology research and development services exclusively to the Company. The contract lasts three years (December 5, 2024 &#x2013; December 5, 2027) and may be extended by mutual agreement. The Company may terminate the contract immediately for specific causes, including felony conviction, fraud, or loss of medical license. Either party may terminate the contract with 30 days' written notice. Certain compensation obligations will remain even after termination. The monthly consideration to be paid to the Contractor is based on the commencement of the Clinical Trials and New Drugs Applications and additional cash and stock consideration is payable based on certain milestones. None of the milestones were met as of March 31, 2025, and thus the Company has incurred no expenses as of the end of the period. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 31, 2024, the Company signed an agreement with a related party, DocPharma SA (the &#x201c;Licensor&#x201d;), through which the Company obtained a royalty-bearing, exclusive worldwide license to actively commercialize the patents owned by the Licensor, through research and preclinical and clinical trials for the useful life of the patents, or for 20 years, whichever is longer. The patents, filed in 2016 and 2017 respectively, cover innovative treatments for cancer.&#160;The terms of the agreement include an initial payment of EUR 500,000 due by the end of 2024, followed by fixed annual payments of EUR 350,000 during the five-year Start-Up Term from 2025 to 2030. After the Start-Up Term, the Company will pay a 1.5% royalty on annual net sales of licensed products covered by an issued patent. Moreover, the Company retains an optional buy-out right for a total amount of EUR 7,500,000, which can be exercised with 60 days' notice and a 60-day close period. The Company also has the right to sublicense the patents. For the 3-month period ended March 31, 2025, the Company incurred no royalties concerning this agreement.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cosm:PaymentTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11164"
      unitRef="USD">99644</cosm:PaymentTax>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="AsOf2024-07-31"
      decimals="0"
      id="fid_10542"
      unitRef="USD">37880</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="fid_10543"
      unitRef="USD">37993</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <cosm:StockIssuedDuringPeriodSharesAwarded
      contextRef="From2023-11-01to2023-11-21_cosm_FourThirdPartyConsultantsMember"
      decimals="0"
      id="fid_10538"
      unitRef="Shares">970000</cosm:StockIssuedDuringPeriodSharesAwarded>
    <us-gaap:StockIssued1
      contextRef="From2023-11-01to2023-11-21_cosm_FourThirdPartyConsultantsMember"
      decimals="0"
      id="fid_10539"
      unitRef="USD">999100</us-gaap:StockIssued1>
    <cosm:ComplementaryCompensationShares
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11165"
      unitRef="Shares">440000</cosm:ComplementaryCompensationShares>
    <cosm:AdditionalStockConsideration
      contextRef="From2023-11-01to2023-11-21"
      decimals="0"
      id="fid_10544"
      unitRef="USD">501600</cosm:AdditionalStockConsideration>
    <cosm:StockIssuedDuringPeriodSharesAwarded
      contextRef="From2024-07-01to2024-07-02"
      decimals="0"
      id="fid_11167"
      unitRef="Shares">240000</cosm:StockIssuedDuringPeriodSharesAwarded>
    <cosm:AdditionalStockConsideration
      contextRef="From2024-07-01to2024-07-02"
      decimals="0"
      id="fid_11168"
      unitRef="USD">264000</cosm:AdditionalStockConsideration>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_cosm_NationalMedicinesAgencyMember"
      decimals="0"
      id="fid_11169"
      unitRef="USD">245310</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_cosm_NationalMedicinesAgencyMember"
      decimals="0"
      id="fid_11171"
      unitRef="USD">231750</us-gaap:AllocatedShareBasedCompensationExpense>
    <cosm:ProjectCosts
      contextRef="From2022-06-01to2022-06-25_cosm_PhaseOneMember"
      decimals="0"
      id="fid_10536"
      unitRef="USD">838450</cosm:ProjectCosts>
    <cosm:ProjectCosts
      contextRef="From2022-06-01to2022-06-25_cosm_PhaseTwoMember"
      decimals="0"
      id="fid_10537"
      unitRef="USD">907084</cosm:ProjectCosts>
    <cosm:PurchasePriceAmount
      contextRef="From2024-01-01to2024-01-23"
      decimals="0"
      id="fid_10547"
      unitRef="USD">637080</cosm:PurchasePriceAmount>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11566"
      unitRef="USD">15629</us-gaap:OtherResearchAndDevelopmentExpense>
    <cosm:StockOptionsAndWarrantsDisclouserTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5977">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 15&#160;&#x2013; STOCK OPTIONS AND WARRANTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On September 19, 2022, the Company held a Board of Directors meeting, whereas, the Board of Directors had elected to adopt an Omnibus Equity Incentive Plan (the &#x201c;2022 Plan&#x201d;), that includes reserving 200,000 shares of common stock eligible for issuance under the 2022 Plan to be registered on a Form S-8 Registration Statement with the SEC. The 2022 Plan is designed to enable the flexibility to grant equity awards to the Company&#x2019;s officers, employees, non-employee directors and consultants and to ensure that it can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. According to the Proxy Statement filed with the SEC on October 20, 2022 the 2022 Plan received final approval by the Company&#x2019;s stockholders&#160;at the Annual Meeting of Stockholders held on December 2, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 3, 2023, the Company approved incentive stock awards for the CFO, certain officers and directors and other employees of the Company. The awards are in the form of restricted stock and will vest in two parts: 50% on October 2, 2023 and 50% on October 2, 2024. For the three-month periods ended March 31, 2025 and 2024, the Company recorded share-based compensation expense of $0 and $108,297, respectively, in connection with the &#x201c;2022 Plan.&#x201d;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On August 21, 2023, the Board adopted, subject to stockholder approval, the Cosmos Health Inc. 2023 Omnibus Equity Incentive Plan (the &#x201c;2023 Plan&#x201d;). The 2023 Plan is designed to enable the flexibility to grant equity awards to our officers, employees, non-employee directors and consultants and to ensure that we can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. Subject to certain adjustments (as provided in Section 4.2 of the 2023 Plan) and exception (as provided in Section 5.6(b) of the 2023 Plan), the maximum number of shares reserved for issuance under the Plan (including incentive share options) is 2,500,000 shares. The 2023 Plan was approved by the Company&#x2019;s stockholders at the Annual Meeting of Stockholders held on September 18, 2023. As of March 31, 2025, no shares remained reserved and available for future issuance under the Company's 2023 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On September 16, 2024, the Company&#x2019;s Board of Directors approved incentive stock awards for the CEO, the CFO, certain officers and directors and other key employees of the Company pursuant to the 2023 Plan. The awards are in the form of restricted stock and will vest in two parts: 50% on September 16, 2025 and 50% on September 16, 2026. A total of 2,500,000 shares were awarded. For the three-month periods ended March 31, 2025 and 2024, the Company recorded share-based compensation expense of $311,301 and $0, respectively, in connection with the &#x201c;2023 Plan.&#x201d; The expense was recorded in accordance with ASC 718 (Compensation&#x2014;Stock Compensation) and is included in the Company&#x2019;s Consolidated Statement of Operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Warrant Anti-Dilution Adjustment and Deemed Dividend&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of March 31, 2025, there were 12,926,506 warrants outstanding and 12,913,172 warrants exercisable with 12,913,172 warrants having expiration dates from May 2026 through October 2029 and 13,334 warrants with no expiration date. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A summary of the Company&#x2019;s warrant activity for the nine months ended March 31, 2025 and the year ending December 31, 2024 is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Remaining&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Intrinsic&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Balance Outstanding, January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,561,476&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.91&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.64&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,801&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,748,252&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.95&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,874,126 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(509,096 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Balance Outstanding, December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.63&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,920&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Balance Outstanding, March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2.63&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2.99&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,814&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Exercisable, March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;12,913,172&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2.63&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cosm:StockOptionsAndWarrantsDisclouserTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-09-19_cosm_TwoZeroTwentyTwoPlanMember"
      decimals="0"
      id="fid_10590"
      unitRef="Shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_11180"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_11179"
      unitRef="USD">108297</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-08-21_cosm_TwoZeroTwentyThreePlanMember"
      decimals="0"
      id="fid_10591"
      unitRef="Shares">2500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cosm:DiscriptionOfIncentiveStockAwards contextRef="From2023-04-01to2023-04-03" id="fid_11182">The awards are in the form of restricted stock and will vest in two parts: 50% on September 16, 2025 and 50% on September 16, 2026</cosm:DiscriptionOfIncentiveStockAwards>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-08-21_cosm_BoardOfDirectorsMember"
      decimals="0"
      id="fid_10592"
      unitRef="Shares">2500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-03-31_cosm_BoardOfDirectorsMember"
      decimals="0"
      id="fid_11183"
      unitRef="USD">311301</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-03-31_cosm_BoardOfDirectorsMember"
      decimals="0"
      id="fid_11567"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-03-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_11191"
      unitRef="Shares">12926506</us-gaap:ClassOfWarrantOrRightOutstanding>
    <cosm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber
      contextRef="AsOf2025-03-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_11190"
      unitRef="Shares">12913172</cosm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber>
    <cosm:WarrantExpirationDateDescription
      contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember"
      id="fid_11188">expiration dates from May 2026 through October 2029</cosm:WarrantExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-03-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_11187"
      unitRef="Shares">13334</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6019">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Remaining&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Intrinsic&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Balance Outstanding, January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,561,476&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.91&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.64&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,801&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,748,252&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.95&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,874,126 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(509,096 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Balance Outstanding, December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.63&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,920&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 11.25pt; text-align:justify;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Balance Outstanding, March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;12,926,506&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2.63&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2.99&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,814&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Exercisable, March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;12,913,172&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2.63&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_10552"
      unitRef="Shares">8561476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_cosm_WarrantsMember"
      decimals="INF"
      id="fid_10563"
      unitRef="USDPShares">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cosm:WeightedAverageRemainingContractualTermOutstandingBeginning
      contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember"
      id="fid_10568">P4Y7M20D</cosm:WeightedAverageRemainingContractualTermOutstandingBeginning>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_10575"
      unitRef="USD">18801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_10554"
      unitRef="Shares">9748252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember"
      decimals="INF"
      id="fid_10565"
      unitRef="USDPShares">0.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_10558"
      unitRef="Shares">4874126</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-01to2024-12-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_10559"
      unitRef="Shares">509096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_10551"
      unitRef="Shares">12926506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_cosm_WarrantsMember"
      decimals="INF"
      id="fid_10562"
      unitRef="USDPShares">2.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cosm:WeightedAverageRemainingContractualTermOutstandingBeginning
      contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember"
      id="fid_10569">P3Y2M26D</cosm:WeightedAverageRemainingContractualTermOutstandingBeginning>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_10574"
      unitRef="USD">8920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_10560"
      unitRef="Shares">12926506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_cosm_WarrantsMember"
      decimals="INF"
      id="fid_10566"
      unitRef="USDPShares">2.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cosm:WeightedAverageRemainingContractualTermOutstandingEnding
      contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember"
      id="fid_10571">P2Y11M26D</cosm:WeightedAverageRemainingContractualTermOutstandingEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-03-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_10576"
      unitRef="USD">5814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <cosm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod
      contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_11172"
      unitRef="Shares">12913172</cosm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExercisableInPeriod>
    <cosm:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92
      contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember"
      decimals="INF"
      id="fid_11173"
      unitRef="USDPShares">2.63</cosm:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice92>
    <cosm:WeightedAverageRemainingContractualTermExercisable
      contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember"
      id="fid_11174">P3Y</cosm:WeightedAverageRemainingContractualTermExercisable>
    <cosm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue
      contextRef="From2025-01-01to2025-03-31_cosm_WarrantsMember"
      decimals="0"
      id="fid_11175"
      unitRef="USD">0</cosm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisableIntrinsicValue>
    <cosm:DisaggregationOfRevenueDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5978">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 16 &#x2013; DISAGGREGATION OF REVENUE&lt;/strong&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity&#x2019;s revenue is disaggregated depends on the facts and circumstances that pertain to the entity&#x2019;s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table presents our revenue disaggregated by country for the three months ended:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Country&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, 2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, 2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Croatia&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,093&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,344&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cyprus&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;52,562&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,737&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Bulgaria&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,183&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,651&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Greece&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,322,494&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,225,572&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Albania&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;36,332&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;UK&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;285,864&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;312,569&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;13,712,528&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;14,584,473&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cosm:DisaggregationOfRevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_6020">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Country&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, 2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;March 31, 2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Croatia&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,093&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,344&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cyprus&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;52,562&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,737&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Bulgaria&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,183&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,651&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Greece&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,322,494&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,225,572&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Albania&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;36,332&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;UK&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;285,864&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;312,569&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;13,712,528&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;14,584,473&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_CroatiaMember"
      decimals="0"
      id="fid_9785"
      unitRef="USD">3093</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31_cosm_CroatiaMember"
      decimals="0"
      id="fid_9786"
      unitRef="USD">19344</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_CyprusMember"
      decimals="0"
      id="fid_9787"
      unitRef="USD">52562</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31_cosm_CyprusMember"
      decimals="0"
      id="fid_9788"
      unitRef="USD">22737</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_BulgariaMember"
      decimals="0"
      id="fid_9789"
      unitRef="USD">12183</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31_cosm_BulgariaMember"
      decimals="0"
      id="fid_9790"
      unitRef="USD">4651</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_GreeceMember"
      decimals="0"
      id="fid_9793"
      unitRef="USD">13322494</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31_cosm_GreeceMember"
      decimals="0"
      id="fid_9794"
      unitRef="USD">14225572</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_AlbaniaMember"
      decimals="0"
      id="fid_9803"
      unitRef="USD">36332</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31_cosm_AlbaniaMember"
      decimals="0"
      id="fid_9802"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_UkMember"
      decimals="0"
      id="fid_9797"
      unitRef="USD">285864</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31_cosm_UkMember"
      decimals="0"
      id="fid_9798"
      unitRef="USD">312569</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_9799"
      unitRef="USD">13712528</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_9784"
      unitRef="USD">14584473</us-gaap:Revenues>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_9419">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 17 &#x2013; SEGMENT REPORTING&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;A. Basis for segmentation&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Group operates through various operating segments, which include the wholesale sector, the pharmaceutical manufacturing sector, the nutraceuticals and pharmaceuticals sector and other, with only the first three of them being reportable segments based on the criteria (quantitative thresholds) of ASC 280. The financial information utilized by our Chief Operating Decision Maker (&#x201c;CODM&#x201d;), which is our CEO, for resource allocation and performance evaluation is included within the operating segments described above.&#160;The reconciling items presented in the tables below are excluded from the segment data provided to the Chief Operating Decision Maker (&#x201c;CODM&#x201d;). The &#x201c;Other&#x201d; category primarily consists of corporate expenses incurred by the Group&#x2019;s parent entity, including, but not limited to, costs related to SEC legal and compliance matters, executive compensation, audit and review fees, and other corporate overhead expenses.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;B. Information about reportable segments&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The table below presents information about the Company's reportable segments for the three-month period ended March 31, 2025. The accounting policies followed in the preparation of the reportable segments are the same with those followed in the preparation of the Company's condensed consolidated financial statements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Three-month period ended March 31, 2025&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Wholesale &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Pharma&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;manufacturing &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nutraceuticals &amp;amp; Pharmaceuticals&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Other&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,504,562&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;268,557&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;939,409&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,712,528&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Cost of Sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(11,320,936 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(70,975 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(270,818 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(11,662,729 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Gross Profit&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;1,183,626&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;197,582&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;668,591&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;2,049,799&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;General and Administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(162,269 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(155,454 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(243,227 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(361,140 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(922,090 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Salaries&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(378,595 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(363,670 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(297,499 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(255 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,040,019 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Sales and Marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(715 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(428 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(27,012 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(28,155 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Research and Development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(15,629 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(15,629 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net finance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(149,274 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;53,493&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(95,781 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Segment profit / (loss)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;492,773&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(321,970 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;154,346&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(377,024 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(51,875 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Reconciling items:&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(52,880 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(131,974 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(99,807 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(35,778 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(320,439 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(556,613 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(556,613 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Foreign currency adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;59,428&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;109,943&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,454&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;175,825&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Other income and expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,556&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,341&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;88,701&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(193,593 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(64,995 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Net profit/(loss) before Income Taxes&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;526,877&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(441,603 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;253,184&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,156,555 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(818,097 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following summary describes the operations of each reportable segment:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:41%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Reportable segments&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:54%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Operations&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Wholesale &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Distribution and export of pharmaceutical products &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Pharma manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Production of pharmaceutical products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nutraceutical and pharmaceuticals &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Trade of owned nutraceutical &amp;amp; pharmaceutical products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_9437">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Wholesale &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Pharma&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;manufacturing &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nutraceuticals &amp;amp; Pharmaceuticals&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Other&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,504,562&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;268,557&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;939,409&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,712,528&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Cost of Sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(11,320,936 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(70,975 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(270,818 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(11,662,729 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Gross Profit&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;1,183,626&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;197,582&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;668,591&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;2,049,799&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;General and Administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(162,269 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(155,454 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(243,227 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(361,140 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(922,090 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Salaries&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(378,595 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(363,670 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(297,499 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(255 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,040,019 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Sales and Marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(715 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(428 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(27,012 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(28,155 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Research and Development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(15,629 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(15,629 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net finance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(149,274 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;53,493&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(95,781 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Segment profit / (loss)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;492,773&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(321,970 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;154,346&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(377,024 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(51,875 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Reconciling items:&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(52,880 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(131,974 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(99,807 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(35,778 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(320,439 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(556,613 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(556,613 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Foreign currency adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;59,428&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;109,943&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,454&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;175,825&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Other income and expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,556&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,341&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;88,701&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(193,593 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(64,995 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Net profit/(loss) before Income Taxes&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;526,877&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(441,603 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;253,184&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,156,555 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(818,097 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11570"
      unitRef="USD">12504562</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11571"
      unitRef="USD">268557</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11572"
      unitRef="USD">939409</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11573"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11568"
      unitRef="USD">13712528</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11576"
      unitRef="USD">11320936</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11577"
      unitRef="USD">70975</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11578"
      unitRef="USD">270818</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11579"
      unitRef="USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11574"
      unitRef="USD">11662729</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11657"
      unitRef="USD">1183626</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11659"
      unitRef="USD">197582</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11661"
      unitRef="USD">668591</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11663"
      unitRef="USD">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11665"
      unitRef="USD">2049799</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11582"
      unitRef="USD">162269</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11583"
      unitRef="USD">155454</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11584"
      unitRef="USD">243227</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11585"
      unitRef="USD">361140</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11580"
      unitRef="USD">922090</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11589"
      unitRef="USD">378595</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11590"
      unitRef="USD">363670</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11591"
      unitRef="USD">297499</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11592"
      unitRef="USD">255</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11587"
      unitRef="USD">1040019</us-gaap:SalariesAndWages>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11595"
      unitRef="USD">715</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11596"
      unitRef="USD">428</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11597"
      unitRef="USD">27012</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11598"
      unitRef="USD">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11593"
      unitRef="USD">28155</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11599"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11600"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11601"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11602"
      unitRef="USD">15629</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11637"
      unitRef="USD">15629</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <cosm:NetFinanceCosts
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11603"
      unitRef="USD">-149274</cosm:NetFinanceCosts>
    <cosm:NetFinanceCosts
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11604"
      unitRef="USD">0</cosm:NetFinanceCosts>
    <cosm:NetFinanceCosts
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11605"
      unitRef="USD">53493</cosm:NetFinanceCosts>
    <cosm:NetFinanceCosts
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11606"
      unitRef="USD">0</cosm:NetFinanceCosts>
    <cosm:NetFinanceCosts
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11639"
      unitRef="USD">-95781</cosm:NetFinanceCosts>
    <cosm:SegmentProfitLoss
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11607"
      unitRef="USD">492773</cosm:SegmentProfitLoss>
    <cosm:SegmentProfitLoss
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11608"
      unitRef="USD">-321970</cosm:SegmentProfitLoss>
    <cosm:SegmentProfitLoss
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11609"
      unitRef="USD">154346</cosm:SegmentProfitLoss>
    <cosm:SegmentProfitLoss
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11610"
      unitRef="USD">-377024</cosm:SegmentProfitLoss>
    <cosm:SegmentProfitLoss
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11638"
      unitRef="USD">-51875</cosm:SegmentProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11613"
      unitRef="USD">52880</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11614"
      unitRef="USD">131974</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11615"
      unitRef="USD">99807</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11616"
      unitRef="USD">35778</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11611"
      unitRef="USD">320439</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11641"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11643"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11645"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11647"
      unitRef="USD">-556613</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11649"
      unitRef="USD">-556613</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11650"
      unitRef="USD">59428</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11652"
      unitRef="USD">0</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11654"
      unitRef="USD">109943</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11656"
      unitRef="USD">6454</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11666"
      unitRef="USD">175825</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <cosm:OtherIncomeAndExpenses
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11627"
      unitRef="USD">27556</cosm:OtherIncomeAndExpenses>
    <cosm:OtherIncomeAndExpenses
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11628"
      unitRef="USD">12341</cosm:OtherIncomeAndExpenses>
    <cosm:OtherIncomeAndExpenses
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11629"
      unitRef="USD">88701</cosm:OtherIncomeAndExpenses>
    <cosm:OtherIncomeAndExpenses
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11630"
      unitRef="USD">-193593</cosm:OtherIncomeAndExpenses>
    <cosm:OtherIncomeAndExpenses
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11640"
      unitRef="USD">-64995</cosm:OtherIncomeAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-03-31_cosm_WholesaleMember"
      decimals="0"
      id="fid_11633"
      unitRef="USD">526877</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-03-31_cosm_PharmamanufacturingMember"
      decimals="0"
      id="fid_11634"
      unitRef="USD">-441603</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-03-31_cosm_NutraceuticalsAndPharmaceuticalsMember"
      decimals="0"
      id="fid_11635"
      unitRef="USD">253184</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-03-31_cosm_OtherMember"
      decimals="0"
      id="fid_11636"
      unitRef="USD">-1156555</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-03-31_cosm_TotalSegmentMember"
      decimals="0"
      id="fid_11631"
      unitRef="USD">-818097</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <cosm:ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock contextRef="From2025-01-01to2025-03-31" id="fid_9438">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:41%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Reportable segments&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:54%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Operations&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Wholesale &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Distribution and export of pharmaceutical products &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Pharma manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Production of pharmaceutical products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nutraceutical and pharmaceuticals &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Trade of owned nutraceutical &amp;amp; pharmaceutical products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cosm:ScheduleofdescribestheoperationsofeachreportablesegmentTableTextblock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-03-31" id="fid_5979">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;NOTE 18 &#x2013; SUBSEQUENT EVENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Between April 21, 2025, and April 24, 2025, the Company issued an aggregate of 1,466,764 shares of common stock to Mr. Grigorios Siokas, the Company&#x2019;s Chief Executive Officer, in settlement of outstanding obligations totalling $526,000. The liabilities settled pertained to unpaid salaries and performance-related bonuses previously accrued by the Company and owed to Mr. Siokas. The shares were issued at the respective fair market value of the Company&#x2019;s common stock on the dates of issuance. The transaction was accounted for as a non-cash settlement of related party debt.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 6, 2025, the Company received a notice from the Nasdaq Stock Market LLC indicating that it had not regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) by the initial deadline of May 5, 2025. However, the Company was granted an additional 180-day compliance period, through November 3, 2025, to meet the requirement. The extension was granted based on the Company&#x2019;s continued compliance with all other initial listing standards for the Nasdaq Capital Market and its intent to cure the deficiency, including through a potential reverse stock split if necessary.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-04-01to2025-04-24_us-gaap_SubsequentEventMember_cosm_GrigoriosSiokasMember"
      decimals="0"
      id="fid_10876"
      unitRef="Shares">1466764</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:AssetRetirementObligationLiabilitiesSettled
      contextRef="From2025-04-01to2025-04-24_us-gaap_SubsequentEventMember_cosm_GrigoriosSiokasMember"
      decimals="0"
      id="fid_11189"
      unitRef="USD">526000</us-gaap:AssetRetirementObligationLiabilitiesSettled>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
